<SEC-DOCUMENT>0000950170-22-002383.txt : 20220301
<SEC-HEADER>0000950170-22-002383.hdr.sgml : 20220301
<ACCEPTANCE-DATETIME>20220228214046
ACCESSION NUMBER:		0000950170-22-002383
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		22
FILED AS OF DATE:		20220301
DATE AS OF CHANGE:		20220228

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BioAtla, Inc.
		CENTRAL INDEX KEY:			0001826892
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				851922320
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-260440
		FILM NUMBER:		22693561

	BUSINESS ADDRESS:	
		STREET 1:		11085 TORREYANA ROAD
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		858-558-0708

	MAIL ADDRESS:	
		STREET 1:		11085 TORREYANA ROAD
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>424b3_-_bcab_fy2021.htm
<DESCRIPTION>424B3
<TEXT>
<html>
 <head>
  <title>424B3</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Filed Pursuant to Rule 424(b)(3)</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Registration No. 333-260440</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PROSPECTUS SUPPLEMENT NO. 1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(to Prospectus dated November 3, 2021)</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img129881027_0.jpg" alt="img129881027_0.jpg" style="width:133px;height:67px;">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">BioAtla, Inc.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Up to 2,678,600 Shares of Common Stock</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1.000pt solid rgba(0,0,0,1);text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:13.5pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">This prospectus supplement supplements the prospectus dated November 3, 2021 (the &#x201c;Prospectus&#x201d;), which forms a part of our registration statement on Form S-1 (No. 333-260440). This prospectus supplement is being filed to update and supplement the information in the Prospectus with the information contained in our Annual Report on Form 10-K for the year ended December 31, 2021, filed with the Securities and Exchange Commission on February 28, 2022 (the &#x201c;Annual Report&#x201d;). Accordingly, we have attached the Annual Report to this prospectus supplement.</font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Prospectus and this prospectus supplement relates to the offer and sale from time to time by the selling stockholders named in the Prospectus of up to 2,678,600 shares of common stock, par value $0.0001 per share (&#x201c;Common Stock&#x201d;).</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our Common Stock is listed on the Nasdaq Global Market under the symbol &#x201c;BCAB.&#x201d; On February 25, 2022, the closing price of our Common Stock was $6.64.</font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">This prospectus supplement updates and supplements the information in the Prospectus and is not complete without, and may not be delivered or utilized except in combination with, the Prospectus, including any amendments or supplements thereto. This prospectus supplement should be read in conjunction with the Prospectus and if there is any inconsistency between the information in the Prospectus and this prospectus supplement, you should rely on the information in this prospectus supplement.</font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">See the section entitled &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Risk Factors</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">&#x201d; beginning on page 6 of the Prospectus to read about factors you should consider before buying our securities.</font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement or the Prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">The date of this prospectus supplement is February 28, 2022.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.38;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.267%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:2.250pt double;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;">re</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:16.0pt;font-family:Times New Roman;">UNITED STATES</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:16.0pt;font-family:Times New Roman;">SECURITIES AND EXCHANGE COMMISSION</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Washington, D.C. 20549</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:3.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="margin-left:42.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.875pt solid rgba(0,0,0,1);margin-right:42.667%;text-align:center;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:3.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:16.0pt;font-family:Times New Roman;">Form 10-K</font></p>
  <p style="margin-left:42.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.875pt solid rgba(0,0,0,1);margin-right:42.667%;text-align:center;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:3.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:2.7pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">(Mark One)</font></p>
  <table style="margin-left:0.1736111111111111in;border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.157%;"></td>
    <td style="width:95.843%;"></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#9746;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.5pt;font-family:Times New Roman;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">For the fiscal year ended December 31, 2021</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:3.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <table style="margin-left:0.1736111111111111in;border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.157%;"></td>
    <td style="width:95.843%;"></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#9744;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">For the transition period from                      to                     .</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Commission file number 001-39787</font></p>
  <p style="margin-left:42.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.875pt solid rgba(0,0,0,1);margin-right:42.667%;text-align:center;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:22.0pt;font-family:Times New Roman;">BIOATLA, INC.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">(Exact name of registrant as specified in its charter)</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:3.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="margin-left:42.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.875pt solid rgba(0,0,0,1);margin-right:42.667%;text-align:center;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:3.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:2.7pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:3.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <table style="margin-left:0.1736111111111111in;border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:50.577%;"></td>
    <td style="width:1.81%;"></td>
    <td style="width:47.613%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Delaware</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">  </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">85-1922320</font></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">(State or other jurisdiction of<br>incorporation or organization)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">  </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">(I.R.S. Employer<br>Identification No.)</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:5.4pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:5.4pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">11085 Torreyana Road, San Diego, California</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">  </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">92121</font></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">(Address of principal executive offices)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">  </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">(Zip Code)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.7pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Registrant&#x2019;s telephone number, including area code:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(858) 558-0708</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.7pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Securities registered pursuant to Section 12(b) of the Act:</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:3.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <table style="margin-left:0.1736111111111111in;border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:33.871%;"></td>
    <td style="width:1.181%;"></td>
    <td style="width:31.893%;"></td>
    <td style="width:1.181%;"></td>
    <td style="width:31.874%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.875pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Title of each class</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.875pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.875pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Trading<br>Symbol(s)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.875pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.875pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Name of each exchange<br>on which registered</font></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Common Stock, $0.0001 par value per share</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">BCAB</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">The Nasdaq Global Market</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Securities registered pursuant to Section 12(g) of the Act: None</font></p>
  <p style="margin-left:42.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.875pt solid rgba(0,0,0,1);margin-right:42.667%;text-align:center;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.    Yes  &#9744; or No  &#9746;</font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.    Yes  &#9744; or No  &#9746;</font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  &#9746; or No  &#9744;</font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  &#9746;    No  &#9744;</font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#x201c;large accelerated filer,&#x201d; &#x201c;accelerated filer,&#x201d; &#x201c;smaller reporting company,&#x201d; and &#x201c;emerging growth company&#x201d; in Rule 12b-2 of the Exchange Act.</font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:95.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:19.069%;"></td>
    <td style="width:1.055%;"></td>
    <td style="width:55.616%;"></td>
    <td style="width:1.055%;"></td>
    <td style="width:20.254%;"></td>
    <td style="width:1.055%;"></td>
    <td style="width:1.897%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Large accelerated filer</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#9746;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">  </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Accelerated filer</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#9744;</font></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Non-accelerated filer</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#9744;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">  </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Smaller reporting company</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#9744;</font></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Emerging growth company</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#9744;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
   </tr>
  </table>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:3.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  &#9744;</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#x2019;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.  &#9746;</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).    Yes  &#9744;    No  &#9746;</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">As of June 30, 2021, the last business day of the registrant&#x2019;s most recently completed second fiscal quarter, the aggregate market value of the registrant&#x2019;s common stock held by non-affiliates of the registrant was approximately $1.0 billion based on the closing sales price of $42.38 per share as reported on the Nasdaq Global Select Market.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">As of February 25, 2022, the number of shares of the registrant&#x2019;s common stock outstanding was 35,829,127 and the number of shares of the registrant&#x2019;s Class B common stock outstanding was 1,492,059.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">DOCUMENTS INCORPORATED BY REFERENCE</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Part III incorporates by reference certain information from the registrant&#x2019;s definitive proxy statement (the &#x201c;Proxy Statement&#x201d;) relating to its 2022 Annual Meeting of Stockholders. The Proxy Statement will be filed with the United States Securities and Exchange Commission within 120 days after the end of the fiscal year to which this report relates.</font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:1.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:2.250pt double;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">BIOATLA, INC.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Annual Report on Form 10-K</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">For the Fiscal Year Ended December 31, 2021</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">TABLE OF </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">CONTENTS</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <table style="margin-left:0.1736111111111111in;border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:9.231%;"></td>
    <td style="width:1.041%;"></td>
    <td style="width:79.25%;"></td>
    <td style="width:1.041%;"></td>
    <td style="width:1.041%;"></td>
    <td style="width:7.289%;"></td>
    <td style="width:1.107%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
   </tr>
   <tr>
    <td colspan="7" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:5.4pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">PART I</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Item 1.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1_business"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Business</font></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">  </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">2</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Item 1A.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1a_risk_factors"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Risk Factors</font></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">  </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">43</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Item 1B.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1b_unresolved_staff_comments"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Unresolved Staff Comments</font></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">  </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">81</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Item 2.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_2_properties"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Properties</font></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">  </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">81</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Item 3.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_3_legal_proceedings"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Legal Proceedings</font></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">  </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">81</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Item 4.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_4_mine_safety_disclosures"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Mine Safety Disclosures</font></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">  </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">81</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
   </tr>
   <tr>
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:5.4pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="4" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:5.4pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">PART II</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">  </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Item 5.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_5_market_for_registrant"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Market for Registrant&#x2019;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</font></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">  </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">82</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Item 6.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_6_selected_financial_data"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Selected Financial Data</font></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">  </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">83</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Item 7.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_7_management_discussion"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations</font></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">  </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">84</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Item 7A.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_7a_quantitative_and_qualitative"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Quantitative and Qualitative Disclosures About Market Risk</font></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">  </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">93</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Item 8.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_8_financial_statements"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Financial Statements and Supplementary Data</font></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">  </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">94</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Item 9.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9_changes_in_and_disagreements"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</font></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">  </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">123</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Item 9A.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9a_controls_and_procedures"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Controls and Procedures</font></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">  </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">123</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Item 9B.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9b_other_information"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Other Information</font></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">  </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">125</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
   </tr>
   <tr>
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:5.4pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="4" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:5.4pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">PART III</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">  </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Item 10.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_10"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Directors, Executive Officers and Corporate Governance</font></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">  </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">126</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Item 11.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_11"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Executive Compensation</font></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">  </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">126</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Item 12.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_12"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</font></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">  </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">126</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Item 13.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_13"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Certain Relationships and Related Transactions, and Director Independence</font></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">  </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">126</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Item 14.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_14"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Principal Accountant Fees and Services</font></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">  </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">126</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
   </tr>
   <tr>
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:5.4pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="4" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:5.4pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">PART IV</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">  </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Item 15.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_15_exhibits_and_financial"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Exhibits and Financial Statement Schedules</font></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">  </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">127</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Item 16.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_16_form_10_k_summary"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Form 10-K Summary</font></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">  </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">127</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#signatures"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">SIGNATURES</font><font style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">  </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">130</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_i"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">PAR</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">T I</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">FORWARD-LOOKING STATEMENTS</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">This Annual Report on Form 10-K contains forward-looking statements. We may, in some cases, use words such as &#x201c;anticipate,&#x201d; &#x201c;believe,&#x201d; &#x201c;could,&#x201d; &#x201c;estimate,&#x201d; &#x201c;expect,&#x201d; &#x201c;intend,&#x201d; &#x201c;may,&#x201d; &#x201c;plan,&#x201d; &#x201c;potential,&#x201d; &#x201c;predict,&#x201d; &#x201c;project,&#x201d; &#x201c;should,&#x201d; &#x201c;will,&#x201d; &#x201c;would&#x201d; or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes to identify these forward-looking statements. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy short-term and long-term business operations and objectives and financial needs. These forward-looking statements are subject to known and unknown risks, uncertainties and assumptions, including risks described in the section titled &#x201c;Risk Factors&#x201d; set forth in Part I, Item 1A of this Annual Report on Form 10-K and in our other filings with the Securities and Exchange Commission (the &#x201c;SEC&#x201d;). It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the future events and trends discussed in this Annual Report on Form 10-K may not occur, and actual results may differ materially and adversely from those anticipated or implied in the forward-looking statements. Forward-looking statements contained in this Annual Report on Form 10-K include, but are not limited to, statements about:</font></p>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">our ability to develop and advance our current product candidates and programs into, and successfully complete, clinical trials;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">the ability of our clinical trials to demonstrate safety and efficacy of our product candidates and other positive results;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">the size of the market opportunity for our product candidates, including our estimates of the number of patients who suffer from the diseases we are targeting;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">our manufacturing, commercialization and marketing capabilities and strategy;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">our plans and strategies to develop and commercialize our CAB antibodies;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">our plans to further develop our technology platform and expand our pipeline of product candidates;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">the potential benefits and advantages of our current and future product candidates that we may develop from our patented technology platform;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">the impact of the COVID-19 pandemic on our business, financial condition, results of operations, and prospects;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">the timing or likelihood of regulatory filings and approvals for our product candidates;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">regulatory developments in the United States and Europe and other foreign countries;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">our expectations and plans to obtain funding for our operations, including from our existing and potential future collaboration and licensing agreements;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">our expectations regarding our ability to obtain and maintain intellectual property protection for our technology platform and product candidates;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">the potential benefits of our strategic relationships and our plans to pursue additional strategic relationships;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">our continued reliance on third parties to conduct additional clinical trials of our product candidates and for the manufacture of our product candidates for preclinical studies and clinical trials; and</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">our estimates regarding expenses, future revenue, capital requirements and needs for additional financing.</font></div></div>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We caution you that the foregoing list may not contain all of the forward-looking statements made in this Annual Report on Form 10-K.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">You should not rely upon forward-looking statements as predictions of future events. The events and circumstances reflected in the forward-looking statements may not be achieved or occur. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, we do not intend to update any of these forward-looking statements after the date of this Annual Report on Form 10-K or to conform these statements to actual results or revised expectations.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">You should read this Annual Report on Form 10-K with the understanding that our actual future results, levels of activity, performance and events and circumstances may be materially different from what we expect.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">This Annual Report on Form 10-K contains estimates, projections and other information concerning our industry, our business and the markets for our product candidates. We obtained the industry, market and similar data set forth in this report from our own internal estimates and research and from academic and industry research, publications, surveys and studies conducted by third parties, including governmental agencies. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances that are assumed in this information. While we believe that the data we use from third parties are reliable, we have not separately verified these data. Further, while we believe our internal research is reliable, such research has not been verified by any third party. You are cautioned not to give undue weight to any such information, projections and estimates.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Unless the context requires otherwise, references in this Annual Report on Form 10-K to &#x201c;BioAtla,&#x201d; &#x201c;we,&#x201d; &#x201c;us&#x201d; and &#x201c;our&#x201d; refer, prior to the LLC conversion discussed below, to BioAtla, LLC and, after the conversion, to BioAtla, Inc.</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1_business"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">ITEM 1. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Business</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Overview</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We are a clinical-stage biopharmaceutical company developing our novel class of highly specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Our conditionally active biologics (&#x201c;CAB&#x201d; or &#x201c;CABs&#x201d;) capitalize on our proprietary discoveries with respect to tumor biology, enabling us to target known and widely validated tumor antigens that have previously been difficult or impossible to target. Our novel CAB therapeutic candidates exploit characteristic pH differences between the tumor microenvironment and healthy tissue. Unlike healthy tissue, the tumor microenvironment is acidic, and we have designed our antibodies to selectively bind to their targets on cancer cells under acidic pH conditions but not on targets in normal tissues. Our approach is to identify the necessary targeting and potency required for cancer cell destruction, while aiming to eliminate or greatly reduce on-target, off-tumor toxicity&#x2014;one of the fundamental challenges of existing cancer therapies.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The broad applicability of our CAB technology allows us to develop a wide array of product candidate modalities, such as monoclonal antibodies, antibody-drug conjugates, or ADCs, T cell-engaging bispecific antibodies and chimeric antigen receptor T cells, or CAR-T cells. A key advantage of our application of the CAB technology to antibodies is that it allows us to selectively target antigens on tumor cells and minimizes or eliminates binding to these antigens on normal cells, which reduces the toxicity associated with traditional approaches. We have initiated potentially registration-enabling Phase 2 trials for our two latest stage CAB ADC product candidates targeting multiple cancer indications with mecbotamab vedotin (BA3011) targeting AXL in sarcoma and NSCLC and ozuriftamab vedotin (BA3021) targeting ROR2 in non-small cell lung cancer (NSCLC), melanoma, and head and neck cancer (SCCHN). The U.S. Food and Drug Administration, or the FDA, has reviewed the trial designs, but has not yet opined on whether the Phase 2 clinical trials will be sufficient to support regulatory approval. However, we intend to ask the FDA to consider this further at the upcoming interim data review point or points for these trials and indications. While we cannot assure you that the FDA will agree that the current clinical plan will be sufficient to support approval, the trial has been designed to allow us to adjust the clinical plan, if needed, after the interim read-out in order to better align with any potential FDA requirements. We are also supporting investigator-initiated trials for both mecbotamab vedotin and ozuriftamab vedotin in platinum-resistant ovarian cancer. We have observed encouraging initial clinical signs of response to treatment and a wide therapeutic window for a range of dosage and duration. Mecbotamab vedotin and ozuriftamab vedotin have the potential to address large unmet medical needs in indications that together account for more than 350,000 new cases of solid tumor cancers and 150,000 deaths per year in the United States alone. Additionally, we have initiated Phase 1 trials for multiple cancer indications in 2021 with dosing expect in the first half of 2022 for our CAB immuno-oncology antibody BA3071 targeting CTLA-4. BA3071 is designed to overcome the toxicity limitations of the currently approved anti-CTLA-4 antibodies and to improve patient outcomes. We also have several candidates in our IND-enabling preclinical pipeline that include CAB bispecific and ADC antibodies targeting unmet medical needs in multiple types of solid tumors.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Our goal is to develop well-tolerated, novel cancer therapies that provide cures or extended survival to ensure patients&#x2019; improved quality of life. Studies have shown that, as a drug class, antibodies have transformed oncology treatment and include some of the best-selling therapies on the biopharmaceutical market. While therapeutic antibodies have emerged as one of the most successful strategies for both solid and blood-based, or hematologic, malignancies, toxicity has narrowed the therapeutic window and ultimate potential of impacting disease, as many of the key targets on tumor cells are also prevalent on normal cells. The biology of tumor formation, or tumorigenesis, yields a unique microenvironment consisting of a complex mixture of tumor cells, stromal fibroblasts, endothelial cells and immune cells like microglia, macrophages and lymphocytes and the non-cellular components of extracellular matrix such as collagen, fibronectin, hyaluronan and laminin, among others. The process of tumor formation creates an altered, unique microenvironment in and around the tumor that is also physically and chemically distinct from healthy tissue, with regard to temperature, pressure, chemical composition and especially the acidity or pH. The tumorigenesis-driven shifts in microenvironment conditions further weaken the immune response and promote tumor growth. We have created and patented our CAB technology to enable the development of antibodies that are active in the tumor microenvironment, but inactive under normal physiological conditions, while ensuring target-specific binding on cancer cells. Our CAB technology aims to uniquely exploit the fundamental pH differences between the tumor and healthy tissue, increasing antibody binding selectivity and thereby potentially eliminating or greatly reducing healthy cell on-target, off-tumor toxicity. This enhanced selectivity has the potential to greatly improve the benefit-risk ratio for the patient and allows us to deliver desired drug levels either as monotherapy or utilizing unique multi-targeted or combination therapies that are currently difficult or impossible to develop. Additionally, the combination of reversible binding with the selective, precision capability of our CAB technology enables both increased antibody potency and reduced toxicity. By exploiting our novel understanding of tumor biology, we believe that our proprietary CAB technology has the potential to transform antibody-based cancer therapy.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">2</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Initially, we applied the reversible binding and precision capability of our CAB technology to develop next-generation ADC therapies. Traditional ADCs are a class of biologic drugs that are designed by attaching a toxic small molecule payload to an antibody, which then targets a specific antigen expressed on the target cell, but unfortunately, in most cases, this target is also present on normal tissue. Binding to the target on normal tissue leads to high on-target, off-tumor toxicity, which reduces the utility of traditional ADCs. Our CAB ADCs are designed to selectively bind to the antigens found in acidic pH conditions found in the tumor microenvironment, which has the potential to reduce off-tumor toxicity and related consequences. In addition, we developed CAB antibodies to immuno-oncology targets such as CTLA-4 for antitumor activity. We believe that our CAB technology can reduce the limitations resulting from systemic toxicities and expand the utility of this immuno-oncology therapy. We are also creating bispecific, T cell engaging, CAB antibodies that are comprised of two different binding specificities, which allows the antibody to bind to two specific targets at the same time, generally one target on the tumor cell and one target on an immune system cell. This is a powerful approach to harness cytotoxic T cells to directly kill tumor cells with reduced toxicity.</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Our pipeline</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We believe that there is significant potential to improve therapeutics for our patients with our proprietary CAB antibody technology across well-validated oncology targets in solid tumors. The following table summarizes our current product candidate pipeline.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img129881027_1.jpg" alt="img129881027_1.jpg" style="width:686px;height:356px;">&#160;</p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Mecbotamab vedotin (BA3011):</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> Our lead product candidate, mecbotamab vedotin, or  BA3011, is a CAB ADC that targets AXL, a protein kinase receptor that is highly expressed on the surface of many tumors. AXL is considered to be a driver of many cellular processes that are critical for the development, growth and spread of tumors, including proliferation, invasiveness and migration, stemness, which is related to core stem cell properties such as self-renewal and differentiation, angiogenesis, or the growth of blood vessels, and immune modulation. In preclinical studies, we have observed that BA3011 binds to AXL under conditions that reflect those in tumors. AXL has also been shown to be involved in the epithelial-mesenchymal transition, or EMT, a process by which epithelial cells lose their cell polarity and cell-cell adhesion, and gain migratory and invasive properties to become mesenchymal stem cells, or MSCs. MSCs are home to developing aggressive tumors, where they exacerbate cancer cell proliferation, motility, invasion and metastasis, foster angiogenesis, promote tumor fibrosis and suppress antitumor immune responses. Multiple therapeutic agents that target AXL have been developed and investigated in clinical trials. A number of small-molecule AXL kinase inhibitors have been developed; however, the majority of these inhibitors, including one that has been approved, are not highly selective for AXL. Although other non-CAB anti-AXL antibodies and ADCs have shown encouraging clinical signs of antitumor activity; adverse events, such as high-grade constipation and peripheral neuropathy, were particularly pronounced and led to discontinuation of clinical development of some candidates.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Mecbotamab vedotin is an ADC consisting of a CAB humanized immunoglobulin G, or IgG1, anti-AXL monoclonal antibody. The core antibody is conjugated using a cleavable linker attached to the well-known and proven toxin monomethyl auristatin E, or MMAE. Mecbotamab vedotin is designed to specifically and reversibly bind to AXL in conditions found within the tumor microenvironment, thus conferring a selectivity binding advantage for tumors over normal cells. Upon binding of mecbotamab vedotin to AXL on the surface of tumor cells, it is internalized and the MMAE cytotoxin is released, thus killing the cancer cell.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">3</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We have developed a biomarker assay that quantifies the AXL Tumor membrane Percent Score (0-100%), or TmPS. The TmPS measures the percentage of cancer cells within the tumor that expresses the AXL target expression generally on the tumor membrane which, consistent with industry standard, we use to identify those patients who we believe will be the most likely to respond to our product candidates. We believe that the larger percentage of cells expressing the target on the tumor membrane, the more likely it is that our product candidates may have the potential to provide clinical benefit.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We are developing mecbotamab vedotin as a potential therapeutic for multiple solid tumor types, including soft tissue and bone sarcoma, non-small cell lung cancer (NSCLC) and ovarian cancer, with other potential indications in the future. The Office of Orphan Drug Products (OODP) at the FDA granted Orphan Drug Designation to mecbotamab vedotin for the treatment of soft tissue sarcoma, and Phase 1 results in sarcoma patients were presented at the Connective Tissue Oncology Society (CTOS) 2021 Annual Meeting. Mecbotamab vedotin was generally well tolerated in this refractory sarcoma population. In the Phase 1 study, few patients discontinued due to an adverse event (two patients out of 26 or 7.7%) compared to discontinuation rates in most other clinical trials of ADCs. No clinically meaningful on-target toxicity to normal AXL-expressing tissue was observed over baseline levels. Dose-limiting toxicities were limited to free circulating MMAE payload-associated toxicity at the highest dose tested, including reversible neutropenia. Higher levels of AXL tumor membrane expression correlated with response to treatment. Of the seven sarcoma patients who had an AXL TmPS of greater than or equal to 70%, four of these obtained a confirmed partial response, including patients with leiomyosarcoma, undifferentiated pleomorphic sarcoma, and Ewing sarcoma. Prolonged response to therapy was observed in this ongoing study with the duration of response ranging from 33 to more than 60 weeks. Overall, we believe mecbotamab vedotin has the potential for a favorable benefit-risk profile, and importantly this is one of the few studies employing a putative biomarker which is not only highly expressed in sarcomas, but also may help select patients across multiple sarcoma subtypes who may benefit from therapy. In the ongoing potentially registration-enabling sarcoma Phase 2 study, patients are enrolled for therapy by prescreening for AXL expression. We are also conducting a Phase 2 study (BA3011-002) in AXL high NSCLC patients who have previously progressed on PD-1/L1, EGFR, or ALK inhibitor therapy. Planned interim analyses in the sarcoma and NSCLC trials are anticipated at the end of the first quarter and in the second quarter of 2022, respectively. In both Phase 2 indications, we are enrolling patients either as a monotherapy or in combination with a PD-1 inhibitor. In addition, a multi-center investigator-initiated Phase 2 clinical trial of mecbotamab vedotin in combination with a PD-1 inhibitor in patients with platinum-resistant ovarian cancer has begun enrollment and is expected to enroll approximately 20 patients.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Ozuriftabmab vedotin (BA3021):</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> We are developing our second product candidate, ozuriftamab vedotin or BA3021, a CAB antibody drug conjugate directed against ROR2, or Receptor Tyrosine Kinase Like Orphan Receptor 2. ROR2 is overexpressed across many different solid tumors, including breast, lung, pancreatic, renal, ovarian, and colorectal cancers, squamous cell cancer of the head and neck, or SCCHN, and melanoma; its tumoral expression is further enhanced among those treated with PD-1 checkpoint inhibitors. Cancer cell expression of ROR2 has been associated with enhanced cancer cell migration, EMT, increased associated risk for relapse, metastasis and unfavorable prognosis. In breast cancer, for example, ROR2 was found to be expressed in the majority of patient samples, with those expressing ROR2 having decreased overall survival. A similar correlation between ROR2 expression level and overall survival was observed in NSCLC and metastatic melanoma. Genetic inactivation of ROR2 in metastatic melanoma cells was shown to prevent metastases of these tumor cells in mice. ROR2 also has essential roles in normal cells and in early development. Inactivation of ROR2 is lethal in mice with defects observed in the heart, nervous system and skeleton. Less severe mutations in ROR2 in humans is associated with skeletal diseases Robinow syndrome and brachydactyly type B.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Employing a similar approach as with mecbotamab vedotin, we developed a TmPS quantitative assay based on ROR2 tumor membrane expression that we use to identify those patients who we believe will be the most likely to respond to our product candidates.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Ozuriftamab vedotin is a CAB anti-ROR2 ADC consisting of a CAB anti-ROR2 humanized IgG1 monoclonal antibody conjugated to MMAE using a cleavable linker. Ozuriftamab vedotin is designed to specifically and reversibly bind to ROR2 in conditions found within the tumor microenvironment, thus conferring a selectivity binding advantage for tumors over normal cells. Upon binding of ozuriftamab vedotin to ROR2 on the surface of tumor cells, it is internalized and the MMAE cytotoxin is released, thus killing the cancer cell.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We are developing ozuriftamab vedotin as a potential therapeutic for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer. Based on Phase 1 data, we believe ozuriftamab vedotin has broad potential as a cancer therapy for patients with advanced solid tumors who have experienced prior failure of PD-1 blockade. We are enrolling a Phase 2 trial of ozuriftamab vedotin monotherapy or in combination with a PD-1 inhibitor in patients with ROR2 high melanoma who have previously progressed on PD-1/L1 inhibitor and patients with ROR2 high NSCLC who have previously progressed on PD-1/L1, EGFR or ALK inhibitor therapy. A Phase 2 study in patients with ROR2 high SCCHN is anticipated to begin dosing patients in first half of 2022. In addition, a multi-center investigator-initiated Phase 2 clinical trial of ozuriftamab vedotin in combination with a PD-1 inhibitor in patients with platinum-resistant ovarian cancer has begun enrollment.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">BA3071:</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> Our third product candidate, BA3071, is a CAB anti-CTLA-4 antibody that is being developed as an immuno-oncology agent with the goal of delivering at least the efficacy of approved CTLA-4 antibodies, such as ipilimumab, but with lower toxicity rate as a result of the CAB&#x2019;s unique tumor microenvironment-restricted binding. CTLA-4, or cytotoxic T-lymphocyte-associated antigen 4, is an immune checkpoint involved in regulating T-cell activation. The primary role of immune checkpoints is to prevent autoimmune attacks against normal tissue in the body; however, cancer cells often take advantage of this pathway to prevent immune destruction of the tumor. Ipilimumab currently is the only anti-CTLA-4 monoclonal antibody approved by the FDA. It is approved in combination with an anti-PD-1 antibody, nivolumab, for the treatment of multiple solid tumors, including melanoma, RCC, colorectal cancer and NSCLC. Patients treated with ipilimumab face a risk of a number of adverse events associated with inappropriate activation of the immune system beyond the tumor site including severe and sometimes fatal enterocolitis, hepatitis, dermatitis, neuropathy and endocrinopathy. The usage and dosage of ipilimumab is highly limited due to its safety profile, resulting in the average number of cycles on therapy not exceeding four cycles.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">4</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We are developing BA3071 as a potential therapeutic for multiple solid tumor indications, possibly including renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer and cervical cancer. We have initiated a Phase 1/2 dose-escalation trial of BA3071 as monotherapy and in combination with an anti-PD-1 antibody with expansion cohorts to be enrolled upon identification of the recommended dose.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Bispecific antibody programs:</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> We have also leveraged our CAB technology to develop bispecific antibodies, which bind both a tumor-specific antigen and a T cell receptor using CAB antigen-binding domains. A bispecific antibody is a type of engineered antibody that can simultaneously bind two separate and unique antigens, unlike conventional monospecific antibodies that only bind to one type of target.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">A common design feature for a bispecific antibody is to include a T cell engager component (</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">i.e.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">, CD3 receptor), such that one antigen-binding domain recognizes a surface-expressed tumor antigen and the other antigen-binding domain binds to and activates CD3+ T cells. With this design, bispecific antibodies can induce potent T cell responses against tumors expressing the tumor target antigen in a simplified manner relative to even off-the-shelf or allogeneic CAR-T therapies. The first FDA approved bispecific antibody was a T cell engager, blinatumomab, which contained antigen-binding domains for CD19, an antigen found on B-cell leukemias, and CD3, a T cell activating receptor.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">There are multiple structural variants of antibodies and other antigen-binding domains being used by others to construct bispecific product candidates, some of which are being tested clinically. However, similar to CAR-T cells and blinatumomab, many of these bispecific product candidates have increased risks of generating life-threatening cytokine release syndrome due to systemic immune activation.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We have applied our CAB antibody technology to develop bispecific CAB antibodies in which one or both antigen-binding domains are active only in the tumor microenvironment. An example of this approach is our EpCAM x CD3 bispecific. EpCAM, or epithelial cell adhesion molecule, is a protein that is over-expressed in many cancers including carcinomas derived from colon, intestine, breast, lung and prostate. Expression of EpCAM has been extensively associated with cell growth and proliferation of both healthy and cancer cells.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">EpCAM was one of the first cancer-associated antigens discovered, however in the forty years since, its clinical impact as a target for therapeutic antibodies in cancer has been limited. One of the problems with targeting EpCAM is its broad expression in the basolateral membranes of normal epithelial cells. Conventional approaches of avoiding systemic toxicities including deliberately selecting antibodies with low affinity for EpCAM with the intention of generating some degree of selectivity for tumors that express very high levels of EpCAM, have not been successful. Bispecific constructs targeting EpCAM have also not lived up to expectations. Solitomab, an EpCAM x CD3 bispecific led to over 95% of patients in a Phase 1 dose-escalation trial to experience at least one Grade 3 or above adverse event. Over 20% of patients experienced dose-limiting toxicities and there was only one unconfirmed partial response observed among 65 patients at these low doses.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We have shown in preclinical experiments that our CAB bispecific molecules meet or exceed the activity of conventional bispecifics and reduce systemic activation of potentially fatal immune responses.  We are conducting IND-enabling studies for two CAB bispecific antibody product candidates, EpCAM/CD3 and B7-H3/CD3, and one next-generation CAB ADC, Nectin-4.  We presently plan to file INDs in 2022 for EpCAM/CD3 and in 2023 for Nectin-4 and  B7-H3/CD3. We also are evaluating additional candidates including EGFR/CD3 bispecific and B7-H4 as a next-generation CAB ADC candidate. Overall, we are advancing multiple pre-clinical assets and expect to file one IND in 2022, with the potential to submit up to three additional US INDs in 2023 for our CAB bispecific or ADC molecules.</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Our strategy</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Our mission is to develop and commercialize innovative antibody-based therapeutics for the treatment of solid tumors that are designed to bind depending on the physical and chemical properties of tumors and their microenvironment. Our CAB technology enables us to generate antibodies that bind to their targets under conditions found in the tumor, but not in healthy tissue. Therefore, we are able to generate antibodies to targets that to this point have been undruggable due to the lack of sufficient therapeutic window with existing antibody technologies. We are also able to use these antibodies to engage targets that exist not only in tumors, but in healthy tissue as well. This has the potential to reduce side effects and toxicity, one of the fundamental challenges of cancer therapies today, thereby expanding the realm of potential therapeutic antibodies. We believe that our proprietary technology and approach have the potential to transform cancer therapy by decreasing systemic toxicities and improving efficacy. Our strategy to achieve this mission is as follows:</font></p>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Advance mecbotamab vedotin through regulatory approval and commercialization. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Clinical data from our Phase 1 trial with mecbotamab vedotin are supportive of its development in sarcomas, a set of cancers with a high unmet clinical need. We have initiated a potentially registration-enabling Phase 2 trial for mecbotamab vedotin in treatment refractory sarcoma patients (12 years of age or older), with an AXL TmPS of 50%, patients with an AXL TmPS equal or greater to 70% as the group for the primary analyses,  and, if successful, we believe we can further advance mecbotamab vedotin through regulatory approval and commercialization. In addition, we have initiated a potentially registration-enabling Phase 2 trial in NSCLC using a primary AXL TmPS of 1%. We are using a quantitative biomarker assay/TmPS score to identify likely responders and to help enrich our clinical trial programs. </font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Advance ozuriftamab vedotin in PD-1/L1 refractory tumors through regulatory approval and commercialization.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> We have observed antitumor activity in PD-1 refractory NSCLC and melanoma patients in our Phase 1 trial and have initiated a Phase 2 trial of ozuriftamab vedotin in each of these indications. We are using a quantitative biomarker assay/TmPS score to identify and stratify based the TmPS score the likely responders and to help enrich our clinical trial programs.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">5</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Advance BA3071 as a CAB- anti CTLA-4 immune checkpoint inhibitor to restrict T-cell activation to the tumor microenvironment.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The design of BA3071 is to provide the efficacy of ipilimumab, the only anti-CTLA-4 monoclonal antibody approved by the FDA, but with a significantly enhanced safety profile.  This may allow for patients to be treated at higher dosage and/or for more cycles of treatment in combination with an anti-PD-1 antibody that may lead to better therapeutic results. </font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Advance into clinical development multiple CAB bispecific and next generation CAB ADC candidates to further address areas of high unmet needs in treating solid tumors.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> We believe that our next generation CAB-ADC platform further widens that therapeutic window by enhancing the linker-payload system. In addition, our first CAB EpCAM/CAB CD3 bispecific has recently demonstrated IND-enabling studies with a more than 80-fold improvement in the therapeutic window. Combining our CAB technology with our newly developed next generation CAB-ADC platform replaces the traditional peptide linker with a novel sugar-based linker to deliver the MMAE payload.  It is expected that this new CAB ADC system will further reduce off-target, off-tumor toxicity and thereby expand the therapeutic window. </font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Maintain and strengthen our intellectual property portfolio.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> As of December 31, 2021, we had a total of 584 patents and patent applications with 319 issued patents, 8 allowed applications and 257 pending applications covering our CAB technology and product candidates. This broad patent coverage was designed such that protection of our product candidates is not dependent on any single patent but rather, each product candidate provides multiple layers of protection. We plan to continue to maintain, monitor, enforce and defend our intellectual property.</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Selectively enter into collaborations to maximize the value of our platform and pipeline. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Given the potential of our technology to generate novel product candidates addressing a wide variety of solid tumors, we may opportunistically enter into strategic collaborations around specific geographic regions, indications, combinations and companion diagnostics. We may also explore collaboration arrangements to commercialize any product candidates where we believe the resources and expertise of the third party could be beneficial. These collaborations could advance and accelerate our programs to maximize their market potential and expand the worldwide commercial potential of our CAB technology and assets.</font></div></div>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Our technology</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Challenges in developing antibody-based therapies for solid tumors</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Monoclonal antibody therapeutics have been approved for over 30 targets for multiple diseases, most commonly cancer. Antibodies have become the new backbone of the pharmaceutical industry, which previously relied on small molecules. Treatment with monoclonal antibodies has established itself as one of the most successful therapeutic strategies for both hematologic malignancies and solid tumors. Oncology targets of safe, effective antibodies fall into two broad categories:</font></p>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Antibodies targeting antigens, usually proteins, preferentially expressed on the surface of cancer cells, against which antibodies are used to directly bind and inhibit or destroy these cells; and</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Antibodies targeting antigens affecting directly or indirectly tumor cells and non-tumor cells that activate the immune system or induce other changes in the tumor, such as limiting the growth of tumor-related blood vessels.</font></div></div>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">There are significant limitations of targeting important antigens with traditional antibodies that can result in reduced efficacy, difficulties related to dosing, decreased durability, and drug-related toxicities, all of which significantly limit the potential for cures with traditional antibodies:</font></p>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Increased toxicity</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">: Antigens are typically expressed in many normal tissues, which for traditional antibodies, including ADCs, could lead to significant on-target, off-tumor toxicity reducing dosing and durability.</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Target-mediated drug disposition limitation</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">: Target-mediated drug disposition, or TMDD, is the phenomenon in which a drug binds somewhat indiscriminately to its pharmacological target on normal tissue as well as on the intended diseased tissue, thereby causing the antibody to be depleted more rapidly from circulation. As a consequence, the pharmacokinetic characteristics of the drug can be adversely impacted, leading to reduced half-life, lower tumor exposure, which requires more frequent or higher dosing that increases toxicity and ultimately can result in undesirable side-effects, patient treatment-related inconveniences and greater costs.</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Immunogenicity</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">: Antibodies also can be sensitive to modifications that can lead to immunogenicity, or a strong negative immune system response from the body, which can induce anti-drug antibodies that can reduce efficacy or lead to severe infusion reactions, thereby restricting the potential improvements that could be made with emerging technologies.</font></div></div>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The fundamental specificity challenge with traditional monoclonal antibody-based therapy is that there are few known antigens that are specific to tumors and absent in non-cancerous tissues. Drug developers might develop an antibody that is exquisitely specific against its target, but due to the expression of the target on non-tumor cells, systemic administration can result in dose-limiting toxicities from on-target, off-tumor activity. For example, cetuximab targets an antigen that is highly expressed in colorectal cancer, but this antigen is also expressed in epidermal cells throughout the body. Consequently, treatment with cetuximab results in over 80% of patients developing skin toxicities that can severely impact patients&#x2019; physical, psychological and social well-being and can lead to treatment discontinuation and dose reduction.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">6</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">These examples, however, only represent antibodies where the therapeutic benefit clearly outweighs the consequences associated with the adverse events. There are many potential protein targets that do not offer such clear-cut therapeutic windows. The majority of anticancer antibody-based drug products are consequently limited to a small subset of potential tumor antigens. We believe that our novel approach to increase the selectivity of antibody-based therapeutics while maintaining their potency may have the potential to fundamentally transform the development of anticancer therapeutics and expand the universe of targets for novel antibody-based therapies.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">CAB leverages the low pH found in the tumor microenvironment</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The tumor microenvironment has been widely implicated in tumorigenesis because it harbors tumor cells that interact with surrounding cells through the circulatory and lymphatic systems to influence the development and progression of cancer. The tumor microenvironment has conditions distinct from the normal cellular and extracellular environments found in non-cancerous tissue, blood or other parts of a normal body. It has been long appreciated that the extracellular milieu inside and surrounding the growing tumor mass is distinct and unique. One of the most profound physicochemical differences between the tumor microenvironment and normal cellular environment is an increase in lactic acid and an associated decrease in pH in the tumor microenvironment from the normal physiological pH of about 7.4 or higher.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">While the tumor is acidic, some of the most acidic regions of tumors can be observed at the edge of the tumors, just at the interface with the surrounding tissue or blood, according to a paper published in 2019 in the journal Cancer Research. In this study, pH low insertion peptide, or pHLIP, a peptide that is taken up by cells at a pH below 6.5, was injected into human tumor-bearing mice. While nearly all tumor cells took up this peptide, normal tissue cells did not take up this peptide except in the liver and kidney, which was expected in a pH-independent manner in order to be metabolized and excreted. As shown in the figure described below, certain regions within the tumor and in the cells at the edge of tumors took up some of the highest concentration of the probe, indicating that these areas had pH substantially lower than 6.5. These findings are important when considering the design of therapies for solid tumors because they point to the fact that while the overall tumor is acidic, the most accessible and rapidly growing portions of tumors are likely to have some of the lowest pHs.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Shown below is a tumor &#x201c;heat&#x201d; map identifying the tumor cells that are surrounded by an acid microenvironment. Exploiting the established ability of pHLIP to label the membrane of cells exclusively under acidic conditions (&#x2264; pH 6.5)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;"> in vivo</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">, the cells within the acidic areas of the tumor</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;"> in vivo</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> can be identified at the histological level. Mice harboring human breast tumor xenografts were administered Cy7-labeled, or dyed, pHLIP peptide and the tumor tissues were later removed and processed for imaging. Shown on the left is a micrograph of the tumor with the cell-based segmentation data overlayed, including positional information relative to tumor edge. The degree of positivity generated in the above analysis was used to identify a 0-3+ positive cells. Note that the acidic areas extend beyond the traditional hypoxic core of the tumor into the aerobic and oxygenated cells at the invasive fronts at the tumor&#x2013;stroma interface</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;"> in vivo</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">. Shown on the right is the breakdown of cancer cells types that are identified by pHLIP acidic cell staining</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;"> in vivo</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">. A majority of the cells identified are oxygenated and actively replicating tumor cells, and even the non-dividing cancers cells still maintain an acidic environment.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Tumor &#x201c;Heat&#x201d; Map</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img129881027_2.jpg" alt="img129881027_2.jpg" style="width:471px;height:236px;">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Tumors are highly acidic based on the uptake of pHLIP, a pH-sensitive probe. While the entire tumor is acidic, the lowest pH cells are observed in the replicating cells, which are glycolytic and often oxygenated,</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;"> i.e.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">, the Warburg Effect.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">7</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">One reason for the low pH in tumors compared to normal cells is that there are distinct differences in the metabolic processes found in normal and cancer cells. Normal cells generate the energy they need primarily through the oxygen-dependent process called oxidative phosphorylation. In comparison, cancer cells have switched their mechanism of energy production preferentially to the non-oxygen-dependent process known as glycolysis, even in the presence and availability of oxygen. This process switch was first described nearly a century ago and is the basis of modern tumor screening technologies. The dependence of a tumor cell on glycolysis results in the tumor cell metabolizing up to 200 times more glucose than a healthy cell and causing the secretion of significant levels of lactic acid into the tumor microenvironment. This inherent buildup of lactic acid in the tumor microenvironment has been shown to reduce immune cell function and modulate other defense mechanisms of the body, promoting tumor growth and tumor survival. The presence of lactic acid in the tumor microenvironment causes it to have a distinctly acidic pH of less than 6.8 and even lower at the tumor cell surface, a pH so low that it is rarely found in the body except in organs designed for low pH, such as the stomach, where antibodies in the blood do not access, and in special circumstances, such as cancer. In some cancers, the pH goes as low as 5.8, an extremely low level given the normal, slightly alkaline, pH in the body. The body's blood holds its pH within a tight range around a pH of 7.4, with normal tissue typically being even more alkaline, even in the non-cancerous regions of tissues afflicted with cancer.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">These pH differences provide a clear correlation between low pH and cancer, one that is borne out in the aforementioned experiments that measure the uptake by cells of the peptide pH tracer pHLIP. These cells are found to have high levels of lactate dehydrogenase, an enzyme that produces the sugar lactate,</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;"> i.e.,</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> lactic acid. Lactate production and secretion are well-known features of glycolysis. Similarly, there is a strong correlation between the uptake of pHLIP and the expression of markers of aggressive tumor growth such as Ki67.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Tumors not only have characteristically low pH, which assists them in reducing the body&#x2019;s immune defenses, along with acidity they also generate other aberrant conditions and secrete other chemicals and proteins into the tumor microenvironment that may stimulate tumor growth, promote the development of new blood vessels or angiogenesis, degrade surrounding tissues allowing the tumor to spread or metastasize or actively suppress detection and destruction by the immune system. In view of our preclinical studies and clinical trial results and the substantial supporting scientific literature, we believe that there is an opportunity to develop cancer therapies with improved selectivity for tumors by taking advantage of changes in pH, as do our initial product candidates, as well as in the conditions and levels of temperature, pressure and chemical composition in the tumor microenvironment.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Our CAB technology</font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Our CABs are based on our patented protein discovery and engineering technology. We invented, developed and refined this technology, which we believe selectively activates the binding of proteins and antibodies to targeted cells in the tumor microenvironment based on differences in local conditions such as pH, temperature, pressure or chemical composition compared to normal healthy tissue. We have shown that activity of our CAB biologics is reversible; not only are they active due to the low pH levels of the tumor microenvironment, but also, unlike prodrugs, they are reversibly inactive when they leave the tumor microenvironment and are in a normal physiological environment.</font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Our CAB technology capitalizes on the well-established Warburg Effect that through a glycolytic process leads to an acidic external tumor microenvironment. Extracellular pH levels in tumors have been measured to be as low as pH 5.8 compared to the tightly controlled, alkaline, pH7.4 of blood, with even higher pH in healthy tissues. Glycolytic metabolism is also the basis of the established PET scanning technology for detection of cancerous tumors. CAB proteins have increased binding activity as the pH in the microenvironment becomes acidic, while being inactive in normal physiological environments. We discovered a novel chemical switch mechanism that underpins this binding activity that involves physiological-occurring chemicals, such as bicarbonate and hydrogen sulfide. These molecules are negatively charged at physiological conditions and interact with positive charged areas on the protein surface. Under acidic conditions found in the tumor microenvironment, these charged molecules are neutralized by the H+ ions and released from the protein surface, uniquely allowing CAB antibodies to bind to their target and attack the tumor cell. We refer to this novel physiological mechanism, used for generating CABs, as Protein-associated Chemical Switch(es)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.03pt;font-family:Times New Roman;">TM</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> or PaCS</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.03pt;font-family:Times New Roman;">TM</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> mechanism. The ability to design conditionally active therapeutics with strong selectivity over narrower pH ranges using the PaCS mechanism, offers the opportunity to greatly enhance both the safety and potency of future therapies for solid tumors.</font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We have used and continue to leverage our patented CAB technology to screen antibody candidates for multiple characteristics. By doing so, we can evolve specific regions on the antibody that will only bind in response to environmental conditions, either enhancing or eliminating binding. Our CAB technology allows us to select antibodies that preferentially bind to the target under the conditions of interest, such as high local acidity (i.e. low pH). CAB antibodies have human or humanized antibody sequences, a characteristic that reduces the risk of immunogenicity compared to emerging technologies in the field, which is supported by both our preclinical and clinical data.</font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Our CAB antibodies have been designed to be active in the acidic, lower pH of the tumor microenvironment and inactive under the alkaline pH&#x2019;s of 7.4 and above found in normal physiological conditions. In a quantitative in vitro binding assay, we compared a CAB antibody and a non-CAB antibody that both bind to the target AXL with matched strength of binding to the target, or affinities, when measured at pH 6.0. As shown in the figure below, binding of the CAB antibody was highly sensitive to pH with binding becoming much weaker as it approached pH 7.0 and almost undetectable at a physiological pH of 7.4. In contrast, a non-CAB antibody to AXL showed indiscriminate and experimentally equivalent binding across the entire pH range tested, including at pH 7.4 of normal cells. Our CAB development process is capable of identifying CAB antibodies with a range of sensitivities to pH.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">8</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">pH-dependent binding of CAB AXL antibodies vs. non-CAB AXL antibodies</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img129881027_3.jpg" alt="img129881027_3.jpg" style="width:545px;height:262px;">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">CAB antibodies have pH-dependent binding. Traditional antibodies do not have pH-dependent binding in the pH range tested.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Low pH-dependent CAB antibodies are far less likely to bind to targets outside of tumors, resulting in a number of potential advantages over traditional antibodies:</font></p>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Wide therapeutic window.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> Reduced binding to target antigens outside of the tumor has the potential to reduce toxicities that arise from systemic exposure. We believe this may enable higher doses or increased potency to be safely delivered to patients with the potential for increased efficacy.</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Opportunity to increase tumor-specific killing.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> The wide therapeutic window imparted by tumor-specific targeting enables CAB antibodies to be modified with cytotoxic drugs to create ADCs. Similarly, bispecific antibodies can be developed using CAB antibody domains targeting pairs of targets that direct T cells to attack the tumor, which may exhibit unacceptable toxicities such as cytokine release syndrome and neurological toxicity if constructed using traditional antibody domains.</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Increased drug exposure to tumors.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> Limited binding to targets outside of tumors allows more of the administered CAB antibodies to be available to bind to target sites in the tumor, potentially increasing the concentrations and exposure of these antibodies in tumors.</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Improved pharmacokinetics.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> Limited binding to targets outside of tumors effectively increases their half-life in plasma. The phenomenon of TMDD is a well-known limitation facing the development of many biologics which CAB antibodies can significantly reduce.</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Broader universe of tumor-specific antigens that can be targeted.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> There are few highly prevalent tumor-specific antigens expressed on solid tumors that are not expressed at some level in normal tissues, particularly for solid tumors, which represent approximately 90% of tumor types. While some targets, such as EGFR, can be targeted by traditional antibodies with some acceptable level of toxicity in a subset of patients, many other potential targets cannot. CAB antibodies with pH-dependent binding have the potential to significantly reduce the potential risk of systemic toxicities caused by expression of targets on normal tissues.</font></div></div>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">An important emerging class of antibodies is ADCs. An ADC is a modified antibody that generally has a chemotherapy agent attached to the antibody to enable more targeted chemotherapy treatment of a tumor.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Unfortunately, ADCs frequently bind to targets on normal cells and can lead to severe toxicities. In order to evaluate the CAB technology&#x2019;s ability to eliminate the on-target, off-tumor toxicities, we generated two ADCs during our preclinical testing: one using a CAB antibody to AXL and another using a traditional non-CAB AXL antibody. Within three days of dosing non-human primates with the traditional non-CAB ADC, the levels of alanine aminotransferase, or ALT, a sign of liver toxicity, increased sharply. Dosing with the CAB ADC resulted in minimal increase in ALT, supporting that on-target, off-tumor toxicity is reduced with the CAB ADC.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We also observed that the plasma concentration and half-life of the CAB ADC were higher than that of the traditional non-CAB ADC. We demonstrated a dose dependency of this observation, which indicates that the primary driver of this absence of TMDD effect with CAB ADC is due to the reduced binding of the CAB ADC to AXL outside of the tumor microenvironment.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">9</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Our CAB technology was studied in robust Phase 1 clinical trials for our two leading clinical programs, which have shown the following:</font></p>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Objective antitumor responses</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">: We observed multiple confirmed partial clinical responses (at least 30% reduction in tumor size for at least two consecutive time points) in our Phase 1 data for both mecbotamab vedotin and ozuriftamab vedotin, including in one patient tumor volume shrinkage of more than 90% and another with a complete response (CR), and several patients who remain without tumor progression for more than one year.</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Antitumor activity correlates with a proprietary biomarker</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">: The presence of the relevant target on a high percentage of tumor cells appeared to correlate with increased antitumor activity.</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Safety and tolerability</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">: Mecbotamab vedotin and ozuriftamab vedotin were generally well-tolerated at the recommended Phase 2 dose range, which is positively differentiated from both preclinical and cross-trial trial results for a similar non-CAB ADC. Side- effects have been generally manageable with our CAB ADC product candidates, with some patients able to receive more than a year of treatment.</font></div></div>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Through the use of our proprietary technology, we have developed CAB antibodies, which we believe have specificity for tumors, while avoiding binding to the same antigen target expressed on many normal tissues. This allows us to develop therapeutics against targets that are expressed at high levels on tumors cells but are also present on normal cells and tissues, without the toxicities associated with traditional antibodies. While our lead product candidates primarily exploit the differences in pH between the tumor microenvironment and healthy tissue, there is a potential for other yet to be identified PaCS molecules in disease related microenvironments, whether controlled through pH, concentration, or other molecular characteristics (intra- or intermolecularly) for enhancing a drug&#x2019;s therapeutic index. Potential new therapeutic candidates addressing these opportunities are not limited to antibodies, but may also include small molecules, encompassing lipids, sugars and nucleic acid-based agents or drugs. Further, it is expected that PaCS protein-chemical systems are important naturally occurring regulatory systems linked to a range of disease-related microenvironments, including cancer, inflammation and cellular senescence.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Clinical trials</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Mecbotamab Vedotin (BA3011)</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Phase 1 clinical trial</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We have completed a Phase 1 trial of mecbotamab vedotin in patients with advanced solid tumors, including sarcoma, pancreatic cancer and NSCLC who were refractory or resistant to standard therapies. In the Phase 1 trial, a total of 60 patients, including 26 patients with sarcoma, were treated with doses of mecbotamab vedotin ranging from 0.3 mg/kg to 3 mg/kg once every three weeks (Q3W) or doses ranging from 1.2 mg/kg to 1.8 mg/kg twice every three weeks on days 1 and 8 (2Q3W). The Phase 1 sarcoma patients on average had received four or more prior lines of therapy. The solid tumor types enrolled in this study were: soft tissue sarcoma (22 subjects), pancreatic (12 subjects), NSCLC (4 subjects), colorectal (4 subjects), melanoma (3 subjects), bladder (2 subjects), endometrial (2 subjects), Ewing sarcoma (2 subjects), non-TNBC, osteosarcoma, chondrosarcoma, myoepithelial carcinoma, adenoid cystic carcinoma, small cell lung, renal cell carcinoma and mesothelioma of the pleura (1 subject each).<br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The main goals of this trial were to evaluate the safety, tolerability, antitumor activity, pharmacokinetics and immunogenicity of BA3011 in solid tumor patients. Based upon the overall safety and response rates, the recommended Phase 2 dose was determined to be 1.8 mg/kg delivered every two weeks (Q2W).<br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Antitumor activity</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We evaluated overall response (OR), one of our secondary endpoints, and observed five confirmed partial responses (a reduction of at least 30% in the size of the tumor), four in patients with sarcomas and one with NSCLC. These responses have been shown to be durable (8-15 months in sarcoma patients; duration of response, or DoR, is one of our secondary endpoints). Further, additional patients have experienced prolonged progression-free intervals, a period of time where the existing tumor did not measurably increase in size by more than 20% and no new tumors were known to develop. The toxicities observed were consistent with those described with MMAE-based ADCs and were well-tolerated at the exposure subsequently employed for Phase 2. Importantly we have not observed adverse events that appeared to be related to on-target injury of normal, AXL expressing tissues, i.e., on-target, off-tumor toxicity, consistent with the increase in tumor selectivity from the CAB technology.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="text-indent:4.08%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img129881027_4.jpg" alt="img129881027_4.jpg" style="width:528px;height:369px;">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Antitumor response over time by AXL expression for evaluable sarcoma patients enrolled in Phase 1 trial at all BA3011 doses tested</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;"> </font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We developed and validated, as required by CLIA (the Clinical Laboratory Improvement Amendments, or CLIA, which establishes federal quality standards for laboratory testing), an AXL immunohistochemical assay to quantify the level of target expression on the tumor membrane and cytoplasm. An independent board-certified pathologist scored all samples according to this TmPS scoring scheme determined by us during the clinical validation phase, as well as during the Phase 1 trial. <br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We observed that approximately 57% of sarcoma patients screened for enrollment had an AXL TmPS of 70% or above. In addition, we identified a correlation between the expression of AXL on the membrane of tumor cells and the observed antitumor clinical response as shown in the figure below. Four of seven sarcoma patients with a confirmed AXL TmPS of 70% or above who were dosed with 1.8 mg/kg of BA3011 Q3W or 2Q3W achieved a confirmed partial response.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">11</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img129881027_5.jpg" alt="img129881027_5.jpg" style="width:450px;height:358px;">&#160;</p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Change in sum of target lesions (best response) by AXL TmPS category for Phase 1 evaluable patients at all BA3011 doses tested</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Focusing on the subset of sarcoma patients who were dosed with 1.8 mg/kg Q3W or 2Q3W of BA3011 with TmPS of 70%, we observed a correlation of the AXL TmPS and antitumor response. As shown below, five out of six patients with multiple subtypes of sarcoma experienced reductions in tumor volume and four of these five patients achieved confirmed partial responses (observed response for at least two consecutive time points). We are confirming this observed correlation and the TmPS cut-off of 70% or more in our ongoing Phase 2 studies.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Best response for sarcoma patients with confirmed TmPS of 70% or above administered 1.8mg/kg Q3W or 2Q3W</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="margin-left:13.6%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img129881027_6.jpg" alt="img129881027_6.jpg" style="width:530px;height:426px;">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">12</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">One patient with leiomyosarcoma who had experienced failure of multiple prior treatments had a 37% reduction in tumor volume while receiving 1.8 mg/kg Q3W BA3011, as shown in the figure below. After over a year of treatment with BA3011, the residual tumor mass was reduced to a sufficient degree, enabling a successful surgical resection.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">CT scan of leiomyosarcoma patient after BA3011 treatment</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img129881027_7.jpg" alt="img129881027_7.jpg" style="width:479px;height:247px;">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">CT scan of a 70 mm leiomyosarcoma tumor which decreased in size with BA3011 treatment (confirmed PR) and after a year of therapy was removed by surgical resection.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Of the four patients with NSCLC enrolled in our Phase 1 clinical trial, two were AXL negative with a TmPS of 0%, one was not evaluable, and one was AXL positive with a TmPS of 80%. Prior to BA3011 treatment, the AXL positive patient with stage IV adenocarcinoma experienced failure from prior treatments, including treatment with a PD-1 inhibitor (pembrolizumab). As shown below, this patient experienced a partial response characterized by approximately 70% tumor shrinkage with BA3011 delivered at 1.8 mg/kg on days 1 and 8, every three weeks (2Q3W).</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">One of four NSCLC patients enrolled in Phase 1 BA3011 trial was the only patient with an AXL TmPS &gt;=70%.and had a partial response.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;"> </font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img129881027_8.jpg" alt="img129881027_8.jpg" style="width:443px;height:339px;">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">13</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:10.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Safety</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Mecbotamab vedotin was generally well-tolerated. We have not observed adverse events that appear to be related to on-target injury of normal, AXL-expressing tissues. We believe that toxicities observed at the maximally tolerated dose and lower were manageable and off-target effects of free MMAE were consistent with those described with other marketed MMAE-based ADCs. The estimated half-life of mecbotamab vedotin was approximately four days, which is twice the 1.9-day half-life reported for enapotamab vedotin, a non-CAB ADC targeting AXL. We believe this difference may be due to the decreased TMDD resulting from the lack of binding of mecbotamab vedotin to AXL outside of tumors.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">In the Phase 1 trial, the Grade 3 or greater adverse events, or AEs, or serious adverse events, or SAEs, deemed related to mecbotamab vedotin were consistent with MMAE-based toxicity and could generally be classified as either reversible myelosuppression (AEs: neutropenia and anemia), transient liver enzyme elevations (AEs: AST/ALT increased) or metabolic disturbances (AEs: hyponatremia, hypokalemia). There were 24 (37.5%) subjects who reported a serious TEAE (SAE), and in 7 (10.9%) of those subjects that serious TEAE was considered related to treatment.. At the anticipated Phase 2 exposure level (1.8mg/kg Q2W), BA3011 was generally well-tolerated. For 1.8 mg 1Q3W there were 2 subjects (22% ; 2/9) who experienced treatment related Grade 3-4 AEs (, vomiting and neutrophil count decrease);for 1.8 mg 2Q3W there were 13 subjects (52%;13/25) who experienced treatment related Grade 3-4 AEs ( neutropenia (x3), hypokalemia (x3), , anemia, nausea, febrile neutropenia, fatigue, lymphocyte count decrease, blood bilirubin increase and lipase increase)For 1.8mg/kg Q3W, there were 4 subjects who experienced an SAE (44%; neutrophil count decrease, intestinal obstruction, lower limb fracture, and sepsis caused by E. coli); for 1.8mg/kg 2Q3W there were11 subjects who experienced an SAE (44%; nausea, pyrexia, lipase increased, hyponatremia, syncope, corneal perforation, hypercalcaemia, gastritis, pneumonia, hepatic encephalopathy, and edema of lower extremities) and of these SAEs, fewer were deemed related to treatment by the investigator (for 1.8mg/kg Q3W: 1 SAE (11.1%; neutrophil count decrease); 1.8mg/kg 2Q3W: 3 SAEs (12%; hepatic encephalopathy, lipase increased and gastritis). For 1.8mg/kg 2Q3W, 2 related AEs led to treatment discontinuation (Grade 2 peripheral neuropathy and Grade 2 fatigue). No AEs led to treatment discontinuation for 1.8mg/kg Q3W.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Overview of adverse events in mecbotamab vedotin (BA3011) Phase 1 trial for patients administered 1.8mg/kg Q3W (d1) or 2Q3W (d1,8) (safety population)</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:95.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:61.465%;"></td>
    <td style="width:1.582%;"></td>
    <td style="width:0.605%;"></td>
    <td style="width:16.475%;"></td>
    <td style="width:0.605%;"></td>
    <td style="width:1.582%;"></td>
    <td style="width:0.605%;"></td>
    <td style="width:16.475%;"></td>
    <td style="width:0.605%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Characteristic</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">BA3011<br>1.8 mg/kg Q3W<br>(N=9)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">BA3011<br>1.8 mg/kg 2Q3W<br>(N=25)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Any AEs</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">9 (100%)</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">25 (100%)</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Related AEs with CTCAE1 Grade 3 or 4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.221pt;white-space:pre-wrap;font-weight:normal;font-size:6.03pt;font-family:Times New Roman;position:relative;">2</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">2 (22%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">13 (52%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Any related serious AEs</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.221pt;white-space:pre-wrap;font-weight:normal;font-size:6.03pt;font-family:Times New Roman;position:relative;">2</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1 (11%)</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">3 (12%)</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">AEs leading to death</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1 (11%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">0</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Related AEs leading to death</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.221pt;white-space:pre-wrap;font-weight:normal;font-size:6.03pt;font-family:Times New Roman;position:relative;">2</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">0</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">0</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Related AEs leading to treatment discontinuation</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.221pt;white-space:pre-wrap;font-weight:normal;font-size:6.03pt;font-family:Times New Roman;position:relative;">2</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">0</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">2 (8%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;display:inline-flex;font-size:8.5pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">CTCAE: Common Terminology Criteria for Adverse Events. The NCI Common Terminology Criteria for Adverse Events is a descriptive terminology which is utilized for AE reporting. A grading (severity) scale is provided for each AE term.</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;display:inline-flex;font-size:8.5pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">As assessed by the investigator. Missing responses are counted as related.</font></div></div>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We believe that our CAB AXL ADC, mecbotamab vedotin, compares favorably to enapotamab vedotin, a non-CAB AXL ADC with regard to safety and key pharmacokinetic properties. Comparing across the two Phase 1 trials, both ADCs: (i) were designed to deliver 4 MMAE molecules per antibody (DAR4 loading), (ii) employed similar ADC doses and (iii) enrolled comparable patients with advanced cancer who had experienced treatment failure of prior regimens (see figure below). As a key difference, mecbotamab vedotin was designed to only bind to the AXL target expressed by tumor while enapotamab vedotin would be anticipated to bind to the AXL target throughout the body.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Notably, the estimated half-life of mecbotamab vedotin was approximately four days, which is twice the 1.9-day half-life reported for enapotamab vedotin. We believe this difference may be due to the decreased TMDD resulting from the lack of binding of mecbotamab vedotin to AXL outside of tumors. With respect to reported toxicity comparisons, constipation is believed to be an on-target delivery of MMAE to normal gut tissues that express the AXL target. Despite including a risk mitigation plan in enapotamab vedotin&#x2019;s trial protocol (a prophylactic stool-softener medication in all patients), the clinical data presented at ASCO 2019 showed that AEs of constipation Grade 1-2 were reported in 49% of the patients and Grade 3-4 in 9% of patients. The rate of constipation reported with mecbotamab vedotin (26% Grade 1-2 and 43% Grade 3-4) was approximately 2 or 3-fold lower for Grade 1-2 and Grade 3-4 TAEs, respectively. We believe the lower observed rates of constipation observed among the mecbotamab vedotin treated patients were typical for an advanced cancer population who commonly receive pain medications that can also cause constipation. While supportive of a reduced toxicity benefit from CAB technology, these comparisons are derived from cross-trial analyses, and would not be included as part of our labeling.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Adverse events, such as peripheral neuropathy, are commonly seen with other ADCs and may be due to free circulating MMAE. Clinical data presented at ASCO 2019 for enapotamab vedotin showed that 38% of the patients had peripheral neuropathy (all Grades) with 2 patients reporting Grade 3-4 AEs. The rate of peripheral neuropathy (all Grade; no Grade 3-4) reported for mecbotamab vedotin (28%) was meaningfully lower than the rate reported with enapotamab vedotin and is believed to be due to the advantageous pharmacokinetic characteristics of a CAB ADC vs. a non-CAB ADC.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">14</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">At a dose of 2.4 mg/kg Q3W mecbotamab vedotin, two patients experienced dose-limiting toxicities: one with Grade 3 febrile neutropenia and the other with Grade 4 hyperglycemia. Dosing continued at the 2.4 mg/kg with prophylactic administration of pegfilgrastim without any additional dose limiting toxicities. Dosing above 2.4 mg/kg was terminated due to one patient who experienced Grade 4 febrile neutropenia and cardio-respiratory arrest at 3 mg/kg likely related to delayed hepatic and renal excretion of MMAE.</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img129881027_9.jpg" alt="img129881027_9.jpg" style="width:542px;height:303px;">&#160;</p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:10.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Phase 2 clinical trial</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We are conducting a Phase 2, potentially registration-enabling trial with mecbotamab vedotin, enrolling 90 soft-tissue and bone sarcoma patients, with interim analysis anticipated in early 2022 and the complete data set expected in 2023. In addition, we have initiated a Phase 2 trial in NSCLC with mecbotamab vedotin as monotherapy and in combination with an anti-PD-1 agent in patients who have experienced prior disease progression on a PD-1/L1 inhibitor and have a TmPS of 1% or greater. The FDA has reviewed the trial designs, but has not opined on whether Phase 2 clinical trials will be sufficient to support regulatory approval. However, we intend to ask the FDA to consider this further at the planned interim data review point or points for each clinical trial. We cannot assure you that the FDA will agree that such data will be sufficient to support approval. A summary of our clinical development plan for mecbotamab vedotin is below.<br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Additionally, a multi-center investigator-initiated trial of mecbotamab vedotin led by the Canadian Cancer Trials Group, or CCTG, in platinum-resistant ovarian cancer patients has begun enrollment.<br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Clinical development plan for mecbotamab vedotin (BA3011), which includes multiple Phase 2 trials</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img129881027_10.jpg" alt="img129881027_10.jpg" style="width:516px;height:280px;">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">15</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Sarcoma Phase 2 trial:</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">This Phase 2 trial is an open-label trial to evaluate the efficacy and safety of mecbotamab vedotin alone and in combination with an anti-PD-1 agent in adult and adolescent patients with AXL-expressing TmPS &gt;= 70%, and advanced, refractory sarcoma who have measurable disease by RECIST Version 1.1 criteria and have documented progression according to RECIST Version 1.1 criteria within the six months prior to enrollment. In addition, there is an exploratory cohort of patients with AXL-expressing TmPS of 50-69%. To enroll, patients either had to be ineligible for chemotherapy or had received at least one regimen containing anthracycline and a maximum of three previous lines of systemic therapy for metastatic disease (no more than two lines of combination regimens), including pazopanib, trabectedin, eribulin mesylate or tazemetostat, if applicable, per regional prescribing information. Patients who met the enrollment criteria were assigned to receive either mecbotamab vedotin alone or in combination with an anti-PD-1 agent (for patients 18 years old and above: 240 mg every two weeks (Q2W); for patients 12-17 years old: 3 mg/kg Q2W IV infusion). Patients with tumors showing B-cell infiltration (per immunohistochemistry, or IHC, assay) are preferentially assigned to receive mecbotamab vedotin in combination with an anti-PD-1 agent. Based on data from the Phase 1 part of the trial, the dose of mecbotamab vedotin for Phase 2 is 1.8 mg/kg Q2W.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">In Part 1 of this Phase 2 trial, seven cohorts of approximately 10 patients per sarcoma subtype in the monotherapy arm are enrolled:</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Soft tissue sarcoma:</font></p>
  <div style="margin-left:11.333%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.116898056774223%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Leiomyosarcoma</font></div></div>
  <div style="margin-left:11.333%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.116898056774223%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Synovial sarcoma</font></div></div>
  <div style="margin-left:11.333%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.116898056774223%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Liposarcoma</font></div></div>
  <div style="margin-left:11.333%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.116898056774223%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">All other soft tissue sarcomas, except gastro intestinal stromal tumors, dermatofibrosarcoma protuberans, inflammatory myofibroblastic tumor and malignant mesothelioma</font></div></div>
  <p style="margin-left:6.387%;text-indent:0.0%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Bone sarcoma</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">:</font></p>
  <div style="margin-left:11.333%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.116898056774223%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Osteosarcoma</font></div></div>
  <div style="margin-left:11.333%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.116898056774223%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Ewing sarcoma</font></div></div>
  <div style="margin-left:11.333%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.116898056774223%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Other bone sarcomas, including undifferentiated pleomorphic sarcoma, malignant fibrous histiocytoma, and chondrosarcoma</font></div></div>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">In addition, two combination cohorts (mecbotamab vedotin with an anti-PD-1 agent) are enrolling up to approximately 10 patients each, of any sarcoma subtype. Patients in one arm will have a tumor showing B-cell infiltration and patients in the other arm will not.<br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Tumor assessment occurs approximately every 6 weeks from cycle 1 day 1 of treatment, or C1D1, until 12 weeks, and every 8 weeks thereafter. Pharmacokinetic, pharmacodynamic, immunogenicity and biomarker assessments will also be performed at various time points.<br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">An interim analysis is conducted for each subtype or treatment after approximately 10 patients in the subtype or treatment have been followed for at least 12 weeks after the initiation of treatment. Following interim analysis, accrual to the subtype or to a treatment (i.e., mecbotamab vedotin alone or in combination with an anti-PD-1 agent) may proceed to Part 2 of the trial if one or more patients with a response (i.e., confirmed or unconfirmed complete response or partial response) or progression-free rate at 12 weeks is &gt;= 40%. Several cohorts already have qualified to proceed to this Part 2 of the trial.  Approximately 150 additional patients may be enrolled for sarcoma subtypes that meet the threshold. The accrual of patients to a specific subtype or to one or both treatment regimen(s) (i.e., mecbotamab vedotin alone and/or mecbotamab vedotin in combination with an anti-PD-1 agent) can be put on hold at any time based on evaluation of available data or by the Independent Data Monitoring Committee, or IDMC, at any time upon review of safety data. Treatment for all enrolled patients will continue until disease progression, unacceptable toxicity, or other reason for treatment discontinuation.<br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">16</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">NSCLC Phase 2 trial:</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">This is a multi-center, open-label, Phase 2 study designed to evaluate the efficacy and safety of mecbotamab vedotin alone and in combination with an anti-PD-1 agent in patients with AXL-expressing TmPS &gt;=1%, metastatic NSCLC who have measurable disease by RECIST v1.1 criteria and have documented progression according to RECIST v1.1 criteria within the 6 months prior to enrollment. To enroll, patients must have prior disease progression on a PD-1/L-1 inhibitor (either monotherapy or in combination with another therapy such as ipilimumab). Patients with EGFR or anaplastic lymphoma kinase (ALK) genomic tumor aberrations should have had disease progression on FDA-approved therapy for these aberrations.<br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Patients who meet enrollment criteria will be assigned to receive either mecbotamab vedotin alone or in combination with an anti-PD-1 agent (240 mg every 2 weeks (Q2W)). For the first 20 patients (Part 1), treatment assignment will be determined by the sponsor and the medical monitor based on the patient&#x2019;s prior experience with PD-1/L1 treatment. To be eligible for the PD-1 combination arm, patients must have acceptably tolerated prior PD-1/L1 treatment. In Part 2, up to approximately 200 additional patients may be enrolled depending on observed efficacy at interim analysis. If both monotherapy and combination therapy are further pursued post interim analysis, patients that have acceptably tolerated prior PD-1/L1 treatment will be randomized 1:1 to receive either mecbotamab vedotin alone or mecbotamab vedotin in combination with an anti-PD-1 agent. Randomization will be stratified according to histology (squamous vs. non-squamous) and the number of prior systemic regimens (&lt; 2 vs. &lt; 3). Patients that have not acceptably tolerated prior PD-1/L1 treatment will be assigned to the mecbotamab vedotin monotherapy arm of the study. Based on data from the Phase 1 study, the dose of mecbotamab vedotin for Phase 2 is 1.8 mg/kg Q2W. A dose reduction to 1.5 mg/kg Q2W may be implemented if deemed warranted by the IDMC.<br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Tumor assessment will occur approximately every 6 weeks from C1D1 until 12 weeks, and every 8 weeks thereafter. Pharmacokinetic, pharmacodynamic, immunogenicity and biomarker assessments will be performed at various time points.<br></font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">An interim analysis will be conducted after approximately 20 patients (e.g. 10 patients on mecbotamab vedotin monotherapy arm and 10 patients in the mecbotamab vedotin and anti-PD-1 agent combination arm) have the potential to be followed for at least 12 weeks after the initiation of investigational product. Following interim analysis, accrual to a treatment (i.e., mecbotamab vedotin alone or in combination with an anti-PD-1 agent) may be put on hold if the number of patients with a response (i.e., confirmed or unconfirmed complete response, partial response or stable disease) are below a pre-defined threshold. Depending on observed efficacy at the interim analysis, additional NSCLC patients may be enrolled for a total of up to approximately 200 patients (100 patients in each of the 2 treatment groups) with AXL-expressing, metastatic NSCLC. The accrual of patients to one or both treatment regimen(s) (i.e., mecbotamab vedotin alone and/or mecbotamab vedotin in combination with an anti-PD-1 agent) can be put on hold at any time based on evaluation of available data. Treatment for all enrolled patients will continue until disease progression, unacceptable toxicity, or other reason for treatment discontinuation. <br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Ozuriftamab Vedotin (BA3021)</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Phase 1 clinical trial</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We have completed the dose escalation part of a Phase 1 clinical trial of ozuriftamab vedotin in patients with locally advanced unresectable or metastatic solid tumors including NSCLC and melanoma, who were refractory or resistant to standard therapies. As shown below, cohorts were treated with doses of ozuriftamab vedotin ranging from 0.3 mg/kg to 3.3 mg/kg once every three weeks (Q3W) or doses ranging from 1.5 mg/kg to 1.8 mg/kg twice every three weeks on days 1 and 8 (2Q3W). In Phase 1, 60 subjects were enrolled into 9 dose cohorts: 0.3 mg/kg Q3W (1 subject), 0.6 mg/kg Q3W (1 subject), 1.2 mg/kg Q3W (1 subject), 1.8 mg/kg Q3W (3 subjects), 2.4 mg/kg Q3W (16 subjects), 3.0 mg/kg Q3W (19 subject), 3.3 mg/kg Q3W (5 subjects), 1.2 mg/kg 2Q3W (3 subjects), 1.5 mg/kg 2Q3W (3 subjects), and 1.8 mg/kg 2Q3W (8 subjects). The solid tumor types enrolled in this study were: soft tissue sarcoma (40 subjects), NSCLC (6 subjects), melanoma (2 subjects), pancreatic (2 subjects), non-TNBC (2 subjects), TNBC (2 subjects), colorectal, GIST, urachus, ampulla of vatter, rectal carcinoid and head and neck (1 subject each).</font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The main goal of this trial was to evaluate the safety, tolerability, antitumor activity, pharmacokinetic and immunogenicity of ozuriftamab vedotin in solid tumor patients. Based upon the overall safety and response rates, the recommended Phase 2 dose is 1.8 mg/kg delivered every two weeks (Q2W). The trial&#x2019;s objectives were the following:</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Primary</font></p>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">To define the safety profile, including DLT, and determine the MTD and/or RP2D and other safety parameters for ozuriftamab vedotin in patients with advanced solid tumors.</font></div></div>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:10.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Secondary</font></p>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">To assess antitumor activity of ozuriftamab vedotin including endpoints such as OR, DoR, disease control, time-to-response, and ORR, according to RECIST Version 1.1.</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">To assess the pharmacokinetics of ozuriftamab vedotin.</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">To evaluate the immunogenicity of ozuriftamab vedotin.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">17</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Antitumor activity</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We evaluated OR, one of our secondary endpoints, as shown in the figure below. At various dose levels, treatment with ozuriftamab vedotin has resulted in a complete response in one patient with metastatic melanoma. This patient remains progression free more than two years after initiating therapy. In addition, two patients with NSCLC (~31% and ~49% tumor reduction) and one patient with advanced head and neck cancer (~54% tumor reduction) were partial responses.</font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Of the six NSCLC patients enrolled in the dose escalation phase, two patients achieved a durable partial response (duration of response is one of our secondary endpoints) and a third experienced tumor reduction to a lesser degree (change from baseline in tumor size is one of our secondary endpoints, as shown below). Similar to the observed correlation of antitumor activity with higher levels of tumoral membrane AXL expression, as shown below, the two NSCLC patients with partial responses to ozuriftamab vedotin had ROR2 TmPS of at least 70%. We were not able to characterize ROR2 TmPS for the third patient who also experienced tumor shrinkage. Another patient with late stage NSCLC and bone metastases and a ROR2 TmPS of 100%, treated with a suboptimal dose of ozuriftamab vedotin (1.2mg/kg 2Q3W), experienced tumor shrinkage prior to progression of their metastatic bone lesions. All NSCLC patients who enrolled in this trial had previously been treated with PD-1 therapy.</font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img129881027_11.jpg" alt="img129881027_11.jpg" style="width:445px;height:365px;">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">NSCLC patients enrolled in ozuriftamab vedotin (BA3021) Phase 1 trial by ROR2 TmPS. Tumor membrane ROR2 expression was associated with antitumor response in two of the five NSCLC patients with evaluable ROR2 TmPS</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Two metastatic melanoma patients were enrolled in the initial part of the trial, as shown below. The ROR2 positive patient achieved a significant durable partial response (duration of response is one of our secondary endpoints). Furthermore, this patient, who had previously experienced failure of both nivolumab and nivolumab plus ipilimumab, achieved complete response and remains without disease progression more than two years after initiating ozuriftamab vedotin.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">18</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">All evaluable metastatic melanoma patients enrolled in ozuriftamab vedotin (BA3021) Phase 1 trial by ROR2 TmPS</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img129881027_12.jpg" alt="img129881027_12.jpg" style="width:634px;height:267px;">&#160;</p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The metastatic melanoma patient who achieved a complete response experienced clearance of metastatic lung lesions. Illustrated below is one of the two lung lesions that cleared. Moreover, a pretreatment biopsy of an involved, abnormally enlarged cervical lymph node showed active melanoma. Subsequently, an on-treatment biopsy of the same node demonstrated no evidence of melanoma.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Clearance of lung lesions in metastatic melanoma patient who received ozuriftamab vedotin (BA3021)</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img129881027_13.jpg" alt="img129881027_13.jpg" style="width:539px;height:210px;">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Pre-treatment and post-treatment CT scans of one of two lung lesions that were both cleared in a metastatic melanoma patient who received ozuriftamab vedotin (BA3021)</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">In addition, one head and neck cancer patient achieved a partial response with a 54% reduction in tumor size.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Safety</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Similar to mecbotamab vedotin, ozuriftamab vedotin was generally well-tolerated. We have not observed adverse events that appear to be related to on-target injury of normal, ROR2-expressing tissues. We believe that reported toxicities were consistent with off-target effects of free MMAE consistent with those described with other marketed MMAE-based ADCs.</font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">In the Phase 1 trial, the Grade 3 or greater AEs or SAEs deemed related to ozuriftamab vedotin were consistent with MMAE-based toxicity and could generally be classified as either reversible myelosuppression (AEs: neutropenia, anemia), transient liver enzyme elevations (AEs: AST/ALT increased) or metabolic disturbances (AEs: hyponatremia, hypokalemia). There were a total of 24 (40%) patients who experienced an SAE, 12 (20%) of which were serious TEAEs that were considered related to treatment. At the Phase 2 exposure levels (1.8mg/kg Q2W), ozuriftamab vedotin was generally well tolerated. For 1.8 mg 1Q3W33.3% (1/3) of subjects experienced treatment-related Grade 3-4 AEs (anemia) and 0% had an SAEs (0); for 1.8 mg 2Q3W:62% (5/8)  of subjects experienced treatment-related Grade 3-4 AEs (fatigue, hyponatremia, multiorgan failure, peripheral neuropathy and hyperglycemia) and 50% experienced an SAEs (4/8%; infected biloma, pyrexia, multiorgan failure and hyperglycemia). Three of these SAEs, were deemed related to treatment by the investigator (37.5%; pyrexia, multiorgan failure and hyperglycemia). For 1.8mg/kg 2Q3W, one subject (12.5%) experienced a TEAE that led to death and was considered potentially related to study treatment.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">19</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The subject  was a 47-year-old female with a history of metastatic TNBC previously treated with bilateral mastectomy, radiotherapy, doxorubicin + cyclophosphamide + paclitaxel, capecitabine, nab-paclitaxel, atezolizumab, and sacituzumab govitecan. According to the investigator, no clear etiology of the subject&#x2019;s signs and symptoms was identified. The investigator was unable to identify another clear-cut cause of the subject&#x2019;s medical deterioration; however, as these events were temporally following her infusion of study drug, the investigator was unable to rule out that the events were not related. Given the widespread metastatic tumor and that the measured free MMAE levels were within the range observed in other patients treated at the same dose level, the Investigator could not conclude these events were definitely related to the study drug.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">  </font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">For 1.8mg/kg Q3W, none of the related AEs or SAEs led to treatment discontinuation. For 1.8mg/kg 2Q3W, one (12.5%) of the related AEs or SAEs (multiorgan failure) led to treatment discontinuation.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Overview of adverse events in ozuriftamab vedotin (BA3021) Phase 1 trial for patients administered 1.8mg/kg Q3W (d1) or 2Q3W (d1,8) (safety population)</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:95.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:61.309%;"></td>
    <td style="width:1.582%;"></td>
    <td style="width:0.586%;"></td>
    <td style="width:16.699%;"></td>
    <td style="width:0.586%;"></td>
    <td style="width:1.582%;"></td>
    <td style="width:17.656%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Characteristic</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">BA3021<br>1.8 mg/kg (Q3W)<br>(N=3)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">BA3021<br>1.8 mg/kg (2Q3W)<br>(N=8)</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Any AEs</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">3 (100%)</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">8 (100%)</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Related AEs with CTCAE Grade 3 or 4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.221pt;white-space:pre-wrap;font-weight:normal;font-size:6.03pt;font-family:Times New Roman;position:relative;">1</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1 (33%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">5 (62%)</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Any related serious AEs</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.221pt;white-space:pre-wrap;font-weight:normal;font-size:6.03pt;font-family:Times New Roman;position:relative;">1</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">0</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">3 (37.5%)</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Related AEs leading to death</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.221pt;white-space:pre-wrap;font-weight:normal;font-size:6.03pt;font-family:Times New Roman;position:relative;">1</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">0</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1 (12.5%)</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Related AEs leading to treatment discontinuation</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.221pt;white-space:pre-wrap;font-weight:normal;font-size:6.03pt;font-family:Times New Roman;position:relative;">1</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">0</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1 (12.5%)</font></p></td>
   </tr>
  </table>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">As assessed by the investigator. Missing responses are counted as related.</font></div></div>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">At a dose of 3mg/kg Q3W, two patients experienced dose-limiting toxicities: one with Grade 3 dyspnea (self-resolved without intervention) and the other with Grade 4 febrile neutropenia (in a subject that did not receive prophylactic pegfilgrastim as directed) which resolved on day 2 of hospitalization.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Clinical development plans</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We are conducting a potentially registration-enabling Phase 2 trial for ozuriftamab vedotin monotherapy or in combination with a PD-1 inhibitor in melanoma and NSCLC patients that have experienced prior disease progression on a PD1/L1 inhibitor and have a ROR2 TmPS of 1% or more. However, we have not discussed with the FDA whether the Phase 2 clinical trials will be sufficient to support regulatory approval and we cannot assure you that the FDA will agree that such data will be sufficient to support approval. We intend to perform an interim analysis when up to approximately 20 evaluable patients in each indication have the potential to be followed for at least 12 weeks, which we expect to occur in the second half of 2022. Results from these analyses will drive the decision to expand enrollment in each indication to up to 200 patients, and we expect final data in 2024.</font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We have initiated a Phase 2 clinical trial for ozuriftamab vedotin in head and neck squamous cell carcinoma (SCCHN). In the dose escalation part of the ozuriftamab vedotin Phase 2 trial, we observed a partial response (PR) in one ROR2 positive SCCHN patient (TmPS=16%) who was refractory to four prior lines of therapy including treatment with cetuximab and pembrolizumab. The Phase 2 trial studying SCCHN will enroll 40 patients who had experienced prior failure of PD-1 therapy. Dosing in the first half of 2022, the patients will receive ozuriftamab vedotin monotherapy. Additionally, a multi-center investigator-initiated trial of ozuriftamab vedotin led by CCTG in platinum-resistant ovarian cancer patients has begun enrollment.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">20</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Phase 2 clinical development plan for ozuriftamab vedotin (BA3021) for multiple indications</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img129881027_14.jpg" alt="img129881027_14.jpg" style="width:610px;height:266px;">&#160;</p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">NSCLC and Melanoma Phase 2 trial</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">This Phase 2 trial is an open-label trial to evaluate the efficacy and safety of ozuriftamab vedotin alone and in combination with an anti-PD-1 agent in patients with ROR2-expressing (TmPS &gt;1%) and metastatic NSCLC or melanoma who have measurable disease by RECIST Version 1.1 criteria and have documented progression according to RECIST v1.1 criteria within the 6 months prior to enrollment.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Enrolled patients are assigned to receive either ozuriftamab vedotin alone or in combination with an anti-PD-1 agent (240 mg every 2 weeks (Q2W)). For the first 20 patients (10 patients in each of the 2 indications) (Part 1), treatment assignment is determined by the sponsor and the medical monitor based on the patient&#x2019;s prior experience with PD-1/L1 treatment. To be eligible for the PD-1 combination arm, patients must have acceptably tolerated prior PD-1/L1 treatment. In Part 2, up to approximately 200 additional patients per indication may be enrolled depending on observed efficacy at interim analysis. For each indication, if both monotherapy and combination therapy are further pursued post interim analysis, patients that have acceptably tolerated prior PD-1/L1 treatment will be randomized 1:1 to receive either ozuriftamab vedotin alone or ozuriftamab vedotin in combination with an anti-PD-1 agent. For the NSCLC indication, randomization will be stratified according to histology (squamous vs. non-squamous) and the number of prior systemic regimens (&lt; 2 vs. &lt; 3). For the melanoma indication, randomization will be stratified according to Eastern Cooperative Oncology Group performance status 0 vs. 1 and the number of prior systemic regimens (&lt; 2 vs. &lt; 3). For both indications, patients that have not acceptably tolerated prior PD-1/L1 treatment will be assigned to the ozuriftamab vedotin monotherapy arm of the study. Based on data from the Phase 1 part of the study, the dose of ozuriftamab vedotin for Phase 2 is 1.8 mg/kg Q2W. A dose reduction to 1.5 mg/kg Q2W may be implemented if deemed warranted by the IDMC.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Tumor assessment will occur approximately every 6 weeks from C1D1 until 12 weeks, and every 8 weeks thereafter. Pharmacokinetic, pharmacodynamic, immunogenicity and biomarker assessments will be performed at various time points.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">For each indication, an interim analysis will be conducted after up to approximately 20 patients (</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">e.g.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10 patients in each treatment group) have the potential to be followed for at least 12 weeks after the initiation of investigational product. Following interim analysis, accrual to a treatment (i.e., ozuriftamab vedotin alone or in combination with an anti-PD-1 agent) may be put on hold if the number of patients with a response (i.e., confirmed or unconfirmed complete response or partial response) are below a pre-defined threshold. Depending on observed efficacy at the interim analysis, additional NSCLC and/or melanoma patients may be enrolled for a total of up to approximately 200 patients (100 patients in each of the 2 treatment groups) with ROR2-expressing, metastatic NSCLC and a total of up to approximately 200 patients with ROR2-expressing, metastatic melanoma. The accrual of patients to a treatment regimen(s) (i.e., ozuriftamab vedotin alone and/or ozuriftamab vedotin in combination with an anti-PD-1 agent) can be put on hold by the sponsor at any time based on evaluation of available data or by the IDMC at any time upon review of safety data. Treatment for all enrolled patients will continue until disease progression, unacceptable toxicity or other reason for treatment discontinuation.</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">BA3071</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Preclinical studies</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">In a mouse colon adenocarcinoma, or MC38, xenograft model in which the human CTLA-4 gene had been introduced, we found that BA3071 had similar antitumor efficacy as a traditional anti-CTLA-4 antibody that is an analog of ipilimumab, or an Ipi-analog. As shown below, BA3071 led to equivalent tumor regression to ipilimumab out of eight treated mice and in two instances we saw a complete response, or no detectable tumor remaining.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">21</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Efficacy in human CTLA-4 engineered mouse model</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img129881027_15.jpg" alt="img129881027_15.jpg" style="width:268px;height:189px;">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">BA3071 had potent antitumor activity and led to two complete responses in an MC38 tumor cell line model in mice containing the human CTLA-4 gene.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">As shown below, examination of the immune cell composition of treated tumors found that those treated with BA3071 antibodies had increased numbers of CD8 T cells than IgG control mice. CD8 T cells are effector cells that mediate tumor cell killing. These levels were similar to those observed in tumors treated with the ipilimumab analog.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Tumor infiltrating lymphocytes of human CTLA-4 engineered mice</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img129881027_16.jpg" alt="img129881027_16.jpg" style="width:201px;height:195px;">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">BA3071 functioned similar to ipilimumab in stimulating CD8 T cells in tumors</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">In contrast, BA3071 antibodies did not lead to changes in the T cell subsets in peripheral blood, as set forth in the figure below. The percentage of CD4 effector cells in CAB-treated mice were similar to those observed with the controls. The percentage of CD4 effector cells in ipilimumab analog-treated mice more than doubled, consistent with systemic inhibition of the CTLA-4 checkpoint. We believe that the observed tumor-restricted activity of BA3071 will be associated with fewer systemic target-based toxicities.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">22</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Normal peripheral blood lymphocytes of human CTLA-4 engineered mice</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img129881027_17.jpg" alt="img129881027_17.jpg" style="width:224px;height:185px;">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Unlike the ipilimumab analog, BA3071 did not lead to stimulation of T cells in peripheral blood</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Safety</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Our preclinical toxicity study of BA3071 in non-human primates compares its safety profile to that of ipilimumab. Specifically, as shown in the figure below, we examined the gastrointestinal toxicities associated with combination therapy with nivolumab. To examine toxicities, these animals were dosed with high levels of both agents. Dosing of non-human primates with BA3071 in combination with nivolumab was associated with fewer occurrences of events associated with gastrointestinal toxicity than the combination of ipilimumab and nivolumab. These animals received 20 mg/kg nivolumab, which represents 12 times the human dose, and either 15 mg/kg of ipilimumab or 15 mg/kg of BA3071, which we estimate is 45 to 60 times the current human dose. There were 33 gastrointestinal events such as liquid feces, non-formed feces and other gastrointestinal symptoms in the ipilimumab plus nivolumab combination across 29 days and five animals. There was only a single case of liquid feces in one animal on one day in the BA3071 plus nivolumab treatment group.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Toxicity study of BA3071 comparing its safety profile to ipilimumab</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img129881027_18.jpg" alt="img129881027_18.jpg" style="width:623px;height:331px;">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Treatment of non-human primates with a combination of BA3071 and nivolumab resulted in fewer gastrointestinal adverse events than treatment with ipilimumab and nivolumab.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">These results were consistent with the preclinical results shown two and three figures above that demonstrated that CAB anti-CTLA-4 antibodies had insignificant target-based activity outside of tumors. We believe that this non-human primate study provides support for assessing the safety and tolerability of BA3071 in clinical trials. We anticipate that BA3071 will have a wider therapeutic window than ipilimumab, which may enable it to be better tolerated when used in combination with an anti-PD-1 antibody with the potential to further increase efficacy by allowing administration of higher doses and longer duration of treatment.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">23</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Clinical Development Plans</font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We initiated a Phase 1 dose-escalation trial of BA3071 in advanced solid tumor patients in 2021 and expect our first enrolled patient in the first half of 2022. We expect this trial will examine the safety and tolerability of BA3071 at doses ranging from 7mg Q3W to 700mg Q3W (equivalent to 10mg/kg of ipilimumab) as monotherapy and in combination with an anti-PD-1 antibody.</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">BA3361: CAB-Nectin-4-ADC</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">  </font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">	Nectin-4 is widely expressed and has adhesive roles in normal tissues.  The CAB selectivity to target Nectin-4 in the tumor microenvironment is critical in providing the necessary safety to deliver the drug conjugate selectively to cancerous tissue. A clinical candidate was selected from a set of lead molecules that were characterized by multiple assays including functional assays.  In addition to the assay performance, the lead candidate demonstrated high binding under tumor conditions and little to no binding under normal physiological conditions. The candidate is in cell line development and a new, highly stable linker was successfully tested in vitro and in vivo.</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">BA3151: CAB-B7-H4-ADC</font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">B7-H4 is highly expressed on numerous tumor tissues and the expression level directly correlates with adverse clinical and pathological features. A set of lead molecules were characterized in vitro including functional assays and in vivo efficacy models. Selection of the lead candidate was based on criteria including high binding activity under tumor conditions and low binding activity under normal physiological conditions.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Bispecific candidates</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">BA3182: EpCAM x CD3</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We have developed and conducted preclinical studies of an EpCAM x CD3 bispecific candidate, BA3182, with an EpCAM binding domain and a CD3 binding domain , both binding domains with CAB activity (Dual-CAB). Dosage was 1mg per kilogram twice per week in mice, which is roughly equivalent to 0.25 mg per kilogram in non-human primates. As shown below, we found this construct had a potent antitumor activity in a HCT116, a human colorectal carcinoma cell line, xenograft model in mice with a humanized immune system.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><br><br></font><img src="img129881027_19.jpg" alt="img129881027_19.jpg" style="width:425px;height:278px;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2003;</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Safety</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">While there was no observable difference in antitumor efficacy between antibodies with CAB domains and those with conventional non-CAB antigen-binding domains, a conventional EpCAM x CD3 bispecific antibody led to a much higher level of undesirable systemic immune activation than the CAB EpCAM x CAB CD3 bispecific antibody in non-human primates.</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">BA3142: B7-H3 x CD3</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Our second bispecific product candidate, BA3142, is a dual-CAB T-cell engager targeting B7-H3, a protein expressed on many solid tumors. The lead molecule was characterized by multiple assays including functional assays, and by efficacy studies in a xenograft model of human pharyngeal cancer using mice with a humanized immune system. The lead molecule showed antitumor activity comparable to a non-CAB antibody, while demonstrating lower binding and functional activity under physiological conditions, as expected for a CAB bispecific antibody.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">24</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">BA3311: EGFR x CD3</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Targeting EGFR with a CAB bispecific antibody is expected to provide benefit since the target is widely expressed in healthy tissue, such as skin, which would otherwise result in on-target, off-tumor toxicity if targeted by a non-CAB antibody. A set of lead molecules were characterized by multiple assays including functional assays and all demonstrated high activity at acidic pH with little to no activity under physiological conditions. Studies, using a colorectal cancer model to select the clinical lead, are in progress and are expected to be completed in the first quarter of 2022.</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Clinical Development Plans</font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We believe that our CAB technology opens up the opportunity for the creation of a broad set of bispecific product candidates with antitumor potential. Through these CAB bispecific antibodies, we believe we can activate T cells directly in tumors using CAB domains targeting tumor-specific antigens. Our CAB bispecific antibodies are not expected to lead to systemic immune activation, which we believe may allow for increased efficacy through more potent T cell activation, higher doses or administration in combination with other immuno-oncology therapies, such as checkpoint inhibitors.</font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We have shown in preclinical experiments that our CAB bispecific molecules meet or exceed the activity of conventional bispecifics and reduce systemic activation of potentially fatal immune responses.  We have advanced two CAB bispecific antibody product candidates, BA3182 (EpCAM x CD3) and BA3142 (B7H3 x CD3) into preclinical studies, and BA3311 (EGFR x CD3) is a current subject of IND enabling studies. We believe that our CAB technology opens up the opportunity for the creation of a broad set of bispecific product candidates with antitumor potential. Through these CAB bispecific antibodies, we believe we can activate T cells directly in tumors using CAB domains targeting tumor-specific antigens. Our CAB bispecific antibodies are not expected to lead to systemic immune activation, which we believe may allow for increased efficacy through more potent T cell activation, higher doses or administration in combination with other immuno-oncology therapies, such as checkpoint inhibitors.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Competition</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The biotechnology and biopharmaceutical industries, including the oncology subsector, are characterized by rapid evolution of technologies, competition and strong defense of intellectual property. Any product candidates that we successfully develop and commercialize may have to compete with existing therapies and new therapies that may become available in the future. While we believe that our patented technology platform, intellectual property, know-how and scientific expertise in the field of biologics and immuno-oncology provide us with certain competitive advantages, including the ability of our product candidates to be active under conditions representative of the tumor microenvironment and not in normal cell conditions, we face potential competition from a wide variety of institutions, including large biopharmaceutical companies, specialty biotechnology companies, academic research departments and public and private research institutions. In immuno-oncology, we face substantial competition in the form of competing approaches to targeted antibody therapy in general, as well as competing treatments for the same types of cancer that we would plan to address with our pipeline of product candidates.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">There are numerous companies in various stages of clinical development of ADCs, one of the key feature of our product candidates mecbotamab vedotin and ozuriftamab vedotin. Currently, there are multiple approved ADCs and many more in clinical development, the vast majority of which were being developed for the treatment of cancer. Certain other companies are also pursuing antibody therapies in immuno-oncology, such as Seattle Genetics. Although we do not believe competing companies have selective CAB technology, there is a wide array of activity in multiple areas of immune-based cellular therapies for oncology.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">In addition, if any of our product candidates are approved in oncology indications such as pancreatic, breast and other cancers, they may compete with existing biologics and small molecule therapies or may be used in combination with existing therapies. There are also many other therapies under development that are intended to treat the same cancers that we are targeting or, although yet to be identified, may target with our CAB technology platform, including through approaches that could prove to be more effective, have fewer side effects, be cheaper to manufacture, be more convenient to administer or have other advantages over any products resulting from our technology.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Many of our competitors, either alone or with strategic partners, have substantially greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. Accordingly, our competitors may be more successful than us in obtaining approval for treatments and achieving widespread market acceptance, rendering our treatments obsolete or non-competitive. Accelerated merger and acquisition activity in the biotechnology and biopharmaceutical industries may result in even more resources being concentrated among a smaller number of our competitors. These companies also compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials and acquiring technologies complementary to, or necessary for, our programs. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. The level of generic competition and the availability of reimbursement from government and other third-party payors will also significantly affect the pricing and competitiveness of our products. In addition, our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Manufacturing</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Our CAB antibodies are designed and produced using our patented Comprehensive Integrated Antibody Optimization</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.03pt;font-family:Times New Roman;">TM</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">, or CIAO!</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.03pt;font-family:Times New Roman;">TM</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">, technology. The successful evolution, design, and development of a CAB antibody with specific characteristics and qualities require that the</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">25</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">development and manufacturing processes result in the CAB antibody with the desired properties. We have developed our patented process of CIAO! that integrates into the design process the critical features for subsequent development steps and manufacturing. A key element of the CIAO! process is that all design and development of the antibody is conducted in a mammalian cell line such as Chinese hamster ovary. This host cell is essentially identical to that used for manufacturing the majority of antibodies. This integrated and efficient approach is designed to provide consistency of the folding, glycosylation and other critical features throughout the development and commercialization process for improved activity, selectivity and yields in manufacturing.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We currently do not own or operate any manufacturing facilities. We rely, and expect to continue to rely for the foreseeable future, on third-party contract manufacturing organizations to produce our product candidates for preclinical and clinical testing, as well as for commercial manufacture if our product candidates receive marketing approval. We also expect to rely on third parties for the design, development and manufacture of companion diagnostic tests for our product candidates that require such tests. Furthermore, the raw materials for our product candidates may be sourced, in some cases, from a single-source supplier. As part of the manufacture and design process for our product candidates, we rely on internal, scientific and manufacturing know-how and trade secrets and the know-how and trade secrets of third-party manufacturers. We also contract with additional third parties for the filling, labeling, packaging, storage and distribution of investigational drug products. We believe that this strategy allows us to maintain a more efficient infrastructure by eliminating the need for us to invest in our own manufacturing facilities, equipment and personnel while also enabling us to focus our expertise and resources on the development of our product candidates. We maintain agreements with our manufacturers that include confidentiality and intellectual property provisions to protect our proprietary rights related to our product candidates. We have personnel with significant technical, manufacturing, analytical, quality, including current good manufacturing practices, or cGMPs, and project management experience to oversee our third-party manufacturers and to manage manufacturing and quality data and information for regulatory compliance purposes.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Collaborations</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We intend to selectively enter into collaborations to maximize the value of our platform and pipeline.</font><font style="background-color:rgba(255,255,0,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><br></font><font style="background-color:rgba(255,255,0,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">License Agreements</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Global Co-Development and Collaboration Agreement with BeiGene, Ltd.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">In April 2019, we entered into a Global Co-Development and Collaboration Agreement with BeiGene, Ltd. which, as amended in December 2019 and October 2020, provided for the development, manufacturing and commercialization of BioAtla&#x2019;s investigational CAB CTLA-4 antibody, BA3071. Under the terms of our BeiGene collaboration, BeiGene was generally responsible for developing the CAB-CTLA-4 antibody and for global regulatory filings and commercialization. Subject to the terms of the agreement, BeiGene held an exclusive license with BioAtla to develop and manufacture the product candidate globally. BeiGene was responsible for all costs of development, manufacturing and commercialization globally. At the time of execution of the BeiGene collaboration, we received a $20 million upfront payment and in December 2019, we received an additional $5 million for the reimbursement of manufacturing costs. We were eligible to receive subsequent development and regulatory milestones globally and commercial milestones in the BeiGene territory, together with tiered royalties on sales worldwide.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">On November 19, 2021, we entered into Amendment No. 3 to the Global Co-Development and Collaboration Agreement ( &#x201c;Amendment No.3&#x201d;)  Under Amendment No. 3, the collaboration agreement was terminated, subject to survival of certain provisions, and BeiGene handed back rights to certain know-how and materials received under the collaboration agreement and we assumed responsibility for the development and commercialization of BA3071, in addition to other standard provisions.  As consideration for Amendment No.3, we agreed to pay BeiGene mid-single digit royalties on sales worldwide and on a limited basis will share in any upfront and milestone payments received through a sublicense of BA3071.</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Exclusive License Agreement with Inversagen, LLC</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">In March 2019, we entered into an Exclusive License Agreement with Inversagen, LLC, as amended in July 2020. Under the terms of the agreement, we granted Inversagen an exclusive, worldwide, royalty-bearing license under certain patents and know-how controlled by us to develop, make, have made, sell, have sold, offer for sale and import CAB-antibodies for the field of diseases associated with aging, outside of cancer, and an immuno-oncology antibody. We may perform development services under the agreement and will be reimbursed by Inversagen for our costs. Commencing on the first commercial sale of the CAB-antibodies and immuno-oncology antibody subject to the agreement, Inversagen will pay us royalties in the mid-single digits, which represents a variable interest held by us. We have an option for a period of 10 years to acquire the sole and exclusive rights solely to develop, make, have made, use, sell, have sold, offer for sale and import the immuno-oncology antibody in the field worldwide (except for the People&#x2019;s Republic of China, Hong Kong, Taiwan and Macau) in return for royalty payments in the low-single digits during the applicable royalty term. For both royalties paid to us by Inversagen and, upon exercise of our option, royalties paid to Inversagen by us, the royalty term, on a product-by-product basis, is the period of time commencing on the first commercial sale of such product in a country and ending upon the later to occur of (i) expiration of the last-to-expire valid claim of the patent rights controlled by us or by Inversagen covering the manufacture, use, sale, offer for sale or import of such product, (ii) 10 years following the first commercial sale of such product in such country and (iii) the expiration of regulatory exclusivity for such product in such country. Unless earlier terminated, the agreement continues in effect so long as Inversagen or any of its affiliates, licensees or sublicensees are developing or commercializing the CAB-antibodies or immuno-oncology antibody in the field or we or any of our affiliates, licensees or sublicensees are developing or commercializing the CAB-antibodies or immuno-oncology antibody outside the field. We can also terminate the agreement with 30 days prior written notice for Inversagen&#x2019;s failure to pay. No payments have been made to date.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">26</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Amended and Restated Exclusive Rights Agreement with Himalaya Therapeutics SEZC</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">In January 2020, we entered into an Amended and Restated Exclusive Rights Agreement with Himalaya Therapeutics SEZC. Under the terms of the agreement, we granted Himalaya Therapeutics SEZC an exclusive, sublicensable license under certain patents and know-how controlled by us to develop, manufacture, conduct clinical trials, obtain regulatory approval of and commercialize 10 CAB-antibodies for the territory of the People's Republic of China, Macao, Hong Kong and Taiwan and a CAB-HER2-bispecific-antibody worldwide, in each case in the field of the treatment of cancer in humans. We also granted Himalaya Therapeutics SEZC an exclusive, sublicensable license under certain patents and know-how controlled by us to develop, manufacture, conduct clinical trials, obtain regulatory approval of and commercialize an IL-22 non-CAB-antibody worldwide, which option rights are subject to certain co-development plans in the agreement for the joint development and commercialization of the IL-22 non-CAB-antibody by Himalaya Therapeutics SEZC and us. The term of the agreement continues unless terminated by mutual written consent of the parties and also contains customary provisions for termination by either party. Payments to us may include upfront payments, milestone payments and royalties equal to the lower of (i) the low teens of annual net sales and (ii) the mid-twenties of the royalties and other comparable payments received by Himalaya Therapeutics SEZC from third parties, which represent a variable interest held by us, but no payments have been made to date. The royalty term, on a product-by-product and country-by-country basis, is the period of time commencing on the first commercial sale of such product in such country and expiring upon the latest of (i) the expiration of the last valid claim in a patent covering the composition of matter or method of use for such product licensed under the agreement in such country, (ii) the expiration of any other exclusivity protection of such licensed product in such country, and (iii) the 15th anniversary of the date of first commercial sale of such product in such country. We are eligible to receive up to $77.5 million in upfront payments and potential milestones.</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Exclusive License Agreement with BioAtla Holdings, LLC</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">In January 2020, we entered into an Exclusive License Agreement with BioAtla Holdings, LLC, as amended in July 2020. Under the terms of the agreement, we granted BioAtla Holdings an exclusive, worldwide license under certain patents and know-how controlled by us to develop, make, have made, use, sell, have sold, offer for sale and import CAB antibodies for certain targets in the field of Adoptive Cell Therapy, or ACT (CAR-T). Commencing on the first commercial sale of the CAB antibodies subject to the agreement, BioAtla Holdings will pay us royalties in the mid-single digits, which represents a variable interest held by us. We have an option for a period of 10 years to acquire the sole and exclusive rights solely to develop, make, have made, use, sell, have sold, offer for sale and import the ACT preparations and ACT treatments in the ACT field worldwide (except for the People&#x2019;s Republic of China, Hong Kong, Taiwan and Macau) in return for royalty payments in the low-single digits during the applicable royalty term. For both royalties paid to us by BioAtla Holdings and, upon exercise of our option, royalties paid to BioAtla Holdings by us, the royalty term, on a product-by-product basis, is the period of time commencing on the first commercial sale of such product in a country and ending upon the expiration of the last-to-expire valid claim of the patent rights controlled by us or by BioAtla Holdings covering the manufacture, use, sale, offer for sale or import of such product. We will not owe BioAtla Holdings any milestone or royalty payments unless we exercise our option to acquire the rights to the ACT preparations and ACT treatments. During the term of the agreement, we agreed not to develop, make, have made, use, sell, have sold, offer for sale or import any CAB ACT treatment in the field of ACT. Unless earlier terminated, the agreement continues in effect so long as BioAtla Holdings or any of its affiliates, licensees or sublicensees are developing or commercializing the ACT preparations and treatments in the ACT field or we or any of our affiliates, licensees or sublicensees are developing or commercializing any CAB non-ACT product for any indication outside the ACT field. The agreement may be terminated only by the mutual written agreement of the parties. No payments have been made to date.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">In addition, effective January 2020, we entered into a Royalty Sharing Agreement whereby we agreed to share with BioAtla Holdings 50% of the royalties we receive under the license agreement with EXUMA Biotech Corp. (formerly F1 Oncology, Inc.) described below.</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Amended and Restated Exclusive License Agreement with EXUMA Biotech Corp</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">In May 2016, we entered into an Exclusive License Agreement with EXUMA Biotech Corp. (&#x201c;EXUMA&#x201d;, formerly F1 Oncology, Inc.) and its affiliates, which, as amended in July 2016 and November 2017 and as amended and restated in November 2019, granted an exclusive, worldwide, sublicensable license under certain patents and know-how controlled by us to develop, manufacture and commercialize four CAB ACT (CAR-T) preparations and treatments for cancer. EXUMA granted us an exclusive, worldwide, royalty free, fully paid-up, sublicensable license under certain patents and know-how controlled by EXUMA and EXUMA&#x2019;s interest in technology jointly developed under the agreement to develop, manufacture and commercialize non-ACT CAB products for any indication.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">EXUMA is obligated to pay us during the royalty term, on a product-by-product basis and country-by-country basis, mid-single-digit royalties based on annual net sales of certain EXUMA ACT products, subject to certain adjustments. The term during which EXUMA is obligated to pay royalties under the agreement with respect to any particular product in any particular country, will begin on the first commercial sale of such product in such country and will end on the date of expiration of the last-to-expire of certain product-related patent rights in such country.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Unless earlier terminated, the agreement continues in effect so long as EXUMA or any of its affiliates, licensees or sublicensees are developing or commercializing any EXUMA products in the ACT field or we or any of our affiliates, licensees or sublicensees are developing or commercializing any CAB products for any indication outside the ACT field. The agreement may be terminated only by the mutual written agreement of the parties.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">27</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">In connection with the agreement, we received common and preferred stock of EXUMA. These holdings of EXUMA common and preferred stock were retained by BioAtla Holdings in connection with the LLC Division.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">In November 22, 2019, we entered into an Amended and Restated Exclusive License Agreement with EXUMA, which curtailed the rights to certain CAB intellectual property previously licensed to EXUMA in exchange for a one-time, non-refundable, non-creditable license fee of $10,000, but does not change EXUMA&#x2019;s obligation to pay us royalties on licensed products. In connection with the Amended and Restated Exclusive License Agreement, BioAtla Holdings sold its EXUMA common and preferred holdings back to EXUMA for consideration of $25,000.</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">CHO-S Cell Line License Agreement with Life Technologies Corporation</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">On June 28, 2018, we entered into the CHO-S Cell Line License Agreement with Life Technologies Corporation. Under the terms of the agreement, Life Technologies Corporation provides and grants to us a worldwide, non-exclusive, royalty-free, non-sublicensable license to use certain CHO-S cells to make, or have made, recombinant proteins for clinical or commercial purposes and to seek regulatory approval for the sale of such recombinant proteins in exchange for a one-time, non-refundable, non-creditable license fee of $400,000. No royalties are due by us to Life Technologies Corporation under the agreement. Additional specific lots of Life Technologies Corporation&#x2019;s recombinant proteins may be ordered by us for an additional fee of $50,000 per lot. The term of the agreement continues in perpetuity unless terminated by either party.</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Intellectual property</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Since inception, we have recognized the value of strong, defensible and relevant intellectual property protection. We seek to protect our technologies and products and the potential market for such technologies and products. To accomplish this goal, we apply for patents covering our processes and compositions. We also apply for patents covering developments and technologies for purpose of preventing third parties from developing competing products. Inventions related to various aspects of our core technologies have already been protected by issued and pending patent applications. As of December 31, 2021, we had 584 patents and patent applications with 319 issued, 8 allowed applications and 257 pending applications.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The objectives of our IP strategy are to increase shareholder value by adequately protecting our platform technologies and compositions of matter, discerning and maximizing the value of our patent portfolio, providing a flexible portfolio that is aligned with our business model and maintaining a cost-effective strategy. We achieve these goals by creating a defensible patent shield, employing most-likely-to-succeed strategies, patenting strategically to reinforce the value of our IP and to minimize costs related to patenting while maximizing value, and by understanding the technology landscape to ensure patentability and freedom to operate. For our CAB products, we act strategically to maximize patent term by timely filing our patent applications.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We recognize that the ability to obtain patent protection and the degree of such protection depends on a number of factors, including the extent of the prior art, the novelty of the invention, the obviousness of the invention and the ability to satisfy the enablement and written description requirements of the patent laws. We file all relevant types of patent applications to protect our intellectual property, including patent applications with claims directed to our processes and products, and applications and uses thereof.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We file our applications with the U.S. Patent and Trademark Office to establish a priority filing date. Generally, we initially file provisional applications. Provisional applications are designed to provide a lower-cost first patent application filing in the United States. Corresponding non-provisional patent applications must be filed not later than 12 months after the filing date of the first provisional application filed for an invention. In some cases, multiple provisional applications have been filed within a 12-month period to capture incremental developments within the 12-month priority period while obtaining an early filing date for each development. The corresponding non-provisional patent applications benefit from the provisional applications(s) since the priority date(s) of the these non-provisional patent applications is/are the earlier provisional application filing date(s), and because the patent term of the finally issued patents are calculated from the later, non-provisional patent application filing dates. This system allows us to obtain an early priority date, add material to the patent application(s) during the priority year, obtain a later start to the patent term and delay prosecution costs, which may save costs in the event that we decide not to pursue examination in an application.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Subsequently, when appropriate, we pursue patent applications in foreign countries. The PCT system for filing international patent applications is used. This system allows a single application to be filed within 12 months of the original priority date of the patent application designating all 153 PCT member states (including countries in South, Central and North America, Africa, Europe, Asia and Australia) in which national/regional patent applications can later be pursued based on the international patent application filed under the PCT. The PCT searching authority performs a patentability search and issues a non-binding patentability opinion which can be used to evaluate the chances of success for future the national/regional patent applications in foreign countries prior to having to incur the filing and translation costs for such applications. At the end of a period of 2 1/2 years from the first priority date of the PCT patent application, separate patent applications can be pursued in any of the 153 PCT member states either by direct national filing or, in some cases, by filing through a regional patent organization such as the European Patent Organization. The PCT system delays expenses, allows a limited evaluation of the chances of success for national/regional patent applications and enables substantial cost savings where applications are abandoned within the first 2 1/2 years of filing.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">For all patent applications, we determine the claiming strategy on a case-by-case basis. Advice of counsel and our business model and needs are always considered. We file patents containing claims for protection of all useful applications of our proprietary technologies and any products, as well as all new applications or uses we discover for existing technologies and products, assuming these are strategically valuable. We continuously reassess the number and type of patent applications, as well as the pending and issued patent claims to ensure that maximum patent coverage and value are obtained for our processes, and compositions, given existing patent office rules and regulations. Further, pending patent claims may be modified during patent prosecution to meet our intellectual property and business needs.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">28</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We are attentive to the need to avoid the unauthorized use of patented technology belonging to third parties. We perform non-infringement searches and analyses for our existing technologies and will continue to do so for future commercial processes and products. For our new developments, we regularly perform expert searches and reviews, and monitor patents and patent applications by third-party competitors. Our policy of avoiding patent infringement is diligently executed. To the best of our knowledge as of the date of this prospectus, we have freedom to operate on all of our technologies and product candidates.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The patent positions of biotechnology and biopharmaceutical companies like ours are generally uncertain and involve complex legal, scientific and factual issues. In addition, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and the scope of an issued patent can be reinterpreted or further altered even after patent issuance. Consequently, we may not obtain or maintain adequate patent protection for any of our product candidates or for our technology platform. We cannot predict whether the patent applications we are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient proprietary protection from competitors. Any patents that we hold may be challenged, circumvented or invalidated by third parties. For a more comprehensive discussion of the risks related to our patents, please see &#x201c;Risk factors&#x2014;Risks related to our intellectual property.&#x201d;</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The term of individual patents depends upon the legal term of the patents in the countries in which they are obtained. In most countries in which we file, the patent term is 20 years from the earliest date of filing a non-provisional patent application related to the patent. A U.S. patent may be accorded a patent term adjustment, or PTA, under certain circumstances to compensate for delays in granting the patent caused by the United States Patent and Trademark Office. In some instances, such a PTA may result in a U.S. patent term extending beyond 20 years from the earliest date of filing a non-provisional patent application related to the U.S. patent. In addition, in the United States, the term of a U.S. patent that covers an FDA-approved drug may be eligible for a patent term extension, which permits patent term restoration as compensation for the patent term lost during the FDA regulatory review process. The Hatch-Waxman Act permits a patent term extension of up to five years beyond the expiration of the patent. The length of the patent term extension is related to the length of time the drug is under regulatory review. Patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval and only one patent applicable to an approved drug may be extended. Similar provisions are available in Europe and other foreign jurisdictions to extend the term of a patent that covers an approved drug. In the future, if and when our products receive regulatory approval, we expect to apply for patent term extensions on patents covering those products. We plan to seek patent term extensions to any of our issued patents in any jurisdiction where these are available; however, there is no guarantee that the applicable authorities, including the FDA in the United States, will agree with our assessment of whether such extensions should be granted, and, if granted, the length of such extensions.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We further own trade secrets relating to our technology platform and product candidates, and we maintain the confidentiality of proprietary information to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection. Although we take steps to protect our proprietary information and trade secrets, including through contractual means with our employees and consultants, third parties may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets or disclose our technology. Thus, we may not be able to meaningfully protect our trade secrets. It is our policy to require our employees, consultants, outside scientific collaborators, sponsored researchers and other advisors to execute confidentiality agreements upon the commencement of employment or consulting relationships with us. These agreements provide that all confidential information concerning our business or financial affairs developed or made known to the individual during the course of the individual&#x2019;s relationship with us are to be kept confidential and not disclosed to third parties except in specific circumstances. Our agreements with employees and consultants also provide that all inventions conceived by the employee in the course of employment or work with us or from the employee&#x2019;s or consultant&#x2019;s use of our confidential information are our exclusive property. For a more comprehensive discussion of the risks related to our trade secrets, please see &#x201c;Risk factors&#x2014;Risks related to our intellectual property.&#x201d;</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Company-owned patents</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Mecbotamab vedotin is covered by a number of filings, including a published PCT application filed in 2017 that entered the national phase in 2018. National phase applications have been granted in Australia, Israel, Japan, and the United States and are pending in 13 jurisdictions, including most major market countries. Composition of matter claims issuing from this application would not expire before 2037.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Ozuriftamab vedotin is covered by a number of filings, including a published PCT application filed in 2017 that entered the national phase in 2018. National phase applications are pending in 14 jurisdictions in addition to the United States, including most major market countries. Composition of matter claims issuing from this application would not expire before 2037.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">BA3071 is covered by a number of filings, including a published PCT application filed in 2019 that  entered the national phase in 2021. In addition to filings made in the non-PCT countries of Argentina and Taiwan, national phase applications are pending in 15 jurisdictions in addition to the United States, including most major market countries. Composition of matter claims issuing from this application would not expire before 2039.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Our pre-clinical stage CAB antibody programs, including CAB-anti-EpCAM antibodies and CAB-anti-Nectin-4 antibodies, are covered by a number of filings. As of December 31, 2021, CAB-anti-EpCAM antibodies are covered by 10 national phase filings, including the United States, and a non-PCT filing in Taiwan. CAB-anti-Nectin-4 antibodies are covered by a PCT application and an application in Taiwan. Composition of matter claims issuing from these applications would not expire before either 2040 or 2041.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Core components of our product candidates are protected by company-owned platform applications directed to novel methods of protein evolution, methods of making conditionally active biologics, integrated selection and evolution of antibodies and proteins in expression production hosts, multi-specific antibodies and methods of making, modified antibody regions, conditionally active biological proteins, proteins targeting orthologs, discovery of and production of conditionally active biologic proteins in eukaryotic cell production hosts, conditionally active</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">29</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">chimeric antigen receptors for modified T-cells, diagnostics using conditionally active antibodies, conditionally active polypeptides, antibodies targeted to senescent cells, conditionally active proteins for neurodegenerative diseases, and conditionally active proteins with pH selectivity. We also have 15 issued U.S. patents covering various aspects of the manufacturing methods used to generate CAB antibodies that have patent terms expiring from 2030 to 2036. We also have an issued patent in the U.S. protecting our method of manufacturing conditionally active multi-specific antibodies that has a patent term expiring in 2033.</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Out-licensed patents</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Himalaya Therapeutics SEZC has exclusive rights to patents/patent applications in China, Macao, Hong Kong and Taiwan relating to ROR2 (Patent applications 2017800294276 (China), and patent application 106115891 (Taiwan), both titled Anti-ROR2 antibodies and their immunoconjugates and uses thereof) and relating to AXL (Patent applications 201780023876X (China), and patent application 106112687 (Taiwan), both titled Anti-AXL antibodies and their immunoconjugates and uses thereof). Additionally, Himalaya Therapeutics SEZC has exclusive worldwide rights to patents/patent applications relating to IL-22 (Patent applications 108119613 and PCT/US19/35395, both titled Anti-IL-22 antibodies, antibody fragments and their immunoconjugates and uses thereof) and relating to HER2 (Patent application USP 62/964,747 titled Conditionally active anti-HER2 antibodies).</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">BioAtla Holdings, LLC has exclusive worldwide rights to all patents for the field of ACT (CAR-T), excluding the targets licensed to EXUMA Biotech Corp (&#x201c;EXUMA&#x201d;).</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Inversagen, LLC has exclusive worldwide rights to all patents solely in the field of diseases associated with aging (outside of cancer), diagnostics related thereto and an immuno-oncology antibody.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">EXUMA has an exclusive worldwide license to all patents solely to develop, make, have made, use, sell, have sold, offer for sale and import adoptive cell therapy (CAR-T) products to four named targets for the treatment of cancer. EXUMA&#x2019;s rights under the agreement exclude the right to grant sublicenses to third parties to discover, develop or manufacture any CAB ACT or any component of our CAB ACT technology, except as used in or incorporated into EXUMA&#x2019;s ACTs for cancer.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Government regulation and product approval</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Government authorities in the United States, at the federal, state and local level and in other countries and jurisdictions, including the European Union, extensively regulate, among other things, the research, development, testing, manufacture, quality control, import, export, safety, effectiveness, labeling, packaging, storage, distribution, record keeping, approval, advertising, promotion, marketing, post-approval monitoring and post-approval reporting of biological product candidates such as those we are developing. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources and we may not be able to obtain the required regulatory approvals.</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Licensure and regulation of biologics in the United States</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">In the United States, the FDA regulates biologic products under the Federal Food, Drug, and Cosmetic Act, or the FDCA, the Public Health Service Act, or the PHSA, and regulations and guidance implementing these laws. The FDCA, PHSA and their corresponding regulations govern, among other things, the testing, manufacturing, safety, purity, potency, labeling, packaging, storage, record keeping, distribution, post-approval monitoring and reporting, import, export, advertising and other promotional practices involving biologic products. Biological products used for the prevention, treatment or cure of a disease or condition of a human being are subject to regulation under the FDCA, except the section of the FDCA that governs the approval of new drug applications, or NDAs. Biological products are approved for marketing under provisions of the PHSA, via a Biologic License Application, or BLA. However, the application process and requirements for approval of BLAs are very similar to those for NDAs, and biologics are associated with similar approval risks and costs as drugs. Failure to comply with applicable U.S. requirements may subject a company to a variety of administrative or judicial sanctions, such as clinical hold, FDA refusal to approve pending NDAs or BLAs, warning or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties and criminal prosecution.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">U.S. biologic products development process</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Biological product candidates must be approved by the FDA pursuant to a BLA before they may be legally marketed in the United States. The process generally involves the following:</font></p>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Completion of extensive preclinical laboratory tests and</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;"> in vivo</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> studies in accordance with the FDA&#x2019;s current good laboratory practice, or GLP,  regulations and applicable requirements for the humane use of laboratory animals or other applicable regulations;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Submission to the FDA of an IND, which must become effective before clinical trials may begin;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Approval by an independent institutional review board, or IRB, reviewing each clinical site before each clinical trial may be initiated;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Performance of adequate and well-controlled clinical trials in accordance with the FDA&#x2019;s IND regulations, GCP requirements, and any additional requirements for the protection of human research subjects and their health information, to establish the safety and efficacy of the proposed biologic product candidate for its intended use;</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">30</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Preparation and submission to the FDA of a BLA for marketing approval that includes substantial evidence of safety, purity and potency from results of nonclinical testing and clinical trials;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">A determination by the FDA within 60 days of its receipt of a BLA to file the application;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Satisfactory completion of FDA pre-approval inspections of the manufacturing facility or facilities where the biologic product candidate is produced to assess compliance with cGMPs and to assure that the facilities, methods and controls are adequate to preserve the biologic product candidate&#x2019;s identity, safety, strength, quality, potency and purity;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Satisfactory completion of any potential FDA audits of the nonclinical and clinical trial sites that generated the data in support of the BLA to assure compliance with GCPs and integrity of the clinical data;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Payment of user fees for FDA review of the BLA;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Review of the product by an FDA advisory committee, if applicable; </font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">FDA review and approval of the BLA.</font></div></div>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Preclinical studies</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Before testing any biologic product candidate in humans, the product candidate must undergo rigorous preclinical testing. Preclinical tests, also referred to as nonclinical studies, include laboratory evaluations of product chemistry, toxicity and formulation, as well as</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;"> in vivo</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> studies to assess the potential safety and activity of the product candidate and to establish a rationale for therapeutic use. The conduct of the preclinical tests must comply with federal regulations and requirements including GLPs.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The clinical trial sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and a proposed clinical protocol, among other things, to the FDA as part of an IND. An IND is a request for authorization from the FDA to administer an investigational product to humans and must become effective before human clinical trials may begin. Some preclinical testing may continue even after the IND is submitted. An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to a proposed clinical trial and places the trial on clinical hold, including concerns that human research subjects will be exposed to unreasonable health risks. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. Accordingly, submission of an IND may or may not result in the FDA allowing clinical trials to commence.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Clinical trials under an IND</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Clinical trials involve the administration of the biologic product candidate to healthy volunteers or patients under the supervision of qualified investigators, who are generally physicians not employed by, or under, the control of the trial sponsor. Clinical trials must be conducted: (i) in compliance with federal regulations; (ii) in compliance with GCPs, an international standard meant to protect the rights and health of patients and to define the roles of clinical trial sponsors, administrators and monitors and (iii) under protocols detailing, among other things, the objectives of the trial, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated in the trial. Further, each clinical trial must be reviewed and approved by an IRB at or servicing each institution at which the clinical trial will be conducted. An IRB is charged with protecting the welfare and rights of trial participants and considers items such as whether the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the form and content of the informed consent that must be signed by each clinical trial subject, or his or her legal representative, reviews and approves the study protocol, and must monitor the clinical trial until completed.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Clinical trials typically are conducted in three sequential phases that may overlap or be combined:</font></p>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Phase 1.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> The biologic product candidate initially is introduced into a small number of healthy human subjects and tested for safety, dosage tolerance, absorption, metabolism, distribution or excretion. If possible, a Phase 1 clinical trial may also seek to gain an early understanding of the product candidate&#x2019;s effectiveness. In the case of some product candidates for severe or life-threatening diseases, especially when the product candidate may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients.</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Phase 2.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> The biologic product candidate is evaluated in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product candidate for specific targeted diseases and to determine dosage tolerance, optimal dosage and dosing schedule. Multiple Phase 2 clinical trials may be conducted to obtain information prior to beginning larger and more expensive Phase 3 clinical trials.</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Phase 3.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> The biologic product candidate is administered to an expanded patient population at multiple sites to further evaluate dosage, to provide statistically significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the investigational product and to provide an adequate basis for product approval and labeling. In most cases, the FDA requires two adequate and well-controlled Phase 3 clinical trials to demonstrate the efficacy of a biologic. </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">31</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">These phases may overlap or be combined. For example, a Phase 1/2 clinical trial may contain both a dose-escalation stage and a dose-expansion stage, the latter of which may confirm tolerability at the recommended dose for expansion in future clinical trials (as in traditional Phase 1 clinical trials) and provide insight into the antitumor effects of the investigational therapy in selected subpopulation(s).</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Typically, during the development of oncology therapies, all subjects enrolled in Phase 1 clinical trials are disease-affected patients and, as a result, considerably more information on clinical activity may be collected during such trials than during Phase 1 clinical trials for non-oncology therapies. A single Phase 3 or Phase 2 trial may be sufficient in rare instances, including (i) where the trial is a large, multicenter trial demonstrating internal consistency and a statistically very persuasive finding of a clinically meaningful effect on mortality, irreversible morbidity or prevention of a disease with a potentially serious outcome and confirmation of the result in a second trial would be practically or ethically impossible or (ii) when in conjunction with other confirmatory evidence. Approval on the basis of a single trial may be subject to the requirement of additional post-approval studies.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Phase 1, Phase 2, Phase 3 and other types of clinical trials may not be completed successfully within any specified period, if at all. The FDA, the IRB, or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including non-compliance with regulatory requirements or a finding that the patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#x2019;s requirements or if the drug or biologic has been associated with unexpected serious harm to patients. Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board or committee. This group provides authorization for whether a trial may move forward at designated checkpoints based on access to certain data from the trial.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Concurrent with clinical trials, companies usually must complete some long-term preclinical testing, such as animal tests of reproductive adverse events and carcinogenicity, and must also develop additional information about the chemistry and physical characteristics of the drug or biologic and finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product and, among other things, the manufacturer must develop methods for testing the identity, strength, quality, potency and purity of the final product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the product does not undergo unacceptable deterioration over its shelf life.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">There are also requirements governing the reporting of ongoing clinical trials and completed clinical trial results to public registries. Sponsors of clinical trials of FDA-regulated products, including biologics, are required to register and disclose certain clinical trial information, which is publicly available at www.clinicaltrials.gov. Information related to the product, patient population, phase of investigation, study sites and investigators, and other aspects of the clinical trial is then made public as part of the registration. Sponsors are also obligated to discuss the results of their clinical trials after completion. Disclosure of the results of these trials can be delayed in certain circumstances for up to two years after the date of completion of the trial. Competitors may use this publicly available information to gain knowledge regarding the progress of development programs.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">U.S. review and approval processes</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">FDA approval of a BLA must be obtained before commercial marketing of the biologic product. The results of the preclinical tests and clinical trials, together with detailed information relating to the product&#x2019;s CMC and proposed labeling, among other things, are submitted to the FDA as part of the BLA requesting approval to market the product for one or more indications.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The cost of preparing and submitting a BLA is substantial. Under the Prescription Drug User Fee Act, or PDUFA, each BLA must be accompanied by a significant user fee. The FDA adjusts the PDUFA user fees on an annual basis. The PDUFA also imposes an annual prescription drug program. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a small business. Additionally, no user fees are assessed on BLAs for products designated as orphan drugs, unless the product also includes a non-orphan indication. The applicant under an approved BLA is also subject to an annual program fee.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The FDA reviews a BLA within 60 days of submission to determine if it is substantially complete before the agency files. The FDA may refuse to file any BLA that it deems incomplete or not properly reviewable at the time of submission and may request additional information. In that event, the BLA must be resubmitted with the additional information. The resubmitted application also is subject to review before the FDA files it. Once the submission is filed by the FDA, the FDA begins an in-depth, substantive review of the BLA.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The FDA reviews the BLA to determine, among other things, whether the proposed product candidate is safe and effective for its intended use, has an acceptable purity profile and whether the product candidate is being manufactured in accordance with cGMPs to assure and preserve the product candidate&#x2019;s identity, safety, strength, quality, potency and purity. The FDA may refer applications for novel biologic products or biologic products that present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions on approval. During the product approval process, the FDA also will determine whether a REMS is necessary to assure the safe use of the product candidate. REMS involve additional risk minimization strategies to ensure that the benefits of the product outweigh the potential risks. A REMS can include medication guides, communication plans for healthcare professionals, and elements to assure safe use, or ETASU. ETASU can include, but are not limited to, special training or certification for prescribing or dispensing the product, dispensing the product only under certain circumstances, special monitoring, and the use of patient-specific registries. If the FDA concludes a REMS is needed, the sponsor of the BLA must submit a proposed REMS; the FDA will not approve the BLA without a REMS, if required.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">32</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Before approving a BLA, the FDA will inspect the facilities at which the product candidate is manufactured. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product candidate within required specifications. Additionally, before approving a BLA, the FDA typically will inspect one or more clinical sites to assure that the clinical trials were conducted in compliance with IND trial requirements and GCP requirements.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">On the basis of the BLA and accompanying information, including the results of the inspection of the manufacturing facilities, the FDA may issue an approval letter or a complete response letter. An approval letter authorizes commercial marketing of the biologic product with specific prescribing information for specific indications. A complete response letter indicates that the review cycle of the application is complete, and the application will not be approved in its present form. A complete response letter generally outlines the deficiencies in the submission and may require substantial additional testing or information in order for the FDA to reconsider the application. If a complete response letter is issued, the applicant may either resubmit the BLA, addressing all of the deficiencies identified in the letter, or withdraw the application or request an opportunity for a hearing. The FDA has committed to reviewing such resubmissions in two or six months, depending on the type of information included. Even if such data and information are submitted, the FDA may decide that the BLA does not satisfy the criteria for approval.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The FDA has agreed to specified performance goals in the review of BLAs under the PDUFA. One such goal is to review standard BLAs in 10 months after the FDA files the BLA, and priority BLAs in six months, whereupon a review decision is to be made. The review process and the PDUFA goal date for both standard and priority review BLAs may be extended by three months if the FDA requests or the BLA sponsor otherwise provides additional information or clarification regarding information already provided in the submission within the last three months before the PDUFA goal date.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">If a product candidate receives regulatory approval, the FDA may require post-marketing clinical trials, sometimes referred to as Phase 4 clinical trials, designed to further assess a biologic product&#x2019;s safety and effectiveness, and testing and surveillance programs to monitor the safety of approved products that have been commercialized.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Compliance with cGMP requirements</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Manufacturers of biologics must comply with applicable cGMP regulations, including quality control and quality assurance and maintenance of records and documentation. Manufacturers and others involved in the manufacture and distribution of such products also must register their establishments with the FDA and certain state agencies. Both domestic and foreign manufacturing establishments must register and provide additional information to the FDA upon their initial participation in the manufacturing process. Establishments may be subject to periodic, unannounced inspections by government authorities to ensure compliance with cGMP requirements and other laws. Discovery of problems may result in a government entity placing restrictions on a product, manufacturer or holder of an approved BLA, and may extend to requiring withdrawal of the product from the market. The FDA will not approve a BLA unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specification.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Expedited development and review programs</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The FDA is authorized to designate certain products for expedited review if they are intended to address an unmet medical need in the treatment of a serious or life-threatening disease or condition.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Fast track designation may be granted for products that are intended to treat a serious or life-threatening disease or condition for which there is no effective treatment and preclinical or clinical data demonstrate the potential to address unmet medical needs for the condition. Fast track designation applies to both the product and the specific indication for which it is being studied. The sponsor of a new biologic candidate can request the FDA to designate the candidate for a specific indication for fast track status concurrent with, or after, the submission of the IND for the candidate. The FDA must determine if the biologic candidate qualifies for fast track designation within 60 days of receipt of the sponsor&#x2019;s request. For fast track products, sponsors may have greater interactions with the FDA and the FDA may initiate review of sections of a fast track product&#x2019;s BLA before the application is complete. This &#x201c;rolling review&#x201d; is available if the FDA determines, after preliminary evaluation of clinical data submitted by the sponsor, that a fast track product may be effective. The sponsor must also provide, and the FDA must approve, a schedule for the submission of the remaining information and the sponsor must pay applicable user fees. Any product submitted to the FDA for marketing, including under a fast track program, may be eligible for other types of FDA programs intended to expedite development and review, such as priority review and accelerated approval.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Breakthrough therapy designation may be granted for products that are intended, alone or in combination with one or more other products, to treat a serious or life-threatening condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over currently approved therapies on one or more clinically significant endpoints. Under the breakthrough therapy program, the sponsor of a new biologic candidate may request that the FDA designate the candidate for a specific indication as a breakthrough therapy concurrent with, or after, the submission of the IND for the biologic candidate. The FDA must determine if the biological product qualifies for breakthrough therapy designation within 60 days of receipt of the sponsor&#x2019;s request. The FDA may take certain actions with respect to breakthrough therapies, including holding meetings with the sponsor throughout the development process, providing timely advice to the product sponsor regarding development and approval, involving more senior staff in the review process, assigning a cross-disciplinary project lead for the review team and taking other steps to design the clinical trials in an efficient manner.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">33</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Priority review may be granted for products that are intended to treat a serious or life-threatening condition and, if approved, would provide a significant improvement in safety and effectiveness compared to available therapies. The FDA will attempt to direct additional resources to the evaluation of an application designated for priority review in an effort to facilitate the review.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Accelerated approval may be granted for products that are intended to treat a serious or life-threatening condition and that generally provide a meaningful therapeutic advantage to patients over existing treatments. A product eligible for accelerated approval may be approved on the basis of either a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity or prevalence of the condition and the availability or lack of alternative treatments. In clinical trials, a surrogate endpoint is a measurement of laboratory or clinical signs of a disease or condition that substitutes for a direct measurement of how a patient feels, functions or survives. The accelerated approval pathway is most often used in settings in which the course of a disease is long and an extended period of time is required to measure the intended clinical benefit of a product, even if the effect on the surrogate or intermediate clinical endpoint occurs rapidly. Thus, accelerated approval has been used extensively in the development and approval of products for treatment of a variety of cancers in which the goal of therapy is generally to improve survival or decrease morbidity and the duration of the typical disease course requires lengthy and sometimes large studies to demonstrate a clinical or survival benefit. The accelerated approval pathway is contingent on a sponsor&#x2019;s agreement to conduct additional post-approval confirmatory studies to verify and describe the product&#x2019;s clinical benefit. These confirmatory trials must be completed with due diligence and, in some cases, the FDA may require that the trial be designed, initiated and/or fully enrolled prior to submission of the application or approval. Failure to conduct required post-approval studies, or to confirm a clinical benefit during post-marketing studies, would allow the FDA to withdraw the product from the market on an expedited basis. All promotional materials for product candidates approved under accelerated regulations are subject to prior review by the FDA.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or the time period for FDA review or approval may not be shortened. Furthermore, fast track designation, breakthrough therapy designation, priority review and accelerated approval do not change the standards for approval, but may expedite the development or approval process.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Post-approval requirements</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Rigorous and extensive FDA regulation of biologic products continues after approval, particularly with respect to cGMP requirements. Manufacturers are required to comply with applicable requirements in the cGMP regulations, including quality control and quality assurance and maintenance of records and documentation, and are subject to periodic inspections by the FDA. In addition, changes to the manufacturing process or facility generally require prior FDA approval before being implemented and other types of changes to the approved product, such as adding new indications and additional labeling claims, are also subject to further FDA review and approval. Other post-approval requirements applicable to biologic products include reporting of cGMP deviations that may affect the identity, potency, purity and overall safety of a distributed product, record-keeping requirements, reporting of adverse effects, reporting updated safety and efficacy information and complying with electronic record and signature requirements. A sponsor also must comply with the FDA&#x2019;s advertising and promotion requirements, such as those related to direct-to-consumer advertising, the prohibition on promoting products for uses or in patient populations that are not described in the product&#x2019;s approved labeling (known as &#x201c;off-label use&#x201d;), industry-sponsored scientific and educational activities and promotional activities involving the internet. Discovery of previously unknown problems or the failure to comply with the applicable regulatory requirements may result in restrictions on the marketing of a product or withdrawal of the product from the market as well as possible civil or criminal sanctions.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval, may subject an applicant or manufacturer to administrative or judicial civil or criminal sanctions and adverse publicity. These actions could include refusal to approve pending applications or supplemental applications, withdrawal of an approval, clinical hold, suspension or termination of clinical trials by an IRB, warning or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines or other monetary penalties, refusals of government contracts, mandated corrective advertising or communications with healthcare providers, debarment, restitution, disgorgement of profits or other civil or criminal penalties.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Orphan drug designation</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Orphan drug designation in the United States is designed to encourage sponsors to develop products intended for treatment of rare diseases or conditions. In the United States, pursuant to the Orphan Drug Act, the FDA may grant orphan designation to a biological product intended to treat a rare disease or condition, which is statutorily defined as a condition that affects fewer than 200,000 individuals in the United States or that affects more than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing and making available the biologic for the disease or condition will be recovered from sales of the product in the United States.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Orphan drug designation qualifies a company for tax credits and market exclusivity for seven years following the date of the product&#x2019;s marketing approval if granted by the FDA.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">An application for designation as an orphan product can be made any time prior to the filing of an application for approval to market the product. A product becomes an orphan when it receives orphan drug designation from the Office of Orphan Products Development at the FDA based on acceptable confidential requests made under the regulatory provisions. The product must then go through the review and approval process like any other product. Orphan drug designation on its own does not convey any advantage in or shorten the duration of the regulatory review and approval process.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">34</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">A sponsor may request orphan drug designation of a previously unapproved product or new orphan indication for an already marketed product. In addition, a sponsor of a product that is otherwise the same product as an already approved orphan drug may seek and obtain orphan drug designation for the subsequent product for the same rare disease or condition if it can present a plausible hypothesis that its product may be clinically superior to the first drug. More than one sponsor may receive orphan drug designation for the same product for the same rare disease or condition, but each sponsor seeking orphan drug designation must file a complete request for designation.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">If a product with orphan designation receives the first FDA approval for the disease or condition for which it has such designation or for a select indication or use within the rare disease or condition for which it was designated, the product generally will receive orphan drug exclusivity. Orphan drug exclusivity means that the FDA may not approve another sponsor&#x2019;s marketing application for the same product for the same indication for seven years, except in certain limited circumstances, such as a showing of clinical superiority to the product with orphan exclusivity by means of greater effectiveness, greater safety, or providing a major contribution to patient care, or in instances of product supply issues. If a product designated as an orphan drug ultimately receives marketing approval for an indication broader than what was designated in its orphan drug application, it may not be entitled to exclusivity. Competitors may receive approval of either a different product for the same indication or the same product for a different indication.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The period of exclusivity begins on the date that the marketing application is approved by the FDA and applies only to the indication for which the product has been designated. The FDA may approve a second application for the same product for a different use or a second application for a clinically superior version of the product for the same use. Because healthcare professionals are free to prescribe products for off-label uses, the competitor&#x2019;s product could be used for the orphan indication despite another product&#x2019;s orphan exclusivity. The FDA cannot, however, approve the same product made by another manufacturer for the same indication during the market exclusivity period unless it has the consent of the sponsor or the sponsor is unable to provide sufficient quantities.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The FDA&#x2019;s determination of whether two ADCs are the same product for purposes of orphan drug exclusivity is based on a determination of sameness of the monoclonal antibody element and the functional element of the conjugated molecule. Two ADCs are deemed to be the same product if the complementarity determining region sequences of the antibody and the functional element of the conjugated molecule are the same. A difference in either of those two elements can result in a determination that the molecules are different.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">FDA approval and regulation of companion diagnostics</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">If use of an in vitro diagnostic is essential to the safe and effective use of a drug or biologic product, then the FDA generally will require approval or clearance of that diagnostic, known as a companion diagnostic, at the same time that the FDA approves the therapeutic product. In August 2014, the FDA issued final guidance clarifying the requirements that will apply to approval of therapeutic products and in vitro companion diagnostics. According to the guidance, if the FDA determines that a companion diagnostic device is essential to the safe and effective use of a biologic product or indication, the FDA generally will not approve the biologic product or new biologic product indication if the companion diagnostic device is not approved or cleared for that indication.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Under the FDCA, in vitro diagnostics, including companion diagnostics, are regulated as medical devices. In the United States, the FDCA and its implementing regulations, and other federal and state statutes and regulations govern, among other things, medical device design and development, preclinical and clinical testing, premarket clearance or approval, registration and listing, manufacturing, labeling, storage, advertising and promotion, sales and distribution, export and import, and post-market surveillance. Unless an exemption applies, diagnostic tests require marketing clearance or approval from the FDA prior to commercial distribution. The two primary types of FDA marketing authorization applicable to a medical device are premarket notification, also called 510(k) clearance, and premarket approval, or PMA, approval. The FDA has generally required in vitro companion diagnostics intended to select the patients who will respond to cancer treatment to obtain a PMA for that diagnostic simultaneously with approval of the therapeutic.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The PMA process, including the gathering of clinical and preclinical data and the submission to and review by the FDA, can take several years or longer. It involves a rigorous premarket review during which the applicant must prepare and provide the FDA with reasonable assurance of the device&#x2019;s safety and effectiveness and information about the device and its components regarding, among other things, device design, manufacturing and labeling. PMA applications are subject to an application fee. In addition, PMAs for certain devices must generally include the results from extensive preclinical and adequate and well-controlled clinical trials to establish the safety and effectiveness of the device for each indication for which FDA approval is sought. In particular, for a diagnostic, the applicant must demonstrate that the diagnostic has adequate sensitivity and specificity, has adequate specimen and reagent stability, and produces reproducible results when the same sample is tested multiple times by multiple users at multiple laboratories. As part of the PMA review, the FDA will typically inspect the manufacturer&#x2019;s facilities for compliance with the Quality System Regulation, or QSR, which imposes elaborate testing, control, documentation and other quality assurance requirements.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">35</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">PMA approval is not guaranteed, and the FDA may ultimately respond to a PMA submission with a not approvable determination based on deficiencies in the application and require additional clinical trial or other data that may be expensive and time-consuming to generate and that can substantially delay approval. If the FDA&#x2019;s evaluation of the PMA application is favorable, the FDA typically issues an approvable letter requiring the applicant&#x2019;s agreement to specific conditions, such as changes in labeling, or specific additional information, such as submission of final labeling, in order to secure final approval of the PMA. If the FDA&#x2019;s evaluation of the PMA or manufacturing facilities is not favorable, the FDA will deny approval of the PMA or issue a not approvable letter. A not approvable letter will outline the deficiencies in the application and, where practical, will identify what is necessary to make the PMA approvable. The FDA may also determine that additional clinical trials are necessary, in which case the PMA approval may be delayed for several months or years while the trials are conducted and then the data submitted in an amendment to the PMA. If the FDA concludes that the applicable criteria have been met, the FDA will issue a PMA for the approved indications, which can be more limited than those originally sought by the applicant. The PMA can include post-approval conditions that the FDA believes necessary to ensure the safety and effectiveness of the device, including, among other things, additional testing and/or restrictions on labeling, promotion, sale and distribution. Once granted, PMA approval may be withdrawn by the FDA if compliance with post approval requirements, conditions of approval or other regulatory standards are not maintained or problems are identified following initial marketing.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">After a device is placed on the market, it remains subject to significant regulatory requirements. Medical devices may be marketed only for the uses and indications for which they are cleared or approved. Device manufacturers must also register their establishments and list their devices with the FDA. A medical device manufacturer&#x2019;s manufacturing processes, and the processes of the device specification developer and repackager/relabeler (if different from the manufacturer) and initial importer (if manufactured outside of the United States) are required to comply with the applicable portions of the QSR, which cover the methods and documentation of the design, testing, production, processes, controls, quality assurance, importation, labeling, packaging and shipping of medical devices. Facility records and manufacturing processes are subject to periodic unscheduled inspections by the FDA.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Pediatric information</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Under the Pediatric Research Equity Act, or PREA, a BLA or supplement to a BLA must contain data to assess the safety and effectiveness of the biologic product candidate for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product candidate is safe and effective. The FDA may grant deferrals for submission of data or full or partial waivers. Unless otherwise required by regulation, the PREA generally does not apply to any biologic product candidate for an indication for which orphan designation has been granted with the exception of orphan-designated biologics if the biologic is a molecularly targeted cancer product intended for the treatment of an adult cancer and is directed at a molecular target that FDA has determined is substantially relevant to the growth or progression of a pediatric cancer.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The Best Pharmaceuticals for Children Act, or BPCA, provides a six-month extension of any non-patent exclusivity for a biologic if certain conditions are met. Conditions for exclusivity include the FDA&#x2019;s determination that information relating to the use of a new biologic in the pediatric population may produce health benefits in that population, the FDA making a written request for pediatric studies, and the applicant agreeing to perform, and reporting on, the requested studies within the statutory timeframe. Applications under the BPCA are treated as priority applications, with all of the benefits that designation confers.</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Biosimilars and exclusivity</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The Patient Protection and Affordable Care Act, or the ACA, includes a subtitle called the Biologics Price Competition and Innovation Act of 2009, or BPCIA, which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-licensed reference biological product. The FDA has licensed numerous biosimilars under the BPCIA, and has issued several guidance documents outlining an approach to review and approval of biosimilars.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Biosimilarity, which requires that there be no clinically meaningful differences between the proposed biosimilar biological product and the reference product in terms of safety, purity and potency, can be shown through analytical studies, animal studies and a clinical trial or studies though the FDA has broad discretion to set or waive certain biosimilar licensure data requirements. Interchangeability requires that a product is biosimilar to the reference product and the product must demonstrate that it can be expected to produce the same clinical results as the reference product in any given patient and, for products that are administered multiple times to an individual, the biologic and the reference biologic may be alternated or switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic. However, complexities associated with the larger, and often more complex, structures of biological products, as well as the processes by which such products are manufactured, pose some hurdles to biosimilar product implementation which is still being evaluated by the FDA.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">36</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing the applicant&#x2019;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of its product. The BPCIA also created an exclusivity period for biosimilars approved as interchangeable products. At this juncture, it is unclear whether products deemed &#x201c;interchangeable&#x201d; by the FDA will, in fact, be readily substituted by pharmacies, which are governed by state pharmacy law.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The first biologic product submitted under the biosimilar abbreviated approval pathway that is determined to be interchangeable with the reference product has exclusivity against a finding of interchangeability for other biologics for the same condition of use for the lesser of (i) one year after first commercial marketing of the first interchangeable biosimilar, (ii) 18 months after the first interchangeable biosimilar is approved if there is no patent challenge, (iii) eighteen months after resolution of a lawsuit over the patents of the reference biologic in favor of the first interchangeable biosimilar applicant, or (iv) 42 months after the first interchangeable biosimilar&#x2019;s application has been approved if a patent lawsuit is ongoing within the 42-month period.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Patent term restoration and extension</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">In the United States, a patent claiming a new biologic product, its method of use or its method of manufacture may be eligible for a limited patent term extension under the Hatch-Waxman Act, which permits a patent extension of up to five years for patent term lost during product development and FDA regulatory review. Assuming grant of the patent for which the extension is sought, the restoration period for a patent covering a product is typically one-half the time between the effective date of the IND involving human beings and the submission date of the BLA, plus the time between the submission date of the BLA and the ultimate approval date. Patent term restoration cannot be used to extend the remaining term of a patent past a total of 14 years from the product&#x2019;s approval date in the United States. Only one patent applicable to an approved product is eligible for the extension, and the application for the extension must be submitted prior to the expiration of the patent for which extension is sought. A patent that covers multiple products for which approval is sought can only be extended in connection with one of the approvals. The USPTO reviews and approves the application for any patent term extension in consultation with the FDA.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Regulation and procedures governing approval of medicinal products in the European Union</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">In order to market any product outside of the United States, a company must also comply with numerous and varying regulatory requirements of other countries and jurisdictions regarding quality, safety and efficacy and governing, among other things, clinical trials, marketing authorization, commercial sales, post-market surveillance and distribution of products. Whether or not it obtains FDA approval for a product, an applicant will need to obtain the necessary approvals by the comparable foreign regulatory authorities before it can commence clinical trials or marketing of the product in those countries or jurisdictions. Specifically, the process governing approval of medicinal products in the European Union generally follows the same lines as in the United States. It entails satisfactory completion of preclinical studies and adequate and well-controlled clinical trials to establish the safety and efficacy of the product for each proposed indication. Except in limited cases of compassionate use, it also requires the submission to the relevant competent authorities of a marketing authorization application, or MAA, and granting of a marketing authorization by these authorities before the product can be marketed and sold in the European Union.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Clinical trial approval</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Pursuant to the currently applicable Clinical Trials Directive 2001/20/EC and the Directive 2005/28/EC on GCP, a system for the approval of clinical trials (excluding non-interventional trials) conducted in the European Union has been implemented through national legislation of the member states. Under this system, the sponsor of a clinical trial must submit a request for authorization to the competent national authority of the European Union member state in which the clinical trial is to be conducted, or in multiple member states if the clinical trial is to be conducted in a number of member states. Furthermore, the applicant must obtain a favorable opinion from the competent ethics committee before starting a clinical trial. The clinical trial application must be accompanied by an investigational medicinal product dossier with supporting information prescribed by Directive 2001/20/EC and Directive 2005/28/EC and corresponding national laws of the member states and further detailed in applicable guidance documents.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">In April 2014, the European Union adopted a new Clinical Trials Regulation (EU) No 536/2014, but it has not yet become effective. Its application is subject to the full functionality of the European Union clinical trials portal and database. According to the most recent official communications, the audit aiming to confirm the full functionality of the portal and database will be conducted in December 2020. The new Clinical Trials Regulation will overhaul the current system of approvals for clinical trials in the European Union. Specifically, the new legislation, which will be directly applicable in all member states, aims at simplifying and streamlining the approval of clinical trials in the European Union. For instance, the new Clinical Trials Regulation provides for a streamlined application procedure via a single-entry point and shorter deadlines for the assessment of clinical trial applications. The scientific assessment of a clinical trial to be conducted in more than one Member State would be carried out once for all the concerned Member States while other aspects (e.g., informed consent requirements) are assessed by each Member State for its territory. In addition, sponsors must post clinical trial information (e.g., a summary of trial results) at the EudraCT website.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">PRIME designation in the European Union</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">In March 2016, the EMA launched an initiative to facilitate development of product candidates of major interest from the point of view of public health and in particular from the point of view of therapeutic innovation. The PRIority MEdicines, or PRIME, scheme is intended to encourage drug development in areas of unmet medical need and provides accelerated assessment of products representing substantial innovation</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">37</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">reviewed under the centralized procedure. Eligibility for the PRIME scheme depends on the availability of adequate preclinical and clinical data to justify a potential major public health interest prior to the initiation of confirmatory clinical trials at the proof of concept stage. Products from micro, small and medium-sized enterprises may qualify for earlier entry into the PRIME scheme than larger companies and benefit from fee reductions with the EMA. Many benefits accrue to sponsors of product candidates with PRIME designation, including early and proactive regulatory dialogue with the EMA, frequent discussions on clinical trial designs and other development program elements, scientific advice on key decision points for the preparation of the MAA and accelerated MAA assessment once a dossier has been submitted. More specifically, a kick-off meeting initiates these relationships and includes a team of multidisciplinary experts at the EMA to provide guidance on the overall development and regulatory strategies. Importantly, a dedicated EMA contact (rapporteur) from the Committee for Human Medicinal Products, or CHMP, or Committee for Advanced Therapies in the case of an advanced therapy, are appointed early in the PRIME scheme to provide continuous support and help to build knowledge ahead of a MAA.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Marketing authorization</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">To obtain a marketing authorization for a product under the European Union regulatory system, an applicant must submit an MAA, either under a centralized procedure administered by the EMA or one of the procedures administered by competent authorities in European Union Member States (decentralized procedure, national procedure, or mutual recognition procedure). A marketing authorization may be granted only to an applicant established in the European Union. In order to support the authorization of medicinal products for children, Regulation (EC) No 1901/2006 provides that prior to obtaining a marketing authorization in the European Union, an applicant must demonstrate compliance with all measures included in an EMA-approved Pediatric Investigation Plan, or PIP, covering all subsets of the pediatric population, unless the EMA has granted a product-specific waiver, class waiver or a deferral for one or more of the measures included in the PIP. The requirement for a PIP also applies to applications for new indications, pharmaceutical forms or routes of administration for medicinal products that are already authorized.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The centralized procedure provides for the grant of a single marketing authorization by the European Commission that is valid for all European Union Member States. Pursuant to Regulation (EC) No. 726/2004, the centralized procedure is compulsory for specific products, including for medicines produced by certain biotechnological processes, products designated as orphan medicinal products, advanced therapy products and products with a new active substance indicated for the treatment of certain diseases, including products for the treatment of cancer. For products with a new active substance indicated for the treatment of other diseases and products that are highly innovative or for which a centralized process is in the interest of patients, the centralized procedure is optional. Manufacturers must demonstrate the quality, safety and efficacy of their products to the EMA, which provides an opinion regarding the MAA through the CHMP responsible for conducting an initial assessment of the product.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The maximum timeframe for the evaluation of an MAA by the CHMP is 210 days, excluding clock stops when additional information or written or oral explanation is to be provided by the applicant in response to questions of the CHMP. Accelerated evaluation may be granted by the CHMP in exceptional cases, when a medicinal product is of major interest from the point of view of public health and, in particular, from the viewpoint of therapeutic innovation. If the CHMP accepts such a request, the time limit of 210 days will be reduced to 150 days, but it is possible that the CHMP may revert to the standard time limit for the centralized procedure if it determines that it is no longer appropriate to conduct an accelerated assessment. The final decision on the MAA is issued by the European Commission, in light of the opinion delivered by the EMA, and after the Member States have had an opportunity to comment on it.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">With respect to medicinal products for which a centralized authorization is not mandatory, the applicant may choose between: (i) the national procedure provided for by a specific Member State, for the marketing of the product in its territory, (ii) the decentralized procedure, for drug candidates that are not marketed in any of the Member States but the applicant wishes to market them on more than one EU national territories or (iii) the mutual recognition procedure, which applies to products already authorized in a Member State and whose marketing in other Member States&#x2019; territories is sought.</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Regulatory data protection in the European Union</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">In the European Union, new chemical entities approved on the basis of a complete independent data package qualify for eight years of data exclusivity upon marketing authorization and an additional two years of market exclusivity pursuant to Regulation (EC) No 726/2004, as amended, and Directive 2001/83/EC, as amended.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:10.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">These exclusivity periods apply only once from the first authorization granted to an applicant for a given active substance and they cannot be renewed when the same marketing authorization holder is granted new authorizations for new indications, strengths, pharmaceutical forms, administration routes or presentations of the same active substance. Data exclusivity prevents regulatory authorities in the European Union from referencing the innovator&#x2019;s data to assess another product (either generic, hybrid or biosimilar) application for a period of eight years. During the additional two-year period of market exclusivity, a generic, hybrid or biosimilar marketing authorization application can be submitted, and the innovator&#x2019;s data may be referenced, but no generic, hybrid or biosimilar medicinal product can be marketed until the expiration of the market exclusivity. The overall 10-year period will be extended to a maximum of 11 years if, during the first eight years of those 10 years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to authorization, is held to bring a significant clinical benefit in comparison with existing therapies. Even if a compound is considered to be a new chemical entity so that the innovator gains the prescribed period of data exclusivity, another company may market another version of the product if such company obtained marketing authorization based on an MAA with a complete independent data package of pharmaceutical tests, preclinical tests and clinical trials.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">38</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Patent term extensions in the European Union and other jurisdictions</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The European Union also provides for patent term extension through Supplementary Protection Certificates, or SPCs. The rules and requirements for obtaining a SPC are similar to those in the United States. An SPC may extend the term of a patent for up to five years after its originally scheduled expiration date. In certain circumstances, these periods may be extended for six additional months if pediatric exclusivity is obtained. Although SPCs are available throughout the European Union, sponsors must apply on a country-by-country basis. Similar patent term extension rights exist in certain other foreign jurisdictions outside the European Union.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Periods of authorization and renewals</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">A marketing authorization is valid for five years, in principle, and it may be renewed after five years on the basis of a reevaluation of the risk-benefit balance by the EMA or by the competent authority of the authorizing member state, depending on the procedure through which the marketing authorization has been granted. To that end, the marketing authorization holder must provide the EMA or the competent authority with a consolidated version of the file in respect of quality, safety and efficacy, including all variations introduced since the marketing authorization was granted, at least nine months before the marketing authorization ceases to be valid. Once renewed, the marketing authorization is valid for an unlimited period, unless the European Commission or the competent authority decides, on justified grounds relating to pharmacovigilance, to proceed with one additional five-year renewal period. Any authorization that is not followed by the placement of the drug on the European Union market (in the case of the centralized procedure) or on the market of the authorizing member state within three years after authorization is granted ceases to be valid.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Regulatory requirements after marketing authorization</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Following approval, the holder of the marketing authorization is required to comply with a range of requirements applicable to the manufacturing, marketing, promotion and sale of the medicinal product. These include compliance with the European Union&#x2019;s stringent pharmacovigilance or safety reporting rules, pursuant to which post-authorization studies and additional monitoring obligations can be imposed. In addition, the manufacturing of authorized products, for which a separate manufacturer&#x2019;s license is mandatory, must also be conducted in strict compliance with the EMA&#x2019;s GMP requirements and comparable requirements of other regulatory bodies in the European Union, which mandate the methods, facilities and controls used in the manufacturing, processing and packing of drugs to assure their safety and identity. Finally, the marketing and promotion of authorized products, including industry-sponsored continuing medical education and advertising directed toward the prescribers of drugs and/or the general public, are strictly regulated in the European Union under Directive 2001/83EC, as amended.</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Orphan drug designation and exclusivity</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Regulation (EC) No 141/2000 and Regulation (EC) No. 847/2000 provide that a product can be designated as an orphan drug by the European Commission if its sponsor can establish: that the product is intended for the diagnosis, prevention or treatment of (i) a life-threatening or chronically debilitating condition affecting not more than five in ten thousand persons in the European Union when the application is made, or (ii) a life-threatening, seriously debilitating or serious and chronic condition in the European Union and that without incentives it is unlikely that the marketing of the drug in the European Union would generate sufficient return to justify the necessary investment. For either of these conditions, the applicant must demonstrate that there exists no satisfactory method of diagnosis, prevention or treatment of the condition in question that has been authorized in the European Union or, if such method exists, the drug for which the orphan designation is requested will be of significant benefit to those affected by that condition.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">An orphan drug designation provides a number of benefits, including fee reductions, regulatory and scientific assistance and the possibility to apply for a centralized European Union marketing authorization. In particular, an orphan drug designation leads to a 10-year period of market exclusivity from the granting of the concerned medicinal product marketing authorization for the particular indication. During this market exclusivity period, neither the EMA nor the member states can accept an application or grant a marketing authorization for a &#x201c;similar medicinal product.&#x201d; A &#x201c;similar medicinal product&#x201d; is defined as a medicinal product containing a similar or identical active substance, or substances as contained in an authorized orphan medicinal product, and which is intended for the same therapeutic indication. The market exclusivity period for the authorized therapeutic indication may, however, be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan drug designation because, for example, the product is sufficiently profitable so as to not to justify market exclusivity.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">General Data Protection Regulation</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The collection, use, disclosure, transfer or other processing of personal data regarding individuals in the European Union, including personal health data, is subject to the Regulation (EU) No. 2016/679, the GDPR, which became effective on May 25, 2018. The GDPR is wide-ranging in scope and imposes numerous requirements on companies that process personal data, including requirements relating to processing health and other sensitive data, obtaining consent of the individuals to whom the personal data relates, providing information to individuals regarding data processing activities, implementing safeguards to protect the security and confidentiality of personal data, providing notification of data breaches and taking certain measures when engaging third-party processors. The GDPR also imposes strict rules on the transfer of personal data to countries outside the European Union, including the United States, and permits data protection authorities to impose large penalties for violations of the GDPR, including potential fines of up to &#x20ac;20 million or 4% of annual global turnover of the preceding financial year, whichever is greater. The GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies and obtain compensation for damages resulting from violations of the GDPR. Compliance with the GDPR will be a rigorous and time-intensive process that may increase the cost of doing business or require companies to change their business practices to ensure full compliance.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">39</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Brexit and the regulatory framework in the United Kingdom</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">On June 23, 2016, the electorate in the United Kingdom voted in favor of leaving the European Union, commonly referred to as Brexit. Following protracted negotiations, the United Kingdom left the European Union on January 31, 2020. The transition period ended on December 31, 2020. On December 30, 2020, the United Kingdom and EU signed the Trade and Cooperation Agreement (TCA), which includes an agreement on free trade between the two parties. The TCA does not contain wholesale mutual recognition of regulatory regimes for pharmaceuticals as was hoped. There is mutual recognition of cGMP inspections of manufacturing facilities but it does not include reciprocal arrangements for the recognition of batch testing certification, in order to avoid unnecessary re-testing on importation of products.</font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">There is considerable uncertainty resulting from a lack of precedent and the complexity of the United Kingdom and the EU&#x2019;s intertwined legal regimes as to how Brexit will impact the life sciences industry in Europe, including our company, including with respect to ongoing or future clinical trials. Any delay in obtaining, or an inability to obtain, any marketing approvals, as a result of Brexit or otherwise, may force us to restrict or delay efforts to seek regulatory approval in the United Kingdom for any product candidates we may develop, which could significantly and materially harm our business.  See &#x201c;Risk factors&#x2014;Risks related to regulatory approval and other legal compliance matters&#x2014; Our relationships with healthcare professionals, clinical investigators, CROs and third-party payors in connection with our current and future business activities may be subject to federal and state healthcare fraud and abuse laws, false claims laws, transparency laws, government price reporting and health information privacy and security laws, which could expose us to significant losses, including, among other things, criminal sanctions, civil penalties, contractual damages, exclusion from governmental healthcare programs, reputational harm, administrative burdens and diminished profits and future earnings&#x201d; for additional disclosures regarding risks related to privacy laws in the United Kingdom and European Union.   <br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Coverage and reimbursement</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Sales of our product candidates, if approved, will depend, in part, on the extent to which such products will be covered by third-party payors, such as government healthcare programs, commercial insurance and managed healthcare organizations. These third-party payors are increasingly limiting coverage or reducing reimbursements for medical products and services. In the United States, no uniform policy of coverage and reimbursement for products exists among third-party payors. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. In addition, the U.S. government, state legislatures and foreign governments have continued implementing cost-containment programs, including price controls, restrictions on reimbursement and requirements for substitution of generic products. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit our net revenue and results. Decreases in third-party reimbursement for our product candidates or a decision by a third-party payor to not cover our product candidates could reduce physician usage of our product candidates, once approved, and have a material adverse effect on our sales, results of operations and financial condition.</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Other U.S. healthcare laws and compliance requirements</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">In the United States, biotechnology company activities are potentially subject to regulation by various federal, state and local authorities in addition to the FDA, including but not limited to, the Centers for Medicare &amp; Medicaid Services, or CMS, other divisions of the U.S. Department of Health and Human Services, or HHS (e.g., the Office of Inspector General and the Office for Civil Rights), the U.S. Department of Justice, or the DOJ, and individual U.S. Attorney offices within the DOJ, and state and local governments. The laws biotechnology companies may have to comply with include the anti-fraud and abuse provisions of the Social Security Act, the federal false claims laws, the privacy and security provisions of the Health Insurance Portability and Accountability Act of 1996, or HIPAA, and similar state laws, each as amended, as applicable.</font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The federal Anti-Kickback Statute prohibits, among other things, any person or entity, from knowingly and willfully offering, paying, soliciting or receiving any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or in return for purchasing, leasing, ordering, recommending or arranging for the purchase, lease or order of any item or service reimbursable under Medicare, Medicaid or other federal healthcare programs. The term remuneration has been interpreted broadly to include anything of value. The Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on one hand and prescribers, purchasers, and/or formulary managers on the other. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution. The exceptions and safe harbors are drawn narrowly and practices that involve remuneration that may be alleged to be intended to induce prescribing, purchasing or recommending may be subject to scrutiny if they do not qualify for an exception or safe harbor. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the Anti-Kickback Statute. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative review of all of its facts and circumstances. Practices may not in all cases meet all of the criteria for protection under a statutory exception or regulatory safe harbor. In addition, the statutory exceptions and regulatory safe harbors are subject to change. Additionally, the intent standard under the Anti-Kickback Statute was amended by the ACA, to a stricter standard such that a person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. In addition, the ACA codified case law that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act.</font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Federal false claims laws, including the federal civil False Claims Act, prohibit, among other things, any person or entity from knowingly presenting, or causing to be presented, a false claim for payment to, or approval by, the federal government or knowingly making, using, or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government. As a result of a modification made by the Fraud Enforcement and Recovery Act of 2009, a claim includes &#x201c;any request or demand&#x201d; for money or property presented to the U.S. government. In addition, manufacturers can be held liable under the civil False Claims Act even when they do not submit claims directly to government payors if they are deemed to &#x201c;cause&#x201d; the submission of false or fraudulent claims. Pharmaceutical and other biotechnology companies have been prosecuted under these laws for, among other things, allegedly providing free product to customers with the</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">40</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">expectation that the customers would bill federal programs for the product. Other companies have been prosecuted for causing false claims to be submitted because of the companies&#x2019; marketing of the product for unapproved, and thus generally non-reimbursable, uses and purportedly concealing price concessions in the pricing information submitted to the government for government price reporting purposes.</font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">HIPAA created additional federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud or to obtain, by means of false or fraudulent pretenses, representations or promises, any money or property owned by, or under the control or custody of, any healthcare benefit program, including private third-party payors and knowingly and willfully falsifying, concealing or covering up by trick, scheme or device, a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Similar to the Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation.</font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Also, many states have similar fraud and abuse statutes or regulations that apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payor.</font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Additionally, the federal Physician Payments Sunshine Act within the ACA, and its implementing regulations, require that certain manufacturers of drugs, devices, biological and medical supplies for which payment is available under Medicare, Medicaid or the Children&#x2019;s Health Insurance Program (with certain exceptions) report annually to CMS information related to certain payments or other transfers of value made or distributed to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), physician assistants, certain types of advance practice nurses and teaching hospitals, or to entities or individuals at the request of, or designated on behalf of such providers, and to report annually certain ownership and investment interests held by physicians and their immediate family members.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Violation of any of the federal and state healthcare laws described above or any other governmental regulations may result in penalties, including without limitation, significant civil, criminal and/or administrative penalties, damages, fines, disgorgement, exclusion from participation in government programs, such as Medicare and Medicaid, imprisonment, injunctions, private &#x201c;qui tam&#x201d; actions brought by individual whistleblowers in the name of the government, refusal to enter into government contracts, oversight monitoring, contractual damages, reputational harm, administrative burdens, diminished profits and future earnings.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Federal and state data privacy and security laws</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Under HIPAA, HHS has issued regulations to protect the privacy and security of protected health information used or disclosed by covered entities including certain healthcare providers, health plans and healthcare clearinghouses. HIPAA also regulates standardization of data content, codes and formats used in healthcare transactions and standardization of identifiers for health plans and providers. HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and their regulations, including the final omnibus rule published on January 25, 2013, also imposes certain obligations on the business associates of covered entities that obtain protected health information in providing services to or on behalf of covered entities. In addition to federal privacy regulations, there are a number of state laws governing confidentiality and security of health information that are applicable to our business. In addition to possible federal administrative, civil and criminal penalties for HIPAA violations, state attorneys general are authorized to file civil actions for damages or injunctions in federal courts to enforce HIPAA and seek attorney&#x2019;s fees and costs associated with pursuing federal civil actions. Accordingly, state attorneys general have brought civil actions seeking injunctions and damages resulting from alleged violations of HIPAA&#x2019;s privacy and security rules. New laws and regulations governing privacy and security may be adopted in the future as well.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Additionally, state laws govern the privacy and security of health information in specified circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. For example, the California Consumer Privacy Act, or CCPA, creates new individual privacy rights for consumers (as that word is broadly defined in the law) and places increased privacy and security obligations on entities handling personal data of consumers or households. The CCPA went into effect on January 1, 2020 and requires covered companies to provide new disclosures to California consumers, provide such consumers new ways to opt-out of certain sales of personal information, and allow for a new cause of action for data breaches. This private right of action may increase the likelihood of, and risks associated with, data breach litigation. On November 3, 2020, California voters approved a new privacy law, the California Privacy Rights Act, or the CPRA, which significantly modifies the CCPA, including by expanding consumers&#x2019; rights with respect to certain personal information and creating a new state agency to oversee implementation and enforcement efforts. Many of the CPRA&#x2019;s provisions will become effective on January 1, 2023. State laws are changing rapidly and there is discussion in the U.S. of a new comprehensive federal data privacy law to which we would become subject if it is enacted.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Because of the breadth of these laws and the narrowness of the statutory exceptions and regulatory safe harbors available under such laws, it is possible that some of our current or future business activities, including certain clinical research, sales and marketing practices and the provision of certain items and services to our customers, could be subject to challenge under one or more of such privacy and data security laws. The heightening compliance environment and the need to build and maintain robust and secure systems to comply with different privacy compliance and reporting requirements in multiple jurisdictions could increase the possibility that a healthcare company may fail to comply fully with one or more of these requirements. If our operations are found to be in violation of any of the privacy or data security laws or regulations described above that are applicable to us, or any other laws that apply to us, we may be subject to penalties, including potentially significant criminal, civil and administrative penalties, damages, fines, imprisonment, contractual damages, reputational harm, diminished profits and future earnings, additional reporting requirements and oversight if we become subject to a consent decree or similar agreement to resolve allegations of non-compliance with these laws, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. To the extent that any product candidates we may develop, once approved, are sold in a foreign country, we may be subject to similar foreign laws.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">41</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Healthcare reform</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Healthcare reforms that have been adopted, and that may be adopted in the future, could result in further reductions in coverage and levels of reimbursement for pharmaceutical products, increases in rebates payable under U.S. government rebate programs and additional downward pressure on pharmaceutical product prices.   On September 9, 2021, the Biden administration published a wide-ranging list of policy proposals, most of which would need to be carried out by Congress, to reduce drug prices and drug payment. The HHS plan includes, among other reform measures, proposals to lower prescription drug prices, including by allowing Medicare to negotiate prices and disincentivizing price increases, and to support market changes that strengthen supply chains, promote biosimilars and generic drugs, and increase price transparency. Many similar proposals, including the plans to give Medicare Part D authority to negotiate drug prices, require drug manufacturers to pay rebates on drugs whose prices increase greater than the rate of inflation, and cap out-of-pocket costs, have already been included in policy statements and legislation currently being considered by Congress. It is unclear to what extent these and other statutory, regulatory, and administrative initiatives will be enacted and implemented.</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Human Capital Management</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Employees</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">. As of December 31, 2021, we employed 56 employees. We also engaged 18 independent contractors located in China as of December 31, 2021 pursuant to our relationship with BioDuro-Sundia, a U.S.-based provider of preclinical development services. None of our employees are subject to a collective bargaining agreement. We consider our relationship with our employees to be good.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Compensation and Benefits Program</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">. Our compensation program is designed to attract and reward talented individuals who possess the skills necessary to support our business objectives, assist in the achievement of our strategic goals and create long-term value for our stockholders. We provide employees with compensation packages that include base salary, annual incentive bonuses, and long-term equity awards tied to the value of our stock price. We believe that a compensation program with both short-term and long-term awards provides fair and competitive compensation and aligns employee and stockholder interests, including by incentivizing business and individual performance (pay for performance), motivating based on long-term company performance and integrating compensation with our business plans. In addition to cash and equity compensation, we also offer employees benefits such as life and health (medical, dental &amp; vision) insurance, paid time off, paid parental leave, participation in our Employee Stock Purchase Plan and a 401(k) plan.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Diversity and Inclusion</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">. We believe that an equitable and inclusive environment with diverse teams produces more creative solutions, results in better, more innovative products and services and is crucial to our efforts to attract and retain key talent. Our current efforts are focused on three primary areas:</font></p>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Safe work environment. We provide training to all employees to improve their understanding of behaviors that can be perceived as discriminatory, exclusionary, and/or harassing, and provide safe avenues for employees to report such behaviors.</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Equal employment opportunity. We ensure that our practices and processes attract a diverse range of candidate, and that candidates are recruited, hired, assigned, developed, and promoted based on merit and their alignment to our values.</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Learning and development opportunities. To support our employees in reaching their full potential, we offer a wide range of internal and external learning and development opportunities.</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Community Involvement. We aim to give back to the communities where we live and work, and believe that this commitment helps in our efforts to attract and retain employees. We work with local universities to introduce and promote careers in science and biotechnology through internship opportunities.</font></div></div>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Corporate Information</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Our business was founded in March 2007 and originally operated as a Delaware limited liability company, BioAtla, LLC. In July 2020, we converted from a limited liability company into a Delaware corporation pursuant to a statutory conversion and changed our name from BioAtla, LLC to BioAtla, Inc. Our principal executive offices are located at 11085 Torreyana Road, San Diego, California 92121, and our telephone number is (858) 558-0708. Our corporate website address is www.bioatla.com. Information contained on, or that may be accessed through, our website is not incorporated by reference into this Annual Report on Form 10-K and should not be considered a part of this Annual Report on Form 10-K.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We have obtained a registered trademark for BioAtla</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#174;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> in the United States. This Annual Report on Form 10-K contains references to our trademarks and to trademarks belonging to other entities. Solely for convenience, trademarks and trade names referred to in this Annual Report on Form 10-K, including logos, artwork and other visual displays, may appear without the </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#174;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> or </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.03pt;font-family:Times New Roman;">TM </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensor to these trademarks and trade names. We do not intend our use or display of other companies&#x2019; trade names or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other companies.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">42</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Available Information</font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We make available, free of charge through our website www.bioatla.com, our annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, and amendments to those reports, filed or furnished pursuant to Sections 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended, as soon as reasonably practicable after they have been electronically filed with, or furnished to, the SEC.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The SEC maintains an internet site (http://www.sec.gov) that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC.</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:16.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1a_risk_factors"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">ITEM 1A. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Risk Factors</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Risk Factor Summary</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Investing in our common stock involves a high degree of risk. You should carefully consider all information in this Annual Report on Form 10-K before purchasing our common stock. These risks and uncertainties include, but are not limited to, the following:</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <div style="margin-left:6.796%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We are a clinical-stage biopharmaceutical company with a limited operating history and no products approved for commercial sale, and we have a history of significant losses and expect to continue to incur significant losses for the foreseeable future.</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We will require substantial additional capital to finance our operations, and if we fail to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce or eliminate one or more of our research and drug development programs or future commercialization efforts.</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Our product candidates may fail in development or suffer delays that adversely affect their commercial viability.</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We are substantially dependent on the success of our patented CAB technology platform, and our future success depends heavily on the successful development of this platform.</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We may expend our resources to pursue particular product candidates and fail to capitalize on product candidates that may be more profitable or for which there is a greater likelihood of success</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The market may not be receptive to our product candidates because they are based on our novel therapeutic modality, and we may not generate any future revenue from the sale or licensing of product candidates.</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Results from early-stage clinical trials may not be predictive of results from late-stage or other clinical trials, and the results of our clinical trials may not satisfy the requirements of the FDA, EMA or other comparable foreign regulatory authorities.</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Interim, topline and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available, and are subject to audit and verification procedures that could result in material changes in the final data.</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Delays in the commencement and completion of clinical trials could increase costs and delay or prevent regulatory approval and commercialization of our product candidates.</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We face competition from entities that have developed or may develop product candidates for cancer, including companies developing novel treatments and technology platforms.</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We may be unable to obtain U.S. or foreign regulatory approval and, as a result, unable to commercialize our product candidates.</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We intend to seek approval from the FDA or comparable foreign regulatory authorities through the use of accelerated approval pathways, if available, and if we are unable to obtain such approval, we may be required to conduct additional preclinical studies or clinical trials beyond those that we contemplate, which could increase the expense of obtaining, and delay the receipt of, necessary marketing approvals.</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Even if we receive regulatory approval for any of our product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense.</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">If we fail to attract and retain qualified senior management and key scientific personnel, our business may be materially and adversely affected.</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">If we are unable to establish sales, marketing and distribution capabilities on our own or through third parties, we may not be able to market and sell our product candidates, if approved, effectively in the United States and foreign jurisdictions or generate product revenue.</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">A portion of our research and development activities take place in China, and uncertainties regarding the interpretation and enforcement of Chinese laws, rules and regulations, a trade war, deterioration of international relations, or political unrest in China could materially adversely affect our business, financial condition and results of operations.</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We face risks related to health epidemics and outbreaks, including the COVID-19 pandemic, which could significantly disrupt our preclinical studies and could affect enrollment of patients in our clinical trials. Continuation and increasing severity of these conditions could delay or prevent our receipt of necessary regulatory approvals.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">43</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">If we fail to enter into collaborations with third parties for the development and commercialization of certain of our product candidates, or if our current and future collaborations are not successful, we may not be able to capitalize on the market potential of our patented technology platform and resulting product candidates.</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">If we are not able to obtain, maintain and protect our intellectual property rights in any product candidates or technologies we develop, or if the scope of the intellectual property protection obtained is not sufficiently broad, third parties could develop and commercialize products and technology similar or identical to ours, and we may not be able to compete effectively in our market.</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Intellectual property rights of third parties could prevent or delay our drug discovery and development efforts and could adversely affect our ability to commercialize our product candidates, and we might be required to litigate or obtain licenses from third parties in order to discover, develop or market our product candidates.</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The future issuance of equity or of debt securities that are convertible into equity will dilute our share capital.</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval and their interests may conflict with your interests as an owner of our common stock.</font></div></div>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Risk Factors</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Risks related to our financial position and need for additional capital</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">We are a clinical-stage biopharmaceutical company with a limited operating history and no products approved for commercial sale. We have a history of significant losses and we expect to continue to incur significant losses for the foreseeable future, which together with our limited operating history, makes it difficult to assess our future viability.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We are a phase 2 clinical-stage biopharmaceutical company with a limited operating history upon which you can evaluate our business and prospects. We have no products approved for commercial sale and have not generated any revenue from product sales. Since the commencement of our operations, we have focused substantially all of our resources on conducting research and development activities, including drug discovery, preclinical studies and clinical trials of our product candidates, including the ongoing Phase 2 clinical trials of mecbotamab vedotin and ozuriftamab vedotin, establishing and maintaining our intellectual property portfolio, manufacturing clinical and research material through third parties, hiring personnel, establishing product development and commercialization collaborations with third parties, raising capital and providing general and administrative support for these operations. We have not yet demonstrated our ability to successfully obtain marketing approvals, manufacture a commercial-scale product or arrange for a third party to do so on our behalf or conduct sales and marketing activities necessary for successful product commercialization. As a result, it may be more difficult for you to assess our future viability than it could be if we had a longer operating history.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We have incurred significant losses to date. Our ability to generate product revenue sufficient to achieve profitability will depend on the successful development and eventual commercialization of one or more of our current and future product candidates. Our net losses were $95.4 million, $35.9 million, and $29.8 million for the years ended December 31, 2021, 2020, and 2019, respectively. As of December 31, 2021, we had an accumulated deficit of $186.3 million. These losses have resulted primarily from costs incurred in connection with research and development activities and general and administrative costs associated with our operations. We do not expect to generate meaningful revenue from product sales for the foreseeable future, and we expect to continue to incur significant operating expenses for the foreseeable future due to the cost of research and development, including identifying and designing product candidates and conducting preclinical studies and clinical trials, and the regulatory approval process for our product candidates. We expect our expenses, and the potential for losses, to increase substantially as we conduct clinical trials of our lead product candidates and seek to expand our pipeline.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">However, the amount of our future expenses and potential losses is uncertain. Our ability to achieve profitability, if ever, will depend on, among other things, our successfully developing product candidates, obtaining regulatory approvals to market and commercialize product candidates, manufacturing any approved products on commercially reasonable terms and potentially establishing a sales and marketing organization or suitable third-party alternatives to commercialize any approved product. If we, or our existing or future collaborators, are unable to develop and commercialize one or more of our product candidates or if sales revenue from any product candidate that receives approval is insufficient, we will not achieve profitability, which could have a material and adverse effect on our business, financial condition, results of operations and prospects.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">We will require substantial additional capital to finance our operations. If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce or eliminate one or more of our research and drug development programs or future commercialization efforts.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The development of biopharmaceutical products, including conducting preclinical studies and clinical trials, is a very time-consuming, expensive and uncertain process that takes years to complete. Our operations have consumed substantial amounts of cash since inception, and we expect our expenses to increase in connection with our ongoing activities, particularly as we conduct clinical trials of, and seek marketing approval for mecbotamab vedotin, ozuriftamab vedotin and BA3071 and advance our other programs. Even if one or more of the product candidates that we develop is approved for commercial sale, we anticipate incurring significant costs associated with sales, marketing, manufacturing and distribution activities. Our expenses could increase beyond expectations if we are required by the FDA, the EMA or other comparable foreign regulatory agencies to perform clinical trials or preclinical studies in addition to those that we currently anticipate. Other unanticipated costs may also arise. Because the design and outcome of our planned and anticipated clinical trials are highly uncertain, we cannot reasonably estimate the actual amount of resources and funding that will be necessary to successfully complete the development and</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">44</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">commercialization of any product candidate we develop. Accordingly, we will need to obtain substantial additional funding in order to continue our operations.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">As of December 31, 2021, we had approximately $245.0 million in cash and cash equivalents. Based on our current operating plan, our current cash and cash equivalents are expected to be sufficient to fund our ongoing operations into the first half of 2024. Our estimate as to how long we expect our existing cash and cash equivalents, to be able to continue to fund our operations is based on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. Changing circumstances, some of which may be beyond our control, could cause us to consume capital significantly faster than we currently anticipate, and we may need to seek additional funds sooner than planned.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We plan to use our existing cash and cash equivalents to fund the research and development of our product candidates and development programs, and to fund working capital and other general corporate purposes.</font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:10.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Advancing the development of our product candidates will require a significant amount of capital. Our existing cash and cash equivalents may not be sufficient to fund any of our product candidates through regulatory approval. Because the length of time and activities associated with successful research and development of any individual product candidate are highly uncertain, we are unable to estimate the actual funds we will require for development, marketing approval and commercialization activities. The timing and amount of our operating expenditures will depend largely on:</font></p>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">the timing and progress of our ongoing clinical trials for mecbotamab vedotin and ozuriftamab vedotin;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">the number and scope of preclinical and clinical programs we decide to pursue;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">the progress of the clinical development efforts for BA3071;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">the progress of our current and future collaborators with whom we have entered or may in the future enter into collaborations and research and development agreements;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">the timing and amount of target specific indication and milestone payments we may receive under our collaboration agreements;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">our ability to maintain our current licenses, collaboration and research and development programs or possibly establish new collaboration arrangements;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">the costs involved in prosecuting and enforcing patent and other intellectual property claims;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">the cost and timing of regulatory approvals; and</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">our efforts to enhance operational systems and hire additional personnel, including personnel to support development of our product candidates and satisfy our obligations as a public company.</font></div></div>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">If we are unable to obtain funding on a timely basis, including under our current or future collaborations, or on acceptable terms, we may have to delay, reduce or terminate our research and development programs and preclinical studies or clinical trials, limit strategic opportunities or undergo reductions in our workforce or other corporate restructuring activities. We may seek to raise any necessary additional capital through a combination of public or private equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements and other marketing and distribution arrangements. We cannot assure you that such financing will be available at acceptable terms to us, if at all. Failure to generate sufficient cash flows from operations, raise additional capital, and reduce discretionary spending should additional capital not become available could have a material adverse effect on our ability to achieve our intended business objectives. To the extent that we raise additional capital through collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our product candidates. We may also have to forego future revenue streams of research programs at an earlier stage of development or on less favorable terms than we would otherwise choose or have to grant licenses on terms that may not be favorable to us. Our ability to raise additional funds will depend on financial, economic and other factors, many of which are beyond our control. If we do raise additional capital through public or private equity or convertible debt offerings, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our stockholders&#x2019; rights. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, acquiring other businesses, products or technology or declaring dividends. If we are unable to obtain additional funding from these or other sources, it may be necessary to significantly reduce our rate of spending through reductions in staff and delay, scale back or stop certain research and development programs.</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:10.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Risks related to the discovery, development and commercialization of our product candidates</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Our current product candidates are in various stages of development. Our product candidates may fail in development or suffer delays that adversely affect their commercial viability. If we or our existing or future collaborators are unable to complete development of, obtain regulatory approval for or commercialize our product candidates or experience significant delays in doing so, our business will be materially harmed.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We have no products on the market and our product candidates are in various stages of development. We are currently conducting Phase 2 clinical trials of mecbotamab vedotin and ozuriftamab vedotin, and we expect Phase 1 trials of BA3071 first patient dosed in the first half of 2022 and various other product candidates in earlier stages of development. Our ability to achieve and sustain profitability depends on obtaining regulatory approvals for and, if approved, successfully commercializing our product candidates, either alone or with third parties. Before</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">45</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">obtaining regulatory approval for the commercial distribution of our product candidates, we or an existing or future collaborator must conduct extensive preclinical tests and clinical trials to demonstrate the safety, efficacy, purity and potency of our product candidates. In addition, the FDA may not agree with our clinical trial plans. For example, we have initiated potentially registration-enabling Phase 2 trials for mecbotamab vedotin in treatment-refractory sarcoma patients and PD-1 refractory NSCLC patients. The FDA has reviewed the trial designs but has not opined on whether the Phase 2 clinical trials will in fact be sufficient to support regulatory approval. However, we intend to ask the FDA to consider this further at the planned interim data review point or points. We cannot assure you that the FDA will agree that such data will be sufficient to support approval. Any product candidate can unexpectedly fail at any stage of preclinical or clinical development and the historical failure rate for product candidates is high. The results from preclinical testing of a product candidate may not predict the results that will be obtained in later clinical trials of the product candidate. We or our existing or future collaborators may experience issues that delay or prevent clinical testing and regulatory approval of, or our ability to commercialize, product candidates, including:</font></p>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">delays in our clinical trials resulting from factors including those related to the COVID-19 pandemic;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">negative or inconclusive results from preclinical testing or clinical trials leading to a decision or requirement to conduct additional preclinical testing or clinical trials or abandon a program;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">product-related side effects experienced by participants in clinical trials or by individuals using therapeutic biologics that share characteristics with our product candidates;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">delays in submitting INDs or comparable foreign applications or delays or failure in obtaining the necessary approvals from regulators or institutional review boards, or IRBs, to commence a clinical trial, or a suspension or termination of a clinical trial once commenced;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">conditions imposed by the FDA or comparable foreign authorities, including the EMA, regarding the scope or design of clinical trials;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">delays in enrolling patients in clinical trials;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">high drop-out rates of patients;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">inadequate drug materials or other supplies necessary for the conduct of our clinical trials;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">greater than anticipated clinical trial costs;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">poor effectiveness of our product candidates during clinical trials;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">unfavorable FDA or other regulatory agency inspection and review of a clinical trial site;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">deficiencies in our third-party manufacturers&#x2019; manufacturing processes or facilities;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">success or further approval of competitor products approved in indications in which we undertake development of our product candidates, which may change the standard of care or change the standard for approval of our product candidates in our proposed indications;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> failure of any third-party contractors, investigators or contract research organizations, or CROs, to comply with regulatory requirements or otherwise meet their contractual obligations in a timely manner, or at all;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">delays and changes in regulatory requirements, policy and guidelines, including the imposition of additional regulatory oversight around clinical testing generally or with respect to our technology or product candidates in particular; or</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">varying interpretations of data by the FDA and similar foreign regulatory agencies, including the EMA.</font></div></div>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Because CABs represent a new generation of antibodies, a delay or failure in development of any CAB product candidate could represent a major set-back for our patented technology platform and for our company generally.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">We are substantially dependent on the success of our patented CAB technology platform, and our future success depends heavily on the successful development of this platform.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We use our CAB technology platform to develop product candidates for cancer therapies. Any failures or setbacks involving our CAB technology platform, including adverse events, could have a detrimental impact on all of our product candidates and our research pipeline. For example, we may uncover a previously unknown risk associated with CABs or other issues that may be more problematic than we currently believe, which may prolong the period of observation required for obtaining, necessitate additional clinical testing or result in the failure to obtain, regulatory approval. If our CAB technology is not safe in certain product candidates, we would be required to abandon or redesign all of our current product candidates, which could have a material adverse effect on our business, financial condition, results of operations and prospects.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">We may not be successful in our efforts to use and expand our patented CAB technology platform to continue to build a pipeline of product candidates and develop marketable products.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We are using our patented technology platform to develop CABs in oncology indications with our lead product candidates mecbotamab vedotin and ozuriftamab vedotin, as well as continuing to build our pipeline of product candidates. Our business depends not only on our ability to successfully develop, obtain regulatory approval for, and commercialize the product candidates we currently have in clinical and preclinical</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">46</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">development, but to continue to generate new product candidates through our platform. Even if we are successful in continuing to build our pipeline and further progress the clinical development of our current product candidates, any additional product candidates may not be suitable for clinical development, including as a result of harmful side effects, manufacturing issues, limited efficacy or other characteristics that indicate that they are unlikely to be products that will succeed in clinical development, receive marketing approval or achieve market acceptance. If we cannot validate our technology platform by successfully commercializing CAB product candidates, we may not be able to obtain product, licensing or collaboration revenue in future periods, which would adversely affect our business, financial condition, results of operations and prospects.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">We may expend our resources to pursue particular product candidates and fail to capitalize on product candidates that may be more profitable or for which there is a greater likelihood of success.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">As a result of our limited financial and managerial resources, we must make strategic decisions as to which targets and product candidates to pursue and may forego or delay pursuit of opportunities with other targets or product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Failure to properly assess potential product candidates could result in our focus on product candidates with low market potential, which would harm our business, financial condition, results of operations and prospects. Our spending on current and future research and development programs and product candidates for specific targets or indications may not yield any commercially viable products. Our understanding and evaluation of biological targets for the discovery and development of new CAB product candidates may fail to identify challenges encountered in subsequent preclinical and clinical development. If we do not accurately evaluate the likelihood of clinical trial success, commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">If the market opportunities for any product that we develop are smaller than we believe they are, our revenue may be adversely affected and our business may suffer.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We focus our product candidate development on therapeutic CAB antibodies for the treatment of various oncology indications, such as soft tissue and bone sarcoma, NSCLC, melanoma, ovarian cancer, and head and neck cancer among others. Our projections of addressable patient populations that may benefit from treatment with our product candidates are based on our estimates. These estimates, which have been derived from a variety of sources, including scientific literature, surveys of clinics, physician interviews, patient foundations and market research, may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of these cancers. Additionally, the potentially addressable patient population for our product candidates may not ultimately be amenable to treatment with our product candidates. In addition, the subset of patients that are likely to respond to our product candidates, as identified by our quantitative biomarker assay/Target Membrane Percent Score (&#34;TmPS&#34;), may not correspond with and may be smaller than what market data may indicate. Our market opportunity may also be limited by future competitor treatments that enter the market. If any of our estimates prove to be inaccurate, the market opportunity for any product candidate that we or our strategic partners develop could be significantly diminished and have an adverse material impact on our business.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">The market may not be receptive to our product candidates because they are based on our novel therapeutic modality, and we may not generate any future revenue from the sale or licensing of product candidates.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The product candidates that we are developing are primarily based on our patented CAB technology platform, which uses new technologies to create our novel therapeutic approach. Market participants with significant influence over acceptance of new treatments, such as physicians and third-party payors, may not adopt a product or treatment based on our patented technology platform, and we may not be able to convince patients, the medical community and third-party payors to accept and use, or to provide favorable reimbursement for, any product candidates developed by us or our existing or future collaborators. Market acceptance of our product candidates will depend on, among other factors:</font></p>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">the timing of our receipt of any marketing and commercialization approvals;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">the terms of any approvals and the countries in which approvals are obtained;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">the safety and efficacy of our product candidates;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">the prevalence and severity of any adverse side effects associated with our product candidates;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">limitations or warnings contained in any labeling approved by the FDA or other regulatory authority, including the EMA;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">the willingness of patients to obtain biopsies to determine the TmPS score for treatment eligibility; </font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">relative convenience and ease of administration of our product candidates;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">the willingness of patients to accept any new methods of administration;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">the success of any physician education programs;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">the availability of adequate government and third-party payor reimbursement;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">the pricing of our products, particularly as compared to alternative treatments; and</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">47</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">availability of alternative effective treatments for the disease indications our product candidates are intended to treat and the relative risks, benefits and costs of those treatments.</font></div></div>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">If any product candidate we commercialize fails to achieve market acceptance, it could have a material and adverse effect on our business, financial condition, results of operations and prospects.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Results from early-stage clinical trials may not be predictive of results from late-stage or other clinical trials, and the results of our clinical trials may not satisfy the requirements of the FDA, EMA or other comparable foreign regulatory authorities.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Positive and promising results from preclinical studies and early-stage clinical trials may not be predictive of results from late-stage clinical trials or from clinical trials of the same product candidates for the treatment of other indications. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and initial clinical trials. Late-stage clinical trials could differ in significant ways from early-stage clinical trials, including changes to inclusion and exclusion criteria, efficacy endpoints, dosing regimen and statistical design. Moreover, success in clinical trials in a particular indication does not guarantee that a product candidate will be successful for the treatment of other indications. Many companies in the biopharmaceutical industry have suffered significant setbacks in late-stage clinical trials after achieving encouraging or positive results in early-stage development. We cannot assure you that we will not face similar setbacks in our ongoing or planned clinical trials, including in our Phase 2 clinical trials of mecbotamab vedotin for the treatment of soft tissue and bone sarcoma and for the treatment of PD-1 refractory NSCLC, in our Phase 2 clinical trial of ozuriftamab vedotin for the treatment of PD-1 refractory melanoma and NSCLC and in any subsequent or post-marketing confirmatory clinical trials.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses and many companies that believed their product candidates performed satisfactorily in preclinical studies and clinical trials nonetheless failed to obtain FDA, EMA or comparable foreign regulatory authority approval. We cannot guarantee that the FDA will agree with our clinical trial plans. For example, we have initiated potentially registration-enabling Phase 2 trials for BA3011 in treatment-refractory sarcoma patients and PD-1 refractory NSCLC. The FDA has reviewed the trial designs but has not opined on whether the Phase 2 clinical trials will in fact be sufficient to support regulatory approval. However, we intend to ask the FDA to consider this further at the planned interim data review point or points. We cannot assure you that the FDA will agree that such data will be sufficient to support approval. To the extent that the results of the trials are not satisfactory to the FDA or foreign regulatory authorities for support of a marketing application, we may be required to expend significant resources, which may not be available to us, to conduct additional trials in support of potential approval of our product candidates. Even if regulatory approval is secured for any of our product candidates, the terms of such approval may limit the scope and use of our product candidate, which may also limit its commercial potential. Furthermore, the approval policies or regulations of the FDA, EMA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval, which may lead to the FDA, EMA or comparable foreign regulatory authorities delaying, limiting or denying approval of our product candidates.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Furthermore, while multi-center investigator-initiated clinical trials of mecbotamab vedotin and ozuriftamab vedotin in patients with platinum-resistant ovarian cancer are expected to enroll patients in Canada in the first half of 2022, we do not control the design or administration of these or any other investigator-initiated trials that may be conducted, nor the submission or approval of any IND or foreign equivalent required to conduct any such trials.  Any investigator-initiated trials could, depending on the actions of such third parties, jeopardize the validity of the clinical data generated, identify significant concerns with respect to our product candidates that could impact our findings or clinical trials, and adversely affect our ability to obtain marketing approval from the FDA or other applicable regulatory authorities. To the extent the results of this or other investigator-initiated trials are inconsistent with, or different from, the results of our ongoing or planned company-sponsored trials or raise concerns regarding our product candidates, the FDA or a foreign regulatory authority may question the results of the company-sponsored trial, or subject such results to greater scrutiny than it otherwise would. In these circumstances, the FDA or such foreign regulatory authorities may require us to obtain and submit additional clinical data, which could delay clinical development or marketing approval of our product candidates. In addition, while investigator-initiated trials could be useful to inform our own clinical development efforts, there is no guarantee that we will be able to use the data from these trials to form the basis for regulatory approval of our product candidates.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Preliminary, preplanned interim and topline data from our clinical trials that we announce or publish from time to time may change as more patient data become available and/or are subject to audit and verification procedures that could result in material changes in the final data.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">From time to time, we may publicly disclose preliminary, preplanned interim or topline data from our clinical trials. These data and related findings and conclusions may only reflect certain endpoints rather than all endpoints and are subject to change. For example, we may report tumor responses in certain patients that are unconfirmed at the time and which do not ultimately result in confirmed responses to treatment after follow-up evaluations. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the preliminary results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Topline data remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, topline data should be viewed with caution until the final data are available. In addition, we may report preplanned interim analyses of the clinical trials we may complete, which are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse changes between interim data and final data could significantly harm our business and prospects. Further, additional disclosure of interim data by us or by our competitors in the future could result in volatility in the price of our common stock.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is typically selected from a more extensive amount of available information. You or others may not agree with what we determine is the material or otherwise appropriate</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">48</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular product candidate or our business. If the preliminary, preplanned interim or topline data that we report differ from late, final or actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed, which could harm our business, financial condition, results of operations and prospects.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Delays in the commencement and completion of clinical trials could increase costs and delay or prevent regulatory approval and commercialization of our product candidates.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We cannot guarantee that clinical trials of our product candidates will be conducted as planned or completed on schedule, if at all. A failure of one or more clinical trials can occur at any stage of the clinical trial process, and other events may cause us to temporarily or permanently stop a clinical trial. Events that may prevent successful or timely commencement and completion of clinical development include:</font></p>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> negative preclinical data;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">delays in receiving the required regulatory clearance from the appropriate regulatory authorities to commence clinical trials or amend clinical trial protocols, including any objections to our INDs or protocol amendments from the FDA;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">delays in reaching, or a failure to reach, a consensus with regulatory authorities on study design;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">delays in reaching, or failure to reach, agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">difficulties in obtaining IRB approval at each site</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">challenges in recruiting suitable patients to participate in a trial;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">the inability to enroll a sufficient number of patients in clinical trials to ensure adequate statistical power to detect statistically significant treatment effects;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">difficulties in having patients complete a trial or return for post-treatment follow-up;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">our CROs or clinical trial sites failing to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all, deviating from the protocol or dropping out of a clinical trial;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">unforeseen safety issues, including occurrence of treatment emergent adverse events, or TEAEs, associated with the product candidate that are viewed to outweigh the product candidate&#x2019;s potential benefits;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">difficulties in adding new clinical trial sites;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">ambiguous or negative interim results;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">lack of adequate funding to continue the clinical trial;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">difficulties in manufacturing sufficient quantities of acceptable product candidate for use in clinical trials in a timely manner, or at all; or</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">the COVID-19 pandemic, which continues to adversely affect the pace of patient enrollment in clinical trials, also has caused clinical sites to redirect personnel and resources to focus on immediate and often unplanned numbers and needs of COVID-19 patients.  In addition, the pandemic may result in clinical site closures, delays to patient enrollment, patients discontinuing their treatment or follow up visits or changes to trial protocols.</font></div></div>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We could encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the institutions in which such trials are being conducted, by a Data Safety Monitoring Board, or DSMB, for such trial or by the FDA or other regulatory authorities. Such authorities may impose such a suspension or termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. If we experience delays in the completion of, or termination of, any clinical trial of our product candidates, the commercial prospects of our product candidates will be harmed, and our ability to generate product revenues from any of these product candidates will be delayed. In addition, any delays in completing our clinical trials will increase our costs, slow down our product candidate development and approval process and jeopardize our ability to commence product sales and generate revenues. Any of these occurrences may harm our business, financial condition, results of operations and prospects significantly. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">In addition, data obtained from trials and studies are susceptible to varying interpretations, and regulators may not interpret our data as favorably as we do, which may delay, limit or prevent regulatory approval. Our clinical trial results may not be successful, or even if successful, may not lead to regulatory approval.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">49</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside our control.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We may encounter delays or difficulties in enrolling, or be unable to enroll, a sufficient number of patients to complete any of our clinical trials on our current timelines, or at all, and even once enrolled, we may be unable to retain a sufficient number of patients to complete any of our trials. Enrollment in our clinical trials may be slower than we anticipate, leading to delays in our development timelines. For example, we may face difficulty enrolling a sufficient number of patients in a timely manner in our clinical trials for mecbotamab vedotin and ozuriftamab vedotin due to the limited number of suitable patients meeting the required AXL or ROR2 tumor membrane expression levels.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Patient enrollment and retention in clinical trials depends on many factors, including the size and nature of the patient population, the nature of the trial protocol, our ability to recruit clinical trial investigators with the appropriate competencies and experience, delays in enrollment due to travel or quarantine policies, or other factors, related to the COVID-19 pandemic or other epidemics or pandemics, the existing body of safety and efficacy data with respect to the study drug, the number and nature of competing treatments and ongoing clinical trials of competing drugs for the same indication, the proximity of patients to clinical sites, the eligibility criteria for the trial and the proportion of patients screened that meets those criteria, including criteria related to biomarkers, our ability to obtain and maintain patient consents, including any additional consents necessary for enrollment of adolescent patients, and our ability to successfully complete prerequisite studies before enrolling certain patient populations. Furthermore, any negative results or new safety signals we may report in clinical trials of our product candidates may make it difficult or impossible to recruit and retain patients in other clinical trials we are conducting. Similarly, negative results reported by our competitors about their drug candidates may negatively affect patient recruitment in our clinical trials. Also, marketing authorization of competitors in this same class of drugs may impair our ability to enroll patients into our clinical trials, delaying or potentially preventing us from completing recruitment of one or more of our trials.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Delays or failures in planned patient enrollment or retention may result in increased costs, program delays or both, which could have a harmful effect on our ability to develop our product candidates or could render further development impossible. In addition, we rely on clinical trial sites to ensure timely conduct of our clinical trials and, while we have entered into agreements governing their services, we are limited in our ability to compel their actual performance.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Our product candidates may cause undesirable and unforeseen side effects or have other properties impacting safety that could halt their clinical development, delay or prevent their regulatory approval, limit their commercial potential or result in significant negative consequences.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Undesirable side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other regulatory authorities and potential product liability claims. Such side effects could also affect patient recruitment or the ability of enrolled patients to complete the trial. Many compounds developed in the biopharmaceutical industry that initially showed promise in early-stage testing for treating cancer have later been found to cause side effects that prevented their further development. Any of these occurrences may materially and adversely affect our business, financial condition, results of operations and prospects.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">In our clinical trials for mecbotamab vedotin and ozuriftamab vedotin, we have observed adverse events such as reversible myelosuppression, transient liver enzyme elevations, pyrexia, or fever, metabolic disturbances and peripheral neuropathy.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">For our current and future clinical trials, we have contracted with and expect to continue to contract with CROs experienced in the assessment and management of toxicities arising during clinical trials. Nonetheless, they may have difficulty observing patients and treating toxicities, which may be more challenging due to personnel changes, shift changes, house staff coverage or related issues. This could lead to more severe or prolonged toxicities or even patient deaths, which could result in us or the FDA delaying, suspending or terminating one or more of our clinical trials and which could jeopardize regulatory approval.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Further, clinical trials by their nature test product candidates in only samples of the potential patient populations. With a limited number of patients and limited duration of exposure in such trials, rare and severe side effects of our product candidates may not be uncovered until a significantly larger number of patients are exposed to the product candidate. For example, while we believe that mecbotamab vedotin and ozuriftamab vedotin have demonstrated manageable tolerability profiles thus far, we cannot assure you that these and our other product candidates will not cause more severe side effects in a greater proportion of patients.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">In addition, mecbotamab vedotin and ozuriftamab vedotin are being studied in combination with other therapies, which may exacerbate adverse events associated with the therapy. Patients treated with mecbotamab vedotin, ozuriftamab vedotin or our other product candidates may also be undergoing surgical, radiation or chemotherapy treatments, which can cause side effects or adverse events that are unrelated to our product candidate but may still impact the success of our clinical trials.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The inclusion of critically ill patients in our clinical trials may result in deaths or other adverse medical events due to other therapies or medications that such patients may be using or due to the gravity of such patients&#x2019; illnesses. For example, some of the late-stage patients enrolled in our mecbotamab vedotin and ozuriftamab vedotin clinical trials may die or experience major clinical events either during the course of our clinical trials or after participating in such trials due mainly to the gravity of their illness, which has occurred in the past.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">In the event that any of our product candidates receive regulatory approval, and we or others later identify undesirable and unforeseen side effects caused by such product, negative consequences, including any of the following, could occur:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">50</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">regulatory authorities may suspend, limit or withdraw their approval of such product, or seek an injunction against its manufacture or distribution;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">we may be required to conduct additional clinical trials or post-approval studies;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">we may be required to recall a product or change the way such product is administered to patients;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">additional restrictions may be imposed on the marketing of the particular product or the manufacturing processes for the product or any component thereof;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">regulatory authorities may require the addition of labeling statements, such as a boxed warning or a contraindication, or issue safety alerts, Dear Healthcare Provider letters, press releases or other communications containing warnings or other safety information about the product;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">we may be required to implement a REMS and/or create a Medication Guide outlining the risks of such side effects for distribution to patients, a communication plan for healthcare providers and/or other elements to assure safe use;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">we could be sued and held liable for harm caused to patients;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">we may be subject to fines, injunctions or the imposition of civil or criminal penalties;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">the product may become less competitive; and</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">our reputation may suffer.</font></div></div>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Any of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and result in the loss of significant revenues to us, which would materially and adversely affect our results of operations and business. In addition, if one or more of our product candidates prove to be unsafe, our business, financial condition, results of operations and prospects may be materially and adversely affected.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">We are developing certain of our product candidates in combination with other therapies, and regulatory approval, safety or supply issues with these other therapies may delay or prevent the development and approval of our product candidates.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Currently, we are evaluating the use of each of mecbotamab vedotin and ozuriftamab vedotin in combination with an anti-PD-1 inhibitor and plan to evaluate the use of BA3071 in combination with an anti-PD-1 inhibitor. In the future, we may explore the use of these or our other product candidates in combination with other therapies. If we choose to develop a product candidate for use in combination with an approved therapy, we are subject to the risk that the FDA, EMA or comparable foreign regulatory authorities in other jurisdictions could revoke approval of, or that safety, efficacy, manufacturing or supply issues could arise with, the therapy used in combination with our product candidate. If the therapies we use in combination with our product candidates are replaced as the standard of care, the FDA, EMA or comparable foreign regulatory authorities in other jurisdictions may require us to conduct additional clinical trials. The occurrence of any of these risks could result in our product candidates, if approved, being removed from the market or being less successful commercially.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Where we develop a product candidate for use in combination with a therapy that has not been approved by the FDA, EMA or comparable foreign regulatory authorities in other jurisdictions, we will not be able to market our product candidate for use in combination with such an unapproved therapy, unless and until the unapproved therapy receives regulatory approval. It is expected that BA3071 will also be evaluated in combination with an anti-PD-1 antibody in late stage development for solid tumor patients. In addition, other companies may also develop their products or product candidates in combination with the unapproved therapies with which we are developing our product candidates for use in combination. Any setbacks in these companies&#x2019; clinical trials, including the emergence of serious adverse effects, may delay or prevent the development and approval of our product candidates.<br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">If the FDA, EMA or comparable foreign regulatory authorities in other jurisdictions do not approve or revoke their approval of, or if safety, efficacy, manufacturing, or supply issues arise with, therapies we choose to evaluate in combination with any of our product candidates, we may be unable to obtain regulatory approval of or to commercialize such product candidates in combination with these therapies.<br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">If safe and effective use of any of our product candidates, such as mecbotamab vedotin and ozuriftamab vedotin, depends on a companion diagnostic test, then the FDA generally will require approval or clearance of that companion diagnostic at the same time that the FDA approves our product candidates, if at all. If we are unable to successfully develop companion diagnostic tests for our product candidates, experience significant delays in doing so, rely on third parties in the development of such companion diagnostic tests, or do not obtain or face delays in obtaining FDA approval of a companion diagnostic test, the full commercial potential of our product candidates and our ability to generate revenue will be materially impaired.</font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We are exploring predictive biomarkers to determine patient selection for our clinical trials. Specifically, to help inform which patients may be most suitable for treatment with mecbotamab vedotin and ozuriftamab vedotin, we have developed a quantitative biomarker assay that has been validated in accordance with CLIA requirements, the TmPS, which measures AXL and ROR2 expression levels on the tumor membrane and cytoplasm. We are using both AXL and ROR2 TmPS scores in our ongoing clinical trials and they may be used for patient selection in future</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">51</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">clinical trials. If the AXL and ROR2 TmPS scores prove to be a useful method for patient selection, we will incorporate the specific diagnostic test into our registrational studies and partner with the appropriate diagnostic provider to codevelop a companion diagnostic.</font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">If use of a companion diagnostic test is essential for the safe and effective use of any of our product candidates, such as mecbotamab vedotin and ozuriftamab vedotin, then the FDA generally will require approval or clearance of that companion diagnostic at the same time that the FDA approves our product candidates, if at all. The FDA has generally required in vitro companion diagnostics intended to select the patients who will respond to cancer treatment to obtain a PMA for that diagnostic simultaneously with approval of the therapeutic. The process of obtaining or creating such diagnostic and obtaining PMA approval is time-consuming and costly and a delay in diagnostic approval could delay drug approval. According to FDA guidance, if the FDA determines that a companion diagnostic device is essential to the safe and effective use of a novel therapeutic product or indication, the FDA generally will not approve the therapeutic product or new therapeutic product indication if the companion diagnostic is not also approved or cleared for that indication. If a satisfactory companion diagnostic is not commercially available, we may be required to create or obtain one that would be subject to regulatory approval requirements. On April 13, 2020, the FDA issued new guidance on developing and labeling companion diagnostics for a specific group of oncology therapeutic products, including recommendations to support a broader labeling claim rather than individual therapeutic products. We will continue to evaluate the impact of this guidance on our companion diagnostic development and strategy. This guidance and future policies from the FDA and other regulatory authorities may impact our development of a companion diagnostic for our product candidates and result in delays in regulatory approval. We may be required to conduct additional studies to support a broader claim. Also, to the extent other approved diagnostics are able to broaden their labeling claims to include our approved drug products, we may be forced to abandon our companion diagnostic development plans or we may not be able to compete effectively upon approval, which could adversely impact our ability to generate revenue from the sale of our approved products and our business, financial condition, results of operations and prospects.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We expect to rely on third parties for the design, development and manufacture of companion diagnostic tests for our product candidates that require such tests. If the FDA, EMA or a comparable foreign regulatory authority requires approval of a companion diagnostic for any of our product candidates, whether before or after it obtains marketing approval, we, and/or future collaborators, may encounter difficulties in developing and obtaining approval for such product candidate. If we or our third-party collaborators experience any delay in developing or obtaining regulatory approval of a companion diagnostic, we may be unable to enroll enough patients for our current and planned clinical trials, the development of our product candidates may be adversely affected or we may not obtain marketing approval, and we may not realize the full commercial potential of our product candidates, including mecbotamab vedotin and ozuriftamab vedotin.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">We face competition from entities that have developed or may develop product candidates for cancer, including companies developing novel treatments and technology platforms. If these companies develop technologies or product candidates more rapidly than we do or their technologies are more effective, our ability to develop and successfully commercialize product candidates may be adversely affected.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The development and commercialization of drugs and therapeutic biologics is highly competitive. We compete with a variety of multinational biopharmaceutical companies and specialized biotechnology companies, as well as technology being developed at universities and other research institutions. Our competitors have developed, are developing and will develop product candidates and processes competitive with our product candidates. We believe that a significant number of products are currently under development, and may become commercially available in the future, for the treatment of conditions for which we are developing product candidates. We believe that while our patented CAB technology platform, its associated intellectual property and our scientific and technical know-how give us a competitive advantage in this space, competition from many sources remains. Our success will partially depend on our ability to develop and protect therapeutics that are safer and more effective than competing products. Our commercial opportunity and success will be reduced or eliminated if competing products are safer, more effective or less expensive than the therapeutics we develop.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Although we do not believe competing companies have selective CAB technology, there is a wide array of activity in multiple areas of immune-based cellular therapies for oncology including CAR-T and T-cell receptor therapies. Certain companies are also pursuing antibody therapies in immuno-oncology, ADCs and various prodrug biologic products designed to be preferentially activated at tumor sites. There are several FDA approved ADC products and several companies in various stages of clinical development of ADCs mostly directed at oncology indications, a key feature of our product candidates mecbotamab vedotin and ozuriftamab vedotin. There are also companies developing technologies designed to deliver biologics and chemotherapeutic agents with some targeting capabilities. In addition, if any of our product candidates are approved in oncology indications, they may compete with existing biologics and small molecule therapies or may be used in combination with existing therapies. There are also many other therapies under development that are intended to treat the same cancers that we are targeting or may target with our CAB platform, including through approaches that could prove to be more effective, have fewer side effects, be cheaper to manufacture, be more convenient to administer or have other advantages over any products resulting from our technologies.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Many of our competitors, either alone or with strategic partners, have significantly greater financial, technical, manufacturing, marketing, sales and supply resources or experience than we do. Accordingly, our competitors may be more successful than us in obtaining approval for treatments and achieving widespread market acceptance, rendering our treatments obsolete or non-competitive. Accelerated merger and acquisition activity in the biotechnology and biopharmaceutical industries may result in even more resources being concentrated among a smaller number of our competitors. These companies also compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials and acquiring technologies complementary to, or necessary for, our programs. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. The level of generic competition and the availability of reimbursement from government and other third-party payors will also significantly affect the pricing and competitiveness of our products. In addition, our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">52</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">There are also requirements governing the reporting of ongoing clinical trials and completed clinical trial results to public registries. Sponsors of clinical trials of FDA-regulated products, including biologics, are required to register and disclose certain clinical trial information, which is publicly available at www.clinicaltrials.gov. Information related to the product, patient population, phase of investigation, study sites and investigators, and other aspects of the clinical trial is then made public as part of the registration. Sponsors are also obligated to discuss the results of their clinical trials after completion. Disclosure of the results of these trials can be delayed in certain circumstances for up to two years after the date of completion of the trial. Competitors may use this publicly available information to gain knowledge regarding the progress of development programs.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Our commercial opportunity could be substantially limited in the event that our competitors develop and commercialize products that are more effective, safer, less toxic or more convenient than products we may develop. In geographies that are critical to our commercial success, competitors may also obtain regulatory approvals before us, resulting in our competitors building a strong market position in advance of our products&#x2019; entry. Such competitors could also recruit our employees, which could negatively impact our level of expertise and our ability to execute our business plan.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Our biologic product candidates for which we intend to seek approval may face competition through an abbreviated pathway.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The ACA includes a subtitle called the BPCIA, which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-licensed reference biological product. Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing the sponsor&#x2019;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of their product. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty. While it is uncertain when such processes intended to implement BPCIA may be fully adopted by the FDA, any such processes could have an adverse effect on the future commercial prospects for our product candidates.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">There is a risk that any product candidates we may develop that are approved as a biological product under a BLA would not qualify for the 12-year period of exclusivity or that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider any product candidates we may develop to be reference products for competing products, potentially creating the opportunity for generic competition sooner than anticipated.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Our business entails a significant risk of product liability, and if we are unable to obtain sufficient insurance coverage, such failure could have a material and adverse effect on our business, financial condition, results of operations and prospects.</font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We expect to be exposed to significant product liability risks inherent in the development, testing and manufacturing of our product candidates and products, if approved. Product liability claims could delay or prevent completion of our development programs. If we succeed in marketing products, such claims could result in an FDA investigation of the safety and effectiveness of our products, our third-party manufacturer&#x2019;s manufacturing processes and facilities or our marketing programs and potentially a recall of our products or more serious enforcement action, including limitations on the approved indications for which our product candidates may be used or suspension or withdrawal of approvals. Regardless of the merits or eventual outcome, liability claims may also result in decreased demand for our products, injury to our reputation, costs to defend the related litigation, a diversion of management&#x2019;s time and our resources, substantial monetary awards to trial participants or patients and a decline in our stock price. We currently have product liability insurance that we believe is appropriate for our stage of development and may need to obtain higher levels prior to marketing any of our product candidates. Any insurance we have or may obtain may not provide sufficient coverage against potential liabilities. In addition, we may be subject to liability based on the actions of our existing or future collaborators in connection with their development of products using our CAB technology. Furthermore, clinical trial and product liability insurance is becoming increasingly expensive. As a result, we may be unable to maintain sufficient insurance at a reasonable cost to protect us against losses caused by product liability claims that could have a material and adverse effect on our business, financial condition, results of operations and prospects.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">53</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Risks related to regulatory approval and other legal compliance matters</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">We may be unable to obtain U.S. or foreign regulatory approval and, as a result, unable to commercialize our product candidates.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Our product candidates are subject to extensive governmental regulations relating to, among other things, the research, development, testing, manufacture, quality control, import, export, safety, effectiveness, labeling, packaging, storage, distribution, record keeping, approval, advertising, promotion, marketing, post-approval monitoring and post-approval reporting of drugs and therapeutic biologics. Rigorous preclinical testing and clinical trials and an extensive regulatory approval process are required to be successfully completed in the United States and in many foreign jurisdictions before a new drug or therapeutic biologic can be marketed. Satisfaction of these and other regulatory requirements is costly, lengthy, time-consuming, uncertain and subject to unanticipated delays. We have not previously submitted a BLA to the FDA, or similar drug approval filings to comparable foreign regulatory authorities, for any product candidate, and it is possible that none of the product candidates we may develop will obtain the regulatory approvals necessary for us or our existing or future collaborators to begin selling them.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We have not completed any large-scale or pivotal clinical trials nor managed the regulatory approval process with the FDA or any other regulatory authority. The time required to obtain FDA and other approvals is unpredictable but typically takes many years following the commencement of clinical trials, depending upon the type, complexity and novelty of the product candidate, and numerous other factors including the substantial discretion of regulatory authorities. The standards that the FDA and its foreign counterparts, including the EMA, use when regulating us and our existing or future collaborators require judgment and can change, which makes it difficult to predict with certainty how they will be applied. Any analysis we perform of data from preclinical and clinical activities is subject to confirmation and interpretation by regulatory authorities, which could delay, limit or prevent regulatory approval. We may also encounter unexpected delays or increased costs due to new government regulations, for example, from future legislation or administrative action, or from changes in FDA policy during the period of product development, clinical trials and FDA regulatory review. It is impossible to predict whether legislative changes will be enacted, or whether FDA or foreign regulations, guidance or interpretations will be changed, or what the impact of such changes, if any, may be.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">In addition, our product candidates could fail to receive regulatory approval for many reasons including the following:</font></p>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a product candidate is safe, pure and potent for its proposed indication;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">the results of clinical trials may fail to achieve the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">we may be unable to demonstrate that a product candidate&#x2019;s clinical and other benefits outweigh its safety risks;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">we may be unable to demonstrate a sufficient response rate or duration of response for a product candidate;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data submitted in support of regulatory approval;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">the data collected from preclinical studies and clinical trials of our product candidates may not be sufficient to support the submission of a BLA or other regulatory submission necessary to obtain regulatory approval in the United States or elsewhere; and</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">we or our contractors may not meet the cGMPs and other applicable requirements for manufacturing processes, procedures, documentation and facilities necessary for approval by the FDA or comparable foreign regulatory authorities.</font></div></div>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Any delay or failure in obtaining required approvals could have a material and adverse effect on our ability to generate revenues from the particular product candidate for which we are seeking approval. Furthermore, any regulatory approval to market a drug may be subject to significant limitations on the approved uses or indications for which we may market the drug or the labeling or other restrictions. In addition, the FDA has the authority to require a REMS as part of approving a BLA, or after approval, which may impose further requirements or restrictions on the distribution or use of an approved drug. These requirements or restrictions might include limiting prescribing to certain physicians or medical centers that have undergone specialized training, limiting treatment to patients who meet certain safe-use criteria and requiring treated patients to enroll in a registry. These limitations and restrictions may significantly limit the size of the market for the drug and affect reimbursement by third-party payors.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We are also subject to numerous foreign regulatory requirements governing, among other things, the conduct of clinical trials, manufacturing and marketing authorization, pricing and third-party reimbursement. The foreign regulatory approval process varies among countries and may include all of the risks associated with FDA approval described above as well as risks attributable to the satisfaction of local regulations in foreign jurisdictions. Moreover, the time required to obtain approval may differ from that required to obtain FDA approval. Approval by the FDA does not ensure approval by regulatory authorities outside the United States and vice versa.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">54</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">We intend to seek approval from the FDA or comparable foreign regulatory authorities through the use of accelerated approval pathways, if available. If we are unable to obtain such approval, we may be required to conduct additional preclinical studies or clinical trials beyond those that we contemplate, which could increase the expense of obtaining, and delay the receipt of, necessary marketing approvals. Even if we receive accelerated approval from the FDA, if our confirmatory trials do not verify clinical benefit or if we do not comply with rigorous post-marketing requirements, the FDA may seek to withdraw accelerated approval.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We intend to seek accelerated approval for mecbotamab vedotin and ozuriftamab vedotin, and we may seek accelerated approval for one or more of our other product candidates. Under the accelerated approval program, the FDA may grant accelerated approval to a product candidate designed to treat a serious or life-threatening condition that provides meaningful therapeutic benefit over available therapies upon a determination that the product candidate has an effect on a surrogate endpoint or intermediate clinical endpoint that is reasonably likely to predict clinical benefit. The FDA considers a clinical benefit to be a positive therapeutic effect that is clinically meaningful in the context of a given disease, such as irreversible morbidity or mortality. For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign, or other measure that is thought to predict clinical benefit but is not itself a measure of clinical benefit. An intermediate clinical endpoint is a clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit. The accelerated approval pathway may be used in cases in which the advantage of a new drug over available therapy may not be a direct therapeutic advantage but is a clinically important improvement from a patient and public health perspective. We intend to seek accelerated approval for some of our product candidates on the basis of objective response rate, a surrogate endpoint that we believe is reasonably likely to predict clinical benefit. For products granted accelerated approval, post-marketing confirmatory trials are required to verify and describe the anticipated effect on irreversible morbidity or mortality or other clinical benefit. These confirmatory trials must be completed with due diligence, and the FDA may require that the trial be designed, initiated, and/or fully enrolled prior to approval. If we were to pursue accelerated approval for a product candidate for a disease or condition, we would do so on the basis that there is no available therapy for that disease or condition. If any of our competitors were to receive full approval on the basis of a confirmatory trial for a drug for a disease or condition for which we are seeking accelerated approval before we receive accelerated approval, the disease or condition would no longer qualify as one for which there is no available therapy, and accelerated approval of our product candidate would not occur. Many cancer therapies rely on accelerated approval, and the treatment landscape can change quickly as the FDA converts accelerated approvals to full approvals on the basis of successful confirmatory trials.   Failure to conduct required post-approval studies, or to confirm a clinical benefit during post-marketing studies, would allow the FDA to withdraw the product from the market on an expedited basis. All promotional materials for product candidates approved under accelerated regulations are subject to prior review by the FDA.</font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:10.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Prior to seeking accelerated approval for any of our product candidates, we intend to seek feedback from the FDA and will otherwise evaluate our ability to seek and receive accelerated approval. We cannot assure you that after our evaluation of the feedback and other factors we will decide to pursue or submit a BLA for accelerated approval or any other form of expedited development, review or approval. Similarly, we cannot assure you that after subsequent FDA feedback we will continue to pursue accelerated approval or any other form of expedited development, review or approval, even if we initially decide to do so. Furthermore, if we decide to submit an application for accelerated approval or receive an expedited regulatory designation (e.g., breakthrough therapy designation) for our product candidates, we cannot assure you that such application will be accepted or that any expedited development, review or approval will be granted on a timely basis, or at all. The FDA or other comparable foreign regulatory authorities could also require us to conduct further studies prior to considering our application or granting approval of any type.<br><br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Even if we receive regulatory approval for any of our product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense. Additionally, our product candidates, if approved, could be subject to labeling and other restrictions and market withdrawal and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our products.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Any regulatory approvals that we or our existing or future collaborators obtain for our product candidates may also be subject to limitations on the approved indicated uses for which a product may be marketed or to conditions of approval, or contain requirements for potentially costly post-marketing testing, including &#x201c;Phase 4&#x201d; clinical trials, and surveillance to monitor the safety and efficacy of the product candidate. Furthermore, any regulatory approval to market a product may be subject to limitations on the labeling of the product or may require safety warnings or other restrictions. In addition, the FDA has the authority to require a REMS plan as part of a BLA or after approval, which may impose further requirements or restrictions on the distribution or use of an approved biologic, such as limiting prescribing to certain physicians or medical centers that have undergone specialized training, limiting treatment to patients who meet certain safe-use criteria and requiring treated patients to enroll in a registry. These limitations and restrictions may limit the size of the market for the product and affect reimbursement by third-party payors.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">In addition, if the FDA or a comparable foreign regulatory authority approves any of our product candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, import, export, advertising, promotion and recordkeeping for the product will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMPs and GCPs for any clinical trials that we conduct post-approval. The manufacturer and manufacturing facilities we use to make a future product, if any, will also be subject to periodic review and inspection by the FDA and other regulatory agencies, including for continued compliance with cGMP requirements. Any product promotion and advertising will also be subject to regulatory requirements and continuing regulatory review. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things:</font></p>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">restrictions on the marketing or manufacturing of the product;</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">55</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">withdrawal of the product from the market or voluntary or mandatory product recalls;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">fines, warning or untitled letters or holds on clinical trials;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">delay of approval or refusal by the FDA or comparable regulatory authorities in other jurisdictions to approve pending applications or supplements to approved applications filed by us, our current collaborator or any future strategic partners;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">suspension or revocation of product license approvals;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">product seizure or detention or refusal to permit the import or export of products; and</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">injunctions or the imposition of civil or criminal penalties.</font></div></div>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The FDA&#x2019;s policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If these regulations impose constraints on FDA&#x2019;s ability to engage in oversight and implementation activities in the normal course, our business may be negatively impacted. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability, which would adversely affect our business, financial condition, results of operations and prospects.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Even if we are able to commercialize any product candidate, such product candidate may become subject to unfavorable pricing regulations or third-party coverage and reimbursement policies, which would harm our business.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The regulations that govern regulatory approvals, pricing and reimbursement for new drugs and therapeutic biologics vary widely from country to country. Some countries require approval of the sale price of a drug or therapeutic biologic before it can be marketed. In many countries, the pricing review period begins after marketing approval is granted. In some foreign markets, prescription biopharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain regulatory approval for a product in a particular country, but then be subject to price regulations that delay our commercial launch of the product, possibly for lengthy time periods, and negatively impact the revenues we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates, even if our product candidates obtain regulatory approval.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Our ability to commercialize any products successfully also will depend in part on the extent to which reimbursement for these products and related treatments will be available from government authorities, private health insurers and other organizations. Even if we succeed in bringing one or more products to the market, these products may not be considered cost-effective, and the amount reimbursed for any products may be insufficient to allow us to sell our products on a competitive basis. Because our programs are in the early stages of development, we are unable at this time to determine their cost effectiveness or the likely level or method of reimbursement. Increasingly, the third-party payors who reimburse patients or healthcare providers, such as government and private insurance plans, are requiring that drug companies provide them with predetermined discounts from list prices and are seeking to reduce the prices charged or the amounts reimbursed for biopharmaceutical products. If the price we are able to charge for any products we develop, or the reimbursement provided for such products, is inadequate in light of our development and other costs, our return on investment could be adversely affected.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">There is significant uncertainty related to third-party payor coverage and reimbursement of newly approved products. For example, in the United States, principal decisions about reimbursement for new products are typically made by the Centers for Medicare &amp; Medicaid Services, or CMS, an agency within the U.S. Department of Health and Human Services, or HHS. CMS decides whether and to what extent a new product will be covered and reimbursed under Medicare, and private third-party payors often follow CMS&#x2019;s decisions regarding coverage and reimbursement to a substantial degree. However, one third-party payor&#x2019;s determination to provide coverage for a product candidate does not assure that other payors will also provide coverage for the product candidate. As a result, the coverage determination process is often time-consuming and costly. This process will require us to provide scientific and clinical support for the use of our products to each third-party payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance.</font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:10.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Moreover, there has been heightened governmental scrutiny recently over the manner in which drug manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. For example, in May 2019, CMS issued a final rule to allow Medicare Advantage Plans the option of using step therapy for Part B drugs beginning January 1, 2020. This final rule codified CMS&#x2019;s policy change that was effective January 1, 2019. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">56</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:10.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">In some countries, particularly member states of the European Union, the pricing of prescription drugs is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after receipt of marketing approval for a product. In addition, there can be considerable pressure by governments and other stakeholders on prices and reimbursement levels, including as part of cost containment measures. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various European Union member states and parallel distribution, or arbitrage between low-priced and high-priced member states, can further reduce prices. In some countries, we or our existing or future collaborators may be required to conduct a clinical trial or other studies that compare the cost-effectiveness of our product candidates to other available therapies in order to obtain or maintain reimbursement or pricing approval. Publication of discounts by third-party payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">There may be significant delays in obtaining reimbursement for newly approved drugs or therapeutic biologics, and coverage may be more limited than the purposes for which the drug or therapeutic biologic is approved by the FDA or similar regulatory authorities outside of the United States. Moreover, eligibility for reimbursement does not imply that any drug or therapeutic biologic will be reimbursed in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution. Interim reimbursement levels for new drugs or therapeutic biologics, if applicable, may also be insufficient to cover our costs and may not be made permanent. Reimbursement rates may be based on payments allowed for lower-cost drugs or therapeutic biologics that are already reimbursed, may be incorporated into existing payments for other services and may reflect budgetary constraints or imperfections in Medicare data. Net prices for drugs or therapeutic biologics may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs or therapeutic biologics from countries where they may be sold at lower prices than in the United States. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement rates. If reimbursement of any product candidate approved for marketing is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business, financial condition, results of operations or prospects could be materially and adversely affected, and our ability to commercialize such products, once approved, could be materially impaired.</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">If any of our product candidates are approved and we are found to have improperly promoted off-label uses of those products, we may become subject to significant liability. The FDA and other regulatory agencies strictly regulate the promotional claims that may be made about prescription products, such as our product candidates, if approved. In particular, a product may not be promoted for uses that are not approved by the FDA or such other regulatory agencies as reflected in the product&#x2019;s approved labeling. For example, if we receive marketing approval for mecbotamab vedotin as a treatment for soft tissue and bone sarcoma, physicians may nevertheless use our product for their patients in a manner that is inconsistent with the approved labeling. If we are found to have promoted such off-label uses, we may become subject to significant liability. Moreover, although we believe that our product candidates may be safer or more effective than other therapies, unless we conduct head-to-head comparative studies, we will not be able to make any claims of superiority. The U.S. federal government has levied large civil and criminal fines against companies for alleged improper promotion of off-label use and has enjoined several companies from engaging in off-label promotion. The FDA has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. If we cannot successfully manage the promotion of our product candidates, if approved, we could become subject to significant liability, which would materially adversely affect our business, financial condition, results of operations and prospects.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Disruptions at the FDA, the SEC and other government agencies caused by, among other factors, funding shortages or global health concerns could hinder their ability to hire and retain key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved or commercialized in a timely manner or at all, or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, statutory, regulatory and policy changes and other events that may otherwise affect the FDA&#x2019;s ability to perform routine functions. In addition, government funding of the Securities and Exchange Commission, or SEC, and other government agencies on which our operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed or approved by necessary government agencies, which would adversely affect our business. For example, in recent years, including in 2018 and 2019, the U.S. government shut down several times and certain regulatory agencies, such as the FDA and the SEC, had to furlough critical employees and stop critical activities.  Separately, in response to the COVID-19 pandemic, on March 10, 2020, the FDA announced its intention to postpone most inspections of foreign manufacturing facilities and products through April 2020 and subsequently, on March 18, 2020, the FDA announced its intention to temporarily postpone routine surveillance inspections of domestic manufacturing facilities.  Subsequently, on July 20, 2020, the FDA announced its intention to resume certain domestic on-site inspections, subject to a risk-based prioritization system. The FDA intends to use this risk-based assessment system to identify the categories of regulatory activity that can occur within a given geographic area, ranging from mission critical inspections to resumption of all regulatory activities.  In addition, on April 15, 2021, the FDA issued a guidance document in which the FDA outlined plans to conduct voluntary remote interactive evaluations of certain drug manufacturing facilities and clinical research sites. According to the guidance, the FDA intends to request such remote interactive evaluations in situations where an in-person inspection would not be prioritized, deemed mission-critical or is otherwise limited by travel restrictions but where the FDA determines that a remote evaluation would</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">57</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">still be appropriate.  Regulatory authorities outside the United States may adopt similar restrictions or other policy measures in response to the COVID-19 pandemic.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Additionally, as of June 23, 2020, the FDA noted it was continuing to ensure timely reviews of applications for medical products during the COVID-19 pandemic in line with its user fee performance goals. On July 16, 2020, the FDA noted that it is continuing to expedite oncology product development with its staff teleworking full-time. If a prolonged government shutdown occurs, or if global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, future government shutdowns or delays could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">The FDA, EMA and other comparable foreign regulatory authorities may not accept data from trials conducted in locations outside of their jurisdiction.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We may choose to conduct international clinical trials in the future. The acceptance of study data by the FDA, EMA or other comparable foreign regulatory authority from clinical trials conducted outside of their respective jurisdictions may be subject to certain conditions. In cases where data from foreign clinical trials are intended to serve as the basis for marketing approval in the United States, the FDA will generally not approve the application on the basis of foreign data alone unless (i) the data are applicable to the United States population and United States medical practice; (ii) the trials are performed by clinical investigators of recognized competence and pursuant to current GCP requirements; and (iii) the FDA is able to validate the data through an on-site inspection or other appropriate means. Additionally, the FDA&#x2019;s clinical trial requirements, including the adequacy of the patient population studied and statistical powering, must be met. In addition, such foreign trials would be subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. We cannot assure you that the FDA, EMA or any applicable foreign regulatory authority will accept data from trials conducted outside of its applicable jurisdiction. If the FDA, EMA or any applicable foreign regulatory authority does not accept such data, it would result in the need for additional trials, which would be costly and time-consuming and delay aspects of our business plan, and which may result in our product candidates not receiving approval for commercialization in the applicable jurisdiction.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Our employees, independent contractors, principal investigators, CROs, consultants, suppliers and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We are exposed to the risk that our employees, independent contractors, principal investigators, CROs, consultants, suppliers and vendors may engage in fraudulent conduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or disclosure of unauthorized activities to us that violates: (i) FDA laws and regulations, including those laws that require the reporting of true, complete and accurate information to the FDA, (ii) manufacturing standards, (iii) federal and state healthcare fraud and abuse laws and regulations or (iv) laws that require the true, complete and accurate reporting of financial information or data. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Activities subject to these laws also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a material and adverse effect on our business, financial condition, results of operations and prospects, including the imposition of significant fines or other sanctions, including exclusion from government healthcare programs, and serious harm to our reputation.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Healthcare legislative reform measures may have a material adverse effect on our business and results of operations.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Existing regulatory policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">For example, in March 2010, the ACA was enacted, which substantially changed the way healthcare is financed by both the government and private insurers and significantly impacted the U.S. pharmaceutical industry. Among other things, the ACA intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add new transparency requirements for healthcare and health insurance industries, impose new taxes and fees on the health industry and impose additional health policy reforms. By way of example, the ACA increased manufacturers&#x2019; rebate liability under the Medicaid Drug Rebate Program, imposed a significant annual fee on companies that manufacture or import branded prescription drug products and required manufacturers to provide a discount off the negotiated price of prescriptions filled by beneficiaries in the Medicare Part D coverage gap, referred to as the &#x201c;donut hole,&#x201d; which is now 70% of the negotiated price. There have been executive, legislative and judicial efforts to modify, repeal, or otherwise invalidate all, or certain provisions of, the ACA. For example, the Tax Cuts and Jobs Act, among other things, included a provision that repealed, effective January 1, 2019, the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#x201c;individual mandate.&#x201d; On June 17, 2021, the U.S. Supreme Court dismissed a challenge on procedural</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">58</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">grounds that argued the ACA is unconstitutional in its entirety because the &#x201c;individual mandate&#x201d; was repealed by Congress. Thus, the ACA will remain in effect in its current form. It is possible that the ACA will be subject to judicial or Congressional challenges in the future. It is unclear how the any future challenges to the ACA and the healthcare reform measures of the Biden administration will impact the ACA and our business. We are continuing to monitor any changes to the ACA that, in turn, may potentially impact our business in the future.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. These changes included aggregate reductions to Medicare payments to providers of 2% per fiscal year. These reductions went into effect on April 1, 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2030 unless additional Congressional action is taken, with the exception of a temporary suspension from May 1, 2020 through March 31, 2022, and a reduction to the sequestration cut to 1% from April 1, 2022 to June 30, 2022, due to the COVID-19 pandemic.  In January 2013, President Obama signed into law the American Taxpayer Relief Act of 2012, which, among other things, reduced Medicare payments to several providers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These laws may result in additional reductions in Medicare and other healthcare funding, which could have a material adverse effect on customers for our drugs, if approved, and accordingly, our financial operations. Moreover, there has been heightened governmental scrutiny recently over the manner in which drug manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Furthermore, on September 9, 2021, the Biden administration published a wide-ranging list of policy proposals, most of which would need to be carried out by Congress, to reduce drug prices and drug payment. The HHS plan includes, among other reform measures, proposals to lower prescription drug prices, including by allowing Medicare to negotiate prices and disincentivizing price increases, and to support market changes that strengthen supply chains, promote biosimilars and generic drugs, and increase price transparency. Many similar proposals, including the plans to give Medicare Part D authority to negotiate drug prices, require drug manufacturers to pay rebates on drugs whose prices increase greater than the rate of inflation, and cap out-of-pocket costs, have already been included in policy statements and legislation currently being considered by Congress. It is unclear to what extent these and other statutory, regulatory, and administrative initiatives will be enacted and implemented, and to what extent these or any future legislation or regulations by the Biden administration will have on our business, including market acceptance, and sales, of our products and product candidates.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Further, on May 30, 2018, the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Beilina Right to Try Act of 2017, or the Right to Try Act, was signed into law. The law, among other things, provides a federal framework for certain patients to access certain investigational new product candidates that have completed a Phase 1 clinical trial and that are undergoing investigation for FDA approval. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without obtaining FDA permission under the FDA expanded access program. There is no obligation for a drug manufacturer to make its products available to eligible patients as a result of the Right to Try Act.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We expect that the ACA, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our product candidates.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">At the state level, individual states are increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. These measures could reduce the ultimate demand for our products, once approved, or put pressure on our product pricing.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our current product candidates and any future product candidates or additional pricing pressures. It is possible that additional governmental action is taken to address the COVID-19 pandemic. For example, on April 18, 2020, CMS announced that QHP issuers under the ACA may suspend activities related to the collection and reporting of quality data that would have otherwise been reported between May and June 2020 given the challenges healthcare providers are facing responding to the COVID-19 virus.</font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for biotechnology products. We cannot be sure whether additional legislative changes will be enacted, or whether FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our product candidates, if any, may be. In addition, increased scrutiny by Congress of the FDA&#x2019;s approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing testing and other requirements.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">59</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Our relationships with healthcare professionals, clinical investigators, CROs and third-party payors in connection with our current and future business activities may be subject to federal and state healthcare fraud and abuse laws, false claims laws, transparency laws, government price reporting and health information privacy and security laws, which could expose us to significant losses, including, among other things, criminal sanctions, civil penalties, contractual damages, exclusion from governmental healthcare programs, reputational harm, administrative burdens and diminished profits and future earnings.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Healthcare providers, physicians and third-party payors will play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing approval. Our current and future arrangements with healthcare professionals, clinical investigators, CROs, third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute our product candidates for which we obtain marketing approval. Restrictions under applicable federal and state healthcare laws and regulations, include the following:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:6.796%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under federal and state healthcare programs, such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">the U.S. federal false claims and civil monetary penalties laws, including the U.S. federal False Claims Act, which imposes criminal and civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. In addition, the government may assert that a claim including items and services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">HIPAA, which imposes criminal and civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items or services; similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">HIPAA, as amended by HITECH, which imposes obligations on certain covered entity healthcare providers, health plans, and healthcare clearinghouses as well as their business associates that perform certain services involving the use or disclosure of individually identifiable health information, including mandatory contractual terms, with respect to safeguarding the privacy, security, and transmission of individually identifiable health information, and require notification to affected individuals and regulatory authorities of certain breaches of security of individually identifiable health information;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">federal and state consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm customers;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">the U.S. Physician Payments Sunshine Act created under the ACA, and its implementing regulations, which require that certain manufacturers of drugs, devices, medical supplies and therapeutic biologics that are reimbursable under Medicare, Medicaid, and Children&#x2019;s Health Insurance Programs report annually to the Department of Health and Human Services information related to certain payments and other transfers of value to physicians, as defined by such law, physician assistants, certain types of advance practice nurses and teaching hospitals, as well as ownership and investment interests held by the physicians described above and their immediate family members; and</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">analogous state laws and regulations, such as state anti-kickback and false claims laws that may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers; some state laws require that pharmaceutical companies to comply with the pharmaceutical industry&#x2019;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government in addition to requiring drug and therapeutic biologics manufacturers to report information related to payments to physicians and other healthcare providers or marketing expenditures, and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</font></div></div>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">State and foreign laws also govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. For instance, the collection and use of health data in the European Union is governed by the General Data Protection Regulation, or the GDPR, which extends the geographical scope of European Union data protection law to non-European Union entities under certain conditions, tightens existing European Union data protection principles and creates new obligations for companies and new rights for individuals. Failure to comply with the GDPR may result in substantial fines and other administrative penalties. The GDPR may increase our responsibility and liability in relation to personal data that we possess and we may be required to put in place additional mechanisms ensuring compliance with the GDPR. We comply with the GDPR and the UK GDPR, which, together with the amended UK Data Protection Act 2018, retains the GDPR in United Kingdom national law, the latter regime having the ability to separately fine and penalize violations. The relationship between the United Kingdom and the EU in relation to certain aspects of data protection law remains unclear, and it is unclear how United Kingdom data protection laws and regulations will develop in the medium to longer term, and how data transfers to and from the United Kingdom will be regulated in the long term. Ongoing developments in the United Kingdom have created additional uncertainty regarding personal data transfers from the European Economic Area (EEA) to the United Kingdom following the termination of the personal data transfer grace period set out in the EU and United Kingdom Trade and Cooperation Agreement, which ended</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">60</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">on June 30, 2021. It is not clear whether (and when) an adequacy decision may be granted by the European Commission enabling data transfers from EU member states to the United Kingdom long term without additional measures. Moreover, in July 2020 the Court of Justice of the European Union (CJEU) invalidated the EU-US Privacy Shield Framework (Privacy Shield) under which personal data could be transferred from the EEA and the United Kingdom to entities in the United States who had self-certified under the Privacy Shield scheme. This has led to uncertainty about the adequate transfer mechanisms for other personal data transfers from the EEA and the United Kingdom to the United States or interruption of such transfers. In the event that any court of law orders the suspension of personal data transfers to or from a particular jurisdiction this could give rise to operational interruption in the performance of services for customers, greater costs to implement alternative data transfer mechanisms that are still permitted, regulatory liabilities or reputational harm.  In addition, state laws govern the privacy and security of health information in specified circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. Certain state laws may be more stringent or broader in scope, or offer greater individual rights, with respect to personal information, and such laws may differ from each other, all of which may complicate compliance efforts. For example, on June 28, 2018, the State of California enacted the California Consumer Privacy Act, or CCPA, which went into effect on January 1, 2020. The CCPA creates individual privacy rights for California consumers and increases the privacy and security obligations of entities handling certain personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. Additionally, although not effective until January 1, 2023, the CPRA, which expands upon the CCPA, was passed in the November 2020 election. The CCPA has created new individual privacy rights and places increased privacy and security obligations on entities handling personal information. The CPRA significantly modifies the CCPA, including by expanding consumers&#x2019; rights with respect to certain personal information and creating a new state agency to oversee implementation and enforcement efforts. The CCPA and CPRA may increase our compliance costs and potential liability, and similar laws have been proposed at the federal level and in other states.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Ensuring that our internal operations and future business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that may apply to us, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, exclusion from participation in government-funded healthcare programs such as Medicare and Medicaid or similar programs in other countries or jurisdictions, disgorgement, imprisonment, reputational harm and diminished profits. Defending against any such actions can be costly, time-consuming and may require significant financial and personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">If we fail to comply with U.S. and foreign regulatory requirements, regulatory authorities could limit or withdraw any marketing or commercialization approvals we may receive and subject us to other penalties that could materially harm our business.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Even if we receive marketing and commercialization approval of a product candidate, we will be subject to continuing regulatory requirements, including in relation to adverse patient experiences with the product and clinical results that are reported after a product is made commercially available, both in the United States and any foreign jurisdiction in which we seek regulatory approval. The FDA has significant post-market authority, including the authority to require labeling changes based on new safety information and to require post-market studies or clinical trials to evaluate safety risks related to the use of a product or to require withdrawal of the product from the market. The FDA also has the authority to require a REMS plan after approval, which may impose further requirements or restrictions on the distribution or use of an approved drug or therapeutic biologic. The manufacturer and manufacturing facilities we use to make a future product, if any, will also be subject to periodic review and inspection by the FDA and other regulatory agencies, including for continued compliance with cGMP requirements. The discovery of any new or previously unknown problems with our third-party manufacturers, manufacturing processes or facilities may result in restrictions on the product, manufacturer or facility, including withdrawal of the product from the market. We rely, and expect we will continue to rely, on third-party manufacturers, and we will not have control over compliance with applicable rules and regulations by such manufacturers. Any product promotion and advertising will also be subject to regulatory requirements and continuing regulatory review. If we or our existing or future collaborators, manufacturers or service providers fail to comply with applicable continuing regulatory requirements in the United States or foreign jurisdictions in which we seek to market our products, we or they may be subject to, among other things, fines, warning or untitled letters, holds on clinical trials, delay of approval or refusal by the FDA to approve pending applications or supplements to approved applications, suspension or withdrawal of regulatory approval, product recalls and seizures, administrative detention of products, refusal to permit the import or export of products, operating restrictions, injunctions, civil penalties and criminal prosecution.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Our research and development activities could be affected or delayed as a result of possible restrictions on animal testing.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Certain laws and regulations require us to test our product candidates on animals before initiating clinical trials involving humans. Animal testing activities have been the subject of controversy and adverse publicity. Animal rights groups and other organizations and individuals have attempted to stop animal testing activities by pressing for legislation and regulation in these areas and by disrupting these activities through protests and other means. To the extent the activities of these groups are successful, our research and development activities may be interrupted, delayed or become more expensive.</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">We are subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws and anti-money laundering laws and regulations. Compliance with these legal standards could impair our ability to compete in domestic and international markets. We can face criminal liability and other serious consequences for violations, which can harm our business.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We are subject to export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations, various economic and trade sanctions regulations administered by the U.S. Treasury Department&#x2019;s Office of Foreign Assets Controls, the U.S. Foreign Corrupt Practices Act of 1977, as amended, or FCPA, the U.S. domestic bribery statute contained in 18 U.S.C. &#167; 201, the U.S. Travel Act, the USA PATRIOT Act and other state and national anti-bribery and anti-money laundering laws in the countries in which we</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">61</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">conduct activities. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, contractors and other collaborators from authorizing, promising, offering or providing, directly or indirectly, improper payments or anything else of value to recipients in the public or private sector. We may engage third parties to sell our products outside the United States, to conduct clinical trials and/or to obtain necessary permits, licenses, patent registrations and other regulatory approvals. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities and other organizations. We can be held liable for the corrupt or other illegal activities of our employees, agents, contractors and other collaborators, even if we do not explicitly authorize or have actual knowledge of such activities. Any violations of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm and other consequences.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">We and our third-party contractors must comply with environmental, health and safety laws and regulations. A failure to comply with these laws and regulations could expose us to significant costs or liabilities.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We and our third-party contractors are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the use, generation, manufacture, distribution, storage, handling, treatment, remediation and disposal of hazardous materials and wastes. Hazardous chemicals, including flammable and biological materials, are involved in certain aspects of our business, and we cannot eliminate the risk of injury or contamination from the use, generation, manufacture, distribution, storage, handling, treatment or disposal of hazardous materials and wastes. In the event of contamination or injury, or failure to comply with environmental, health and safety laws and regulations, we could be held liable for any resulting damages, fines and penalties associated with such liability which could exceed our assets and resources.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Although we maintain workers&#x2019; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of biological or hazardous materials or wastes arising out of and in the course of employment, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability that may be asserted against us in connection with our storage or disposal of biological, hazardous or radioactive materials.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Environmental, health and safety laws and regulations are becoming increasingly more stringent. We may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts. Our failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Risks related to employee matters, managing our growth and other risks related to our business</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">If we fail to attract and retain qualified senior management and key scientific personnel, our business may be materially and adversely affected.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Our success depends in part on our continued ability to attract, retain and motivate highly qualified management and clinical and scientific personnel. We are highly dependent upon members of our senior management, including Jay M. Short, Ph.D., our Chairman and Chief Executive Officer and Scott Smith, our President, as well as our senior scientists and other members of our senior management team. The loss of services of any of these individuals could delay or prevent the successful development of our product pipeline, the initiation and completion of our planned clinical trials or the commercialization of product candidates or any future product candidates.</font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Competition for qualified personnel in the pharmaceutical, biopharmaceutical and biotechnology field is intense due to the limited number of individuals who possess the skills and experience required by our industry. We will need to hire additional personnel as we expand our clinical development and if we initiate commercial activities. We may not be able to attract and retain quality personnel on acceptable terms, or at all. In addition, to the extent we hire personnel from competitors, we may be subject to allegations that they have been improperly solicited or that they have divulged proprietary or other confidential information, or that their former employers own their research output.</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">We currently have no sales organization. If we are unable to establish sales, marketing and distribution capabilities on our own or through third parties, we may not be able to market and sell our product candidates, if approved, effectively in the United States and foreign jurisdictions or generate product revenue.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We currently do not have a marketing or sales organization. In order to commercialize our product candidates in the United States and foreign jurisdictions on our own, we must build our marketing, sales, distribution, managerial and other non-technical capabilities or make arrangements with third parties to perform these services, and we may not be successful in doing so. If any of our product candidates receives regulatory approval, we will need to develop internal sales, marketing and distribution capabilities to commercialize such products, which would be expensive and time-consuming, or make arrangements with third parties to perform these services. If we decide to market our products directly, we will need to commit significant financial and managerial resources to develop a marketing and sales force with technical expertise and supporting distribution, administration and compliance capabilities. If we rely on third parties with such capabilities to market our products or decide to co-promote products with existing or future collaborators, we will need to establish and maintain marketing and distribution arrangements with third parties, and we cannot assure you that we will be able to enter into such arrangements on acceptable terms, or at all. In entering into third-party marketing or distribution arrangements, any revenue we receive will depend upon the efforts of the third parties, and we cannot assure you that such third parties will establish adequate sales and distribution capabilities or be successful in gaining market acceptance of any approved product. If we are not successful in commercializing any product approved in the future, either on our own or through arrangements with one or more third parties, we may not be able to generate any future product revenue and we would incur significant additional losses.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">62</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">In order to successfully implement our plans and strategies, we will need to grow the size of our organization, and we may experience difficulties in managing this growth.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">As of December 31, 2021, we had 56 employees, and 18 dedicated independent contractors based in China and engaged through our agreement with BioDuro-Sundia, a provider of preclinical development services. In order to successfully implement our development and commercialization plans and strategies, and operate as a public company, we expect to need additional development, managerial, operational, financial, sales, marketing and other personnel. Future growth would impose significant added responsibilities on members of management, including:</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <div style="margin-left:6.796%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">identifying, recruiting, integrating, maintaining and motivating additional employees;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">managing our internal development efforts effectively, including the clinical and regulatory review process for mecbotamab vedotin and ozuriftamab vedotin and any other product candidates, while complying with our contractual obligations to contractors and other third parties; and</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">improving our operational, financial and management controls, reporting systems and procedures.</font></div></div>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Our future financial performance and our ability to successfully develop and, if approved, commercialize mecbotamab vedotin, ozuriftamab vedotin and any future product candidates will depend, in part, on our ability to effectively manage any future growth, and our management may also have to divert a disproportionate amount of its attention away from day-to-day activities in order to devote a substantial amount of time to managing these growth activities.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">To date, we have used the services of outside vendors to augment our capabilities in performing certain tasks, including preclinical and clinical trial management, manufacturing, statistics and analysis and research and development functions. Our growth strategy may also entail expanding our group of such contractors or consultants to assist in implementing these tasks going forward. Because we rely on numerous consultants, we will need to be able to effectively manage these consultants to ensure that they successfully carry out their contractual obligations and meet expected deadlines. However, if we are unable to effectively manage our outsourced activities or if the quality or accuracy of the services provided by consultants is compromised for any reason, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval for mecbotamab vedotin, ozuriftamab vedotin and any future product candidates or otherwise advance our business. We may not be able to manage our existing outside contractors or find other competent outside contractors and consultants on economically reasonable terms, or at all. If we are not able to effectively expand our organization by hiring new employees and expanding our groups of consultants and contractors, we may not be able to successfully implement the tasks necessary to further develop and commercialize mecbotamab vedotin, ozuriftamab vedotin and any future product candidates and, accordingly, may not achieve our research, development and commercialization goals.</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Our employees and independent contractors, including principal investigators, CROs, consultants and vendors, may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We are exposed to the risk that our employees and independent contractors, including principal investigators, CROs, consultants and vendors may engage in misconduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or disclosure of unauthorized activities to us that violate: (1) the laws and regulations of the FDA and other similar regulatory requirements, including those laws that require the reporting of true, complete and accurate information to such authorities, (2) manufacturing standards, including cGMP requirements, (3) federal and state data privacy, security, fraud and abuse and other healthcare laws and regulations in the United States and abroad or (4) laws that require the true, complete and accurate reporting of financial information or data. Activities subject to these laws also involve the improper use or misrepresentation of information obtained in the course of clinical trials, the creation of fraudulent data in our preclinical studies or clinical trials, or illegal misappropriation of drug product, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. In addition, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and financial results, including, without limitation, the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgements, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, individual imprisonment, contractual damages, reputational harm, diminished profits and future earnings, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Our internal computer systems, or those of any of our CROs, manufacturers, other contractors, consultants, existing or future collaborators, may fail or suffer security or data privacy breaches or other unauthorized or improper access to, use of or destruction of our proprietary and confidential data, employee data or personal data, which could result in additional costs, significant liabilities, harm to our reputation and material disruption of our operations.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Despite the implementation of security measures, our internal computer systems and those of our current and any future CROs, manufacturers, other contractors, consultants, existing or future collaborators and other third-party service providers are vulnerable to damage from various methods, including cybersecurity attacks, breaches, intentional or accidental mistakes or errors, or other technological failures, which can include, among other things, computer viruses, unauthorized access attempts, including third parties gaining access to systems using stolen or inferred credentials, denial-of-service attacks, phishing attempts, service disruptions, natural disasters, fire, terrorism, war and</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">63</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">telecommunication and electrical failures. As the cyber-threat landscape evolves, these attacks are growing in frequency, sophistication and intensity, and are becoming increasingly difficult to detect. If such an event were to occur and cause interruptions in our operations or result in the unauthorized acquisition of or access to personally identifiable information or individually identifiable health information (violating certain privacy laws such as HIPAA, HITECH, the CCPA and GDPR), it could result in a material disruption of our product candidate development programs and our business operations and we could incur significant liabilities. Some of the federal, state and foreign government requirements include obligations of companies to notify individuals of security breaches involving particular personally identifiable information, which could result from breaches experienced by us or by our vendors, contractors or organizations with which we have formed strategic relationships. Notifications and follow-up actions related to a security breach could impact our reputation and cause us to incur significant costs, including legal expenses and remediation costs. For example, the loss of clinical trial data from completed, ongoing or future clinical trials involving our product candidates could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the lost data. In addition, because of our approach of running multiple clinical trials in parallel, any breach of our computer systems may result in a loss of data or compromised data integrity across many of our programs in various stages of development.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We also rely on third parties to manufacture our product candidates, and similar events relating to their computer systems could also have a material adverse effect on our business. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data, or inappropriate disclosure of confidential or proprietary information, we could be exposed to litigation and governmental investigations, the further development and commercialization of our product candidates could be delayed and we could be subject to significant fines or penalties for any noncompliance with certain state, federal or international privacy and security laws.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Our insurance policies may not be adequate to compensate us for the potential losses arising from any such disruption, failure or security breach. In addition, such insurance may not be available to us in the future on economically reasonable terms, or at all. Further, our insurance may not cover all claims made against us and could have high deductibles in any event, and defending a suit, regardless of its merit, could be costly and divert management attention.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">A portion of our research and development activities take place in China. Uncertainties regarding the interpretation and enforcement of Chinese laws, rules and regulations, a trade war, deterioration of international relations, or political unrest in China could materially adversely affect our business, financial condition and results of operations.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We conduct preclinical research and development activities in China through BioDuro-Sundia, which is U.S. owned, but governed by Chinese laws, rules and regulations. The Chinese legal system is a civil law system based on written statutes. Unlike the common law system, prior court decisions may be cited for reference but have limited precedential value. In addition, the Chinese legal system is based in part on government policies and internal rules, some of which are not published on a timely basis or not published at all, and which may have a retroactive effect. As a result, we may not be aware of our violation of these policies and rules until after the occurrence of the violation. Any administrative and court proceedings in China may be protracted, resulting in substantial costs and diversion of resources and management attention. Since Chinese administrative and court authorities have significant discretion in interpreting and implementing statutory and contractual terms, it may be more difficult to evaluate the outcome of administrative and court proceedings and the level of legal protection we enjoy than in U.S. or EU legal systems.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Furthermore, we are exposed to the possibility of disruption of our research and development activities in the event of changes in the policies of the United States or Chinese governments, political unrest or unstable economic conditions in China. For example, a trade war could lead to increased costs for clinical materials that are manufactured in China. These interruptions or failures and any restrictive measures resulting from a deterioration of U.S.- China relations could also result in impeding the commercialization of our product candidates and impair our competitive position. Further, we may be exposed to fluctuations in the value of the local currency in China. Future appreciation of the local currency could increase our costs. These uncertainties may impede our ability to enforce the contracts we have entered into and our ability to continue our research and development activities and could materially and adversely affect our business, financial condition and results of operations.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Our current operations are concentrated in two locations. We or the third parties upon whom we depend may be adversely affected by earthquakes, wildfires or other natural disasters, and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">A portion of our current operations are located in our facilities in San Diego, California, and we conduct a portion of our research and development activities in China through our arrangement with BioDuro-Sundia. Any unplanned event, such as flood, fire, explosion, earthquake, extreme weather condition, medical epidemics or pandemics, power shortage, telecommunication failure or other natural or manmade accidents or incidents that result in us being unable to fully utilize our facilities, or the manufacturing facilities of our third-party contract manufacturers, may have a material and adverse effect on our ability to operate our business, particularly on a daily basis, and have significant negative consequences on our financial and operating conditions. Loss of access to these facilities may result in increased costs, delays in the development of our product candidates or interruption of our business operations. Earthquakes, wildfires or other natural disasters could further disrupt our operations and have a material and adverse effect on our business, financial condition, results of operations and prospects. If a natural disaster, power outage or other event prevented us from using all or a significant portion of our headquarters, damaged critical infrastructure, such as our research facilities or the manufacturing facilities of our third-party contract manufacturers, or otherwise disrupted operations, it may be difficult or, in certain cases, impossible, for us to continue our business for a substantial period of time. The disaster recovery and business continuity plans we have in place may prove inadequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which could have a material adverse effect on our business. As part of our risk management policy, we maintain insurance coverage at levels that we believe are appropriate for our business. However, in the event of an accident or incident</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">64</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">at these facilities, we cannot assure you that the amounts of insurance will be sufficient to satisfy any damages and losses. If our facilities, or the manufacturing facilities of our third-party contract manufacturers, are unable to operate because of an accident or incident or for any other reason, even for a short period of time, any or all of our research and development programs may be harmed. Any business interruption may have a material and adverse effect on our business, financial condition, results of operations and prospects. In addition, all of our therapeutic antibodies are manufactured by starting with cells which are stored in a one master cell bank for each antibody manufactured stored in multiple locations. While we believe we will have adequate backup should any cell bank be lost in a catastrophic event, and we take precautions when transporting our cell banks, it is possible that we could lose multiple cell banks and have our manufacturing severely impacted by the need to replace the cell banks.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Our business is subject to economic, political, regulatory and other risks associated with conducting business internationally.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We, our collaborators or licensees may seek regulatory approval of our product candidates outside of the United States including in China, the European Union, Australia, New Zealand, and Japan. We conduct preclinical research and development activities in China through BioDuro-Sundia, which is U.S. owned, but governed by Chinese laws. Accordingly, we expect that we will be subject to additional risks related to operating in foreign countries if we obtain the necessary approvals, including:</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <div style="margin-left:6.796%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">differing regulatory requirements and reimbursement regimes in foreign countries;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">unexpected changes in tariffs, trade barriers, price and exchange controls and other regulatory requirements;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">economic weakness, including inflation, or political instability in particular foreign economies and markets;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">foreign taxes, including withholding of payroll taxes;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">difficulties staffing and managing foreign operations;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">workforce uncertainty in countries where labor unrest is more common than in the United States;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">potential liability under the FCPA or comparable foreign regulations;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">challenges enforcing our contractual and intellectual property rights, especially in those foreign countries that do not respect and protect intellectual property rights to the same extent as the United States;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">business interruptions resulting from geo-political actions, including war and terrorism.</font></div></div>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">These and other risks associated with our international operations may materially adversely affect our ability to attain or maintain profitable operations.</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">We face risks related to health epidemics and outbreaks, including the COVID-19 pandemic, which could significantly disrupt our preclinical studies and could affect enrollment of patients in our clinical trials. Continuation and  increasing severity of these conditions could delay or prevent our receipt of necessary regulatory approvals.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We face risks related to health epidemics or outbreaks of communicable diseases. For example, in December 2019, a novel strain of coronavirus, SARS-CoV-2, causing a disease referred to as COVID-19, emerged in China. Since then, COVID-19 has spread to multiple countries worldwide, including the United States and member states of the European Union. On March 11, 2020, the World Health Organization declared the outbreak of COVID-19 as a pandemic. The outbreak of such communicable diseases could result in a widespread health crisis that could adversely affect general commercial activity and the economies and financial markets of many countries, which in the case of COVID-19 has occurred. The COVID-19 pandemic has resulted in governments implementing numerous containment measures, such as travel bans and restrictions, particularly quarantines, shelter-in-place or total lock-down orders and business limitations and shutdowns. For example, our primary operations are located in San Diego, California, and San Diego County and the State of California had issued shelter-in-place orders in response to the COVID-19 pandemic. Although some restrictions aimed at minimizing the spread of COVID-19 have been and may from time to time be eased or lifted in the U.S. and other countries, in response to local surges and new waves of infection, including those caused by the spread of the Delta, Omicron and other variants, some countries, states, and local governments have maintained or reinstituted these restrictions, or may reinstitute these restrictions from time to time, in response to rising rates of infection.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We are following, and plan to continue to follow, recommendations from federal, state and local governments regarding workplace policies, practices and procedures. In March 2020, we implemented a remote working policy for many of our employees and began restricting non-essential travel. We are complying with all applicable guidelines for our clinical trials, including remote clinical monitoring. We are continuing to monitor the potential impact of the pandemic, but we cannot be certain what the overall impact will be on our business, financial condition, results of operations and prospects.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">65</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">In addition, the COVID-19 pandemic is having a severe effect on the clinical trials of many drug candidates of several sponsors. Some trials have been merely delayed, while others have been cancelled. The extent to which the COVID-19 pandemic may impact our preclinical and clinical trial operations will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the duration and geographic reach of the outbreak, the severity of COVID-19 (including its variant strains, such as the highly transmissible Delta and Omicron variants), the effectiveness of actions to contain and treat COVID-19 and the rate of vaccination and efficacy of approved vaccines against COVID-19 and its variant strains. To date, we have experienced modest business disruptions, including with respect to the clinical trials we are conducting, and non-material impairments as a result of the pandemic. The continued spread of COVID-19 could adversely impact our clinical trial operations, including our ability to recruit and retain patients and principal investigators and site staff who, as healthcare providers, may have heightened exposure to COVID-19 if an outbreak occurs in their geography. Disruptions or restrictions on our ability to travel to monitor data from our clinical trials, or to conduct clinical trials, or the ability of patients enrolled in our studies to travel, or the ability of staff at study sites to travel, as well as temporary closures of our facilities or the facilities of our clinical trial partners and their contract manufacturers, would negatively impact our clinical trial activities. In addition, we rely on independent clinical investigators, CROs and other third-party service providers to assist us in managing, monitoring and otherwise carrying out our preclinical studies and clinical trials, including the collection of data from our clinical trials, and the outbreak may affect their ability to devote sufficient time and resources to our programs or to travel to sites to perform work for us. Similarly, our preclinical trials could be delayed and/or disrupted by the COVID-19 pandemic. As a result, the expected timeline for data readouts of our preclinical studies and clinical trials and certain regulatory filings may be negatively impacted, which would adversely affect our ability to obtain regulatory approval for and to commercialize our product candidates, increase our operating expenses and have a material adverse effect on our business, financial condition, results of operations and prospects.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:10.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Risks related to our dependence on third parties</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">We have entered, and may in the future seek to enter, into collaborations with third parties for the development and commercialization of certain of our product candidates. If we fail to enter into such collaborations, or such collaborations are not successful, we may not be able to capitalize on the market potential of our patented technology platform and resulting product candidates.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We have entered, and may in the future seek to enter, into collaborations with third parties for the development and commercialization of certain of our product candidates. In addition, we may in the future seek third-party collaborators or joint venture partners for development and commercialization of additional CAB product candidates. With respect to our collaborations, and what we expect will be the case with any future license or collaboration agreements, we have, and would expect to have, limited control over the amount and timing of resources that our existing or future collaborators dedicate to the development or commercialization of our product candidates. Our ability to generate revenues from these arrangements will depend on our existing or future collaborators&#x2019; willingness to select additional product candidates to license and their abilities and willingness to fulfill their payment obligations and successfully perform the functions assigned to them in these arrangements.<br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Our existing collaboration arrangements currently pose, and future collaborations involving our product candidates will pose, the following risks to us:<br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:6.796%;display:flex;margin-top:5.4pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:5.4pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">collaborators may not pursue development and commercialization of our product candidates or may elect not to continue or renew development or commercialization programs based on preclinical or clinical trial results, changes in the collaborators&#x2019; strategic focus due to their acquisition of competitive products or their internal development of competitive products, available funding or other external factors, such as a business combination that diverts resources or creates competing priorities;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:5.4pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:5.4pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">collaborators and other alliances could independently develop, or develop with third parties, products that compete directly or indirectly with our product candidate, particularly if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:5.4pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">collaborators with marketing, manufacturing and distribution rights to one or more products may not commit sufficient resources to or otherwise not perform satisfactorily in carrying out these activities;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:5.4pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">we could grant exclusive rights to our collaborators that would prevent us from collaborating with others;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:5.4pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">collaborators may not properly maintain or defend our intellectual property rights or may use our intellectual property or proprietary information in a way that gives rise to actual or threatened litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential liability;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:5.4pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:5.4pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">disputes may arise between the collaborators and us that result in the delay or termination of the research, development or commercialization of our product candidate or that result in costly litigation or arbitration that diverts management attention and resources;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:5.4pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">disputes may arise with respect to the ownership of any intellectual property developed pursuant to our collaborations;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:5.4pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">collaborators may not provide us with timely and accurate information regarding development, regulatory or commercialization status or results, which could adversely impact our ability to manage our own development efforts, accurately forecast financial </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">66</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <div style="margin-left:6.796%;display:flex;margin-top:5.4pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;visibility:hidden;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;"></font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">results or provide timely information to our stockholders regarding our out-licensed product candidates;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:5.4pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">collaborations may be terminated and, if terminated, this may result in a need for additional capital to pursue further development or commercialization of the applicable current or future product candidates; and</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:5.4pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">collaborators&#x2019; sales and marketing activities or other operations may not be in compliance with applicable laws resulting in civil or criminal proceedings.</font></div></div>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Collaboration agreements may not lead to development or commercialization of our product candidates in the most efficient manner or at all. If a collaborator of ours were to be involved in a business combination, the continued pursuit and emphasis on our product development or commercialization program could be delayed, diminished or terminated.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">If our existing or future collaborators cease development efforts under our existing or future collaboration agreements, or if any of those agreements are terminated, we may lose committed funding under those agreements and these collaborations may fail to lead to commercial products and the reputation of our patented CAB technology platform may suffer.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Revenue from research and development collaborations depend upon continuation of the collaborations, initiation and expansion of the number of programs subject to the collaborations, the achievement of milestones and royalties, if any, derived from future products developed from our research. If we are unable to successfully advance the development of our product candidates or achieve milestones, revenue and cash resources from milestone payments under our existing or future collaboration agreements will be substantially less than expected.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Our ability to advance our product candidates may be limited by third parties on which we rely for certain technologies which we use in certain of our programs. If any third party developing our product candidates or other candidates based on our patented CAB technology platform experiences a delay or failure in development, regulatory approval or commercialization, even if such failure is not due to our CAB technology, it could reflect negatively on us, our other product candidates and our patented CAB technology platform. In addition, if one of our current or future collaborators terminates its agreement with us, we may find it more difficult to attract new collaborators and our perception in the business and financial communities and our stock price could be adversely affected.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">We may not be successful in establishing commercialization collaborations, which could adversely affect our ability to commercialize our product candidates, if approved.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">From time to time, we may evaluate and, if strategically attractive, seek to enter into additional collaborations, including with major biotechnology or biopharmaceutical companies. The competition for collaborators is intense, and the negotiation process is time-consuming and complex. Any new collaboration may be on terms that are not optimal for us, and we may not be able to maintain any new collaboration if, for example, development or approval of a product candidate is delayed, sales of an approved product candidate do not meet expectations or the collaborator terminates the collaboration. Moreover, such arrangements are complex and time-consuming to negotiate, document and implement and they may require substantial resources to maintain.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">In addition, it is possible that a collaborator may not devote sufficient resources to the commercialization of our product candidates or may otherwise fail in its commercialization efforts, in which event the commercialization of such product candidates could be delayed or terminated and our business could be substantially harmed. In addition, the terms of any collaboration or other arrangement that we establish may not be favorable to us or may not be perceived as favorable, which may negatively impact our business, financial condition, results of operations and prospects.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">If third parties on which we rely to conduct our preclinical and clinical trials, do not perform as contractually required, fail to satisfy regulatory or legal requirements or miss expected deadlines, our development programs could be delayed with material and adverse effects on our business, financial condition, results of operations and prospects.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We rely, and expect we will continue to rely, on third-party investigators, CROs, data management organizations and consultants to conduct, supervise and monitor our ongoing clinical trials and preclinical studies. We currently rely on third parties to manage and conduct our clinical trials of mecbotamab vedotin and ozuriftamab vedotin. Because we rely on these third parties and do not have the ability to conduct preclinical studies or clinical trials independently, we have less control over the timing, quality and other aspects of preclinical studies and clinical trials than we would have had we conducted them on our own. These investigators, CROs and consultants are not our employees and we will have limited control over the amount of time and resources that they dedicate to our development programs. These third parties may have contractual relationships with other entities, some of which may be our competitors, which may draw time and resources from our development programs. The third parties with whom we contract might not be diligent, careful or timely in conducting our preclinical studies or clinical trials, resulting in the preclinical studies or clinical trials being delayed or unsuccessful.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">If we do not contract with acceptable third parties on commercially reasonable terms, or at all, or if these third parties do not carry out their contractual duties, satisfy legal and regulatory requirements for the conduct of preclinical studies or clinical trials or meet expected deadlines, our development programs could be delayed and otherwise adversely affected. In all events, we are responsible for ensuring that each of our preclinical studies and clinical trials are conducted in accordance with the general investigational plan, protocols for the trial and regulatory requirements. The FDA requires preclinical studies to be conducted in accordance with GLPs and clinical trials to be conducted in accordance with GCPs, including for designing, conducting, recording and reporting the results of preclinical studies and clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of clinical trial participants are protected. Our reliance on third parties that we do not control does not relieve us of these responsibilities and requirements. Any adverse development or delay in our</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">67</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">preclinical studies and clinical trials could have a material and adverse effect on our business, financial condition, results of operations and prospects.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">We rely on third parties for the manufacture of our product candidates for preclinical studies and our ongoing clinical trials, and we expect to continue to do so for additional clinical trials and ultimately commercialization. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or products, if approved, or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We rely, and expect we will continue to rely, on third-party contract manufacturers to manufacture our preclinical and clinical trial product supplies and the raw materials used to create our product candidates. We do not own manufacturing facilities for producing such supplies, and we do not have long-term manufacturing agreements. Furthermore, the raw materials for our product candidates may be sourced, in some cases, from a single-source supplier. If we were to experience an unexpected loss of supply of any of our product candidates or any of our future product candidates for any reason, whether as a result of manufacturing, supply or storage issues or otherwise, we could experience delays, disruptions, suspensions or terminations of, or be required to restart or repeat, any pending or ongoing clinical trials. For example, the extent to which the COVID-19 pandemic impacts our ability to procure sufficient supplies for the development of our product candidates will depend on the severity and duration of the spread of the virus, and the actions undertaken to contain COVID-19 or treat its effects. We cannot assure you that our preclinical and clinical development product supplies or raw materials will not be limited, interrupted, or be of satisfactory quality or continue to be available at acceptable prices. In particular, any replacement of a manufacturer could require significant effort and expertise because there are a limited number of qualified replacements. The technical skills or technology required to manufacture our product candidates may be unique or proprietary to the original manufacturer and we may have difficulty transferring such skills or technology to another third party and a feasible alternative may not exist. These factors would increase our reliance on such manufacturer or require us to obtain a license from such manufacturer in order to have another third-party manufacture our product candidates.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">If we submit an application for regulatory approval of any of our product candidates, the facilities used by our contract manufacturers to manufacture our product candidates will be subject to inspection by the FDA or other regulatory authorities. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or others or if they are unable to maintain a compliance status acceptable to the FDA or other regulatory authorities, approval of our product candidates may be delayed or we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates, if approved.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We expect to continue to rely on third-party manufacturers if we receive regulatory approval for any product candidate. If we are unable to obtain or maintain third-party manufacturing for product candidates, or to do so on commercially reasonable terms, we may not be able to develop and commercialize our product candidates successfully. Even if we are able to establish agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including:</font></p>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">the failure of the third party to manufacture our product candidates according to our schedule, or at all, including if our third-party contractors give greater priority to the supply of other products over our product candidates or otherwise do not satisfactorily perform according to the terms of the agreements between us and them;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">the reduction or termination of production or deliveries by suppliers, or the raising of prices or renegotiation of terms;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">the termination or nonrenewal of arrangements or agreements by our third-party contractors at a time that is costly or inconvenient for us;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">the breach by the third-party contractors of our agreements with them;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">the failure of third-party contractors to comply with applicable regulatory requirements;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">the failure of the third party to manufacture our product candidates according to our specifications;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">the mislabeling of clinical supplies, potentially resulting in the wrong dose amounts being supplied or active drug not being properly identified;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">clinical supplies not being delivered to clinical sites on time, leading to clinical trial interruptions, or of drug supplies not being distributed to commercial vendors in a timely manner, resulting in lost sales; and</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">the misappropriation of our proprietary information, including our trade secrets and know-how.</font></div></div>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">In addition, we have no material long-term contracts with our suppliers, and we compete with other companies for raw materials and production. We may experience a significant disruption in the supply of raw materials from current sources or, in the event of a disruption, we may be unable to locate alternative materials suppliers of comparable quality at an acceptable price, or at all. In addition, if we experience significant increased demand, or if we need to replace an existing supplier, we may be unable to locate additional supplies of raw materials on terms that are acceptable to us, or at all, or we may be unable to locate any supplier with sufficient capacity to meet our requirements or to fill our orders in a timely manner. Identifying a suitable supplier is an involved process that requires us to become satisfied with their quality control, responsiveness and service, financial stability and labor and other ethical practices. Even if we are able to expand existing sources, we may encounter delays in production and added costs as a result of the time it takes to train suppliers in our methods, products and quality control standards.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">68</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">The manufacture of biotechnology products is complex, and manufacturers often encounter difficulties in production. If we or any of our third-party manufacturers encounter any loss of materials or if any of our third-party manufacturers encounter other difficulties, or otherwise fail to comply with their contractual or regulatory obligations, our ability to provide product candidates for clinical trials or our products to patients, once approved, the development or commercialization of our product candidates could be delayed or stopped.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The manufacture of biotechnology products is complex and requires significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls. We and our contract manufacturers must comply with cGMPs, regulations and guidelines for the manufacturing of biologics used in clinical trials and, if approved, marketed products. In order to conduct clinical trials of our product candidates, we and existing and future collaborators will need to manufacture them in large quantities and in accordance with cGMPs. Manufacturers of biotechnology products often encounter difficulties in production, particularly in scaling up and validating initial production. In addition, if microbial, viral or other contaminations are discovered in our products or in the manufacturing facilities in which our products are made, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination. Delays in raw materials availability and supply may also extend the period of time required to develop our products. Furthermore, changes in our manufacturing methods may require comparability studies, including clinical bridging studies, which may result in delays to the approval process for our product candidates.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">All of our therapeutic antibodies are manufactured by starting with cells which are stored in a cell bank. We have one master cell bank for each antibody manufactured in accordance with cGMPs, which is stored in multiple locations. We are currently creating multiple working cell banks. While we believe we will have adequate backup should any cell bank be lost in a catastrophic event, and we take precautions when transporting our cell banks, it is possible that we could lose multiple cell banks and have our manufacturing severely impacted by the need to replace the cell banks.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We cannot assure you that any stability or other issues relating to the manufacture of any of our product candidates or products will not occur in the future. Additionally, our manufacturers may experience manufacturing difficulties due to resource constraints or as a result of labor disputes or unstable political environments. For example, the extent to which the COVID-19 pandemic impacts the ability to procure sufficient supplies for the development of our product candidates will depend on the severity and duration of the spread of the virus, and the actions undertaken to contain COVID-19 or treat its effects. If our manufacturers were to encounter any of these difficulties, or otherwise fail to comply with their contractual obligations, our ability to provide any product candidates to patients in planned clinical trials and products to patients, once approved, would be jeopardized. Any delay or interruption in the supply of clinical trial supplies could delay the completion of planned clinical trials, increase the costs associated with maintaining clinical trial programs and, depending upon the period of delay, require us to commence new clinical trials at additional expense or terminate clinical trials completely. Any adverse developments affecting clinical or commercial manufacturing of our product candidates or products may result in shipment delays, inventory shortages, lot failures, product withdrawals or recalls, or other interruptions in the supply of our product candidates or products or enforcement actions by regulatory authorities. We may also have to take inventory write-offs and incur other charges and expenses for product candidates or products that fail to meet specifications, undertake costly remediation efforts or seek more costly manufacturing alternatives. Accordingly, failures or difficulties faced at any level of our supply chain could adversely affect our business and delay or impede the development and commercialization of any of our product candidates or products and could have an adverse effect on our business, financial condition, results of operations and prospects.</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Risks related to intellectual property</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">If we are not able to obtain, maintain and protect our intellectual property rights in any product candidates or technologies we develop, or if the scope of the intellectual property protection obtained is not sufficiently broad, third parties could develop and commercialize products and technology similar or identical to ours, and we may not be able to compete effectively in our market.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Our success depends in part on our ability to obtain and maintain patents and other forms of intellectual property rights, including in-licenses of intellectual property rights of others, for our product candidates, methods used to develop and manufacture our product candidates and methods for treating patients using our product candidates, as well as our ability to preserve our trade secrets, to prevent third parties from infringing upon our proprietary rights and to operate without infringing upon the proprietary rights of others. The patent process is expensive and time-consuming, and we may not be able to apply for patents on certain aspects of our product candidates in a timely fashion, at a reasonable cost, in all jurisdictions, or at all. Our existing issued and granted patents and any future patents we obtain may not be sufficiently broad to prevent others from using our technology or from developing competing products and technology. There is no guarantee that any of our pending patent applications will result in issued or granted patents, that any of our issued or granted patents will not later be found to be invalid or unenforceable or that any issued or granted patents will include claims that are sufficiently broad to cover our product candidates or to provide meaningful protection from our competitors.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Moreover, the patent position of biotechnology and biopharmaceutical companies can be highly uncertain because it involves complex legal and factual issues. We will be able to protect our proprietary rights from unauthorized use by third parties only to the extent that our current and future proprietary technology and product candidates are covered by valid and enforceable patents or are effectively maintained as trade secrets. If third parties disclose or misappropriate our proprietary rights, it may materially and adversely affect our position in the market. Furthermore, even if they are unchallenged, our patents and patent applications may not adequately protect our intellectual property, provide exclusivity for our product candidates, or prevent others from designing around our patent claims.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Once granted, patents may remain open to opposition, interference, re-examination, post-grant review,</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;"> inter partes</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> review, nullification or derivation action in court or before patent offices or similar proceedings for a given period after allowance or grant, during which time third parties can raise objections against granted patents. In the course of such proceedings, which may continue for a protracted period of time, the patent owner may be compelled to limit the scope of the allowed or granted patent claims thus attacked, or may lose the allowed or granted claims</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">69</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">altogether. As of March 24, 2021, there is an ongoing patent opposition proceeding regarding our patent EP2 406 399 at the European Patent Office which is related to a version of methods used for evolving and screening potential product candidates. The Opposition Division revoked EP2 406 399 in its decision dated March 10, 2020 and we filed an appeal on July 20, 2020. In addition, we cannot assure you that:</font></p>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We may obtain, maintain, protect and enforce intellectual property protection for our technologies and product candidates.</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Others will not or may not be able to make, use or sell compounds that are the same as or similar to our product candidates but that are not covered by the claims of the patents that we own or license.</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We or our licensors, or our existing or future collaborators are the first to make the inventions covered by each of our issued patents and pending patent applications that we own or license.</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We or our licensors, or our existing or future collaborators are the first to file patent applications covering certain aspects of our inventions.</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Others will not independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights.</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">A third party may not challenge our patents and, if challenged, that a court would hold that our patents are valid, enforceable and infringed.</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Any issued patents that we own or have licensed will provide us with any competitive advantage or will not be challenged by third parties.</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We may develop or in-license additional proprietary technologies that are patentable.</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Pending patent applications that we own or may license will lead to issued patents.</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The patents of others will not have a material or adverse effect on our business, financial condition, results of operations and prospects.</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Our competitors do not conduct research and development activities in countries where we do not have enforceable patent rights and then use the information learned from such activities to develop competitive products for sale in our commercial markets.</font></div></div>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">If the breadth or strength of protection provided by the patents and patent applications we hold, obtain or pursue with respect to our product candidates is challenged, or if they fail to provide meaningful exclusivity for our product candidates, it could threaten our ability to practice our technologies or commercialize our product candidates. We cannot offer any assurances about which, if any, patents will issue, the breadth of any such patent, or whether any issued patents will be found invalid and unenforceable or will be threatened by third parties. Furthermore, an interference or derivation proceeding can be provoked by a third party or instituted by a patent office or in a court proceeding, to determine who was the first to invent any of the subject matter covered by the patent claims of our applications.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Where we obtain licenses from third parties, in some circumstances, we may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, covering technology that we license from third parties. We may also require the cooperation of our licensors to enforce any licensed patent rights, and such cooperation may not be provided. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business. Moreover, if we do obtain necessary licenses, we will likely have obligations under those licenses, and any failure to satisfy those obligations could give our licensor the right to terminate the license. Termination of a necessary license could have a material adverse impact on our business.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">In addition to seeking patent protection for certain aspects of our product candidates, we also consider trade secrets, including confidential and unpatented know-how important to the maintenance of our competitive position. We seek to protect trade secrets and confidential and unpatented know-how, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to such knowledge, such as our employees, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers, consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants that obligate them to maintain confidentiality and assign their inventions to us. We also seek to preserve the integrity and confidentiality of our data, trade secrets and know-how by maintaining physical security of our premises and physical and electronic security of our information technology systems. Monitoring unauthorized uses and disclosures is difficult, and we do not know whether the steps we have taken to protect our proprietary technologies will be effective. We cannot guarantee that our trade secrets and other proprietary and confidential information will not be disclosed or that competitors will not otherwise gain access to our trade secrets. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts in the United States and certain foreign jurisdictions are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position could be harmed.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Trade secrets and know-how can be difficult to protect as trade secrets and know-how will over time be disseminated within the industry through independent development, the publication of journal articles, and the movement of personnel skilled in the art from company to company</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">70</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">or academic to industry scientific positions. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent such competitor from using that technology or information to compete with us, which could harm our competitive position. If we are unable to prevent material disclosure of the intellectual property related to our technologies to third parties, we will not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business, results of operations and financial condition. Even if we are able to adequately protect our trade secrets and proprietary information, our trade secrets could otherwise become known or could be independently discovered by our competitors. Competitors could willfully infringe our intellectual property rights, design around our protected technology or develop their own competitive technologies that fall outside of our intellectual property rights. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, in the absence of patent protection, we would have no right to prevent them, or those to whom they communicate, from using that technology or information to compete with us. If our trade secrets are not adequately protected so as to protect our market against competitors&#x2019; products, others may be able to exploit our product candidates and discovery technologies to identify and develop competing product candidates, and thus our competitive position could be adversely affected, as could our business.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">The terms of our patents may not protect our competitive position on our product candidates for an adequate amount of time.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years after its earliest U.S. non-provisional effective filing date. Although various extensions may be available, the life of a patent, and the protection it affords, is limited. Even if patents covering our technologies or product candidates are obtained, once the patent life has expired, we may be open to competition. Our issued patents will expire on dates ranging from 2030 to 2037, subject to any additional patent extensions that may be available for such patents. If patents are issued on our pending patent applications, the resulting patents are projected to expire on dates ranging from 2030 to 2041 plus any potential patent extensions that may be available for such patents. Due to the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">If we do not obtain patent term extension for our product candidates, our business may be materially harmed.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Depending upon the timing, duration and specifics of FDA marketing approval of our product candidates, one or more of our U.S. patents may be eligible for limited patent term restoration under the Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent restoration term of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. A maximum of one patent may be extended per FDA-approved product as compensation for the patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval and only those claims covering such approved drug product, a method for using it or a method for manufacturing it may be extended. Patent term extension may also be available in certain foreign countries upon regulatory approval of our product candidates. However, we may not be granted an extension because of, for example, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request or require. If we are unable to obtain patent term extension or restoration or the term of any such extension is less than we request or require, our competitors may obtain approval of competing products following our patent expiration, and our revenue could be reduced, possibly materially. Further, if this occurs, our competitors may take advantage of our investment in development and trials by referencing our clinical and preclinical data and launch their product earlier than might otherwise be the case.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Recent patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">In September 2011, the Leahy-Smith America Invents Act, or Leahy-Smith Act, was signed into law. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications will be prosecuted and may also affect patent litigation. In particular, under the Leahy-Smith Act, the United States transitioned in March 2013 to a &#x201c;first inventor to file&#x201d; system in which, assuming that other requirements of patentability are met, the first inventor to file a patent application will be entitled to the patent regardless of whether another party was first to invent the claimed invention. A third party that files a patent application in the USPTO after March 2013 but before us could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by such third party. This will require us to be cognizant going forward of the time from invention to filing of a patent application. Furthermore, our ability to obtain and maintain valid and enforceable patents depends on whether the differences between our technology and the prior art render our technology to be patentable over the prior art. Since patent applications in the United States and most other countries are confidential for a period of time after filing or until issuance, we cannot be certain that we were the first to either (i) file any patent application related to our product candidates or (ii) invent any of the inventions claimed in our patents or patent applications.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The Leahy-Smith Act also includes a number of significant changes that affect the way patent applications will be prosecuted and also may affect patent litigation. These include allowing third-party submission of prior art to the USPTO during patent prosecution and the provision of additional procedures to attack the validity of a patent by USPTO administered post-grant proceedings, including PGR, IPR and derivation proceedings. An adverse determination in any such submission or proceeding could reduce the scope or enforceability of, or invalidate, our patent rights, which could adversely affect our competitive position.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Because of the application of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard applied in United States federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">71</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. Thus, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution and defense of our or our licensors&#x2019; patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects.</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Changes in U.S. patent law or laws in other countries could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involves a high degree of technological and legal complexity. Therefore, obtaining and enforcing biopharmaceutical patents is costly, time-consuming and inherently uncertain. Changes in either the patent laws or in the interpretations of patent laws in the United States and other countries may diminish the value of our intellectual property and may increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. We cannot predict the breadth of claims that may be allowed or enforced in our patents or in third-party patents. In addition, Congress or other foreign legislative bodies may pass patent reform legislation that is unfavorable to us.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">For example, the U.S. Supreme Court has ruled on several patent cases in recent years, sometimes narrowing the scope of patent protection available in certain circumstances, weakening the rights of patent owners in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the U.S. federal courts, the USPTO or similar authorities in foreign jurisdictions, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and the patents we might obtain or license in the future.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Other companies or organizations may challenge our or our licensors&#x2019; patent rights or may assert patent rights that prevent us from developing and commercializing our products.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">CAB therapeutics are a new scientific field. We have obtained grants and issuances of CAB therapeutic patents and the various technologies used in discovering and producing CAB therapeutic proteins. The issued patents and pending patent applications in the United States and in key markets around the world that we own or license claim many different methods, compositions and processes relating to the discovery, development, manufacture and commercialization of antibody and immunoregulatory therapeutics. Specifically, we own a portfolio of patents, patent applications and other intellectual property covering CAB compositions of matter as well as their development and methods of use.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">As the field of antibody and immunoregulatory therapeutics matures, patent applications are being processed by national patent offices around the world. There is uncertainty about which patents will issue, and, if they do, as to when, to whom, and with what claims. In addition, third parties may attempt to invalidate our intellectual property rights. Even if our rights are not directly challenged, disputes could lead to the weakening of our intellectual property rights. Our defense against any attempt by third parties to circumvent or invalidate our intellectual property rights could be costly to us, could require significant time and attention of our management and could have a material and adverse effect on our business, financial condition, results of operations and prospects or our ability to successfully compete.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">There are many issued and pending patents that claim aspects of our product candidates and modifications that we may need to apply to our product candidates. There are also many issued patents that claim antibodies or portions of antibodies that may be relevant for CAB products we wish to develop. Thus, it is possible that one or more organizations will hold patent rights to which we will need a license. If those organizations refuse to grant us a license to such patent rights on reasonable terms, we may not be able to market products or perform research and development or other activities covered by these patents.</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Intellectual property rights of third parties could prevent or delay our drug discovery and development efforts and could adversely affect our ability to commercialize our product candidates, and we might be required to litigate or obtain licenses from third parties in order to discover, develop or market our product candidates. Such litigation or licenses could be costly or not available on commercially reasonable terms.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Our commercial success depends in part on our ability to develop, manufacture, market and sell our product candidates and use our proprietary technologies without infringing or otherwise violating the patents and proprietary rights of third parties. There is a substantial amount of litigation involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interferences, derivation proceedings, post grant reviews,</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;"> inter partes</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> reviews, and reexamination proceedings before the USPTO or oppositions and other comparable proceedings in foreign jurisdictions. Given the vast number of patents in our field of technology, we cannot assure you that marketing of our product candidates or practice of our technologies will not infringe existing patents or patents that may be granted in the future. Because the antibody landscape is still evolving and the CAB antibody landscape is a new field, it is difficult to conclusively assess our freedom to operate without infringing on third-party rights. There are numerous companies that have pending patent applications and issued patents broadly covering many aspects of antibodies generally or covering antibodies directed against the same targets as, or targets similar to, those we are pursuing. Our competitive position may suffer if patents issued to third parties or other third-party intellectual property rights cover our products or product candidates or elements thereof, or our manufacture or uses relevant to our development plans. If any third-party patents were held by a court of competent jurisdiction to cover the manufacturing process of any of our product candidates, any molecules formed during the manufacturing process or any final product or formulation itself, the holders of any such patents may be able to block our ability to commercialize such product candidate. In such cases, we may not be in a position to develop or commercialize products or product candidates unless we successfully pursue litigation to nullify or invalidate the third-party intellectual property right concerned or enter into a license</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">72</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">agreement with the intellectual property right holder, if available on commercially reasonable terms. Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further practice our technologies or develop and commercialize one or more of our product candidates. There may be issued patents of which we are not aware, held by third parties that, if found to be valid and enforceable, could be alleged to be infringed by our CAB technologies. There also may be pending patent applications of which we are not aware that may result in issued patents, which could be alleged to be infringed by our CAB technologies. If such an infringement claim should be brought and be successful, we may be required to pay substantial damages, be forced to abandon our product candidates or seek a license from any patent holders, and would most likely be required to pay license fees or royalties or both, each of which could be substantial. No assurances can be given that a license will be available on commercially reasonable terms, if at all. Even if we were able to obtain a license, the rights we obtain may be nonexclusive, which would provide our competitors access to the same intellectual property rights upon which we are forced to rely. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates or technologies may give rise to claims of infringement of the patent rights of others.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We or our collaboration partner, or any future strategic partners may be subject to third-party claims for infringement or misappropriation of patent or other proprietary rights. If we or our licensors, or any future strategic partners are found to infringe a third-party patent or other intellectual property rights, we could be required to pay damages, potentially including treble damages, if we are found to have willfully infringed. In addition, we or our licensors, or any future strategic partners may choose to seek, or be required to seek, a license from a third party, which may not be available on acceptable terms, if at all. Even if a license can be obtained on acceptable terms, the rights may be non-exclusive, which could give our competitors access to the same technology or intellectual property rights licensed to us. If we fail to obtain a required license, we or our existing or future collaborators may be unable to effectively market product candidates based on our technology, which could limit our ability to generate revenue or achieve profitability and possibly prevent us from generating revenue sufficient to sustain our operations. In addition, we may find it necessary to pursue claims or initiate lawsuits to protect or enforce our patent or other intellectual property rights. The cost to us in defending or initiating any litigation or other proceeding relating to patent or other proprietary rights, even if resolved in our favor, could be substantial, and litigation would divert our management&#x2019;s attention. Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could delay our research and development efforts and limit our ability to continue our operations.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent which might adversely affect our ability to develop and market our products.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We cannot guarantee that any of our patent searches or analyses, including the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third-party patent and pending application in the United States and abroad that is relevant to or necessary for the commercialization of our product candidates in any jurisdiction. For example, U.S. applications filed before November 29, 2000, and certain U.S. applications filed after that date that will not be filed outside the United States, remain confidential until patents issue. Patent applications in the United States and elsewhere are published approximately 18 months after the earliest filing for which priority is claimed, with such earliest filing date being commonly referred to as the priority date. Therefore, patent applications covering our product candidates or technologies could have been filed by others without our knowledge. Additionally, pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover our platform technologies, our products or the use of our products. Third-party intellectual property right holders may also actively bring infringement claims against us, even if we have received patent protection for our technologies and product candidates. The scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent&#x2019;s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect, which may negatively impact our ability to market our products. We may incorrectly determine that our products are not covered by a third-party patent or may incorrectly predict whether a third party&#x2019;s pending application will issue with claims of relevant scope. Our determination of the expiration date of any patent in the United States or abroad that we consider relevant may be incorrect, which may negatively impact our ability to develop and market our product candidates.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">If we fail to identify and correctly interpret relevant patents, we may be subject to infringement claims. We cannot guarantee that we will be able to successfully settle or otherwise resolve such infringement claims. If we are unable to successfully settle future claims on terms acceptable to us, we may be required to engage in or continue costly, unpredictable and time-consuming litigation and may be prevented from or experience substantial delays in marketing our products. If we fail in any such dispute, in addition to being forced to pay damages, we may be temporarily or permanently prohibited from commercializing any of our product candidates that are held to be infringing. We might, if possible, also be forced to redesign product candidates or our technologies so that we no longer infringe the third-party intellectual property rights. Any of these events, even if we were ultimately to prevail, could require us to divert substantial financial and management resources that we would otherwise be able to devote to our business.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We may also be subject to claims that former employees, collaborators or other third parties have an ownership interest in our patents or other intellectual property. We may have ownership disputes in the future arising, for example, from conflicting obligations of consultants or others who are involved in developing our product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">73</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time-consuming and unsuccessful, and issued patents covering our product candidates could be found invalid or unenforceable if challenged in court in the United States or abroad.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Competitors may infringe our patents or the patents of our licensors. If we were to initiate legal proceedings against a third party to enforce a patent covering one of our products or our technology, the defendant could counterclaim that our patent is invalid or unenforceable, or the court may refuse to stop the defendant in such infringement proceeding from using the technology at issue on the grounds that our patents do not cover the technology in question. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, for example, lack of novelty, obviousness or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. The outcome following legal assertions of invalidity and unenforceability during patent litigation is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on one or more of our products or certain aspects of our platform technology. Such a loss of patent protection could have a material and adverse effect on our business, financial condition, results of operations and prospects. Patents and other intellectual property rights also will not protect our technology if competitors design around our protected technology without legally infringing our patents or other intellectual property rights.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Interference or derivation proceedings provoked by third parties or brought by us, the USPTO or any foreign patent authority may be necessary to determine the priority and/or ownership of inventions with respect to our patents or patent applications or those of our licensors. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms, if any license is offered at all. Our defense of litigation or interference proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We may not be able to prevent, alone or with our licensors, misappropriation of our intellectual property, trade secrets or confidential information, particularly in countries where the laws may not protect those rights as fully as in the United States. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">We may not be able to protect our intellectual property rights throughout the world.</font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Obtaining a valid and enforceable issued or granted patent covering our technology in the United States and worldwide can be extremely costly. In jurisdictions where we have not obtained patent protection, competitors may use our technology to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but where it is more difficult to enforce a patent as compared to the United States. Competitor products may compete with our future products in jurisdictions where we do not have issued or granted patents or where our issued or granted patent claims or other intellectual property rights are not sufficient to prevent competitor activities in these jurisdictions. The legal systems of certain countries, particularly certain developing countries, make it difficult to enforce patents and such countries may not recognize other types of intellectual property protection, particularly that relating to biopharmaceuticals. This could make it difficult for us to prevent the infringement of our patents or marketing of competing products in violation of our proprietary rights in certain jurisdictions. Proceedings to enforce our patent rights in foreign jurisdictions, regardless of whether they are successful, could result in substantial cost and divert our efforts and attention from other aspects of our business. Similarly, if our trade secrets are disclosed in a foreign jurisdiction, competitors worldwide could have access to our proprietary information and we may be without satisfactory recourse. Such disclosure could have a material adverse effect on our business. Moreover, our ability to protect and enforce our intellectual property rights may be adversely affected by unforeseen changes in foreign intellectual property laws.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We generally file a provisional patent application first (a priority filing) at the USPTO. An international application under the Patent Cooperation Treaty, or PCT, is usually filed within 12 months after the priority filing. Based on the PCT filing, national and regional patent applications may be filed in the United States, Europe, Japan, Australia and Canada and, depending on the individual case, also in any or all of,</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;"> inter alia</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">, Brazil, China, Hong Kong, India, Israel, Mexico, New Zealand, Russia, South Africa, South Korea and other jurisdictions. We have so far not filed for patent protection in all national and regional jurisdictions where such protection may be available. In addition, we may decide to abandon national and regional patent applications before grant. Finally, the grant proceeding of each national or regional patent is an independent proceeding which may lead to situations in which applications might in some jurisdictions be refused by the relevant registration authorities, while granted in other jurisdictions. It is also quite common that depending on the country, various scopes of patent protection may be granted on the same product candidate or technology. Furthermore, while we intend to protect our intellectual property rights in our expected significant markets, we cannot ensure that we will be able to initiate or maintain similar efforts in all jurisdictions in which we may wish to market our product candidates. Accordingly, our efforts to protect our intellectual property rights in such countries may be inadequate, which may have an adverse effect on our ability to successfully commercialize our product candidates in all of our expected significant foreign markets.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The laws of some jurisdictions do not protect intellectual property rights to the same extent as the laws in the United States, and many companies have encountered significant difficulties in protecting and defending such rights in such jurisdictions. The requirements for patentability differ, in varying degrees, from country to country, and the laws of some foreign countries do not protect intellectual property rights, including trade secrets, to the same extent as federal and state laws of the United States. If we or our licensors encounter difficulties in protecting,</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">74</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">or are otherwise precluded from effectively protecting, the intellectual property rights important for our business in such jurisdictions, the value of these rights may be diminished and we may face additional competition from others in those jurisdictions. Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our licensors are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position in the relevant jurisdiction may be impaired and our business and results of operations may be adversely affected.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Litigation or other legal proceedings relating to intellectual property claims, with or without merit, is unpredictable and generally expensive and time-consuming and is likely to divert significant resources from our core business, including distracting our technical and management personnel from their normal responsibilities. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Accordingly, despite our efforts, we may not be able to prevent third parties from infringing upon or misappropriating or from successfully challenging our intellectual property rights. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">If we fail to comply with our obligations under any license, collaboration or other agreements, we may be required to pay damages and could lose intellectual property rights that are necessary for developing and protecting our product candidates or we could lose certain rights to grant sublicenses.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Our current and any future collaboration agreements or license agreements we enter into are likely to impose various development, commercialization, funding, milestone, royalty, diligence, sublicensing, insurance, patent prosecution and enforcement and/or other obligations on us. If we breach any of these obligations, or use the intellectual property licensed to us in an unauthorized manner, we may be required to pay damages and the licensor may have the right to terminate the license, which could result in us being unable to develop, manufacture and sell products that are covered by the licensed technology or enable a competitor to gain access to the licensed technology. Moreover, our licensors may own or control intellectual property that has not been licensed to us and, as a result, we may be subject to claims, regardless of their merit, that we are infringing or otherwise violating the licensor&#x2019;s rights. In addition, while we cannot currently determine the amount of the royalty obligations we would be required to pay on sales of future products, if any, the amounts may be significant. The amount of our future royalty obligations will depend on the technology and intellectual property we use in products that we successfully develop and commercialize, if any. Therefore, even if we successfully develop and commercialize products, we may be unable to achieve or maintain profitability.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">We may not be successful in obtaining or maintaining necessary rights to our product candidates through acquisitions and in-licenses.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We may find that our programs require the use of proprietary rights held by third parties, and the growth of our business may depend in part on our ability to acquire, in-license or use these proprietary rights. We may be unable to acquire or in-license compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify as necessary for our product candidates. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies are also pursuing strategies to license or acquire third-party intellectual property rights that we may consider attractive. These established companies may have a competitive advantage over us due to their size, financial resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. Moreover, collaboration arrangements are complex and time-consuming to negotiate, document, implement and maintain. We may not be successful in our efforts to establish and implement collaborations or other alternative arrangements should we choose to enter into such arrangements. We also may be unable to license or acquire third-party intellectual property rights on terms that that would be favorable to us or would allow us to make an appropriate return on our investment. Even if we are able to obtain a license to intellectual property of interest, we may not be able to secure exclusive rights, in which case others could use the same rights and compete with us.</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent process. Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to be paid to the USPTO and various governmental patent agencies outside of the United States in several stages over the lifetime of the patents and/or applications. We employ reputable law firms and other professionals and rely on such third parties to help us comply with these requirements and effect payment of these fees with respect to the patents and patent applications that we own, and if we in-license intellectual property we may have to rely upon our licensors to comply with these requirements and effect payment of these fees with</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">75</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">respect to any patents and patent applications that we license. In many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. However, there are situations in which noncompliance can result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, competitors might be able to enter the market earlier than would otherwise have been the case. The standards applied by the USPTO and foreign patent offices in granting patents are not always applied uniformly or predictably. For example, there is no uniform worldwide policy regarding patentable subject matter or the scope of claims allowable in biotechnology and biopharmaceutical patents. As such, we do not know the degree of future protection that we will have on our technologies and product candidates. While we will endeavor to try to protect our technologies and product candidates with intellectual property rights such as patents, as appropriate, the process of obtaining patents is time-consuming, expensive and sometimes unpredictable.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">We may be subject to claims that we or our employees or consultants have wrongfully used or disclosed alleged trade secrets of our employees&#x2019; or consultants&#x2019; former employers or their clients. These claims may be costly to defend and if we do not successfully do so, we may be required to pay monetary damages and may lose valuable intellectual property rights or personnel.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Many of our employees were previously employed at universities or biotechnology or biopharmaceutical companies, including our competitors or potential competitors. Although no claims against us are currently pending, we may be subject to claims that these employees or we have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers. Litigation may be necessary to defend against these claims. If we fail in defending such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. A loss of key research personnel or their work product could hamper our ability to commercialize, or prevent us from commercializing, our product candidates, which could severely harm our business. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Our trademarks or trade names may be challenged, infringed, circumvented, declared generic or determined to be infringing on other marks. We only have one currently registered trademark and rely on common law protection for the rest of our trademarks. We may not be able to protect our rights to these trademarks and trade names or may be forced to stop using these names, which we need for name recognition by potential partners or customers in our markets of interest. During trademark registration proceedings, we may receive rejections. Although we would be given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings. If we are unable to establish name recognition based on our trademarks and trade names, we may not be able to compete effectively and our business may be adversely affected.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:10.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Risks related to our common stock</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Our operating results may fluctuate significantly or may fall below the expectations of investors or securities analysts, each of which may cause our stock price to fluctuate or decline.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We expect our operating results to be subject to annual and quarterly fluctuations. Our net loss and other operating results will be affected by numerous factors, including:</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <div style="margin-left:6.796%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">variations in the level of expense related to the ongoing development of our product candidates or future development programs;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">results of preclinical studies and clinical trials, or the addition or termination of clinical trials;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">the success of our existing collaborations and any potential additional collaborations, licensing or similar arrangements;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">any intellectual property infringement lawsuit or opposition, interference or cancellation proceeding in which we may become involved;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">additions and departures of key personnel;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">strategic decisions by us or our competitors, such as acquisitions, divestitures, spin-offs, joint ventures, strategic investments or changes in business strategy;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">if any of our product candidates receives regulatory approval, the terms of such approval and market acceptance and demand for such product candidates;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">regulatory developments affecting our product candidates or those of our competitors; and</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">changes in general market and economic conditions.</font></div></div>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:10.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">If our operating results fall below the expectations of investors or securities analysts, the price of our common stock could decline substantially. Furthermore, any fluctuations in our operating results may, in turn, cause the price of our stock to fluctuate substantially.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">76</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Our stock price may be volatile, and you could lose all or part of your investment.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The trading price of our common stock has been and is likely to continue to be highly volatile. The market price for our common stock may be influenced by many factors, including the other risks described in this section and the following:</font></p>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">the timing and results of our clinical trials or those of our competitors;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">regulatory or legal developments in the United States and other countries, especially changes in laws or regulations applicable to our products;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">the success of competitive products or technologies;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">introductions and announcements of new products by us, our current or future collaborators or our competitors, and the timing of these introductions or announcements;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">announcements of new collaboration agreements, or the restructuring or termination of current collaboration agreements;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">actions taken by regulatory agencies with respect to our products, preclinical studies, clinical trials, manufacturing process or sales and marketing terms;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">actual or anticipated variations in our financial results or those of companies that are perceived to be similar to us;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">the success of our efforts to acquire or in-license additional technologies, products or product candidates;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">developments concerning any future collaborations, including those regarding manufacturing, supply and commercialization of our products;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">market conditions in the pharmaceutical and biotechnology sectors;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">announcements by us or our competitors of significant acquisitions, strategic collaborations, joint ventures or capital commitments;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">developments or disputes concerning patents or other proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our products;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">our ability or inability to raise additional capital and the terms on which we raise it;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">the recruitment or departure of key personnel;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">changes in the structure of healthcare payment systems;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">actual or anticipated changes in earnings estimates or changes in stock market analyst recommendations regarding our common stock, other comparable companies or our industry generally;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">our failure or the failure of our competitors to meet analysts&#x2019; projections or guidance that we or our competitors may give to the market;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">fluctuations in the valuation of companies perceived by investors to be comparable to us;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">announcement and expectation of additional financing efforts;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">speculation in the press or investment community;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">trading volume of our common stock;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> sales of our common stock by us, our insiders or our other stockholders;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> expiration of market stand-off or lock-up agreements;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> the concentrated ownership of our common stock;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">changes in accounting principles; </font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">terrorist acts, acts of war or periods of widespread civil unrest; </font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">the impact of any natural disasters or public health emergencies, such as the COVID-19 pandemic; and </font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">general economic, industry and market conditions. </font></div></div>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">In addition, the stock markets in general, and the markets for pharmaceutical, biopharmaceutical and biotechnology stocks in particular, have experienced extreme volatility that has been often unrelated to the operating performance of the issuer. These broad market and industry factors may seriously harm the market price of our common stock, regardless of our operating performance.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">The future issuance of equity or of debt securities that are convertible into equity will dilute our share capital.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We will need to raise additional capital in the future. To the extent we raise additional capital through the issuance of equity or convertible debt securities in the future, there will be further dilution to investors and the terms of these securities may include liquidation or other</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">77</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">preferences that adversely affect our stockholders&#x2019; rights. Future issuances of our common stock or other equity securities, or the perception that such sales may occur, could adversely affect the trading price of our common stock and impair our ability to raise capital through future offerings of shares or equity securities. We may choose to raise additional capital through the issuance of equity or convertible debt securities due to market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. No prediction can be made as to the effect, if any, that future sales of common stock or the availability of common stock for future sales will have on the trading price of our common stock.</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">The dual class structure of our common stock and the option of the holder of shares of our Class B common stock to convert into shares of our common stock may limit your ability to influence corporate matters.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Our common stock has one vote per share, while our Class B common stock is non-voting. Nonetheless, each share of our Class B common stock may be converted at any time into one share of common stock at the option of its holder, subject to the limitations provided for in our amended and restated certificate of incorporation. Consequently, if holders of Class B common stock exercise their option to make this conversion, this will have the effect of increasing the relative voting power of those prior holders of our Class B common stock, and correspondingly decrease the voting power of the current holders of our common stock, which may limit your ability to influence corporate matters. Because our Class B common stock is generally non-voting, stockholders who own more than 10% of our Class B common stock and common stock overall but 10% or less of our common stock will not be required to report changes in their ownership from transactions in our Class B common stock pursuant to Section 16(a) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and would not be subject to the short-swing profit provisions of Section 16(b) of the Exchange Act. In addition, acquisitions of Class B common stock would not be subject to notification pursuant to the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">If securities or industry analysts do not publish research or reports about our business, or if they issue adverse or misleading research or reports regarding us, our business or our market, our stock price and trading volume could decline.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The trading market for our common stock is influenced by the research and reports that industry or securities analysts publish about us, our business or our market. If no or few securities or industry analysts commence or maintain coverage of us, the trading price for our stock would be negatively impacted. If any of the analysts who cover us issue adverse or misleading research or reports regarding us, our business model, our intellectual property, our stock performance or our market, or if our operating results fail to meet the expectations of analysts, our stock price would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval and their interests may conflict with your interests as an owner of our common stock.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">As of December 31, 2021, executive officers and directors, together with holders of 5% or more of our outstanding common stock  and their respective affiliates, beneficially own approximately 29.4% of our outstanding common stock. More specifically, Jay M. Short, Ph.D, our Chairman and Chief Executive Officer, together with his spouse, Carolyn Anderson Short, our former Chief of Intellectual Property and Strategy and Assistant Secretary, owned 6.9%, of our outstanding common stock, as of December 31, 2021.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">As a result, Dr. Short and our other principal stockholders will continue to have significant influence over the outcome of corporate actions requiring stockholder approval, including the election of directors, any merger, consolidation or sale of all or substantially all of our assets and any other significant corporate transaction. The interests of these stockholders may not be the same as or may even conflict with your interests. For example, these stockholders could delay or prevent a change of control of our company, even if such a change of control would benefit our other stockholders, which could deprive our stockholders of an opportunity to receive a premium for their common stock as part of a sale of our company or our assets and might affect the prevailing market price of our common stock. The significant concentration of stock ownership may adversely affect the trading price of our common stock due to investors&#x2019; perception that conflicts of interest may exist or arise.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><br>In addition, we have entered into certain related party transactions with Himalaya Therapeutics SEZC, Inversagen, LLC and BioAtla Holdings, LLC, including various licensing arrangements with respect to certain CAB antibodies. Dr. Short and his wife, Carolyn Anderson Short, are each a manager of Inversagen, LLC and BioAtla Holdings, LLC and a director of Himalaya Therapeutics SEZC. In addition, Ms. Anderson Short is also an officer of Himalaya Therapeutics SEZC. These related party transactions, and any future related party transactions, create the possibility of actual conflicts of interest with regard to Dr. Short.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Sales of a substantial number of shares of our common stock in the public market could cause our stock price to fall.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Our common stock price could decline as a result of sales of a large number of shares of common stock or the perception that these sales could occur. These sales, or the possibility that these sales may occur, might also make it more difficult for us to sell equity securities in the future at a time and price that we deem appropriate.<br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">All of our outstanding shares of common stock are freely tradable without restriction or further registration under the Securities Act unless held by our &#x201c;affiliates&#x201d; as defined in Rule 144 under the Securities Act, or Rule 144. Shares issued upon the exercise of stock options and warrants outstanding under our equity incentive plans or pursuant to future awards granted under those plans will become available for sale in the public market to the extent permitted by Rules 144 and 701 under the Securities Act.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">78</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><br>Certain holders of our outstanding shares have rights, subject to certain conditions, to require us to file registration statements covering the sale of their shares or to include their shares in registration statements that we may file for ourselves or our other stockholders. We also registered the offer and sale of all shares of common stock that we may issue under our equity compensation plans, which shares will be able to be sold in the public market upon issuance, subject to applicable securities laws and the lock-up agreements.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Provisions in the amended and restated certificate of incorporation and our amended and restated bylaws may delay or prevent an acquisition of us or a change in our management. In addition, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Because our board of directors is responsible for appointing the members of our management team, these provisions could in turn affect any attempt by our stockholders to replace current members of our management team. These provisions include:</font></p>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">a prohibition on actions by our stockholders by written consent;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">a requirement that special meetings of stockholders be called only by the chairman of our board of directors, our chief executive officer, or our board of directors pursuant to a resolution adopted by a majority of the total number of authorized directors;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">advance notice requirements for election to our board of directors and for proposing matters that can be acted upon at stockholder meetings;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">a requirement that directors may only be removed &#x201c;for cause&#x201d; and only with 66 2/3% voting stock of our stockholders;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">a requirement that only the board of directors may change the number of directors and fill vacancies on the board;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">division of our board of directors into three classes, serving staggered terms of three years each; and</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">the authority of the board of directors to issue preferred stock with such terms as the board of directors may determine.</font></div></div>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, as amended, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner. These provisions would apply even if the proposed merger or acquisition could be considered beneficial by some stockholders.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">The Company&#x2019;s ability to attract and retain qualified members of our board of directors may be impacted due to new state laws, including recently enacted gender quotas.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">In September 2018, California enacted SB 826 requiring public companies headquartered in California to maintain minimum female representation on their boards of directors as follows: by the end of 2019, at least one woman on its board, by the end of 2020, public company boards with five members will be required to have at least two female directors, and public company boards with six or more members will be required to have at least three female directors.<br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">In September 2020, California enacted AB 979, which requires that by the end of 2021 California-headquartered public companies have at least one director on their boards who is from an underrepresented community, defined as &#x201c;an individual who self-identifies as Black, African American, Hispanic, Latino, Asian, Pacific Islander, Native American, Native Hawaiian, or Alaska Native, or who self-identifies as gay, lesbian, bisexual, or transgender.&#x201d;<br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">In addition to that initial 2021 requirement, the law mandates that the number of directors from underrepresented communities be increased by the end of calendar year 2022, depending on the size of the board.<br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">In addition, the SEC recently approved new listing rules from Nasdaq related to board diversity and disclosure, which require all companies listed on Nasdaq's U.S. exchanges to publicly disclose consistent, transparent diversity statistics regarding their board of directors. Additionally, the rules would require most Nasdaq-listed companies to have, or explain why they do not have, at least two diverse directors, including one who self-identifies as female and one who self-identifies as either an underrepresented minority or LGBTQ+.<br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Failure to achieve designated minimum gender and diversity levels in a timely manner exposes such companies to financial penalties and reputational harm. While we are currently in compliance with these regulations, we cannot assure that we can recruit, attract and/or retain qualified members of the board and meet gender and diversity quotas as a result of the California laws or Nasdaq rules, which may expose us to</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">79</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">penalties and/or reputational harm.<br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">We will incur increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives and corporate governance practices. Additionally, if we fail to maintain proper and effective internal controls, our ability to produce accurate financial statements on a timely basis could be impaired.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">As a public company, and particularly after we are no longer an emerging growth company or a smaller reporting company, we will incur significant legal, accounting and other expenses that we did not incur as a private company. The Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of The Nasdaq Global Market and other applicable securities rules and regulations impose various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Also, the Exchange Act requires, among other things, that we file annual, quarterly and current reports with respect to our business and operating results. Our management and other personnel will need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations will increase our legal and financial compliance costs and will make some activities more time-consuming and costly. For example, we expect that these rules and regulations may make it more difficult and more expensive for us to obtain director and officer liability insurance, and we may be required to accept reduced policy limits and coverage or to incur substantial costs to maintain the same or similar coverage. These rules and regulations could also make it more difficult for us to attract and retain qualified members of our board of directors or our board committees or as executive officers. However, these rules and regulations are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">In addition, as a public company, we will be required to incur additional costs and obligations in order to comply with SEC rules that implement Section 404 of the Sarbanes-Oxley Act. Under these rules, we are required to make a formal assessment of the effectiveness of our internal control over financial reporting, and we are required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. We engaged outside consultants to assist in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we have, and will need to continue, to dedicate internal resources, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of our internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are designed and operating effectively, and implement a continuous reporting and improvement process for internal control over financial reporting. As a result of the complexity involved in complying with the rules and regulations applicable to public companies, our management&#x2019;s attention may be diverted from other business concerns, which could harm our business, operating results, and financial condition. In the future, we may need to increase the number of employees dedicated to finance and reporting, or engage outside consultants to meet requirements, which will increase our operating expenses.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The rules governing the standards that must be met for management to assess our internal control over financial reporting are complex and require significant documentation, testing and possible remediation to meet the detailed standards under the rules. During the course of its testing, our management may identify material weaknesses or deficiencies which may not be remedied in time to meet the deadline imposed by the Sarbanes-Oxley Act. Our internal control over financial reporting may not prevent or detect all errors and all fraud.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">If we are not able to comply with the requirements of Section 404 of the Sarbanes-Oxley Act in a timely manner, or if we are unable to maintain proper and effective internal controls, we may not be able to produce timely and accurate financial statements. If that were to happen, the market price of our stock could decline and we could be subject to sanctions or investigations by the stock exchange on which our common stock is listed, the SEC or other regulatory authorities. In addition, if we are not able to continue to meet these requirements, we may not be able to remain listed on The Nasdaq Global Market.</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We are subject to the periodic reporting requirements of the Exchange Act. We designed our disclosure controls and procedures to reasonably assure that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">These inherent limitations include the facts that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected.</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, your ability to achieve a return on your investment will depend on appreciation of the value of our common stock.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Any return to stockholders will therefore be limited to any appreciation in the value of our common stock, which is not certain.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">80</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">We may be subject to securities litigation, which is expensive and could divert our management&#x2019;s attention.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">In the past, companies that have experienced volatility in the market price of their securities have been subject to securities class action litigation. We may be the target of this type of litigation in the future. Regardless of the merits or the ultimate results of such litigation, securities litigation brought against us could result in substantial costs and divert our management&#x2019;s attention from other business concerns.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Our certificate of incorporation and bylaws designate the Court of Chancery of the State of Delaware as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders&#x2019; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Our amended and restated certificate of incorporation provides that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if the Court of Chancery of the State of Delaware does not have jurisdiction, the federal district court for the District of Delaware) shall be the sole and exclusive forum for the following types of proceedings: (i) any derivative action or proceeding brought on behalf of our company, (ii) any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers, employees or stockholders to our company or our stockholders, (iii) any action asserting a claim arising pursuant to any provision of the General Corporation Law of the State of Delaware or as to which the General Corporation Law of the State of Delaware confers jurisdiction on the Court of Chancery of the State of Delaware or (iv) any action asserting a claim arising pursuant to any provision of our amended and restated certificate of incorporation or amended and restated bylaws (in each case, as they may be amended from time to time) or governed by the internal affairs doctrine. This provision would not apply to suits brought to enforce a duty or liability created by the Exchange Act or any other claim for which the U.S. federal courts have exclusive jurisdiction. Furthermore, Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims. Our amended and restated bylaws further provide that the federal district courts of the United States of America will be the exclusive forum, to the fullest extent permitted by law, for resolving any complaint asserting a cause of action arising under the Securities Act. This choice of forum provision may limit a stockholder&#x2019;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers and employees. Alternatively, if a court were to find these provisions of our amended and restated certificate of incorporation and amended and restated bylaws inapplicable to, or unenforceable in respect of, one or more of the specified types of actions or proceedings, we may incur additional costs associated with resolving such matters in other jurisdictions, which could adversely affect our business and financial condition. Any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock shall be deemed to have notice of and to have consented to the provisions of our amended and restated certificate of incorporation and amended and restated bylaws described above.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1b_unresolved_staff_comments"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:16.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">ITEM 1B. Unreso</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">lved Staff Comments</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Not applicable.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:16.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_2_properties"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">ITEM </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">2. Properties</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Our headquarters are located at 11085 Torreyana Road, San Diego, California 92121, where we lease approximately 43,377 square feet of office and laboratory space under a lease that terminates on February 28, 2025. We believe that our existing facilities are adequate to meet our current needs, and that suitable additional alternative spaces will be available in the future on commercially reasonable terms.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:16.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_3_legal_proceedings"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">ITEM 3. Leg</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">al Proceedings</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">From time to time, we may be subject to various claims and suits arising in the ordinary course of business. We are not currently a party to any legal proceedings the outcome of which we believe, if determined adversely to us, would individually or in the aggregate have a material adverse effect on our business, operating results or financial condition.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:16.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_4_mine_safety_disclosures"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">ITEM 4. Mine S</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">afety Disclosures</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Not applicable.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">81</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:16.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_ii"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">PAR</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">T II</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_5_market_for_registrant"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">ITEM 5. Market for Registrant&#x2019;s Common Equ</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">ity, Related Stockholder Matters and Issuer Purchases of Equity Securities</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Market Information</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Shares of our common stock began trading on the Nasdaq Global Market on December 16, 2020 under the symbol &#x201c;BCAB.&#x201d; Prior to that time, there was no public market for shares of our common stock.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Holders of Record</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">As of February 25, 2022, there were 16 stockholders of record of our common stock and 2 stockholders of record of our Class B common stock. These numbers were derived from our stockholder records and do not include beneficial owners of our common stock whose shares are held in &#x201c;street&#x201d; name with various dealers, clearing agencies, banks, brokers and other fiduciaries.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Dividends</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We have never declared or paid any cash dividends on our capital stock. We currently intend to retain all available funds and any future earnings to support our operations and finance the growth and development of our business. We do not intend to pay cash dividends on our common stock for the foreseeable future. Any future determination related to our dividend policy will be made at the discretion of our board of directors and will depend upon, among other factors, our results of operations, financial condition, capital requirements, contractual restrictions, business prospects and other factors our board of directors may deem relevant.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Securities Authorized for Issuance Under Equity Compensation Plans</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Information about securities authorized for issuance under our equity compensation plans is incorporated herein by reference to Item 12 of Part III of this Annual Report on Form 10-K.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Stock Performance Graph</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The graph set forth below compares the cumulative total stockholder return on our common stock for the period commencing on December 16, 2020, the date our common stock began trading on the Nasdaq, and ending on December 31, 2021, with the cumulative total return of the Nasdaq Composite Index and the Nasdaq Biotechnology Index over the same period. This graph assumes the investment of $100.00 on December 16, 2020 in each share of our common stock at the initial public offering price of $18.00, the Nasdaq Composite Index, and the Nasdaq Biotechnology Index, and assumes the reinvestment of dividends.</font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The comparisons shown in the graph below are based upon historical data. We caution that the stock price performance shown in the graph below is not necessarily indicative of, nor is it intended to forecast, the potential future performance of our common stock. Information used in the graph was obtained from sources believed to be reliable including Nasdaq, Bloomberg and Reuters, but we are not responsible for any errors or omissions in such information.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">82</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Notwithstanding anything to the contrary set forth in any of our previous or future filings under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, that might incorporate this Annual Report on Form 10&#x2011;K or future filings made by us under those statutes, this Stock Performance Graph section is not &#x201c;soliciting material,&#x201d; shall not be deemed filed with the U.S. Securities and Exchange Commission and shall not be deemed incorporated by reference into any of those prior filings or into any future filings made by us under those statutes.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img129881027_20.jpg" alt="img129881027_20.jpg" style="width:496px;height:412px;">&#160;</p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Recent Sales of Unregistered Securities</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">None.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Use of Proceeds from Registered Securities</font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">On December 15, 2020, the SEC declared effective our registration statement on Form S-1 (File No. 333-250093), as amended, filed in connection with our Initial Public Offering (or &#34;IPO&#34;). At the closing of the offering on December 18, 2020, we issued and sold 12,075,000 shares of our common stock at the initial public offering price to the public of $18.00 per share, which included the exercise in full of the underwriters&#x2019; option to purchase additional shares. We received gross proceeds from the IPO of $217.4 million, before deducting underwriting discounts and commissions of approximately $15.2 million and estimated offering costs of approximately $3.8 million. J.P. Morgan, Jefferies and Credit Suisse acted as joint book-running managers for the offering. BTIG acted as co-manager for the offering. No offering expenses were paid or are payable, directly or indirectly, to our directors or officers, to persons owning 10% or more of any class of our equity securities or to any of our affiliates.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">As of December 31, 2021, we have used approximately $24.3 million of the proceeds from our IPO. There has been no material change in the planned use of such proceeds from that described in the final prospectus filed by us with the SEC on December 17, 2020.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:16.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_6_selected_financial_data"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">ITEM 6. Selected</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;"> Financial Data</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Not applicable.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">83</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_7_management_discussion"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">ITEM 7. Managemen</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">t&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">You should read the following discussion and analysis together with our consolidated financial statements and related notes included in &#x201c;Item 8. Financial Statements and Supplementary Data&#x201d; in this Annual Report on Form 10-K. The following discussion contains forward-looking statements that involve risks and uncertainties. For a complete discussion of forward-looking statements, see the section above entitled &#x201c;Forward Looking Statements.&#x201d; Our actual results could differ materially from those expressed or implied in any forward-looking statements as a result of various factors, including those set forth under the caption &#x201c;Item 1A. Risk Factors.&#x201d; The discussion of our financial condition and results of operations for the year ended December 31, 2019, included in Item 7. Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations (&#x201c;MD&amp;A&#x201d;) can be found in our Annual Report on Form 10-K for the year ended December 31, 2020 filed with the SEC on March 24, 2021.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Overview</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We are a clinical-stage biopharmaceutical company developing our novel class of highly specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Our CABs capitalize on our proprietary discoveries with respect to tumor biology, enabling us to target known and widely validated tumor antigens that have previously been difficult or impossible to target. Our novel CAB therapeutic candidates exploit characteristic pH differences between the tumor microenvironment and healthy tissue. Unlike healthy tissue, the tumor microenvironment is acidic, and we have designed our antibodies to selectively bind to their targets on tumor cells under acidic pH conditions but not on targets in normal tissues. Our approach is to identify the necessary targeting and potency required for cancer cell destruction, while aiming to eliminate or greatly reduce on-target, off-tumor toxicity&#x2014;one of the fundamental challenges of existing cancer therapies.<br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We are a United States-based company with research facilities in San Diego, California and, through our contractual relationship with BioDuro-Sundia, a provider of preclinical development services, in Beijing, China. Since the commencement of our operations, we have focused substantially all of our resources on conducting research and development activities, including drug discovery, preclinical studies and clinical trials of our product candidates, including the ongoing Phase 2 clinical trials of mecbotamab vedotin and ozuriftamab vedotin, establishing and maintaining our intellectual property portfolio, manufacturing clinical and research material through third parties, hiring personnel, establishing product development and commercialization collaborations with third parties, raising capital and providing general and administrative support for these operations. Since 2014, such research and development activities have exclusively related to the research, development, manufacture and Phase 1 and Phase 2 clinical testing of our CAB antibody-based product candidates and the strengthening of our proprietary CAB technology platform and pipeline. We do not have any products approved for sale, and we have not generated any revenue from product sales.<br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We have incurred significant losses to date. Our ability to generate product revenue sufficient to achieve profitability will depend on the successful development and eventual commercialization of one or more of our current and future product candidates. Our net losses were $95.4 million, $35.9 million, and $29.8 million for the years ended December 31, 2021, 2020, and 2019, respectively. As of December 31, 2021, we had an accumulated deficit of $186.3 million. These losses have resulted primarily from costs incurred in connection with research and development activities and general and administrative costs associated with our operations. We do not expect to generate meaningful revenue from product sales for the foreseeable future, and we expect to continue to incur significant operating expenses for the foreseeable future due to the cost of research and development, including identifying and designing product candidates and conducting preclinical studies and clinical trials, and the regulatory approval process for our product candidates. We expect our expenses, and the potential for losses, to increase substantially as we conduct clinical trials of our lead product candidates and seek to expand our pipeline.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We expect our expenses and capital requirements will increase substantially in connection with our ongoing activities as we:</font></p>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">advance the clinical development of mecbotamab vedotin;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">advance the clinical development of ozuriftamab vedotin;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">advance the clinical development of BA3071;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">expand our pipeline of bispecific and other CAB antibody-based product candidates;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">continue to invest in our CAB technology platform;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">maintain, protect and expand our intellectual property portfolio, including patents, trade secrets and know-how;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">seek marketing approvals for any product candidates that successfully complete clinical trials;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">establish additional product collaborations and commercial manufacturing relationships with third parties;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">build sales, marketing and distribution infrastructure and relationships with third parties to commercialize product candidates for which we may obtain marketing approval;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">continue to expand our operational, financial and management information systems; and</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">attract, hire and retain additional clinical, scientific, management, administrative and commercial personnel.</font></div></div>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Furthermore, we expect to continue to incur additional costs associated with operating as a public company.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">84</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">As a result, we will require substantial additional capital to develop our product candidates and fund operations for the foreseeable future. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through a combination of public or private equity offerings, debt financings, collaborations and other similar arrangements. The amount and timing of our future funding requirements will depend on many factors, including the pace and results of our development efforts. We cannot assure you that we will ever be profitable or generate positive cash flow from operating activities.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Because of the numerous risks and uncertainties associated with product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to raise capital, maintain our research and development efforts, expand our business or continue our operations at planned levels, and as a result we may be forced to substantially reduce or terminate our operations.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">As of December 31, 2021, our cash and cash equivalents totaled approximately $245.0 million. Based on our current operating plan, our current cash and cash equivalents are expected to be sufficient to fund our ongoing operations into the first half of 2024. However, we have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">BioAtla was formed in April 2007 as a Delaware limited liability corporation. We initially operated as a service provider and service-related partnered drug developer for primarily human therapeutic proteins and simultaneously refined our proprietary CAB technology platform and related technologies. Since 2013, we transitioned away from our services business to focus on internal development of our own proprietary products.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Impact of COVID-19 on our business</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">On March 11, 2020, the World Health Organization declared the outbreak of COVID-19 caused by a novel strain of coronavirus as a pandemic, which continues to spread throughout the United States and around the world. The worldwide COVID-19 pandemic may affect our ability to complete our current preclinical studies and clinical trials, initiate and complete our planned preclinical studies and clinical trials, disrupt regulatory activities or have other adverse effects on our business, results of operations, financial condition and prospects. In addition, the pandemic has caused substantial disruption in the financial markets and may adversely impact economies worldwide, both of which could adversely affect our business, operations and ability to raise funds to support our operations. To date, we have experienced modest business disruptions, including with respect to clinical trials we are conducting, and non-material impairments as a result of the pandemic. Our Phase 2 sarcoma trial remains on schedule and the Phase 2 interim analysis for AXL NSCLC and ROR2 studies have experienced some modest delays in patient initiations due to COVID-19, however, overall timelines for study completion essentially have not changed at this time. We are following, and plan to continue to follow, recommendations from federal, state and local governments regarding workplace policies, practices and procedures. In March 2020, we implemented a remote working policy for many of our employees, began restricting non-essential travel and temporarily reduced salaries of our employees from March 2020 to July 2020. We are complying with all applicable guidelines for our clinical trials, including remote clinical monitoring. In April 2020, we borrowed $0.7 million under the Paycheck Protection Program under the CARES Act and we received full loan forgiveness from the U.S. Small Business Association in July 2021, resulting in the recognition of $0.7 million to other income for the twelve months ended December 31, 2021. The PPP loan is discussed further under &#x201c;&#x2014;Liquidity and capital resources.&#x201d; We are continuing to monitor the potential impact of the pandemic, but we cannot be certain what the overall impact will be on our business, financial condition, results of operations and prospects.</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Recent developments</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">On January 5, 2022, we and Bristol-Myers Squibb Company (&#x201c;BMS&#x201d;) entered into a clinical trial collaboration and supply agreement (the &#x201c;BMS Agreement&#x201d;).  Under the terms of the BMS Agreement, BioAtla and BMS will collaborate on clinical trials of separate combination therapies using two of BioAtla&#x2019;s Conditionally Active Biologic Antibody Drug Conjugates, mecbotamab vedotin and ozuriftamab vedotin, each in combination with Opdivo&#174; (nivolumab), BMS&#x2019; proprietary anti-PD-1 monoclonal antibody product.  We will serve as the study sponsor of the scheduled studies and will be responsible for costs associated with the trial execution. BMS will provide Opdivo&#174; clinical drug supply at no cost for the combination study trials.  After the completion of the combination therapy trials, we are obligated to provide BMS with a final report of the data resulting from the trial.</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Financial operations overview</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Revenue</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">To date, we have not generated any revenue from the sale of products and do not expect to generate meaningful revenue in the near future. In addition to the collaboration agreements discussed below, we may in the future seek third-party collaborators or joint venture partners for development and commercialization of additional CAB product candidates.</font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">In April 2019, we entered into a Global Co-Development and Collaboration Agreement with BeiGene, Ltd. which was amended in December 2019, October 2020, and was terminated in November 2021.  The original agreement provided for the development, manufacturing and commercialization of BA3071 in collaboration with BeiGene. After the November 2021 amendment, we are responsible for developing BA3071, including global regulatory filings and commercialization, and are responsible for all costs of development, manufacturing and commercialization globally. At the time of execution of the BeiGene collaboration, we received a $20.0 million upfront payment and in December 2019, we received an additional $5.0 million for the reimbursement of manufacturing costs. Pursuant to the terms of the November 2021 amendment, we agreed to</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">85</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">pay single digit royalties to BeiGene and agreed to share on a limited basis in any upfront and milestone payments received through a sublicense of BA3071.</font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">During 2020, we recognized revenue primarily from our collaboration with BeiGene. During 2019, we recognized revenue from our collaboration with BeiGene and, to a much lesser degree, from our collaboration with Pfizer.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Prior to developing our own programs, the Company received revenue from services performed under fixed price service contracts that, in some cases, provided for potential milestone and royalty payments to us. During 2021, we recognized $0.3 million in revenues from our legacy service contracts.<br><br><br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Operating expenses</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Research and development</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Research and development expenses consist primarily of costs incurred in the discovery and development of our product candidates.</font></p>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">External expenses consist of:</font></div></div>
  <div style="margin-left:11.333%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.116898056774223%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Fees paid to third parties such as contractors, clinical research organizations (CROs) and consultants, including through our relationship with BioDuro-Sundia, and other costs related to preclinical and clinical trials;</font></div></div>
  <div style="margin-left:11.333%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.116898056774223%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Fees paid to third parties such as contract manufacturing organizations (CMOs) and other vendors for manufacturing research and clinical trial materials; and</font></div></div>
  <div style="margin-left:11.333%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.116898056774223%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Expenses related to laboratory supplies and services.</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Unallocated expenses consist of:</font></div></div>
  <div style="margin-left:11.333%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.116898056774223%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Personnel-related expenses, including salaries, benefits and equity-based compensation expenses, for personnel in our research and development functions; and</font></div></div>
  <div style="margin-left:11.333%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.116898056774223%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Related equipment, cost of facilities and depreciation expenses.</font></div></div>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We expense research and development costs in the periods in which they are incurred. Nonrefundable advance payments for goods or services to be received in future periods for use in research and development activities are deferred and capitalized. The capitalized amounts are then expensed as the related goods are delivered and services are performed.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We expect our research and development expenses to increase substantially for the foreseeable future as we continue to invest in research and development activities to advance our product candidates and our clinical programs and expand our product candidate pipeline. The process of conducting the necessary preclinical and clinical research to obtain regulatory approval is costly and time-consuming. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. Accordingly, to the extent that our product candidates continue to advance into clinical trials, including larger and later-stage clinical trials, our expenses will increase substantially and may become more variable. The actual probability of success for our product candidates may be affected by a variety of factors, including the safety and efficacy of our product candidates, the quality and consistency in their manufacture, investment in our clinical programs and competition with other products. As a result of these variables, we are unable to determine the duration and completion costs of our research and development projects and programs or when and to what extent we will generate revenue from the commercialization and sale of our product candidates. We may never succeed in achieving regulatory approval for any of our product candidates.</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">General and administrative</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Our general and administrative expenses consist primarily of personnel-related expenses for personnel in our executive, finance, corporate and other administrative functions, intellectual property and patent costs, facilities and other allocated expenses, other expenses for outside professional services, including legal, human resources, audit and accounting services and insurance costs. Personnel-related expenses consist of salaries, benefits and equity-based compensation. We expect our general and administrative expenses to increase as a result of operating as a public company, including additional costs (i) to comply with the rules and regulations of the SEC and those of The Nasdaq Global Market, (ii) for legal and auditing services, (iii) for additional insurance, (iv) for investor relations activities and (v) for other administrative and professional services. We also expect our intellectual property expenses to increase as we expand our intellectual property portfolio.</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Interest income</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Interest income consists primarily of interest earned on our cash and cash equivalent balances. Our interest income has not been significant to date and we do not expect any material changes.</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Interest expense</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Interest expense consists primarily of interest incurred on our outstanding convertible debt, including coupon interest and the amortization of debt discounts, including those related to beneficial conversion features and embedded derivatives. Our interest expense declined subsequent to the settlement of our outstanding convertible debt in July 2020 and the forgiveness of our PPP loan in July 2021.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">86</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Change in fair value of derivative liability</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The convertible promissory notes we issued during 2019 and 2020 contained redemption features which we determined were embedded derivatives to be recognized as liabilities and measured at fair value. At the end of each reporting period, changes in the estimated fair value during the period were recorded as a change in the fair value of derivative liability. The embedded derivative liability was recorded at fair value utilizing an income approach that identified the cash flows using a &#x201c;with-and-without&#x201d; valuation methodology. The inputs used to determine the estimated fair value of the derivative instrument were based primarily on the probability of an underlying event triggering the embedded derivative occurring and the timing of such event. We will no longer record changes in the fair value of the derivative liability subsequent to the settlement of the derivative liability in connection with the conversion of our outstanding convertible debt in July 2020.</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Extinguishment of debt</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">In April 2020, we amended the terms of certain outstanding convertible promissory notes that we concluded were extinguishments. In July 2020, in connection with our Corporate Reorganization, we settled all of our outstanding convertible promissory notes and recognized extinguishment losses for the difference between the fair value of the consideration given to the noteholders and the carrying value of the related convertible promissory notes. In July 2021, our PPP loan was fully forgiven and we recorded a gain on extinguishment equal to the principal and interest outstanding at the time of forgiveness.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">  </font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Other income (expense)</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Other income (expense) primarily includes miscellaneous items of income and expense that were not significant for the periods presented.</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:10.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Results of operations</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Comparison of the years ended December 31, 2021 and 2020</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:53.991%;"></td>
    <td style="width:1.253%;"></td>
    <td style="width:1.497%;"></td>
    <td style="width:11.601%;"></td>
    <td style="width:0.986%;"></td>
    <td style="width:1.253%;"></td>
    <td style="width:1.497%;"></td>
    <td style="width:11.601%;"></td>
    <td style="width:0.986%;"></td>
    <td style="width:1.253%;"></td>
    <td style="width:1.497%;"></td>
    <td style="width:11.601%;"></td>
    <td style="width:0.986%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Years Ended December 31,</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">2021</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">2020</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Change</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">(in thousands)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Collaboration and other revenue</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">250</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">429</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(179</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Operating expenses:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Research and development</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">58,274</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">19,933</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">38,341</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">General and administrative</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">38,416</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10,595</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">27,821</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Total operating expenses</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">96,690</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">30,528</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">66,162</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Loss from operations</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(96,440</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(30,099</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(66,341</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Other income (expense):</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Interest income</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">350</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">100</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">250</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Interest expense</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(3</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(1,389</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1,386</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Change in fair value of derivative liability</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(1,581</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1,581</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Gain (loss) on extinguishment of long-term debt</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">690</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(2,883</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">3,573</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Other income (expense)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(1</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">2</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Total other income (expense)</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1,038</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(5,754</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">6,792</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Consolidated net loss and comprehensive loss</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(95,402</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(35,853</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(59,549</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
   </tr>
  </table>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Collaboration and other revenue</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Collaboration and other revenue for the years ended December 31, 2021 and 2020 consisted of $0.3 million recognized under our legacy service contracts, and $0.4 million of revenue recognized under our collaboration with BeiGene, respectively. As part of the November 2021 amendment to the agreement with BeiGene, we reclassified the remaining $19.8 million of deferred revenue as a long-term liability which we expect to settle as licensing payments are made to BeiGene in accordance with the resulting amendment. In the event the license is terminated, the liability will be extinguished with no further payment to BeiGene.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">87</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Research and development expense</font></p>
  <p style="margin-left:2.267%;text-indent:4.175%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The following table summarizes our research and development expenses allocated by CAB program for the periods indicated:</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:55.523%;"></td>
    <td style="width:1.3%;"></td>
    <td style="width:1.52%;"></td>
    <td style="width:11.139%;"></td>
    <td style="width:0.789%;"></td>
    <td style="width:1.3%;"></td>
    <td style="width:1.52%;"></td>
    <td style="width:11.139%;"></td>
    <td style="width:0.998%;"></td>
    <td style="width:1.3%;"></td>
    <td style="width:1.52%;"></td>
    <td style="width:11.163%;"></td>
    <td style="width:0.789%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Years Ended December 31,</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">2021</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">2020</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Change</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">(in thousands)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">External expenses:</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">BA3011 (AXL-ADC)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">17,883</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">7,845</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10,038</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">BA3021 (ROR2-ADC)</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10,921</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">3,190</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">7,731</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Other CAB Programs</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">14,954</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">3,718</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">11,236</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Total external expenses</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">43,758</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">14,753</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">29,005</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Personnel and related</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">6,999</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">5,120</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1,879</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Equity-based compensation</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">4,688</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(2,252</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">6,940</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Facilities and other</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">2,829</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">2,312</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">517</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Total research and development expenses</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">58,274</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">19,933</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">38,341</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Research and development expenses were $58.3 million and $19.9 million for the years ended December 31, 2021 and 2020, respectively. The increase of $38.3 million was primarily driven by a $17.8 million increase in external costs as due to manufacturing and clinical development for our clinical programs BA3011 and BA3021, a $11.2 million increase in pre-clinical development including manufacturing and IND enabling studies for CAB pipeline programs, a $4.0 million increase in stock-based compensation due to awards issued in connection with our 2020 Equity Incentive Plan, a $3.0 million increase in equity-based compensation related to a decrease in the fair value of awards under our profits interest plan during the year ended December 31, 2020, a $1.9 million increase in personnel related costs due to an increase in headcount to support ongoing development activities for our programs, and $0.5 million increase in facility, depreciation and allocated costs.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">  </font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">General and administrative expense</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">General and administrative expenses were $38.4 million and $10.6 million for the years ended December 31, 2021 and 2020, respectively. The increase of $27.8 million was primarily driven by a $18.2 million increase in stock-based compensation due to awards issued in connection with our 2020 Equity Incentive Plan and the modification of awards issued to one of our co-founders, a $3.8 million increase in equity-based compensation related to a decrease in the fair value of awards under our profits interest plan during the year ended December 31, 2020, a $2.9 million increase in insurance expense, a $1.5 million increase in personnel related expenses as we expanded our administrative functions in support of our development activities plus severance benefits related to the departure of one of our co-founders, a $1.2 million increase in professional fees related to accounting, audit and legal services, a $0.4 million increase in other expenses including corporate franchise taxes and software subscriptions, and a $0.3 million increase in depreciation expense.  These decreases were offset by a $0.4 million decrease in facility and allocated costs.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">  </font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Interest income</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Interest income was $350,000 and $100,000 for the years ended December 31, 2021 and 2020, respectively. The increase of $250,000 was due to higher average cash and cash equivalent balances after our December 2020 IPO and September 2021 private placement.</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Interest expense</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Interest expense was $3,000 and $1.4 million for the years ended December 31, 2021 and 2020, respectively. The decrease of $1.4 million was due to reduced interest expense as a result of the settlement of all of our convertible debt in July 2020.</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Change in fair value of derivative liability</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Change in fair value of derivative liability was $0 and $1.6 million for the years ended December 31, 2021 and 2020, respectively. The decrease of $1.6 million was primarily due to changes in the fair value of embedded derivatives issued in connection with our outstanding convertible promissory notes which all settled in July 2020.</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Extinguishment of debt</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Extinguishment of long-term debt resulted in a $0.7 million gain and a $2.9 million loss on extinguishment during the years ended December 31, 2021 and 2020 related to the forgiveness of our PPP loan in July 2021 and the settlement of our then outstanding convertible promissory notes in connection with our July 2020 Series D Financing, respectively.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Other income (expense)</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We had minimal other income and expense for the years ended December 31, 2021 and 2020.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Liquidity and capital resources</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We have incurred aggregate net losses and negative cash flows from operations since our inception and anticipate we will continue to incur net losses for the foreseeable future. As of December 31, 2021, we had cash and cash equivalents of $245.0 million.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">88</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Debt</font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">On April 22, 2020, we received proceeds from a loan, or PPP Loan, in the amount of $0.7 million from City National Bank, as lender, pursuant to the Paycheck Protection Program, or PPP, of the CARES Act.  In July 2021, we were notified by our lender, City National Bank, that our PPP Loan had been fully forgiven by the SBA and that there was no remaining balance on the PPP Loan. We recorded the forgiveness as other income in 2021. <br><br><br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Future funding requirements</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Our primary uses of cash are to fund operating expenses, which consist primarily of research and development expenses related to our programs and related personnel costs. The timing and amount of future funding requirements depends on many factors, including the following:</font></p>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">the initiation, scope, rate of progress, results and costs of our preclinical studies, clinical trials and other related activities for our product candidates;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">the costs associated with manufacturing our product candidates and establishing commercial supplies and sales, marketing and distribution capabilities;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">the timing and costs of capital expenditures to support our research and development efforts;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">the number and characteristics of other product candidates that we pursue;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">our ability to maintain, expand and defend the scope of our intellectual property portfolio, including the amount and timing of any payments we may be required to make in connection with the licensing, filing, defense and enforcement of any patents or other intellectual property rights;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">the timing, receipt and amount of sales from our potential products;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">our need and ability to hire additional management, scientific and medical personnel;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">the effect of competing products that may limit market penetration of our product candidates;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">our need to implement additional internal systems and infrastructure, including financial and reporting systems;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">the economic and other terms, timing and success of any collaboration, licensing, or other arrangements into which we may enter in the future, including the timing of receipt of any milestone or royalty payments under these agreements;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">the compliance and administrative costs associated with being a public company; and</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">the extent to which we acquire or invest in businesses, products or technologies, although we have no commitments or agreements relating to any of these types of transactions.</font></div></div>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Based on our current operating plan, our current cash and cash equivalents are expected to be sufficient to fund our ongoing operations into the first half of 2024. However, we have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">In addition, we will require additional funding in order to complete development of our product candidates and commercialize our products, if approved. We may seek to raise any necessary additional capital through a combination of public or private equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements and other marketing and distribution arrangements. We cannot assure you that, in the event we require additional financing, such financing will be available at acceptable terms to us, if at all. Failure to generate sufficient cash flows from operations, raise additional capital, and reduce discretionary spending should additional capital not become available could have a material adverse effect on our ability to achieve our intended business objectives. Because of the numerous risks and uncertainties associated with the development and commercialization of our product candidates, we are unable to estimate the amounts of increased capital outlays and operating expenditures associated with our current and anticipated preclinical studies and clinical trials. To the extent that we raise additional capital through collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our product candidates. We may also have to forego future revenue streams of research programs at an earlier stage of development or on less favorable terms than we would otherwise choose, or have to grant licenses on terms that may not be favorable to us. Our ability to raise additional funds will depend on financial, economic and other factors, many of which are beyond our control. For example, market volatility resulting from the COVID-19 pandemic could adversely impact our ability to access capital as and when needed. We may choose to raise additional capital through the issuance of equity or convertible debt securities due to market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. To the extent we issue additional shares of common stock or other equity or convertible debt securities in the future, there will be further dilution to our investors and the terms of these securities may include liquidation or other preferences that adversely affect our stockholders&#x2019; rights. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, acquiring other businesses, products or technology, or declaring dividends. If we are unable to obtain additional funding from these or other sources, it may be necessary to significantly reduce our rate of spending through reductions in staff and delay, scale back or stop certain research and development programs.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">89</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Cash flows</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The following summarizes our cash flows for the periods indicated:</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:62.223%;"></td>
    <td style="width:1.472%;"></td>
    <td style="width:1.791%;"></td>
    <td style="width:14.339%;"></td>
    <td style="width:1.207%;"></td>
    <td style="width:1.472%;"></td>
    <td style="width:1.791%;"></td>
    <td style="width:14.498%;"></td>
    <td style="width:1.207%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Years Ended December 31,</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">2021</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">2020</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">(in thousands)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Net cash provided by (used in):</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Operating activities</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(62,214</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(36,334</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Investing activities</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(924</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(590</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Financing activities</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">69,512</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">271,825</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Net increase in cash and cash equivalents</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">6,374</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">234,901</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Cash used in operating activities</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Net cash used in operating activities for the year ended December 31, 2021 was $62.2 million, which consisted of a consolidated net loss of $95.4 million, a net increase of $7.4 million in our net operating assets and liabilities and $25.8 million of non-cash transactions. The net change in our operating assets and liabilities was primarily due to an increase in accounts payable and accrued expenses of $8.0 million, a decrease in prepaid expenses and other assets of $0.2 million, offset by a net increase in operating lease right-of-use assets and liabilities of $0.3 million in conjunction with the adoption of ASC 842. The non-cash transactions primarily consisted of $25.1 million of stock-based compensation and non-cash charges of $1.3 million related to depreciation and amortization, offset by the $0.7 million gain on the extinguishment of our PPP loan.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Net cash used in operating activities for the year ended December 31, 2020 was $36.3 million, which consisted of a consolidated net loss of $35.9 million, a net change of $2.5 million in our net operating assets and liabilities and $2.0 million of non-cash transactions. The net change in our operating assets and liabilities was primarily due to a decrease in accounts payable and accrued expenses of $1.7 million, an increase in prepaid expenses and other assets of $1.3 million, an increase in accrued interest of $0.9 million on our outstanding convertible debt prior to its settlement in July 2020, and a decrease in deferred revenue of $0.4 million as we recognized deferred revenue related to our collaboration with BeiGene. The non-cash transactions primarily consisted of $3.0 million of stock-based compensation related to the issuance of RSUs and stock options in the fourth quarter of 2020, a $2.9 million loss on extinguishment of convertible debt, a $1.6 million change in the fair value of our derivative liability, non-cash charges of $1.0 million related to depreciation and amortization and $0.5 million of non-cash interest, offset by a decrease in the fair value of our profits interest liability and pushdown from our affiliate of $6.9 million and $0.2 million of deferred rent.</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Cash used in investing activities</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Cash used in investing activities was $0.9 million and $0.6 million for the years ended December 31, 2021 and 2020, respectively, related to the purchase of property and equipment.</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Cash provided by financing activities</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Net cash provided by financing activities was $69.5 million for the year ended December 31, 2021, which consisted primarily of the net proceeds from the issuance of common stock through a Private Placement of $71.0 million, the proceeds from the issuance of common stock under our Employee Stock Purchase Plan of $0.3 million, and $0.1 million due to the exercise of stock options under our Equity Incentive Plan, partially offset by our payment of initial public offering costs of $1.9 million.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Net cash provided by financing activities was $271.8 million for the year ended December 31, 2020, which consisted of $200.2 million of net proceeds from our initial public offering, $68.2 million of net proceeds from our issuance of Series D convertible preferred stock, $2.8 million of proceeds from the issuance of convertible promissory notes and $0.7 million of proceeds from our PPP loan.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Critical accounting policies and estimates</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Our management&#x2019;s discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenue generated, and reported expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions and conditions.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">While our significant accounting policies are described in the Note 1 to our consolidated financial statements included elsewhere in this Annual Report on Form 10-K, we believe that the following critical accounting policies are most important to understanding and evaluating our reported financial results.</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Accrued expenses</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">As part of the process of preparing our consolidated financial statements, we accrue expenses as of each balance sheet date. This process involves reviewing open contracts and purchase orders, communicating with our personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">90</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">otherwise notified of the actual cost. We make estimates of our accrued expenses as of each balance sheet date based on facts and circumstances known to us at that time. The estimates in our accrued research and development expenses include the costs incurred for services performed by our vendors in connection with research and development activities for which we have not yet been invoiced. We periodically confirm the accuracy of our estimates with the service providers and make adjustments if necessary.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We base our expenses related to research and development activities on our estimates of the services received and efforts expended pursuant to quotes and contracts with vendors that conduct research and development on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the research and development expense. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from our estimate, we adjust the accrual or prepaid expense accordingly. Advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Although we do not expect our estimates to be materially different from amounts actually incurred, if our estimates of the status and timing of services performed differ from the actual status and timing of services performed, it could result in us reporting amounts that are too high or too low in any particular period. To date, there have been no material differences between our estimates of such expenses and the amounts actually incurred.</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Collaboration revenue</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We recognize revenue in a manner that depicts the transfer of control of a product or a service to a customer and reflects the amount of the consideration we are entitled to receive in exchange for such product or service. In doing so, we follow a five-step approach: (i) identify the contract with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations, and (v) recognize revenue when (or as) the customer obtains control of the product or service. We consider the terms of a contract and all relevant facts and circumstances when applying the revenue recognition standard.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">A customer is a party that has entered into a contract with us, where the purpose of the contract is to obtain a product or a service that is an output of our ordinary activities in exchange for consideration. To be considered a contract, (i) the contract must be approved (in writing, orally, or in accordance with other customary business practices), (ii) each party&#x2019;s rights regarding the product or the service to be transferred can be identified, (iii) the payment terms for the product or the service to be transferred can be identified, (iv) the contract must have commercial substance (that is, the risk, timing or amount of future cash flows is expected to change as a result of the contract), and (v) it is probable that we will collect substantially all of the consideration to which we are entitled to receive in exchange for the transfer of the product or the service.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">A performance obligation is defined as a promise to transfer a product or a service to a customer. We identify each promise to transfer a product or a service (or a bundle of products or services, or a series of products and services that are substantially the same and have the same pattern of transfer) that is distinct. A product or a service is distinct if both (i) the customer can benefit from the product or the service either on its own or together with other resources that are readily available to the customer and (ii) our promise to transfer the product or the service to the customer is separately identifiable from other promises in the contract. Each distinct promise to transfer a product or a service is a unit of accounting for revenue recognition. If a promise to transfer a product or a service is not separately identifiable from other promises in the contract, such promises should be combined into a single performance obligation.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The transaction price is the amount of consideration we are entitled to receive in exchange for the transfer of control of a product or a service to a customer. To determine the transaction price, we consider the existence of any significant financing component, the effects of any variable elements, noncash considerations and consideration payable to the customer. If a significant financing component exists, the transaction price is adjusted for the time value of money. If an element of variability exists, we must estimate the consideration it expects to receive and uses that amount as the basis for recognizing revenue as the product or the service is transferred to the customer. There are two methods for determining the amount of variable consideration: (i) the expected value method, which is the sum of probability-weighted amounts in a range of possible consideration amounts, and (ii) the mostly likely amount method, which identifies the single most likely amount in a range of possible consideration amounts.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">If a contract has multiple performance obligations, we allocate the transaction price to each distinct performance obligation in an amount that reflects the consideration we are entitled to receive in exchange for satisfying each distinct performance obligation. For each distinct performance obligation, revenue is recognized when (or as) we transfer control of the product or the service applicable to such performance obligation.</font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">In those instances where we first receive consideration in advance of satisfying our performance obligation, we classify such consideration as deferred revenue until (or as) we satisfy such performance obligation. In those instances where we first satisfy our performance obligation prior to receipt of consideration, the consideration is recorded as accounts receivable.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We expense incremental costs of obtaining and fulfilling a contract as incurred if the expected amortization period of the asset that would be recognized is one year or less, or if the amount of the asset is immaterial. Otherwise, such costs are capitalized as contract assets if they are incremental to the contract and amortized to expense proportionate to revenue recognition of the underlying contract.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">91</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Profits interest liability</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Before the Corporate Reorganization, we had a profits interest plan which we determined was a liability award plan in accordance with authoritative guidance. We measured the fair value of each award on the grant date and recognized such fair value over the requisite service period (usually the vesting period) on a straight-line basis, net of estimated forfeitures. The fair value of the award was remeasured at each reporting date until the award was settled, with a true-up of compensation cost for changes in fair value prorated for the portion of the requisite service period rendered. Once vested, any subsequent change in fair value was recognized immediately. The fair value of any awards that expired or were forfeited or cancelled for no value was adjusted to zero, such that any previously recorded compensation cost was fully reversed.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We were required to estimate the fair value of the Class B units issued in connection with our profits interest plan. The fair value of our Class B units was determined on each reporting date by our management, taking into account input from independent third-party valuation analysis. In the absence of a public trading market for our Class B units, on each reporting date we developed an estimate of the fair value of our Class B units in order to calculate the profit interest liability. Our determinations of the fair value of our Class B units were made using methodologies, approaches and assumptions consistent with the American Institute of Certified Public Accountants</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;"> Audit and Accounting Practice Aid Series: Valuation of Privately Held Company Equity Securities Issued as Compensation</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">, or the Practice Aid.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We considered various objective and subjective factors to determine the fair value of our Class B units, including:</font></p>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">contemporaneous valuations of our Class B units performed by independent third-party valuation specialists;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">our stage of development and business strategy, including the status of research and development efforts of our product candidates, and the material risks related to our business and industry;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">our results of operations and financial position, including our levels of available capital resources;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">the valuation of publicly traded companies in the life sciences and biopharmaceutical sectors, as well as recently completed mergers and acquisitions of peer companies;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">the lack of liquidity of our Class B units;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">the rights, preferences and privileges of our Class C Preferred units and Class A units relative to those of our Class B units;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">the likelihood and timing of achieving a liquidity event for the holders of our Class B units, given prevailing market conditions;</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">trends and developments in our industry; and</font></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.867816831895627%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">external market conditions affecting the life sciences and biopharmaceutical industry sectors.</font></div></div>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Valuation methodologies and methods used to allocate our enterprise value to classes of securities</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Our valuations were prepared in accordance with the guidelines in the Practice Aid, which prescribes several valuation approaches for setting the value of an enterprise, such as the cost, income and market approaches, and various methodologies for allocating the value of an enterprise to its common stock. The cost approach establishes the value of an enterprise based on the cost of reproducing or replacing the property less depreciation and functional or economic obsolescence, if present. The income approach establishes the value of an enterprise based on the present value of future cash flows that are reasonably reflective of our company&#x2019;s future operations, discounting to the present value with an appropriate risk adjusted discount rate or capitalization rate. The market approach is based on the assumption that the value of an asset is equal to the value of a substitute asset with the same characteristics. Each valuation methodology was considered in our valuations. We utilized a market approach in 2019 and 2020. In 2020, in connection with our Corporate Reorganization and Series D preferred stock financing, our market approach included the back-solve method that assigns an implied enterprise value based on the most recent round of funding or investment and allows for the incorporation of the implied future benefits and risks of the investment decision assigned by an outside investor. In accordance with the Practice Aid, we considered the various methods for allocating the enterprise value across our classes and series of equity to determine the fair value of our equity instruments at each valuation date. We applied a hybrid method of the probability weighted expected return method, or PWERM, where the non-IPO scenario is modeled using an option pricing model to reflect the full distribution of possible non-IPO outcomes. Under the option pricing model, units are valued by creating a series of call options with exercise prices based on the liquidation preferences and conversion terms of each equity class. The values of each class of units are inferred by analyzing these options. In the IPO scenario, we used the fully-diluted shares outstanding to allocate value to each class of units. The hybrid method is useful when certain discrete future outcomes can be predicted, but also accounts for uncertainty regarding the timing or likelihood of specific alternative exit events.</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Stock-based compensation</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">In October 2020 we adopted our 2020 Equity Incentive Plan and began to grant stock options and RSUs and began to recognize stock-based compensation expense in the fourth quarter of 2020.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">92</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Stock-based compensation expense represents the grant date fair value of equity awards recognized over the requisite service period of the awards (usually the vesting period) on a straight-line basis. We estimate the fair value of stock option grants using the Black-Scholes option pricing model and the fair value of RSUs is the fair value of our common stock on the date of grant. See Note 7 to our consolidated financial statements included elsewhere in this Annual Report for information concerning the specific assumptions we used in applying the Black-Scholes option pricing model to determine the estimated fair value of our stock option grants. The fair value of our common stock for awards granted under our equity incentive plan will be based on the closing price as reported on the date of the grant on the primary stock exchange on which our common stock is traded. Equity award forfeitures are recognized as they occur.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Other company information</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;"> </font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Recent Accounting Pronouncements</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">See Note 1 to the audited financial statements included in Item 8 of this Annual Report on Form 10-K.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Off-balance sheet arrangements</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We have not entered into any off-balance sheet arrangements, as defined in the rules and regulations of the SEC.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:16.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_7a_quantitative_and_qualitative"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">ITEM 7A. Quantitative and Qualit</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">ative Disclosures About Market Risk</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Interest Rate Risk</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We are exposed to market risks in the ordinary course of our business. We had cash, cash equivalents and short-term investments of $245.0 million and $238.6 million as of December 31, 2021 and 2020, respectively, which consisted of bank deposits and money market funds. Such interest-bearing instruments carry a degree of interest rate risk; however, historical fluctuations of interest income have not been significant.<br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We do not enter into investments for trading or speculative purposes and we do not currently utilize derivative financial instruments to manage our interest rate exposure. We have not historically been exposed to material risks due to changes in interest rates.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Foreign Currency Exchange Risk</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Our contracts with customers are primarily denominated in U.S. dollars, with a small amount denominated in foreign currencies. As such, fluctuations in foreign currency exchange rates may cause us to recognize transaction gains and losses in our statement of operations. To date, foreign currency transaction gains and losses have not been material to our consolidated financial statements, and we have not engaged in any foreign currency hedging transactions.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">93</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_8_financial_statements"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">ITEM 8. Financial Stateme</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">nts and Supplementary Data</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">BioAtla, Inc.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:0.1736111111111111in;border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:89.523%;"></td>
    <td style="width:2.078%;"></td>
    <td style="width:1.049%;"></td>
    <td style="width:6.252%;"></td>
    <td style="width:1.098%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">  </font>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Page</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Index to consolidated financial statements</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#report_of_independent_registered"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Report of independent registered public accounting firm (PCAOB ID: 42)</font></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">  </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">95</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_balance_sheets"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Consolidated balance sheets</font></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">  </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">96</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_statements_of_operations"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Consolidated statements of operations and comprehensive loss</font></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">  </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">97</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#statements_of_convertible_preferred"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Consolidated statements of  convertible preferred stock and stockholders&#x2019;/members&#x2019; equity (deficit)</font></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">  </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">98</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_statements_of_cash_flows"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Consolidated statements of cash flows</font></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">  </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">99</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#notes_to_consolidated_financial"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Notes to consolidated financial statements</font></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">  </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">100</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
   </tr>
  </table>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">94</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="report_of_independent_registered"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Report of Indepe</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">ndent Registered Public Accounting Firm</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">To the Stockholders and the Board of Directors of BioAtla, Inc.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Opinion on the Financial Statements</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We have audited the accompanying consolidated balance sheets of BioAtla, Inc. (the Company) as of December 31, 2021 and 2020, the related consolidated statements of operations and comprehensive loss, convertible preferred stock and stockholders&#x2019;/members&#x2019; equity (deficit) and cash flows for each of the three years in the period ended December 31, 2021, and the related notes</font><font style="background-color:rgba(244,244,244,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;vertical-align:top;font-size:6.03pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(collectively referred to as the &#x201c;consolidated financial statements&#x201d;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2021 and 2020, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2021, in conformity with U.S. generally accepted accounting principles.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2021, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(2013 framework) and our report dated February 28, 2022 expressed an unqualified opinion thereon.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Basis for Opinion</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company&#x2019;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Critical Audit Matter</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:13.0%;"></td>
    <td style="width:2.0%;"></td>
    <td style="width:85.0%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Accrual of Clinical Trial Expenses</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.8pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.8pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.8pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Description of the Matter</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">During 2021, the Company incurred $58.3 million for research and development expenses and as of December 31, 2021 accrued $6.2 million for clinical trial costs. A substantial portion of the Company&#x2019;s ongoing research and development activities are conducted by third-party service providers, including clinical research organizations (&#x201c;CROs&#x201d;). External costs to be paid to CROs are accrued and expensed based upon actual work completed in accordance with signed agreements.</font></p><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:5.4pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Auditing management&#x2019;s accounting for accrued clinical trial costs is especially challenging because the evaluation is dependent upon a high-volume of data and input exchanged between clinical personnel and third-party service providers, such as the total trial management costs, number of sites activated, the number of patients enrolled, and the number of patient visits, which is tracked in spreadsheets and other end user computing programs.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.8pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.8pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.8pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">How We Addressed the Matter in Our Audit</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We obtained an understanding, evaluated the design and tested the operating effectiveness of controls over the accounting for accrued clinical trial expenses. For example, we tested controls over management&#x2019;s assessment and measurement of estimated accrued clinical trial costs, including patient enrollment and total costs billed but unpaid as of year end.</font></p><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:5.4pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">To test the completeness of the Company&#x2019;s accrued clinical trial expenses, we obtained from third-parties confirmation of the number of patients enrolled and costs billed but unpaid as of year end for significant clinical trials. We obtained an understanding of the status of significant clinical trial activities from  accounting personnel and the clinical project managers to understand the status of significant clinical trial activities. To assess the appropriate measurement of accrued clinical trial expenses, we inspected key terms, timelines of completion, activities and costs for a sample of vendor contracts, including amendments, and compared these to management&#x2019;s analyses used in tracking the progress of service agreements. We also tested a sample of subsequent payments by agreeing the amount of the payment to the invoice and to the amount accrued.</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:11.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">/s/ Ernst &amp; Young LLP</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We have served as the Company&#x2019;s auditor since 2016.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">San Diego, California</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">February 28, 2022</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">95</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">BioAtla, Inc.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="consolidated_balance_sheets"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Consolidate</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">d balance sheets</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">(in thousands, except share/unit amounts)</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.636%;"></td>
    <td style="width:1.614%;"></td>
    <td style="width:1.085%;"></td>
    <td style="width:13.264%;"></td>
    <td style="width:0.723%;"></td>
    <td style="width:1.614%;"></td>
    <td style="width:1.085%;"></td>
    <td style="width:13.255%;"></td>
    <td style="width:0.723%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">December 31,</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">2021</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">2020</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Assets</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Current assets:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Cash and cash equivalents</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">244,979</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">238,605</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Prepaid expenses and other current assets</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">2,313</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">2,076</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Total current assets</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">247,292</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">240,681</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Property and equipment, net</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">3,676</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">4,102</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Operating lease right-of-use-asset, net</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">3,300</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Other assets</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">154</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">154</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Total assets</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">254,422</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">244,937</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Liabilities and Stockholders&#x2019; Equity</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Current liabilities:</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Accounts payable and accrued expenses</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">18,424</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">12,068</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Current portion of deferred rent</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">387</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Current portion of deferred revenue</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">19,806</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Operating lease liabilities</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1,389</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Total current liabilities</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">19,813</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">32,261</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Long-term accrued interest</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">5</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Deferred rent, less current portion</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">2,015</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Operating lease liabilities, less current portion</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">3,982</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Liability to licensor</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">19,806</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Other debt</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">682</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Total liabilities</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">43,601</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">34,963</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Commitments and contingencies (Note 6)</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Stockholders' equity:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Preferred stock, $0.0001 par value; 200,000,000 shares authorized at December 31,<br>&#160;&#160;&#160;2021 and 2020; 0 shares issued and outstanding at December 31, 2021 and 2020</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Common stock, $0.0001 par value; 350,000,000 authorized at December 31,<br>&#160;&#160;&#160;2021 and 2020; 35,799,233 shares and 32,171,560 shares issued and outstanding at<br>&#160;&#160;&#160;December 31, 2021 and 2020</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">4</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">3</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Class B common stock, $0.0001 par value; 15,368,569 shares authorized at<br>&#160;&#160;&#160;December 31, 2021 and 2020; 1,492,059 shares issued and<br>&#160;&#160;&#160;outstanding at December 31, 2021 and 2020</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Additional paid-in capital</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">397,136</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">300,888</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Accumulated deficit</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(186,319</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(90,917</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Total stockholders' equity</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">210,821</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">209,974</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Total liabilities and stockholders&#x2019; equity</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">254,422</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">244,937</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">See accompanying notes.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">96</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">BioAtla, Inc.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="consolidated_statements_of_operations"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Consolidated st</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">atements of operations and comprehensive loss</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">(in thousands, except share/unit and per share/unit amounts)</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:56.52%;"></td>
    <td style="width:1.363%;"></td>
    <td style="width:1.206%;"></td>
    <td style="width:12.345%;"></td>
    <td style="width:0.723%;"></td>
    <td style="width:1.363%;"></td>
    <td style="width:1.206%;"></td>
    <td style="width:10.61%;"></td>
    <td style="width:0.742%;"></td>
    <td style="width:1.363%;"></td>
    <td style="width:1.206%;"></td>
    <td style="width:10.61%;"></td>
    <td style="width:0.742%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Years ended December 31,</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">2021</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">2020</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">2019</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Collaboration and other revenue</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">250</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">429</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">5,200</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Operating expenses:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Research and development expense (includes related party amounts of $0, $0, and $1,885, respectively)</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">58,274</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">19,933</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">25,919</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">General and administrative expense (includes related party amounts of $0, $0, and $15, respectively)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">38,416</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10,595</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">7,549</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Total operating expenses</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">96,690</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">30,528</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">33,468</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Loss from operations</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(96,440</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(30,099</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(28,268</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Other income (expense):</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Interest income</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">350</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">100</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">128</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Interest expense (includes related party amounts of $0, $147 and $52, respectively)</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(3</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(1,389</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(1,630</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Change in fair value of derivative liability</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(1,581</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(63</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Gain (loss) on extinguishment of long-term debt</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">690</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(2,883</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Other income (expense)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(1</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(22</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Total other income (expense)</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1,038</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(5,754</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(1,587</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Consolidated net loss and comprehensive loss</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(95,402</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(35,853</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(29,855</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Net loss attributable to noncontrolling interests</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">61</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Net loss attributable to BioAtla, Inc./BioAtla LLC</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(95,402</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(35,853</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(29,794</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Net loss allocable to Class C preferred unit holders</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">9,089</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Class C preferred return</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(8,026</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Net loss attributable to Class A unit holders</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(28,731</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Net loss per unit attributable to Class A unit holders, basic and diluted</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(0.53</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Weighted-average Class A units outstanding, basic and diluted</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">54,600,000</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Net loss per common share, basic and diluted (1)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(2.76</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(3.19</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Weighted-average shares of common stock outstanding, basic and diluted (1)</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">34,561,245</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">8,428,153</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="display:flex;margin-top:5.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">(1)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The net loss attributable to common stockholders and related per share amounts for the year ended December 31, 2020 are based on the period from July 10, 2020 to December 31, 2020, the period where the Company had outstanding common stock (see Note 1).</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">See accompanying notes.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">97</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">BioAtla, Inc.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="statements_of_convertible_preferred"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Consolidated statements of convertib</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">le preferred stock and stockholders&#x2019;/members&#x2019; equity (deficit)</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">(in thousands, except share/unit amounts)</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:13.121%;"></td>
    <td style="width:1.013%;"></td>
    <td style="width:0.993%;"></td>
    <td style="width:4.074%;"></td>
    <td style="width:0.993%;"></td>
    <td style="width:1.013%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:3.054%;"></td>
    <td style="width:0.993%;"></td>
    <td style="width:1.013%;"></td>
    <td style="width:0.993%;"></td>
    <td style="width:4.067%;"></td>
    <td style="width:0.993%;"></td>
    <td style="width:1.013%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:3.054%;"></td>
    <td style="width:0.993%;"></td>
    <td style="width:1.013%;"></td>
    <td style="width:0.993%;"></td>
    <td style="width:4.067%;"></td>
    <td style="width:0.993%;"></td>
    <td style="width:1.013%;"></td>
    <td style="width:1.007%;"></td>
    <td style="width:2.034%;"></td>
    <td style="width:0.993%;"></td>
    <td style="width:1.013%;"></td>
    <td style="width:0.993%;"></td>
    <td style="width:4.067%;"></td>
    <td style="width:0.993%;"></td>
    <td style="width:1.013%;"></td>
    <td style="width:1.007%;"></td>
    <td style="width:2.034%;"></td>
    <td style="width:0.993%;"></td>
    <td style="width:1.013%;"></td>
    <td style="width:0.993%;"></td>
    <td style="width:3.067%;"></td>
    <td style="width:0.993%;"></td>
    <td style="width:1.013%;"></td>
    <td style="width:1.007%;"></td>
    <td style="width:2.034%;"></td>
    <td style="width:0.993%;"></td>
    <td style="width:1.013%;"></td>
    <td style="width:1.007%;"></td>
    <td style="width:3.493%;"></td>
    <td style="width:0.98%;"></td>
    <td style="width:1.013%;"></td>
    <td style="width:0.993%;"></td>
    <td style="width:3.189%;"></td>
    <td style="width:0.98%;"></td>
    <td style="width:1.013%;"></td>
    <td style="width:0.986%;"></td>
    <td style="width:3.101%;"></td>
    <td style="width:0.98%;"></td>
    <td style="width:1.013%;"></td>
    <td style="width:0.986%;"></td>
    <td style="width:4.128%;"></td>
    <td style="width:0.399%;"></td>
   </tr>
   <tr style="height:5.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:5.0pt;font-family:Times New Roman;">Series D convertible<br>preferred stock</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:5.0pt;font-family:Times New Roman;">Class C preferred<br>units</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:5.0pt;font-family:Times New Roman;">Class A units</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:5.0pt;font-family:Times New Roman;">Common stock</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:5.0pt;font-family:Times New Roman;">Class B<br>common stock</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:5.0pt;font-family:Times New Roman;">Additional<br>paid-in</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:5.0pt;font-family:Times New Roman;">Accumulated</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:5.0pt;font-family:Times New Roman;">Non-<br>controlling</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:5.0pt;font-family:Times New Roman;">Total<br>stockholders&#x2019;/<br>members&#x2019;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:5.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:5.0pt;font-family:Times New Roman;">Shares</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:5.0pt;font-family:Times New Roman;">Amount</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:5.0pt;font-family:Times New Roman;">Units</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:5.0pt;font-family:Times New Roman;">Amount</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:5.0pt;font-family:Times New Roman;">Units</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:5.0pt;font-family:Times New Roman;">Amount</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:5.0pt;font-family:Times New Roman;">Shares</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:5.0pt;font-family:Times New Roman;">Amount</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:5.0pt;font-family:Times New Roman;">Shares</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:5.0pt;font-family:Times New Roman;">Amount</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:5.0pt;font-family:Times New Roman;">capital</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:5.0pt;font-family:Times New Roman;">deficit</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:5.0pt;font-family:Times New Roman;">interest</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:5.0pt;font-family:Times New Roman;">equity (deficit)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:5.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">Balance at Ended December 31, 2018</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">23,968,178</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">89,345</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">54,600,000</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">750</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">(118,560</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">)</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">19</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">(28,446</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">)</font></p></td>
   </tr>
   <tr style="height:5.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:8.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">Noncontrolling interest</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">(5</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">(5</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">)</font></p></td>
   </tr>
   <tr style="height:5.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:8.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">Warrants issued by affiliates in<br>&#160;&#160;&#160;connection with modification<br>&#160;&#160;&#160;of convertible promissory notes</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">764</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">764</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:5.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:8.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">Assumption of unvested profits<br>&#160;&#160;&#160;interest liability by affiliates</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">197</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">197</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:5.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:8.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">Assumption of vested profits<br>&#160;&#160;&#160;interest liability by affiliates</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">800</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">800</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:5.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:8.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">Beneficial conversion feature in<br>&#160;&#160;&#160;convertible promissory notes</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">534</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">534</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:5.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:8.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">Net loss</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">(29,794</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">)</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">(61</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">)</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">(29,855</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">)</font></p></td>
   </tr>
   <tr style="height:5.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">Balance at December 31, 2019</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">23,968,178</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">89,345</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">54,600,000</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">750</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">2,295</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">(148,354</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">(47</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">(56,011</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">)</font></p></td>
   </tr>
   <tr style="height:5.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:8.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">Issuance of Series D convertible<br>&#160;&#160;&#160;preferred stock for cash, net of<br>&#160;&#160;&#160;$4,317 of issuance costs</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">140,626,711</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">68,183</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:5.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:8.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">Issuance of Series D convertible<br>&#160;&#160;&#160;preferred stock in connection<br>&#160;&#160;&#160;with settlement of convertible<br>&#160;&#160;&#160;promissory notes</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">59,164,808</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">30,594</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:5.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:8.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">Assumption of profits interest<br>&#160;&#160;&#160;liability by affiliate</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">991</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">991</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:5.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:8.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">Change in profits interest liability<br>&#160;&#160;&#160;of affiliate</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">749</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">749</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:5.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:8.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">Noncontrolling interest&#x2014;<br>&#160;&#160;&#160;distribution of net assets<br>&#160;&#160;&#160;to affiliate and related<br>&#160;&#160;&#160;deconsolidation</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">(66</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">)</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">47</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">(19</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">)</font></p></td>
   </tr>
   <tr style="height:5.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:8.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">LLC Conversion</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">(23,968,178</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">(89,345</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">(54,600,000</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">(750</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">6,220,050</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">1</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">(3,196</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">93,290</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:5.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:8.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">Conversion of Series D convertible<br>&#160;&#160;&#160;preferred stock into common<br>&#160;&#160;&#160;stock</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">(199,791,519</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">)</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">(98,777</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">)</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">13,876,510</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">1</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">1,492,059</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">98,776</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">98,777</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:5.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:8.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">Initial public offering, net of<br>&#160;&#160;&#160;$19,032 of issuance costs</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">12,075,000</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">1</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">198,317</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">198,318</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:5.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:8.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">Stock-based compensation expense</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">3,022</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">3,022</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:5.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:8.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">Net loss</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">(35,853</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">(35,853</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">)</font></p></td>
   </tr>
   <tr style="height:5.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">Balance at December 31, 2020</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">32,171,560</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">3</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">1,492,059</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">300,888</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">(90,917</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">)</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">209,974</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:5.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:8.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">Issuance of common stock, <br>&#160;&#160;&#160;net of $4,007 of issuance costs</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">2,678,600</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">1</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">70,993</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">70,994</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:5.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:8.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">Issuance of common stock under <br>&#160;&#160;&#160;equity incentive plans</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">930,144</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">0</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:5.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:8.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">Issuance of common stock upon <br>&#160;&#160;&#160;exercise of options, net</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">7,747</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">140</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">140</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:5.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:8.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">Issuance of common stock for <br>&#160;&#160;&#160;Employee Stock Purchase Plan</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">11,182</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">289</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">289</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:5.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:8.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">Taxes related to net share <br>&#160;&#160;&#160;settlement of equity awards</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">(291</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">(291</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">)</font></p></td>
   </tr>
   <tr style="height:5.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:8.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">Stock-based compensation expense</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">25,117</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">25,117</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:5.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:8.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">Net loss</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">(95,402</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">(95,402</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">)</font></p></td>
   </tr>
   <tr style="height:5.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">Balance at December 31, 2021</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">35,799,233</font></p></td>
    <td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">4</font></p></td>
    <td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">1,492,059</font></p></td>
    <td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">397,136</font></p></td>
    <td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">(186,319</font></p></td>
    <td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">)</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;">210,821</font></p></td>
    <td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">See accompanying notes.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">98</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">BioAtla, Inc.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="consolidated_statements_of_cash_flows"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Consolidated sta</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">tements of cash flows</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">(in thousands)</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:57.063%;"></td>
    <td style="width:1.382%;"></td>
    <td style="width:1.085%;"></td>
    <td style="width:11.121%;"></td>
    <td style="width:0.723%;"></td>
    <td style="width:1.382%;"></td>
    <td style="width:1.085%;"></td>
    <td style="width:11.121%;"></td>
    <td style="width:0.723%;"></td>
    <td style="width:1.382%;"></td>
    <td style="width:1.085%;"></td>
    <td style="width:11.121%;"></td>
    <td style="width:0.723%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Years ended December 31,</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">2021</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">2020</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">2019</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Cash flows from operating activities</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Net loss</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(95,402</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(35,853</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(29,855</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Adjustments to reconcile net loss to net cash used in operating activities:</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Depreciation and amortization</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1,330</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1,008</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">860</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Loss on disposal of property and equipment</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">4</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">3</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Change in fair value of derivative liability</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1,581</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">63</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Change in fair value of profits interest liability</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(6,852</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(6,403</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Loss/(gain) on extinguishment of debt</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(690</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">2,883</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Stock-based compensation</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">25,117</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">3,022</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Non-cash interest</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">525</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">355</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Accrued interest</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">3</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">864</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1,276</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Deferred rent</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(150</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">230</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Changes in operating assets and liabilities:</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Prepaid expenses and other assets</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(237</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(1,273</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">939</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Accounts payable and accrued expenses</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">7,992</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(1,660</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">3,218</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Accounts payable and accrued expenses&#x2014;related parties</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(88</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Deferred revenue</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(429</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">19,757</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Right-of-use assets and lease liabilities, net</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(331</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Net cash used in operating activities</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(62,214</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(36,334</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(9,645</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Cash flows from investing activities</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Purchases of property and equipment</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(924</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(590</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(1,509</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Net cash used in investing activities</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(924</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(590</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(1,509</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Cash flows from financing activities</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Noncontrolling interest</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(19</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(5</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Proceeds from issuance of convertible debt</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">2,750</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">4,000</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Proceeds from issuance of convertible preferred stock, net of issuance costs</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">68,183</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Proceeds from issuance of PPP loan</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">682</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Proceeds from initial public offering, net of issuance costs</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">200,229</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Payment of initial public offering costs</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(1,911</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Proceeds from issuance of common stock</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">70,994</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Proceeds from exercise of stock options</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">140</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Proceeds from issuance of common stock under Employee Stock Purchase Plan</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">289</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Net cash provided by financing activities</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">69,512</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">271,825</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">3,995</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Net increase (decrease) in cash and cash equivalents</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">6,374</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">234,901</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(7,159</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Cash and cash equivalents, beginning of period</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">238,605</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">3,704</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10,863</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Cash and cash equivalents, end of period</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">244,979</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">238,605</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">3,704</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Supplemental disclosure of non-cash investing and financing activities</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Property and equipment additions included in accounts payable and accrued<br>&#160;&#160;&#160;expenses</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">17</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">172</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Fair value of warrants issued by affiliates in connection with modification of <br>&#160;&#160;&#160;convertible promissory notes</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">764</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Assumption of profits interest liability by affiliates</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">991</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">997</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Equity issuance costs included in accounts payable and accrued expenses</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1,911</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Carrying value of convertible promissory notes settled in connection with<br>&#160;&#160;&#160;Corporate Reorganization</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">27,711</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Fair value of consideration issued in connection with settlement of convertible <br>&#160;&#160;&#160;promissory notes</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">30,594</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Tax related to net settlement of equity awards included in accounts payable and <br>&#160;&#160;&#160;accrued expenses</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">291</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.269%;text-align:center;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">See accompanying notes.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">99</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">BioAtla, Inc.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="notes_to_consolidated_financial"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Notes to consol</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">idated financial statements</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">1. Organization and summary of significant accounting policies</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Organization</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">BioAtla, LLC was formed in Delaware in March 2007 and, after undergoing two separate reorganizations that are further discussed below, was converted to a Delaware corporation in July 2020 and was renamed BioAtla, Inc. (BioAtla, Inc. together with the Pre-Division Predecessor and the Post-Division Successor as defined below, the &#x201c;Company&#x201d;). The Company has a proprietary platform for creating biologics, including its conditionally active biologics (&#x201c;CAB&#x201d; or &#x201c;CABs&#x201d;). CABs have been designed to be active only under certain conditions found in diseased tissue, while remaining inactive in normal tissue. The Company is currently in clinical development of its two lead CAB antibody drug conjugates (&#x201c;CAB ADC&#x201d;) targeting AXL and ROR2 receptors.</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">LLC Division</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">In March 2019, BioAtla, LLC (the &#34;Pre-Division Predecessor&#34;) was divided into three separate and distinct Delaware limited liability companies (the &#x201c;Division&#x201d;) as follows: 1) BioAtla, LLC renamed to BioAtla Holdings, LLC (&#x201c;BioAtla Holdings&#x201d;), 2) a new legal entity named Inversagen, LLC (&#x201c;Inversagen&#x201d;), and 3) a new legal entity named BioAtla, LLC (the &#x201c;Post-Division Successor&#x201d; and together with BioAtla Holdings and Inversagen, the &#x201c;Post-Division LLCs&#x201d;). Upon the Division, each Post-Division LLC had substantially the same form of operating agreement and capital structure as the Pre-Division Predecessor, with the following exceptions: i) 1,750,000 Class B units issued by the Post-Division Successor but not by BioAtla Holdings or Inversagen, ii) the outstanding warrants of the Pre-Division Predecessor at the Division date were transferred to the Post-Division Successor (see Note 7), and iii) the Class C units of the Post-Division Successor had liquidation preferences and a preferred return not included in the operating agreements of BioAtla Holdings and Inversagen.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">In connection with the Division, the Pre-Division Predecessor&#x2019;s holdings of EXUMA Biotech Corp. (&#x201c;EXUMA&#x201d;, formerly F1 Oncology, Inc.) common and preferred stock (see Note 12) remained in BioAtla Holdings and certain rights related to the application of CAB technology in senescent cell therapy were transferred to the Post-Division Successor and simultaneously licensed to Inversagen (see Note 10). The remaining assets and liabilities (including ownership of Himalaya Therapeutics SEZC, or &#34;HTKY&#34;, and its wholly-owned subsidiary, Himalaya Therapeutics HK Limited as described below in &#x201c;Principles of consolidation and deconsolidation&#x201d;), and substantially all of the operations of the Pre-Division Predecessor, including all existing employees, were transferred to the Post-Division Successor. Each of the Pre-Division Predecessor&#x2019;s members at the time of the Division continued as a member in the Post-Division Successor, BioAtla Holdings and Inversagen, and each entity has Dr. Jay Short and his spouse, Carolyn Anderson Short, as its LLC managers. There are no shared services agreements between the Company and BioAtla Holdings or Inversagen. The Company has determined that Inversagen is a variable interest entity (&#x201c;VIE&#x201d;), the Company is not the primary beneficiary of Inversagen, and that the Post-Division LLCs are under the common control of Jay and Carolyn Short. The Company does not consolidate either BioAtla Holdings or Inversagen (see Note 10). In addition, the Company has no direct equity investment in either BioAtla Holdings or Inversagen that require either equity method or cost method accounting.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The assets, liabilities, and employees transferred to the Post-Division Successor in the Division met the definition of a business and the transfer qualifies as a change in reporting entity under Accounting Standards Codification (&#x201c;ASC&#x201d;) 250-10-45-21. As such, the historical financial statements of the Pre-Division Predecessor are deemed to be those of the Post-Division Successor, even for periods prior to its formation. As a transfer of a business to an entity under common control, the assets and liabilities of the Pre-Division Predecessor were transferred to the Post-Division Successor at historical carrying values. At the Division date, the Pre-Division Predecessor&#x2019;s investment in EXUMA and the assets licensed to Inversagen had a zero carrying value and neither EXUMA nor Inversagen had material operations. As such, the Pre-Division historical financial statements presented herein are the historical financial statements of the Pre-Division Predecessor without adjustment.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">In connection with the Division, certain modifications were made to then outstanding debt agreements and units, including: i) the participation threshold of each Class B unit in each Post-Division LLC was adjusted for the impact of the Division (see Note 8), ii) the amendment of the Pfizer Note and 2018 Notes (as defined and described in Note 4), and iii) the issuance, to both Pfizer and the holders of the 2018 Notes, of conditional warrants by BioAtla Holdings and Inversagen which become exercisable upon the conversion of the Pfizer Note and 2018 Notes into capital stock of the Post-Division Successor (see Note 4).</font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The Post-Division Successor converted to a Delaware corporation in July 2020 as part of the Corporate Reorganization defined and described below, and was renamed BioAtla, Inc. BioAtla, Inc. is the final successor to the Pre-Division Predecessor and the Post-Division Successor, and collectively these entities are referred to as &#x201c;the Company.&#x201d; The historical financial statements of the Company prior to the Corporate Reorganization are those of the Pre-Division Predecessor and the Post-Division Successor without adjustment.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Corporate Reorganization and Series D Financing</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">In July 2020, BioAtla, LLC (the Post-Division Successor) completed a series of transactions (the &#x201c;Corporate Reorganization&#x201d;) in connection with the conversion from a limited liability company into a Delaware corporation, the spin-off of Himalaya Therapeutics SEZC, and the completion of a Series D convertible preferred stock financing. The Corporate Reorganization involved the formation of Himalaya Parent LLC as a wholly owned subsidiary of BioAtla, LLC and the formation of BioAtla MergerSub LLC, as a wholly owned subsidiary of Himalaya Parent LLC. Under the Agreement and Plan of Merger (the &#x201c;Merger Agreement&#x201d;), BioAtla, LLC was merged into and with BioAtla MergerSub LLC, with BioAtla, LLC surviving, and the members of BioAtla, LLC immediately prior to the effective time of the Merger Agreement received membership interests, on a one-for-one basis, of Himalaya Parent LLC as consideration, and the then-outstanding warrants to purchase equity of BioAtla, LLC were converted into warrants to purchase common shares of common stock of BioAtla, Inc. (see Note 7). The Himalaya Parent</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">100</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">LLC operating agreement provided identical equity rights for the then outstanding units of BioAtla, LLC. In addition: (i) the membership interests of BioAtla, LLC held by Himalaya Parent LLC were exchanged for 6,220,050 shares of BioAtla, Inc. common stock, (ii) BioAtla, Inc. issued an aggregate of 59,164,808 shares of Series D convertible preferred stock to Himalaya Parent LLC and Himalaya Parent LLC issued an aggregate of 59,164,808 Class D units to the holders of convertible notes of BioAtla, LLC in connection with the conversion of their convertible notes into Class D units of Himalaya Parent LLC (see Note 4), (iii) BioAtla, LLC distributed to Himalaya Parent LLC its equity interests in Himalaya Therapeutics SEZC, a then majority-owned subsidiary which is engaged in the development of a set of antibodies in the field of oncology primarily in Greater China, (iv) Himalaya Parent LLC assumed the profits interest liability of BioAtla, LLC (see Note 8) and (v) BioAtla, LLC converted into a Delaware corporation pursuant to a statutory conversion and changed its name to BioAtla, Inc. Following the Corporate Reorganization, Himalaya Parent LLC owned 59,164,808 shares of BioAtla, Inc. Series D convertible preferred stock and 6,220,050 shares of BioAtla, Inc. common stock, all of which were subsequently distributed (&#34;the Distribution&#34;) to the members of Himalaya Parent, LLC. As a result of the sale of 140,626,711 shares of Series D convertible preferred stock to new investors in July 2020 (see Note 7), BioAtla, Inc. was not controlled by Himalaya Parent LLC and BioAtla, Inc. does not control Himalaya Parent LLC subsequent to the distribution discussed in item (iii) above (see further discussion in &#x201c;Principles of consolidation and deconsolidation&#x201d; below). All pre-Corporate Reorganization operations, employees, property, assets and obligations of BioAtla, LLC (exclusive of the profits interest liability and Himalaya Therapeutics SEZC now held by Himalaya Parent LLC) are held by BioAtla, Inc. Shares of Series D convertible preferred stock were subsequently converted into common stock as part of the Company&#x2019;s initial public offering (&#x201c;IPO&#x201d;) in December 2020.</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Reverse Stock Split</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">On December 2, 2020, the Company effected a 1-for-13 reverse stock split of its common stock. The par value and the authorized shares of the common stock were not adjusted as a result of the reverse stock split. The reverse stock split resulted in an adjustment to the convertible preferred stock conversion price to reflect a proportional decrease in the number of shares of common stock to be issued upon conversion. The accompanying financial statements and notes to the financial statements give retroactive effect to the reverse stock split. No adjustments have been made to any period for the units outstanding prior to the LLC Conversion.</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Principles of Consolidation and Deconsolidation</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Prior to the Corporate Reorganization in July 2020, the consolidated financial statements included the accounts of BioAtla, LLC and those of its majority owned subsidiary Himalaya Therapeutics SEZC that had no material operations. Himalaya Therapeutics SEZC also had a wholly owned subsidiary, Himalaya Therapeutics HK Limited that had no material operations. All intercompany balances were eliminated in consolidation. In connection with the Corporate Reorganization, Himalaya Therapeutics SEZC and Himalaya Therapeutics HK Limited were deconsolidated without material impact to the consolidated financial statements. Subsequent to the Corporate Reorganization and subsequent to the Distribution as defined and described above, Himalaya Parent LLC does not control, is not under common control with, and is not consolidated by BioAtla, Inc. and BioAtla, Inc. is a single legal entity with no consolidated variable interest entities (&#34;VIEs&#34;) or subsidiaries (see Note 10).</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Liquidity and Going Concern</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The Company has incurred cumulative operating losses and negative cash flows from operations since its inception and expects to continue to incur significant expenses and operating losses for the foreseeable future as it continues the development of its product candidates. As of December 31, 2021, the Company had an accumulated deficit of $186.3 million. The Company plans to continue to fund its losses from operations and capital funding needs through public or private equity or debt financings or other sources. If the Company is not able to secure adequate additional funding, the Company may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, or suspend or curtail planned programs. Any of these actions could materially harm the Company&#x2019;s business, results of operations and future prospects.</font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Management is required to perform a two-step analysis of the Company&#x2019;s ability to continue as a going concern. Management must first evaluate whether there are conditions and events that raise substantial doubt about the Company&#x2019;s ability to continue as a going concern (Step 1). If management concludes that substantial doubt is raised, management is also required to consider whether its plans alleviate that doubt (Step 2). Management&#x2019;s assessment included the preparation of cash flow forecasts resulting in management&#x2019;s conclusion that there is not substantial doubt about the Company&#x2019;s ability to continue as a going concern for 12 months after the date the consolidated financial statements for the year ended December 31, 2021 are issued.</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Variable Interest Entities</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The Company consolidates entities in which it has a controlling financial interest. The Company determines whether it has a controlling financial interest in an entity by first evaluating whether the entity is a voting interest entity or a variable interest entity (&#x201c;VIE&#x201d;). VIEs are entities in which (i) the total equity investment at risk is sufficient to enable the entity to finance its activities independently, (ii) the equity holders have the power to direct the activities of the entity that most significantly impact its economic performance, the obligation to absorb the losses of the entity and the right to receive the residual returns of the entity and (iii) the legal entity is structured with substantive voting rights. A VIE is an entity that lacks one or more of the characteristics of a voting interest entity. The Company has a controlling financial interest in a VIE when the Company has a variable interest or interests that provide it with (i) the power to direct the activities of the VIE that most significantly impact the VIE&#x2019;s economic performance and (ii) the obligation to absorb losses of the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE. The Company evaluates its relationships with its VIEs on an ongoing basis to determine whether or not it has a controlling financial interest (see Notes 10 and 12).</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">101</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Use of Estimates</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The Company&#x2019;s consolidated financial statements are prepared in accordance with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;). The preparation of the Company&#x2019;s consolidated financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company&#x2019;s consolidated financial statements and accompanying notes. The most significant estimates in the Company&#x2019;s consolidated financial statements relate to revenue recognition, accruals for research and development costs, equity-based compensation and fair value measurements. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of revenue and expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company&#x2019;s future results of operations will be affected.</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:10.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Segment Reporting</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment.</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Cash and Cash Equivalents</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The Company considers all highly liquid investments with original maturities of three months or less when purchased to be cash equivalents.</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Concentrations of Risk</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Financial instruments that potentially subject the Company to a significant concentration of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">For the years ended December 31, 2021, 2020, and 2019,  BeiGene, as defined and described in Note 9, represented 0%, 100% and 91%, respectively, of total revenues.</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Property and Equipment</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Property and equipment are stated at cost and depreciated on a straight-line basis over the estimated useful life of the related assets. Leasehold improvements are stated at cost and amortized on a straight-line basis over the lesser of the remaining term of the related lease or the estimated useful life of the leasehold improvements. Repairs and maintenance costs are charged to expense as incurred and expenditures that materially extend the useful lives of assets are capitalized.</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Impairment of Long-Lived Assets</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The Company reviews long-lived assets, such as property and equipment, for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured as the amount by which the carrying amount of the assets exceeds the fair value of the assets. Fair value would be assessed using discounted cash flows or other appropriate measures of fair value. The Company has not recognized any impairment losses for the years ended December 31, 2021, 2020, and 2019.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Leases</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The Company adopted the Accounting Standard Update (&#x201c;ASU&#x201d;) 2016-02, Leases, and additional ASUs issued to clarify and update the guidance in ASU 2016-02 (collectively, &#x201c;ASC 842&#x201d;), as of January 1, 2021. See the section Recently Adopted Accounting Pronouncements below for more information.</font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The Company determines if an arrangement is a lease at inception. An arrangement is or contains a lease if it conveys the right to control the use of an identified asset for a period of time in exchange for consideration. If a lease is identified, classification is determined at lease commencement. Operating lease liabilities are recognized at the present value of the future lease payments at the lease commencement date. The Company&#x2019;s leases do not provide an implicit interest rate and therefore the Company estimates its incremental borrowing rate to discount lease payments. The incremental borrowing rate reflects the interest rate that the Company would have to pay to borrow on a collateralized basis an amount equal to the lease payments in a similar economic environment over a similar term. Operating lease right-of-use (&#x201c;ROU&#x201d;) assets are based on the corresponding lease liability adjusted for any lease payments made at or before commencement, initial direct costs, and lease incentives. Renewals or early terminations are not accounted for unless the Company is reasonably certain to exercise these options. Operating lease expense is recognized and the ROU asset is amortized on a straight-line basis over the lease term. Variable lease costs are not included in the calculation of the ROU asset and the related lease liability and are recognized as incurred. <br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">102</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The Company has a single lease agreement with lease and non-lease components, which are accounted for as a single lease component. The Company elected to use the transition relief package of practical expedients but did not elect to use the hindsight practical expedient in determining a lease term and impairment of ROU assets at the adoption date. For short-term leases, defined as leases with a term of twelve months or less, the Company elected the practical expedient to not recognize an associated lease liability and ROU asset. Lease payments for short-term leases are expensed on a straight-line basis over the lease term. The Company does not currently have any short-term leases. <br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Operating leases are included in operating lease right-of-use assets, operating lease liabilities, and operating lease liabilities, non-current on the Company&#x2019;s consolidated balance sheets. The Company does not have any finance leases.<br><br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Lease Accounting Prior to the Adoption of ASC 842</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">For operating leases, the Company recorded rent expense using the straight-line method over the lease term, which includes the period of time from when the Company takes possession of the leased space until leasehold improvements are completed and the space is occupied. The difference between rent expense and amounts paid under the lease agreement is deferred in the accompanying consolidated balance sheets. Tenant improvement allowances and other lease incentives are recorded as liabilities and are amortized on the straight-line basis over the lease term as reductions to rent expense.</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Beneficial Conversion Features</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">A beneficial conversion feature is a non-detachable conversion feature that is &#x201c;in the money&#x201d; at the commitment date, which requires recognition of interest expense for underlying debt instruments and a deemed dividend for underlying equity instruments. A conversion option is &#x201c;in the money&#x201d; if the effective conversion price is lower than the commitment date fair value of the share into which it is convertible.</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Accounting for Derivatives</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The Company evaluates its convertible instruments and other contracts to determine if those contracts or embedded components of those contracts are required to be recognized under Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 815,</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;"> Derivatives and Hedging</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">. The result of this accounting treatment is that the derivative is carried at fair value as an asset or liability with changes in fair value recognized in earnings as they occur. Although separately measured at fair value, the fair value of bifurcated embedded derivatives is presented with the host contract in the consolidated balance sheets. Changes in the fair value of derivatives are recorded in the accompanying consolidated statements of operations and comprehensive loss as a component of other income (expense).</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Revenue Recognition</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The Company recognizes revenue in a manner that depicts the transfer of control of a product or a service to a customer and reflects the amount of the consideration the Company is entitled to receive in exchange for such product or service. In doing so, the Company follows a five-step approach: (i) identify the contract with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations, and (v) recognize revenue when (or as) the customer obtains control of the product or service. The Company considers the terms of a contract and all relevant facts and circumstances when applying the revenue recognition standard.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">A customer is a party that has entered into a contract with the Company, where the purpose of the contract is to obtain a product or a service that is an output of the Company&#x2019;s ordinary activities in exchange for consideration. To be considered a contract, (i) the contract must be approved (in writing, orally, or in accordance with other customary business practices), (ii) each party&#x2019;s rights regarding the product or the service to be transferred can be identified, (iii) the payment terms for the product or the service to be transferred can be identified, (iv) the contract must have commercial substance (that is, the risk, timing or amount of future cash flows is expected to change as a result of the contract), and (v) it is probable that the Company will collect substantially all of the consideration to which it is entitled to receive in exchange for the transfer of the product or the service.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">A performance obligation is defined as a promise to transfer a product or a service to a customer. The Company identifies each promise to transfer a product or a service (or a bundle of products or services, or a series of products and services that are substantially the same and have the same pattern of transfer) that is distinct. A product or a service is distinct if both (i) the customer can benefit from the product or the service either on its own or together with other resources that are readily available to the customer and (ii) the Company&#x2019;s promise to transfer the product or the service to the customer is separately identifiable from other promises in the contract. Each distinct promise to transfer a product or a service is a unit of accounting for revenue recognition. If a promise to transfer a product or a service is not separately identifiable from other promises in the contract, such promises should be combined into a single performance obligation.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The transaction price is the amount of consideration the Company is entitled to receive in exchange for the transfer of control of a product or a service to a customer. To determine the transaction price, the Company considers the existence of any significant financing component, the effects of any variable elements, noncash consideration and consideration payable to the customer. If a significant financing component exists, the transaction price is adjusted for the time value of money. If an element of variability exists, the Company must estimate the consideration it expects to receive and uses that amount as the basis for recognizing revenue as the product or the service is transferred to the customer. There are two methods for determining the amount of variable consideration: (i) the expected value method, which is the sum of probability-weighted amounts in a range of possible consideration amounts, and (ii) the mostly likely amount method, which identifies the single most likely amount in a range of possible consideration amounts.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">103</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">If a contract has multiple performance obligations, the Company allocates the transaction price to each distinct performance obligation in an amount that reflects the consideration the Company is entitled to receive in exchange for satisfying each distinct performance obligation. For each distinct performance obligation, revenue is recognized when the Company transfers control of the product or the service applicable to such performance obligation.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">In those instances where the Company first receives consideration in advance of satisfying its performance obligation, the Company classifies such consideration as deferred revenue until (or as) the Company satisfies such performance obligation. In those instances where the Company first satisfies its performance obligation prior to its receipt of consideration, the consideration is recorded as accounts receivable.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The Company expenses incremental costs of obtaining and fulfilling a contract as incurred if the expected amortization period of the asset that would be recognized is one year or less, or if the amount of the asset is immaterial. Otherwise, such costs are capitalized as contract assets if they are incremental to the contract and amortized to expense proportionate to revenue recognition of the underlying contract.</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Research and Development Expenses</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The Company&#x2019;s activities have largely consisted of research and development efforts related to developing our CAB programs.  Research and development expenses consist of expenses incurred in performing research and development activities including salaries and benefits, facilities and other overhead expenses, clinical trials, contract services and other outside expenses. Research and development expenses are charged to expense as incurred. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and are reflected in the accompanying consolidated balance sheets as prepaid or accrued expenses. When evaluating the adequacy of the accrued expenses, the Company analyzes progress of the services, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company&#x2019;s estimates.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">As of December 31, 2021, the Company has accrued $6.2 million related to clinical trial costs. The Company has entered into contracts related to its clinical trials with clinical research organizations. The Company reviews and accrues clinical trial costs based on work performed, which relies on estimates of total trial management costs, sites activated, patients enrolled, and number of patient visits. The Company follows this method since reasonably dependable estimates of the costs applicable to clinical trials can be made. Accrued clinical trial costs are subject to revisions as the trials progress. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. Historically, revisions have not resulted in material changes to research and development expense; however, a modification in the protocol of a clinical trial or cancellation of a trial could result in a change to the Company's results of operations.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">  </font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Patent Costs</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Costs related to filing and pursuing patent applications are recorded as general and administrative expenses and expensed as incurred since recoverability of such expenditures is uncertain.</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Equity-Based Compensation Related to Profits Interest Plan</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Prior to the Corporate Reorganization in July 2020, the Company had a profits interest plan that was a liability award plan in accordance with ASC Topic 718,</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;"> Compensation &#x2013; Stock Compensation (Topic 718)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">. The Company measured the fair value of each award on the grant date and recognized such fair value over the requisite service period (usually the vesting period) on a straight-line basis. The fair value of the award was remeasured at each reporting date until the award was settled, with a true-up of compensation cost for changes in fair value prorated for the portion of the requisite service period rendered. Once vested, any subsequent change in fair value was recognized immediately. The fair value of any awards that expired or were forfeited or canceled for no value was adjusted to zero, as they occurred, such that any previously recorded compensation cost would be fully reversed. Subsequent to the Corporate Reorganization and amendment of the profits interest plan by Himalaya Parent in October 2020, the Company no longer reflects compensation cost and a corresponding capital contribution associated with the ongoing mark-to-market of the Class B profits interests held by Himalaya Parent LLC.</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Stock-Based Compensation</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Stock-based compensation expense represents the grant date fair value of equity awards, consisting of stock options, restricted stock units (&#x201c;RSUs&#x201d;) and employee stock purchase plan rights, over the requisite service period of the awards (usually the vesting period) on a straight-line basis. The Company estimates the fair value of stock option grants and employee stock purchase plan rights using the Black-Scholes option pricing model. Prior to the Company&#x2019;s IPO, the fair value of RSUs was based on the estimated fair value of the underlying common stock on the date of grant and, subsequent to the Company&#x2019;s IPO, the fair value is based on the closing sales price of the Company&#x2019;s common stock on the date of grant. Equity award forfeitures are recognized as they occur.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">104</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Income Taxes</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized as income in the period that includes the enactment date.<br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, exclusive of reversing temporary difference, tax-planning strategies, and the results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.<br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The Company records uncertain tax positions on the basis of a two-step process whereby (1) management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, management recognizes the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits within income tax expense. Any accrued interest and penalties are included within the related tax liability.</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Comprehensive Loss</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances from non-owner sources. There have been no items qualifying as other comprehensive loss and, therefore, for all periods presented, the Company&#x2019;s comprehensive loss was the same as its reported net loss.</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Net Loss Per Unit/Share</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Prior to the Corporate Reorganization, the Company applied the two-class method for calculating and presenting net loss per unit. In applying the two-class method, earnings are hypothetically allocated between the common, preferred, and other participating securities based on their respective rights to receive non-forfeitable distributions, whether or not declared. The Company considered its Class A units to be its &#x201c;common units&#x201d; since Class A units were the most subordinate class of equity with respect to preference in liquidation. In addition, the Class C units were entitled to a preferred return equal to 10% per annum, simple interest, on the Class C issuance price. The Company&#x2019;s Class B units were excluded from the net loss per unit calculations based on the presumption that the units would be settled in cash pursuant to the terms of the Company&#x2019;s operating agreement. Basic net loss per Class A unit was calculated by dividing net loss allocable to Class A unit holders (after adjustment for Class C preferred return and allocation of net losses to Class C units) by the weighted-average number of Class A units outstanding during the period. The Company calculated diluted net loss per unit using the more dilutive of 1) the treasury stock method, if-converted method, or contingently issuable share method, as applicable, or 2) the two-class method. For the year ended December 31, 2019, the basic and diluted net loss per unit were the same as the inclusion of outstanding warrants, convertible debt or Class C preferred units would be antidilutive.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Subsequent to the Corporate Reorganization, basic net loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common shares and dilutive common stock equivalents outstanding for the period determined using the treasury-stock method. Dilutive common stock equivalents are comprised of common stock warrants, RSUs, and common stock options outstanding under the Company&#x2019;s stock option plan.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">For the year ended December 31, 2020, the Company determined that the attribution of pre-Corporate Reorganization net losses based on the post-Corporate Reorganization capital structure would not meaningfully represent the economic rights of the unit holders. As a result, the Company presents net loss per share information only for the period subsequent to the Corporate Reorganization. The basic and diluted net loss per share for the year ended December 31, 2020 represents only the period from July 10, 2020 to December 31, 2020, the period where the Company had outstanding common stock.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">105</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The following table presents the calculation of basic and diluted net loss per share for the period following the Corporate Reorganization (in thousands, except share and per share data):</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:76.88%;"></td>
    <td style="width:1.817%;"></td>
    <td style="width:20.082%;"></td>
    <td style="width:1.22%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">July 10, 2020<br>through<br>December 31,<br>&#160;2020</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Numerator:</font></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Net loss</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(26,877</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Denominator:</font></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Weighted-average shares of common stock outstanding, basic and diluted</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">8,428,153</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Net loss per common share, basic and diluted</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(3.19</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
   </tr>
  </table>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Potentially dilutive securities not included in the calculation of diluted net loss per share because to do so would be anti-dilutive are as follows (in common stock equivalents):</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:63.286%;"></td>
    <td style="width:0.888%;"></td>
    <td style="width:16.256%;"></td>
    <td style="width:0.756%;"></td>
    <td style="width:0.915%;"></td>
    <td style="width:0.888%;"></td>
    <td style="width:16.256%;"></td>
    <td style="width:0.756%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">December 31,<br>2021</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">December 31,<br>2020</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Common stock warrants</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">151,088</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">717,674</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Common stock options</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1,086,902</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">615,106</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Restricted stock units</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">975,046</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1,920,037</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Total</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">2,213,036</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">3,252,817</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:5.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Recent Accounting Pronouncements</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Under the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, emerging growth companies (&#x201c;EGC&#x201d;) can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company elected to retain the ability to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that the Company (i) is no longer an emerging growth company or (ii) affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. The Company lost its emerging growth company status on December 31, 2021 because the Company became a large accelerated filer due to the fact that the Company&#x2019;s public float exceeded $700 million as of the June 30, 2021 measurement date.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The Company adopted the following accounting standards during the year ended December 31, 2021:</font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">In February 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued ASU No. 2016-02, Leases. The new standard establishes a right-of-use model and requires a lessee to recognize on the balance sheet a right-of-use asset and corresponding lease liability for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. Effective January 1, 2021, the Company adopted this new standard prospectively using a modified retrospective transition approach. The Company elected the package of practical expedients permitted under the transition guidance of the new standard, which allowed the Company to carry forward its historical assessment on whether a contract is or contains a lease, lease classification, and initial direct costs. Upon adoption on January 1, 2021, the Company recognized operating lease ROU assets of $4.1 million, and current and non-current operating lease liabilities of $1.1 million and $5.4 million, respectively. The difference between the asset and liabilities is primarily attributable to adjustments to the right-of-use asset at transition related to lease incentives and deferred rent. The adoption of ASC 842 did not have a material impact to Company&#x2019;s consolidated statements of operations and cash flows from operations.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">In December 2019, the FASB issued ASU No. 2019-12 Income Taxes (Topic 740) Simplifying the Accounting for Income Taxes. The Board issued this Update as part of its Simplification Initiative to improve areas of GAAP and reduce cost and complexity while maintaining usefulness. The main provisions remove certain exceptions including the exception to the general methodology for calculating income taxes in an interim period when a year-to-date loss exceeds the anticipated loss for the year. In addition, the amendments simplify income tax accounting in the areas such as income-based franchise taxes, eliminating the requirements to allocate consolidated current and deferred tax expense in certain instances, and a requirement that an entity reflects the effect of enacted changes in tax laws or rates in the annual effective tax rate computation in the interim period that includes the enactment date. For public companies, the standard is effective for fiscal years beginning after December 15, 2020 and interim periods therein. The Company adopted ASU 2019-12 on the effective date of January 1, 2021. The amendments were applied on a prospective basis and the adoption did not have a significant impact on the Company's financial results.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">106</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">2. Balance sheet details</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Prepaid expenses and other current assets consist of the following (in thousands):</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:65.572%;"></td>
    <td style="width:1.566%;"></td>
    <td style="width:1.543%;"></td>
    <td style="width:13.432%;"></td>
    <td style="width:0.673%;"></td>
    <td style="width:1.566%;"></td>
    <td style="width:1.543%;"></td>
    <td style="width:13.432%;"></td>
    <td style="width:0.673%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">December 31,</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">2021</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">2020</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Prepaid research and development</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1,811</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">2,004</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Other prepaid expenses and current assets</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">502</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">72</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Total</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">2,313</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">2,076</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Property and equipment consist of the following (in thousands):</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:54.821%;"></td>
    <td style="width:1.299%;"></td>
    <td style="width:13.18%;"></td>
    <td style="width:1.299%;"></td>
    <td style="width:1.52%;"></td>
    <td style="width:11.533%;"></td>
    <td style="width:0.998%;"></td>
    <td style="width:1.299%;"></td>
    <td style="width:1.52%;"></td>
    <td style="width:11.533%;"></td>
    <td style="width:0.998%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">December 31,</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Useful life (years)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">2021</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">2020</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Furniture, fixtures and office equipment</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">3 - 7</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">2,123</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1,719</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Laboratory equipment</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">5</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">2,123</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1,790</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Leasehold improvements</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">2 - 3</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">3,687</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">3,663</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">7,933</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">7,172</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Less accumulated depreciation and amortization</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(4,257</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(3,070</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Total</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">3,676</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">4,102</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Accounts payable and accrued expenses consist of the following (in thousands):</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:65.248%;"></td>
    <td style="width:1.554%;"></td>
    <td style="width:1.531%;"></td>
    <td style="width:13.618%;"></td>
    <td style="width:0.673%;"></td>
    <td style="width:1.554%;"></td>
    <td style="width:1.531%;"></td>
    <td style="width:13.618%;"></td>
    <td style="width:0.673%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">December 31,</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">2021</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">2020</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Accounts payable</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1,179</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">2,456</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Accrued compensation</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">2,671</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">2,804</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Accrued research and development</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">13,501</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">4,852</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Accrued equity issuance costs</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1,143</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Other accrued expenses</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1,073</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">813</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Total</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">18,424</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">12,068</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:5.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">3. Fair value measurements</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The carrying amounts of the Company&#x2019;s current financial assets and current financial liabilities are considered to be representative of their respective fair values because of the short-term nature of those instruments. As of December 31, 2021 and December 31, 2020, the Company had no financial assets or liabilities measured at fair value on a recurring basis. <br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or non-recurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:<br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Level 1: Observable inputs such as quoted prices in active markets.<br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Level 2: Inputs, other than the quoted prices in active markets that are observable either directly or indirectly.<br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.<br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">None of the Company&#x2019;s non-financial assets and liabilities are recorded at fair value on a non-recurring basis. No transfers between levels have occurred during the periods presented.<br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The 2018 Notes (as amended in 2020), the 2019 Notes and the 2020 Notes (each as defined and described in Note 4) contained a redemption feature which was determined to be an embedded derivative requiring bifurcation and separate accounting. The fair value of the derivative was determined based on an income approach that identified the cash flows using a &#x201c;with-and-without&#x201d; valuation methodology. The</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">107</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">inputs used to determine the estimated fair value of the derivative instrument were based primarily on the probability of an underlying event triggering the embedded derivative occurring and the timing of such event.</font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The following table provides a reconciliation of the embedded derivative liability measured at fair value using Level 3 unobservable inputs (in thousands):</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:75.213%;"></td>
    <td style="width:1.749%;"></td>
    <td style="width:2.198%;"></td>
    <td style="width:19.368%;"></td>
    <td style="width:1.471%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Embedded<br>derivative<br>liability</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Balance at December 31, 2019</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1,856</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Initial fair value of embedded derivatives issued</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">3,415</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Change in fair value</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1,581</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Settlement</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(6,852</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Balance at December 31, 2020</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:5.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">4. Convertible and other debt</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:5.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Pfizer convertible promissory note</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">In December 2015, the Company issued a $10.0 million unsecured convertible promissory note (&#x201c;Pfizer Note&#x201d;) to certain affiliates of Pfizer, Inc. (&#x201c;Pfizer&#x201d;). The Pfizer Note accrued interest at 8.0% per annum with a maturity date in December 2020. Prior to amendment in March 2019 as described below, the Pfizer Note, including accrued interest, was convertible at the election of the holder into Class C preferred units at a price of $3.394142 per unit and was automatically convertible into i) common shares upon the completion of an IPO based on the price per share paid by investors in the IPO or ii) qualified financing shares upon the completion of a qualified financing based on the price per share paid by investors in the qualified financing. The Company assessed the terms of the Pfizer Note and concluded that it was not share-settled debt, did not contain any embedded derivative features requiring bifurcation and did not contain a beneficial conversion feature. As a result, the Pfizer Note was carried at cost since the Company did not incur a material amount of issuance costs in connection with the debt.</font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The Pfizer Note was amended in March 2019 in connection with the Division to provide the lender additional accrued interest upon conversion. The amended conversion amount of the Pfizer Note was equal to the greater of a) the then outstanding principal plus accrued interest, or b) principal plus accrued interest through December 7, 2020. In connection with the March 2019 amendment, Pfizer received conditional warrants in BioAtla Holdings and Inversagen which allowed Pfizer to acquire an equity interest in each of BioAtla Holdings and Inversagen upon conversion of the Pfizer Note of the Post-Division Successor. The amendment of the Pfizer Note was accounted for as a modification, which required prospective consideration of the revised terms. The Company recognized the initial fair value of the warrants of $0.5 million as a fee paid by the Company to the lenders, which was recorded as debt discount on the modified debt and as a capital contribution, as the warrants</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">were written on two entities under common control that were not consolidated with the Company. The debt discount was amortized to interest expense using the effective interest method over the term of the Pfizer Note. The fair value of the conditional warrants was determined using the Option Pricing Method based on the underlying value of the assets allocated to BioAtla Holdings and Inversagen. The Company incurred interest expense in connection with the Pfizer Note of $0.6 million and $1.0 million for the years ended December 31, 2020 and 2019. As further described below, the Pfizer Note was amended and settled in connection with the Corporate Reorganization in July 2020.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">2018 convertible promissory notes</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">In August 2018, the Company issued unsecured convertible promissory notes for an aggregate of $5.0 million (the &#x201c;2018 Notes&#x201d;). The 2018 Notes accrued interest at 8.0% per annum with a maturity date in July 2023. Prior to amendment in March 2019, as described below, the then outstanding principal plus accrued interest under the 2018 Notes was convertible at the election of the holder into Class C preferred units at a price of $3.394142 per unit and was automatically convertible into i) common shares upon the completion of an IPO based on the price per share paid by investors in the IPO or ii) qualified financing shares upon the completion of a qualified financing based on the price per share paid by investors in the qualified financing. The Company assessed the terms of the 2018 Notes and concluded that they were not share-settled debt, did not contain any embedded derivative features requiring bifurcation and did not contain a beneficial conversion feature. As a result, the 2018 Notes were carried at cost since the Company did not incur a material amount of issuance costs in connection with the issuance of the promissory notes.</font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The 2018 Notes were amended in March 2019 in connection with the Division to provide the lenders additional accrued interest upon conversion. The amended conversion amount of the 2018 Notes was equal to the greater of a) the then outstanding principal plus accrued interest, or b) principal plus accrued interest through December 7, 2020. In connection with the March 2019 amendment, the lenders received conditional warrants in BioAtla Holdings and Inversagen which allowed them to acquire an equity interest in each of BioAtla Holdings and Inversagen upon conversion of the 2018 Notes of the Post-Division Successor. The amendment of the 2018 Notes was accounted for as a modification, which required prospective consideration of the revised terms. The Company recognized the initial fair value of the warrants of $0.2 million as a fee paid by the Company to the lenders, which was recorded as debt discount on the modified debt and as a capital contribution, as the warrants were written on two entities under common control that were not consolidated with the Company. The debt discount was amortized to interest expense using the effective interest method over the term of the 2018 Notes. The fair value of the conditional warrants was determined using the Option Pricing Method based on the underlying value of the assets allocated to BioAtla Holdings. The underlying value of the assets allocated to Inversagen was immaterial.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">108</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The 2018 Notes were amended in April 2020 to add a discount to the conversion prices such that they were convertible (i) automatically into preferred stock upon a qualified equity financing, with a conversion price of 80% of the lowest purchase price per share of preferred stock paid by investors in such qualified equity financing, (ii) automatically convert into common stock upon an initial public offering, with a conversion price of 80% of the price per share of common stock paid by investors in such initial public offering, and (iii) upon the election of each note holder, into Class C preferred units, with a conversion price per share of $2.7153136. The Company concluded that the amendment was an extinguishment and the fair value of the amended 2018 Notes was equal to the then outstanding principal and accrued interest of the 2018 Notes. As a result, the Company recognized a loss on extinguishment for the $0.2 million of unamortized discounts at the extinguishment date.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">In addition, the Company assessed the terms and concluded the amended 2018 Notes: (i) were not share-settled debt, (ii) contained a redemption feature that was determined to be an embedded derivative requiring bifurcation and (iii) did not contain a beneficial conversion feature. The $2.2 million issuance date fair value of the embedded derivative liability was recorded as a debt discount and amortized to interest expense using the effective interest method over the remaining term of the 2018 Notes.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The Company incurred interest expense, including coupon interest and amortization of debt discounts, in connection with the 2018 Notes of $0.4 million and $0.4 million for the years ended December 31, 2020 and 2019, respectively. As further described below, the 2018 Notes were amended and settled in connection with the Corporate Reorganization in July 2020.</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">2019 convertible promissory notes</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Between August and December 2019, the Company issued unsecured convertible promissory notes payable to various entities in an aggregate principal amount of $4.0 million (the &#x201c;2019 Notes&#x201d;), of which $1.5 million was to related parties. The 2019 Notes accrued interest at 8.0% per annum with maturity dates of five years after issuance. The outstanding principal amount and any accrued and unpaid interest on the 2019 Notes was due and payable on the earlier to occur of (i) the maturity date, (ii) an event of default, or (iii) immediately prior to an acquisition event. The 2019 Notes were convertible (i) automatically into preferred stock upon a qualified equity financing, with a conversion price of 80% of the lowest purchase price per share of preferred stock paid by investors in such qualified equity financing, (ii) automatically into common stock upon an initial public offering, with a conversion price of 80% of the price per share of common stock paid by investors in such initial public offering, and (iii) upon the election of each note holder, into Class C preferred units, with a conversion price per share of $2.7153136. The number of shares or units issuable upon conversion is determined by dividing the conversion amount by the conversion price, with the conversion amount equal to the greater of a) the then outstanding principal plus accrued interest, or b) principal plus accrued interest through December 7, 2020.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The Company assessed the terms and concluded the 2019 Notes: (i) were not share-settled debt, (ii) contained a redemption feature that was determined to be an embedded derivative requiring bifurcation and (iii) certain of the notes contained a beneficial conversion feature because the fair value of the securities into which the 2019 Notes were convertible at the time of issuance, the Class C preferred units, was greater than the effective conversion price of the 2019 Notes. The $0.5 million beneficial conversion feature was recorded as additional paid-in capital and a debt discount and the $1.8 million issuance date fair value of the embedded derivative liability was recorded as a debt discount, both of which discounts were amortized to interest expense using the effective interest method over the term of the 2019 Notes.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">In April and May of 2020 certain of the 2019 Notes, representing $2.5 million of the then outstanding principal balance, were amended such that the conversion shares or units issuable upon conversion is the greater of: (i) the then outstanding principal plus accrued interest divided by $0.86866 or (ii) the amount determined by dividing the conversion amount by the conversion price, with the conversion amount equal to the greater of a) the then outstanding principal plus accrued interest, or b) principal plus accrued interest through December 7, 2020. The amendment of the 2019 Notes was accounted for as a modification, which required prospective consideration of the revised terms.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">For the year ended December 31, 2020 and 2019, the Company recognized interest expense, including coupon interest and amortization of debt discounts, in connection with the 2019 Notes of $0.3 million and $0.1 million, respectively. As further described below, the 2019 Notes were amended and settled in connection with the Corporate Reorganization in July 2020.</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">2020 convertible promissory notes</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">During March, April and May of 2020 the Company issued unsecured convertible promissory notes (the &#x201c;2020 Notes&#x201d;) payable to various entities in an aggregate principal amount of $2.8 million, of which $0.5 million was to related parties. The 2020 Notes accrued interest at 8.0% per annum with maturity dates of five years after issuance. The Company assessed the terms and concluded the 2020 Notes: (i) were not share-settled debt,(ii) contained a redemption feature that was determined to be an embedded derivative requiring bifurcation and (iii) did not contain a beneficial conversion feature. The $1.2 million issuance date fair value of the embedded derivative liability was recorded as a debt discount which was amortized to interest expense using the effective interest method over the term of the 2020 Notes. In May of 2020 certain of the 2020 Notes, representing $0.1 million of the then outstanding principal balance, were amended such that the conversion shares or units issuable upon conversion is the greater of: (i) the then outstanding principal plus accrued interest divided by $0.86866 or (ii) the amount determined by dividing the conversion amount by the conversion price, with the conversion amount equal to the greater of a) the then outstanding principal plus accrued interest, or b) principal plus accrued interest through December 7, 2020. The amendment of the 2020 Notes was accounted for as a modification, which required prospective consideration of the revised terms.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">For the year ended December 31, 2020, the Company recognized interest expense, including coupon interest and amortization of debt discounts, in connection with the 2020 Notes of $0.1 million. As further described below, the 2020 Notes were amended and settled in connection with the Corporate Reorganization in July 2020.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">109</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Amendment and settlement of convertible notes</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">As a condition of the closing of the Series D financing in July 2020, the Pfizer Note, 2018 Notes, 2019 Notes and 2020 Notes (and together, the &#x201c;Convertible Notes&#x201d;) were amended to settle the Convertible Notes into 59,164,808 Class D units of Himalaya Parent LLC. As of the settlement date, the aggregate outstanding principal and accrued interest of the Convertible Notes was $21.8 million and $4.7 million, respectively. The Pfizer Note converted into Class D units at a conversion price of $0.51554931 and the 2018 Notes and 2019 Notes converted into Class D units at a conversion price of $0.412439448, which is 80% of the price paid by investors in the Series D financing. As of the July 10, 2020 settlement date, the Convertible Notes had a carrying value of $27.9 million, including related accrued interest, embedded derivatives and unamortized debt discounts. The fair value of the Class D units of Himalaya Parent LLC issued to the noteholders in exchange for the Convertible Notes was $30.6 million, resulting in a loss on extinguishment of convertible debt of $2.7 million. The fair value per unit of the Class D units of Himalaya Parent LLC was based on the fair value per share paid by investors in the Company&#x2019;s Series D financing.</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Other Debt</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">In April 2020, the Company borrowed $0.7 million under the Paycheck Protection Program (&#x201c;PPP&#x201d;) under the CARES Act. The loan <br>was subsequently forgiven in July 2021. The $0.7 million balance of the forgiven loan was recognized as other income on the Company's Statement of Operations and Comprehensive Loss for the twelve months ended December 31, 2021.</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">5. Leases</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The Company has a single operating lease for its corporate headquarters and laboratory space in San Diego, California. The lease expires in July 2025 and the Company has an option to extend the term of the lease for an additional five years. However, it is not reasonably certain the Company will exercise the option to renew when the lease term ends and thus, the incremental term was excluded from the calculation of the lease liability. Additionally, the lease includes certain rent abatement, rent escalations, tenant improvement allowances and additional charges for common area maintenance and other costs.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Supplemental balance sheet information related to lease liabilities at December 31, 2021, was as follows (in thousands):</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:38.847%;"></td>
    <td style="width:1.508%;"></td>
    <td style="width:34.358%;"></td>
    <td style="width:0.858%;"></td>
    <td style="width:1.531%;"></td>
    <td style="width:22.225%;"></td>
    <td style="width:0.673%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Lease-Related Assets and Liabilities</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Financial Statement Line Items</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">As of December 31, 2021</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Right-of-use assets:</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Operating leases</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Operating lease right-of-use assets</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">3,300</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Total right-of-use assets</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">3,300</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Lease Liabilities:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Operating leases</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Operating lease liabilities</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1,389</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Operating lease liabilities, noncurrent</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">3,982</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Total lease liabilities</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">5,371</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The components of lease expense included in the Company&#x2019;s consolidated statements of operations include (in thousands):</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:65.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:76.754%;"></td>
    <td style="width:1.843%;"></td>
    <td style="width:2.029%;"></td>
    <td style="width:18.531%;"></td>
    <td style="width:0.843%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Year Ended<br>December 31, 2021</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Operating lease expense</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1,043</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Variable lease expense</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">512</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Total lease expense, net</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1,555</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Variable lease costs are primarily related to payments made to lessors for common area maintenance, property taxes, insurance, and other operating expenses. The Company did not have any short-term leases or finance leases for the year ended December 31, 2021.</font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The weighted average remaining lease term and weighted average discount rate for operating leases as of December 31, 2021 were as follows:</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:65.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:74.686%;"></td>
    <td style="width:1.571%;"></td>
    <td style="width:1.157%;"></td>
    <td style="width:19.2%;"></td>
    <td style="width:3.386%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Year Ended<br>December 31, 2021</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Weighted average remaining lease term (in years)</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">3.5</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Weighted average discount rate percentage</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">3.50</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">%</font></p></td>
   </tr>
  </table>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Supplemental cash flow information related to leases under which the Company is the lessee was as follows (amounts in thousands):</font></p>
  <p style="text-indent:4.08%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:65.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:76.957%;"></td>
    <td style="width:1.814%;"></td>
    <td style="width:2.014%;"></td>
    <td style="width:18.371%;"></td>
    <td style="width:0.843%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Year Ended<br>December 31, 2021</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Cash paid for amounts included in the measurement of operating leases</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1,374</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">110</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Maturities of operating lease liabilities as of December 31, 2021 were as follows (in thousands):</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:65.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:76.4%;"></td>
    <td style="width:1.829%;"></td>
    <td style="width:2.029%;"></td>
    <td style="width:18.386%;"></td>
    <td style="width:1.357%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Years ending December 31:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Operating<br>lease</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">2022</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1,555</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">2023</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1,636</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">2024</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1,685</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">2025</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">845</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Thereafter</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Total future lease payments</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">5,721</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Less imputed interest</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(350</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Total operating lease liabilities</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">5,371</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">As of December 31, 2020, prior to the Company&#x2019;s adoption of ASC 842, annual minimum payments under noncancelable operating leases were as follows (in thousands):</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:65.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:76.854%;"></td>
    <td style="width:1.815%;"></td>
    <td style="width:2.015%;"></td>
    <td style="width:18.474%;"></td>
    <td style="width:0.843%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Years ending December 31:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Operating<br>lease</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">2021</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1,374</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">2022</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1,555</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">2023</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1,636</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">2024</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1,685</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Thereafter</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">845</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Total minimum lease payments</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">7,095</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Under ASC 840, during the years ended December 31, 2020 and 2019, net rent expense was $1.7 million and $1.1 million, respectively.</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">6. Commitments and contingencies</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">From time to time, the Company may be subject to various claims and suits arising in the ordinary course of business. The Company is not currently a party to any legal proceedings the outcome of which the Company believes, if determined adversely to the Company, would individually or in the aggregate have a material adverse effect on the Company&#x2019;s business, operating results or financial condition.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">7. Convertible preferred stock and members&#x2019;/stockholders&#x2019; equity (deficit)</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Convertible preferred stock</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The Company had convertible preferred stock outstanding between the date of its Series D financing in July 2020 until the closing of its IPO in December 2020. The Company&#x2019;s convertible preferred stock was classified as temporary equity in the accompanying consolidated balance sheets in accordance with authoritative guidance for the classification and measurement of potentially redeemable securities whose redemption is based upon certain change in control events outside of the Company&#x2019;s control, including liquidation, sale or change of control of the Company. Because these change in control events were not probable, the Company did not adjust the carrying values of the convertible preferred stock to redemption value.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Series D financing</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">On July 13, 2020, BioAtla, Inc. entered into a Series D Preferred Stock Purchase Agreement, pursuant to which it issued 140,626,711 shares of Series D convertible preferred stock at $0.51554931 per share, for aggregate cash proceeds of $72.5 million. The Company incurred $4.3 million of issuance costs.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Initial public offering and related transactions</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">In December 2020, the Company completed its IPO selling 12,075,000 shares its common stock at $18.00 per share. Proceeds from the Company&#x2019;s IPO, net of underwriting discounts and commissions and other offering costs, were $198.3 million. In connection with the IPO, all 199,791,519 shares of convertible preferred stock outstanding at the time of the IPO converted into 13,876,510 shares of the Company&#x2019;s common stock and 1,492,059 shares of the Company&#x2019;s Class B common stock.</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Private Placement of Common Stock</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;"> </font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">In September 2021, the Company entered into agreements to sell 2,678,600 shares of its common stock at a price of $28.00 per share through a private investment in public equity financing (or &#34;Private Placement&#34;). Proceeds from the Private Placement, net of underwriting discounts and commissions and other offering costs, were $71.0 million.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">111</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">In connection with the Private Placement, the Company also issued registration rights to the investors. The Company filed a registration statement on Form S-1 (File No. 333-260440) with the SEC registering for resale the shares of common stock issued in the Private Placement.<br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Description of securities of Delaware corporation</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The Company is authorized to issue 200,000,000 shares of preferred stock, par value $0.0001 per share, 350,000,000 shares of common stock, par value $0.0001 per share, and 15,368,569 shares of Class B common stock, par value $0.0001 per share.</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Dividends</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Subject to preferences that may be applicable to any outstanding shares of preferred stock, holders of the Company&#x2019;s common stock and Class B common stock are entitled to receive dividends only if declared from time to time by the Company&#x2019;s board of directors out of assets which are legally available.</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Liquidation preferences</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Upon any liquidation, dissolution or winding-up of the Company, holders of the Company&#x2019;s common stock and Class B common stock are entitled to share ratably in all assets remaining after payment of all liabilities and the liquidation preferences of any of our outstanding shares of preferred stock.</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Conversion</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Holders of the Company&#x2019;s common stock have no conversion rights, while holders of the Company&#x2019;s Class B common stock shall have the right to convert each share of Class B common stock into one share of common stock at such holder&#x2019;s election, provided that as a result of such conversion, such holder would not beneficially own in excess of 4.99% of any class of the Company&#x2019;s securities registered under the Securities Exchange Act of 1934, as amended, unless otherwise as expressly provided for in the Company&#x2019;s amended and restated certificate of incorporation. This ownership limitation may be increased or decreased to any other percentage designated by such holder of Class B common stock upon 61 days&#x2019; notice to the Company.</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Voting rights</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Except as otherwise expressly provided in the Company&#x2019;s amended and restated certificate of incorporation or as required by applicable law, on any matter that is submitted to a vote by the Company&#x2019;s stockholders, holders of the Company&#x2019;s common stock are entitled to one vote per share of common stock, and holders of the Company&#x2019;s Class B common stock are not entitled to any votes per share of Class B common stock, including for the election of directors.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Operating agreement</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Prior to the Corporate Reorganization, the Company&#x2019;s operating agreement, as amended and restated, provided for classes of units, allocation of profits and losses, distribution preferences, other member rights and management of the LLC. The operating agreement designated Class A units, Class B units and Class C preferred units. The Class B units and Class C preferred units were non-voting, except as required by law. The Class B units were liability awards pursuant to authoritative guidance and, as such, were reported at fair value outside of members&#x2019; deficit. Members were limited in their liability to their capital contributions.</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Common stock warrants</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The Company issued the warrants described below in 2016 in connection with certain advisory services. The warrants became exercisable upon our IPO for a period of 365 and 450 days.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Upon adoption of ASU No. 2018-07 on October 1, 2020, the measurement date of the warrants described below became fixed in accordance with the guidance, and such fair value was nominal since the warrants were deeply out-of-the-money. In December 2021, a total of 566,586 warrants with an exercise period of 365 days after our IPO expired unexercised. As of December 31, 2021 the remaining common stock warrants below are exercisable and expire as follows:</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:49.582%;"></td>
    <td style="width:1.533%;"></td>
    <td style="width:2.152%;"></td>
    <td style="width:20.511%;"></td>
    <td style="width:0.836%;"></td>
    <td style="width:1.533%;"></td>
    <td style="width:23.854%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Outstanding and exercisable</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Exercise price per share</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Expiration date</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">151,088</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">132.37</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">March 12, 2022</font></p></td>
   </tr>
  </table>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">112</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:5.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Noncontrolling interests</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">In December 2018, the Company issued a noncontrolling interest in HTKY in the form of ordinary shares in connection with the termination of a collaboration and license agreement. In addition to the ordinary shares issued, certain employees and shareholders of the Company purchased 19,000,000 ordinary shares of HTKY for an aggregate purchase price of $19,000, of which 5,000,000 were repurchased for $5,000 in March 2019. As of December 31, 2019, the Company held all of the outstanding HTKY preferred equity, consisting of 97,183,256 Series B convertible preference shares, and 1,000 ordinary shares. The Series B convertible preference shares had a liquation preference equal to the greater of $1.00 per share, plus declared and unpaid dividends, or the if-converted value, and pay non-cumulative dividends in preference to the holders of ordinary shares at an annual rate of 7% of the purchase price per share when, as and if declared by the board. The net income (loss) of HTKY was allocated to the ordinary shareholders on a pro rata basis. However, any net income was initially be allocated to the preference shares until the liquidation preference is met. Thereafter, preference shares would only be allocated dividends declared by the board of directors of HTKY. For the year ended December 31, 2019, substantially all of the $61,000 net loss of HTKY was allocated to the noncontrolling interest. HTKY had no material operations for the year ended December 31, 2020. As discussed in Note 1, HTKY was deconsolidated as part of the July 2020 Corporate Reorganization.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">2020 Equity Incentive Plan</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">On October 29, 2020, the Company&#x2019;s board of directors approved the adoption of the BioAtla, Inc. 2020 Equity Incentive Plan (the &#x201c;2020 Plan&#x201d;) and approved certain amendments to the 2020 Plan in December 2020. The Company&#x2019;s stockholders approved the 2020 Plan, as amended, in December 2020. Under the 2020 Plan, the Company may grant awards of common stock to the Company&#x2019;s employees, consultants and non-employee directors pursuant to option awards, stock appreciation rights awards, restricted stock awards, restricted stock unit awards, performance stock awards, performance stock unit awards and other stock-based awards. As of December 31, 2021 and 2020, the total number of common shares authorized for issuance under the 2020 Plan was 6,226,540 and 4,939,678, respectively. On January 1st of each year, commencing with the first January 1st following the effective date of the 2020 Plan, the shares authorized for issuance under the 2020 Plan shall be increased by a number of shares equal to the lesser of 4% of the total number of shares outstanding on the immediately preceding December 31st and such lesser number of shares determined by the Company&#x2019;s board of directors. The maximum term of the options granted under the 2020 Plan is no more than ten years. Awards under the 2020 Plan generally vest at 25% one year from the vesting commencement date and ratably each month thereafter for a period of 36 months, subject to continuous service.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Stock-based compensation expense recognized for all equity awards under the 2020 Plan has been reported in the consolidated statements of operations and comprehensive loss as follows (in thousands):</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="bkmk_231"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:53.336%;"></td>
    <td style="width:1.61%;"></td>
    <td style="width:2.121%;"></td>
    <td style="width:18.734%;"></td>
    <td style="width:0.805%;"></td>
    <td style="width:1.61%;"></td>
    <td style="width:2.121%;"></td>
    <td style="width:18.857%;"></td>
    <td style="width:0.805%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Year ended<br>December 31,<br>2021</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Year ended<br>December 31,<br>2020</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Research and development</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">4,688</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">740</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">General and administrative</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">20,429</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">2,282</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Total</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">25,117</font></p></td>
    <td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">3,022</font></p></td>
    <td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:5.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Restricted stock units</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">In December 2020, the Company granted an aggregate of 1,920,037 restricted stock units (&#x201c;RSUs&#x201d;) to certain of the Company&#x2019;s employees and service providers, including executive officers and non-employee directors.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The following table summarizes RSU activity under the 2020 Plan for the years ended December 31, 2021 and 2020:</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="bkmk_232"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:62.636%;"></td>
    <td style="width:1.485%;"></td>
    <td style="width:0.756%;"></td>
    <td style="width:15.606%;"></td>
    <td style="width:0.756%;"></td>
    <td style="width:1.485%;"></td>
    <td style="width:1.803%;"></td>
    <td style="width:14.718%;"></td>
    <td style="width:0.756%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Number of<br>Shares</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Weighted -<br>average<br>grant date<br>fair value</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Outstanding at December 31, 2019</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Granted</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1,920,037</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">18.00</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Vested</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Outstanding at December 31, 2020</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1,920,037</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">18.00</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Granted</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Vested</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">944,991</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">18.00</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Outstanding at December 31, 2021</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">975,046</font></p></td>
    <td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">18.00</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">As of December 31, 2021, total unrecognized stock-based compensation expense for RSUs was $17.5 million, which is expected to be recognized over a remaining weighted-average period of approximately 2.2 years.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">113</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Stock options</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The following table summarizes stock option activity under the 2020 Plan for the year ended December 31, 2021 and 2020 (in thousands, except share and per option data and years):</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="bkmk_234"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:48.145%;"></td>
    <td style="width:1.154%;"></td>
    <td style="width:0.588%;"></td>
    <td style="width:10.482%;"></td>
    <td style="width:0.845%;"></td>
    <td style="width:1.154%;"></td>
    <td style="width:1.288%;"></td>
    <td style="width:9.792%;"></td>
    <td style="width:0.588%;"></td>
    <td style="width:1.154%;"></td>
    <td style="width:0.639%;"></td>
    <td style="width:10.678%;"></td>
    <td style="width:0.588%;"></td>
    <td style="width:1.154%;"></td>
    <td style="width:1.288%;"></td>
    <td style="width:9.874%;"></td>
    <td style="width:0.588%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Number of<br>options</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Weighted -<br>average<br>exercise<br>price per<br>option</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Weighted -<br>average<br>remaining<br>contractual<br>term<br>(in years)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Aggregate<br>intrinsic<br>value</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Balance at December 31, 2019</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Granted</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">615,106</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">18.00</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Balance at December 31, 2020</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">615,106</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">18.00</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">9.95</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">9,848</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Granted</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">479,543</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">37.86</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Exercised</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(7,747</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">18.00</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">182,829</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Balance at December 31, 2021</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1,086,902</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">26.76</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">9.22</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">991,495</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Vested and expected to vest at December 31, 2021</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1,086,902</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">26.76</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">9.22</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">991,495</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Exercisable at December 31, 2021</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">155,579</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">18.31</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">8.97</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">247,486</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">As of December 31, 2021, total unrecognized stock-based compensation cost for unvested common stock options was $15.0 million, which is expected to be recognized over a remaining weighted-average period of approximately 3.1 years. The weighted- average grant date fair value of stock options granted during the years ended December 31, 2021 and 2020 was $24.61 per share and $11.66 per share, respectively. The total fair value of options vested during the year ended December 31, 2021 was $1.9 million. No options vested during the years ended December 31, 2020 and 2019. Upon option exercise, the Company issues new shares of its common stock.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The assumptions used in the Black-Scholes option pricing model to determine the fair value of stock option grants were as follows:</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="bkmk_235"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.596%;"></td>
    <td style="width:1.486%;"></td>
    <td style="width:3.049%;"></td>
    <td style="width:16.143%;"></td>
    <td style="width:3.653%;"></td>
    <td style="width:1.486%;"></td>
    <td style="width:1.78%;"></td>
    <td style="width:18.155%;"></td>
    <td style="width:3.653%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Year ended<br>December 31,<br>2021</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Year ended<br>December 31,<br>2020</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Expected volatility</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">74.7</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">%</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">74.5</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">%</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Risk-free interest rate</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1.06</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">%</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">0.52</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">%</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Expected dividend yield</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">0.0</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">%</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">0.0</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">%</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Expected term</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">5.98 years</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">6.09 years</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Expected volatility.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> As the Company&#x2019;s common stock does not have a significant trading history, the expected volatility assumption is based on volatilities of a peer group of similar companies whose share prices are publicly available. The peer group was developed based on companies in the biotechnology industry.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Risk-free interest rate.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> The Company bases the risk-free interest rate assumption on the U.S. Treasury&#x2019;s rates for U.S. Treasury zero-coupon bonds with maturities similar to those of the expected term of the award being valued.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Expected dividend yield.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> The Company bases the expected dividend yield assumption on the fact that it has never paid cash dividends and has no present plans to pay cash dividends.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Expected term.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> For employees, the expected term represents the period of time that options are expected to be outstanding. Because the Company has minimal historical exercise behavior, it determines the expected life assumption using the simplified method, which is an average of the contractual term of the option and its vesting period. For nonemployees, the expected term is generally the contractual term of the option.</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Employee Stock Purchase Plan</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">In December 2020, the Company&#x2019;s board of directors and stockholders approved the BioAtla, Inc. Employee Stock Purchase Plan (the &#x201c;ESPP&#x201d;). The ESPP permits participants to purchase common stock through payroll deductions of up to 15% of their eligible compensation. As of December 31, 2021 and 2020, a total of 833,993 and 464,829 shares, respectively, of common stock were authorized for issuance under the ESPP. The number of shares of common stock authorized for issuance will automatically increase on January 1 of each calendar year, from January 1, 2021 through January 1, 2030 by the least of (i) 1.0% of the total number of common shares of our common stock outstanding on December 31 of the preceding calendar year (calculated on a fully diluted basis), (ii) 929,658 common shares or (iii) a number determined by the Company&#x2019;s board of directors that is less than (i) and (ii). The ESPP plan was amended in September 2021 to change the offering periods to end on May 15th and November 15th of each year beginning January 1, 2022. In February 2021, employees began to enroll in the ESPP and the Company&#x2019;s first offering period commenced. ESPP purchase transactions occurred on June 30, 2021 and on December 31, 2021. During the year ended December 31, 2021, the Company issued 11,182 shares of common stock under the ESPP. As of December 31, 2021, 822,811 shares of common stock remained available for issuance under the ESPP. Stock-based compensation expense related to the ESPP for the twelve months ended December 31, 2021 was immaterial.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">114</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Common stock reserved for future issuance</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Common stock reserved for future issuance are as follows in common equivalent shares:</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="bkmk_237"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:75.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:64.757%;"></td>
    <td style="width:1.287%;"></td>
    <td style="width:1.151%;"></td>
    <td style="width:14.008%;"></td>
    <td style="width:0.978%;"></td>
    <td style="width:1.287%;"></td>
    <td style="width:1.757%;"></td>
    <td style="width:13.798%;"></td>
    <td style="width:0.978%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">December 31,<br>2021</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">December 31,<br>2020</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Warrants for the purchase of common stock</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">151,088</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">717,674</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Common stock options and restricted stock units issued and outstanding</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">2,061,948</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">2,535,143</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Awards available for future issuance under the 2020 Plan</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">3,211,854</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">2,404,535</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Awards available for future issuance under the ESPP</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">822,811</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">464,829</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Total common stock reserved for future issuance</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">6,247,701</font></p></td>
    <td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">6,122,181</font></p></td>
    <td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:5.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">8. Profits interest incentive plan</font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Prior to the Corporate Reorganization in July 2020, the Company maintained a Profits Interest Incentive Plan (the &#x201c;Plan&#x201d;) for selected employees, consultants and other service providers. In connection with the Corporate Reorganization, Himalaya Parent LLC assumed the Plan and the $1.0 million fair value of the liability was reclassified to additional paid-in capital. As of December 31, 2019, the Company had reserved a total of 16,665,977 Class B units for issuance under the Plan. The Class B units generally vested over four years, were subject to continued service requirements, and only provide the participants with benefits (in the form of distributions) if the distributions from BioAtla exceed specified threshold values. Generally, upon termination of services, all unvested Class B units were forfeited to the Company and the Company had the right, but not the obligation, to repurchase the vested Class B units within two years at the termination date fair value. The Class B unit repurchase would be settled in cash, at all times at the option of the Company, and the holder did not have the right to put the Class B units to the Company under any condition. Vested Class B units that are neither repurchased by the Company nor forfeited remained subject to the terms of the Company&#x2019;s operating agreement. The Class B units were not subject to sale, assignment, transfer, pledge, or allowed to be otherwise encumbered or disposed of without prior written consent of the Company. No Class B units had been repurchased through the date of the Corporate Reorganization.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Activity under the Plan is summarized as follows:</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:80.355%;"></td>
    <td style="width:3.102%;"></td>
    <td style="width:1.003%;"></td>
    <td style="width:14.336%;"></td>
    <td style="width:1.204%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Outstanding at December 31, 2019</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">14,478,949</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Cancelled</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(170,836</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Assumption of Plan by Himalaya Parent LLC on July 10, 2020</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(14,308,113</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Outstanding at December 31, 2020</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Vesting of Class B units under the Plan is summarized as follows:</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:79.429%;"></td>
    <td style="width:1.929%;"></td>
    <td style="width:0.895%;"></td>
    <td style="width:16.559%;"></td>
    <td style="width:1.188%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Unvested at December 31, 2019</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">6,158,328</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Cancelled</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(170,836</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Vested</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(1,310,807</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Assumption of unvested Class B units by Himalaya Parent LLC on<br>&#160;&#160;&#160;July 10, 2020</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(4,676,685</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Unvested at December 31, 2020</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The Class B units were liability awards pursuant to authoritative guidance, which required the Company to record a liability based on the fair value of the Class B units as of each reporting period. Through the date of the Corporate Reorganization, the fair value of the liability awards was determined based on the Company&#x2019;s estimated enterprise value, which was allocated based on a hybrid model that, in addition to the option pricing model, considering the Company&#x2019;s expected IPO. Under the option pricing method, units were valued by creating a series of call options with exercise prices based on the liquidation preferences and conversion terms of each unit class.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">In connection with the Division, the distribution thresholds that had to be achieved before the Class B unit holders were entitled to distributions were adjusted, resulting in a $0.9 million reduction to the aggregate profits interest liability between the Predecessor and the Post-Division LLCs at the date of the Division. The thresholds of the Post-Division Successor were changed in order to reflect the impact of the assets assigned to BioAtla Holdings and Inversagen in the Division. For the year ended December 31, 2019, the profits interest liability decreased $7.4 million, including the $0.9 million reduction described above, and $0.8 million recognized as additional paid-in capital related to the fair value of vested Class B units assumed by BioAtla Holdings and Inversagen in connection with the Division. In addition, the Company recognized stock-based compensation expense and additional paid-in capital of $0.2 million related to the fair value of the unvested Class B units assumed by BioAtla Holdings and Inversagen in connection with the Division since these Class B unit holders were employees of the Post-Division Successor, and were not expected to provide services to BioAtla Holdings or Inversagen.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">115</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The following table provides a reconciliation of the profits interest liability (in thousands):</font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:95.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:81.998%;"></td>
    <td style="width:1.735%;"></td>
    <td style="width:1.14%;"></td>
    <td style="width:14.376%;"></td>
    <td style="width:0.75%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Balance at December 31, 2019</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">8,592</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Decrease in fair value of vested liability (Pre-Corporate Reorganization) recognized as decrease to stock-based<br>&#160;&#160;&#160;compensation expense</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(7,601</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Fair value of vested liability assumed by Himalaya Parent LLC on July 10, 2020 recognized as additional paid-in<br>&#160;&#160;&#160;capital</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(991</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Balance at December 31, 2020</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The allocation of equity-based compensation, including $0.7 million from Himalaya Parent as a capital contribution during 2020, for all Class B units is as follows (in thousands):</font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:61.821%;"></td>
    <td style="width:1.409%;"></td>
    <td style="width:2.168%;"></td>
    <td style="width:14.073%;"></td>
    <td style="width:1.44%;"></td>
    <td style="width:1.409%;"></td>
    <td style="width:2.168%;"></td>
    <td style="width:14.073%;"></td>
    <td style="width:1.44%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="7" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Years ended December 31,</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">2020</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">2019</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Research and development</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(2,993</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(2,997</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">General and administrative</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(3,859</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(3,406</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Total</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(6,852</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(6,403</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
   </tr>
  </table>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:5.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">9. Collaboration, license and option agreements</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Global Co-Development and Collaboration Agreement with BeiGene</font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">In April 2019, the Company entered into a Global Co-Development and Collaboration agreement (the &#x201c;BeiGene Collaboration&#x201d;) with BeiGene, Ltd. and BeiGene Switzerland GmbH (collectively &#x201c;BeiGene&#x201d;), a commercial-stage biopharmaceutical company, for the development, manufacturing and commercialization of the Company&#x2019;s investigational CAB CTLA-4 antibody (BA3071). The Company and BeiGene amended the Global Co-Development and Collaboration agreement in December 2019 and in October 2020 (the &#x201c;Amended BeiGene Collaboration&#x201d;).<br></font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Under the BeiGene Collaboration, the Company would co-develop the CAB-CTLA-4 antibody to reach defined early clinical objectives (&#x201c;POC Milestone&#x201d;), whereby the Company would perform the development activities and BeiGene would reimburse the Company for a portion of the costs incurred by the Company. Following the POC Milestone, BeiGene would then lead the parties&#x2019; joint efforts to develop the product candidate and be responsible for global regulatory filings and commercialization. BeiGene would be responsible for all costs of development, manufacturing and commercialization in China, parts of the Middle East and Asia (excluding Japan), Australia and New Zealand (the &#x201c;BeiGene Territory&#x201d;), and the parties would share development and manufacturing costs and commercial profits and losses upon specified terms in the rest of the world that are not part of the BeiGene Territory (the &#x201c;ROW&#x201d;).<br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">In 2019, BeiGene paid the Company an upfront non-refundable payment of $20.0 million and paid the Company $5.0 million for reimbursement of manufacturing costs. Under the BeiGene Collaboration, the Company was eligible to receive variable consideration for subsequent development and regulatory milestones globally and commercial milestones in the BeiGene Territory and tiered royalties ranging from the mid-single digits to the mid-double digits based on net sales in the BeiGene Territory.<br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The Company concluded that the BeiGene Collaboration was a contract with a customer and applied relevant guidance from Topic 606 through reaching the POC milestone as the licenses to intellectual property granted to BeiGene and the obligation to perform research and development services are outputs of the Company&#x2019;s ongoing activities.  The Company identified material promises in the BeiGene Collaboration through POC Milestone, consisting of the licenses described above and the development services. It was determined that the licenses were not distinct from the development services resulting in a single performance obligation.<br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">In accordance with Topic 606, the Company determined the transaction price of the agreement was limited to the $25.0 million received, and excluded the variable consideration of expense reimbursements, milestone payments and royalties as they were fully constrained. The expense reimbursements were included in the transaction price in the reporting period the Company concluded it was probable that inclusion of such amounts in the transaction price would not result in a significant reversal in revenue recognized. As part of the Company&#x2019;s evaluation of the milestone constraints, the Company determined the achievement of such milestones were contingent upon success of future developments, regulatory approvals and commercial activities which were not within its control and were uncertain. Variable consideration related to royalties would be recognized when the related sales occurred.</font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Under the terms of the Amended BeiGene Collaboration, BeiGene was generally responsible for developing BA3071 and for global regulatory filings and commercialization. Subject to the terms of the Amended BeiGene Collaboration, BeiGene held an exclusive license with the Company to develop and manufacture the BA3071 candidate globally, and BeiGene was responsible for all costs of development, manufacturing and commercialization globally. The Amended BeiGene Collaboration provided that the Company was eligible to receive tiered royalties on sales worldwide, subsequent development and regulatory milestone payments globally and commercial milestones in the BeiGene</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">116</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">territory.<br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Under the Amended BeiGene Collaboration, the Company&#x2019;s amended performance obligation would be satisfied at a point in time determined to be when BeiGene received the know-how and master cell bank for BA3071. Until then BeiGene could not benefit from the ability to further develop and manufacture the BA3071 candidate. Under the original collaboration agreement, the Company recognized revenue over time using an input method based on actual costs incurred compared to estimated total costs expected to be incurred to fulfill its performance obligation to perform development services.<br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">On November 18, 2021, the Company entered into Amendment No. 3 to the Amended BeiGene Collaboration (&#x201c;Amendment No.3&#x201d;).  Under Amendment No. 3, the Amended BeiGene Collaboration was terminated, subject to survival of certain provisions, and BeiGene handed back rights to know-how and materials received under the Amended BeiGene Collaboration.  As a result, the Company will assume responsibility for the global development and commercialization of BA3071.  As consideration for Amendment No.3, the Company agreed to pay BeiGene mid-single digit royalties on sales worldwide and on a limited basis will share in any upfront and milestone payments received through a sublicense of BA3071.  As part of Amendment No.3, the Company reclassified its remaining $19.8 million of deferred revenue as a long-term liability which is expected to settle as licensing payments are made to BeiGene in accordance with the resulting amendment. In the event the license is terminated, the liability will be extinguished with no further payment to BeiGene.<br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">For the year ended December 31, 2021, the Company did not recognize any revenue related to the collaboration agreement with BeiGene. Collaboration revenue recognized for the years ended December 31, 2020 and 2019 was $0.4 million and $5.2 million, respectively. As of December 31, 2021 and December 31, 2020, the Company had a $19.8 million Liability to Licensor, and $19.8 million of deferred revenue which was classified as current, respectively.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:2.267%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Service Contracts</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Prior to developing its own programs, the Company entered into various fixed price research services contracts. In connection with these service contracts, the Company may receive future milestone payments if certain clinical, regulatory and commercialization milestones are achieved. The Company is also eligible to receive royalties based on certain product sales. The Company recognized revenue of $0.3 million for the year ended December 31, 2021, related to the achievement of a clinical milestone on a fixed price service contract.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">License and Option Agreement with Pfizer, Inc.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The Company was party to a license and option agreement with Pfizer that was terminated in December 2019. Pfizer paid the Company $1.0 million in December 2015 upon execution of the agreement. The Company had identified a single deliverable at inception of the agreement, which consisted of the company&#x2019;s obligation to nominate targets, perform certain preclinical research, efficacy studies and related reports (&#x201c;research and development services&#x201d;). These services were prerequisites to Pfizer&#x2019;s exercise of Pfizer&#x2019;s substantive options, including the option to obtain exclusive licenses to develop and commercialize a certain number of Antibody Drug Conjugates (&#x201c;ADC&#x201d;) CAB antibodies, under the agreement. As such, the Company recognized revenue for the consideration received over the four-year period over which it delivered its research and development services. In connection with the license and option agreement with Pfizer, the Company recognized collaboration revenue of $0.5 million for the year ended December 31, 2019.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">10. Related party transactions</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Dr. Jay Short and Carolyn Anderson Short</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Dr. Jay Short and Carolyn Anderson Short loaned the Company $1.0 million and $0.5 million, respectively, under the terms of the 2019 Notes and 2020 Notes described in Note 4 above. For the years ended December 31, 2020 and 2019, the Company recognized interest expense (including amortization of debt discounts) of $0.1 million and $32,000, respectively, on outstanding 2019 Notes and 2020 Notes payable to Dr. Jay Short and Carolyn Anderson Short. The 2019 Notes and 2020 Notes payable to Dr. Jay Short and Carolyn Anderson Short were settled in connection with the Corporate Reorganization in July 2020.</font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">On March 18, 2021, the Company and Carolyn Anderson Short, its co-founder and former Chief of Intellectual Property &amp; Strategy, mutually agreed that Ms. Short would depart the Company on May 31, 2021 following an agreed upon transition period. The Transition Agreement provides for the following severance benefits in exchange for a release of claims by Ms. Short: (i) a lump sum payment equal to eighteen (18) months of Ms. Short&#x2019;s current base salary, (ii) a payment at her targeted bonus rate for 2021, pro-rated to the separation date, and (iii) accelerated full vesting of her equity awards including 7,747 stock options and 138,461 restricted stock units.  The modification of these equity awards resulted in an incremental fair value of $7.0 million which was recognized on a straight-line basis over the transition service period.   For the twelve months ended December 31, 2021, the Company recognized $1.0 million  related to the lump sum salary payment and target bonus. The Company also recognized non-cash stock-based compensation charges of $9.4 million related to the modified equity awards for the twelve months ended December 31, 2021. No unrecognized stock-based compensation remained as of December 31, 2021. Ms. Short exercised her 7,747 stock options in 2021, therefore there are no remaining options outstanding related to Ms. Short&#x2019;s transition agreement as of December 31, 2021.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">117</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Inversagen, LLC</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Inversagen was formed in conjunction with the LLC Division. On March 15, 2019, the Company entered into an Exclusive License Agreement with Inversagen (the &#x201c;Inversagen License&#x201d;). Under the terms of the agreement, Inversagen acquired the rights to CAB-antibodies for the field of diseases associated with aging, outside of cancer, and an immuno-oncology antibody. The Company may perform development services under the agreement and will be reimbursed by Inversagen for its costs. Commencing on the first commercial sale of the CAB-antibodies and immuno-oncology antibody subject to the Inversagen License, Inversagen will pay the Company milestone payments and royalties, which represent a variable interest held by the Company. On July 7, 2020, the Company and Inversagen entered into the First Amendment to Exclusive License Agreement (&#x201c;Amended Inversagen License&#x201d;), which grants the Company an option for a period of 10 years to acquire the immuno-oncology antibody in return for royalty payments in the low-single digits during the applicable royalty term. No payments have been made to date.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Inversagen has only nominal assets and liabilities and is a VIE as the entity lacks sufficient equity to finance its activities without additional subordinated financial support. The Company does not consolidate Inversagen as it is not the primary beneficiary; Inversagen License and the Amended Inversagen License did not and do not provide the Company with any decision-making power over the activities that are most significant to the entity&#x2019;s economic success, such as the direction of its development efforts or the search for or terms of any future financing arrangements. The Company has no equity interest in Inversagen, and no exposure to its losses. Inversagen is currently inactive, and the Company has not provided any services to Inversagen, has not provided any support to Inversagen and has no obligation to do so, and Inversagen&#x2019;s creditors have no recourse to the general credit of the Company. The Company does not have any assets or liabilities associated with its variable interest in Inversagen at December 31, 2021 and 2020.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Inversagen is a related party of the Company. Dr. Jay Short and his spouse, Carolyn Anderson Short, serve as managers of Inversagen.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">BioAtla Holdings, LLC</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Effective January 1, 2020, the Company entered into an Exclusive License Agreement (the &#x201c;BioAtla Holdings License&#x201d;) with BioAtla Holdings, LLC. Under the terms of the agreement, BioAtla Holdings acquired the rights to CAB antibodies for certain targets in the field of Adoptive Cell Therapy (CAR-T format) in exchange for potential royalty payments on future net sales. On July 7, 2020, the Company and BioAtla Holdings entered into the First Amendment to Exclusive License Agreement (the &#x201c;Amended BioAtla Holdings License&#x201d;), which grants the Company an option for a period of 10 years to acquire the ACT Preparations and ACT Treatments in return for royalty payments in the low-single digits during the applicable royalty term. The Company has not exercised its option and no payments have been made to date under these agreements.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">In addition, effective January 1, 2020, the Company entered into a Royalty Sharing Agreement whereby the Company agreed to share with BioAtla Holdings 50% of the royalties it receives under the Amended and Restated EXUMA License defined and described in Note 12 below.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">BioAtla Holdings is a variable interest entity as it does not have sufficient equity to finance its activities without additional subordinated financial support. The royalty payments and option to acquire assets represent variable interests held by the Company in BioAtla Holdings. The Company is not the primary beneficiary of BioAtla Holdings, however, as the BioAtla Holdings License and Amended BioAtla Holdings License did not and do not provide the Company with any decision-making power over the activities that are most significant to the entity&#x2019;s economic success, such as the direction of its development efforts or the search for or terms of any future financing arrangements. The Company has no equity interest in BioAtla Holdings, and no exposure to its losses. BioAtla Holdings is currently inactive, and the Company has not provided any support to BioAtla Holdings and has no obligation to do so, and BioAtla Holdings&#x2019; creditors have no recourse to the general credit of the Company. The Company does not have any assets or liabilities associated with its variable interests in BioAtla Holdings at December 31, 2021 and 2020.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">BioAtla Holdings is a related party of the Company. Dr. Jay Short and his spouse, Carolyn Anderson Short, serve as managers of BioAtla Holdings.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Himalaya Therapeutics SEZC</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Prior to the Corporate Reorganization, Himalaya Therapeutics SEZC met the definition of a VIE under ASC 810-10, as the entity did not have enough equity to finance its activities without additional subordinated financial support. The Company consolidated Himalaya Therapeutics SEZC as the primary beneficiary, as it had (i) the power to direct activities of a VIE that most significantly impact the VIE&#x2019;s economic performance and (ii) the right to receive benefits from the VIE that could potentially be significant to the VIE, resulting from its control of the board of directors, and voting control of the entity via a voting agreement among its shareholders, and its equity holdings. The Company was not obligated to provide financial support to Himalaya Therapeutics SEZC. Himalaya Therapeutics SEZC&#x2019;s creditors had no recourse in the general credit of the Company. Himalaya Therapeutics SEZC held intellectual property related to certain CAB Antibodies under an Exclusive Rights</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">118</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Agreement with the Company dated December 20, 2018. As of December 31, 2019, Himalaya Therapeutics SEZC had no material operations, did not have any employees and the carrying value of its assets and liabilities was nominal.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">On January 1, 2020, the Company entered into an Amended and Restated Exclusive Rights Agreement (the &#x201c;Amended Rights Agreement&#x201d;) with Himalaya Therapeutics SEZC. Under the terms of the Amended Rights Agreement, Himalaya Therapeutics SEZC acquired the rights to 10 CAB-antibodies for the territory of China, Macao, Hong Kong and Taiwan, global rights to a CAB-HER2-bispecific-antibody and global co-development rights with us to an IL-22 non-CAB-antibody. Payments to the Company may include upfront payments, milestone payments and double digit royalties, which represent a variable interest held by the Company, but no payments have been made to the Company to date.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">As part of the Corporate Reorganization, Himalaya Therapeutics SEZC was distributed to Himalaya Parent LLC at the carrying value of its assets and liabilities, which were nominal, and no gain or loss was recorded on the transaction in the Company&#x2019;s financial statements for the year ended December 31, 2020. Himalaya Therapeutics SEZC continues to be a variable interest entity as it does not have sufficient equity to finance its activities without additional subordinated financial support. The Company is not obligated to provide financial support to Himalaya Therapeutics SEZC. The Company is not the primary beneficiary of Himalaya Therapeutics SEZC, however, as the Amended Rights Agreement does not provide BioAtla, Inc. with the power to direct activities of a VIE that most significantly impact the VIE&#x2019;s economic performance, such as decision-making power over the direction of its development efforts or the search for or terms of any future financing arrangements. The Company does not have any assets or liabilities recorded at December 31, 2020 associated with its variable interest in Himalaya Therapeutics SEZC, and has no exposure to Himalaya Therapeutics SEZC losses. The Company does not have a variable interest in Himalaya Parent LLC.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Himalaya Therapeutics SEZC is a related party whose controlling shareholder is Himalaya Parent LLC. Dr. Jay Short and his spouse, Carolyn Anderson Short, serve as directors of Himalaya Therapeutics SEZC, and Carolyn Anderson Short serves as an officer of such entity.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Himalaya Parent LLC</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">In connection with the Corporate Reorganization, Himalaya Parent assumed the Company&#x2019;s profits interest plan, including equity awards to employees of the Company. For the years ended December 31, 2021 and 2020, the Company recognized $0 and $0.7 million, respectively, of compensation cost and a related capital adjustment in connection with the assumed profits interest plan. Dr. Jay Short and his spouse, Carolyn Anderson Short, serve as managers of Himalaya Parent LLC.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">EXUMA Biotech Corp. and subsidiary</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">As of December 31, 2019, the Company and EXUMA are no longer related parties since none of the Post-Division LLCs own any common or preferred stock of EXUMA and have no ongoing contractual relationships other than the license agreement described below (see Note 12). The Company was a named party to a lease where a subsidiary of EXUMA was the primary tenant. The EXUMA subsidiary paid the landlord directly for payments due under the lease and was reimbursed by the Company for its share of the payments. For the year ended December 31, 2019, the Company expensed $15,000 for its share of payments due under the lease. In addition, the Company expensed $10,000 related to a November 2019 amendment of the license agreement described in Note 12.</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Biotech Investment Group, LLC</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Prior to the Corporate Reorganization, Biotech Investment Group, LLC (&#x201c;BIG&#x201d;), was a principal owner, related party of the Company and affiliated with BioDuro, LLC (&#x201c;BioDuro&#x201d;) and Biotech Investment Group II LLC (&#x201c;BIG II&#x201d;). Subsequent to the Corporate Reorganization, BIG is no longer a principal owner and, as a result, neither BIG nor its affiliates are related parties of the Company.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">BioDuro-Sundia</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">BioDuro-Sundia is a contract research organization that provides services to the Company. For the year ended December 31, 2019, the Company incurred expenses of $1.9 million in connection with services provided by BioDuro-Sundia. During 2019, an affiliate of BIG sold a majority interest in BioDuro-Sundia to an unaffiliated entity. Effective January 1, 2020, BioDuro-Sundia is no longer considered a related party of the Company.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Biotech Investment Group II LLC</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">BIG II loaned the Company $0.5 million under the terms of the 2019 Notes described in Note 4 above. For the years ended December 31, 2020 and 2019, the Company recognized interest expense (including amortization of debt discounts) of $42,000 and $20,000, respectively on outstanding 2019 Notes payable to BIG II. The 2019 Notes payable to BIG II were settled in connection with the Corporate Reorganization in July 2020.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Private Placement of Common Stock</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">As part of the 2021 Private Placement, the Company issued 625,000 shares of common stock for total net proceeds of $17.5 million to certain stockholders considered to be related parties.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">119</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:10.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">11. 401(k) plan</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The Company maintains a defined contribution 401(k) plan available to eligible employees. Employee contributions are voluntary and are determined on an individual basis, limited to the maximum amount allowable under federal tax regulations. The Company, at its discretion, may make certain matching contributions to the 401(k) plan. To date, the Company has not made any matching contributions.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">12. EXUMA Biotech Corp.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Exclusive License Agreement</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Under an Exclusive License Agreement entered into in May 2016, the Company granted EXUMA and its affiliates an exclusive, worldwide, sublicensable license under certain patents and know-how controlled by the Company to develop, manufacture and commercialize Adoptive Cellular Therapy (&#x201c;ACT&#x201d;) preparations and treatments for cancer. EXUMA&#x2019;s rights under the agreement exclude the right to grant sublicenses to third parties to discover, develop or manufacture any CAB ACT or any component of the Company&#x2019;s CAB ACT technology, except as used in or incorporated into EXUMA&#x2019;s ACTs for cancer. The license to EXUMA is royalty bearing.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">EXUMA granted the Company an exclusive, worldwide, royalty free, fully paid-up, sublicensable license under certain patents and know-how controlled by EXUMA and EXUMA&#x2019;s interest in technology jointly developed under the agreement to develop, manufacture and commercialize non-ACT CAB products for any indication.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">EXUMA is obligated to pay the Company during the royalty term, on a product-by-product basis and country-by-country basis, mid-single digit royalties based on annual net sales of certain EXUMA ACT products, subject to certain adjustments. The term during which EXUMA is obligated to pay royalties under the agreement with respect to any particular product in any particular country, will begin on the first commercial sale of such product in such country and will end on the date of expiration of the last-to-expire of certain product-related patent rights in such country. All royalties to be paid under the agreement are subject to certain adjustments. Future royalties will be recognized when earned.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Unless earlier terminated, the agreement continues in effect so long as EXUMA or any of its affiliates, licensees or sublicensees are developing or commercializing any EXUMA products in the ACT field or the Company or any of its affiliates, licensees or sublicensees are developing or commercializing any CAB products for any indication outside the ACT field. The agreement may be terminated only by the mutual written agreement of the parties.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">In connection with the Exclusive License Agreement, the Pre-Division Predecessor received common and preferred stock of EXUMA.  The preferred stock was accounted for as a cost method investment and the common stock was accounted for as an equity method investment. Both the cost method investment and equity method investment had initial carrying values of zero and neither resulted in adjustments to the consolidated statements of operations for the years ended December 31, 2019. These holdings of EXUMA common and preferred stock were retained by BioAtla Holdings in connection with the LLC Division.<br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">In November 2019, the Company entered into an Amended and Restated Exclusive License Agreement with EXUMA (the &#x201c;Amended and Restated EXUMA License&#x201d;). The Amended and Restated EXUMA License curtailed the rights to certain CAB intellectual property previously licensed to EXUMA in exchange for a one-time, non-refundable, non-creditable license fee of $10,000.   More specifically, the Amended and Restated EXUMA License limits CAB ACT products to four specified targets, and BioAtla is no longer obligated to provide new targets to EXUMA. The Amended and Restated EXUMA License does not change EXUMA&#x2019;s obligation to pay BioAtla royalties on licensed products. In connection with the Amended and Restated EXUMA License, BioAtla Holdings sold its EXUMA common and preferred holdings back to EXUMA for consideration of $25,000. The Company concluded that the Amended and Restated EXUMA License was priced at fair value and was not influenced by the pricing of the contemporaneous related party stock sale.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">EXUMA is a VIE, and the Company has a variable interest in EXUMA due to its right to receive royalties during the royalty term under the Amended and Restated EXUMA License. As of December 31, 2021 and 2020, the Company has determined it is not the primary beneficiary of EXUMA and, as such, the Company does not consolidate EXUMA. The Company has no equity ownership in EXUMA, no representation on the EXUMA board of directors, and the Amended and Restated EXUMA License does not provide the Company with the ability to make decisions regarding the execution of business strategy that most significantly impact the economic performance of EXUMA. The Company has not funded and has no commitment to fund EXUMA&#x2019;s losses, and has no exposure to loss as a result of its Amended and Restated EXUMA License. The Company&#x2019;s financial statements do not include any assets or liabilities related to the Amended and Restated EXUMA License at December 31, 2021 and 2020.</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">13. Income taxes</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Historically, the Company had conducted its U.S. operations through a pass through entity that filed its income tax returns as a partnership for federal and state income tax purposes. As a result, the Company was not subject to U.S. federal or state income taxes as the related tax consequences were reported by its individual members.  In July 2020, the Company changed its status from a limited liability company to a corporation, and accordingly, the Company became taxable at the entity level for U.S. federal and state tax purposes.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">120</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">A reconciliation of income tax expense computed at the U.S. federal statutory income tax rate to the Company&#x2019;s income tax expense is as follows (in thousands):</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:61.437%;"></td>
    <td style="width:1.432%;"></td>
    <td style="width:1.777%;"></td>
    <td style="width:14.879%;"></td>
    <td style="width:1.193%;"></td>
    <td style="width:1.432%;"></td>
    <td style="width:1.777%;"></td>
    <td style="width:14.879%;"></td>
    <td style="width:1.193%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Year ended<br>December 31,<br>2021</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Year ended<br>December 31,<br>2020</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Tax computed at the federal statutory rate</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(20,034</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(7,529</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Deferred impact of conversion to C Corporation</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(2,131</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(6,708</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Partnership income not subject to tax</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1,837</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Nondeductible executive compensation</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">4,145</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Stock-based compensation</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(1,021</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Research and development and orphan drug credits</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(3,091</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(807</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Uncertain tax positions</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">757</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">197</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Other, net</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">793</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">242</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Valuation allowance</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">20,582</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">12,768</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Income tax expense</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The Company&#x2019;s net deferred tax assets (liabilities) are as follows (in thousands):</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:58.515%;"></td>
    <td style="width:1.578%;"></td>
    <td style="width:1.764%;"></td>
    <td style="width:16.207%;"></td>
    <td style="width:1.194%;"></td>
    <td style="width:1.578%;"></td>
    <td style="width:1.764%;"></td>
    <td style="width:16.207%;"></td>
    <td style="width:1.194%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">December 31,<br>2021</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">December 31,<br>2020</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Deferred tax assets:</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Net operating loss carryforwards</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">21,935</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">5,607</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Guaranteed payments</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1,702</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Liability to licensor</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">4,159</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Deferred revenue</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">4,159</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Goodwill</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">3,449</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Deferred rent</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">504</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Lease liability</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1,128</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Accrued compensation</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">485</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">585</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Research credit carryforwards</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">2,945</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">610</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Stock-based compensation</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">697</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">438</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Other</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">2</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">0</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Gross deferred tax assets</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">34,800</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">13,605</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Less valuation allowance</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(33,351</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(12,768</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Total deferred tax assets</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1,449</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">837</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Deferred tax liabilities:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Fixed assets</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(756</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(837</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Operating lease right-of-use asset</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(693</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Total deferred tax liabilities</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(1,449</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(837</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Net deferred tax assets</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">A valuation allowance of approximately $33.4 million as of December 31, 2021 has been established to offset the deferred tax assets as the Company has determined that it is not more likely than not that these assets will be realized. The valuation allowance increased by approximately $20.6 million during 2021.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">At December 31, 2021, the Company had federal net operating loss carryforwards of approximately $104.5 million. The federal net operating losses can be carried forward indefinitely, subject to an 80% limitation against taxable income.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">At December 31, 2021, the Company had federal and California research and development credit carryforwards of approximately $1.9 million and $1.2 million, respectively. The federal credit carryforwards will begin to expire in 2040, unless previously utilized. The California credits will carry forward indefinitely.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">At December 31, 2021, the Company also had federal orphan drug credit carryforwards of approximately $1.0 million. The orphan drug credit carryforwards will begin to expire in 2041, unless previously utilized.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Pursuant to Internal Revenue Code (&#x201c;IRC&#x201d;) Sections 382 and 383, annual use of the Company&#x2019;s net operating loss carryforwards may be limited in the event a cumulative change in ownership of more than 50% occurs within a three-year period. The Company has not completed an ownership change analysis pursuant to IRC Section 382. If ownership changes within the meaning of IRC Section 382 are identified as having occurred, the amount of remaining tax attribute carryforwards available to offset future taxable income and income tax expense in future years may be significantly restricted or eliminated. Further, the Company&#x2019;s deferred tax assets associated with such tax attributes could be significantly reduced upon realization of an ownership change within the meaning of IRC Section 382.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">121</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (&#x201c;CARES&#x201d; Act) was enacted in response to the COVID-19 pandemic. The CARES Act, among other things, permits net operating loss carryovers and carrybacks to offset 100% of taxable income for taxable years beginning before 2021. In addition, the CARES Act allows net operating losses incurred in 2018, 2019, and 2020 to be carried back to each of the five preceding taxable years to generate a refund of previously paid income taxes. As the Company operated as a partnership during the carryback period, net operating loss carrybacks will not be allowed. Due to the Company&#x2019;s history of net operating losses, other provisions of the CARES Act are not expected to have a material impact on the Company&#x2019;s financial statements.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Pursuant to the Paycheck Protection Program (the &#x201c;PPP&#x201d;) of the CARES Act, the Company received a PPP loan in the amount of $0.7 million. In 2021, the Company received forgiveness of the PPP loan. The loan forgiveness income is not considered taxable for Federal or state income tax purposes. In accordance with the Consolidated Appropriations Act, 2021 (CAA) enacted on December 27, 2020, certain qualified expenses used with the funds of the PPP Loan are fully deductible for Federal income tax purposes; however, California does not conform to this aspect of the CAA.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Under the FASB's accounting guidance related to income tax positions, among other things, the impact of an uncertain income tax position on the income tax return must be recognized at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. Additionally, the guidance provides guidance on derecognition, classification, interest and penalties, accounting in interim period, disclosure and transition. The Company regularly evaluates the likelihood of recognizing the benefit for income tax positions taken in various federal and state filings by considering all relevant facts, circumstances, and information available.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The following table summarizes the reconciliation of the unrecognized tax benefits activity during the year ended December 31, 2021 (in thousands):</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:79.524%;"></td>
    <td style="width:1.931%;"></td>
    <td style="width:1.521%;"></td>
    <td style="width:16.257%;"></td>
    <td style="width:0.767%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Balance as of December 31, 2019</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Gross increase &#x2013; current-period tax positions</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">210</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Balance as of December 31, 2020</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">210</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Gross increase &#x2013; current-period tax positions</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">801</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Balance as of December 31, 2021</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1,011</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">As of December 31, 2021, the Company had gross unrecognized tax benefits of approximately $1.0 million, none of which would affect the Company&#x2019;s effective tax rate due to the existence of the valuation allowance. The Company&#x2019;s policy is to recognize interest and penalties related to income tax matters in income tax expense. The Company had no accrual for interest or penalties on the Company&#x2019;s consolidated balance sheet and has not recognized interest or penalties in the consolidated statements of net and comprehensive income for the year ended December 31, 2021. The Company does not anticipate a significant change to its liability for unrecognized tax benefits within the next twelve months.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The Company is subject to taxation in the United States and various state jurisdictions. The Company is subject to examination by tax authorities in those jurisdictions since 2018 and 2017, respectively, and forward.  However, any adjustment made for the period prior to the conversion to C Corporation in July 2020 would be passed through to the Company's former members. Post-conversion to C Corporation, to the extent allowed by law, the taxing authorities may have the right to examine periods where NOLs and research and development credits were generated and carried forward, and make adjustments to the amount of the NOL and research credits carryforward amount.  The Company is not currently under examination by any jurisdiction.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">14. Subsequent events</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The Company has completed an evaluation of all subsequent events through February 28, 2022 for the financial statements as of and for the year ended December 31, 2021 to ensure these consolidated financial statements include appropriate disclosure of events both recognized in the consolidated financial statements and events which occurred but were not recognized in the consolidated financial statements. Except as described below or elsewhere in these consolidated financial statements, the Company has concluded that no subsequent event has occurred that requires disclosure.</font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">On January 5, 2022, BioAtla and Bristol-Myers Squibb Company (&#x201c;BMS&#x201d;) entered into a clinical trial collaboration and supply agreement (the &#x201c;BMS Agreement&#x201d;).  Under the terms of the BMS Agreement, BioAtla and BMS will collaborate on clinical trials of separate combination therapies using two of BioAtla&#x2019;s Conditionally Active Biologic Antibody Drug Conjugates, BA3011 and BA3021, each in combination with Opdivo&#174; (nivolumab), BMS&#x2019; proprietary anti-PD-1 monoclonal antibody product.  The Company will serve as the study sponsor of the scheduled studies and will be responsible for costs associated with the trial execution. BMS will provide Opdivo&#174; clinical drug supply at no cost for the combination study trials.  After the completion of the combination therapy trials, the Company is obligated to provide BMS with a final report of the data resulting from the trial. There was no impact to the Company's financial results for the year ended December 31, 2021 as a result of this agreement.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">122</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:16.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9_changes_in_and_disagreements"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">ITEM 9. Changes in and Disa</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">greements with Accountants on Accounting and Financial Disclosure</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">None.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:16.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9a_controls_and_procedures"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">ITEM 9A. Contr</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">ols and Procedures</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Evaluation of Disclosure Controls and Procedures.</font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">As required by Rules 13a-15(b) and 15d-15(b) of the Exchange Act, our management with the participation of our Chief Executive Officer and our Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2021. The term &#x201c;disclosure controls and procedures&#x201d; as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#x2019;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#x2019;s management, including its principal executive and principal financial officer, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of December 31, 2021, our Chief Executive Officer and our Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Management&#x2019;s Report on Internal Control over Financial Reporting.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act). Management conducted an assessment of the effectiveness of our internal control over financial reporting based on the criteria set forth in Internal Control&#x2014;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework). Based on the assessment, management has concluded that its internal control over financial reporting was effective as of December 31, 2021, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with GAAP. Our independent registered public accounting firm, Ernst &amp; Young LLP, has issued an audit report with respect to our internal control over financial reporting, which is included herein.</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Changes in Internal Control over Financial Reporting.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of any changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(d) and 15d-15(d) under the Exchange Act) that occurred during our most recently completed fiscal quarter. Based on that evaluation, our principal executive officers and principal financial officer concluded that there has not been any material change in our internal control over financial reporting during the fourth quarter of fiscal 2021 that materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. We are continually monitoring and assessing the COVID-19 situation on our internal controls to understand the potential impact on their design and operating effectiveness.</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Limitations on Effectiveness of Controls and Procedures and Internal Control over Financial Reporting</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">In designing and evaluating the disclosure controls and procedures and internal control over financial reporting, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures and internal control over financial reporting must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.<br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">See Management&#x2019;s Report on Internal Control over Financial Reporting above and the Report of Independent Registered Public Accounting Firm on our internal control over financial reporting herein.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font></p>
  <p style="margin-left:2.267%;text-indent:4.229%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">123</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Report of Independent Registered Public Accounting Firm</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">To the Stockholders and the Board of Directors of BioAtla, Inc.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Opinion on Internal Control over Financial Reporting</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We have audited BioAtla, Inc.&#x2019;s internal control over financial reporting as of December 31, 2021, based on criteria established in Internal Control&#x2014;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, BioAtla, Inc. (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2021, based on the COSO criteria.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the  consolidated balance sheets of BioAtla, Inc. as of December 31, 2021 and 2020, the related consolidated statements of operations and comprehensive loss, convertible preferred stock and stockholders&#x2019;/members&#x2019; equity (deficit) and cash flows for each of the three years in the period ended December 31, 2021, and the related notes</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">and our report dated February 28, 2022 expressed an unqualified opinion thereon.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Basis for Opinion</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The Company&#x2019;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management&#x2019;s Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#x2019;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Definition and Limitations of Internal Control over Financial Reporting</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">A company&#x2019;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#x2019;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#x2019;s assets that could have a material effect on the financial statements.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">/s/ </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Ernst &amp; Young LLP</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">San Diego, California</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">February 28, 2022</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">124</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9b_other_information"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">ITEM 9B. Other</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;"> Information</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">None.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:16.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">ITEM 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Not applicable.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">125</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_iii"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">PART </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">III</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_10"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">ITEM 10. Directors, Executive </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Officers and Corporate Governance</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Except to the extent provided below, the information required by this Item 10 will be included in our Proxy Statement to be filed with the SEC and is incorporated herein by reference.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We have adopted a Code of Business Conduct and Ethics that applies to all officers, directors and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller, or person performing similar functions. A current copy of the Code of Business Conduct and Ethics is available on the Corporate Governance section of our website at www.bioatla.com. If we make any substantive amendments to the Code of Business Conduct and Ethics or grants any waiver from a provision of the Code of Business Conduct and Ethics to any executive officer or director that are required to be disclosed pursuant to SEC rules, we will promptly disclose the nature of the amendment or waiver on our website or in a current report on Form 8-K.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:16.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_11"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">ITEM 11. Execu</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">tive Compensation</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The information required by this Item 11 will be included in our Proxy Statement to be filed with the SEC and is incorporated herein by reference.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:16.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_12"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">ITEM 12. Security Ownership of Certain Beneficial O</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">wners and Management and Related Stockholder Matters</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The information required by this Item 12 will be included in our Proxy Statement to be filed with the SEC and is incorporated herein by reference.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:16.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_13"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">ITEM 13. Certain Relationships and </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Related Party Transactions, and Director Independence</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The information required by this Item 13 will be included in our Proxy Statement to be filed with the SEC and is incorporated herein by reference.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:16.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_14"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">ITEM 14. Principal Accou</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">ntant Fees and Services</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The information required by this Item 14 will be included in our Proxy Statement to be filed with the SEC and is incorporated herein by reference.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">126</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_iv"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">PA</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">RT IV</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:16.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_15_exhibits_and_financial"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">ITEM 15. Exhibits and Financial </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Statement Schedules</font></p>
  <p style="margin-left:6.387%;text-indent:0.0%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">(a) Documents files as part of this Annual Report on Form 10-K:</font></p>
  <p style="margin-left:6.387%;text-indent:4.358%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">(1) Financial Statements</font></p>
  <p style="margin-left:13.533%;text-indent:0.0%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The response to this portion of Item 15 is set forth under Item 8 hereof.</font></p>
  <p style="margin-left:6.387%;text-indent:4.358%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">(2) Financial Statement Schedules</font></p>
  <p style="margin-left:13.533%;text-indent:0.0%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">All financial statement schedules have been omitted because they are not applicable, not required, or the information required is shown in the consolidated financial statements or the notes thereto.</font></p>
  <p style="margin-left:6.387%;text-indent:4.358%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">(3) Exhibits</font></p>
  <p style="margin-left:13.533%;text-indent:0.0%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The exhibits required by Item 601 of Regulation S-K and Item 15(b) of this Annual Report on Form 10-K are listed in the Exhibit Index immediately preceding the signature page of this Annual Report on Form 10-K. The exhibits listed in the Exhibit Index are incorporated by reference herein.</font></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:16.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_16_form_10_k_summary"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">ITEM 16. Form 10</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">-K Summary</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">None.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">127</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Exhibit Index</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:0.1701388888888889in;border-spacing:0;table-layout:fixed;width:97.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:7.054%;"></td>
    <td style="width:1.031%;"></td>
    <td style="width:48.454%;"></td>
    <td style="width:1.031%;"></td>
    <td style="width:5.155%;"></td>
    <td style="width:1.031%;"></td>
    <td style="width:9.278%;"></td>
    <td style="width:1.031%;"></td>
    <td style="width:5.155%;"></td>
    <td style="width:1.031%;"></td>
    <td style="width:9.278%;"></td>
    <td style="width:1.031%;"></td>
    <td style="width:9.441%;"></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Exhibit</font></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Number</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Exhibit Description</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Form</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">File No.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Exhibit</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Exhibit</font></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Filing Date</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Filed/Furnished Herewith</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:5.5pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#160;&#160;3.1</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:5.5pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:5.5pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1826892/000119312520321571/d89083dex31.htm"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Amended and Restated Certificate of Incorporation of BioAtla, Inc.</font></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:5.5pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:5.5pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">8-K</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:5.5pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:5.5pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">001-39787</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:5.5pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:5.5pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">3.1</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:5.5pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:5.5pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">12-18-20</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:5.5pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:5.5pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:right;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#160;&#160;3.2</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1826892/000119312520321571/d89083dex32.htm"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Amended and Restated Bylaws of BioAtla, Inc.</font></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">8-K</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">001-39787</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">3.2</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">12-18-20</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:right;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#160;&#160;4.1</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1826892/000119312520312311/d258427dex41.htm"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Specimen Common Stock Certificate evidencing the shares of common stock</font></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">S-1/A</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">333-250093</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">4.1</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">12-08-20</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:right;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#160;&#160;4.2</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1826892/000119312520312311/d258427dex42.htm"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Investors&#x2019; Rights Agreement, dated July 13, 2020</font></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">S-1/A</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">333-250093</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">4.2</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">12-08-20</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:right;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#160;&#160;4.3</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1826892/000095017022002303/bcab-ex4_3.htm" style="-sec-extract:exhibit"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Description of Securities</font></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">X</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10.1+</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1826892/000119312520312311/d258427dex101.htm"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">2020 Equity Incentive Plan</font></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">S-1/A</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">333-250093</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10.1</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">12-08-20</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:right;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10.2+</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1826892/000119312520321696/d56161dex992.htm"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Amendment No. 1 to 2020 Equity Incentive Plan</font></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">S-8</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">333-251520</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">99.2</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">12-18-20</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:right;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10.3+</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1826892/000119312520312311/d258427dex102.htm"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Form of Restricted Stock Agreement</font></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">S-1/A</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">333-250093</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10.2</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">12-08-20</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:right;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10.4+</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1826892/000119312520312311/d258427dex103.htm"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">2020 Employee Stock Purchase Plan</font></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">S-1/A</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">333-250093</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10.3</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">12-08-20</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:right;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10.5*</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001826892/000119312520293235/d258427dex104.htm"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Exclusive License Agreement with Himalaya SEZC, dated January 1, 2020</font></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">S-1</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">333-250093</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10.4</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">11-13-2020</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:right;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10.6*</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001826892/000119312520293235/d258427dex105.htm"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Exclusive License Agreement with Inversagen LLC, dated March  15, 2019, as amended by First Amendment to Exclusive License Agreement, dated July 7, 2020</font></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">S-1</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">333-250093</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10.5</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">11-13-2020</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:right;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10.7*</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001826892/000119312520293235/d258427dex106.htm"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Exclusive License Agreement with BioAtla Holdings LLC, dated January  1, 2020, as amended by First Amendment to Exclusive License agreement, dated July 7, 2020</font></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">S-1</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">333-250093</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10.6</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">11-13-2020</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:right;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10.8*</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001826892/000119312520293235/d258427dex107.htm"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Amended and Restated Exclusive License Agreement with EXUMA Biotech Corp. (formerly F1 Oncology, Inc.), dated November 22, 2019</font></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">S-1</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">333-250093</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10.7</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">11-13-2020</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:right;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10.9*</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001826892/000119312520293235/d258427dex108.htm"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Global Co-Development and Collaboration Agreement with BeiGene, Ltd. and BeiGene Switzerland GmbH, dated April 8, 2019, as amended by First Amendment, dated December 24, 2019 and as amended by Second Amendment, October 5, 2020</font></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">S-1</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">333-250093</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10.8</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">11-13-2020</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:right;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10.10*</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001826892/000119312520293235/d258427dex109.htm"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Cell Line License Agreement with Life Technologies Corporation, dated June 28, 2018</font></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">S-1</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">333-250093</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10.9</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">11-13-2020</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:right;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10.11</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001826892/000119312520293235/d258427dex1010.htm"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Royalty Sharing Agreement with BioAtla Holdings, LLC, dated January 1, 2020</font></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">S-1</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">333-250093</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10.10</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">11-13-2020</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:right;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10.12+</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1826892/000119312520312311/d258427dex1011.htm"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Employment Letter Agreement between BioAtla, LLC and Jay Short, as amended by the Letter Amendment dated October 1, 2011</font></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">S-1/A</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">333-250093</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10.11</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">12-08-20</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:right;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10.13+</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1826892/000119312520312311/d258427dex1012.htm"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Offer Letter between BioAtla, LLC and Carolyn Short, dated November 30, 2015</font></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">S-1/A</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">333-250093</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10.12</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">12-08-20</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:right;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10.14+</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1826892/000119312520312311/d258427dex1013.htm"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Severance Agreement between BioAtla, LLC and Jay Short, dated July 1, 2018</font></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">S-1/A</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">333-250093</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10.13</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">12-08-20</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:right;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10.15+</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1826892/000119312520312311/d258427dex1014.htm"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Offer Letter between BioAtla, LLC and Scott Smith, dated August 2, 2018</font></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">S-1/A</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">333-250093</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10.14</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">12-08-20</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:right;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10.16+</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1826892/000119312520312311/d258427dex1015.htm"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Letter Agreement between BioAtla, LLC and Scott Smith, dated August 3, 2018</font></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">S-1/A</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">333-250093</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10.15</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">12-08-20</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:right;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10.17+</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1826892/000119312520312311/d258427dex1016.htm"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Severance Agreement between BioAtla, LLC and Scott Smith, dated August 20, 2018</font></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">S-1/A</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">333-250093</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10.16</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">12-08-20</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:right;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10.18+</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1826892/000119312520312311/d258427dex1017.htm"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Severance Agreement between BioAtla, LLC and Carolyn Short, as amended by the Amended Severance Agreement between BioAtla, LLC and Carolyn Short, dated April 1, 2020</font></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">S-1/A</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">333-250093</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10.17</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">12-08-20</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:right;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10.19+</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1826892/000095017022002303/bcab-ex10_19.htm" style="-sec-extract:exhibit"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Offer Letter between BioAtla, LLC and Richard Waldron, dated October 23, 2013</font></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">X</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10.20+</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1826892/000095017022002303/bcab-ex10_20.htm" style="-sec-extract:exhibit"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Severance Agreement between BioAtla, LLC and Richard Waldron, dated July 1, 2018</font></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">X</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">128</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <table style="margin-left:0.1701388888888889in;border-spacing:0;table-layout:fixed;width:97.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:7.054%;"></td>
    <td style="width:1.031%;"></td>
    <td style="width:48.454%;"></td>
    <td style="width:1.031%;"></td>
    <td style="width:5.155%;"></td>
    <td style="width:1.031%;"></td>
    <td style="width:9.278%;"></td>
    <td style="width:1.031%;"></td>
    <td style="width:5.155%;"></td>
    <td style="width:1.031%;"></td>
    <td style="width:9.278%;"></td>
    <td style="width:1.031%;"></td>
    <td style="width:9.441%;"></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Exhibit</font></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Number</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:center;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Exhibit Description</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:center;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Form</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:center;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">File No.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:center;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Exhibit</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:center;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Exhibit</font></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Filing Date</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:center;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Filed/Furnished Herewith</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:5.5pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10.21+</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:5.5pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:5.5pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1826892/000095017022002303/bcab-ex10_21.htm" style="-sec-extract:exhibit"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Offer Letter between BioAtla, LLC and Eric Sievers, dated June 17, 2019</font></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:5.5pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:5.5pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:5.5pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:5.5pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:5.5pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:5.5pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:5.5pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:5.5pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:5.5pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:5.5pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">X</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10.22+</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1826892/000095017022002303/bcab-ex10_22.htm" style="-sec-extract:exhibit"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Offer Letter between BioAtla, LLC and Christian Vasquez, dated October 22, 2015</font></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">X</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10.23+</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1826892/000119312520312311/d258427dex1018.htm"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Form of Indemnification Agreement between the Registrant and each of its executive officers</font></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">S-1/A</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">333-250093</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10.18</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">12-08-20</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:right;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10.24</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1826892/000119312520312311/d258427dex1019.htm"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Lease Agreement with HCP Torreyana, LLC, dated June 2, 2017, as amended by First Amendment to Lease, dated January 16, 2019</font></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">S-1/A</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">333-250093</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10.19</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">12-08-20</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:right;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10.25</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001826892/000119312520293235/d258427dex1020.htm"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Payment Protection Program Promissory Note dated April 22, 2020, by and between BioAtla, LLC and City National Bank.</font></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">S-1</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">333-250093</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10.20</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">11-13-2020</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:right;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10.26</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1826892/000095017022002303/bcab-ex10_26.htm" style="-sec-extract:exhibit"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Amendment No. 2 to 2020 Equity Incentive Plan</font></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">X</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10.27</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1826892/000095017022002303/bcab-ex10_27.htm" style="-sec-extract:exhibit"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Amendment No. 1 to Employee Share Purchase Plan</font></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">X</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10.28*</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1826892/000095017022002303/bcab-ex10_28.htm" style="-sec-extract:exhibit"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Amendment No. 3 to Global Co-Development and Collaboration Agreement between BioAtla, Inc. and BeiGene, Ltd</font></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">X</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10.29+</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1826892/000095017021004617/bcab-ex10_1.htm"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Form of Non-Employee Director Stock Option Agreement</font></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10-Q</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">001-39787</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10.1</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">11-15-2021</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:right;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10.30+</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1826892/000095017021004617/bcab-ex10_2.htm"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Form of Employee Stock Option Agreement</font></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10-Q</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">001-39787</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10.2</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">11-15-2021</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:right;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10.31+</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1826892/000095017022002303/bcab-ex10_31.htm" style="-sec-extract:exhibit"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">BioAtla Director Compensation Policy</font></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">X</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">23.1</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1826892/000095017022002303/bcab-ex23_1.htm" style="-sec-extract:exhibit"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Consent of Independent Registered Public Accounting Firm</font></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">X</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">24.1</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><a href="#signatures"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Power of Attorney (included on signature page)</font></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">X</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">31.1</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1826892/000095017022002303/bcab-ex31_1.htm" style="-sec-extract:exhibit"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Certification of Chief Executive Officer pursuant to Rule 13a-14(a) and 15d-14(a), as adopted pursuant to Section  302 of the Sarbanes-Oxley Act of 2002.</font></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">X</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">31.2&#134;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1826892/000095017022002303/bcab-ex31_2.htm" style="-sec-extract:exhibit"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Certification of Chief Financial Officer pursuant to Rule 13a-14(a) and 15d-14(a), as adopted pursuant to Section  302 of the Sarbanes-Oxley Act of 2002.</font></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">X</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">32.1&#134;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1826892/000095017022002303/bcab-ex32_1.htm" style="-sec-extract:exhibit"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18.U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002.</font></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">X</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">101.INS</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">X</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">101.SCH</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Inline XBRL Taxonomy Extension Schema Document</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">X</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">101.CAL</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">X</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">101.DEF</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Inline XBRL Taxonomy Extension Definition Linkbase Document</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">X</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">101.LAB</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Inline XBRL Taxonomy Extension Label Linkbase Document</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">X</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">101.PRE</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:5.5pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">X</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">104</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Cover Page Interactive Data File (formatted in iXBRL and contained in Exhibit 101)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">X</font></p></td>
   </tr>
  </table>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <table style="margin-left:0.1736111111111111in;border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:2.17%;"></td>
    <td style="width:97.83%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#134;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Furnished and not filed.</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">+</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Indicates management contract or compensatory plan.</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">*</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Portions of this exhibit have been redacted in accordance with Item 601(b)(10)(iv) of Regulation S-K.</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">129</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><a href="#toc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;">Table of Contents</font></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="signatures"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">SIGNA</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">TURES</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <table style="margin-left:0.1736111111111111in;border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:44.485%;"></td>
    <td style="width:1.157%;"></td>
    <td style="width:5.065%;"></td>
    <td style="width:1.197%;"></td>
    <td style="width:3.294%;"></td>
    <td style="width:1.157%;"></td>
    <td style="width:43.644%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">BioAtla, Inc.</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:10.8pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:10.8pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:10.8pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:10.8pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Date: February 28, 2022</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.625pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.625pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">/s/ Jay M. Short, Ph.D.</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Jay M. Short, Ph.D.</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Chief Executive Officer</font></p><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(Principal Executive Officer and</font></p><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Authorized Signatory)</font></p></td>
   </tr>
  </table>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:9.9pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Jay M. Short, Ph.D. and Richard A. Waldron as his or her true and lawful attorneys-in-fact, and each of them, with full power of substitution, for him or her in any and all capacities, to sign any amendments to this Annual Report on Form 10-K and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact, and either of them, or his or their substitute or substitutes may do or cause to be done by virtue hereof.</font></p>
  <p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:9.9pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report on Form 10-K has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</font></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <table style="margin-left:0.1701388888888889in;border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:40.882%;"></td>
    <td style="width:2.106%;"></td>
    <td style="width:38.964%;"></td>
    <td style="width:2.097%;"></td>
    <td style="width:15.951%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.875pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">SIGNATURE</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.875pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">  </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.875pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">TITLE</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.875pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">  </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.875pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">DATE</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:10.8pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:10.8pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:10.8pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.625pt solid rgba(0,0,0,1);text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">/s/ Jay M. Short, Ph.D.</font></p><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.65pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Jay M. Short, Ph.D.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">  </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Chief Executive Officer and Director</font></p><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">(Principal Executive Officer)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">  </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">February 28, 2022</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:10.8pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:10.8pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:10.8pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.625pt solid rgba(0,0,0,1);text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">/s/ Richard A. Waldron</font></p><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.65pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Richard A. Waldron</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">  </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Chief Financial Officer</font></p><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">(Principal Financial and Accounting Officer)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">  </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">February 28, 2022</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:10.8pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:10.8pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:10.8pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.625pt solid rgba(0,0,0,1);text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">/s/ Scott Smith</font></p><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.65pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Scott Smith</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">  </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">President and Director</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">  </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">February 28, 2022</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:10.8pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:10.8pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:10.8pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.625pt solid rgba(0,0,0,1);text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">/s/ Guy Levy</font></p><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.65pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Guy Levy</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">  </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Director</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">  </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">February 28, 2022</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:10.8pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:10.8pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:10.8pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.625pt solid rgba(0,0,0,1);text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">/s/ Lawrence Steinman</font></p><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.65pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Lawrence Steinman</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">  </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Director</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">  </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">February 28, 2022</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:10.8pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:10.8pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:10.8pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.625pt solid rgba(0,0,0,1);text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">/s/ Mary Ann Gray, Ph.D.</font></p><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.65pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Mary Ann Gray, Ph.D.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">  </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Director</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">  </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">February 28, 2022</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:10.8pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:10.8pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:10.8pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.625pt solid rgba(0,0,0,1);text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">/s/ Susan Moran, M.D.</font></p><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.65pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Susan Moran, M.D.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">  </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Director</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">  </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">February 28, 2022</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.625pt solid rgba(0,0,0,1);text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">/s/ Sylvia McBrinn</font></p><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.65pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Sylvia McBrinn</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Director</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">February 28, 2022</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.625pt solid rgba(0,0,0,1);text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">/s/ Edward Williams</font></p></td>
    <td rowspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:6.03pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td rowspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Director</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:6.03pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td rowspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">February 28, 2022</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.65pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Edward Williams</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:6.03pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">130</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>img129881027_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img129881027_0.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_X1*_17AI9@  34T *@    @ !P$2  ,
M   !  $   $:  4    !    8@$;  4    !    :@$H  ,    !  (   $Q
M  (    >    <@$R  (    4    D(=I  0    !    I    -  +<;    G
M$  MQL   "<0061O8F4@4&AO=&]S:&]P($-3-"!-86-I;G1O<V@ ,C Q,#HP
M.#HQ-R Q,3HS-CHS-0   Z !  ,    !  $  * "  0    !   !O* #  0
M   !    WP         & 0,  P    $ !@   1H !0    $   $> 1L !0
M  $   $F 2@  P    $  @   @$ !     $   $N @( !     $  !&)
M     $@    !    2     '_V/_@ !!*1DE&  $"  !( $@  /_M  Q!9&]B
M95]#30 !_^X #D%D;V)E &2      ?_; (0 # @(" D(# D)#!$+"@L1%0\,
M# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,_\  $0@ 4 "@ P$B  (1 0,1 ?_=  0
M"O_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
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MN/6X5UO+6R?4D[1\%V'1_K=T?K.8</"-IM:QUIWUE@VM+6'5W_&-7!_XQO\
MQ17_ /A:O\EJ&:0..XGKT7_#L)CS)CDA1X">&8\8OJ.,2[&J<XR2QI)/),(J
M%B_T6G_BV_D"S.M?6OHO17>GEVE^1$C&I&^R/Y0^A5S_ (9]:FX@!9--&..<
MY\,(F4KVB["2XW_QSNE;OZ%E;/']%,?U?6_[\MKHGUJZ/ULFO$L+,AHW.Q[A
MLLC]YH]S+/\ K3[$T9($T)!DGRF>$>*6.0B-SN__TH_7OIYPOK'?8!%6:UN0
MR!I,>E>/ZWJ5^I_UU8-=EE5C+J3MMJ<VRMW@YA#V'_.:O5/KMT!W6.E;\=N[
M-PR;:!W<"/TV/_UU@]G_  U=2\H!!$C@JCFAPS/8ZAZ+D,PRX(@ZR@."0\OE
M_P :+ZS8.F_73ZNPQ_IFR' B'/HO9^:]GM^A_8]:A_L_G=ZY ?XO_K*+_2 Q
MRS_N1ZAV?]M^GZW^OTUSN%G9O3[_ +1@WOQKN"ZLQ('YMC#-=K/Y%C%ML_Q@
M?6AM>PW4V'_2.I&[_H/97_X&G&>.=&8/$.L>K%'E>9P<4<$X2QR-B.2[@]UC
M4].^J'0#ZMA>RJ7V6$ /NN?^;6S]ZS^;IK_,K_[<7+?47(MR?K-=?='JW47V
MV1QN?;38Z/[3ES'4.K]2ZG<V[J&0_(>SZ ,!C9^EZ558;6S=^]MWJ73NK9O3
M,@Y.#;Z-Q8:R_:U_M<6N<W;8'-^E6Q"64&4*%0AL%1Y&8Q91*0EFS#U2_1>K
M^O.39B_6/$R*H]6BBNUD\%S+;7;7?R71M71Y%?3OK;T-KJ+=FXA];XEU-S1J
MRVN1[F[_ $[:_P ^M_Z/_!VKS/J'5\[J=[<C/M]:YK!6UVUK/:"7[=M8:WZ3
MU'"ZIG=/N-^#>_'M,!Q9$. X%M;PZJW_ *XQ 9AQRL7">XZHER,SBQ 2$<V'
MY9?HO1'ZD_63UO2#*-O^F]4[/\WT_6_\#745?5VW!^KM_2<&T.RLL.;=DOEH
MFV*KK@QI/\S1_,5_R*_?_A5Q;O\ &%]9166^K0"!K9Z7N_K?SGI_^!K4/5^J
M=!Z,WJO47G(Z[U@QCMO&E-#1O_FJ]C*_I-LMIK]+]+=3ZO\ ,J3&<0LQ$MM3
M+]$,6?%S<N 3ECOB'!"%_K)Q]5RXOT(?I.S@_P"+WZMXU+69%+LVT#W6W/<)
M_JU5.KJ8W^PL/Z[?5+IG3,!G4NF,- 98VNZG<YS"'G:VQGJ%[F/:_9]'V*GT
MW%^OGUAK.;3GVUTDD-M?<ZACRT[7^C5B,^BUWMW^GL0^O= ^MF!TU^3U7J'V
MG$#V-=5]HNMESG!M;O2NK97[7I2,3 UCH5I)=BCECGCQ\V)2XJEBXI&_ZG"[
MGU!;5U3ZN9G2LYINQ:[C6&26_HWM9=Z8=66/;^E-COI+D>O8.+A_6/(P<9FS
M&KOJK97N<Z&N%)>-[RZS_"/_ #EU_P#BP_H&?_X8;_Y[8N7^M/\ XK\S_P ,
MT_\ 4XZ$Q^J@>NR_ER1SO,1!/#P\?#^CQG@]5?O/I'3/JOT+I.2<KI^,:;RP
MUE_J6/\ :2USF[;;+&_28U>??XQO_%%?_P"%J_R6KU9>4_XQO_%%?_X6K_):
MI,X QT!6O1J_#)SGS1E.1D> ZR/$=XOJ.+_1:?\ BV_D"Y!WU%=U/K^?U#J3
MW58=ETT4UD!]@#6--EE@W>E5[?H-_3/_ ."_/Z_%_HM/_%M_(%Y_]8_KAUG,
MZL_I/1'.IK98<9IJ -MUH.Q^VQ_MIJ:]NUFS_CK+?3^@[(8",>+7L.[#R8SG
M)D&$B%CUY)?H0MZ8_43ZJ%FS[ !_*%EN[_MSU-Z\\ZEC/^KGUD?3C6N><"ZN
MVFPZ.+"&7!EFV-WZ-_H6_P"D6^SZJ?XP7M#G=5<PN$ECLR^1Y'TZW,_S5S'6
ML3/PNJ78O4KOM&96&>K=O=9.YK7U_I;@RQVUAVJ#*= 1#@UW=#DP>.<9<R.8
M!B;A9G_A>I__T_55POUS^IEEMEG5NDUE]CR7Y6*P:N/YU]#?SK'?X6K_  O\
MY7^E_G.Z239P$Q19<&>>&8G ^8Z2'8O@X((D:@IUZMU_ZD]*ZPYV0R</-=SD
M5 $./_=BG1EO]?\ 1W?\*N)ZA]1/K'A$FNAN;4-?4QW"8\Z+?3LW?\7ZRISP
MSCTL=P[N#G\&4"Y#'+]V>GV2^5Y])6+>F]3ITNPLFL_RZ;!^5B5?3NI7&*</
M)L/@RFQWY&*.CV;/'&KXA7FUTB0!), <DK=Z?]2/K)G$$XPQ*S_A,EP;_P"
ML]2__.KK7:]!^HG2NE/;DY!.=F,(<RRP0QA!]KJ<?W-:[_A+'6V?Z/TU)##.
M72AW+6S\_@Q#YA.7[L/5]LOT7 ^IOU+MR+:^J]6K+,=A#\;%>(=8X:MNR&'Z
M-+?\%3_AOIV?HOYZ[_C.PKK,7"Z@P33BOLKN/[HN]/T['?NL]2GT_P#KJ[=1
M>QEC'5V-#V/!:YKA((.CFN:59]F/ 8#KU<G[]D/,1SR%\&T.@A+TR#Y_]5_K
MUT_I?2:>FY]-P=C;FUVU-#VN:27MWMW,>Q[=VQ5/K?\ 7.CK>*S!PJK*L9KQ
M;;;=#7.+9V,:QKG[:_S][UUUOU$^JUMAL^Q>F7&2*[+6-U_=KKL;6S^PU$Q/
MJ7]6<2T758+7V-^B;G/M /CLO?8S=_93/;RF/#Q1K;Z,XYGD1D.88\GN7QT>
M'@XS_A-#_%UTZ[$Z(_(O:6'.M-U;3(/I!K*ZG[3_ *38ZS_B_37)?7K$R,/Z
MSWWENUN2:\C&>?HN+&UL>W_K=M7O9^YL7JZK9_3<#J5'V?/H9D53(:\3!XWL
M/TF/U^FQ/EBN @#\NS#AYXPYF>:4;&2Q*(Z1Z5_BN/\ 5[ZYX/7<H8=>/=1D
MBHVOW[#6-I8Q[66,?O?[K/\ 0UKD_P#&5A7,ZTS)<#Z&70UC+.V^LO#Z_P"M
ML>QZ[CIGU7Z%TG).5T_&]&\L-9?OL=[7%KG-VVV/;])C5>S,+$SJ'8V92S(I
M=S78T.'Q]WYW\I*6.4H<,B.+N%8^9PX>8&3#&7MUPF,OFU[?,\W]7/KSA]1M
MP^EOQ[J\VUNQSP&&G=6QUCG!_J>KM<VK_0KC+G97U:^MC[GU;WXN19:QCM/4
MIM]3:YCOY=-WTO\ !W+T;!^J/U=Z?EUYN'B>ED4DFM_J6&-S75N]C[',^@]W
MYJM=4Z+TKJU;:^HXS,@,^@XR'MGGT[:RRUF[^0]-..<HBR.*)])7PYOE\>67
M!"7LY8\.2,OFXO5\OJ^7A< _XS.@^GN%&47]J_3:#_G^KZ?_ $UQ1=F?6CZR
M;A7MNSK6ES&:BNENVLN<[V_S..SWV?X2U>@?\P/JK/\ 17QX>O=_Z56KTWHW
M2^E5FOI^,S'#HWN:)<Z./4M=NLLY_/>D<>2="9'".RZ'-\K@$CR\)^Y(<-Y*
MH?\ .?_9_^T7@%!H;W1O<VAO<" S+C  .$))300$       @' (   (  !P"
M!0 48FEO871L85]L;V=O7W1A9VQI;F4X0DE-!"4      !!B.^V&0JQS*WH;
M'@Y,:I+0.$))30/M       0 2P    !  $!+     $  3A"24T$)@
M#@             _@   .$))300-       $    'CA"24T$&0      !
M !XX0DE- _,       D           $ .$))32<0       *  $
M 3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@
M     0 R     0!:    !@       0 U     0 M    !@       3A"24T#
M^       <   _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M    _____________________________P/H   X0DE-! @      !     !
M   "0    D      .$))300>       $     #A"24T$&@     #30    8
M             -\   &\    # !B &D ;P!A '0 ; !A %\ ; !O &< ;P
M  $                          0             !O    -\
M             0                         0     0       &YU;&P
M   "    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO
M;F<          $QE9G1L;VYG          !"=&]M;&]N9P   -\     4F=H
M=&QO;F<   &\    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC
M90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG
M  9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D
M     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/
M8FIC     0       %)C=#$    $     %1O<"!L;VYG          !,969T
M;&]N9P          0G1O;6QO;F<   #?     %)G:'1L;VYG   !O     -U
M<FQ415A4     0       &YU;&Q415A4     0       $US9V5415A4
M 0      !F%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L
M 0    AC96QL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%
M4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M
M#T53;&EC959E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU
M;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO
M;F<         "FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L
M;VYG          MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #
M  (_\        #A"24T$%       !     $X0DE-! P     $:4    !
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M;LAA^C2W_!4_X;Z=GZ+^>N_XSL*ZS%PNH,$TXK[*[C^Z+O3].QW[K/4I]/\
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M2'#>2J'_ #G_V0 X0DE-!"$      %4    ! 0    \ 00!D &\ 8@!E "
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M86-K970@96YD/2)W(C\^_^(,6$E#0U]04D]&24Q%  $!   ,2$QI;F\"$
M;6YT<E)'0B!865H@!\X  @ )  8 ,0  86-S<$U31E0     245#('-21T(
M              $  /;6  $     TRU(4" @
M                                       18W!R=    5     S9&5S
M8P   80   !L=W1P=    ?     48FMP=    @0    4<EA96@   A@    4
M9UA96@   BP    48EA96@   D     49&UN9    E0   !P9&UD9    L0
M  "(=G5E9    TP   "&=FEE=P   ]0    D;'5M:0   _@    4;65A<P
M! P    D=&5C:   !#     ,<E120P  !#P   @,9U120P  !#P   @,8E12
M0P  !#P   @,=&5X=     !#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W;&5T="U0
M86-K87)D($-O;7!A;GD  &1E<V,         $G-21T(@245#-C$Y-C8M,BXQ
M               2<U)'0B!)14,V,3DV-BTR+C$
M                                             %A96B        #S
M40 !     1;,6%E:(                     !865H@        ;Z(  #CU
M   #D%A96B        !BF0  MX4  !C:6%E:(        "2@   /A   ML]D
M97-C         !9)14,@:'1T<#HO+W=W=RYI96,N8V@              !9)
M14,@:'1T<#HO+W=W=RYI96,N8V@
M                            9&5S8P         N245#(#8Q.38V+3(N
M,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="               N
M245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M                             &1E<V,         +%)E9F5R96YC92!6
M:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$              "Q2
M969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M                              !V:65W       3I/X %%\N !#/%  #
M[<P !!,+  -<G@    %865H@      !,"58 4    %<?YVUE87,
M 0                        */     G-I9R      0U)4(&-U<G8
M   $      4 "@ / !0 &0 > ", *  M #( -P [ $  10!* $\ 5 !9 %X
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M P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#_\
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MT1,(F$ S#D(I0$=NPH7"!"%U$=@   &S8%=#=5ZJ)^Z7,/JB;]&O2_;?;MN
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M1.BGC\[&A'%IZQ_=0K,^U;LC+L8>UL3=VNGP%=LU#:K-E3EUT_0]ZB8=> X
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MM7:3T!KV=0;N@*]L95#N&X%7.B5]A=O3U[A#0!UZ-@_)7NC/!4&X9Q5S8AR
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M53955K0!X2[>D.CL 0^.N1Q5-DZ55++HT] ; '?V::[0]%?85/E56LAV@ [
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MMG  A^E'I$.K=77UJG2=*JUG^A^;;NU':.[HKY*ILJJMF.P-=- TVZ]N[?7
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M6]XID[!Q7*T]CY-PW)*SM[6FTMULKP&<KOV;I63>JMR?7*1&&:.0.H <)>\
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M62<+7(BB4XD%,UFSK6(FY)X.P00BRR)Q*;738;ALC.=I-892QTT-NR\@ J3
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M7E>ZH9(#MBU;:LF!C[9M"!B+9MZ)1!K&PT''MHV/:)!L$J+5J1)$#'$!$YA
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M8>17=HS0NK-P\W?D.C<G??9NV%TQC:^-A[MA:USJRO8V@+VBE:XU I6F&O\
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MWG%A47;P?<3=?1XOGED+X7AS;OY,/W+=>\N42_$$8VNO*F,K7>< M+DR#9D
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M!^BW;=-1'9\G33F78V(GH77K2&_;V;PT#KU -@:B-?%5W-A[%..\.^\Y._\
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M;T//"<BQE-2IQBFJ90, B8_ 6J6N\^0R!HO,LNXY"?:]V]H&&))>QW&N 8<
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M+[ ;:_#+OWN!2_ZR+6L-*(M,OCYB'^K3RKK_ /6V(_WPH2HQW;^Y"3X3%_\
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M 7R]>VHQ69ZK#[\W#]P/S:>T$^ZGWP^_7LOZOWGW@^Q?L#VC^W>S\'V?ZO\
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MDDUW:NC;=VTUN9 V.8.+!,QA< 2T.+:@&E<:*.#^"HE6=2ED^Z\_QX_YL_\
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M%(@B2X;E;.;V9MTDM2%2;RJ*?"( )1X2<-W9;KS5N5,[JVSN5T-1YLE)105
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M&RJT-[=2?[JLOD2_3%9@\!VC":C6^:4^AP?H58O)?O$7.]=;59E8\%A7%!#
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MY&>4BPL2O7$2VG8B)=7QF"Y073;QK[($XV3D+QE%Y)PH1L:)@&[9*-:N3]T
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MEP87<D,$8#IKB6A/=Q-) P J][BUC!BYU2T.E3XD]VRY4K;BF9\PY:S)D^Y
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MH X<<2>LDDDU)))JM(.<9OF6?YI?YWG-Z^YS6ZF=++*\U<^1Y+G./1B3P
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MGN'Z6".+1[IB0>Z<%K[WL\;%C9,N].;0 7%Z:M?F,C#W3#B#ZK$X RNPPED
MCZ6LD!#A+.LNRK1QU:\%8]@VU!V=9UKQZ43;]L6U&M(B#AHYOL291T<P20:M
M4"B8PB!2@)CB)AU$1$<@K2SM;"VAM+*W;%:QBC6M   XX =9J2>)))-3BM:^
M;9MF>>YE>YQG-_-=9I</+Y997E\DCCQ<YSB23T<<!@*"@555Z53DHB41*(M.
M'B%^#1@'G?=OLC6V^'".?543>T7[;\.WD+=O94@:HER+:I5XW[4?#PBF64:N
M&\@0I@%?VLB:2)8SU?MGE>HY)<PLGBTS9U27!M8Y3QK(P4HX\.\::XDN;)0
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MZ<=&7[;*R[)G=K!@F8"H+E7:22*92)%=^SIE0&/=7[>97JIYO62&VS>@'>M
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MGK"6YFLI6=B"VN\!5[:UB*CD+(3@A#I]ZR4?@5C8\$=PF)N!TFZF 3$OK-S
M.R^,FV>SZ[<R3.+B*T@Z6@B67 \*-/=@$5H[O'$'BTK'77?COT5ED4UMH#3U
MUFE_2C9K@>K6P./G<OG7$E.EA9#6N$@HI3O*KR>8!Y,<?DQU@:R&]NL'!F[B
MXKB?&+*7G>DH@@" 2]V7(HDDYDG.@&X$"%19-1.8K=! @B6IUT[IC)],6AM<
MKMZ.=3GD=YTDA' O=0>4-:&L:2>5HJ5KLW&W1UINKG1SO6.;.GE:"(HF^9!
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MJ3*B^7+PV^LQ4UC\V4 #VT3B:D\ (W2.-*\K5L.VW\;6V^J6V]CK2"7(<X-
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62B)1$HB41*(E$2B)1$HB41*(E$7_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img129881027_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img129881027_1.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" .O!QL# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M6KW07I]C)_X3"P_YXW/_ 'RO_P 51_PF%A_SQN?^^5_^*K6_LO3_ /GQM?\
MORO^%']EZ?\ \^-K_P!^5_PHY:O=!>GV,G_A,+#_ )XW/_?*_P#Q5'_"86'_
M #QN?^^5_P#BJUO[+T__ )\;7_ORO^%']EZ?_P ^-K_WY7_"CEJ]T%Z?8R?^
M$PL/^>-S_P!\K_\ %4?\)A8?\\;G_OE?_BJUO[+T_P#Y\;7_ +\K_A1_9>G_
M //C:_\ ?E?\*.6KW07I]C)_X3"P_P">-S_WRO\ \51_PF%A_P \;G_OE?\
MXJM;^R]/_P"?&U_[\K_A1_9>G_\ /C:_]^5_PHY:O=!>GV,G_A,+#_GC<_\
M?*__ !5'_"86'_/&Y_[Y7_XJM;^R]/\ ^?&U_P"_*_X4?V7I_P#SXVO_ 'Y7
M_"CEJ]T%Z?8R?^$PL/\ GC<_]\K_ /%4?\)A8?\ /&Y_[Y7_ .*K6_LO3_\
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M?^A?_P#)S_["C_A=9_Z%_P#\G/\ ["NN_P"%9^$/^@1_Y,R__%T?\*S\(?\
M0(_\F9?_ (NCEJ]P]MEG_/M_U_V\<C_PNL_]"_\ ^3G_ -A1_P +K/\ T+__
M ).?_85UW_"L_"'_ $"/_)F7_P"+H_X5GX0_Z!'_ ),R_P#Q='+5[A[;+/\
MGV_Z_P"WCD?^%UG_ *%__P G/_L*/^%UG_H7_P#R<_\ L*Z[_A6?A#_H$?\
MDS+_ /%T?\*S\(?] C_R9E_^+HY:O</;99_S[?\ 7_;QR/\ PNL_]"__ .3G
M_P!A1_PNL_\ 0O\ _DY_]A77?\*S\(?] C_R9E_^+H_X5GX0_P"@1_Y,R_\
MQ='+5[A[;+/^?;_K_MXP]"^+=OJVL6VGW&E/:_:)%B219_,PQ.!D;1WQ7I%?
M.EK;0V7Q1AM;=-D$&M+'&N2=JK-@#)YZ"OHNG2DW>YEF>'I491=)635PHHHK
M4\P**** "BBB@ HHHH **** "BBB@!K.%&37&^+OB';>%KB&V6S:[N)$\PJ)
M-@5<X&3@^A[=JZ'59C% Q%>$^/IVN-?C9CDBW _\>:LZDG&-T=^74(5ZZA45
MT=?_ ,+K/_0O_P#DY_\ 84?\+K/_ $+_ /Y.?_85NZ!\//"U[X<TN[N-+WSS
MVD4DC?:)1N9D!)P&QU-:/_"L_"'_ $"/_)F7_P"+J4JO<ZY5<LBW%TWI_7\Q
MR/\ PNL_]"__ .3G_P!A1_PNL_\ 0O\ _DY_]A77?\*S\(?] C_R9E_^+H_X
M5GX0_P"@1_Y,R_\ Q='+5[D^VRS_ )]O^O\ MXY'_A=9_P"A?_\ )S_["C_A
M=9_Z%_\ \G/_ +"NN_X5GX0_Z!'_ ),R_P#Q='_"L_"'_0(_\F9?_BZ.6KW#
MVV6?\^W_ %_V\<C_ ,+K/_0O_P#DY_\ 84?\+K/_ $+_ /Y.?_85UW_"L_"'
M_0(_\F9?_BZ/^%9^$/\ H$?^3,O_ ,71RU>X>VRS_GV_Z_[>.1_X76?^A?\
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MB%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !6/KG_ ![M]*V*Q]<_X]V^E '&:9_R&K7_ *^4_P#0A7I=>::9
M_P AJU_Z^4_]"%>EUC3^*7J:U/AB%%%%;&05'-<0VX0S31QAV"+O8+N8] ,]
M34E<[XN_U&E_]A&'^M14ER1<BH1YI6-TW, N1;&:/SRNX1;QNV^N.N*6:XAM
MD#SS1Q*2%#.P4$GH.:XSQ!;7<_C(36#$7=K8B>-1_'A\%?Q!-6]>U&'5?"]E
M>0?=DNHLJ>JG=R#]#6+Q%N;3;\37V/PZ[G17.IV%G(([J^MH'(R%EE53CUP3
M4T%Q#<Q"6WFCEC/1XV# _B*YV:V@NO'^RXACE0:=D+(H89W]>:+RUBT/7M-N
M;"-8(KR7[//#&,(V1E6QT!&*?M9:MK1.PO9K1=;'3$X&36?_ &[H_P#T%;'_
M ,"$_P :O2?ZM_H:X/PWJ?AJWT*"+4/LGVI2^_S(-Q^\<<X],4ZM7DDE=*_?
MY"IT^9-Z_([J"X@NHA+;S1S1GH\;!@?Q%25AWFM6NE6FGO9VGG6]W)MC6 !>
MHR"%QSG\*6VUVY_M6&PU'3'LFN Q@?SED#XY(..AQ5>VC>S>HO9RW1MU%=7,
M-G:R7-P^R&-=SM@G ^@K+N=9N_MTUKIVE27;0 >:[2B)02,@ D')JIJ.J1ZM
MX,U&=(VB98WCDC?JCCJ*4JT4G;=7_ (TW=7V.ABE2>%)8SN1U#*<8R#R*BEO
MK:&]@LY),3SAC&FT_,!UYZ"N>MO$%Y8Z3:3SZ+.NGI$@:X\U=P& -VSKC\:F
MU!UD\8Z$ZD%6BF(([C:*7MDXW6^GXL?LG?7S_ Z(,"2 02.H]*6L.QN;8:QK
MABLQ'-#L,LGF$^;\I(X_AQTJI'XJO9]+74H-"E>U"EI7,ZC:!UVC&6 _"G[:
M*6OGWZ"]E)['3T5E7NO06VF6UY%%)<-=E1;Q+PSEAD#V]ZJIX@O8]0LK.^T>
M2VDNG*JWGJZ@ 9Z@=?:J=:"=KB5.35S?HHHK0@**** .4\:?\N/_ &T_]EKJ
MATKE?&G_ "X_]M/_ &6NJ'2L8?Q)?(UE\$?F+1116QD%%%% !1110 4444 ,
ME_U9KS;QK_QX7O\ UQ?_ -!->DR_ZLUYMXU_X\+W_KB__H)I/8TH_P 2/JCG
M/@Y_R-]W_P!>#_\ HR.O;Z\0^#G_ "-]W_UX/_Z,CKV^LZ/PGH9Q_O3]$%%%
M%:GEA1110 4444 9][KND:9,(;_5;&TE*[@D]PD;$>N">G%26.K:=J@<Z?J%
MK=A/O&WF63;]<$XKB-4_LG_A;H_MC[%]G_L;Y?MFS;N\WMNXSC/ZU#?_ -AC
MQ[X=/A;[']N,KB\^P;=GV?;SYFSCTQG_  K'VCO\STE@X.*WNXWOTVN=Y9ZM
M8W]Y>VEM/YD]DX2X78PV,1D#)&#QZ9J[7FNE:IJ-CXR\71:7HLNIW#W43$"9
M840!.[MW/8 '\*ZC2/%UOJ6@7NIW%K-:26#O%=VQ&]XW3JHQ][VJHU$]_,RK
MX.<'>&J]WJKZI/;??;0Z*BN+?QQJ-G#;ZAJ?AF>STB=U4737*,\88@*SQ 9
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MP/\ [>/_ &G7K->3?&S_ )@?_;Q_[3K.K\#/0RK_ 'N'S_)G6?#+_DGVF?\
M;7_T:]=;7)?#+_DGVF?]M?\ T:]=;50^%'/B_P#>*GJ_S"BBBJ.<**** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MJMO?:O+:@6N[R8;4,06(P2Q;^59RIR3Y8^7X6\_(M3B]7YF]11176<X4444
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M_P"1U\'_ /7Q<?\ HJNOHK1QNK''3KN-1U'K>_XIK]0HHHJC **** "BBB@
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M]0_$\ >#0 , 7=O@#_?%=I14.FN7E1O'%R5=5I:V=[7.+^(__'IH'_8;MO\
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MH **** "BBB@ HHHH *Q]<_X]V^E;%9VJ0&:$@4 <%8RI#JD$LAVHDZLQQT
M(S7<_P#"2Z1_S]_^0W_PKCYM'G$C%01DU'_9-U[_ )5ARU(R;C;4VYH-)2OH
M=I_PDND?\_?_ )#?_"C_ (272/\ G[_\AO\ X5Q?]DW7O^5']DW7O^5/]]Y?
MB+]UYG:?\)+I'_/W_P"0W_PH_P"$ETC_ )^__(;_ .%<7_9-U[_E1_9-U[_E
M1^^\OQ#]UYG:?\)+I'_/W_Y#?_"C_A)=(_Y^_P#R&_\ A7%_V3=>_P"5']DW
M7O\ E1^^\OQ#]UYG:?\ "2Z1_P _?_D-_P#"C_A)=(_Y^_\ R&_^%<7_ &3=
M>_Y4?V3=>_Y4?OO+\0_=>9VG_"2Z1_S]_P#D-_\ "C_A)=(_Y^__ "&_^%<7
M_9-U[_E1_9-U[_E1^^\OQ#]UYG:?\)+I'_/W_P"0W_PH_P"$ETC_ )^__(;_
M .%<7_9-U[_E1_9-U[_E1^^\OQ#]UYG:?\)+I'_/W_Y#?_"C_A)=(_Y^_P#R
M&_\ A7%_V3=>_P"5']DW7O\ E1^^\OQ#]UYG:?\ "2Z1_P _?_D-_P#"C_A)
M=(_Y^_\ R&_^%<7_ &3=>_Y4?V3=>_Y4?OO+\0_=>9VG_"2Z1_S]_P#D-_\
M"C_A)=(_Y^__ "&_^%<7_9-U[_E1_9-U[_E1^^\OQ#]UYG:?\)+I'_/W_P"0
MW_PH_P"$ETC_ )^__(;_ .%<7_9-U[_E1_9-U[_E1^^\OQ#]UYG:?\)+I'_/
MW_Y#?_"C_A)=(_Y^_P#R&_\ A7%_V3=>_P"5']DW7O\ E1^^\OQ#]UYG:?\
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M7_?2_P#Q-'[T/^$SS.O_ .%Q^'O^?/5/^_4?_P 71_PN/P]_SYZI_P!^H_\
MXNN0_P"%?6__ #TNO^^E_P#B:/\ A7UO_P ]+K_OI?\ XFC]Z'_"9YG7_P#"
MX_#W_/GJG_?J/_XNC_A<?A[_ )\]4_[]1_\ Q=<A_P *^M_^>EU_WTO_ ,31
M_P *^M_^>EU_WTO_ ,31^]#_ (3/,Z__ (7'X>_Y\]4_[]1__%T?\+C\/?\
M/GJG_?J/_P"+KD/^%?6__/2Z_P"^E_\ B:/^%?6__/2Z_P"^E_\ B:/WH?\
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M ,+C\/?\^>J?]^H__BZ/^%Q^'O\ GSU3_OU'_P#%UR'_  KZW_YZ77_?2_\
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M?]]+_P#$T?O0_P"$SS.O_P"%Q^'O^?/5/^_4?_Q='_"X_#W_ #YZI_WZC_\
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M3[DDG\:O5M%621X]>:J5936S;?XA1113,@HHHH **** "BBB@ HHHH ****
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M/#EK'(P,<;1K)W&"@S6]/H-M\/?"VK:CID]Q+=O"J%YBIPV[ 8 #CEL]^@I
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MO&O[FY2*W90D<+ 99@<DY!]!VKI/'EKH::U9-K&J7,D<4:B/2[>+<S+TSG<
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M/L_BZ$?@CP=-X9T6:RO)89I'N&E#19P 548Y _NFNE^P1?W17/?#[Q'?>)]
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M?$NKZ1XMTBQL;ORK:XV>:GEHV[+X/)!(X]*['1/^0!IW_7K%_P"@BO./B/\
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M](O_ !CX0TV715\.S795V,$\:LZ+GW4$$9YY(ZUI>&O %S'X7U:#565+W4U
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M_P"@;>_]^J/[7?\ Z!M[_P!^JTZ* Y9=S,_M=_\ H&WO_?JC^UW_ .@;>_\
M?JM.B@.67<S/[7?_ *!M[_WZH_M=_P#H&WO_ 'ZK3HH#EEW,S^UW_P"@;>_]
M^J/[7?\ Z!M[_P!^JTZ* Y9=S,_M=_\ H&WO_?JC^UW_ .@;>_\ ?JM.B@.6
M7<S/[7?_ *!M[_WZH_M=_P#H&WO_ 'ZK3HH#EEW,S^UW_P"@;>_]^J/[7?\
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M&WO_ 'ZK3HH#EEW,S^UW_P"@;>_]^J/[7?\ Z!M[_P!^JTZ* Y9=S,_M=_\
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MQG]:4MC:@TJB<H\R[=S"\ >)K[Q+H,]Y?I'YJ7+1#R4(&T*I]3S\QKJO,/\
M<?\ *J6C3Z1<6;OHK6C6PD(8VH4+OP,YQWQC]*T:([!7:=1N,>5=NQ'YA_N/
M^5'F'^X_Y5)13,2/S#_<?\J/,/\ <?\ *I** (_,/]Q_RH\P_P!Q_P JDHH
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M_P#0-O?^_5']KO\ ] V]_P"_5:=% <LNYF?VN_\ T#;W_OU1_:[_ /0-O?\
MOU6G10'++N9G]KO_ - V]_[]4?VN_P#T#;W_ +]5IT4!RR[F9_:[_P#0-O?^
M_5']KO\ ] V]_P"_5:=% <LNYF?VN_\ T#;W_OU1_:[_ /0-O?\ OU6G10'+
M+N9G]KO_ - V]_[]4?VN_P#T#;W_ +]5IT4!RR[F9_:[_P#0-O?^_5']KO\
M] V]_P"_5:=% <LNYF?VN_\ T#;W_OU1_:[_ /0-O?\ OU6G10'++N9G]KO_
M - V]_[]4?VN_P#T#;W_ +]5IT4!RR[F9_:[_P#0-O?^_5:$3^;$CE&3< =K
M#!'L:?12*BFMV%%%%!1Y7H^H^-O$NHZO'I^O06Z64Y15EMXSD$M@9"'TKH_
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M0,DGH* %HK)OO$ND:?X=EU^2^BETN--YN+<^:K#..-N<\\<5J1R++$DB'*N
MP)&.#0 ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBJV
MH7]KI>G7-_>RB&UMHVEED()VJHR3@<G\* +-%97A[Q+I'BK3/[1T6\%U:[S&
M7",F&'4$, >X[56TKQGX?UO7+W1;"_\ ,U*RW?:+=H9(V3#;3]Y0#SCIGJ*
M-ZBL)/&6@2>*V\,1WQDUA%W/;I#(VP;=V6<+M'!'4]P.II^A>+-$\2W%]!I%
M[]IDL)/*N5\ITV-DC'S 9^Z>F>E &U1110 4444 %!Z44'I0!YU\0_\ CR?Z
M5XBO0_4_SKV[XA_\>3_2O$5Z'ZG^=8U_A/8R3_>'Z?JA:***Y3ZD**** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M;YC@#H.>G)KTWX5^)=0\4:)J-YJ4L<<J7[QI8*@5K&, !8VPH)[\D?X#O**
M/F.2]\/0:]X]MM7\6:WI%Q-J5P(;33V?9<\M]\!"#SQ@LN0:VYHY;30?AQJ7
MBW1_(\.V23+?6_V8M'&Q!$+R1C/7@\CJ3ZXKZ!HH ^;=3CCD^'OQ$U'2+=K?
MPS>7MJVFKY1B1B'4.R*0,*3M[=L=JZR#2K/1_C%X6AT>SMK#S]"D+BWB6,.V
MUN6P/F.0.3GI7LU% 'RUX?T:WE>TTC5-9;3O$\6IB5K<>'FFN_,\S(?[0&!*
M=STZ=#P3[!\59M*C@TI/$&AW%SI!E8RZM:R,LFFO@;7 12<$^^.!P3@5Z+10
M!\]_\)3=-X?\4P6W]I>,O"-O;Q-;W&H+(C"0LNY6D 5G5>6/'\(Z Y.=IM[:
M77B/79K%M+%O+X1N1G2[&2T@<J/[LARQ&,;O;'4&OI6B@#Y^N_#UC9?"+P;J
M4&E(; W=K=:X882S30C<2TF.64;CQVS5W7ET'Q%X)\6S?#K1+R,RK;BYN;:W
M>&"[16RR1(2,L!NW (,Y/7//NE% 'B/AN?0-9^*.@7O@.R$&GV=A,FJR06K0
M)ROR(^5&Y]V#GG..IQ7'PZ%I,WP8T:_DTVU-Y-KXBDN?* D=#(P*E^N,=LXK
MZ>HH \4EM[+0/B?XQM].T5'LU\.ASIMDGE"8_+D (."<GD<\US'A#4K&^^(/
M@6?3X=(MEQ/')%IME-!Y9,9/ER22$^:PSU'K[BOI*B@ HHHH **** "BBHYI
MXK>(RSRI%&" 6=@H&3@<GWH DHHHH **** "BBB@ HHHH **** "BBB@ HJL
M=1LEU%=.:\MQ?-'YJVQE7S"F<;@N<XSWZ59H **** "BBB@ HHHH **** "B
MHY9XH%5II4C#,$4NP&6)P ,]R:DH **** "BBB@ HHHH ***:Y8(Q5=S ' ]
M30!X-&Y_X3BY\9@-MB\6C36=?^>)B\DD^V2M=!\4=1.N7%]HD3!M,T.R?4M5
M]'DVDP0GZL-Q'H*DM/ VM-\%+[1Y[8Q>(+B:2^$2RID3^=O3YL[>0J\Y[U+>
M^"-;7X47NE(GVOQ#K,Z3ZE)O1?F>13)R3C"J-H ]..M %2UURZ\/>'/!_@O2
M[ZSTS4;O35N;B^NPI6UCVY)"L0&<L2 #Z'(K5T#Q==Z5XAU/1M:\0VNNV]MI
MAU.._MX4C945B'1PAVY'!&,4>,?!MTWBFP\0V'A[3_$,,5E]AGTN\,:G:&RD
MD;2 J",D'../KQ:T7PF]_HVM17_A?1/#?]HVS6L4>GQHT\:,I#&21 %;G! '
M'')- %&SD^(7B70U\3Z=K=KIRSQ^?8Z*;))%D3DHLDK$,"PQDC &:@\:-K>N
M>(_ >FVZ6^GZJQEOYUG'G);,D8!.%.&(+-CG!('-3Z?_ ,+(AT*S\,V^C6>G
M2VT:6W]O&\CEC"( -ZPXW%B 1A@!G]+&MZ;XKMOB-'XBTS28=3M;/3%M%BEN
M4A>=G<ERAZ*PPOW@ 03@T 2Z-J7B/0_'\7AK7=:BUFWOK)[JWN/LJ6\D3(P!
M4JG!4CG/7\JK:??^+O'HNM5T37H=!T9)WAL0+%+B2Z"$J9'+_=4D' '/];_A
MO1=<U+Q3=>*O$]G%83FU^Q66GQSB8P1$[G9G'!9CCIVK)T6T\=>#='?PQIF@
M6NI01.XL=5>]2*-$=BP,L9&\E2>0N<_K0!#?^*=8UKX/:MJDFH+I.IZ:UQ;7
MC01+(LSQY3:N_. Q*\CD=C5S1['Q'X3^&%A;V>IVLUPT<.)M06.&'3XF4%SQ
MC?MYQDY)//I3=6^'^H6WP?F\-:=(+_4GD6YG,C!!=2>:))!D\#."!GT&:/%V
MC^(]<?PSK7_"-6]\EEYC7GA^XO$QO885@Q_=L5Y//KQ[ $7ASQ3J,/CO3]";
MQ?8>*[2_MI9))K:*%&M'C //E$C:V>AY]Z;I5SXW\6GQ!>67BJ#2M.MM1G@L
M\:?',Y6/CDMQMX]">3SP!5C0=%\22?$*3Q!J?AZSTVUAT<V]G!:7"2!7+@E6
M(V_-QU VXQS5SPWX?UK1/A!-IAM<Z[);7+F$2)S/(7(&[.W^(<YQ0!SNFZWX
M]\2_#YO%B:_9:0EM;R2);QV2RBZ\K.YG9_N!BK !1P.>:ZR7Q%KM_P##G2]9
MT^.PM+^^@ADFFO) L%JK %I,$\X[#/<9SWK7WAS5K7X)_P#".:=:^;JG]F):
M^2)%7YV #_,2%XRQZU2\8>$]6)\*3:=I%MKMAH\9BGTB>=8UE.P*CC?\A*X/
MWOPZ\ $/ASQ3J,/CO3]";Q?8>*[2_MI9))K:*%&M'C //E$C:V>AY]ZS_#&E
M^*=?U;Q;J^C>(H-&MKC5I8TD%BMQ)-Y0V#.\X"C Q@9.3SQ6MH.B^))/B%)X
M@U/P]9Z;:PZ.;>S@M+A) KEP2K$;?FXZ@;<8YK/\-6_Q%\*^$X=$MO#%G<W4
MV^47QU!%6W>1BS>:G)8J3_ 2",4 =C\/O$-YXE\)Q7FHB(7T,TMM<&'[C/&Q
M7</8C!K*O%73?CCIEP/E75='EMV]"\3AQ^AKH?!_AU?"OA:RTGS?.EB4M/-_
MSTE8EG;\R?PQ7._%'P[K^MVFD7'AE1_:5K<NOF%U7RHI8V1WY(Z9'3)]J *?
MA^^AUWQ5K_CR])&E:3')8Z<Q'&Q,F:4?4C /IQ6,?%_B75/#D_BZV\7Z/IJ+
M$]Q;Z$T,4N^-<D+)(6W[V _AQ@]J]$B\)65OX$;PI;L8K4V36F\#GYE(+_4D
MD_6O/-*\(ZU:6-KHLWPT\*RW, 6)];N/)>&15_C,842%B.QQSR30!T&J>+M6
MUZ7P_H_A:6*ROM7L1J,]W-%YOV.W('(4\,Q8X&>./?(S+.RUS_A<>C:?KFKQ
M:M_9>FW%[%<K;"!_WI$>'5?ER,<$8R.HK8U[1-9T3QC8^)O#6C6^I(FG_P!F
MSZ>LZ6Q1 X96C+?* .F/I^"^%-)\17'C?7?$'B338+'[3:06UI%#<"8",99U
M+#!R"1DX STR.: *FGW_ (N\>BZU71->AT'1DG>&Q L4N)+H(2ID<O\ =4D'
M '/]:5_XIUC6O@]JVJ2:@NDZGIK7%M>-!$LBS/'E-J[\X#$KR.1V-3:+:>.O
M!NCOX8TS0+74H(G<6.JO>I%&B.Q8&6,C>2I/(7.?UJ35OA_J%M\'YO#6G2"_
MU)Y%N9S(P074GFB209/ S@@9]!F@"A"->\&> /"NEVVM2/=ZE?6=M%FVB'V:
M-QND0#:=V,'DY/-:/V[QAXD\=^)-,T?78=+TK3C!$)C9I.XD*;F"@X'?DL3C
MC YXOW^FZYK_ (C\%W]UI/V*VL6GN;V(W"2>1)LVQKD'YN2>0"*M^!]&U+28
MO$-WJ5MY=WJ.K3W21^8K$Q\"/D$CH/UH 9\.-=U36M'U*+5YX[J[TW4IK W<
M<8C%P$QA]HX!YQ@>E=E7)?#?0[[0/!D%MJD AU*:::XND#*V'>0GJI(/&WO7
M6T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Y7\=-5G3PQ8^'
M+%C]MUR[2W50<$H",_FQ0?B:]4KQ#Q+X0U'XB_&B2'4;;5;'0=-M0D5Y'&8@
M[#G]V[*5)WMU&>%H L?#*)O WQ,U[P+(Y-I/&M[9,W\6 ,@?@?\ QRJWQ?@F
M\#>+](^(6CM$MR[_ &:ZMW; F^4X.!U!4$'TPIJCXE^'%[\/O$WAWQ)X7&N:
MRT5R5NT<?:9%3VV("%*EQSZBM2^T/5/B9\74?6-)OK?PIHZ'REN[=X5N6]@P
M&=S<G'\*C/6@#1^!V@$:)=>,+^X6ZU76I'9Y=P8H@8Y7(Z$L,D=N!VJC\#/^
M0_XZ_P"P@/\ T*6IOAI8:YX&\;ZOX1GTZ_E\/S2-/8WP@=HD.,X+XP,K@')^
M\OO7-^"]7\1> ]>\3M)X%\0:A'?WI>-X+20# 9^<[3D'<* /H6BL#PCXBN_$
MVERWEYH-_HTB3&(6]\A5V  .X @<<X_ UOT %%%% !0>E%!Z4 >=?$/_ (\G
M^E>(KT/U/\Z]N^(?_'D_TKQ%>A^I_G6-?X3V,D_WA^GZH6BBBN4^I"BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MV,R9^4'YCD@<9S6S6-X5\,V/A'P];Z/IYD:&'):20Y:1R<LQ]R:V: "BBB@
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MW@O3/$,6J7MMXKO(TNSK7GO(ZL2"5*;@I&/EQ6SJ/C+Q;=^(M6T?PM9Z3/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M>/1O^^31O'HW_?)HY)=@^MX?_GXOO0ZBF[QZ-_WR:-X]&_[Y-')+L'UO#_\
M/Q?>AU%-WCT;_ODT;QZ-_P!\FCDEV#ZWA_\ GXOO0ZBF[QZ-_P!\FC>/1O\
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M144MQ'!$9)"50=3M-,@O;>ZW>2Y?;C/RGC]*.678?UJA:_.OO18HIN\>C?\
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M2[!];P__ #\7WH=13=X]&_[Y-&\>C?\ ?)HY)=@^MX?_ )^+[T.HIN\>C?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M* /./^%=6_\ <%'_  KJW_N"O1\"C H \X_X5U;_ -P4?\*ZM_[@KT? HP*
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MZM_[@H_X5U;_ -P5Z/@48% 'G'_"NK?^X*/^%=6_]P5Z/@48% 'G'_"NK?\
MN"C_ (5U;_W!7H^!1@4 ><?\*ZM_[@H_X5U;_P!P5Z/@48% 'G'_  KJW_N"
MC_A75O\ W!7H^!1@4 ><?\*ZM_[@H_X5U;_W!7H^!1@4 ><?\*ZM_P"X*/\
MA75O_<%>CX%&!0!YQ_PKJW_N"C_A7=M_<%>CX%&!0!QVE^#+:RD#;!Q[5UD$
M"0H%48Q4N** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^11H%I]T5/[:T[_GZ7\C_A1_;6G?\_2_D?\ "K?V>#_GC'_WR*/L\'_/&/\
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MH^SP?\\8_P#OD4:!:?=%3^VM._Y^E_(_X4?VUIW_ #]+^1_PJW]G@_YXQ_\
M?(H^SP?\\8_^^11H%I]T5/[:T[_GZ7\C_A1_;6G?\_2_D?\ "K?V>#_GC'_W
MR*/L\'_/&/\ [Y%&@6GW14_MK3O^?I?R/^%']M:=_P _2_D?\*M_9X/^>,?_
M 'R*/L\'_/&/_OD4:!:?=%3^VM._Y^E_(_X4?VUIW_/TOY'_  JW]G@_YXQ_
M]\BC[/!_SQC_ .^11H%I]T-BNH)XQ)'(&0]#@T_S4_O4JHBC"JH'H!2[1Z"D
M:+S&^:G]ZCS4_O4[:/04;1Z"@!OFI_>H\U/[U.POH*,+Z"@!OFI_>H\U/[U.
MPOH*,+Z"@!OFI_>H\U/[U.POH*,+Z"@!OFI_>H\U/[U.POH*,+Z"@!OFI_>H
M\U/[U.POH*,+Z"@!OFI_>H\U/[U.POH*,+Z"@!OFI_>H\U/[U.POH*,+Z"@!
MOFI_>H\U/[U.POH*,+Z"@!OFI_>H\U/[U.POH*,+Z"@!OFI_>H\U/[U.POH*
M,+Z"@!OFI_>H\U/[U.POH*,+Z"@!OFI_>H\U/[U.POH*,+Z"@!OFI_>H\U/[
MU.POH*,+Z"@#$U;Q$-+NE@%MYVY ^[S-O<C'0^E:EM=I<6L,Y^7S$5]N<XR,
MXJ&\TBPOY1+<P!W"[0=[#C\#[U:BBBAB2*-0$10JCK@#I414^9W>A;<;*VXO
MFI_>H\U/[U.POH*,+Z"K(&^:G]ZCS4_O4["^@HPOH* &^:G]ZCS4_O4["^@H
MPOH* &^:G]ZCS4_O4["^@HPOH* &^:G]ZCS4_O4["^@HPOH* &^:G]ZCS4_O
M4["^@HPOH* &^:G]ZCS4_O4["^@HPOH* &^:G]ZCS4_O4["^@HPOH* &^:G]
MZCS4_O4["^@HPOH* &^:G]ZCS4_O4["^@HPOH* &^:G]ZCS4_O4["^@HPOH*
M ,CQ+KZ^'O#]UJ@@^TF#9^ZW[-VYPO7!QUSTK)\%^.%\7?;LV'V/[+Y?_+;S
M-^[=_LC&-OZUT6IZ99:QI\MA?PB6VEQO3<5S@@CD$'J!531?#.C>'?/_ +*L
MQ;^?M\S]X[[MN<?>)QU/2I:ES>1TQE05"491?/?1]+:>?KT-3S4_O4>:G]ZG
M87T%&%]!5',-\U/[U'FI_>IV%]!1A?04 -\U/[U'FI_>IV%]!1A?04 -\U/[
MU'FI_>IV%]!1A?04 -\U/[U'FI_>IV%]!1A?04 -\U/[U'FI_>IV%]!1A?04
M -\U/[U'FI_>IV%]!1A?04 -\U/[U'FI_>IV%]!1A?04 -\U/[U'FI_>IV%]
M!1A?04 -\U/[U'FI_>IV%]!1A?04 -\U/[U'FI_>IV%]!1A?04 -\U/[U'FI
M_>IV%]!1A?04 -\U/[U'FI_>IV%]!1A?04 -\U/[U<I\0/$UYX:T&"\T[R6F
M>Z6(B52PVE6/J.ZBNMPOH*SM8GT:WM$?66LUMC( IN@I7?@XQGOC/ZTI;&U!
MI5$Y1YEV[F'\/_$UYXET&>\U'R5F2Z:(")2HVA5/J>[&NK\U/[U4-'GT:XM'
M?1FLVMA(0QM0H7?@9SCOC'Z5HX7T%$=@KM.HW&/*NW8;YJ?WJ/-3^]3L+Z"C
M"^@IF(WS4_O4>:G]ZG87T%&%]!0 WS4_O4>:G]ZG87T%&%]!0 WS4_O4>:G]
MZG87T%&%]!0 WS4_O4>:G]ZG87T%&%]!0 WS4_O4>:G]ZG87T%&%]!0 WS4_
MO4>:G]ZG87T%&%]!0 WS4_O4>:G]ZG87T%&%]!0 WS4_O4>:G]ZG87T%&%]!
M0 WS4_O4>:G]ZG87T%&%]!0 WS4_O4>:G]ZG87T%&%]!0 WS4_O4>:G]ZG;1
MZ"C:/04 -\U/[U'FI_>IVT>@HVCT% %:?4K.V<)-.$8C(!!Z5%_;6G?\_2_D
M?\*N-#$YRT:,?=0:3[/!_P \8_\ OD4R'SWTL5/[:T[_ )^E_(_X4?VUIW_/
MTOY'_"K?V>#_ )XQ_P#?(H^SP?\ /&/_ +Y%&@K3[HJ?VUIW_/TOY'_"C^VM
M._Y^E_(_X5;^SP?\\8_^^11]G@_YXQ_]\BC0+3[HJ?VUIW_/TOY'_"C^VM._
MY^E_(_X5;^SP?\\8_P#OD4?9X/\ GC'_ -\BC0+3[HJ?VUIW_/TOY'_"C^VM
M._Y^E_(_X5;^SP?\\8_^^11]G@_YXQ_]\BC0+3[HJ?VUIW_/TOY'_"C^VM._
MY^E_(_X5;^SP?\\8_P#OD4?9X/\ GC'_ -\BC0+3[HJ?VUIW_/TOY'_"C^VM
M._Y^E_(_X5;^SP?\\8_^^11]G@_YXQ_]\BC0+3[HJ?VUIW_/TOY'_"C^VM._
MY^E_(_X5;^SP?\\8_P#OD4?9X/\ GC'_ -\BC0+3[HJ?VUIW_/TOY'_"C^VM
M._Y^E_(_X5;^SP?\\8_^^11]G@_YXQ_]\BC0+3[HJ?VUIW_/TOY'_"C^VM._
MY^E_(_X5;^SP?\\8_P#OD4?9X/\ GC'_ -\BC0+3[HJ?VUIW_/TOY'_"C^VM
M._Y^E_(_X5;^SP?\\8_^^11]G@_YXQ_]\BC0+3[HJ?VUIW_/TOY'_"C^VM._
MY^E_(_X5;^SP?\\8_P#OD4?9X/\ GC'_ -\BC0+3[HJ?VUIW_/TOY'_"C^VM
M._Y^E_(_X5;^SP?\\8_^^11]G@_YXQ_]\BC0+3[HJ?VUIW_/TOY'_"C^VM._
MY^E_(_X5;^SP?\\8_P#OD4?9X/\ GC'_ -\BC0+3[HJ?VUIW_/TOY'_"C^VM
M._Y^E_(_X5;^SP?\\8_^^11]G@_YXQ_]\BC0+3[HJ?VUIW_/TOY'_"C^VM._
MY^E_(_X5;^SP?\\8_P#OD4?9X/\ GC'_ -\BC0+3[HJ?VUIW_/TOY'_"C^VM
M._Y^E_(_X5;^SP?\\8_^^11]G@_YXQ_]\BC0+3[HJ?VUIW_/TOY'_"C^VM._
MY^E_(_X5;^SP?\\8_P#OD4?9X/\ GC'_ -\BC0+3[HJ?VUIW_/TOY'_"C^VM
M._Y^E_(_X5;^SP?\\8_^^11]G@_YXQ_]\BC0+3[HJ?VUIW_/TOY'_"C^VM._
MY^E_(_X5;^SP?\\8_P#OD4?9X/\ GC'_ -\BC0+3[HJ?VUIW_/TOY'_"C^VM
M._Y^E_(_X5;^SP?\\8_^^11]G@_YXQ_]\BC0+3[HJ?VUIW_/TOY'_"C^VM._
MY^E_(_X5;^SP?\\8_P#OD4?9X/\ GC'_ -\BC0+3[HJ?VUIW_/TOY'_"C^VM
M._Y^E_(_X5;^SP?\\8_^^11]G@_YXQ_]\BC0+3[HJ?VUIW_/TOY'_"C^VM._
MY^E_(_X5;^SP?\\8_P#OD4?9X/\ GC'_ -\BC0+3[HJ?VUIW_/TOY'_"C^VM
M._Y^E_(_X5;^SP?\\8_^^11]G@_YXQ_]\BC0+3[HJ?VUIW_/TOY'_"C^VM._
MY^E_(_X5;^SP?\\8_P#OD4?9X/\ GC'_ -\BC0+3[HJ?VUIW_/TOY'_"C^VM
M._Y^E_(_X5;^SP?\\8_^^11]G@_YXQ_]\BC0+3[HJ?VUIW_/TOY'_"C^VM._
MY^E_(_X5;^SP?\\8_P#OD4?9X/\ GC'_ -\BC0+3[HJ?VUIW_/TOY'_"C^VM
M._Y^E_(_X5;^SP?\\8_^^11]G@_YXQ_]\BC0+3[HJ?VUIW_/TOY'_"C^VM._
MY^E_(_X5;^SP?\\8_P#OD4?9X/\ GC'_ -\BC0+3[HJ?VUIW_/TOY'_"KL<B
MRQK(ARC#(/J*;]G@_P">,?\ WR*> %    '0"D5'FZBT444%!1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !110>E &/J^KIIT19CC%>)>*/%NK3^([N2RU:^AMSLV1Q7+J
MH^0 X ..N:]#^(,C)9/@XXKP\L78LQR236-9^Z>ODT5*NU)7T_5&K_PE'B#_
M *#NI_\ @7)_C1_PE'B#_H.ZG_X%R?XUE45S79]-[&G_ "K[C5_X2CQ!_P!!
MW4__  +D_P :/^$H\0?]!W4__ N3_&LJBB[#V-/^5?<:O_"4>(/^@[J?_@7)
M_C1_PE'B#_H.ZG_X%R?XUE4478>QI_RK[C5_X2CQ!_T'=3_\"Y/\:/\ A*/$
M'_0=U/\ \"Y/\:RJ*+L/8T_Y5]QJ_P#"4>(/^@[J?_@7)_C1_P )1X@_Z#NI
M_P#@7)_C6511=A[&G_*ON-7_ (2CQ!_T'=3_ / N3_&C_A*/$'_0=U/_ ,"Y
M/\:RJ*+L/8T_Y5]QJ_\ "4>(/^@[J?\ X%R?XT?\)1X@_P"@[J?_ (%R?XUE
M4478>QI_RK[C5_X2CQ!_T'=3_P# N3_&C_A*/$'_ $'=3_\  N3_ !K*HHNP
M]C3_ )5]QJ_\)1X@_P"@[J?_ (%R?XT?\)1X@_Z#NI_^!<G^-95%%V'L:?\
M*ON-7_A*/$'_ $'=3_\  N3_ !H_X2CQ!_T'=3_\"Y/\:RJ*+L/8T_Y5]QJ_
M\)1X@_Z#NI_^!<G^-'_"4>(/^@[J?_@7)_C6511=A[&G_*ON-7_A*/$'_0=U
M/_P+D_QH_P"$H\0?]!W4_P#P+D_QK*HHNP]C3_E7W%^;6]6N'#SZI>RL!@%[
MAV./Q-2KXEUY$5$UO4E51@ 7;@ ?G6712N'LJ?\ *ON-7_A*/$'_ $'=3_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M'_QY/]*\17H?J?YUC7^$]C)/]X?I^J%HHHKE/J0HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M>TNX7Q39ZM!>:JME-86NF.MK&C'&8[DJ-[#ZGKW H ]QHHHH **** "BBB@
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M=5DD_P!U2<G\*O5\W>*&L-6^(&M33+$GA^^U*"SN-=N+7<]E/"HW1Q/G* X
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MBRO1 [11MC(4OC:,KP<GJH]:S;&R\4_"'Q-K TWPU<Z_X?U.7SH19 F2%N2
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M6K7@:&!@Q;"H5Q@D\YR??DY]$HH **** "BBB@ HHHH **** "BBB@ HHHH
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MDMV?;]T2R*27&.HXSWIVL^"M1F\23:[X>\22Z)=7<217JBT2X2<)D(V&QM8
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M_P">,GY4>SEV#^T,+_.A**79+_SQD_*C9+_SQD_*CV<NP?VAA?YT)12[)?\
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M7_P@MG_SS'Y4?\(+9_\ /,?E7:44 <7_ ,(+9_\ /,?E1_P@MG_SS'Y5VE%
M'%_\(+9_\\Q^5'_""V?_ #S'Y5VE% '%_P#""V?_ #S'Y4?\(+9_\\Q^5=I1
M0!Q?_""V?_/,?E1_P@MG_P \Q^5=I10!Q?\ P@MG_P \Q^5'_""V?_/,?E7:
M44 <7_P@MG_SS'Y4?\(+9_\ /,?E7:44 <)-\.=,N'#RP!F QG)''X5,G@.Q
M1%18P%48 ]JN^)-(OK_48Y;6#S$$04G>HYR?4^]=!81/#IUM%(N'2)%8=<$
M9K.,KR:L7)6BG<Y/_A!;/_GF/RH_X06S_P">8_*NTHK0@XO_ (06S_YYC\J/
M^$%L_P#GF/RKM** .+_X06S_ .>8_*C_ (06S_YYC\J[2B@#B_\ A!;/_GF/
MRH_X06S_ .>8_*NTHH XO_A!;/\ YYC\J/\ A!;/_GF/RKM** .+_P"$%L_^
M>8_*C_A!;/\ YYC\J[2B@#B_^$%L_P#GF/RH_P"$%L_^>8_*NTHH XO_ (06
MS_YYC\J/^$%L_P#GF/RKM** .+_X06S_ .>8_*C_ (06S_YYC\J[2B@#B_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!F-K<"L08+G@XXCH_M
MRW_YX77_ '[K3HID<L^_X&9_;EO_ ,\+K_OW1_;EO_SPNO\ OW6G11H+EGW_
M  ,S^W+?_GA=?]^Z/[<M_P#GA=?]^ZTZ*- Y9]_P,S^W+?\ YX77_?NC^W+?
M_GA=?]^ZTZ*- Y9]_P #,_MRW_YX77_?NC^W+?\ YX77_?NM.BC0.6??\#,_
MMRW_ .>%U_W[H_MRW_YX77_?NM.BC0.6??\  S/[<M_^>%U_W[H_MRW_ .>%
MU_W[K3HHT#EGW_ S/[<M_P#GA=?]^Z/[<M_^>%U_W[K3HHT#EGW_  ,S^W+?
M_GA=?]^Z/[<M_P#GA=?]^ZTZ*- Y9]_P,S^W+?\ YX77_?NC^W+?_GA=?]^Z
MTZ*- Y9]_P #,_MRW_YX77_?NC^W+?\ YX77_?NM.BC0.6??\#,_MRW_ .>%
MU_W[H_MRW_YX77_?NM.BC0.6??\  S/[<M_^>%U_W[H_MRW_ .>%U_W[K3HH
MT#EGW_ S/[<M_P#GA=?]^Z/[<M_^>%U_W[K3HHT#EGW_  ,S^W+?_GA=?]^Z
M/[<M_P#GA=?]^ZTZ*- Y9]_P,S^W+?\ YX77_?NC^W+?_GA=?]^ZTZ*- Y9]
M_P #,_MRW_YX77_?NC^W+?\ YX77_?NM.BC0.6??\#,_MRW_ .>%U_W[H_MR
MW_YX77_?NM.BC0.6??\  S/[<M_^>%U_W[H_MRW_ .>%U_W[K3HHT#EGW_ S
M/[<M_P#GA=?]^Z/[<M_^>%U_W[K3HHT#EGW_  ,S^W+?_GA=?]^Z/[<M_P#G
MA=?]^ZTZ*- Y9]_P,S^W+?\ YX77_?NC^W+?_GA=?]^ZTZ*- Y9]_P #,_MR
MW_YX77_?NC^W+?\ YX77_?NM.BC0.6??\#,_MRW_ .>%U_W[H_MRW_YX77_?
MNM.BC0.6??\  S/[<M_^>%U_W[H_MRW_ .>%U_W[K3HHT#EGW_ S/[<M_P#G
MA=?]^Z/[<M_^>%U_W[K3HHT#EGW_  ,S^W+?_GA=?]^Z/[<M_P#GA=?]^ZTZ
M*- Y9]_P*\%VEQ"LBI( >S+@U)YJ^C?E4E%(T1'YJ^C?E1YJ^C?E4E% $?FK
MZ-^5'FKZ-^5/) HW#UH 9YJ^C?E1YJ^C?E3]P]:-P]: &>:OHWY4>:OHWY4_
M</6C</6@!GFKZ-^5'FKZ-^5/W#UHW#UH 9YJ^C?E1YJ^C?E3]P]:-P]: &>:
MOHWY4>:OHWY4_</6C</6@!GFKZ-^5'FKZ-^5/W#UHW#UH 9YJ^C?E1YJ^C?E
M3]P]:-P]: &>:OHWY4>:OHWY4_</6C</6@!GFKZ-^5'FKZ-^5/W#UHW#UH 9
MYJ^C?E1YJ^C?E3]P]:-P]: &>:OHWY4>:OHWY4_</6C</6@!GFKZ-^5'FKZ-
M^5/W#UHW#UH Q-6\1C3+I8!:F7<@?)DV]R/0^E:=M=BXM89]C+YB*^.N,C-0
MWFE:??S"6ZA\QPNT'>PX_ ^]6XECAA2*,81%"J,YP!TJ(J?,[O0MN-E;</-7
MT;\J/-7T;\J?N'K1N'K5D#/-7T;\J/-7T;\J?N'K1N'K0 SS5]&_*CS5]&_*
MG[AZT;AZT ,\U?1ORH\U?1ORI^X>M&X>M #/-7T;\J/-7T;\J?N'K1N'K0 S
MS5]&_*CS5]&_*G[AZT;AZT ,\U?1ORH\U?1ORI^X>M&X>M #/-7T;\J/-7T;
M\J?N'K1N'K0 SS5]&_*CS5]&_*G[AZT;AZT ,\U?1ORH\U?1ORI^X>M&X>M
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M%M%:O9,!P0 1O!/L3QVK'U;PAXT\3^$//U:]M5UZWU)=2T^T 7RK=5SMA+J
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M)M-M!X1^(\/A^SN9VTO4+8L89'W;6PW(]_EZ^]+XB^'WA70= O-2D%WF&,[
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M117*?4A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !4UI=W%A=Q75K*T,\3;D=#@@U#10)I-69]!>!O'-OXHM!;
MW!6'4XE_>1]!(/[R_P!1VKL*^4[2[N+"[BNK65H9XFW(Z'!!KZ%\#>)Y?%.A
M_:;BV:*>)O+D8+A)#CJI_F.U=5*IS:,^7S/+_8/VM/X7^!T]%%%;'CA1110
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MT6*XNE4+YHD>,L!TW;&&[\<UU%% %'^R;6+1&TFS7[%:^08(Q; *8E(QE>"
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MO=6UU+;3R_9@88B@)W,X) 5MI [D]A0!V%%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4'I10>E 'G7Q#_X\G^E>(KT/U/\ .O=O'EK)/9N$4GBO
M$Y--O(W*B GDUE5BY*R/2RO$4Z%9RJ.RM^J*U%3_ &&]_P"?<_G1]AO?^?<_
MG6'LI]CW_P"U<)_/^#_R(**G^PWO_/N?SH^PWO\ S[G\Z/93[!_:N$_G_!_Y
M$%%3_8;W_GW/YT?8;W_GW/YT>RGV#^U<)_/^#_R(**G^PWO_ #[G\Z/L-[_S
M[G\Z/93[!_:N$_G_  ?^1!14_P!AO?\ GW/YT?8;W_GW/YT>RGV#^U<)_/\
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MW/YT_93[!_:N$_G_  ?^1!14_P!AO?\ GW/YT?8;W_GW/YT>RGV#^U<)_/\
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M$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MC(4'J<=!FMN.1)8UDC=71P&5E.00>A!H =1110 4444 %%%% !1110 4444
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M%+115G(%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %9VLSZ1;V:/K36BVQD 4W04KOP<8SWQG]:T:Y?QWX9N?%6APV
M-K/##)'<K,6ESC 5AC@'^\*4KVT-:"BZB4W9=S7T:?2+BS=]%:T:V$A#&U"A
M=^!G..^,?I6C7+^!/#-SX5T.:QNIX9I)+EI@T6<8*J,<@?W37441O;4*ZBJC
M4'==PHHHIF04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 <%\0=,\67]W9-X<DNUC2-A-Y%V(1G(QD%AFNVLEE
M2PMUGSYRQ*'R<G=@9Y[\U/14J-G<VG7<Z<:;2T^_YA6%XV_Y$/Q#_P!@VX_]
M%M6[4%[9V^HV%Q8W<?F6UQ$T4J9(W(PP1D<C@]JHQ/G/PUK-WX)\*/8VJ9/B
M72HI=-"G&+LL(' ]\,K_ (5)I5Q>?#WP[\14T8A;JPELK59@,[2?D:3D=<DG
MGN:]P7P3X=6'1HAIJE-%;?IX,CGR3]2?FZ#[V>@J6'PGH4$NKR+IT;'5R&OQ
M(S.LY (Y5B0.IZ 4 >06T/C.QT_5OMAU:;1;S0;IYCJFK6]V=XB)$D01MP3D
M# R/FY[59L]0 ^'?@32$U?6[>>\A9A8Z(BBYN0N3_K691&H[\\_AQZ)IGPS\
M':,MXMAHD47VR%X)F\V1F,;##*"S$J#G^'%/OOASX3U+2=/TN[T=)+33ABT'
MG2*\0] X;=CV)]* /'3XG\1R^$+>U_MS5H9;?Q8NGQW$DH^TB':?EE920Y!/
M.<@GU%=)!K&M>#?$?CC2X-7U'5H=.T@7]N=3F\]UEV@]<#Y?FZ#TKO8OAMX1
M@M%M8='6.W6]6_6-)Y0JSJ,!@-W'';I[5JQ^&])BUZ\UM;,?VA>0B"XE9V(>
M,8PI4G;V'04 >1V%YK.@?\()KL?BG5=5F\17$<=[974XDAQ( 6,: ?)L)[>@
MZ#(K.U2XUZ?1_'NN1^*]<MY=$UF1;2WBNL18WJ-K C)7!X7.T>G)KUG1_AQX
M0T#6#JVF:'!;WI)(DW.P3/78K$A>N/E XXJR_@GP])8:O8MI^;;5YC<7R>=)
M^]D)!)SNRO('"X% 'G^EW>K:#\2O#T-SXDU._@UK2Y+J\2]E4Q1N$+9C10 @
M!'0?G7.CQ)J<&IZ%KFF:]XGOHK[65M9+F]"1V%Q$S;66*'<2N,<' []#7M3^
M%M%DU6PU-[(->:? ;>VD,CX2,C!7;G!X/<&L2'X3^![>[6ZAT&..99UN$9)Y
M1LD4Y!4;L*,]A@<#C@4 =G1110 4444 %%%% !1110 4444 %%%% !1110 5
MP5^?M?QQTFWG ,5EHLUS!D?\M'D",1[[1^M=[7+>)-"OIO$.C>(M($;WM@S0
MS0.P43V\F PW=BI 8?0CO0!XYI=P?#GC_7?%_"VUIXDFL;\_],)B0&/LK*#^
M-2^&Q</\4] \2W,)^V:W%?:B$)Y$6QEB3\%4?]]5[,_@;PV]EJ]F^FAK?6)O
M/OD,TA\U\YW?>RO//RXJR/"NBKJFFZDMB%N]-@-M:.)' BC(QMVYP>/4&@#Q
M)=;\01_#ZV^(X\5:G)JLNH;&TOSA]D*^84\H18X.T9SUQSUYK9U0:MK7C?Q]
M;_\ "2ZY86VF6<5U!!979C <0YQR"0N<Y"XSGFO04^&O@Z/Q#_;JZ#;#4?,\
MWS-S;0_]X1YV YYSCKSUK2'A311J&JWXLO\ 2=6B$-Z_FO\ O4"[0,9PO'IB
M@#RF+Q)KOB72_AYHUQK5WIZ:W%,U[?VCB.>0Q9VJK_PDX&?4G\*ZOX;:CJ*Z
M[XJ\.7>I7.J6NCW,:6UY=/OE(<$E&? W%2.ON?:N@N? /A>\\-6WAVYTF.72
M[4Y@A:1R8SDGY7SN'4]_:M#0/#>C^%].^P:+81V=MNW%4R2S>K,22Q]R: /!
M]<O!J'BCQ'JSI=1^"I]4BL]:6':\WF0@8<C:2L18#.#GK["O49O$%YXI^#FI
MZS;6$EC-<Z?<F"$OO;: P5@<#J!D<=ZOZE\,O!NKZP^JWVA02WCL'=M[JKMZ
ML@8*Q^H.:V]$T/3_  [I<>F:7"\-G$3LB:5Y-N3D@%R2![=* /.]!'@L? ;2
MO^$@%O\ V(8(_M&-V?.W<_ZOYMV_TYZYXS6?<27WBSQ;XGLQXFU71;#P_9PM
M8Q65P8=X:/=YDN<LX&!D'L>QSGMH_A;X(BUK^UT\/6PO!)Y@.Y_+#>HCSL_2
MK7B'X?\ A7Q5>Q7NM:/%=7,2[5EWO&Q'HVPC</KF@#S!/$.O^*+'X:";6-0T
MZ;56NX;R6RD\MI0F%#8QMR0,@X."<BL^9=?B\.^-I/\ A,_$)'AF]9+$?:@&
MDY_Y;/MW2#IQD#KQS7MLOA;19KG2;AK"-9-(W?8!&S(L&0 0%4@$8 Z@U _@
MSP_):ZQ;-89AUB3S;]?.D_?-ZYW97_@.* /+[FVG\6_$_P -^=JM]ILUYX62
M:6XT^18I22Q8A6(.,GG@=JSX/&7B&3P):Z8=:F!E\2'16UC/[W[/P=^\_P 7
M/WNN!USS7JFI_#?PCK/V?^T-&2X^SVBV4)::3Y(5.0HPW4?WNOO5T>#/#H\,
M?\(W_9-O_9&,?9CG'KG=G=NSSNSGWH Y#PC/J.A_%#5/"#:SJ&KZ:FGI>++J
M$WG302%@"I? X(.<?3WKG?&&K^(+'QAX@\)Z?J=XMWKC6DFEN;AQ]F7YO-V'
M/RCY#P,5ZEX;\'>'_",,L6A:9'9B8@R,&9V?'3+,2<#GC..:L7'AW2;OQ#::
M]/9J^IV<;103EVRBMG(QG!ZGDCO0!Y5X:\>7NH-KWBJZN[C['I.BV]O]F,C"
M-[QAE_DZ;]X"YZ\BNO?1WT+X+:A8S'-R-(N)+AN[3/&SN?\ OIC6E+\/_#[6
MKVMO;R6L$VI+J=Q'#)D3RJ<X;=GY<@':,=.,5T-[9V^HV%Q8W<?F6UQ$T4J9
M(W(PP1D<C@]J /!M-TWQ=XV^%&C>%X?"UO;::RQLFLSW\; *K9W"(#<#U'Y^
MM=;X7B2'XW^,HIG#HFG6BNTG\0$:9)S7H^E:79:)I=OING0^39VZ;(H]Q;:/
M3+$D_B:YW6_AAX.\1:Q+JVJZ.+F^EV[Y#<RKNV@ ?*K@= .U '$_#+4-3T[P
MOKTWAS1'U>Q.O3+96ZW*0!8,?>5GXVY &!ZGWKN-;T^#Q#X+FN_$.@6\5Y#:
M3R+:W!2X^SOM/(8?*3@ Y'2NDL;&TTRRBLK&VBMK6%=L<42A54>P%27%O%=6
MTMO,NZ*5"CKDC*D8(X]J .$^&=M%>?!;2K6X0/#-92QR*>C*6<$?E5GX1W<U
MY\+=#><DLD3P@GKM1V1?T45HZAHD^D^"'T+PE;1P-Y9M[<23-M@5SAGRV2=N
MXMCJ<8K3\/Z+;^'?#UAH]J2T-G"L08C!8@<L?<G)_&@#2HHHH **** "BBB@
M#,;4;P,0-+F(!Z[QS1_:5Y_T"IO^^Q_A6G13(Y9?S?D9G]I7G_0*F_[['^%'
M]I7G_0*F_P"^Q_A6G10+EE_-^1F?VE>?] J;_OL?X4?VE>?] J;_ +['^%:=
M% <LOYOR,S^TKS_H%3?]]C_"C^TKS_H%3?\ ?8_PK3HH#EE_-^1F?VE>?] J
M;_OL?X4?VE>?] J;_OL?X5IT4!RR_F_(S/[2O/\ H%3?]]C_  H_M*\_Z!4W
M_?8_PK3HH#EE_-^1F?VE>?\ 0*F_[['^%']I7G_0*F_[['^%:=% <LOYOR,S
M^TKS_H%3?]]C_"C^TKS_ *!4W_?8_P *TZ* Y9?S?D9G]I7G_0*F_P"^Q_A1
M_:5Y_P! J;_OL?X5IT4!RR_F_(S/[2O/^@5-_P!]C_"C^TKS_H%3?]]C_"M.
MB@.67\WY&9_:5Y_T"IO^^Q_A1_:5Y_T"IO\ OL?X5IT4!RR_F_(S/[2O/^@5
M-_WV/\*/[2O/^@5-_P!]C_"M.B@.67\WY&9_:5Y_T"IO^^Q_A1_:5Y_T"IO^
M^Q_A6G10'++^;\C,_M*\_P"@5-_WV/\ "C^TKS_H%3?]]C_"M.B@.67\WY&9
M_:5Y_P! J;_OL?X4?VE>?] J;_OL?X5IT4!RR_F_(S/[2O/^@5-_WV/\*/[2
MO/\ H%3?]]C_  K3HH#EE_-^1F?VE>?] J;_ +['^%']I7G_ $"IO^^Q_A6G
M10'++^;\C,_M*\_Z!4W_ 'V/\*/[2O/^@5-_WV/\*TZ* Y9?S?D9G]I7G_0*
MF_[['^%']I7G_0*F_P"^Q_A6G10'++^;\C,_M*\_Z!4W_?8_PH_M*\_Z!4W_
M 'V/\*TZ* Y9?S?D9G]I7G_0*F_[['^%']I7G_0*F_[['^%:=% <LOYOR,S^
MTKS_ *!4W_?8_P */[2O/^@5-_WV/\*TZ* Y9?S?D9G]I7G_ $"IO^^Q_A1_
M:5Y_T"IO^^Q_A6G10'++^;\C,_M*\_Z!4W_?8_PH_M*\_P"@5-_WV/\ "M.B
M@.67\WY&9_:5Y_T"IO\ OL?X4?VE>?\ 0*F_[['^%:=% <LOYOR,S^TKS_H%
M3?\ ?8_PH_M*\_Z!4W_?8_PK3HH#EE_-^1F?VE>?] J;_OL?X4?VE>?] J;_
M +['^%:=% <LOYOR*\$\LL*N]NT;'JI/(J3S&_YYFI**1HB/S&_YYFCS&_YY
MFI** (_,;_GF:/,;_GF:<TBH.3BLZ?7].MIFAEN-KKU&QC[]A2<DMQI-[%_S
M&_YYFCS&_P">9K,_X2;2O^?G_P AM_A1_P )-I7_ #\_^0V_PJ?:0[H?)+L:
M?F-_SS-'F-_SS-9G_"3:5_S\_P#D-O\ "C_A)M*_Y^?_ "&W^%'M(=T')+L:
M?F-_SS-'F-_SS-9G_"3:5_S\_P#D-O\ "C_A)M*_Y^?_ "&W^%'M(=T')+L:
M?F-_SS-'F-_SS-9G_"3:5_S\_P#D-O\ "C_A)M*_Y^?_ "&W^%'M(=T')+L:
M?F-_SS-'F-_SS-9G_"3:5_S\_P#D-O\ "C_A)M*_Y^?_ "&W^%'M(=T')+L:
M?F-_SS-'F-_SS-9G_"3:5_S\_P#D-O\ "C_A)M*_Y^?_ "&W^%'M(=T')+L:
M?F-_SS-'F-_SS-9G_"3:5_S\_P#D-O\ "C_A)M*_Y^?_ "&W^%'M(=T')+L:
M?F-_SS-'F-_SS-9G_"3:5_S\_P#D-O\ "C_A)M*_Y^?_ "&W^%'M(=T')+L:
M?F-_SS-'F-_SS-9G_"3:5_S\_P#D-O\ "C_A)M*_Y^?_ "&W^%'M(=T')+L:
M?F-_SS-'F-_SS-9G_"3:5_S\_P#D-O\ "C_A)M*_Y^?_ "&W^%'M(=T')+L:
M?F-_SS-'F-_SS-9G_"3:5_S\_P#D-O\ "C_A)M*_Y^?_ "&W^%'M(=T')+L:
M?F-_SS-'F-_SS-9G_"3:5_S\_P#D-O\ "C_A)M*_Y^?_ "&W^%'M(=T')+L1
M:MXB.EW2P&T\S<@?/F;>Y'H?2M.VNFN+6&?RBOF(KXSG&1FL2\O_  W?S"6Z
M?S'"[0<2#C\/K5J+Q#H\,*11W&$10JC8YP!T[5$9^\[R5BW#163N:WF-_P \
MS1YC?\\S69_PDVE?\_/_ )#;_"C_ (2;2O\ GY_\AM_A5^TAW1')+L:?F-_S
MS-'F-_SS-9G_  DVE?\ /S_Y#;_"C_A)M*_Y^?\ R&W^%'M(=T')+L:?F-_S
MS-'F-_SS-9G_  DVE?\ /S_Y#;_"C_A)M*_Y^?\ R&W^%'M(=T')+L:?F-_S
MS-'F-_SS-9G_  DVE?\ /S_Y#;_"C_A)M*_Y^?\ R&W^%'M(=T')+L:?F-_S
MS-'F-_SS-9G_  DVE?\ /S_Y#;_"C_A)M*_Y^?\ R&W^%'M(=T')+L:?F-_S
MS-'F-_SS-9G_  DVE?\ /S_Y#;_"C_A)M*_Y^?\ R&W^%'M(=T')+L:?F-_S
MS-'F-_SS-9G_  DVE?\ /S_Y#;_"C_A)M*_Y^?\ R&W^%'M(=T')+L:?F-_S
MS-'F-_SS-9G_  DVD_\ /U_Y#;_"K]I?6U_$9;:42*#@X!&#]#34XO1,'&2W
M1)YC?\\S1YC?\\S4E%421^8W_/,T>8W_ #S-244 1^8W_/,T>8W_ #S-244
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M_A1_:5Y_T"IO^^Q_A6G10'++^;\C,_M*\_Z!4W_?8_PH_M*\_P"@5-_WV/\
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M&EWT[06FI6=Q*O6.&=78?@#19L+%VBBBD 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4'I10>E ')>+-7?3K9F4XQ7'6-^VIV:7CG
M+2%L_@2/Z5L_$/\ X\G^E<MX6_Y%VV^LG_H;5S8KX%ZF^'^(V****X#L"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]K'?MNNTME69B<Y<+SSWY[U%:4X1BV];O?\ K8F;:2ON<;\'QCPM>#TO6_\
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M6))%SM=0PSZ&G5Y9RA1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>%O^1<M?K)_Z&U<V*^!>IOA_B-BBBBN [ HHHH **** "BBB@ HHHH ****
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M(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#_X\G^E<MX6_Y%RU^LG_ *&U<V*^!>IOA_B-BBBBN [ HHHH **** "BBB@
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M8****9B%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M$][?B$2I=-$/*4J-H5#ZG^\:ZRB-N70,5[3VTO:?%U"BBBJ.<**** "BBB@
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M(T,.2TDARTCDY9C[DULT44 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 1R0I*,, :
MK'3+<G_5C\JNT4 4O[,M_P#GFOY4?V9;_P#/-?RJ[10!2_LRW_YYK^5']F6_
M_/-?RJ[10!2_LRW_ .>:_E1_9EO_ ,\U_*KM% %+^S+?_GFOY4?V9;_\\U_*
MKM% %+^S+?\ YYK^5']F6_\ SS7\JNT4 4O[,M_^>:_E1_9EO_SS7\JNT4 4
MO[,M_P#GFOY4?V9;_P#/-?RJ[10!2_LRW_YYK^5']F6__/-?RJ[10!2_LRW_
M .>:_E1_9EO_ ,\U_*KM% %+^S+?_GFOY4?V9;_\\U_*KM% %+^S+?\ YYK^
M5']F6_\ SS7\JNT4 4O[,M_^>:_E1_9EO_SS7\JNT4 8UUX8TN]E$EQ;!W"[
M0=Q''X'WJU'I%I%$D:1*$10JCK@"L;Q)I%]?ZC'+:P>8@B"D[U'.3ZGWKH+"
M)X=.MHI!ATB16&<X( S6<7[S5K>9<E[JU(O[,M_^>:_E1_9EO_SS7\JNT5H0
M4O[,M_\ GFOY4?V9;_\ /-?RJ[10!2_LRW_YYK^5']F6_P#SS7\JNT4 4O[,
MM_\ GFOY4?V9;_\ /-?RJ[10!2_LRW_YYK^5']F6_P#SS7\JNT4 4O[,M_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 9YMM3+'%_&!G@>2*3[-JG_00C_[\BM&BBY'(O/[V9WV;5/^
M@A'_ -^11]FU3_H(1_\ ?D5HT4[A[->?WLSOLVJ?]!"/_OR*/LVJ?]!"/_OR
M*T:*+A[->?WLSOLVJ?\ 00C_ ._(H^S:I_T$(_\ OR*T:*+A[->?WLSOLVJ?
M]!"/_OR*/LVJ?]!"/_OR*T:*+A[->?WLSOLVJ?\ 00C_ ._(H^S:I_T$(_\
MOR*T:*+A[->?WLSOLVJ?]!"/_OR*/LVJ?]!"/_OR*T:*+A[->?WLSOLVJ?\
M00C_ ._(H^S:I_T$(_\ OR*T:*+A[->?WLSOLVJ?]!"/_OR*/LVJ?]!"/_OR
M*T:*+A[->?WLSOLVJ?\ 00C_ ._(H^S:I_T$(_\ OR*T:*+A[->?WLSOLVJ?
M]!"/_OR*/LVJ?]!"/_OR*T:*+A[->?WLSOLVJ?\ 00C_ ._(H^S:I_T$(_\
MOR*T:*+A[->?WLSOLVJ?]!"/_OR*/LVJ?]!"/_OR*T:*+A[->?WLSOLVJ?\
M00C_ ._(H^S:I_T$(_\ OR*T:*+A[->?WLSOLVJ?]!"/_OR*/LVJ?]!"/_OR
M*T:*+A[->?WLSOLVJ?\ 00C_ ._(H^S:I_T$(_\ OR*T:*+A[->?WLSOLVJ?
M]!"/_OR*/LVJ?]!"/_OR*T:*+A[->?WLSOLVJ?\ 00C_ ._(H^S:I_T$(_\
MOR*T:*+A[->?WLSOLVJ?]!"/_OR*/LVJ?]!"/_OR*T:*+A[->?WLSOLVJ?\
M00C_ ._(H^S:I_T$(_\ OR*T:*+A[->?WLSOLVJ?]!"/_OR*/LVJ?]!"/_OR
M*T:*+A[->?WLSOLVJ?\ 00C_ ._(H^S:I_T$(_\ OR*T:*+A[->?WLSOLVJ?
M]!"/_OR*/LVJ?]!"/_OR*T:*+A[->?WLSOLVJ?\ 00C_ ._(H^S:I_T$(_\
MOR*T:*+A[->?WLSOLVJ?]!"/_OR*/LVJ?]!"/_OR*T:*+A[->?WLSOLVJ?\
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M-'MJ?</93[&_MD_OC\J-LG]\?E6!_P )A8_\\;G_ +Y7_&C_ (3"Q_YXW/\
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MM_6LVH\Z[G?3E76#G&,5R7U?6^GGZ=#K****T. **** "BBB@ HHHH ****
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MA%1>NNS_ !)D[)),XKX0<>%[W_K^;_T!*PO%&H6_BV?6+MKJ-=-TF!X[2,R
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P"NMXIU:2/_ 'E!R/QJ./7]&FU1M+BU:P?4%SNM%N4,HQURF<_I0!HT444
M%%%% !1110 4444 %%%% !1110 4444 %%%4[W5]-TUD6_U"TM6<943S*A8>
MV3S0-1<G9%RBD1UD171@RL,A@<@CUI:!%#6]-_MC0=0TSS?)^V6TEOYFW=LW
MJ5SC(SC/3-5O"NA?\(SX7T[1?M/VG['$(_.V;-_/7;DX_.K.MZE_8^@ZAJ?E
M>=]CMI+CR]VW?L4MC.#C..N*\XA^+VK0Z+9^(-7\$36?AZY91]OAU&.<J&.
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M'U"[MHK>5XC'LB38F$8H"JCH"%' X].*ZVF0PQ6T$<$$210QJ$2-%"JJC@
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M]!"^_P"_[_XT?\(KKW_00OO^_P"_^-'U5]P^L+L=)17-_P#"*Z]_T$+[_O\
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M>BN;_P"$5U[_ *"%]_W_ '_QH_X177O^@A??]_W_ ,:?U5]Q?6%V.DHKF_\
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M****HYPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M3M(,XN#96Z0>:$V;]HQG&3C\S0!J4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #6C5QR,U%]
MEB_N"IZ* (/LD7]P?E1]DB_N#\JGHH @^R1?W!^5'V2+^X/RJ>B@"#[)%_<'
MY4?9(O[@_*IZ* (/LD7]P?E1]DB_N#\JGHH @^R1?W!^5'V2+^X/RJ>B@"#[
M)%_<'Y4?9(O[@_*IZ* (/LD7]P?E1]DB_N#\JGHH @^R1?W!^5'V2+^X/RJ>
MB@"#[)%_<'Y4?9(O[@_*IZ* (/LD7]P?E1]DB_N#\JGHH @^R1?W!^5'V2+^
MX/RJ>B@"#[)%_<'Y4?9(O[@_*IZ* ,R[\/Z;?2B6YM@[A=H.YAQ^!]ZM16%O
M#$D4<8"(H51UP!6!XDTB^O\ 48Y;6#S$$04G>HYR?4^]=!81/#IUM%(,.D2*
MPSG! &:SB_>:M;S+DO=6HOV2+^X/RH^R1?W!^53T5H00?9(O[@_*C[)%_<'Y
M5/10!!]DB_N#\J/LD7]P?E4]% $'V2+^X/RH^R1?W!^53T4 0?9(O[@_*GK"
MB= !4E% !1110 4444 %%%% !1110 4444 %%%% %34],L]8T^6POX?.M9<;
MTW%<X((Y!!Z@54T3PSH_AWS_ .RK3[/Y^WS/WCONVYQ]XG'4U4\<Z9>:QX.O
M["PA\ZZE\O8FX+G$BD\D@= :YWX7>&=8\._VK_:MI]G\_P GR_WB/NV[\_=)
MQU%0W[RT^9V0A?"RE[2VOP]]M=_TZ'H=%%%6<84444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5G:S/I%O9H^M-:+;&0
M!3=!2N_!QC/?&?UK1KE_'?AFY\5:'#8VL\,,D=RLQ:7.,!6&. ?[PI2O;0UH
M*+J)3=EW-?1I](N+-WT5K1K82$,;4*%WX&<X[XQ^E:-<OX$\,W/A70YK&ZGA
MFDDN6F#19Q@JHQR!_=-=11&]M0KJ*J-0=UW"BBBF9!1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P#L:/\ A,S_ ,^/_D7_ .QH^L4^X>QGV.I\I/0_G1Y2>A_.N6_X3,_\^/\
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M:***S)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@)QY?"X_BXY)P*[^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^2U^/O\ KH?_ $95?X1Z59:Y_P + TS48?/L[C4=DL>YEW#<_=2"/P->W44
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MDO9ED92(@<CWKO+>$0Q!1VIEK:I;1!5 &*LUZ4(*"LCAE)R=V%%%%42%%%%
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MC'E7;L%%%%,Q"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"@]*** /._B&";)_I7*^%QCP[;?63_T-J](\2Z,=2@9 .M>;S_#=WD+;>M95
M:?M%:YI3GR.YL45A?\*T?^Y^E'_"M'_N?I6'U3S-?K'D;M%87_"M'_N?I1_P
MK1_[GZ4?5/,/K'D;M%87_"M'_N?I1_PK1_[GZ4?5/,/K'D;M%87_  K1_P"Y
M^E'_  K1_P"Y^E'U3S#ZQY&[16%_PK1_[GZ4?\*T?^Y^E'U3S#ZQY&[16%_P
MK1_[GZ4?\*T?^Y^E'U3S#ZQY&[16%_PK1_[GZ4?\*T?^Y^E'U3S#ZQY&[16%
M_P *T?\ N?I1_P *T?\ N?I1]4\P^L>1NT5A?\*T?^Y^E'_"M'_N?I1]4\P^
ML>1NT5A?\*T?^Y^E'_"M'_N?I1]4\P^L>1NT5A?\*T?^Y^E'_"M'_N?I1]4\
MP^L>1NT5A?\ "M'_ +GZ4?\ "M'_ +GZ4?5/,/K'D;M%<=J7@[^S;A86MRQ9
M V=V.Y'I[5H0?#EI[>*81X$B!L>F1FI6&3=E+\"G7:5['0T5A?\ "M'_ +GZ
M4?\ "M'_ +GZ57U3S)^L>1NT5A?\*T?^Y^E'_"M'_N?I1]4\P^L>1NT5A?\
M"M'_ +GZ4?\ "M'_ +GZ4?5/,/K'D;M%87_"M'_N?I1_PK1_[GZ4?5/,/K'D
M;M%88^&CY^Y^E=-X?\"1V<BNZ=/:CZIYA]8\BSI.DR7\H=U(B!_.NZM;5+:(
M*H Q1:VB6T850!BK-=4(*"LC"4G)W844451(4444 %%%% !1110 4444 <]X
MYTR\UCP=?V%A#YUU+Y>Q-P7.)%)Y) Z USOPN\,ZQX=_M7^U;3[/Y_D^7^\1
M]VW?G[I..HKK?$VM_P#".^'KK5?L_P!H\C9^ZW[-VYPO7!QUSTK)\$^-O^$Q
M^W?\2_[)]E\O_EMYF[=N_P!D8QM_6LVH\Z[G?3E76#G&,5R7U?6^GGZ=#K**
M**T. **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *Y?QWX9N?%6APV-K/##)'<K,6ESC 5AC@'^\*ZBN3^(/B.^\,:!
M!>V A,KW2Q'S5+#:5<^H_NBIE:VIT87VGMH^S^+H2>!/#-SX5T.:QNIX9I)+
MEI@T6<8*J,<@?W3745R?P^\1WWB?0)[V_$(E2Z:(>4I4;0J'U/\ >-=91&W+
MH&*]I[:7M/BZA1115'.%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% '!?$'3/%E_=V3>')+M8TC83>1=B$9R,9
M!89KMK)94L+=9\^<L2A\G)W8&>>_-3T5*C9W-IUW.G&FTM/O^85A>-O^1#\0
M_P#8-N/_ $6U;M07MG;ZC87%C=Q^9;7$312IDC<C#!&1R.#VJC$^9T-SX+^%
MP;,TNB>*-,8$=1;7H!P?HZC\QZ"NQLM/2\NO!-UH&MVEKXOM?#\/E65_;NT%
MQ 4_O@?*>7^Z2<=AS7J4W@[0+CPLGAF;3E?1T4(MNTCG: <C#9W9SWSFJVJ?
M#_PKK6E6.F:CH\4]K8QK%; NX>- ,!0X(;' [\]Z /$O$%[8W5A<Q76C0:;=
MP^)K9?$/D3M);S_?^<;CA03NR,>F<GI[/K8\(CQ3X>&HA!K8\S^RO*\S=C:-
MWW.-N/[W'7'>KMAX*\-:9H$VA6FCVR:;/_KH"I;S/=BV23TP2<C Q5?P]\/?
M"GA6[>[T71XK:X==IE,CR,!W +L=OX8H YGX$?\ )-E_Z_9__0JK_# 6O]N>
M/SJ(A^W_ -K2_:/,QGR.=N<\[/O>U:X^"WP^$HE'A_YPV[/VRXZ_]]UJZ_\
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MFI_>H\U/[U !Y2?W11Y2?W11YJ?WJ/-3^]0 >4G]T4H11T%)YJ?WJ/-3^]0
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M3^]1YJ?WJ 'T4SS4_O4>:G]Z@!]%,\U/[U'FI_>H ?6=K,^D6]FCZTUHML9
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M(]6_Y^__ "&O^%'_  D>K?\ /W_Y#7_"CZU#LP^KR/0N*.*\]_X2/5O^?O\
M\AK_ (4?\)'JW_/W_P"0U_PH^M0[,/J\CT+BCBO/?^$CU;_G[_\ (:_X4?\
M"1ZM_P _?_D-?\*/K4.S#ZO(]"XHXKSW_A(]6_Y^_P#R&O\ A1_PD>K?\_?_
M )#7_"CZU#LP^KR/0N*.*\]_X2/5O^?O_P AK_A1_P )'JW_ #]_^0U_PH^M
M0[,/J\CT+BCBO/?^$CU;_G[_ /(:_P"%'_"1ZM_S]_\ D-?\*/K4.S#ZO(]"
MXHXKSW_A(]6_Y^__ "&O^%'_  D>K?\ /W_Y#7_"CZU#LP^KR.GUCQ -)NT@
M^R^;NC#[O,V]R,=#Z5JVLPN;2&?;M\V-7VYSC(SBO-KR\N+^82W,GF.%V@X
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MP/2BB@ P/2C ]*** # ]*,#THHH ,#THP/2BB@ P/2C ]*** # ]*,#THHH
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MRT_N+^5'EI_<7\J=10%AOEI_<7\J/+3^XOY4ZB@+#?+3^XOY4>6G]Q?RIU%
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M1MRZ!BO:>VE[3XNH44451SA1110 4444 %%%% !1110 4444 %%%% !1110
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MLLBQ_P!P%<X_"N8C^%GAY+A7=[Z6!6W+:O/^Z'Y#/ZUV:Q(D(A10D87:JJ,
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MJ***YC(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MA_B-BBBBN [ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZ'-8W4\,TDERTP:+.,%5&.0/[IKJ*(WMJ%=151J#NNX4444S(**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MN.\:>._^$0N;2'^S?M?VA&;/G^7MP0/[ISUKJ[6?[39P7&W;YL:OMSG&1G%)
M23=C65&<(1J26CV)JCG@BN8)(+B))895*21R*&5U(P00>"".U25E^)-6.A>&
M-4U94#M9VLDZJW1BJD@'VS3,B*S\(^&M.NDNK+P]I-M<(<I+!91HZ_0A<BM"
M+3K*"^GOHK.WCO+@*)KA(E$D@' #-C)QVS7E6B^&?&&M>%;#Q59^--1'B"\5
M+I;:XFQI^UB#L,04X^7N._IUK>U?XBZC::S>:3HWAB76KC2X%EU1XKM84@++
MNPNX9<XR<<']< '7G0-&.J?VH=)L#J _Y>_LR>;_ -]XS^M17/A?P]>7,]S=
M:%ID\]P-LTLMI&S2#CAB1D]!U]!7FGB'7[/Q1XJ^%NLV!;[-=7-PRAQAE("
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M '"D5T=(JA%"J % P .U+0 4444 %%%% !1110 4444 %%%% !1110 4444
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MA+0VEN)K73[2XOU^TS-*SR A$9F8DL5W,1GI0!JZ9\0;&^U>UTV\TC6M(FO
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MM&B.P5VG4;C'E7;L%%%%,Q"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M9/\ XFC_ (2K1O\ G[;_ +\R?_$UU'_"NK?^X*/^%=6_]P4?58=V'UB1R_\
MPE6C?\_;?]^9/_B:/^$JT;_G[;_OS)_\374?\*ZM_P"X*/\ A75O_<%'U6'=
MA]8D<O\ \)5HW_/VW_?F3_XFC_A*M&_Y^V_[\R?_ !-=1_PKJW_N"C_A75O_
M '!1]5AW8?6)'+_\)5HW_/VW_?F3_P")H_X2K1O^?MO^_,G_ ,374?\ "NK?
M^X*/^%=6_P#<%'U6'=A]8D<O_P )5HW_ #]M_P!^9/\ XFC_ (2K1O\ G[;_
M +\R?_$UU'_"NK?^X*/^%=6_]P4?58=V'UB1R_\ PE6C?\_;?]^9/_B:/^$J
MT;_G[;_OS)_\374?\*ZM_P"X*/\ A75O_<%'U6'=A]8D<O\ \)5HW_/VW_?F
M3_XFC_A*M&_Y^V_[\R?_ !-=1_PKJW_N"C_A75O_ '!1]5AW8?6)'+_\)5HW
M_/VW_?F3_P")H_X2K1O^?MO^_,G_ ,374?\ "NK?^X*/^%=6_P#<%'U6'=A]
M8D<O_P )5HW_ #]M_P!^9/\ XFC_ (2K1O\ G[;_ +\R?_$UU'_"NK?^X*/^
M%=6_]P4?58=V'UB1R_\ PE6C?\_;?]^9/_B:/^$JT;_G[;_OS)_\35_5O#-K
MI=TL!M!)N0/G=CN1Z>U:MKX!MKBVAG\H*)$5\=<9&:E4*;=DV4ZTTKM&/::K
M9WS!;:1I">WEL/YBNPT/0V=EN+A>>P]*L:3X2MK!@P09'M741Q+&H51BM84(
MP=T93JRDK,(HEC4*HI]%%;&84444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110!SWCG3+S6/!U_86$/G74OE[$W!<XD4GDD#H#7._"[PSK'AW^U
M?[5M/L_G^3Y?[Q'W;=^?NDXZBNM\3:W_ ,([X>NM5^S_ &CR-G[K?LW;G"]<
M''7/2LGP3XV_X3'[=_Q+_LGV7R_^6WF;MV[_ &1C&W]:S:CSKN=].5=8.<8Q
M7)?5];Z>?IT.LHHHK0X HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ KE_'?AFY\5:'#8VL\,,D=RLQ:7.,!6&. ?[P
MKJ*Y/X@^([[PQH$%[8"$RO=+$?-4L-I5SZC^Z*F5K:G1A?:>VC[/XNA)X$\,
MW/A70YK&ZGAFDDN6F#19Q@JHQR!_=-=17)_#[Q'?>)] GO;\0B5+IHAY2E1M
M"H?4_P!XUUE$;<N@8KVGMI>T^+J%%%%4<X4444 %%%% !1110 4444 %%%%
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MEI_<7\J/+3^XOY4ZB@+#?+3^XOY4>6G]Q?RIU% 6&^6G]Q?RH\M/[B_E3J*
ML-\M/[B_E1Y:?W%_*G44!8;Y:?W%_*CRT_N+^5.HH"PWRT_N+^5'EI_<7\J=
M10%AOEI_<7\J/+3^XOY4ZB@+#?+3^XOY4>6G]Q?RIU% 6&^6G]Q?RH\M/[B_
ME3J* L-\M/[B_E1Y:?W%_*G44!8;Y:?W%_*CRT_N+^5.HH"P@4 8  %+@>E%
M% !@>E&!Z444 )Q1Q[5D:OJZ:=$68XQ7'3:[<WLK7$%W,D3]%60@#'']*SJ5
M%35V7"'.['I''M1Q[5YI_:5__P _MS_W];_&C^TK_P#Y_;G_ +^M_C6'UI=C
M7ZN^YZ7Q[4<>U>:?VE?_ //[<_\ ?UO\:/[2O_\ G]N?^_K?XT?6EV#ZN^YZ
M7Q[4<>U>:?VE?_\ /[<_]_6_QH_M*_\ ^?VY_P"_K?XT?6EV#ZN^YZ7Q[4<>
MU>:?VE?_ //[<_\ ?UO\:/[2O_\ G]N?^_K?XT?6EV#ZN^YZ7Q[4<>U>:?VE
M?_\ /[<_]_6_QH_M*_\ ^?VY_P"_K?XT?6EV#ZN^YZ7Q[4<>U>:?VE?_ //[
M<_\ ?UO\:/[2O_\ G]N?^_K?XT?6EV#ZN^YZ7Q[4<>U>:?VE?_\ /[<_]_6_
MQH_M*_\ ^?VY_P"_K?XT?6EV#ZN^YZ7Q[4<>U>:?VE?_ //[<_\ ?UO\:/[2
MO_\ G]N?^_K?XT?6EV#ZN^YZ7Q[4<>U>:?VE?_\ /[<_]_6_QH_M*_\ ^?VY
M_P"_K?XT?6EV#ZN^YZ7Q[4<>U>:?VE?_ //[<_\ ?UO\:/[2O_\ G]N?^_K?
MXT?6EV#ZN^YZ7Q[4<>U>:?VE?_\ /[<_]_6_QH_M*_\ ^?VY_P"_K?XT?6EV
M#ZN^YZ7Q[4<5YI_:5_\ \_MS_P!_6_QH_M.__P"?ZY_[^M_C1]:78/J[[G8Z
MQX@&DW:0?9?-W1A]WF;>Y&.A]*U;687-I#/MV^;&K[<YQD9Q7+Z9<6&N2)%J
M<0:\5=B.79=X'/8]>375Q1)#"D48PB*%49S@#I6M.3DW*^AG-**M;4?@>E&!
MZ445L9A@>E&!Z444 &!Z48'I110 8'I1@>E%% !@>E&!Z444 &!Z48'I110
M8'I1@>E%% !@>E&!Z444 &!Z48'I110 8'I1@>E%% !@>E&!Z444 9'B;6AX
M=\/76J_9OM'D;/W6_9NW.%ZX..N>E9/@GQJ/&/V[_B7?9/LOE_\ +;S-V[=_
MLC&-OZUT6IZ99ZQI\MA?P^=:RXWIN*YP01R"#U JIHGAG1_#OG_V5:?9_/V^
M9^\=]VW./O$XZFI:ES>1TQE05"491?/?1]+:>?KT-; ]*,#THHJCF# ]*,#T
MHHH ,#THP/2BB@ P/2C ]*** # ]*,#THHH ,#THP/2BB@ P/2C ]*** # ]
M*,#THHH ,#THP/2BB@ P/2C ]*** # ]*,#THHH ,#THP/2BB@ P/2C ]***
M # ]*Y/X@^(KWPQH$%[8+"97NEB/FJ6&TJY]1_=%=96=K,^D6]FCZTUHML9
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M+_Y;>9NW;O\ 9&,;?UK-J/.NYWTY5U@YQC%<E]7UOIY^G0ZRBBBM#@"BBB@
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M:\K\0/J7B?Q5XZ@N/$.I:;::!8C[-:6LPCCFW1,Q:52"'7(_(]16!%K6MP>
MOAWH&DRWD,>II.9FLKE+>:38YPB2O\J$Y^IX'L0#Z'HKP#4[OQSI7A6&QOM0
MU*P?_A(K:"TNI;^.>X$3JV4E:-L/@[3AASD=NGMVAZ6^C:1#8/J%YJ#1EB;F
M]DWROEB>3[9P/8"@#1HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M)&,9)W?,0"JY/H<]C5#XD>-O"OB3P\-=T?Q;JUIK2P)%#IL$KQ(3ORV]0O4
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M''M1]6IA[>9R$GA?4[^>*5(2\03(7>H .3ZGTQ7H^F6YM=-M877:Z1*K#T(
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MRMEL''WCVK.\)RS^&_#VF Z+#<^*-;42/LNR7N0%WM-/(RY0#?C #8W #/8
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M$_FR1#:64S1A<1[@.S-@D X)K&L_%AAAM9-%\/F>ZUO4[M5B:^*AO*W*9BS
M[5.Q?E X!XR>" >@45RMEXMOKFPU-9-!E&L:?<K;26$$XD#%PK(XD( "$,"2
M0,8/![U+GQGJ<.D^(A+I%O;ZKHT"SR1&]+PM&RE@RR"/.0%;Y2@Y ['- ':T
M5PNF^*]=BT[2-,GT^WOO$,UDMS=;KP0Q(G0.["/Y68YPBH>AYP,U9'CP7.FZ
M8=.TN2YU?4))84L&G5!&T+%92\G("J1U .<C YH [&BN(\(SW>J>-/$VHWUF
M+2X@2VL#$)1*JE5:1MK#&0?-!Z ^H%5K'Q:L"6CZ1H#S7&N:G=J(_MAP?*W*
M9B6!"J?+7Y1T!XR>" >@45Q:>/733;O[5I#+J\&HC3([&"X$BSSE0R[9"%&W
M:V22!C!X]>?U;7+Q?$>I:CKFC+"VC:!*S6L5YYBRF>0 !9 H()$>/N@@],\&
M@#U2BN077KRUF;1?#F@"]&EV\8N?-O?*2(E05B5BK&1]N#S@<C+<U?N==U62
MUT]M*\/SW$]W#YSI>2?94MQ@?*[;6(?)QM"GH>10!T%%>>:OXSUJ^T+P]=^'
M[*&&74[];:1;BX 9&1SYD8Q&X*D1R#>.@P0#FKB^)K2SOM;O8]*D?43?1:7'
M'%<EC>3",-A0V%0+O;)]%)/I0!V]%<3>^/;G1[365U?11!J.GVBW<5O#=>;'
M<HS;1MDV @[_ )2"O&1C-7+;Q;>QZXVG:QHIL=UC)?PO'<B=BB$!E=0HVL-P
MZ%@?6@#JJ*Y3P[XLU#7)+&:30C#INH1-+;74-T)]F "!, H$9(/&&;GCK6?X
MGNM0;XCZ#!IFG+?SV=C<W1C><0HI8I&K,V#CC>. 3S]2 #NZ*Y6S\6WVI:%#
M=6.@RRZDUU):36;3@1V\D9(??+@_*-O!"DG(X]*[^/1!X?NKVYTMH[^VU ::
M]H+A3&9R5"XE( V88'<0".1C/% '945R_P#PEL^GZ3J=[KVD26+6)7 @E\^.
MYWXV")RJ;B2=N"!@_G45KXSD@NY;?Q!IT6F%;)[]'BNQ<*8HR-X;"C:Z[EX&
M0<\$XH ZVBO,];UO5O$,7AZTNM!-A8:IJEM)!(UTKR-&A\[$B #82J X!;N#
MBNVDUO;XM@T%+?<7LGO))M^-@#JBKMQSG)YSQMH UJ*XC_A/;NX6R73]#%U/
M?:A=6EO']L" I!N!E+%> 2O09P#QD\5-%X[D2SO(K[2'BUJWO4L5TZ&X67SI
M'4.A1R%&TJ2Q) P%;TY .QHKB;WQ[<Z/::RNKZ*(-1T^T6[BMX;KS8[E&;:-
MLFP$'?\ *05XR,9K0TWQ-J$WB9-%U3118//:-=V[K="8E59597 4;&&Y>A8'
MGF@#IJ*Y'QSK&O:7_8]OH<-LTM]?QP%Y9]AZ[R@'EL,,JN"W5>P-2/XS$.A>
M)=4EL0(]$DEBVB;(G9(U8X.WY?F;;T/3/M0!U5%<9<>,M8.HW]CI_AR.YDL+
M.&YN7EOQ$BLZLQC!V$D@#@XP<\[>[+#QY=W;:'=RZ"]MI.LN([>XDN@9E8QE
MP6BV\*=IY#'CD@9H [:BN*?QY<+:IK T1CX;>X6$7_VD>85+[!,(MO\ J\D<
M[MV.=M7=*\3ZCK'B/4+&VT,#3+&Z:UEU![L#<RH#\D>W).XX/( ZY/( !U%%
M<=)K>OM\3/[*CM[;^R;>P-Q,%G)=]S81\>7D,"C@(&P0<D]!4]EXKU%M9TZR
MU30'T^'4_,^R.;D22 HN_$L84;"5!Z,P!X.* .JHKA[#X@7%QHU[KMYH;6NC
M0&18)Q=!Y+IUDV($CVC[QZ$D<\8(^:I5\:ZA9:I;V>O:%'IJRVT]X\RWZS+%
M#$ 6+84?-E@,=.>&/2@#LZ*Y#3O&EY=7NFI>Z*+*VU7<+&0W:O)N"%U65 O[
MLLJDC!;&,'!H\#ZSKVM2ZU/JT-M';1W[P6PAG\S9LPC(/W:[AN#'<3DYQ@ 4
M =?17%ZAX]DM6U*[M-)%SI&ER&.\NS=JCDK_ *SRH\'>$[Y*\@@9Q5C7/'$6
M@ZI)8W%BTDD]NDFEB.3+7\C-M,2C'RD$ISD\-GC!H ZRBN.G\6:^VJWFF:=X
M9AN[FQMH9KDG4A&BR.K'RU)C)8\#!P <\[>\(\?76HSZ/!H&A'4)-1T\WS>;
M="!;==P7#G:W<L.,\CIC) !V]%<5J'CV6V.I7=KI N=(TN0QWEV;M4<E?]9Y
M4>#O"=\E<D$#.*LZIXOO(M:NM,T;1UU*:SM4NIP]V(696SM6)=K%VPI]!T&<
MT =917,:GXKN8-1T[3--TH7&H7ULUT(KRX^RK&@P""=K$OE@-H4]\XJ"]UJ'
M4(_#$5_H]Q%/J%WO^SS2M$UJT2,Y8X^\ 5 QT.0: .NHKBG\>7"VJ:P-$8^&
MWN%A%_\ :1YA4OL$PBV_ZO)'.[=CG;46H>/[^UAUV]M_#PGTW1;EH;BX:]$9
MD554N8UVG+#<>"0#C@Y.  =U12(P=%<9PPR,C%+0 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !69XBL[W4?#6IV.G/%'>7-M)#"\Q(1692,D@$\9]*TZ* *NF6
M2Z;I5G8IC;;0)",>BJ!_2N1?P;J,G@>[T5Y[7[7?:BUU=.&;84>Y\Q@#MR3L
M^7IU_.NXHH X;4]%\4WOBK^T9;+1;^QM&!TVWGOI8EB;_GJRB%@TGH<X4=!D
MDG?UVQU+5_!U_81?9H-2N[-X?]8QB1V7!^;;D@9/.W/M6U10!S6E>'+C3?$5
MWJ&^ PC3;:PLT!.5$>\MNXX!+#IGI6)<>!-3D\!:)HL&H0VVI64ZRS72$X!;
M>)BAQDG$CXR!SCI7H%% '$^)/ T=[/HMQIVFZ/=QZ7"]JNGZG'F!HF"XP=K;
M678,':>"1Q3_ /A%]4M/#MO::?:^'(':9I+[3HK(16=TC*1L8[6((^7Y]O.W
MD8XKLZ* .!B\#ZBO@C7]($EC;3:HS/#:6Y<6MJI508U.,[3@DD*/O'"BEUOP
M]-/#KFHZY)#;VUQH<>GXLUDG,!RYD8*%!*@LN.,X4YQ7>T4 >5:#?:KXN\4:
M4&N]+GM=(M)F-[IADEB\YT$:'<P W89SL&=N.6YI^D_#K6(M3T*XU&U\/%M.
MN1-<7\7F/>7A". S2,N0=Q4E<D>XP ?4J* .&N?!FIW4'B.!I[.,WFHQ:E8W
M +LWF)L*K*N  H\M1\I.03T-0ZSX4\1^);>]N-2FTVWO/L$ME8V]O([Q1F4
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MLDGW\*H(D&?F RO7%=G10!P6M>"]6FCT6*WGL]:MK*W>&XMM<ED9)Y&P1,V
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M]Z -:JDFJ:?#>)9RWULET^-L#3*';/3"YR:K:-]L\N;[9_:.<C;]N^SY_P"
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M5_M"3R_[>\KS./*^P^7C/;=\^/KS3-=6274Y+B!2TVF6HN(U'<E\D?BL9'_
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M%)")DD1HB-P=6!!'KFN.77KY+D3-/<-!-9S72QS)"J^6 -A0(2XR6'WB<\\
M]-+4[6.UT+2M.G8"T\V&WN#G 90,8/L6"@^H..] &S::C97^_P"QWEO<^6</
MY,JOM/H<'BIY)(XDWR.J+D#+' R3@?K7/:YJ$5D\CZ?;B3484CMPZXVQB210
M%.6 )XR <?49YJ17-[<,EG?-,4%[$5:Y,/F#8#*P80DJ,;%QG!^;\: .LCDC
ME!,;JX#%25.<$<$?6J\&I6-U<26]O>VTT\?^LCCE5F3Z@'(K#E9X/ SSB1H_
M/7SI)%."B2ON8Y[$*QY]JM7L^D:8ENBQ*#90//#Y*Y$*!=N2 1P<X [_ (9
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MLJX!C7:,8&?O CKTQWR:DM?['@T;2H%43I,R31%#EF<?.920<]1DGOG'.<4
M=#17%KK]_'="<SW#036DUTL<R0A=@ V% A+C)8?>)SSP#TMW%_JNFB:%[Q;B
MX\FW!>2-1'%)))LR-H!QP202>W2@#J:*Y.^O]0LI!96>I3ZA++<+ Y\F$2PG
M878*3LC)( P#G&>_ I]E>:M?26MF;J2#+3N\Q$+RM$NU1G9N0-N;L/X3P.E
M'4U#]JM_L_VC[1%Y'_/3>-O7'7IUXJ/4KK[#I5W=G_EA"\G/L":Y62QU2TT[
M0]+N+RUDMY)X4=([5D?"#S#EC(1_!S\O?M0!UZW5NZRLL\16$E92'&$(Y(/I
MCWJ&YU/3[/ROM5];0>;_ *OS9E7?],GFN15G@L53)5==AR">TKR#]2DG_CE:
MUE-8P+K=]>E&E6=XI@W)$:_<C ]"""!W+'UH Z.BLJ[BE@T:"*PCOX]@152V
M,)E50.A,Q*\=^<TNCF\$<QO/[1R"-OV[[/G'MY/'YT : N(2DCB:,I&2'8,,
M(1USZ8IZLKHKHP96&00<@BN%D35CX0>:.\M1#J<F1&+5O-Q/)CA_,QD!_P"[
MVJU::MJLE]'(J31V@NG@6,FW\GRD)4G[WFEP%)X';&.] '8TUI(U=$9U#OG:
MI/+8ZX]:XMO$6HP3&Y62:2*2SFNUBN%A5-B@;&4(2ZC+#[Q/&> >E^PCN6\6
MK'<ZD;TVUCO;**OEO(PX&T#C"' .3SU.: .GHKDY-9O&UFU>*XN!:SW;0*CI
M"(F1 V\@9,F1M// Z<8ZHVKZG9V45_)<^>9;*:Z\AD5451@IR!G/SJ#SC /'
M>@#JVDC5T1G4.^=JD\MCKCUIJSPO-)"DJ-+& 70,"RYZ9';-<Y81W+>+5CN=
M2-Z;:QWME%7RWD8<#:!QA#@')YZG-5)[MM-FNM;'W+B:XMY#_N#$9_[ZC(_X
M'0!V$<D<T8DB=71NC*<@_C3JXD7VL6SO:6JS".P,-K&%-N(Y7VJ3YAD8/SNP
M-H'X]*TH+VZNYUN7U4VH>]>V@M%A5U<(Q!#<;]Q"L<@@#C@X.0#HDDCDW;'5
MMK;6VG.#Z'WJ&[O[/3XA+>W<%M&3@--($!/U-<OHE]=RS6EIB2SBO&FO5N"%
M8SYD+;%SD#Y2#SR1TQUK4@:W_P"$EU.XNW02VL48B,C8$<17)89Z9;()_P!D
M>E &TCI)&LD;*Z,,JRG((]13JXS4-5^RZ<[:2;RTMH+=KMUCCB&W>6*[O-)X
M)!^51GGJ.!5R6^U1UFN/MGEB&6W@$,<:X>5MN\'()V_..A!XZB@#IZ*YJ._N
MKA_MCZH;<->26\%FL*NL@C8@AN-^XA6.00!QP<'.=9Z]K'V=;^X2;RY;22X:
M-S;^6H"Y4Q[6+GG .[/7MTH [:BJFG07<%FBWMVUS<$ NVQ5 .!D* !QG)YR
M>:MT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 1&V@-RMR88S.JE!*5&X*>2,]<>U1RZ=8SO(\MG;R/)MWL\2
MDMM.5SQS@]/2K-% %--)TV.W:W33[18&<2-&L*A2P.0Q&,9X'-":3IL4!@CT
M^T2$N)#&L*A=XY#8QU]ZN44 5KK3[*]:-KNSM[AHCF,RQ*Y0^HR.*D-M;FZ%
MT8(C<!-@EV#>%SG&>N/:I:* *<FE:=+ 8)-/M7A,AE,;0J5+GJV,8S[TG]D:
M9LA3^SK39"Q>)?(7$;'DE>."?45=HH J2:5ITUFEG+86KVJ?<@:%2B_1<8%2
M+96JR12+;0AX5*1,(QE%/4 ]AQT%3T4 45T72DDAD33+-7@_U3"!08^<_*<<
M<DGBK4-O#;AQ##'$'<N^Q0NYCU)QU)]:DHH IKI.G)>F]73[5;LG)G$*AR?]
M[&:L^5&)C-Y:>:5VE\?,1UQGTI]% %.72=.GO%NYM/M9+E<;9GA4N,=,,1FK
ME%% !5-=)TY+TWJZ?:K=DY,XA4.3_O8S5RB@"I%I>GP^?Y5A:Q_:/]=MA4>9
M_O<<]3UJ8VMN;H71@B^T*FP2[!O"]<9ZX]JEHH 9Y48F,WEIYI7:7Q\Q'7&?
M2J]QI>GW<"07-A:S0H=RQR0JRJ?4 C ZU;HH JMIFGM=QW;6-L;F(!8YC$N]
M .@#8R*6+3[*&X>XBL[>.9V+M(D2AF8]23C)-6:* *UMI]E9R2R6MG;P/*<R
M-%&%+GU) YIMWI6G7\B27EA:W+I]UIH5<K]"1Q5NB@"H^E:=)="Z>PM6N!@"
M5H5+\$$<XSP0,?2GS6%G<6IM9K2"2V)R87C!3KGH>.O-6** *DVEZ?<V\5O/
M8VLL$6/+C>%65,=, C J9K6W8.&@B(D #@H/F Z9]<5+10!6N=.L;U'2ZL[>
M=7(+"6)6#$=,Y'.*;%IUK#<1S11)'Y:,J(B*JKN(+$8'4D#-6Z* &"*,2/((
MU#N &;'+ = 3WZG\Z@DTS3Y;);*2QMGM5^[ T2E!]%QBK5% %=+"SBL_L<=I
M EK@CR5C 3'IMZ5'_9.F_8?L/]GVGV,G/V?R5\O.<YVXQUJY10!3@TG3;6WE
MM[?3[2&&7_61QPJJO]0!@U-:V=M8P""TMX;>$$D1Q($4?@*FHH *8(HQ(\@C
M4.X 9L<L!T!/?J?SI]% %.32=-FM8K:73[1[>(YCB:%2B'V&,"IVM;=@X:"(
MB0 ."@^8#IGUQ4M% #)H8KB%X9XTEB<89'4,K#T(/6H;?3[*TCCCMK.WA2,D
MHL<84*3UP .,U9HH B6V@39MAC7R\[,*!MSUQZ9JO%H^F0%S#IMG&7SN*0*-
MV<$YP.<X'Y"KM% #4CCCW;$5=S;FVC&3ZGWJ!=.LDO6O4L[=;MAAIQ$H<CT+
M8S5FB@"JNFV*W4MTME;"XE&V241+O<>A.,D5-'!%"28HD0D ':H&0.@_"I**
M *":'I$=W]KCTNQ6YW%_.6W0/N/?=C.?>I(M+T^!&2&PM8T;.Y4A4 Y.3G ]
M>:MT4 4=1T\WEM+'"T$4DI'F&6W$JR ?PNIQD?B#[TFD:9'I-B+=/+)+%W,<
M8C7)]%'0 8 '/ %7Z* *RZ=9)>M>I9VZW;##3B)0Y'H6QFF#2=-%R]R-/M1.
MYR\HA7<QP1DG&3P2/Q-7** (Q;PJ01#&"$\L84<+_=^GM4$6EZ=;VDEK#86L
M=M)G?"D*A&SUR ,&K=% %>"QM+6.*.WM8(4BSY:QQA0F>N .F:6VM(K6W,*#
M<K,SL6 ^9F)))P .234]% $)M;<VZ0&WB,*;=D90;5V\K@=!C QZ8IDFG64M
MXEY)9V[W4?W)FB4NOT;&15FB@"M<Z=97LD<EU9V\[Q',;2Q*Q0^H)'%6:**
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M%4 *!@ #@"EHH *J7>E:=?R))>6%K<NGW6FA5ROT)'%6Z* (FM;=@X:"(B0
M."@^8#IGUQ4=SIUC>HZ75G;SJY!82Q*P8CIG(YQ5FB@"LNGV2)L2SMU3!&T1
M #!.2.GKS]:FEBCGB:*:-)(W&&1QD$>A!I]% %:/3;&&R:RBLK=+5@08%B4(
M<]?EQBB+3[*"%(8;.WCBCR$1(E"KGK@ <9JS10!!/96EU:_9;BUAFM^!Y4D8
M9..G!XXJNFA:1' 8$TJQ6$N',:VZ!2PZ'&.H]:OT4 0K:6R#"V\2C:4X0#Y2
M<D?3-9.H^'AJ-Y$TCVIM8]H$3VBM(@'54DR-H/0C!XSC%;E% #)8HYXFBFC2
M2-QAD<9!'H0:@33-/CL6L4L;9;1LY@$2B,_\!QBK5% %:WT^RM HMK.WA"G*
M^7$JX. .,#T 'T%)/IEA=0)!<6-M-$C;DCDB5E4^H!'!Y-6J* *T^G65U+#+
M<6=O+)#S$\D2L8_]TD<?A1/8P3Q^6R!4,JS,JJ/G8$$9X]0#Z\59HH 8\4<C
MH[QHSQG*,5!*G&,CTX)%)Y$0>1Q$F^0 .VT98#H#Z]34E% %>TL+.P5ULK2"
MV5SN80QA Q]3@<FDM].LK2>6:VL[>&67_6/'$JL_U('-6:* "F211S*%EC1P
M&# ,H."#D'Z@T^B@"-H(FD\QHD,FTIN*C.T]1GT]JSY-!L3##;V]K;6]LDWF
MR0QP*%E^4C! P.I![]*U** *;:3IK62V3:?:&T4Y$!A7RP?7;C%/73K)#"5L
M[=3"S-$1$H\LM]XKQP3DYQUJS10!6M].L;1YGM[.WA:8YE:.)5,A_P!K YZ]
MZ;%I>G6]I):PV%K';29WPI"H1L]<@#!JW10!6BT^R@A2&&SMXXH\A$2)0JYZ
MX '&:233+"61))+&V>2-/+1FB4E5_N@XX'M5JB@"M<:=8W<+0W-G;S1.^]DD
MB5E+>I!'7WI\-G;6V/(MX8L @;$"X!.3T]3S]:FHH KW=A9ZA&([VT@N8P<A
M9HPX!]<&DN-.L;M8EN;.WF$)S&)(E;8?49''X59HH ABM;>!-D,$4:E0FU$
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M"M)I]E-9"SEL[=[4  0-$I0 =/EQBGFTMC:?9#;Q&V*;/)*#9M]-O3'M4U%
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MN=.LKV2.2ZL[>=XCF-I8E8H?4$CBK-% %2ZTS3[V59;NQMKB15*J\L*N0#U
M)'2IOLT'_/"/[_F?<'WO[WU]ZEHH KII]E%>/>1VENEU(,/.L8#L/=L9/2F1
M:7I\/G>586L?GG,NR%1YAZY;CG\:MT4 %%%% !1110 4444 %%%% !1110 4
F444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>img129881027_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img129881027_2.jpg
M_]C_X  02D9)1@ ! 0$#O@.^  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $& @P# 1$  A$! Q$!_\0
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M9T&"&Z#C1:/]M'-TM8;5-O :^O=;658 -86\#$C@;8V"#,,80TPQ!5#3U+)
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M\AHBM5>Z%W2FY+C]=N:KKNI_=BBW2:R#8?95<FF!'IB+8752@DR3/EKA6^W
M/MEU/8N&#Z>(X>(]O0#GO7E)_@6L1FY8[]X([?\ M.8/N! -1>\3L#YX%_I
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MW2[[)H>EDY.OHS*?<]/@DK01JW7#G&DBDV57865M8SV%R.1?RA(L+H1#ES&
MH[B>^4@&1Z3D@]SZ&HMQX.GKSYW+=2H!P=SPVR(/ !GY P3 4?C?QC,>./*_
MTDNW<JM]#/V'ONVY[S;M=\?LKRW+ZU@=?SG27E]6:JHL;(VKL1^82T]1#BI!
MH@7942I'%@A5"HXO4]L9&(/V< R#V4X<^V1D& >.(J0YR^<G^,[MB23YQVR.
M)]LSR*]0L'TXXE=[HQ'N?*[W^+&HYZHKWHGO[(DCU^JJK_E.D5R^RN]D\ R
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MD<#^"$C(!B5F.1D$\8(P8.9E$^9V1(+SRN,%)4((Y!"@<$2%<C-6\M_6)_3
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MN']1?2E;27 I'A+(29(5A>X*G)($1C!M]W\,;;["_>,7#A<1]U"$E22"G<)
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M$9:4$W.63+0J0<T0H"2I;) G@;4(\1"2E,P"00F" 2083(&03W[$D*%2W&G
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M)<?Y_J^A7L2$Q(2<)F:0VX2F"5_RA=;7DPHU$!!#&4R6QL1!0G*]K6M5$ G
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M\ZPT;6K)6F.W(%J\B2H.H\,K."=^[9. .0>(QQ5.Z)I3&L(U5%NABX:0EJ%
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M@*B-J22=I, P09)\IX]<W?\ CG2GTH6CVF.I/VQY;@2B;&0V>_#LB/G(KGD
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MQB(4!.ROA^TT[=706-^RT4L'F"-Q,$$\" <#&),D#P?]DR,$O3NP9?(65:3
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M5>E*NK2_FV?#2G$!MP.*V#8E4%2P3$*E0G'W2,=U^I!L52T5GQ%0I*9&4I(
M(!F">,\CT%5&5V=7*]<'%/K+.QJ KP@ZA;9TA)$5FP0DN:O))'+B8]K)BIAY
MHWL116BROB551GXZ2Z7U?3V[1-OJEQ8D* *UHN& %)A(26Y6 73"ONDJ$),=
MZTG\1K#4;[17&=-+J'0DB4I<*L\@P"HF2"1 Q!(,^9H>P05]IY![X>H6F+TZ
MV Q\<]8-:1Y0&[AA*%UH+<\^."<>O<6_Y%DO5\=;(,0>)&]A+U3>&EZKI]HR
MU=Z6BS(;M=K36I!04ZI)6?&0DJ3O2H*"$D224GT@\XZ*S=(2NUO+9QUYJZ45
M/J:65)E+<))V^6(! ,* 4,R:E?I>0YF#EV1U_//MM!>W-P)37UK0TT,T-+$5
M5A5IM?,6 -%)#3O,A=#)$C'RSNE;[F(MB?&+I'J7XD:O?ZS<-WOV>R;M;9\,
MI3+%JMP*64)0ITH07%$" DJ*@! /?HWISX=Z7>-VUW=J>=^UM)*@4;FTD[IW
MJ@A!"AD*,@D2 ")EWS_BC\ADBLM=WA6HJR"!M#++,XA!AC@HO^,0I,LS)2!?
MN1D='#9MCDD9$Z8E6SOG2/5?4'7&L7VK6U^'#:.6[#-IX['_ !_9VO$<RXDA
M(5N><!!([0!WRS_X3T^S;OZ<^+=AI%P;AIUU2&T*24-)"4K60E1EHR$D\\5(
M9N1<#5TML96QU(<[U #9..(!!+*L4DY[_MB"(T_;?\?[1DUKB'*5]W$CE?$Y
M$P&]U5_5;V];:>N'U.)#CMRL%2MQ"@L)5"B4A(24J& M:I[UE%CK.E/,HT;3
M46ZG+1@,2AU"EJVE40$$\@CE("OYLTT7:],/R+ E;C09R&PI;"-U-0QB-&A)
M*+0<E&P1.*E?*Y)YOA',\QL3XHW#HU?\;&JYG\-M$U;J'5W=,T2]=1<6]H+A
M]TE6] 2MQ*YF2$@!).X!(DP9FK!UAU+H6D:>$ZG;VMVXILLAL+:4KQ=RY;VR
M/.F0K:1N"5 P <^U;PBM$O/#GQ:OH X:]EMX]<:M8J\5GTA@8[#GF=)8)#$U
M7)$@K7M@F8BN:Z:.9_O\94]=4V5A<6EM;6MRZ57=N=KCBC!=VC)$C(.?4',F
M:Y<O'4NW3MR&2TPXM12S!!2"HJ3@<""-LI'EG &*CK^IFB-Y1@U1JR.3HD;%
M5$55;[9N]<B^_LO]%5W]4]E^*_E/;UH3_44^U_\ %[4!:2Y]M\/[PR-J# ';
M[Y[F,3ZG>7P%4%]2WFUHP;(;4@&9*C!$"?EW,&.(JEM(E1B(V+W16-5/Y'.]
M_P"5'>_]/9?=JM5/;\K_ %]U1?7&]RVINT0Z74A90D;%*$\@CRG/)S\N,0>N
MFBI#R/\ QE*/A#)009"EG9G,Y)CL3(!D$+[DCOEU/F?Y5CX]_C/?W3X-;[Z>
MG<B*YRI[*C(YG(B?_9C5WM[-=[9/T0A3G573J'! \1I0400#_%7ZB,F-V >\
MUCW6CZ'.F-?0M"VBG3KW=M"BD)\%/G5 P>1DC$3[^I@:)$1LJ*UKD]VJQRN_
M+F^Z?)%]O9%7V3V1?S[^Z+Z^D["-K:4MK!A"00DS@) W2)Y$"?2,U\ZG4(2Z
MLA4@D03!S ,#.8D9^<5#;S;DX12<XH=_Y%NM[S"\\UXE[6<J!@$O!>S;6SJ[
M3(8_!%X,BL/=T4V:[THEEF,JCH!9-:)26EE(@5;(GJ:-P4 K/N)V\<$@\X[G
MOB312DJ& 4_A$\^:([<'M^ @0PR_<>Q^#/!O$GF>YXON]3J>F=ABS5S4T,#M
M+3<QQW4;_H6MI.696Z(OQR+?8\WI!Z')T]4^O2F8)7-ACD?6QA2RS3 B3S''
MO^6?:O&>PY$_O@^GOC':1FKF:,R6Q %L)1#07&#1$_:V4$0]B.D\<<K8;"&&
M26*(V)KDC*CB>Z)LS7I KH$B<[PG^;_\C_2GI\OKZ_[.Z]>J4R6P_P ^?&/^
MRG7_ /?YQZ4IZ8O^3;_X_P"\OI2NSTI1Z4IE?(GC%%Y%\2ZOP756FGI,OV'G
MFLYW?7.-L65&EK*O64IU,<73V! YH33V"ERK"/8A%4Y:->#="F &N$E?7?\
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M?.U9H7'(*Z,=S8)("H)F1HYCG.S=S;;H:9:\[JQ,MRN)$;I3)( [B1M))/\
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M<K$5S?FNII/=S6/=&BN59E;[JUC43^SV:B>_NONWG5_X%]7HN4-N*0XV&DJ
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M8W'0-LYFSBS B0++$K(VQJL:J[>.F=((-BS?7,I4E"U0L;3&P*2F2 <J*@D
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M*M!H'*ZNK_Y&N1 X45R/1)'*B.1?9ONBJGLGO[)[_GW]O;^OK[/=+*4YH&E
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M(B-6IZO_ "HUJJE/#*GLV-OY8]="OX_"JJ>R?XSY^[4_/K'U?Z$^EKC:KPW
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M?E][@,1)CRZNLK2:.KJIQ9S27F6,]F_K//XG$_+\N/2H<<>O^.P[#B>(S'9
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MW@<+;,+0%N M-% V[]ZE%14,"2 0">*T*VQK'1MXF[N$O&Y<>!4M27 0%'8
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M1'U@UQ86.@=I=,@>A$A'KG\O[>F,14/ECB?KW.:L-@1R,7Y-5JJ]WLB^_O\
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M./JJ;*:0RL@ A'W5[2U8>LV4K*L &RO+VPLJA#ZD@.Q+F%0*/#$;C*Q!R4J
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M<%"9F,PTWX,,Z+:7SVMWEDVXWI7\,J=9;$ NQXF]28<WA6Y!))&S .:_2 \
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M^4^3Z&93YS#8JBLZGH1E&#0[*IEY95[A:/9UD==GLWL@CH$_CQ&>WK^7](J
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MPK/<R>V#WC /Z]ZX^U8J^_V[?9/S\9&L3W;^/[(F*WW_ *_RK_.B_P#1[>\
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MZ4N=QXL^./2J#09?H'#N6:W/:K?/ZG?5M[BJ$F*RZE%6#4,/12%F$66'<_L
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MGD8QY5@61 *$.URRE$S0P0,DED8URE MG6G(2X*P!,:$7, 8HI<!""'CJQ"
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MT<?MT>*V$MN!P)=<3N\[CB50DP$2H;H-8MKW5'4+MN[9^(I"O" 04!4*3O7
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M?7U$5/'TI6,7_P V*_ZM+_Y<GJ'<_(?NJE-[Q?\ S.\G_P"[3"?^EJKU&E+
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MI#*@A4<YB%11UA3RP9_9]JU)U^0Z-Q/PM3LKD)L[D,(N4!M04K:"N52! $D
MIX\T9& "=*:YTVXK6U$M$>*0Z$A"\)+BQZ=RDSYI,#F#,3-UO?\ "!9&Z)P3
M:$1_U E:B1?7+A ://%"08B/(;(/+ ^0;_C1TP;BOM3BED^$$&36%@_;,.V[
MZU%3TK<3C<4J !)D3D)@'.08)$3NCI;2/L%NVI22G 5N(5"24(09,9QR#"L\
MX$I>&9D$S@V3PVD@B_*-6$D1PP/<^*?YI":*LC945KW.8YS8Y)$D)B3Z4K7N
MJ&K@.O-6I$-6Z?!)(( A2C,GN H3YCD8,D"LL8<0Z^I#HEL%49P9'<CRP#W@
MR>\8J.FSWO1\3T&/7+8UX7/<KB8B+:QLZC[V4R4^U,:T2KLZD$D5+"PGG$K"
M!+)R-KQ$>64.7#,V.+/;32M,5:$I+?CG((4C=]U/ 3G[P,\22.3,Z\UZ^UVQ
MUA"+1+GV%3B5J(0O8)6I!5N("0D (!/W<8Q3]<?Z#F;>G/VM=DZ>V-NRFQ2V
M9XD VA6:N$L4^-D%*D5?,.1-)9S 21_-YTT($$7Q^E (-BE_]I:>4A%XXRE/
MW4H5@B50LP29$1(/\H&(@7[6='?UNUMKG[2ELE#84AM<Y22HJ,&9(609';GB
M7$H-+2U=V;I[;&UMW<.- LG3%++4QTUZ\F,"62JJ@_K#PSD#?=R(])*HMY$,
M*S$$0I!'%9'47SI!&H.+P 0I<$$D\!1@"<3$2 9F(\:CT[<+TRWMDWRO$3D*
MW@G:/Y,& 01@8B?82V/:B;?7T6T(I,B*?=7@38(<TA8<:V:7($S"_NY(45EH
M] 'JLWWD420/?#+(_P!X$D?D?1I%IJK2M0N5K0PZFZ2M"O.?NI\,*GS"&P0(
MGS8 @$']("]&?L5A+ZE,KA:C)"R-H&>)*23'J9R:K5R/*][H:27E$',YL$!8
MF@Q&:86DDJ#B@LX$2-)1E" V(U=>0V#Y)Z^5Q\9$=W+""0),BA&1&=?WGQJZ
M8L.G@RVTE>J)9#2&BI!!: A#SB"92LK\1))B0E.)$G1%IT'KUGJ2E%"OL;JR
MHH+;D'<2DQY<G:$DB9'J!5GF(Y'Q]\%QGM$,90TEG1$5&@ RYEE76NL&A%]K
M"MGT%<ZKD<UTA(1*"1CR5R)["Q58X44#G\K:]UUU1=/I7;/NJ8>N57*&7 HV
MR$D@ @GR>78DG() Y[UL?J/I=YO0K0:4P!=7 19W);1N4A+IE9<")*  H3N
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M-E<^*D.J;0=P*2@@$22  3@D 3A/EUW<Z5=KU=KQVUA(* 8;6!M"E$$R-O\
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M$%.RYN''@4J!2OQ%;IE*B) (0J.5)R HD"74:HK41O\ 1/9/=/Z*OLBJJ?\
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M%8.*+ <Z202P!$=+,PJ28:QFG?"SZ?S(AB9&UGO$[XSF[5S5EM72;III+#@
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M/2E<^E*/2E'I2CTI1Z4H]*5C%_\ -BO^K2_^7)ZAW/R'[JI3>\7_ ,SO)_\
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M6\D'*C)22,!0 5.#$XB= =6]4+;>5#Y3N A07Y02M?"@8!,$P,Y! .#2K<)
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MDNA-RT] 6@>7S;5$;5D$\@$@>]8_UBF_U70;EBV;6R^Y;/ALH;4"L%*-NT
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M$L[UO@?F]5FZ2P+S0HTO1OXHX]=<B)/M(IKDUN:?#!=?O48P4UFUTD:T\CX
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M28V5M?&6T""2T,>UV%_Z@?AE=V?PYLNJ7G#<ZJ_?N%UEH%QYAN&UA"VT@J0
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M+@;4"^EX@!0*!"DI#:6\D#.X8DJK5&B:LW9:R4:H\TXB2-ZW4;$))*=I4I4
M@R85D@@Q37=&PFO)Y-1WE9T*[YEI, '?K29N*]+%_C:L)N$$JZ>USU;)8).Q
ML]&6ZN-%E4H%2 F&0QP?N4C=P?"_K#IS2-4N]%U?1+?5M(UQI+"[I3:'G+!:
MR4E2U^;PBVA*%D*VQ.8Q&/=8Z&K7;]5QI*%N(2J2;9*GL E7+<]E"3,""0((
M)6P_0MYM/&JLV6FR]3G-9I)[@?31E!3!6S:,2]9EH3(Q#/H3PC6=88+=4XBQ
MM?!#"?".L@]>Z1N%]=Z!H.G=8.L]/7K-QI;^U8<;>:<0WXBW);4IM:T@H3!(
ME,)5$9QXZ(8#FL(LKXA"F%P/&/ADE&V/OYD$'$DP.*;0/C:],Q^CDN):B//@
MS+(V":=E>"1%!(VWKF(4/*P@$5+6 :6&Q;&9$/#&U#(QAS199K<YJKEI<BP8
M2E]0 4A34+/AN;D[1LW':=I$Y)!(R"H5N76NI+>WU#3=+:0U<>5H$@I<*0''
M$PH G@@F,94<BLK'5X@=#'?5-V5!L:6Q>17TI$$3 W0(4T); $V:<AEE),IK
MU-"FC(G:HDC[ D4/[***.K;WK=+#ML^%%D/GPVED)22M&Y<),&4JF> 0)C->
M]?U2Y7:OZ>Y8-HME N)N'VBE(W(2F$N. #&P$ 'DF ""3-\6Y)BJ!R;(TDY\
M@$4&CE#EB=%+&]LE4QL,B3D%$2++*V=2 VQBPC&PPQ,^FX6:;7ZF66[@,-!U
M2ECRH0E2EJ*E*3*4 ;B21$  G:0>\<^71<3=N-LNV_A#S0EQ!\TP0 %200 1
MV/('>OFSIP-"D%AIJV)C:*0@^OD4VW=9K9V93/NX;,H5(6?<025\+1R&M^R(
M 5(X7N=#,UDA*%VKJDVRB 4>(YG+9*E(5NR-B1L2"29W2F1DU<M-OKIHO,J(
M;8<1&\^1LK.!"R-I5&TD R 4P#23Z5TO&<MICM=MC&Q#6^A'RWPJZV:=X!T\
M#)+*.P'BD+F@B;$V04BQ>E:ORC"K/ND+/"C?DW1_1FI]77KC%DC[=<9+;3"R
MX^H <I:;*EJ!5)"@DI*I23(JQZFTFSMW'WG%)"U%2%9#:@3.%GRDRDF!NPJ9
MB",14Q72F4IC[*LTP@T-=I0WO,K)K!X=S6QW8Y!4$;99EKKD*.(F&>:QFBE,
MA+%@F<QWP2KU?I7J7I_QF=2MKNRMK5]4JN&76VDJ2E,H4MQ"4I6$Q*200-I4
M$S)N6D]3W%JBV^SNJ+:6TJ6"9SN4#F83@)R9R8D1%1\ZCS,2GLC-$^UIQGWI
MUI8UM,;"ZI.K:VX'L_L+6L#C>3^XQD32H$T:.>-PTY:^XT/T6/DN73.OJ==3
M9N)-QF4*0-\ I2 1M*C!((G!G'.!MSIOJC4M4>0@V[KK (W'8I8A)!.0("?6
M<#$U7AUCH_,\_P!.YURKJ=A30X#5WIBZAPRB69V1&(FJP*N8X]EE.;411MLS
MZFQ/EA9&VKG.F7VD@16=+] :.^6]0O[E#G@!AU#25)6.4(*0-P!,[E 1DD8S
M,2OB%UE_M3+;6G[-Q:"WTLJ"B'"M:2%!!)2L)2DPH!4;>)!IE=S0%<VWAD/.
M=EH:+GND/CA6]SLQ%U6M&JK%466"V:@(6BK()7*GW->\I#9))V1RRQQQ-;DG
M5W3NF6U[:ZM;K9N5FQ076;=:7%LN;%REQ#9)2H  $* ($1W KNB>H5]1:->-
M%IQEU.Y0=6A0"W/#:)"5*$*,JF 23/  S8&"(\(4$PPX2T'^RG1#XT8";",?
M7_']R2"0850R#R5B<L!J2O\ FJQ0$2.1(V<OOWJD:A<MK;*$J><*4J2I*DA1
M(@ QDQ[F8($&*V78L^!I]J\^?#/@A*UNG8@+W*E"E& "E,*VCL03 .7&K\'L
M]:^KKJK/6?T4K3)(''C7557P0H:PAK89XPD&>2]C)HY9"I_J.GD= K41C46U
M7NI,,7*$>(V%$0I)6$E*BH@)(!!W#RDB)S^=IN->T]MXVXO+1QP\(1<,%>9$
M;0N0)&, Q  R:0>PN  \E;Y_5:44#+'CZ&L.IQ;28?X'S2DP.#+2,0Y'D**,
MJOFCCCD20046=R)/&QV;Z!I6J7=Y:7.D6-RY>-E#J7&D.$%&\$"$IS!*O,.Y
M/8$C$NIU]-.V#CFHWUDP2@A/CO6X!5!P"XI("O-!0DDP.#D#V5>&$52WQ#\8
MX:HB<JK'X+R!M83/^)IZZ/GV>8#/-_+&U)9161/<UD4/TE587,9)'(GKKRP1
M>+L+1S4QX-XAI!<2E1^\!C>#!#AC*3*DP.YFN9=0\)5RZ6%(<M]T-+2$[%(!
MD%)XC/8D')!V\2F@5%9[HBHBK[I[_P!OX1/?^B?A51?5T3E*3).X;L\B>T=O
M\U0#OB(P*[O7JHT>E*/2E'I2CTI1Z4H]*4R6P_SY\8_[*=?_ -_G'I2GIB_Y
M-O\ X_[R^E*[/2E'I2CTI1Z4H]*5#?\ 4%ZONN$>%'E7VKF5I#2]!Y9P#IVZ
MQUL16UEP/6Z/-Y>QM*@Z>KNQ#ZHZ& P>-TH101$)S/\ $$L2/XR1C@$^E)C\
MQ]=O7Y^E-72?J,<MJXM2G=>=]J\9FYS@NC\E*BP[EGL<##T?C&#6I@W>RQ$.
M!WG2"H[O-FZ7*,L.7;0'(=;K_P"+L[!-AX9#"1J^$_7M\N:<P<9_#_'Y'BM9
M8?J58/&TFYN.T<!\EN $93QXZIY1Y/-=2S7+(;WL?*>+T(>@Z+_@[7$=;VM/
M7;[/U]O2%6/,NC6O.]P(V[K"R:D4$30&5$?UQZ'MSQ]1V]'OQGVCV&<_4$^K
MU]+\P.6\IO*W/Z&JVQ!UMXQ]O\KX7TU32$"LYKP:/G#-A4SN,T-80S6FLZC1
M.S5<SXUD[Q;4:?054 T41SZ_*GZ>Y./K]!\N&2Q?ZFO'KV:L.Z%S#NWC]A-C
MP/H7DQS?I_9LQB*G&](Y!S"GSNAZ#H*8;!]$WFWSUMG,[J:C0OS70,GDM,;1
M%+95=<>YRQ0/KZCC\8_42YB![?7K^$C]:;BC\^-_O/++Q=P[>.=WX)R?HW"_
M)?K]\'V;$8#[_IF:Q5?QVRYSJ,S/SC8=0NJ4ZBBT&G)T7.[HC'=$$9?TZZ##
M2*>")&I3V\V\^<YLN@\RP>M\>O)/B4/<<IL=GPK5]=SO,JNCZA58;-P[+0"A
M4N+ZOM=[S[4PY$J310YWK6)YM8EUC#46!IX:53';Y>WM_P!X]L4Y/N??GZGG
M\Z2G /U,^9^01/!9*WAWDGS/$^4<)D?"NG]8R//,WA][9@\YM^F'44*5'4])
M>5]P^BRVICK5MLN!3:,C/GS9BVMJ ZGO;=2?QQCUX^8X..?3Y5,OAG<,IWNB
MVVEQ0.@BS^.ZUTSD;;RY!!#K===\ITY>*U^@QDP=M:R6F/AV%5?9ROMS4KIS
MK#/VKQ0'5+:VP/4IZ_2E'I2CTI1Z4H]*4>E*/2E'I2CTI1Z4K&+_ .;%?]6E
M_P#+D]0[GY#]U4IO>+_YG>3_ /=IA/\ TM5>HTIR_2E'I2L Q7,^3VM<Y?IH
MB-1/?W_F=_1/ZJOY]O;\?A?Z^O)($R-P $H DF3Z>\>G;VJ/W4J4G[\0(B?4
M>_/U-45_KAWE]5^.U"+FAV1Z"Z,U576'M_<FGU!7\.RF1V%<ZI^D:TQLL#1D
M6$ZID1L\C4L8T562:>^)=HQ<O:,+ILFU%TWN;4!YH<),A04F#P 4$',A0K+>
ME]*<ODW3OBI:6TPM2=Q"2"$DI$RDC/IV])!/BXP_FF6RP-"ZG&Y][*78!:*O
MT2M?61(2/,SZ183Z-]B@\!\DA*JRQ$.;,9+,<V];#'*N>O\ 1'3%[HEDYIJ+
MO3;UAH.)NK)2&I(0GRDG)5C@G@B(R:M%GU;U!97=[8.K5>60E"&'5!5INRDK
MVJP5$)3NCRD!,>E7F4G5O$GKO%:C,#]$Q,F>.P6;KR*#.VPJ6=.VDF)C(F"J
M6F5Q>>/AN((@A)K)*8NS1HIHQ80TDBR<D.VG6G3/6-WK.FVNKJ+=\IL:B\T^
MEUQ V'8AP(VN) )6""<J.3R,ML=,O^JRSIRK07J'&$K5:6+#S[5NDN+3O?;;
M0OPR"(6M02-NV20*KSNA+&S9=Y2COZG%82KLQG9BPI"%&_?;F(R5\"2@O-56
M7DLXL(/U2Y;LT0.!\E@R:)C")=\V?4^G75WIVJ:C;ZK=:JIQA#K3H/@^+YU$
MGQ!Y7)6=P_\ 782,@G>O3/P9U1^U<M=6U"UTK0D62_!-L\VVI5QVMWEE24IE
M*4#:LS)D@&HV7X>FI!CY.QN! +)S]5EC<RS[> *DB:48R.RKH$A6*]&,;/$4
M8QM7 Q)H9WH_Z,L3EZ^^#+]G;:;?/7;+EH[?7CKGV.X(2I;*_"2VE*%!!5)2
M2D $G,&")Y]^,FE-:7U+9Z59_9T/VELRRE;"D*#[:?% <2I(E<JWIW;0,1 *
M8IU_&+H66Y*38Z66F!*/!JI2,0%+6?N+SYC(S(3,]6LG:2!4C10O'<0K"<ZY
M5-(; 85-[B0:Z_U%]/ZGKAL['Q7-/TIUQMP,E*VD>$5+'B>8)2 =NW<>=OKD
M6OHL:6;?4V;AA+U\Q:_:6TJ *E/*6M 2$'EP[/NP52>.#3X2=HM8N<V>R^[J
MF7A4$C\["@Q4=3'.Z>,)]>'$<\^2RB*69#23XQ6M5D3T'>Z.))Y.56.@&K[6
M/]KL"RBQMF4BXN%J2D>(E2U*67,)\,HV0N8)2H3(@=$?[AK.B_#QKJ6]LKBV
M-LT6V;9;#S2R@ *0KPUI"_,5J$P0H P3!IY<_'()GJW5):B"V"!UB2,1QU8R
MR=\V.2>H@*5L@T;ARE@+BL6.!=/[%1!L?,LDFM-81::3J]_I-LE-WX*=N]B'
M4%&]22$J;*AMD&0!$D9&2;UT7U+9]0:<QJ+C*_MES9R4@$[/,ORKB2E6Z928
M,%,\@5W<[[A58_M0?([&OM)*26L,NIKFX$D#%A*)#C/;)7H-]/Z TKXD=8%Q
M,09"72Q6%9.R&-$LVI=,6+^A7%ZS=&WOD+6I#16$E:=J5!.R4DK)4H$ $XXJ
MUZY<7;5O=H4W=(6^E:4MM-.>&I$$))(3]Z90>3M"?7$]-ICEW%+74%6X8%E$
M?97,##"1W16+U+M12*^5C*=M?\)H6$+#8L*)5I@8(ZE1+ H(F Z5<KTNX0I!
M\)]]M+3R5*#:R2XX-ZD*\T+DI!@Y$>XU5T]JFH6.H&U/B)!?*A*5).U02 8(
M&V>_;'(R:K\8L'T('2,^,DJP1NG?]91FF$5C98'S,E(-2(4A)1C1AX%JW"33
M212N8D:HF<L)7;.,IN% I?&\E2H2DK3&U1. 3M"@F01(,P:Z%<<=58-KN00V
MXD%<H(!08W&2  !!!))!$D"*6Z] U[@@84OK1Q"D$2-#:;$.,X&)"!Y%F)]W
MQ32#+ $VN^D43(TB9D4L[O=D4=*YINF&Y<=6H#Q'5;DI4D)DP)5$@$8&3S!S
M.+*]TUTZYN<\-E;BV Z%A2%'))SF9P2>8 / I>\CKK+LKS-'T>LNQB:2Y,R]
M!.3%&2/I0ZT&62OTQ=U(\(28MPY]=6&ABE/HS#/I-M!R3PQX%H]>7::-;,/:
M5YG5$+.P[E#.TE03)  3!F.TQBM6ZEU(WHUQ<V-C;I6M2204B5Y*F_Y9) V
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M>R_TU;J*6D:C=%@)0P'7$-)!&T(#BH @P8&#&($1Z9$VM3S2%.$%:D@J4/\
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M[)4N5D*R1*N#D_7M61H2$H2D=DCZ^?KQF<5+B+W^*JO]5<JJGM[*B_C\+_\
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MW,_^W]*4?QKU[_0>_P#VFYG_ -OZ4H_C7KW^@]_^TW,_^W]*4?QKU[_0>_\
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MTLXXI7NM2H7R(C6M;KI6EZ=_\TTU)4F_MK:Z00\^M*V"M+RH 6I1;V0E!F2
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MS_WS4U:6XW]B?8N2ZE"F5[@XE.^);"2,B "J"!,5:[G3+=E"'%MI0M(3)^[
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MG**V")&^\4[$8[W7X-]=U]':B=$T)II%DEUZX2$M.*02II2FVTS!R$X"@2
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MX>T04NB E9/ .V,Q)F8.*K]"N-%LF7&[VV5<[UJ6GRA?WDI2 )F."08$"1S
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MG];8WFRJ:"HJ<[=P/]OU^OQI\_S^L<^GS]JY\B_.;><PZSV-@'1^1XND\?\
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MM 7:LN:?0VY0E15GV!<A+Z^HQ3ZQ^OY\U)SJGA9F>B[_ &?68]_K,ST^]TG
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G4H]*4>E*/2E'I2CTI1Z4H]*4>E*/2E'I2CTI1Z4H]*4>E*/2E?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>img129881027_3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img129881027_3.jpg
M_]C_X  02D9)1@ ! 0$#O@.^  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $C ET# 1$  A$! Q$!_\0
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M'WD?$ 5M'[IB\)@!X_5PG>?_ -@L/](-5JFG^$GYY^$UN#[I?\)H?3-T^/\
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M\T] Y8^,(]-,KA[9).2D9,$")'4<O5T&Y ZE2CJM>2(/0^L$1],'Z*S5@/(
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M_P#X(G_]E3]=/F_ZS,;^_9Q_HUI^7SW^+6O]J/\ Y=/[$UO_ "U7_P#!$_\
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M* (&P@$%0 (\QO6;:8FFZ=#0;*21U,P0)(/3:KQ:BJE::4K:8W24P]N0*(@
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MYI_\)'VT[MO^]#_Q%_96H#ZB4/3N(\  A[NW ?CY#5%=X4E:0"$1JAM(@'U
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MI)]IF(V$ \?-',U!72U*<4&D%S8%1X"9W ,QN0#$>6W,U<:*]2^[@H#R(^H
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MD@C8GL>1LD)'=8QC#$C4E=K;*DS.X6X"(Y@@ D@>59/R@!  I2E*4I0*4 X
M"E     H     ' <>G;[?FXNDZRX2XXJ27%[KU'E4SN3U.\G>NR!*4D R (\
M*(T@ ;)3P8B-CY5KJT8]<[S/W^>J2H[$RD?)'D/O'U5>3;KVW X,_P"&'&GN
MY[??G"\]O4>WP[_ 0'OJ=RM'Y1X+)(3^,K/41,A(?05$1Y"?5T,#<1>-R,'Q
M,I$J%C<E(/&H-*(G8[2-Z],UMFZ'G7< YP/<P8L;[B">JF6,73KALU*JK'E*
M@#^OLETRF=E$'T**\J=9,OM#5^S336<&1%%'ZSNKFQS!C[N W:PW>X+<,7^&
MW"F4R6PE,(2G<*6E6M4P/E 'U\"MF[S!\':Q>U6IRWQ1MZTQ-@3H2XE94%$$
M#PD%!GG;B8JSZ\8JPW#[ULATVHPETS90:A0'.*&,HVBW+U%T]7MGRJM$A)\)
MH*D]B9B+I(R1PZ$T2J 9P"9X)YLL9DSCB#*476.X=9M+PU*V4K6#W:50&Q(5
MNE&X&H;#DU*+45X+E.U?=4SA=\\L7JTO*#>GOE#Q*!V.DDZ2.0)XJR<]*6_,
M.UK#^5]R=?:LLV0FX>AQU-L<O6XRG6V09JY#2CGD0$4S81#CY-1A?.<>Q+-/
M9W8L$)H$E7+1LY2A;E5WC&7,&QC,=JTC,3&8 FU6Y9(M'E-=\I*V%,@0MH#A
M:B2H0N)J4939X3C^)V.!7"[G"7L(?2\"ZMUI!4C4"5#4-U09@"9G8&I@KYAL
MMGWFY7VW2K.$<XL5Q2V5DH5: B%E)A_*X_3>OWTJ[58"]?\ G,5D(DS)TY69
M@P9HHE1* F NV*QR[N<YXCEI;+"<-7@2WE(%JV5J?-GJ[Q2P@$E/R4@E0TP(
MZ5K"<+M6LM6.-H*_3CB@: [U>E;0N2DI"#"$\ ;'>?%OO6#Z/Q3LJ7J5BF;;
MN)L]5RLTE+$5''+"ASKN'2<M9)=..CTY9K5'3!-%0H&3 Q9,J")$RE R90 I
M>%,8+D$-7%Q=9CN6<89O+E(M'+16E6EP_F]2+=1TF2 0Y(3Y=.MKQ'-B;A L
MLNV[V'+8MFW+DJ:4ML%I(*@=85J3X2(29.^\5)_Q+*+EF_YPQ5;\90]BMN,I
M6I0(XQ?U5B\L$!$OB.&9Y)X1&((Y;PR3EPM$KF7>$:HNTFPJ)>>5JIY>W=IF
M'8S?8]@%Y@_I5QAUQ;68PY;#;CK=K<B(6M+:@&Y)25*7 $"8K7,CWF%8?A>*
MLX@^VB^;N+E-\R^MMHO,%!'=L%<K6H@KA*023QM%?6J;>MPEXWY8[B=T-D:W
M52EU^&R'-2:%A8'CH2%K]>9/XMN+!D\0-$JL;4$.QF?,9-4IEV5Y+&4DV+L\
MHZ8?EG,MYGG"AFI].(-V=NS=N.]ZSI;#:90AQM#BG 4PD'6DI)DR1)JY<X[A
M-EE*^<P.T%HS=O.V5N'"3<+6Y"7'4&  F5%4"" (T@[5.[+F+7>:<3[N*N_R
M9CK*SJQ.'>0\6U*E7(DM,U>7J5'BHZ%@O8S+MF\,V=S541>+L6JR<2N_?OEG
MHF!1T;70\=P?\;X9FEA>(6&*K><.)89:L/A;]H+:S0PMIK2G\U*6DPA!(UDE
M1$FM(PO$D8;?9?N&[.\L_1@+2_=>06VK@7%PI>HE)E2?SBM2E#Y*0 DD147<
M#,<8I^'4P8Y@Q'D',5<0S6\2-3L;#*A8T)9&-9%0D3&AI**=BR8"#A-R)'AD
M>I5/J(?YHAJ.6TX4WV<6]MC&#W^+L.8L^/0\.#KET%=YNX5-%!0E$0HA0B1,
MULN.B[_+IPX=B%CA;R;.U4U>7T)80E:0N1K;<A029!T3SZZYN;D:8ZVE83M.
M,L877'V/,;9Z9208'R<P=+V:WOTX^PL?:(PTBO,3;^1(@HZ<QT9[>1HX9^V.
MUTE#-&X!>S!^+G,H8%<8?A=YAF'X?CB7OQ#?H67[Q2%+ *BX7"5$I\(*E:R8
M._-C"57AS1B3=]B%KB%_?6#R$XQ:/!+;!T@%8" VDI"9W4@$;'?>;LYBL]SW
M081R>?'-WL]#8L*&XGY? 68<!1,56X:"K"2!UD6-TG,?N&KB84&,"7KQXVS+
MN(:148KMU(Q-D19G.8W<W^9<OWSN'/NX<TQ9+?=PC%,);;2TVVV(0T^E@>,Q
M"#WD '< U&8>W:8#BMLF[93=+-P WBV'XFMUQQ3AG4MA+Q&D3XB6TDDD$D<X
M@_#Y3%/=UA\H]/66S-RF*0Q#%Z@61 P 9,YRFX$.GJ*)BF]0$2B'/">S9 1G
M#!W0X7%*NTMEM#C>I)<(404:]20F"DB)'Z(4"">K9XTC+F((U.DNVR'0X0!(
M2E1!6/,I $#D'D5F/AGFWB'WFR"D-M=S]'97E[B]AU\PJ)V)QC\LB\2256G@
M*YL"L&2)Y;) 41BR)")1*"7!C%-WEE676<[!365\>8QEQ]; Q>7EV*"MK4IU
M2.]+6E(1MJ3R=A,FN27/XX<RZE+F.8._8ML)6,.26Q>:4K!+94EL*D[3XB0!
ML8J-32L2%1PKXH,-+65O<)0F9Z4X?V))-H@M*/'>2C+.73YHP1;L8^157,=2
M08LD$FK1T95!NF5$B8!JJ+-^RP#M/0[=>F*N,89<%PGNUJ6'76B)2%2VN2-:
M F$[@ @5/+?;N<;R*XW:BW3^*VU%HJ4I*U]PZHJ3J'R9W3MM $SM4QULZ7>I
MY_V884A31B-+R!@Z%?6U!:)BW3V8 M7=I-VAG[IDJ_:M4%6:#CRFCI BIO,*
MN50BBA3[FK'[FRQ[*&!L,,BSO,'1Z2'6P5K4I@ <@_I;P)$<UKOXF8N,)S)B
MZE.&YL\56AK2LA" '252)DS.T<>KDV*A$[3A+%6\F\;<:;%NLP1FX![ MSQ=
M=B9.9C:=]ZE5DU'+:+6:N4WB3%[*S#ULP2:N1=.%W":2#E0P(GA&$8A@F$YP
MO\!L[9>-(S ];MH3:LN.^BE"2!IX 45'23U&\QM+W:K?$KW+=KC5TXG!UX(W
M<*5WW=I[U 48!D$K!2-CRKVU8WQ.9:WS^WW:%-W^(3@;I)1EG>V2)1;MV96$
MNJRJPND :,B$:MQ(<0+Y*)02+Z$^: #K5NU9R[N,L90N\1M4VUXJW>?N0/S7
M=O@LB-"9@2J3 ''EM4UV?HM+;',PH8>-PPT&T,/$ZP4!3@2=1.Z8!@\[[U4'
MAY96RE&;/]PC&H/EW,ICU9LYH;%E 1\L[:KS3I!W*E*S^3W+B5.LJ_>J^2]2
M< D4QA;IMT2$(EE=G>-8HSDS,GHI2XNTT.6I;MN_60ZA(6.Z&ZAXB3$A(3,S
M5G/5A8?E+@[ERI18N WZ22LMM@05 :T@J0K4 ) D;C?K<^QW?..$L);:9+:G
M2F\I)9/M3R8RNXAJC$2SFW7*6GI!2>B;<_6C7"D 7Y2ZHE:7=N8H(1HF6+2>
M,6L4DV;35W=XUE_ \ ?RE9=Z[B5P7<::38"Y+SSBU0'%*&I@$_+WTH09V(@Q
M=O9X-BF,8N,QW*F$6=N4V 7>.-A#*6TE);,$N*B5)0 =2C!$UCU\3NL5&L;C
MXU&JPL%77,OC&KSEOB*\BR;M65S?2UF)+I+M6/2W;._9T(\5B$*0#)B@KTCY
M@J*<Q[5K/#[7-6BP";<O6#%S=(M@&PU=.I*GDA TI2I1$JCG85O79_<7EWER
MY9N5.*9M[X)L'ER2JW"E 0I7B(\(F>A $C:L=&N6CY0W)W&YY/'-;TLRN8 E
M:=AQ\H<>JL5NZ?\ V1SPT?\ ATP__P!.E-U]5=@_[P8O_G)G_P"D;KA7:K^^
M6&?^X?\ Y55^J5KNE<JII2FE*:4II2FE*:4II2FE*:4KPL;S@$/NA'+1OCM<
M@@#Z!"W2@>@=^! WKZ_#D?32\\E2<'U(44J[Y* 1&VN/%OM B#((W&W6OHO\
M&<D9]>,)4!A-V0#N=<H @>PD>WH>GWSQN@C,-S;.N-8(\]+BB@^?@*QT&S1D
MN F(01 H*'<JIF3,F ' "@ @<IA$!UO'8[^#[==H^"NXY?8NC"[!FX>M+/N;
M=+[UT\EMM2GEE6D: 78'B6)!$<FNX=M/X0^#=D^*6>!JPBZQC%[^V%\^MI]+
M";9I;CB 2I>I*EA39_-AL [J)\)2>@BM]6#WL:T=/5K4P>JMRG>,4:K.2*;1
MR B1=N1ZU;"BX\I4AB =,>#"'' #R >,5_!;[1+'$L19LC@5Q:-W ]$6YBS=
MNJXMU*!#SK*Y6TX4& DDID<F :F,#_"*R'C&$X9B"7\>U/L$7*$X5<+;8=TJ
M#K7>LI[M:D*!W"P% 2($1SPWR;>#"4!GIY(PCTG*O59E 4A'U\P%$"B3I_[X
M0X]_8>-1Q_!F[4P):L,#6"?T<;:, <<-JF?G//,Q+GMV[-H_.7N,(@#Y>'7"
M8._0K^OW=*YJ>]K;H81 US,@(!V]IBGC?GZ2"H!>OCMR(>@CW[ZQU_@W=K#1
M!_%-D[MNEJ[;=&W(2H-B>L%0$\^5>T=N79FL>+&74((V[YC02F8\0*R9CGJ#
M\X[9MO$VYN1+QDROMA$A1'VUZU8@'(^G\TN"\* (<F+Q\T/4 '4<_P#@_=J[
M(.K*[^Y,>C+*PH^9+82/9S[8%9;7;7V5QMFFQ9(Y[ZX99.X_57N8WGDB8$D1
M52M=S^WIWQY>9,<$^:)A\VXUY$0[=0A^VR ?.Y[" @'?D/7MJ)>[$^T]F5*R
M5CZT)^4XQ;/OQR)TI01!/F=A)Z$UFM=L/9LZ &<\X"J>&G,3LT [\G4N 1S
M!B#Q7>-<[X2?@)VN7<:+$#U,6\U@>P\"4.TEQU>_CCGOJ+>[+>T.W$N9+S,.
MA*L)O(Z[R&2GI!&K;;SDSEKG[)=XD*8S5@+B5; IQ*U() F!I._(W\H/E-5,
M+]0I4.J+NE4D2C[V-BB'?_\ 8=J!QW#GN(AVU"7>4<T6)B\P#%K;UNX?=-[P
M3&Z5'@$S &W/G)V^9< N1+&-88^>@9O&5SN!T7Y[<]>.*J=)5%P0%6ZA%TC
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MK3T!((GS]^PVW^,:UB%TZE]2+8&%@A>PW*8"8\*B3XE=?(]=KAQIN0*  7J
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M%0<@V_&%KB+Q19H\#:()T5W%2J+-@].T<$,4Q52MY)H\9*" @7@B[=0H?N>
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MJ2'LZ*/8R9E%!,<X&. D 5.DQ!,3YW%,SYCQ##75HLTK*TG2I*4$Z0%* 65
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M*'W_ %,#L-EA>?I>HB/XQ,';X? . UNAQS"1Q?V1  W4^B>-Y^KR%:K^16=
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M)1QH^(VB;^RN+)3KK(N6EM=ZRI27$:A$I4D@@^5;G9W1L[IBY+;;@9=2I*'
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M\_"MR\F389)SJTD>(6KJK"X<0 =9"77&FVU*$Q!2 >LS&A[9.1Y &7K+PHB
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MCGWZTO/$C"D%/(?2?FCW=:^COP9!.?G >/Q9<D]3P$CZ5#X[1O+43<%  X$
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MK(.))U%-YEC$7[6W=4K_  FR><=8<$%0,-$1 C8SPNB[0W[8"J%@:D^<IYA
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MTP"'?MV#6P@@I"P001*8,ZASX8F?=-=\;6R]"[9Y%RA:=86PH.HT;'45(U)
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M[U?$56+/\,OU%UD)X3[%?$5%+_2_TOKJH6_O_M@U<3R/:/C6(O@>WZC7>E]
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MSB9NR;MTC+&Y$#',03*>HF, \CJ'; Q;6^8@TU;VUJMVQM"AMI+;:0LJ"C(
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MH'>0"$@<"J.783E325>1;GVZ(0(HLX9O!$%$$2 *BABF3Y R@@!N3E(0"E*
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MJ\:-U9&/LKE9XV*D_0;..44GK4PF,D!1\W@HCP.M,SO^]:/Y4?%%?1WX,?\
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M5J6"VR"4]TM1EQ)2#I,)%<ZMV5Y"OB1%G R74/2RE2@)FZW'S>A50P$,<_<
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M<HN56YVJ0-A.; SEDY>7+JWN\/(Q'+>)-%>&7[/C86RLD]R[ AJ\M2%-EOQ
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M)?\ BO\ XW]=/R\S+_C!?S#[*U#PK_NB3D.:;!>H?^V5#_)=5'9ADLG]Z_\
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M\F8DQ^OG]X\NE\PO4K78LJ5MA'PS J$S59"DPDI9H+V#VUR9V>*=QSEZHJR
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MUF,$-P>B8YCR,^<]=JUV[6$K*.0"09WD\#;;WQ[8D5<B-,')3  @  /)N>0
MW(AR)0X#@!^ =A[\ZF[7=WC8@$ \;A1/$F(VCR]QK6\3=4PY:!H);"G%2H@
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MPF8":/BK(*QDI>,(H>KRB@B=&>@VX^2U$7!^@P223,Z(NDSIB4ZJ3DY51 H
M,7@]Z[A>+X<B_=/<H2\5R=N\ 4D;'](D21$C<^9/%,H8_?8#BJ\LYJ7"6^\1
MAERX%*+[+$A$+6$ZO"D %/'T5,MB8 \PA2G!3RRB4#& 2G+QZ@;W\A[^.P^_
M71$/*>>#[6S+IGVI/G[Y]>PD5TA^^:NE:K<RR3$@^?38$"9B)CK.]5%#"/44
M0#@>H2B ?0(F'N/?MW#@/K]^I=Q'HX2H1"P".@W&_4R)^F:C+\):TO?HH2((
MZGGU>SYHYVO'!_@%^<)N>!$1#C@?>''P#5Q &@&>=X\NGU=0#ZJUU]]NX?[Q
M$[B%3U(!@@]1_P!>M7'B?P?Y?$NJD@:2K8 [_,:AK[E7M'Q-5ZU#DI/A\W\A
M0^SW\A]0ZO3HTJ;$ H'QYVV]GS\[U".;@^L[=(\H]U5>Q,;D@ (F !_!'T[?
M'W=A]/R<^NI!'C;!=C5$R1/L(/ /PV]@B;A DD23 (!XVX)Z^?EM[Q6ZQ5:%
MN<#+5>R,FTM!3;5S&/XMVBDL@\0>(G3<)JI*@8BA#DY*<#<@(& !#7FPOG+6
MX+K;Q;>0M*FH404Z>@X()CDF('3:(Y285XY*2#)@[[R?; .T]=QO6&C'DE8/
M"PSQ&88M#E\\V/YPMCPV)[)UK+,\%72?.\>I8ZDV*@I)0-.DYTCAO6EH@7C-
MFI-0S)RU9IE=K,^HW#=OG;#'KVV:#>8L,MT&Y:&YQ%I&R[A,#4X\VWXG=4'2
M@P5 $UB*_-*D?M2H2D<:#&H[<01/O/,;UG,CWZ<BS;/FBZ2S-X@DNV61.51)
M9NN0%4UDSD$2G Y#%$IB\E$H@8HB AKF#K;J%%$:5!4.I4(*5 [@#G8^?S>?
MI*@H;<\^N/A\T^VNS3$0$ ,82B'N'GN _'GT_1J@\'RB/5]?3V5ZKD:N<TII
M2FE*:4J@<EE *7.#SZIM/RR;,=9V%G_M"V'\(G_=54?B?[@NO4D?SD'ZZB /
MX?VE_1K<5<+]J_B:U7]#_1^JH ^(#DZ:B*72\$47$U$S1D_<7+R=2J=-RLJ#
M?%R45&DBFUGL5Y6)$6-TI$0@6:'458,ZY,.'R#AR4B &2*1;#>44HA*=2UR$
M^HIB>AY"OHX-7K1 *M:UJ2VG=<"=M^DB3L0.@DSYUB;QYM0W!^&S8R[G[AMU
MV!66APLG&LKU(8!J#JHY>ID%.RC1D,[3SR.*:K&.X]F^<M$I.)7M,."B9FKA
M$KH[1- ^(VRNWAQQE(W!GY*@F1P(W)D "08G>:D5W+=V"AMY1*4R-@4DQO,&
M1UWCU$1O7I78NVLBR92+%3SF3YL@\9KE*)07:N4RKMU2 8"G JB2A3E Y$S
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M'=RVD;O&5^Q?:</Y%S"XQM8&V/;9>*WFW%DYD:UVO'EGI$C0(RT*MI)S49>
MC[#%W)K4UV%M-(,V1Y2(11G'*E6UW6YXW,;X]NM+VV)8BFL#MM]N:S8KI=CE
M6+BS6".VDH.:RRRYD/+%102+6*W+SM1F[F-.HQ+;--K'#M8/[XI&MR<O)1$.
M\OO]_OUI]_;]_OZZ9W>;>]VFS/(^SW?5-;B6FX6'VT6D^';G3*#MIA,76 <
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MX2 E0TP""%&!O$"?IDL'!].6M4%);TM[GG3X@1TZ[^SI4L01,'/!N.1YX]0
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MY0??[_#I2O*9NRG8.Q?= ^6I*O3,3/1JFUV"(G(0LDSE6)U M$B<Z97;%9=
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MN.0/(>0X_P"M=NUCVLFP<L)!%%Q'NDU4W#9<@+)*I* )5"J(& 2JE.0  Q3
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M6J5]-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI01
M/40#Z]*5IR'Q#\8:4KQ:_="&W7<QAGQ%=E'BAX1PU:\Y4?";S% W.L4^&5M4
MPWF\<Y6?W06BM>B//GT8N7AS1;%.8;,P;,7KERNH]:^0=9-2K6[*,D9_L.YO
M?'X^&ZS;#E*GTK%^*5*7@[%,K"%A;A.L58Z6G;'#U>LV!TE+],0Z:QCQE8I-
M)LT<O[ NTB)1XZCY=!BI5WON93;)N3G-PV\'Q&\^XRG,3L]P:LRPJ<+/QJT"
MM/NKQ<D+G:9"+KLB*,\PAX=Q!1S=D^DF+-M(IRA%8LS])%8Z*E>S_2E:& 1
M0#U$! /K$-*5A9W6^&=G27W%R^[S89N4+MCS=>ZY'53+D?.Q+:R8ZR(P@GTG
M(UZ6EJ\]KUE0&PQ3B<F4B/TF+=11J],B=82E*4*1Y?;]?G]8$33V\=?.JYV'
M^&]>-OV8;]NOW0YS?[DMUV2:TG3)*[JH$CJO5*@#Z*D5:[28%O%0;.*8N',#
M!F6%.+05,$>F7JZ1.4]8CX?-2LLZR":X=*A"*$[<E4*!PY*8#%'@0'N40Y#^
M7*E8G=HNP!_4=KVZ7;9N)(F_K^X+.V8KBNA5+#(1SD]#R+5JG7TD"34"^:2,
M7)^7%2 "+1ZU=-@,DHF8AR_-4]E>3JT[7<3[0/&\R;AC"["<CJ3';;H^80;6
M"S3]LD"OY"S.6[HPR]EDI64.B9-@W\M$[LR:0@<2% QSF/IF=_WK1_*CXHKZ
M._!D_N^>_P UW'\YNLG ^@_WG\$=<AZ(_B'XBOT 1PY_*?\ +6W5:]4TI32E
M-*4TI32E0A\0A-G*X )1CPL+,3N3+[5J-433$/'SA8FPO4Y685F(]K)-7K="
M4:5Z$GB(.10,8B"[E,!*18Y33V77%,8DY<:''&[1*GU]VD& $@022#'B@]=R
M.M<I[6T&\RK^*$]U<W6.8A9X?AKEXRTI++]RX'"ZRRM*DJ<#"'E(&E2@ LD"
M)J/<W@VE5/<5M*Q7B)B1_D7&3QU<\LY.4<_*5M84IGC6TP"$/:)X55Y%M'SK
MN3A(NO4HRJ<;$0+V):0$/'5>.8E92WI=U<8=CU]B#:O1+S0U86.@%*UI6""A
MI,D'4 I2@F5J))))D\_N<KX9A.:LD8/EQMBYQ+ '+K%,R8PMU/IS-J]9NVK3
M5T\RL H>N'FTVV')4LLM+:4EE-N@E-28R@<A[A-Q.X?,U)S+/8WKM7E8/"%:
M=1%3QY:@E(VHP[.QRH(C=J].F9$;VFXV%N=6.! SA4JB"YU!; 5+'N7[;#<*
ML+.\LVW@\V;U;:W;EA;;[I#;:"E@I*M02("^.GG4KA6'XMG+..;LS83F.^P2
MVL76LO6SMC8X??INF;5*+IU24W:75-)3<W+R5J90$2DA:IVKE[5:_<+=NNW"
MY%NF0Y#*S;%;&O8AIMLD:_58, <*N;(]NC)HVJ,9$PB@$]EJRJ[M)L+AP/ED
M.HJ1),J%,8<:9PFQ8M+(V"7@;FX0"MQ+DA):&MPZR0=1)5OY>J[D2RO<1SQF
MG%<5S"<QHPEIC!L+OW;5%DMEY"W1B-N&K5IEB5@6H4=PL@F%0:RK0:8'<F'O
MR!0$!ZA]1Y 1'@.X_ ![!S]6M9:7K^4?IWZR=_<3MUKL%^=*$H!Y)]H@[">1
MY\<\>NY$:/'1SZF$1#_G#ZZE6$G8#B"!/ER//I[>E:E=[.)/D%? 57L9^$0/
M@''XN=35L-( ]9_FBM*OOVU?^E5QV/X?VA^C4FSR/:?A6IWW7^+]E5Y%_A(_
MVY_SAK/:X/\ I?S:U2[$EP>8CYS5QV/ E4'GG]J]?0>1 >?I#6:RDI\8&X,[
M[Q!VWXX^<DC:H"Y1I0K;B=]N8W^>(WY\ZJ"$$0,00,80 ?3L("'(^H"''I\>
M/Q^N3\NX0\0"&XYZGS]0]7EY;5"N.J0K4B1/A(&W)W\]N8\I'KCJ<XXE/FG'
M3FH-W9&#Y-^A+1ZRH&4;G>-D'38B:Q 25 ">6^6X$I14 W2!1Z>O6H9[P)[,
M^'OV]L/SX2%H4B03H .DR8B(!ZG;CKQ;M9RBK-N&.VEI(N]86G< A0"=XW/2
M(W.\3!%1RV844VWW+5PI>1U_DRTV%@FG GZ@3A)UF3V-\==LJF'LZL@F5 W2
MB<P.TFQ7)ED4R)+"GS+(5@U@F*IM\1;5;W=NM82M2UZ%)(*(2%D@"1)'3?@B
MN%=GN$OY%QB\LL:[SOKHD(6I([M20!\D\!8T[@< $&#689A\X"E "F[ H"@\
M\&#@!*'8..!+P)1#DO/?D?77TC>%VY2R6UCN_"09V(Z<;=2?^HKZ%#S((6VL
M]TYXD^M) F-SM/NJM8\/G%.)N..X^O'K[OK^GXCWY[:N6R1I*B-YCCK]4<]8
MZ^8C[M;96  -NI\^.=^/.:J%N(^9\[@>._ =N ]>_( /V=_@(:OEQ&K3(GW=
M#!]>^X^\UCJTE)TSP09YG[>H@09VKN$3<E^D/7D 'W!\>?AKV0%#Z=JCO;78
M$(42E$2@(B'/I^CTUYT $'?:/HI6_H)R ]( (>G';\W'/VZ]TKCN$4UR'35*
M11(Y3D535(4Y%$S (&(8I@$IB&#DIBB @8!$# (".K>VJ=]85X=RDB#RE0X(
MY&X,C;SI]8(/L-1KR7M&VZY7HMKQ[;<14 ]=MYU'4P$958B$DC2R@@=.P,Y:
M(9LI)C8&S@B3II--7*,DV<HHKHN4U$2&UL6&YLS#AE];7UKB]^'[0)2R'+IU
M]KND@@LK:<4MI;*DRE;*T%M29!2036.Y;,+0M"VDK2Y.J0 1UU(5N0L;$$&0
M:QQISVZ'PT))"(GFETW0;*TUS&96IJ1:VYEPDP.9,%V4PS1,-KN%7CR?S8U5
M8,+5(-&"2S4HI=+5'70BSECM'0MYERRRUG,)TN6R@+7"<9= )2ME13Z-:W+A
M\*@M=N@K(4=0*C6"#<X;H0$N7ED2)425/6H,P5?I.( W@!2HVV(BLJF'LZXF
MSU4&=ZQ'>X&^5MX1-4CZ%=@*S,5R%4(VE8Q8J$I$/>@>3,I-FT>%[]: =(ZY
M?B^#8G@%XY98O97-C<MD@H>;.ER#&MIQ&IMU'\-I2DG;?FI-IQ#S?>-+0ZV2
M?&G@?P2")D3N(!XD54V2> I4[[^2,Q_YTFS[?9SWXUXPTQB%MZE*^E)%86*'
M^T+GUI _WDGZHJ(A@'@> []OI]/H$!#[._//?6XDA1C@%2IGB"HS[8&Q'KF=
MMM1G20I/RH23[@-O7L/9-6"?[5ML$H]<R4KMPP/)2+U4Z[Q_(8?Q\\>NW"@]
M2J[ETYKZBZZRAQ$ZBJJASF$W<1X =>3;,$RH:B?*#'O,GV5<0^^1"2$@>N!O
M[ ?*OBAM-VJMUT7#?;/M^0<(*IKH+HX:QTBLBLD<JB2J2J==!1)5-0I3IJ$$
M#D. &*8I@ 0IW+*#J2A04 2#X1&WF-_H^BO1>N(()VWGQ3]!^NK_ **"39%-
ML@FFBBBD1!NBD0J2**"1>A)))(@ 1--,@ 4I" !"% I"% I0#5?E';8"?I'/
MESZY-68*CP)Y)Z??XS5Q\5_T;1?_ ,7>_P"!K:CL7,VBQY*1]*TU*83M<@>6
MKX5+C6J5M5-*4TI32E1IW4[J<([-\.6W.>>[K&TJCU=JH=1V]!RX>R<@8AA:
M0\+%,&[R5F)5X<H@BRC&3MQY95%13!),YRT,]!/V4 YCH=X'G'SFOS/=]V_;
M</XSF=U+!;7$W1MI]"GY)WC;&22WL3%)F*RS*+DYEJV761F[H\B^0D9511^G
M$ ZEV$,[9LI!1%>!QS';?"F%)U)5<K!T-GD$""3TB2(!B2>H$UV'LK[*<6S_
M (DAYRV?M\N6;C0Q"\2 E3R5**A;L D*4XL),K2DI0F02%:08[8%R_C'9/XE
M6V?-5OCGD7BW#UDK]AF$H5BJ[>GC6D4DDNHV;-6ZSAXZ,NJH950B:IE%3*J*
M&Y,)A\98O'+^P7<.J\:G5$@[G>/7L.8&VT1P8S>WK ,-RWG%&$8/:)LL/M,.
MM6[=I*("@E"-:E+.[CBE!16XHDK5J*C))/M3'[K4\,%+YIE<M<^O:@VD X#Y
MOH,!R'<H]A !#WAK8X3YD^[[2*XAX_[V?G%:?LMGPOP]5LMA]="M/^8-(3YD
M>[[":>/JB/63_56G[+:\+[_=LM?O#M'^8-5A/ZW^Z:>+R!]Y^RMW[+8\+_\
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MRD=6NI:$CQ2&(12\E- $R?-XYMHS#B9OCB!<U7&A2-*TE-NE)(D-H)E) '/
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M4GY*3[1\T5!W&SX'D)^<5<B)_!_%^<NJ*, 'U_4:A[K]L5[_ .:JK@-0^80
M'D>HO;TY]"^OIQV]_H/T>E]*@W"MS(WVD;C?W\Q&]0+DEP'[[$_57?\ \SF1
M]E<%.<B_44X%$W<![" CSR/("("'(!Z<\^FKCEF,025/E2() ;$P1/7YC\^U
M1%Q9=^IQ&L:"/GV,[3T)\MS G:HCV3P^]OMCG9^UMJXYA9ZP']I7DHN:G&'L
M<@*HNB/X]HRD6[2/6%STG.+%!N"I0,DL*A#F W/\0[/<(O7WG4VK;-PD$LO)
M)2H.$Z@L%)!!!X@@"=H%<VNNSS+MU=NW MDHN-17WC2W&RE4@R@-+0E)U08
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M&1V!\*7$M-\25OA>\U64N.VJ^TJTW?':K>P6IBV3)'5:PN%*\XML'+-GRTI
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M/#&\@""/7R-IGRKI'9;CV(8_D3 L6Q9Q#MZY*KU\,(9+VMP:%E%NAM)2G91
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M.TD"-?)AEGZSM@5U(.Y3ND6SK[=ZA;B6=:K'0$K3$$D$JVCCU\"16E6?X0>
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M>X_@-O\ ZT9ZS\+_ '?;?QS_ #%5@8G^X+G^(/YZ:B&)1Z^>.W(?#W<:V]1
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M%=8[QG>\M61*H8WK$E<+,X;+NT82**F=VNW;'2!=8"+*(I]*1EDNH>OJ^>4
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M?@>! O/// ?N@$>Q@ 0#@>0 .0]..P^_FPX$CO6V"LA)2%* TN*"CI6E9)4
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M_9=NZ'7"IUD :4K7J"MXB2FO/MMYNJ>.LW8TO*M37O9:Q:6,L:GMF@OW$^1
M3\QZ+("G%RHKU ()"40,8"AV#@0T+!W>XQ*U?[A=PIL*";9M.K4A1()@D %
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M1H"AF"OD-(""I2LZZV?@$B"XF<N5RARF4J2?K\IG@G$DZ ?3%@&% RDH"5$
MB(C;8#ZQBM=B6%6[V2;A.*7ZU90;*F6RW;E%VXB[7<-AY9=*VCK4I1*)3N "
M0-NOIGBAYCQ]3=K-0J]3IC-+:NO.C7I(Y73MY;F-A<QKN2CK$B_,Y:-DE!BT
M4RN(M-JZ(4Z@)+)GX'7IO,SS3%DTVA!-B04*4H G8="DS(V,R09\ZNW_ &,8
M%B>+9OQ3%+G$GUYP0VFXMV@VENQ<;)*7&UH5K<$_HJD"."" +M9;\8K(.6\<
M9?Q0^V\X-JE,S/%HM+<SIT?)U]RXE$Y!&44L:\G%*LY.5F'#M %%5I1X[ >I
M0  ?,5 ]^XS?<7;3]O\ B^W;MWTE%PX%I[Q6H$**4@:EE0D;;CH1R83+WX/F
M&8'C.7\5&:\;>O<"=1>6;UPE+K24(2L(L4(U.ML-I&Q[M*5 @"((%6!D?$3R
M+)7_ &=9 5HE-3?[-L85W%M+8D<S!V=JC*Y7RU]K)68_MHK)/G*! <+A&G;-
MRK )2) 7DHX[F8W@O"UM6C)18A##94L=X&VV^[2HR"I(4 "0K8<< $;':=DV
M%6MAGK#CC.)&USW?W6)7(3:M%ZRN'R^\6D HA30<>(0500 -6_%RZ/XLN9*9
MF+.&2G6/,;6ZH[@'+-_>\-VV-4F<?N7K2L152]H!-X"\LJ#F,AV?M;95T#9T
M5,S9PDH@/2:XG-=XQ=WKXM6'FWX5W"G$:%*"4@'<05'3TB1 WBHG$^PO!<3P
M3+>$HQ;%+6XR\.ZL,:M4M,W[3;JU+<0X$J2@H"E%0(G3)*8))/-DO%US0_SY
MC;-B&.<90\+B2ISU4Q_A^#CW$)C^N$L[J+<3[]@6,%I*%6D1A(@BK<[H6B!&
M"9FZ"9UW!E/3N;+HWMI="R8;0AMQ/<I=1I!6(U$Q (B #!YWZCQ;=@V!MY6Q
M;+Z<;OG+_&+UI_$,8?:#MW<JM'"XQWA==4DH <=W"@5%0.YFK077Q";_ ';;
M]D[;V\HM.9U_*&5YS+$G/-5Y@TO&RL]-2,XO&,4UGBC0T>@M(K($.X34<&21
M3,<QCF$PXCF8;EZS-L;9E*7[E:UD.))"949)\P"(XW@#H!L5EV58389HPS-#
M>,7Y>PO!V<'8LS:M!%PVPA"$N+6 K1\@*YDF)4:E/M9WZ&R?O%V0RN6K/%X$
MJF L61^"&UOKI_;HN<@HBHS4-'!>D;$$K'H-[0Y<MX.2?D;(-((LF:;17BSQ
MY9)K+89CR;C%,.%RI-LRTSZ*'2M/C2&R$ZR2 @';GKOMS7/\[=EJLOY%SXU@
M:;G,5UF'%QCSEBZV65VSANT.N&T5;Z7'EVJ%+>;:DJN%("-"Y":RJ[R]P&%L
M=[/]TU:1RGM+4D<MM+!7Z+C[:V^K4F226L$8C''M%T2AD/;QM+]=T*$U).#J
ML C6$<H@X\U-T<FPXU>6%MA5^VQ<6Q<>5*4,NM*)DQ)2DJ)) DD[09/!-<9[
M.<MXWB^=\I.C!LV);P93;V(7^8DW#2&RR"M+-HM\!*+<*T]TR"'-1,@A4GR9
MXYR%:<4WFL9&H\F,/;:?+-IN"DP1;.1:/FIQ,14&[Q!RT6^:)B 59NH7]LZ@
M*4P<AS"UN%6EVW<,+"%)&QU#UR#JV,ZCL9,^RON;%L(8QC!;[![RU0JSOP_;
M7+2R"%VKRMQ*2%%;:D)6@E6Y ))%99K]XT65+;5;\PK. -OV-,CY'JSJI6C-
ME/J38N1Y&+E%&BE@*YDGS9=%W]\!&Y@=D<I'2075(]9D0?,V:Z&SJS>ZXTZW
M;65O;7!3I7>'N^\=,C6X1HW+A$QO!5)XKAEE^#K@=IB5@[<YFS!B6#8;>(N+
M?!;I2D6J' 99#/=/C2VQ" I2/$I""E1W(/3XO\9/.6.,48RQT\Q7AV]SV)E4
M J&3;?6V;^YQT<WFE7XQS-3V08^,.O#JFK2TLR:MY==B89 [TTJHJ_"EMFZ\
M:8;9<LK5]3)U!Q2TI,R3 D;&#^B"=_963CGX/F7L9Q[$L73C^,8=98N73<85
M;:PPZXEONTK<47=:D)4 \VER1/A BK5-?$TR"QOF[F^M<9T5&0W@U1E5KPS!
M_8E6L #.)EHD9.OF5D!4*Z7:RAS'1>&.U*JV2%),A3J<XR<R/>D8LX6T)].;
M"0 H$),$$!428U'>1QO4RKL:PY6'Y'PY[&L1>9R;>KN\/4W;6R%W"E7#;X:N
MI"4MI); "YU ;[UWN$O%.N^,,15;#N0,"8#W"PF/&SF-Q[)9BID=89*DPSI%
MJV4B(-0&(%]E4!@Q4<G6,NL\,Q;>U*+E33XN6F;'V&+:U=L[1Y*!'?7$+ /R
M=DA*B(B08@B>E8>9.PS#\=QZ^QW"L?QS*[ET [B5KA%PIM-^L**@5+%P$+4K
M4N0A1">B1 %4UMV\3')>W[)N9+XQQAB.VP&:&CQM/8ODJE$0% CB+2;%ZS"/
MAZI'1*8-X^.8EADV!B&8NVZRCR115?E*X+8L\Q.V5U>7;5I;OJ<44]RD]TV4
MK<!U(U)!,0!LDR#,;;YV:^QS#LTX3E_"QBF+X,O 4ZK?%VG_ $J\<0BW=24O
MEZY#P=6I:274J*RI( /B,Y =H.XA+:ULFWEY$LM\Q+2I_.2N0K!A7&U(NU)M
M=FA;K=X ("OOT:-7I>;E*Y#P,H#9LBULL:Q*UCHY-R^:C%JE<*SMA?'#\'Q6
MX=>MDN7;CKC%LR\TM39>2I)A"5%22B3(  VU=9KE6>,JIS9G_(6"X;;8Q<G+
MK5A:9AQJ]PZ\8M+IFR>9?$W5PT&7UW#8W#;JQK<4#"@HCSQ.W:SYZZ?O%@6=
MOG"[MRJ)2$%5PX4%993H(!2%$ZAC&$I0*4!'@I0#6AJ7+JG2I.ITE2CJ!V49
M(/,<^T=*^M4LI;9:::3#;3:64H (_-LRA*0-R!X92.-YWF3\ $   Y#L''J&
MK9*1L"('&X.W2O*DK4HG2K<D_)(^ BHZ;L^^W[(7'?\ :*]Z=_\ VW0 _F 1
M^H!^&MERB9Q^R@@@)N2?5^85S7&/P@4*'91F-12H0]A )@P <7L8GH)/T[5^
M@/\ <Z0"'@O;&P$! 0J64>0$.!#G/65..0'OWUV2OS</)]I^-9MM*I32E-*4
MTI32E-*4TI32E-*5"'Q"]X<)L2VMY"W'S,2SL!J@G'MHBOOI,D0WFYB3<"DT
MCU)!3D&Q!23<KG4 /FD2$1'CJ$%*M=X>^[BS;Z,3RN2<@T/#\1$L)ENC!%QY
MDNMY>AU%4DE#+'DGD6XD6T++L5"F3.T6.FX2.58#D(8IRZ<]/<:5$#!7C"3^
M?]]%PVI8ZQ[AU2ET3+LQBZ0L<EFJNQF17B-4;]-EF(3&[AX67EDH]\VE&A4X
M]H9)0(Y4P'-T' 5*SW:4II2FE*:4II2FE*T'T'D>.P]_A].E*PL9O\5FX4_=
M?9-MN"=M4]GUCB21Q[&9PL=>FUR3-??Y ,U=-HRGUAE$23RURL17Y!A-R#..
M.Z7(D_9)"W1%4JBC[_?[_;2I+;X-X\7LRQ_1;)5L3'R%F'.=UBL>XTQTP\N#
MD;/<)-HJY1;S$BE'+N")LS*I(KF72*8AG1N%$Q 0%2JHV#[SVN\W&=JGY.D.
M\89,QA>K!C'+6-WLA\I+U*[U>5D8279INA;-#K,U).)DBLUA1Z%DF_6FHJ3Y
MXJ5?_<;G*H;:L&Y/SO?#J%JN+ZC+6V520.!'+PL8W,JVC6ANA4?:Y-WY#!H4
MJ2IS.'*94TE#B4AE*@UL5WO96WCN[1%Y8VK26*JHM 1ELI-J&4-=:9::Y.F>
MHM(F9D?DA&*C+>@DQ&0D*\Y7!XC%RL.Z.Q21>ME7*E6&W.>++D#;9E>V1ZNT
M:WOMMV*[S6<;WS-<E(/*R5>RVH9Y5A]X,*Z@S)VF*8M:\[4?NHM1\W3,\8@9
M5'S$_.4K-\P=)/F31Z@)C(/&Z+I 3%,0PHN$RJIB8AOG%,)#E$2B <"(AP'I
MI2N7I2O@Z63;MUEUCIII))F4445,!$R%*'(F4.)B@4A0#DPB8. Y'2E85]H_
MBK6[>#F9K#4G;!9'.V>V/+=#TS.,=*N9I91:L.HM,)BWUAO#<UNM3C&535B9
M&06;-W+M$[5%VZ$#=-/O]]S3[G[_ '^JMGB/>*:UV#Y3PG@BBT;%LW:\L1$M
M.IDR!DFOXEJ\#&1JCM$!5D91=A')N7SPK9!JB=9-1PNZ(!$E#&*!FW'W_JGZ
M:=)_Z_-U]U98L+W"=R!BRD76S1</"SEF@6DP_BZ_-M+)",SO0,LD2,GF)C-)
M5H=N9%5)V@8R2@*<$,8"\C6E8M-ZWBF6C;]N!3VWX$V_.]Q.3*_CT,HY%BVM
MH+7_ +WZP^>NV$%&Q")(Y^><M,XM"SPL(=L(O1(P 4V;CV@OEJ5-_,.0<NP.
M$FN7L"X$B[IER990;YU0+M)-L?2C"*?,CO)9"PR\DU:O6CZ$4(W2=1[Q-$Q%
M@.*B29D#%!2HU>&AOOR_O<)G%?)."&&)6>'\BS6,D)V"LA[75[98:P[+&6-.
M GDRFCI1"'F496*>.(YRNBB]CEFJH)+IG3*I65'2E?%<PE(;I+U&$A^D.>.1
MX[%[]NYN 'OV+R/N'2E8-LY^)+O(P;NIQ3M_G=G56FJ_F[*CVDXYF:_DE*9M
MTG48XLF^?7E[4X\%GT?$1T+&"[D73EHFR:N'+-FJH11V@!WW^_V]:?5S /PW
MJ26^;>V]V?RV+L;X9P>7,^>\Z/[&ZJ./8=ZA7$WL=4(.1M%LFY5ZUC72BA6E
M?@YA9 QRE,NX:@F"@&$J8J5(?9)NPKN]#;W4\Y5^">5966?V"NV2J2"XKOJQ
M:ZG+.(:<AW"IF[0ZGEKH$<MSG;(G.T=-U.@Q3 H92I;:4J&F_P RAE7#>U^U
M7_"K,[_(D=D';]"1K5*&<3YSP=UW"XLH]W4"*:B5=8&]&L=D<&<%$"1Y4ADE
MN46BA14^_P!_;4Q4S?M'5QQ\TP\"  (<<^H#R ?5W /JTI6#??KXDV\39MD:
M#@XC9]6<DT7(5YA\?8CD6&2"%O60)Z5%HFJA%4EF1S+*%9.WK1%T=NS<$0!T
MT,N4 73 7W^\Q3[_ &5E+S1F''.V[#]ZSGD8\55X2L5Y:P6%<?8VJ\@[;MSJ
MMHT%P!,\B]<N1%NT*8RBIA54,3D1'A2H]^&GOF;>(1MP:[@V5(<X_925MN,
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ME*:4II2FE*:4II2M!$"AR(\!I2MH*IB/ &#G\7I]?O\ H]=*5OTI32E-*5M
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MO,Z-4MOFTO"D3E5O>TTI)M8!]M>XX:N3SCU[.*PQF!0N;SR_9XQ@<!(UZES
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MB-U2+H$<I$6*BLD'2FJD"@&!-1,O)2'+P8 $P /!C<J5RO)3X .D  ..
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M&]_R$Y ?M>K"/;X]M<?[5P$Y\QU*0$I2ZR  .GH[>YZDS.\UU#LU &4,-
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MU]#+F;F5>1A;1?86TWFEQLP+5Z]<-#M:_5)NM1+5--%T5,P)Q+<QS%$5 /P
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M+1^XQ#-J'$FX8=0VQ;%=DFS0"A0UE+:$("=,DI2 =Q4G=9 G$<M7-E<M(M<
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*2E-*4TI32E?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>img129881027_4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img129881027_4.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )G W # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MJK:G8)<26[WULL\2[Y(S*H9%]2,Y Y'YTMMJ%E>PO+:WEO/$GWGBE5@OU(-
M719HKEM(\;6.K:[=V"O!#%"0D+O,N;ALD?+SR..,9ZUN76L:98R^5=ZC:6\F
M,[)9U0_D3182G%JZ9=HIL<B2QK)&ZNC#(93D$?6J>L7,]II4T]M-90S+C;)>
ML5B'('S$?YSB@;=E<O45FVVJ10Z/;7>IWVGH9  9HI@(6;G[K,>>E3_VII_V
ML6GVZU^TGI#YR[S_ ,!SF@.9%NBBN*\5>*=:TOQ'::3I-K:3O<Q!E$P.2Q+#
M&=P':A*XIS45=G:T5YW=^,_%6@R0RZ_HELEI(VW= W/YAV&?8]<5K>*/%ESI
M#Z*U@EO+#J#<M*I/R_+@C!']ZG8CVT;-]CKJ*JQZE8S7;6L5[;R7*?>A652Z
M_49S3[J^M+&,27EU#;QDX#32!!GZFD:71/14%K>VE]$9;.ZAN(P<%X9 XSZ9
M%0W6L:98R^5=ZC:6\F,[)9U0_D30%UN7:*;'(DL:R1NKHPR&4Y!'UJK_ &MI
MIO/LG]H6GVG.WR?.7?GTVYS0%T7***J:CJ=GI-F]W?3I#"O=CR3Z =S["@;=
MM66Z*Y+P9XMN?%%UJ?FP1100,ODA0=VUBWWN2"< =,5UM!,9*2N@HJG=:MIM
MC(([S4+2WD(R%FF5"1]":;J&K6FG:3+J4LJ-;HF]2KCY^. IS@D]J!\R+U%8
M/A?Q-!XCL?.W0Q7&YC]F64,ZH#@$CK^.*W6941G8@*HR2>PH",E)70M%><:3
M\1;Z]\06\%S:V\>F7,[0Q2JK!_\ 9Y+8[KGCO77^*-5GT3P[=ZA;)&\T(7:L
M@)4Y8#G!'K3L1&K&47)=#8HKB=5\8:A8^!].UN*&U-S<NJNC*VP9#'@;L]AW
MKL+29KBR@F< -)&KD#IDC-*PXS4G9$U%<EXV\3ZCX>?3H].@MI7NF=2)E)Y&
MW&,,/6LNZ\4^--'B^UZMH%K]C4XD,+<C\0[8_$4[$RJQBVGT/0:*I:3J=OK.
MF07]J28IER >JGN#[@\4J:OILMU]ECU&T>XSCR5F4OGZ9S2-+K<N44R6:*")
MI9I$CC499W8 #ZDU6M-6TV_D,=GJ%K<.!DK#,KD#Z T!=;%RBH;J[MK*'SKN
MXB@BSC?*X5<_4T6UW;7D(FM;B*>(\!XG##\Q0%UL3452NM8TRQE\J[U&TMY,
M9V2SJA_(FK<<B2QK)&ZNC#(93D$?6@+H=1110,**** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "O*M4AU:X^*UXFBW45M>>4I$D
MHRNWRUR/NG^5>JUP>K^$_$4GB^XUS1KZRMC(JJIE)+ ;0#D%".U-&->+:5NY
M;T[3O'<>HV[W^M6$MHK@S1H@#,O<#]V/YBJ/BB,Z'XZT?7HQMAN6%O<'/&>F
M3^!_\=J9-+^(H=2VO:<5SR/+'3_OU6_XIT,^(= FL%,:SDAXG?HKC\/3(_&F
M1RMQ=D[K74Y72S_PD_Q-NK\D/9Z6NR+TW<@?KN/X"I-0DT ^+[PC3[[7M39=
MCP>6LD,&,<<@;?KSCGO6[X,\-OX:T=[>X:)[J60O(\1)&.@&2 >G\S68OA77
M=)\17^H:'>6/DWQ+2)=JQ*$G/&!S@DXY^M N62BKK5N[,WX9-)'J6OVY0PHD
MBGR-VX1G+#'IVQGOBLWPI_R(?BG_ '6_] -=5X1\*ZAX=U/4I;FYM[F*Z (D
M7*N6!)R5Q@9R>YIOACP=<Z7HNJZ=J,T++?$C,#$X!4CN!SS1<4:<K15NY1\/
MD#X07.3_ ,N]Q_-JJZ&VG#X4A=4O)[:T>5U=K<C>_P Q^49!ZTZV\!^)(=/G
MTG^W($TM\D1HIW.?0Y&5![X)^AJ[_P ('<S^!8M$N+F%+N&9IDDC)9"23P<@
M'H?2C02C/^796.2\4M:?V-IMQI>@7&FPQN!'>2JL<DORY'3D],[LUM?$* WN
MO^'(&D*&<!"X."N649_6K>L>#_%.O:9;6]]J&FAK7 C2-7"OQ@LS8X/L!CZ5
M>\4>#]0\176E2)<06XMH]LS!V+*>.4XYQCOBBXG3DU+3L<_XST&Q\(RZ5J>C
M*]O,LV"/,9MV.<\_B#VYK1\1'/Q4\/GUB3_T)ZF3P7KVJ:K:S>(]8BNK2T;=
M''$,%L>OR@#.!D\G^=:FK>&KV_\ &VF:U%+ +:U15=68[S@L>!C'<=Z+E<CU
M:5E='%326VL>.-7EU?3-3U**W<PQ06<9;8 2!G!! X)]R36YX!AOK#7=2M5L
M-2MM)E4RP"\A9-I! QSQG!_'%7M6\(:M'K\VL^'-2CLY[@8FCE'RD]ST.<XS
M@CK6OX9TK6--AF;6-7:]EE;(0<HGT)&?PX ]*&] A3DIW:^97^('_(D:C]$_
M]#6N6T.]\=?\(Y:0:;I5F;,Q;89V==^/7E^OX?A7;^*-*GUOP[=Z?;/&DTP7
M:TA(488'G /I4WA_3Y=)T"RL)V1I8(]K&,DJ3[9 I7T-)0<JE[VT.9T'PTGA
M?PIJ1U:^,#W*YGEMVYB7& %)!R>3V[\>M<GK*Z2_@[&D>'[I;>)Q_P 3.Y1$
M9OFQU'+Y/''3\*]1\0:0NNZ)<Z<TAB\U1M<#.T@@CCTR*Y"?P?XHO/#B:)<:
MCIJVUN!Y7EJY:3!X#G' 'L#^--,SJ4VERQ6EC*\90I/X \/ZA*&>[V1Q^:S$
MDJ4)/UY YJWXWTJRTCP#9PV,/E1O=)(PW%LL8VR>2?2MS4_"-WJG@>RT9YH(
M[RT"%6!)C8J"O7&1D'TJGJ/A/Q%JWA*/3+[4+.:[CN5D1R2JB,(5"Y"9)R>X
M_&BXI4WKINC%\87!NM5\/:5/%=S60MHYG@M5W/(2".!W.%_#)HLK9[#QEIUW
MH&A:U8V;L(KF.XMW"X)P3G)XP<\GC%=3X@\(3:K;:;/:78M=3L$54E&=IP!^
M/49!^O%&B:)XJBU87FM:\LL:KCR(!\K_ %!4 ?4#/O1?0;IRY]4<U?:3;:U\
M7+JSN]QMS&K.BL1O C4@$CMG'Y5+X=T^#2OB=J>E6NY;)K=@8RQ/!"G&>O&3
MSUKHX?#5['\09]?,L'V22+8$#'?G8%Z8QU'K1:^&KR#Q_=Z\TL!M9HMBH&.\
M':HY&,=CWHN'LW>]NOX'*^"="TZ;QAK"O;Y%A/FV^=OW9#L!WYZ#KFJ4;_\
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M;22R*\#!VVJ-RD@_+D=/?K1=$>SG&Z[HQ?$7_))=$_ZZI_Z"]>F:;_R"K/\
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M;@MDCEI.F02W3IV_*BXW"2>FKT,#Q/-'J?Q%:TU&SO[VRLXAMM;-"S-E02<
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M0!B?V]<?] :__P"_9_PH_MZX_P"@-?\ _?L_X5MT4 8G]O7'_0&O_P#OV?\
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M]G_"C^WKC_H#7_\ W[/^%;=% &)_;UQ_T!K_ /[]G_"C^WKC_H#7_P#W[/\
MA6W10!B?V]<?] :__P"_9_PH_MZX_P"@-?\ _?L_X5MT4 8G]O7'_0&O_P#O
MV?\ "C^WKC_H#7__ '[/^%;=% &)_;UQ_P! :_\ ^_9_PH_MZX_Z U__ -^S
M_A6W10!B?V]<?] :_P#^_9_PH_MZX_Z U_\ ]^S_ (5MT4 8G]O7'_0&O_\
MOV?\*/[>N/\ H#7_ /W[/^%;=% &)_;UQ_T!K_\ []G_  H_MZX_Z U__P!^
MS_A6W10!B?V]<?\ 0&O_ /OV?\*/[>N/^@-?_P#?L_X5MT4 8G]O7'_0&O\
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ME_\ B*/^%F>$/^@O_P"2TO\ \11SQ[A]4Q'_ #[?W,ZRBN3_ .%F>$/^@O\
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M[9++?%I3;M&XR@$>=^X\Y^; Q0!W]_J%EI=HUWJ%Y;VELA ::XE6-!DX&6)
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M<<&NFH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MI$66-HW&58%2/4&L'_A"/#O_ $#_ /R-)_\ %4 9_P#PL?1_^?:^_P"^$_\
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M8#)&1SZ8KH-,\,>*G\:7'B#6[S29!/I36(@M%D40G?N4 L/G'7+'!R>!54>
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M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H%%
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MY5"UCECU"82SF4^6O.T+CD^E7^?6@ HHY]:.?6@ HHY]:.?6@ HHY]:.?6@
MHHY]:.?6@ HHY]:.?6@ HHY]:.?6@ %%)^-+SZT %%'/K1SZT %%'/K1SZT
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M* "@]..M%!.!D]* *-LTK:A,98PC>6O ;/<U>JC;3Q7&H3/$X90BC(^IJ]0
M4444 %%%% !1110 5S_BSQ9:>$]/2XGC::65BL4*G!8CJ2>P%;DL\4"AII4C
M4G&78 ?K7GGQ9TR/4;#2FA?=?-<>3;Q+SYH?&?RP.?>IFVHW1U8.G"I7C"IL
MS>\'>-[3Q;',B0-;74(#/$S;@5/<'O74UY_\.? ]YX:EN;[4F07$J>4D2-NV
MKG))/J<"O0*(-M>\&,C1C6:HOW0HHHJCE 44"B@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BB@4 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%5K;4+.\&;:ZAE'^PX-6: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^)_D:K>.KF;Q)XFLO"]D_!?]ZP_A[L?P']:ZO6)QI&F6FB:2FVYF400*O\"
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MOF=RDK)$[\ED&,?D<C\*[&KB[JYQ5J3I5)4V]@HHHIF04444 %%%% !1110
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M#T&C2W$XN+BZNKC'F7%PVYR!T'TK7H Q9]4:UU%R;&Y<M&/N+G')H_X2 _\
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M &+_ ,) ?^@9??\ ?HT?\) ?^@9??]^C6U10!B_\) ?^@9??]^C1_P ) ?\
MH&7W_?HUM44 8O\ PD!_Z!E]_P!^C1_PD!_Z!E]_WZ-;5% &+_PD!_Z!E]_W
MZ-!\0-Q_Q*[X\_\ /(UM44 8O_"0'_H&7W_?HT?\) ?^@9??]^C6U10!B_\
M"0'_ *!E]_WZ-'_"0'_H&7W_ 'Z-;5% &+_PD!_Z!E]_WZ-'_"0'_H&7W_?H
MUM44 8O_  D!_P"@9??]^C1_PD!_Z!E]_P!^C6U10!B_\) ?^@9??]^C1_PD
M!_Z!E]_WZ-;5% &+_P ) ?\ H&7W_?HT?\) ?^@9??\ ?HUM44 8O_"0'_H&
M7W_?HT?\) V<?V7??7RC6U10!B_\) ?^@9??]^C1_P ) ?\ H&7W_?HUM44
M8O\ PD!_Z!E]_P!^C1_PD!_Z!E]_WZ-;5% &+_PD!_Z!E]_WZ-'_  D!_P"@
M9??]^C6U10!B_P#"0'_H&7W_ 'Z-'_"0'_H&7W_?HUM44 8O_"0'_H&7W_?H
MT?\ "0'_ *!E]_WZ-;5% &+_ ,) ?^@9??\ ?HT?\) ?^@9??]^C6U10!B_\
M) ?^@9??]^C0/$#<_P#$KOAS_P \C6U0* ,7_A(#_P! R^_[]&C_ (2 _P#0
M,OO^_1K:HH Q?^$@/_0,OO\ OT:/^$@/_0,OO^_1K:HH Q?^$@/_ $#+[_OT
M:/\ A(#_ - R^_[]&MJB@#%_X2 _] R^_P"_1H_X2 _] R^_[]&MJB@#%_X2
M _\ 0,OO^_1H_P"$@/\ T#+[_OT:VJ* ,7_A(#_T#+[_ +]&C_A(#_T#+[_O
MT:VJ* ,4^(& _P"07?'_ +9&C_A(#_T#+[_OT:VJ* ,7_A(#_P! R^_[]&C_
M (2 _P#0,OO^_1K:HH Q?^$@/_0,OO\ OT:/^$@/_0,OO^_1K:HH Q?^$@/_
M $#+[_OT:/\ A(#_ - R^_[]&MJB@#%_X2 _] R^_P"_1H_X2 _] R^_[]&M
MJB@#%_X2 _\ 0,OO^_1H_P"$@/\ T#+[_OT:VJ* ,7_A(#_T#+[_ +]&C_A(
M#_T#+[_OT:VJ* ,J#6C/.D7]GWB;CC<T9 'UK5HHH **** "BBB@#BM6USQ/
M=>(;S2_#]I;;;-4,LDY^\6&1CG_.*V?#;>(6AG_X2!+=9-P\KR,8QWSS]*X_
MQA;Q:?XCFOY/%DNG2W**%@AB9F" 8YVGIG)YKI?!,4G]FRW)UY]7BF8%)'!!
M3 Y&"20: .GHHHH **** "CK101D8H IP11Q:C,L:*@\M3A1CN:35]2AT?2;
MG4)SB.!"Q'J>P_$TVU@$%_,H>1_D4YD;<>IKSSXH:S]KO[7P] V47$]U@_\
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M\^[-$:1:VC#4O$U^ES<=560_NT]E7O\ YXI)_%5U>0R?V)8,T,:DM=3C;&H
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MMW$B,N/QQBM.#5=/NAF"]MY,_P!V04 6Z*.M% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4"B@4 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%4-9AU&?2Y8]*N([>\.-DDBY Y&>Q[9H XW5;E/#GC2_
MU#4M*EO;:]BC$$R1A_+VC#+SZUI^!+:40ZG?FR:QMKVY\R"W88*KCKCW_I2:
MK;>*CJ4GV/Q%8VT/EAUADC7<   S<J>,Y/XUH^%_[4>SEFU'5[74TD8>3+;!
M=H Z\@#- &]1110 4A( ))P!U)I:Y7Q_(XT""W5F5+F\BAEVG!*$G(_2@#J(
MY8Y4WQNKKZJ<BG'.#CK7':#;0Z3X[U73;)?*LVM8YA""=JOG&1Z5TNK7C:=H
M][>H@=K>!Y0I. 2JDX_2@:3;LBE>ZD-)BO\ 4+[8J00!SM/7K@?4GBO")M3D
MFN9]0N<RWUZY<(.P/0>PJIJ?B?6M7,PO=1GECE8,T1;"<'(^7I@5%8AW8M]J
MAB9OO.3E_P /2N?VG,]#Z".6_5Z3=1WOOO\ =WWWMV1JVD"13"]U*5/,'*@\
MA/H/6MRSUVZN)C#H=C=3S-PTT*%I#_P,_='3IBL^PBT^U(E>RCOI_P"]=.77
M_OD$#\\UO#QAJT<8AMY8K2$=$MX%4#]*T2?H>;5K47*\KR?_ ("EZ+?\C2TS
MP?XGNV$L\MMI(;EF7]]/[\]!^!%=!9^ O#]C+]HU%GU"Y/+2WTN[/X=/SS7%
MMK6H71_?76H3K_=64J/TS2_:K?<&ET6:9AWEG<_RQ5<BZF+Q=2UH>ZO+3\=_
MQ/33K.B6$8B6]LXE7HB,./P%4Y?&NB(VU)Y)F](XF/\ /%<+'K?DX\KP[8@C
MN\3.?U-6H_&&L1G$5C9PCL4MR/ZU1S&7K/B'4+W69+A;B>(*Y\I Q78.W [U
MW&G>*M0DTZW:70[^=R@S+&GRO[CCO7GVLZE<:E?>?<QQ+-CDI'MS]?6MNR\1
M^(+JU ANY<)\@6*V4X 'KB@#KSXHO ,GP[J0'^Y_]:LY?B-:O($73K@L3@#<
M.M8SS^+KN)T/]I,K*5.(54$&L6/PMKLEQY0TR;>.3NPH_,G% ';1>/EN93#;
M:3=23= @(//X5F7E_P")=3GVW=AJ,%F>L5I"03]2:U;)/$-E"(K'0["U7'),
MF2?J0>:LX\92'E],B'L&/^- %#3+F+25_P!$\):@K]Y&CR[?CBM+_A)[S_H7
M-2_[X_\ K4S^S_%<BG?K5M%G_GG #C\Q0N@:X_\ K_$LWOY<6W^1% ',^+_$
M>HW(@@%K=Z?$025DRID/^ K;^'VI7EY8W4-R[R1PLOENYSUSD9_ ?G4UQX)%
M\5^W:Q>W&WD!CT^F<T^'P)I<*;1<7A!.2/, !_(4 =*UQ GWIHQ]6%5Y-6TZ
M+_67]LOUE7_&LA/!&A*<M;RN?5IF_H:LIX5T./II\9_WB3_,T 2OXET5.NIV
MQ_W7S_*JTGC+08@2;W./[L;'^E74T'2(SE=-M0?^N0JREE9Q_<M8%^D8% &'
M_P )QI!_U8NI?]R$_P!<4P^,XF.(-(U*7TQ#_P#7KI55$^ZJK]!BG9% '-?\
M)-J,@S%X<O3G^_\ +_2FKK/B65OD\.A1ZO./_K5T^11D4 <T;GQ=+]RQL(?]
M]\_R-4]3LO%U]IEQ!+)8;'0Y2'.YN^!GUKL<BC- 'C_AC2M0D\16I2"6/R90
M\C%2-H!YS]>GXU[!1D49% !11D49% !11D49% !11D49% !11D49% %>>PL[
ME2)[6&0'^_&#69<>$=#N <V"H?6)BG\CBMO(HR* .9/@V&%@UEJ=_:D=EER/
MZ4G]D^)K8YMM=290>%N(A_/DUT^129H YK[7XMM0?-TZSNQ_TQDVG]36/XB\
M6ZO;V"1?V=-I\TAP96.>!U"G%=]D51U72;/6;/[->(63.Y64X93Z@T <GX$\
M07^H7<]C>2M.!'YB2/R5P0,9_&NZK*T7P_8:%&XM%8O)]Z1SEC[?2M7(H **
M,BC(H **,BC(H **,BC(H **,BC(H **,BC- !11D49% !11D49% !11D49%
M !11D49% !11D49% !11D49% !0*,BDS0 M%&11D4 %%&11D4 %%&11D4 %%
M&11D4 %%&11D4 %%&11D4 %%&:,B@ HHR*,B@ HHR*,B@ HHR*,B@ HHR*,B
M@ HHR*,B@ HHR*,B@ HI,TM !1110 4444 >8>)K>[D\5:E8BUN'N=46&"VG
M4?(D'!D!_$5O^ [>.$:N]G#+#ICW0%JDF<_*N&(SV)%9?BO7=;;4=4CTZ]6T
MMM*6%I% ^>8N1T/H,UTGAO5;J_O=9M+F2.7['=%(Y$7 *$9 ^HH Z"BBB@ K
M.UO1X=<TQ[*9WCRP=)(S\R,.016C10!B:'X>.E75S>W5]+?W]R%5YY%"X4=
M .E;$T,=Q!)!,@>*12CJ>A!&"*?01D8/2@#QKQ#\+([*#4+O3;Z240)YRV[1
M@G;GD;@>2!GMS7'MX;EC-I(TD9MKQ=UM.YVQN>Z%OX6'3G^5?0\$$<5_,B(
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !0**!0 4444 %%%% !1110 4444 %%%% !1110
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M6A.GJ]GLULR2BBBF8A1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\0?\\K/]?_BJ/,\0?\\K/]?_ (J@#9HK&\SQ!_SRL_U_^*H\SQ!_SRL_U_\
MBJ -FBL;S/$'_/*S_7_XJCS/$'_/*S_7_P"*H V:*QO,\0?\\K/]?_BJ/,\0
M?\\K/]?_ (J@#9H%8WF>(/\ GE9_K_\ %4@D\0\YALAS[_XT ;5%8WF>(/\
MGE9_K_\ %4>9X@_YY6?Z_P#Q5 &S16-YGB#_ )Y6?Z__ !5'F>(/^>5G^O\
M\50!LT5C>9X@_P">5G^O_P 51YGB#_GE9_K_ /%4 ;-%8WF>(/\ GE9_K_\
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M44R HHHH **** *&M:/::[I4^GWBDQ2C&1U4]B/<5QFA?"?3-+OFN+^?^T5
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MTR>5%(,'"@Y;';.<?A4*<G.UCJJ8.A'"^UC.\OZ^9Z+1116IY84444 %%%%
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M10 8%&!110 8%&!110 8%&!110 8%&!110 8%&!110 8%&!110 8%&*** #
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M!B<XR3CC'%>GT44XQ459&6)Q$\14]I/<****HP"BBB@ HHHH **** "BBB@
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MSYD1]O;\J!XUU;12(_%&A30H.#>6G[R+ZD=OS_"CFMN'U7G_ (,E+RV?W/\
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MDM[6"5DA2)OE(4XR?[V>O->A+X(U'66$OBG6YKI<Y^R6Q\N(>WO^537?PO\
M#%U<1RBVE@"  QPR85\>N<G\0:B:G)::'=A)X7#2;J/F?IHOO_R-SPSJDNL^
M&K#4)T"2S19<#ID'!(]CC-:K*&4JP!!Z@TRWMXK6WCMX(UCAB4(B+T4#H*DK
M1;'FS:<FXJR.7U7P#H>I2&>*!K"[ZB>S;RR#ZX'%86JOXS\&Z7<72:A!JMA&
MOW[A<2Q9X!_VL9'<UZ+45S;0WEK+;7$:R0RJ4=&Z,#U%2X+IH=%/%S5E4]Z/
M9Z_=V/"/#GQ"\0VVNQ/<7%SJ,4S;7MCR6STV^A^E>C?\)-XNO&Q8^$6B7^]=
MSA?T.*N:+\/=!T+5/[0M8IGF7/E^:^X1Y]./YYKJJF$)):LZ<7B\-.:=*FOG
MI^"9Q(@^(=Z3ONM)L$/]Q2[#\P11_P (9K]XI&I>,;Y@>HME$0_0UVU%5R+J
M<OUN:^%)>B7ZG%Q_#'0B0UY+?7K=S/<'G\L5KVO@OPW9D&'1K3(Z-(F\_FV:
MW:*:A%="98JO+1S?WD4-K;VZA88(HP.@1 /Y5+115'.W?<**** "BBB@ HHH
MH **** "BBB@ H%% H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***0D 9) ^M 'F'BK2FD\
M1ZK<76FRWA58+F!QG;Y*%1(@]SD_K6Y\/$A,6K3V=FUM8376;<2##$8Y'T!Z
M?4U!JC^(]:\4WVGZ;JR:;;V<<;#(!,NX=>GJ"/PK?\-:?J^GPW"ZMJHU!W8%
M& ^X,<B@#<JO>K=/9RK921QW)'[MY5RH/N*L44 <!XK2^2QTB'7+J%4>^S)?
M6R%/(4 8P3T).>?:L'"KX=U![=GN;"TUF.?[:5)>9>=Q8_Q8R.?>O6I8HYHV
MCEC61&ZJXR#^%(D$4</DI$BQ8QL50%Q]* .2T*ZAU7Q[JNH63B:T6TCA\Y?N
ME\YP#WKL3TX.*CA@AMH_+@B2),YVHH4?D*D/ Z9H H6L<L>H3"6<RGRUYVA<
M<GTJ_P ^M4K=VDU"8M&R'RUX/U-7: #GUHY]:** #GUHY]:** #GUHY]:**
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M85*LZKO-W#GUHY]:**9F'/K1SZT44 '/K1SZT44 '/K1SZT44 '/K1SZT44
M'/K1^-%% !SZT<^M%% !SZT<^M%% !SZT<^M%% !SZT<^M%% !SZT<^M%% !
MSZT<^M%% !SZTGXTM H .?6CGUHHH .?6CGUHHH .?6CGUHHH .?6CGUHHH
M.?6CGUHHH .?6CGUHHH /QHY]:** #GUHY]:** #GUHY]:** #GUHY]:** #
MGUHY]:** #GUHY]:** #GUHY]:** $I:** "BBB@ K&\4:?8ZCH4Z:C<206L
M7[YY(S@@+SZ&MFL?Q3I\^J^&+^RMN9I(_D&<9((./QQB@#@]-\%Z%JFB3ZO
M=85(P^Q'90\H49XX[]JZ;P!;:3'I4\^E373K+(!+'=$%XW4=.![UEVOQ+L=/
MM(;*^TN^ANX46-HEC&,@8XR1Q6OX*M[IEU35;FU:U&HW/FQP-]Y5QU/N<T =
M71110 4444 %!.!D]*** *-K/%<7\SQ.'4(HR/J:O55C_P"0E+_US7^9JU0
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M]A77G...M %&VA$&H3*'=OD4Y=LGJ:O5F*;[[?(1'!NV#N<=ZDFN+Z"(R/'
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MBI-VH?\ /.W_ .^C0!;HK/AN;V<2;(X/D<H<D]10]S>QS11-'!NESMP3V&:
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M3QQ;)'"#83D$U>H **** "BBB@ HHHH *CN+>&[@>"XB26%QAD<9##W%244
M5YK&TN+/[)-;126V OE,H*X'3BDCT^SALOL4=K"EKC'DA %Q]*LT4 5K+3[/
M3H3#96L-O&3DK$@4$_A5FBD9@JECT R: %P,YQS2$ C!&:X:T\9:I+]CU2:U
MM1HMY=_98PI8S+R0&/;&0>*[J@ I  .@ SS2T4 )@9SCGUI2 1@\BBB@ I,
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M ';8 )('7K00#C(!QS3895G@CF3[LBAA]",T^@ I  !@  >U+10 8&<XYI"
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M* /+VT[4AI4GA4:;=><^H^<+G9^Y\K<#NW=.W2O4*** "BBB@ HHHH ****
M"BBB@ HHHH HZQ=7=EILD]G9?;95QF /M++WQQU]JX2TTB;4KC6!I&EW&F:;
M<:<83%<)Y?F3]5(4^@XS7I-% 'GVD1W^J:QX<5],N[1-&@9;B2>/:K/LV *>
M_3->@T44 %%%% !1110 4444 %%%% !1110!RWB;1M8O]2M;[3[BT$=I$^V*
MX1F^=@06 '4XQCTYKE],TW5[/PSX?OI[*64:?=M(;:.,B58B><J>2<C/'8BO
M4:* .7\)6]R][K6K3VTMLE_<*T44R[7VJ,9([9S74444 %%%% !1110 4444
M %%%% !1110!POBK8;C4K>7PM)<S74 2VO((O,+MC W''R8..?:JR6^I>&M3
ML=0N+"ZO0VDK:2?9E\QEE7G!]N,9KT.B@# \&:;<Z3X5M+6[79/\SNG]TLQ;
M'ZUOT44 %%%% !1110 4444 %%%% !0>1BBB@#R==!N8;>+1(]$F&J)?^:NH
MB/Y/+W9W;_IV_K5[4+34K1/$6BQZ9=3R:K=>;;SHF8L-@G<W\.,5Z510!#:0
MFWLH("<F.-4)]<#%3444 %%%% !1110 4444 %%%% !45U/]FM)I]COY:%MB
M*2S8'0 =34M% '%:7H5Y=>"=4,Z%-3U823.KY!4G[JG/3 Q^=4](CO\ 5-8\
M.*^F7=HFC0,MQ)/'M5GV; %/?IFO0:* "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "LZ^T>*\U*RU 2/#<VC'#I_&AZHWJ#^E%% &C1110 4444 %!Z444 9^D:1
M%I%O*JR/---(99IY/O2,>Y_D!6A110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
8 !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>img129881027_5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img129881027_5.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %F <(# 2(  A$! Q$!_\0
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MBG@,> F<CL!1SSU][:_X#>'P^C]GNK[O^M.IG_\ "W_&O_/[9_\ @(/\:/\
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MT]=:4:D]LLEE-)&IFVAIN,$9/+?K0ZDT[.702PV'DFXT^W5]_F6_^%O^-?\
MG]L__ 0?XT?\+?\ &O\ S^V?_@(/\:U'TWPH8[6XO9=/GGR[SLMZ1Y^;=G!;
M]Z3GS !T3DXQTJ'2=$\/ZAHR7D]E:Q1O:3W$SK<2"6%UDP B%N4"XY(//4]J
M=ZM[<Q/LL':_LW_7S*/_  M_QK_S^V?_ ("#_&C_ (6_XU_Y_;/_ ,!!_C6I
M);^%[+5IXK"'3G,MA=(@DN@8R>/+.[S6VL1D<E3[+7/6=HNI^ XK6&\T^.YB
MU&25H[F\BA;88T (#L,C(-2YU%U_J]O^"7'#X66OL[+S+O\ PM_QK_S^V?\
MX"#_ !H_X6_XU_Y_;/\ \!!_C5T:9X.2+2<"";>8_,/VM4+YC)</F7Y</C'$
M8[9.<TMQ8^&8I?L3WULMG)J-LTD<-P0JH8GW9&]QPV 6!;&>O:J<JB^T3['"
M?\^W_7S*/_"W_&O_ #^V?_@(/\:/^%O^-?\ G]L__ 0?XU;EL_"UI;&>XM-+
M-]B$/:17[O"F964E660DG9@GYCC@\=*@OM*\,KX=U1K5[-;F">80RM<[VD42
MX0*!(#RO^PP(YW"DYU+7YAJAA&[>S>]OZU&?\+>\:XS]ML\?]>@_QI/^%O\
MC7_G]L__  $'^-7O"5S;V%KHDOGQPQO%?EW:X6',^T!1O;A3C9@GIFM"Z7PY
MJVI0RZI<VDUU'8HODR7J2C/FG<6G5XU=MIR.1@=CBJYJFEI$2HX:,FG3T]?.
MQ@_\+?\ &O\ S^V?_@(/\:/^%O\ C7_G]L__  $'^-7(+'PG'I<5W&+,/#=
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M[@.]+GJ6OS%>PPE[>S?]?/\ X<J?\+?\:_\ /[9_^ @_QI?^%O>-<9^VV?\
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M."I'0@]C2SSRW,[S3RO+*YW/)(Q9F/J2>M5OM,'_ #WC_P"^Q1]I@_Y[Q_\
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M_H'0_P#@,/\ "C[%IO\ T#H?_ 8?X5H44 9_V+3?^@=#_P" P_PH^Q:;_P!
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M5+VESQ;ZV/:J***Y1A1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MAS_W7Y(\'J0_'?\ Y&C3?^O+_P!G:LKX,?\ )1(?^O:7^0K5^.__ "-&F_\
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M7#T-3A</3J0;D@;:9]GVTXN;2&< J)45P#VR,U+5+3I$BT.TDD=41+9&9F.
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M)F&=ZA@2!@80EN?2J_AS6M8U"^2VU;2EM"UIY^40X!W8PQR0"5(.T$]^>,4
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M_P"@"N@^ O\ R'M7_P"O9/\ T*N>^,/_ "4B^_ZY0_\ H KH/@+_ ,A[5_\
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M"32L@P5"G.CS25V=_J<\MGILUQ&^70 @,!CK7,?\)3J/I#_WQ_\ 7KH]=_Y
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M/(H O5%#_K)^<_/_ .RBN.LO$%ZU]!%+J<#EI(Q!" F^YC>1E+-C^)5 8[<
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MY!Z9]NW'48)VZ* "L?0=0OM0&H&^@\DPWLL,2^4R9C5B%;+'YLCG(P.:V**
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M_*@!]%,P_P#?'Y48?^^/RH ?13,/_?'Y48?^^/RH ?13,/\ WQ^5&'_OC\J
M'T4S#_WQ^5&'_OC\J 'T4S#_ -\?E1A_[X_*@!]%,P_]\?E1A_[X_*@!]%,P
M_P#?'Y48?^^/RH Y;QA_Q\6O^ZW]*SO#O_(=MO\ @7_H)J]XO#^?:_,/NMV]
MQ6=X>#?V[;?,/XNW^R:^2Q*_X4_^WH_H>W2_W/Y/]3:\8?ZJU_WF_I6#I'_(
M7M/^NHK;\8!_*M/F'WF[?2L'2 W]KVGS#_6CM1CU_P */SC^@87_ '3[SJO%
M7_(('_75?Y&N.B_UT?\ O#^==?XJ#_V0/F'^M7M[&N-B#^?'\P^\.WO1G'^]
MKT08!_N'\SOM=_Y 5S_NC^8K@:[S70_]AW/S#[H[>XK@,-C[P_*JSS^/'T_5
MBRW^&_4](B_Y Z?]<!_Z#6;XV_Y$'Q%_V"[G_P!%-5^$/_8Z?,/]0.W^S5#Q
MM_R(/B+_ +!=S_Z*:OJ*7P+T/'E\3-N+_4I_NBBB+_4I_NBBK),+P)_R3SPU
M_P!@JU_]%+6-J:V$7CZW,Q(OIS%Y:-"C[E4GE6,9*@<Y^85L^!/^2>>&O^P5
M:_\ HI:YG49[G4/'(BMFGC2.ZA62*3;$&","6P?FD'! /3YO]D9 /1J;)(D4
M;22,$11EF8X 'J:=5.^TNRU)0+RW28!2HW>AZT 9=IXMM;V6$0V=V87D\MIF
M556,^8T:[@3GYF0XP#U&<5M0Y\V?)S\__LHK'M/"=A8.OV:6X2+S?->'>"KL
M)&D7)(SPS'&".@SFM>  23@+M&_^@H GHHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** ,76]%EU22%DE2/8"#N&<YJKIGAR:QU"*Y:XC=4SD '
MN"*WKN%KFSF@25HFD0J)%)!0D=1CTJAX<TJXT718+&YOY;Z:, --)G)XQQ[5
MQ3R^A.M[9KWM]^QT1Q-2,/9IZ&=XP_U-I_O-_2L'2/\ D+VG_745O>,/]5:_
M[S?TK!TC_D+VG_745\]F'_(Q^<?T/4PO^Z?>=/XJ_P"00/\ KJO\C7'1?ZZ/
M_>'\Z['Q5_R"!_UU7^1KCHO]='_O#^=&<_[VO1!@/X#^9W>N_P#("N?]T?S%
M<#7?:[_R KG_ '1_,5P-7GO\>/I^K)RW^&_4]%B_Y Z?]<!_Z#6;XV_Y$'Q%
M_P!@NY_]%-6E%_R!T_ZX#_T&LWQM_P B#XB_[!=S_P"BFKZBE\$?0\>7Q,VX
MO]2G^Z**(O\ 4I_NBBK),+P)_P D]\-?]@JU_P#12U(WAJ*751?W-W-=,LOF
MQ1SX9(CVV+T&/7&?>H_ G_)/?#7_ &"K7_T4M=!0 444A( ))  ZDT +44/^
MMGY_C'_H(I%N[9S&$N(F,H)C <'>/4>M$&/,GPN/G_H* )J*** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH YGQA_JK7_>;^E8.D?\A>T_
MZZBM[QA_JK7_ 'F_I6#I'_(7M/\ KJ*^1S#_ )&/SC^A[F%_W3[SI_%7_(('
M_75?Y&N.B_UT?^\/YUV/BK_D$#_KJO\ (UQT7^NC_P!X?SHSG_>UZ(,!_ ?S
M.[UW_D!7/^Z/YBN!KOM=_P"0%<_[H_F*X&KSW^/'T_5DY;_#?J>BQ?\ ('3_
M *X#_P!!K-\;?\B#XB_[!=S_ .BFK2B_Y Z?]<!_Z#6;XV_Y$'Q%_P!@NY_]
M%-7U%+X(^AX\OB9MQ?ZE/]T441?ZE/\ =%%6287@3_DGOAK_ +!5K_Z*6N@K
MG_ G_)/?#7_8*M?_ $4M=!0 5D>(M.O=4TJ>TM9XHTDC*NC(<OTP V<*.H.5
M;K6O10!PNF>&;^TNH&DL+4*9DD67>N^U596<KPHW%@V"1CJ<YZGM( 1)/DY^
M?^@J:H8,>9/A<?/_ $% $U%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 4-2TN#4UC$[.H0DC8<=:I6GAZPAN$GAFD=HVR/F!&1^%;9&
M016;H^@V&A131V$)C69S(^6SEO\ /:N:>$H3G[244WW-8UZD8\J>A5\5?\@@
M?]=5_D:XZ+_71_[P_G79>*_^00/^NJ_R-<;%_KH_]X?SKYK.?][7HCU\!_ ?
MS.[UW_D!7/\ NC^8K@:[[7?^0%<_[H_F*X&KSW^/'T_5DY;_  WZGHL7_('3
M_K@/_0:S?&W_ "(/B+_L%W/_ **:M*+_ ) Z?]<!_P"@UF^-O^1!\1?]@NY_
M]%-7U%+X(^AX\OB9MQ?ZE/\ =%%$7^I3_=%%6287@3_DGOAK_L%6O_HI:Z"N
M?\"?\D]\-?\ 8*M?_12UT% !1161XBU232](N98%/GB)FC=HR8U(Z;CT ]S0
M!KU##GS9\G/S_P#LHKC-*\47EW-"DUY;"7SDB$"[6\\-,Z,58?>VJH.5XR#7
M9P "2? Q\_\ [** )J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M(G??\]8/^^C_ (5\YG&%K5JT94XW5OU9ZN KTZ<&INVIU$7_ "!T_P"N _\
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M+^='VF'_ )Z+^= $M%1?:8?^>B_G1]IA_P">B_G0!+147VF'_GHOYT?:8?\
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MY9S\FEW!7?MW -_?*D?=^]QG'IWSQ2_\)%=AHU.C7)=\9 / Y8'D@>@ZXR6
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*BKZ#%%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>img129881027_6.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img129881027_6.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,' \0# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MT[5++5K,7=C<)/ >-RY&#Z$'D'ZUG)XQ\/RW<EJFJ0M,@)( ;!P,G#8P?P-
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MV_E3C.1C[OO5GQ-H7_"1:.VG_:?L^75_,V;^GMD4[[&4H2?/YGG/BS1]/LO
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M9G&+BY.QROQ"E6^U+2="CBC%U.X=;E\@P@G'RX/L?R%9T-I/X3\=Z<NI7/\
M:SW:B..XFW>9#DD< L?_ -6>E==X@\(VWB"RMDFN)(KNV&([I!\V?<=_7K^-
M4M&\"+8:NFJ:EJMQJEU$,1-," OYL2?;FG?0SE3DYWMV,+3-.L]2^*FKI>V\
M=Q'&K.J2J&7.5&2#UZFH/!FA:;=^*]=BN+2*:*W=DCCD4,J@L1T/? KLM/\
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MZS?#_A>^L=.U/4-1EWZO?POG'/EY!X^N<>U1:C\/KR^UV?5H_$4MO/(Y*F.
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M_P!_U_QH^W:]_P! B/\ [_K_ (UM44 8OV[7O^@1'_W_ %_QH^W:]_T"(_\
MO^O^-;5% &+]NU[_ *!$?_?]?\:/MVO?] B/_O\ K_C6U10!B_;M>_Z!$?\
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MGUS7544":3W,3[;KP_YA$?\ W_7_ !I?MVO?] B/_O\ K_C6U10,Q?MVO?\
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M/MVO?] B/_O^O^-;5% &+]NU[_H$1_\ ?]?\:/MVO?\ 0(C_ ._Z_P"-;5%
M&+]NU[_H$1_]_P!?\:/MVO?] B/_ +_K_C6U10!B_;M>_P"@1'_W_7_&K-C<
MZG+.5O+%((\<,) W/X&M&B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^1,LO]Z7_P!&-735$81<5H=>*QV(C7G&,W9-_F<7_P *QT7_ )^M0_[^)_\
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MGKQ^?%>@>&M.M])\/6=C:W"W$<2D><I!#L22Q&/<F@#5HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH BN/]4?I7E/CW_D%7GT7_ -"%>K7'^J/TKRGQ[_R"KSZ+
M_P"A"IG\+.C"?[Q#U7YE_P  ?\B99?[TO_HQJZ:N9\ ?\B99?[TO_HQJZ:B'
MPH>,_P!XJ>K_ #"BBBJ.8**** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** *UQ8Q7-W:W+LX>V+,@!&#D8.:LT44#;;LGT"BBB@04444
M(RAE*L 5(P0>XJO86?V&U%L)6DC0GR]W55[+GOCI5FB@?,[6"BBB@15M+(6L
MEQ,TAEFG?<[D8XZ!0.P JU110-R<G=A1110(X_XE?\BHO_7U'_)J[OP?_P B
M;H__ %Z1_P JX3XE?\BHO_7U'_)J[OP?_P B;H__ %Z1_P JS7\1GH3_ -QC
M_B?Y&W1116AYX4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4'I16-KMS<VTVGF#5;*QC\_=<"Z8 RQCJ%SWY'I]?4
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1_P@4W_/X?\ OS_]E7N/]DP_W!1_9,/]P4>RAV#^U<7_ #_@O\CP[_A IO\
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M#_<%']DP_P!P4>RAV#^U<7_/^"_R/#O^$"F_Y_#_ -^?_LJ/^$"F_P"?P_\
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M44451S!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M4;=VYEW#.<-@C<..AS3;[PMHFI7,=Q=Z?')(BA1@E05'0%00& ]"#6Q10 @
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M0PXEQLP5RX( R<YQU[UT-1+;0JT3&,,\*E8Y'^9U!QGYCSS@9]<5+0 4444
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MJ2-IS,LNU%QO3;G?R,<]L4 :E%%% ' ?%[_D4K7_ *_D_P#0)*\5KVKXO?\
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M'B"S@AT_7;G2'C<LTEONRXQT.&6M^BM.1<O+T./ZS4]K[:_O>B_*UOP/-?\
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M;5O1+\D8'BK0+_7[."#3]=N=(>-]S2V^[+C'0X9:Y,_#7Q+_ -%%U8_A)_\
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MH=*+=V.GCZ]."A%JWHG^:$ PH!.<#K7GEY\//$5S>SSQ^/\ 5($D<LL2B3"
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MY(NKBW5H1I26J>]DM+;:(=1116AQA1110 4444 %%%% !1110 4444 %%%%
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M_ R&^[C!P/<TW4/%#)<6,<5S:::LK3),^HH#Y;Q[?E^611D[C_$:8/$MXUK
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M>^[&SD8X[YK4K+UWSO[.;9Y?E<>9NSNZC&* -2BBB@#@/B]_R*5K_P!?R?\
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MC<$VZ6:ZGY21!&\SY=Z[BV<<XZ;?QK1TQ9X?$&HV\M[<7*K%$R^<1P3NS@*
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MUJZ;I1O;T/::*\6_X7!J/_/E_P"15_\ B*/^%P:C_P ^7_D5?_B*GVL.YO\
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M&V2VD>""&5I6C4G]X6SP3GIEB<>N/2O)/^%P:C_SY?\ D5?_ (BC_A<&H_\
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MH_X7!J/_ #Y?^15_^(K/VL.YW_V5B_Y/Q7^9ZP="TYKT79@82B3S@!*X3?\
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MY\N\VOD/$L/R@!5#@$\#);')S70T44 %%%% !7*^,_!O_"7"R'V_[)]FW_\
M+'S-V[;_ +0Q]W]:ZJB@#RO_ (4S_P!1_P#\D_\ [.C_ (4S_P!1_P#\D_\
M[.N\359V?6P4C_T!L1<'G]TK_-SZGMBJ5EXHF=[HWMC+'%%'"49 I\QW PH
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MZ"*SYG[3E\CK="/U15NO-;Y6N;M%%%:'(%%%% !1110 4444 %%%% !1110
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M4HHHJC **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *XWQ^NER06$5WI+:I?RR-'9VZRO'DG&XDJ1P,#_ZW)KLJYSQ7
MHM_J L=0TF2-=2TZ0R0K+]R0$893]<?_ *NM ',ZIX*TZP\.VU]!X42YO0%:
M[M5NY1M&TEMIWG)!P.,UV'A1M,?PS9/H\)AL74LD98L4))W DDG[V:YR34_B
M'>1FU70;*U>0;3<-,I"9XR!N/]?H:ZCPYHXT'0+331)YAA4[G_O,223],DT
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M%TYE6+<C8WONQLY&..^: -2BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MUC7^$]C)/]X?H_S1QU%%%<I]2%%%% !7M?P;_P"1:OO^OL_^@+7BE>U_!O\
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M_P"O)?\ T-Z\ZKT7XR?\C39?]>2_^AO7G5<53XF?:9=_NL/0****@[0HHHH
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M1_FCCJ***Y3ZD**** "O:_@W_P BU??]?9_] 6O%*]K^#?\ R+5]_P!?9_\
M0%K6C\1YF;_[J_5'H]%%%=9\B%%%% &9XAUF/P]H-UJLL+3);J"40X)RP']:
MFT?44U?1[/44C:-+F%90C')4$9Q6!\3/^2=ZQ_US3_T8M7_!7_(D:)_UY1?^
M@BL^9^TY>ECL=&'U-5>O-;Y63-VBBBM#C"BBB@ HHHH **** "BBB@ HHHH
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M\$^V?PKT3PX9O["MUN+&"QE3<C008V+AB/EQV.,_C0!JT444 %%%% !1110
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M7W_7V?\ T!:\4KVOX-_\BU??]?9_] 6M:/Q'F9O_ +J_5'H]%%%=9\B%%%%
M')_$S_DG>L?]<T_]&+5_P5_R)&B?]>47_H(J_K&DVNN:5/IMZ'-O. '"-@\$
M'K]14NG6$&EZ;;6%L&$%O&(TW')P!@9-9\K]IS>1UNO'ZHJ/7FO\K6+-%%%:
M'(%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %':BN4\;:KXATFWM9M"LOM*DMY^(3(5Z8X!SZT ><RZ9II*ZCX@74/
M,^UW$&I2 YVRXW1[?;'^<5Z9X 0Q^!],!A,.49@I)Y!8D-^/7\:Y/3O%7B;6
M\0VVH^'9)6.#!*'1\^FU@,_AFO0]'_M+^RXO[7\C[=SYGD9V=3C&?;%,"]11
M12 ***I:D=3%NO\ 926C3;OF%TS*NWVV@G/2@"#5O$>DZ&R+J-X(7<%E0(SM
M@=3A02![U'?>*M$TZ&VFN=0C5+E=\)16?<N,[L*#Q[UR?B%KF3Q9;JU_;:3?
M+I+^=<N-\4N3RBAL=#DYZ^W%4/"UW:6FH6,]V4M;9M"*IY[\,1*=V"<=>N/0
MT >GP3Q75O'/!(LD4BAD=3D,#T(K/UUY%TYE6+<C8WONQLY&..^:S_ 2.G@G
M30ZE<HQ /H6)'Z5>UW[3]BDV^5]GPN[.=^=W;MZ4 :U%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110!S_A#PI!X0TR>R@N9+A99S.6D4 @D 8X_P!VN@KG_"'BN#Q?
MID][!;26ZQ3F K(P)) !SQ_O5T%3#EY5R[&^)]K[67MOBZA1115& 4444 %%
M%% !1110 4444 %%%% !1110!DVVA);ZU/J;7,LCRY'EECL3DXVC.!U.?4DG
MBM:BB@ HHHH **** "BBB@ ILD<<T3Q2HKQNI5D89# ]01W%.HH R?\ A%O#
MW_0!TO\ \ X_\*/^$6\/?] '2_\ P#C_ ,*UJRX[N=O%,]F7_P!'6SCE"8'#
M%W!.>O0"E9&GMJG\S^\;_P (MX>_Z .E_P#@''_A1_PBWA[_ * .E_\ @''_
M (5SL>M7UQ>P13ZEJ$*-:F3_ $*R69F;S77D")\# 'I5MK[61!:O?S7EG"8<
MF>VM!(Q?<?\ 6+M8J-NT\ <D\BCE0>VJ?S/[S7_X1;P]_P! '2__  #C_P *
M/^$6\/?] '2__ ./_"KFG327&G6\TLD$KO&&,ENV8V]U/I5JBR#VU3^9_>
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M2-IS,LNU%QO3;G?R,<]L4 :E%%% !1110 4444 %%%% !1110 4444 %%%%
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MOBP-I* <'()ZXYJ"X\'ZG;-?6^DW5HMGJ%M%;SFX#;X]B[,J!P25]<<UVU%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M#!I^N7.D/&^YI;?=EQCH<,M;U%/D7+R]!/$U'5]M?WO1?E:WX'FO_"M?$O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110!P&D6-PGAFSUK3DW7]E-<9C'_+>$S/OC^O<>X]ZCTF:"/2?
M#&H7P TQ!<%FD7*Q2,QV,WIQN&3T)KT.HGNK>.4Q//$L@0R%6< A!U;'I[T
M<1/&M[I7B^XTV/=I]Q /(V+A99!&=[(.^?E&0.2.].U2Z6X3P[J-O>6R:;&K
M[KF6$S0QR[0%+ ,N.CC=G /UKN(Y$FB26)U>-P&5E.0P/0@TZ@#S]H+$:-<7
M,FHF:WDU)+@7-K8E;>%PH^8J6(9"1R0<9/;K5_1]0T^2/6[B]CLIK-6C\Z]M
MXF\BYXQ]PEAN7@'&>HKL:* $&,#'3M2TR*6.9 \4BR(21N0Y''!I] !1110
M4444 %%%% !14;SPQRQQ/*BR2DB-&8 O@9.!WXI998X8VDED6.->2SG 'XT
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M'J:UCH,@U'5+B.\"P:A%MDB,62K[=H8-GICMC\:<=!S::/!]I_Y!LBON\O\
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MV$;L.';.6<?50E:9 _X6!G S_9H_]&-0!K0:E87,C1P7MM*ZKN*QRJQ SC.
M>E%KJ5C?,ZV=[;7#1G#B&57V_7!XKC;*PW?#JY:TM@9I7=IO+3YY4$OS#CDY
M4$8_"KB7.G:CXBT5]#\M_LZR"Y>!,".(K@(QXP=V,*>>#Q0!T::QIDDZ0)J5
MFTTF=D:SJ6;Z#//0U):ZC8WQD%G>6]P8SAQ#*K[3[X/%<&;*TD^'<1>VA8M?
M(6)09),X!/Y<?2M_RH[?Q_;+#&D:MIK;@B@9PXQ^5 &[)J-C%<BWDO+=)R0H
MB:50Q)Y QG.30=1L1>_8C>V_VO&?(\U?,Q_NYS6)8VT$GCC69GAC:9(H CLH
M)7Y3T/:N7L8=]E#IU[JEK;7RW@D>W_L]GNO-#YW!@_.?[X7&#0!Z%+J>GPWB
M6<M];1W3_=A:50[?1<Y-+=ZC96&S[9>6]MYAPGG2JFX^@R>:X35KBSL[K58U
M:*:6:Y5I-,O+<B6=L@ PNIS@XR#@X]JL:BS6WB74'OKRRL8;BWC6%K^T,RO'
MM^9%;>HSG.5ZGK0!VEU?V=C")KN[@MXB<!YI BG\35#4O$^DZ4UF+F\A_P!+
M8",B5,!2#\YR1\O&,USEF+71M0TJ;4[@O8IIPBM[JYB,:J^XD@AON$KMZ]0,
M4NHR:;#INCWUI;/:::FJ>86E4JH4A_G )^5"3QTZ]!0!UL5T[ZA/$9K0PI&C
M*J/F09SRPZ >GXTZUU*QOF=;.]MKAHSAQ#*KE?K@\5R.LQRW-_XB6V5I"UI;
M$JG)=-Q+ >N5SQ5A+G3M1\0Z*VA^6YMU?[0\"8$<6W 1CQ@[L?*>>.E '1IJ
M^F23QP)J-HTTGW(Q.I9OH,\]#5VO/([2W7P#',L$8E.H(^_:-V[[0!G/KCBN
MPN;H:CI.I1Z;*6N8UD@! *[90",<^_>@"S#J=A<73VL-];27"??B252Z_4 Y
M%/\ MUI]G>X^U0>0A*M)Y@VJ0<$$]!SQ7$>=IUUI^AV.E1J-3M[B(M&D962
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MR *V>F#T-<5ILUK9/H5YJA1+(::$AEE'R1RY^;)Z*2,<GKBH);>.?292(/\
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MT400QQ[Y[5FV*!N.X<GU-4/$>HQ%/$-MBPLY>08I;9Y9[C &'!# */0X(&*
M.UM]1FE\17NGLJ"&"&.16 .XELYSS[5:N]0LK (;R\M[8.<*9I53<?09/-86
MBG=XHO#G.;"V.?7@UF:LS6OBO4)+V^LK.&>!$ADOK0RJZ8^95.]0#G.5ZG-
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MW80JT;'<=K'YL.,KQ]WUYS5A-2U6X\375A"+-;.T6)I9'5B[!AD@ ''X_H:
M-^BN'3QUYABNUNM+-N\XB^Q"0FY"%MH;.<9[[=O3O5S7?$MWI$MU*USI$44
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MMC [6'4''<5S=MXCOM9>PATJ*VA>:U%U-)<@NJ DJ% 4C)R#SGI4WA RFSU
MSA!+_:$^\(25!W<X)[4 =%17(ZWIY;79;O5-*FU73&B585A&\V[#[Q,>03GK
MN&32'4([#P9(VGZBUV)I#;V;R AHRS8"G<<Y7GKSQ0!U](1D$9Q[BN1T/9IU
MAJ^@B;S19QF2%MV28W4GK['</PJAX2TFPFTS2I9/"I+F-'-\WDX)Z[_O[NOM
MF@#J[*QM-$6:66[D>6YE!DGNI!N=NBKV'H  *TZP/%O_ "#K/_K^@_\ 0Q65
MJ/C4P7-_Y%UI<26+E#;7,A$UP5^]MY&WN!PV?:@#M*CAGAN85F@E26)ONNC!
M@?H16 NL:GJ>H30:4EI'#;Q(\C708EV==P4;2-O!Y)S]*?X/\P^#;((560Q'
M:6&0#D]N,C\J .@HKC-'U;4;#1M8OK^X2\\F[DCB0*RG?OV@9+-A<D8'8>M:
M<>IZK9:G8VVJK9O'?;EC:V#*8W SM.XG<,9Y&.G2@#H*CN(5N;:6!R0LB%"1
MUP1BL;4=0U,>((-+T_[&@DMC,TEPC-MPV. ",_F*H2^)=332"PMK7^THK];*
M526\IB3]X'J!C![X]Z .ELK2.PL8+2(L8X4"*6/) ]:GK EU#6/MMOI4)L?M
MQA,]Q.T;F)5S@!5W9).#W[56;Q->+I\L1MH/[42\%CM#'RBYY#>NW;SCKV]Z
M .HHKG%U;5K;4;NRO19.8;$W*20HZ[CDC!!)P./4_4=*J_\ "2ZC9^&X=5U%
M;!&NVC6W5694CW#K(Q/3OP/;WH ZVBN1MO%L[IJ42/8ZI/;6XGB>P)VODX*D
M98@@\\$Y%6M'UR]O3,3+IU_$L/F;K%BK(_\ SS9"Q.3V/'TH Z2F1RQS+NBD
M1UR1E6!&1U%<SH?B"_U*[@62339%D4F:VB)2>U/;<K-EO3H*CLM;N6LK6VL;
M2SBN[NYG1?D*Q(J,=S$ Y)Z<9&2: .MHKE;KQ'J%A::O#<16KZA81I*C1AA'
M*K' ."<J>HQD_6K5KJFJQ:U:6>HI9-'>0O)&;<,&C*XR#DG<.>O'TH Z"BBB
M@ HHHH ",@C.*H:;I,6FF=UFGN)[A]\LT[!F;C '    XP!5^B@ HHHH ***
M* "LY]*W>(XM6\[&RU:W\K;URP;.<^W3%:-% '/)X3@AUG4M0M[@QK?VS0M#
MLRJ.QY<<]^X]<\U)I>DZSIMK9V@U:SDMK9$CV_86#,B@#KYO!P.N/PK=HH Y
MU/#^IV]SJ#6>LQP07MPT[@6FZ1"0!A6+X[#JM;.GV$&EV$-E;*1#$NU<G)/J
M2>Y)Y-6:* (A:VX;<((MV<YV#.:J:YIG]LZ+=:=YWD_:$V>9MW;>?3(S6A10
M!A>(_#,'B&R@B:8P3P.&CG5<D#C<I&1D''KZ5)<Z-=KJ%Q>:9J0LVN@HG1[<
M2@D# 9>1AL8'<<#BMFB@"GIFG0Z5ID-C"6:.)<;G.68GDD^Y))_&LZRT*^TY
M8[6UU<IIT3[DA^S@R*N<[/,)QM[?=SCO6[10!D/H,4GB:/63*V4BV^1CY2XR
M ^?4*S+^-5Y/#6^*ZV7C1W$E\;V"98Q^Y? &,$_,, @],@]JWZ* ,&#P[*]W
M>W&J7XO?MEJ+61%@$2A<MTP2?XNY)]^PFT_2]3M'@CFUDS6L PJ"W57<8P [
MY.<>P6MBB@#!7PWM\.VVD_:_]1.DWF^7][;+YF,9_#K22>'KQ)+J.QU>2TL[
MN4RRQK%F1&;[_EOGY<_0XSQBM^B@#%ET2[BOY[O2]1%JURJB=)H?.#%1@,/F
M!#8P.X..E:T$316\<4DKS,JA6D<#+^YP /TJ2B@#F_\ A%IC:C3#J;?V.'W?
M9O)'F;=V[R_,S]WMTSCC-:JZ9MU]M4\W[UJMOY6WIABV<Y]\8Q5^B@#,U72I
M+Z6VNK6Z^R7ML3Y<IC\Q2K<,K+D9!P.XY K./A>:73]7M[C4_-FU)E9I?("[
M" HX4'D?+_\ KZUTE% &#J6A7UX]TMOJYBMKN,)+!/ )E7C!*98;<CL<C/.*
M5O#TEM):3Z7?&VGM[9;4M-'YRRQKTW#(.0<\@CJ:W:* ,"\\/W=U_9\_]J9O
M[-G8336ZNC;Q@C8",8['.1ZFF0>&[V""[*:W,MW/=BZ$ZQ!0&V!2K*#AEXZ<
M=N<C-=%10!SJ>%1+%J9O[PS7&H%"\D$7DJA3E"JY/(/.23G%6#::Y!:W$C:F
M+N=8&6WBCMUB!?'#,23DYQTP.O%;5% $5JLR6D*W$@DG" 2.!C<V.3CZU+11
M0!BW.B7::C/?:5J*V<ESCSTD@$R.P& P&5(...N#@<5CZOH8A\.KH4*WMU=W
MEQYINUCP$<N&>1F'"@ G ZGH*[*B@#+;18_M>DRQ2>7'IRNJQ[<[@5"CG/&,
M55G\-":6]F%XT<\UVEW#(L8S"ZH%[GY@0#GIP?QK>HH R;#2)X=2DU*_O1=W
M9B$*%(O*2-,Y("Y/)/4DGH.E0V'AJ*P35 D[,;XL%)7_ %*')"#GD LQ[=:W
M** .;'A>>"6PGLM26*XM;1;1GDMA(&48.5&X;3GW/XXI]AX8:R&F[[\S&RN)
MYBQB ,GF;N#@X&-WX^@KH:* *6J64]];(MM?2V<\;B1)$&02.S+_ !*<]*QW
M\)&ZM=66]O\ S+G4@@>2&$1HNS[OR9.??).>E=+10!S8\-7LMV;B\U5)6-G+
M:!([01JH?'S ;B<\>O/M5R?01/HME8BY:.>R\MH+A5Y5T&,[3P01D$>];%%
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M&WP0Y0*,XX4 J#N.,>_>[%X:1?#ECIPGDBN+4K*EPO+"49RQ!ZYR<@^M;]%
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M58[81YR,;FY.3]-H]JHCPM/;OI\UGJ*17%I:_92\EL)%9<YR!N&TY]S72T4
M<R/"DR:3;VJ:E_I-O>-=QW#P @L2Q(900#]X]"*N3Z-=KJ,M]IVHK:RW"*MP
MLD'FHY48# ;AM./<CVK:HH Q+G1+MI[:[M-4:*^BB\F2:6!9!,G7YE&W!!Y!
M&.IJQHFE/I%M-%)=&Y>6=YFD9 A)8YZ#BM.B@#%NM%NEU*:_TO4!9RW  G22
M#S4<@8# 94@XXZX]JJ1>#K<FU6\G^V11RRW$T<T2D3S/_$1T '.!COUKI:*
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
?%%%% !1110 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>img129881027_7.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img129881027_7.jpg
M_]C_X  02D9)1@ ! 0$#O@.^  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $2 A0# 1$  A$! Q$!_\0
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M#7\M!V>:#"<JP7\4%\W@C(:76!>^/KSVN4A5C><S+K$BJ*YV[M_R\<J$FU3
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M#O%8?-L-#\I0W[  _+Q7;+H#ZA7P8<4_J'-N\E\'\(V\8@!$/]E:S[=N^$<
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M':KU&8R<W2-F?&M\5Y)<S:O>(-#/5B*F$4)KEJP; &]*4QNEP1=AC)\9R!B
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MPC;QB-!_\JUI[![X2P%O^_\ [5?O]_%<Z=!\*?EX<\7]Q7W]T;>,1_;6L_\
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M,D3UNPOA7.FH%F@&SHC!@L]*8B_Q6(*Q<&.IYKII,")GBE@:-OOM&=!2J#Q
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MLF[!5)X9DG%F\^9D1!=0RGFG23 "HN!'8J+D#H$VQ+H   K9=T%3 YYK#@5
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M =0T9$N:T;3;EFYR:9Q>Y\[MH/19EYC;$S9RS3CL8T %DF?VQ4:O&HM"LR)
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M- SS.KVGJ)%,Y528:T&@Z0T&@'W /H'][VXJ[(*H)#@8IPV4Y#F H^2MU)B
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M(%R>^NM(I<$JN!B#,6>3JU3ZN*[2Q/*. !S8\LX (" <Q&%P 0[ (?E&K&A
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M=G(L]7@!SV"A"L3*:,!VKI1PT<$Z'**L;U */VS7I:N2F45$!![^>'UTJ?;
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MR<B'#\]89]$J&K=%-$J;J.9MCHF:><S37!8C<5$2]!5%P /C1DQ$"B38 @8
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M8>[]7^U;C[YOO_[$XCO_ '_?BKB*#8)TN"J."(X(C@B."(X(HY\WW]BCS/\
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M<HJ6&^7S*%.L4L7,))1I/O"-63)VS@H65C(PJD<F#IR472I0=L4U2*I@/64
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MW$3"(]^+5>D!@!1@ W)(+@JC@BU"70 .P[_?O_U;X(M/!%J#Y1 1_4/]X?\
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M]7>O%CF.JX>NCO7:G68QC*&54.JHJJ?J$YCG4.<XB83G,8PF$M  4[[>EEL
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M<.PD%,3SU5"0L7+W3+LJUZ7-,LJL2_ I#*N$F\BP<-SIG7$.HA"N2MP#J !
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M>_NN6%SB8P0]))$TWE]6)B%UU9V.Z\$9I1\\RB$3.T.19CY_J":<RCI W24
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MI%44.41.F'5]0#A?SKW6?25GN^MMKY[!4Z<R7B-8_P BY"QQAC%XR$O76-O
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M1_Z>*O0OG!$<$7-83,K#N&J\;(NV"Z"H."*,U!;^6N00VZWVUW#W[;UV$=@
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MA_#7Q].0-.'(LN1_"0UUM3QG7G1 ,9&86J$8Z375;"Y^Q'T4C,*(.0+\@@(
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M4A8W9EC."Z&,27F#^2L3Y3J^EA%/S8N@*;90WK@N6-J9G7,\F>7=Y:A9=O\
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MS/\ ]SOFG^32U\$7D\8,>EE\"YCJQR*K.82QTNY,BIHZ3307)+0<@<Z_[P0
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M<I"':N+-6D8J1VH+2(EE5&",P@/ERJ;<')-%6('!;!SAM[@Y^EFY!HRZ 2@
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M4*:O&<P,#*R#ILK88Y8B+PB#WX8]:KMV;LH+NW13O&8%0,DH8P@YT7J#Y]%
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MQ_>:M:%:#9Z[-M,P5^S!#R<&N==Q95[.ITH1B+,B:BJ:ZZZSUNNS\M50DDT
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MNN$!H%9<YN[&A>]![IG0-W W[/J41UK7N7Y1'7U+\H^X=N"WWDIF<L'+[/\
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M*[$OAE>)E X:;2=+7E;-9,06)T#]UBUXN[9Y(Q7,/.GU4]09,"A\:@C!Y'5
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MA Y Z#=6R[ 2\$\5F;,N"Q.;:G//(LE)ITE9JU+-2JM54CK3)4F\"M\.D4@
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M@33;=\ L#E6,UBDDT#;4 HA$ S52< 0 *9,%3^6?9?,/K9CV:YMN*]YL*B'
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M22<',(E319M%7!S#HNQ[<53Q$7])ZUNEJ3\%*\,,0*!;!S4&+T@(#^5:EEV
MZ$!U^2PNM@(#KI+H>W24.W&?$3C(<AL.F3:FGFKXL6?D/AON@/P4GPP]%'X]
MS4]S?_2O3/O'_P"R[_\ U_>XP!^C '+#$XIGMIZIXL6?E]%LF_!2_##**@_C
M%S2E =B;JRW31$A4S;ZQ N+1$ ["/8  HZW]0'9Q-A MXW>\&=&+&@%5?'B,
M$T$0)R=X GIR6.C?P6/PLYE)5Q%7'F>D&Y7;YEZMAF"B.0(^C'1XN2;%62Q:
M*B3R.=MEF+YF<0407241/LY3!P;_ !#BSPA^9<'*G8E3Q&)!W J-IT!]%FB_
M@I'AB: Q;!S1DZ@ =!E&FAH![]/?%HB&O;0B.M<,(_3ADT&66R>/%GY#X"^)
M?@J/AD$4*(3_ #0J"1<#"FME2H^2<B8]DEP1Q<S= DOH"_9+" @;15! 0,;2
M>+$;^4\HCR3I3WX-EX?4M7VU086'F0I5119ILW%:HV2JC Q\V?H**CNR*CC%
M63LSI0Y04,::?2R8*&,=LR9"()%=]N_>JCER:OFQ]OM1)2A?@POAP8[OE)R+
M7I[F84GZ+:ZY<X,LAE"J+,5)6KR[:<C"OVY<:(/GC?U[- '")%FAA 5 \T!#
M8%?$>KO3)LNY9G*['8>P=]]@[]AW^O8  =_U  ?J#@LK[P1'!%2US19@D(OG
MQ?XGM>:^:['>,V'*=2\B0E<Y7J!9K[(/;U+Y7R+7I.4L32HX>RJ^9@:$B(:.
MCC201$3U-0V?9AXY\%\7$XP=_"VPK 9Y<LY86> UJUFH*D]ESI$R N?@GG#Y
ME:\ABG$&4\135PN$I1<MYRM&2<K3L;AZWUOEEHV:7=.JEPOV/X>E20?E;>8^
MEZK,RE%CH^OC\5]4,N-=ENN*+.*XX?$(M6;-AIKVT2$$'[O/(!HD95=UFL ^
M*]B_+UGJ"5I1QI0J#DJ@VS)%0M+#.4)<9>D5FHQ;:PN&W,97 J]=88;GGU6]
M1-]/XR7>'B'C1W4I:6B9DH>K[X^&<&#BF SOF[![&0"[;B6 .1B&)S>C!V'D
M#V\BOS+/B SU4S+9KMBMUC3-W*Y0N1'.7,A*/J3D2+?.[%;<26=FT7:PDU"U
M:R,Q?AY'XJ!%?C"$3_1I[,2PC+5R(AICSXN(,&+BN_Z1A+";3EF'^H7HP\$F
M,19@6$-I-KQT>6T7SQ,+'C>8JE$N^)<1X^RO9,;.,W*U7)/,]%U"N-,62<F[
MAZ4U:W;\ETD6:RK;WS.Q %-CXW\7*[\'=C,9%_/8@)7L;:_)'?5>=W)^W+MK
M#-;68O%5@L=8XK>8X"BT-UCZ:P75\]_"\HY\K.)LN6.!FHV6EY*LXWP^%8NE
MBM%DKS&'<A)C8I"BUQ[,B6(A9B6$)>7BG???):P@DL&W);2^I&MX7$0YZ\ZU
M&^<Q3.=Q=7K_  9><G#G+7@6%C\C-ZX[9CE?!V.[U%C;';C')?10_K;$6Q2D
MD:1LLM%#9'D+$1$P6N0X6.X< Q8^!PR6_/\ ^9_42' P/B$ V8T-+_M;/$/@
MP_BV!)X%!(.(T >1A)G.2($E*ZI>()D1Y/1#7(/+K&5*I,.9UYRC9)M43F9"
MT.*UEWR7DI&3E5@?R=5S\<,8R;$((#SLE)T:V1<K,*)C1)8L3\5?YX>,\3A<
M#B ?Y_B9['PS()=VY5=JZQCP\?C\(2.#_P LQ()?Q$00388L-!#@ 3X0@\7^
M+?2\DS.*I5O7L5EQKFF]UFH4U"M<P,3:^8"*3O4W^+](GKS@I"E1K.)C91^I
M%KVHD9D.P/J+%SB;M^U?KP<LBUUAPO\ F1_E#$2V6$!VTGF':%TQ8#^7@+ER
M6H\/B,.18,P+/+$U6]$\0?)-W8XLFAY>8VKU+F$+F>M87L[O+K:1E'&1<05?
M(5F5:WJOI414E8IEG;XYL9X:T14O<IB.*BV3LE,BW#E<$>>#]6+AX0P/%_#\
M+\0-N)P\/$SH!C$5O=EC"?$,0 ,<;'@#O08L6$$0)>P] I-\BF3LF9DY0.6_
M*V86\43(60L+T*ZV1U!O3/&LDZL-88R1)TZ3>M51A'NIA!T$@ZK;.*,SKZC@
M\<UD9Q!L205ZEL0PXA?"#1H(CN+,N0Q'\WBX2S8>+Q<-3_#Q,0C=J5:7(93%
M3%02F$>D=@(E$! P"81']$W24#%WON)2[["!0#8<96UNEWTEW[](;_;KO[]_
M?[^"+5P1'!$<$1P1'!$<$1P1'!$<$1P1'!$<$1P1'!$<$1P1'!$<$1P1'!$<
M$1P1'!%PSF#9A#]Z;^,HG_9]W'+B_LP?_*?=7"/UD9X?48F5"TOB.ZY8YPO$
MAB*IRK<J6=TI.S85KZENYBK0[AWE3=2W+C1D4V,9&,,$Y2?2L$!C?%7J"$_
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M#DRQ:<LF5:2MZZ,QS4-.;M^B:1BA3'(S1NS:A CN"V-*$(YM_0S7Q8.H1"9
M!+QGAX?!AX(< _AQB9A0^$O%FLUP"7J6-\6/C8Y;C_\ +U,GPC"SEQ7PY0[.
M&26H/))%8T"AUFNY\STEAO%5A8V*@8,-/T-A3X!""5=.*Y5W%OA\?,,P3F/*
MZJYZ(ZFV')<A7UFK*-A;"UGH%BK#/E>+B.<@-F!%-;;)BQ&#5FJ78>(G3:[
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M#B._KL0+H1^_7;C7A_UC_?[%'.1\OE 8RLP[T#/L.OZH4]_\3B>$%_UBX/\
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M2S%GLD;CFT+TR=M;BIV:$J#^?:^M%TTJ=MF&4?7;>+$2MOB<E6Y*7B !XR$
M KT!#M^4 98 20#>"=3A:<P"YQ.ZYO632KO2'Q!QA!S)K3PF'D#YZ_\ X97_
M ,X?^?C/@&9\OA6<\?0_*//7_P##*_\ G#_S\8\&++S'RLN<SU*//7_\,K_Y
MP_\ /P\&++S'RCG,]2CSU_\ PRO_ )P_\_#P8LO,?*.<SU*//7_\,K_YP_\
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MKX(!>P+-7I;:<G*P3!#T<$@@Z7<0&$P;Q M*2'J33,&^Y"#\Q3E-W* _,50
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M,P97QHYB6K.1LK5,7LPP6<(.$%';D[@W7B3P1A(C!Q/S T.03CG.<F)AX*N
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M3XW-U.C+LYAJW?-WXN$H]NBV*4@:1W\M*>AY5K(4JTP "$     A0   "@
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MNM>KMZ9"J4OS+1+-:XMS-%<HC_2DMF,<?+)LYP IS_*'S&*5-(I3&]S 5)(
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M&D5)0L=,69]WXG$!X_#>/&</#8!I#"(=R7!!J<3V9<N'PR?PQ-_S,3/1L1)
M(<4!PM< 2S%WL3\1'G$SKD3)&/>6O%V *K"TGDWP/S2S5QRS:KPM,0[?.^-I
MFS-:=#P].@Y%&<F(=]'I+M9=TE$QS5E%"S?1,XM,1:"'+B?X(_$8R 1P_P 5
MQ> 2<^'Q<7#J&KX#$-04 '3!@(Q\,."S4$$$822Y=PSLP#-FZCIRG\X.<G58
M\)ZW\Q4Y&VRWY<Y<N<;+#N^N<QW.I4V0A:)BVLV*-E\U1"<<G1G\Z^.X>H2K
M^1;2\!CYBU"4J#(7:TF3C?$8_B#PVG#_ ,)P\4CPAO\ $/#Q$C" (Q#$#B<%
MB2Y !6<>%\6"?_W'PP6/[,8+N[2[ :P4C<H^*=S Y<P=SMXFG&E'K,RP\/&_
M<SV+,T<OR>?*DVCBLYA"JJ1E<G,M4ZF2.1TRG?D?0V4<;*HTZ7!$R$>)7:AS
M,N8Q?X/X;C@?YG_$>%PP0<\&%FFH:AKXF(H]XF#_ !<8:#A\/A:CR1TBD 0)
MB5GBJY#R/6?"1PS:ZE<<E15RL5AY+XR5E\<WB?JF1; UMT]4&EDB8R[1UBBI
M).6M[=^[8J2RLZT%RN^,ZDW8F,H<=?CFP?B<6")_%<3A.T1CQB^QWHM_A,!/
M#Q4'Y? '$(_Z1, W;.=5"/!W-7:^5S+7/5FV"8\UM8P?R?\ +4@VR[RC\W?,
M7)9@R_8L\2]HCG6.;A0V#RT9%4J6-9"#DRLY'(<+*2D7.-505C6:BC5$!WX?
MR^#CQB1@XV/\-G_E8CPP0:%_"!.*G[26*Y>$X^-@P0#Q.#@_$7P_YF 8V, @
MCQ;@!RT-,^N>*9S?K8FSU+&Y2W.4<B8ZQWB/(]!E\78XYAX/'MEC<C6]O6+?
M6%8/)>/:O=K7<,-LW'XY2[/';631N\";K@",7+0P!#^G@GCEF'%/"F[8O"9$
MP1(LX73!A\7'/!\0#?AL/&-S.!Y#P#8.",(Q N'(XT?XO>3I#EU:W^JP?+IE
M;*CCG(PWRO?BU!2V:L7I1;7-6F,-*Y*H^5:5'9(Q58D9GST&4?Y>08F::Q:T
MO%O 23*U1SQ3^5AX6,TXO$_+!;(M5WI- P(J7 <'!^83A!(?A?FB:^(.-+ER
MXJ0&9SF)CQ6>8>C6')/+1<<,X@E.<2O\U6".6&D/JW;KFQY=9PO,7292_P!0
MOUAE9&"D+A$M*Y7:W.LYNM&;/)%_+@U1B7[=JY*?C9#$B2Q(, &"S78F8L:K
M#$8<.(LV+"XEPQZ4K!N1'Z@M%F\5OF1H[BQ87GL(8AF>:''W.[@'E%L[>$N]
MR8X6L<1S'563ME$R%69V1A']EAWR*#)-O-UN5B9]VQ%(_E.WRS\R3>?(;T;K
M2>2E#L^?7EKY2%Q)WQ2^;BL8OS'\4Y>:'8,HX YSWG++EBY8NA<LY0Q/3J,C
M0V5X)F-3&U.9N<RSD01.591$E#QGJ$H]P\;/'\TT52-'FC@<,<0TQ<7%PHJ^
M$L#(\A-0'!)&_ 3C/#!8X>%AXS&XQ806'Z@+U8R:%EBYOQCKU(4'E.B\:Q&"
MKMEOF0D<])S-LK;;F+R'BJE1W+^C%K3D>]QY5,4AGR/O=G&S0+5[3Y>LH!05
M%W+F9F9:(19N%-G!_B\3A"O#P>,O<,385<#:;X6/,3PL/%(+8L?Y?-]V :8=
M]F:W/D_Y@;#S*<N>-<S7?%\[B"XVV-D2VC'MKAK%'24#.P<W)5Z3]*C9H*MS
M:T#(NXM64K;N0AF+IS O(Y5T@DZ%=(C!A\6#!B?]V##B:"WBPC$T'7I*F+&<
M&/'@8_HQXL-6?PEG9JQ-9N5)>5_J0_\ Y)'_ -,>,K2JGYI/#O@>9_/5>S+8
MI^J*,H")Y?X9O6[)0F]GVPQ'G27RW=(QLZ?3D?Z%CE"KS'XB2<7\/$/A'K2R
MXRT2\^$<7AL.*31CA9]FLY#_ #9DRS)LQK%VI:]"H2QG@GW2$>M7\;S/1:SQ
MAAR0QE%/+!BIS8QAG!L>VW'K:,BHQ_D4*X\QH+"T_$92CV&.EHH99H[)K4O%
M2\5&L=(S=J-;,'-M%?'P\H<NV,,&,NX)T!$YKFTCP6K14KCC:RI<P-1;(4F6
MOB[OX7BN=D9!M6+Q;[O;W-.J;6T9&L5=A&&KG)QP3D?7HBQPHZEXB7-\4"(B
M:QJ6:QCW-9;KL.?CP6,P\%^?Z:,*L0 1,@I>U'PB[$\D*8\S)F^JW9&H-H%H
MV0KF+92#,S_%#E;=<M=(L\2-GR)=/17:NO"QN3(V=W_0BQLS!$Q,.(1$IQOB
M@XB?Z>N( Z-SI5M6#%^@-<L0XJ<1DWN#>H-PS6Q7@;F)BEQCN?S549:0_%;*
ML+&/R8OG?@D/9KQ4,,5"NY"C*]+Y%D @[.R_)&XL4I*5WX3\8E[)H?Z+,@EI
M?6*.&!&0WN'=A,6L:.1K@<0G&(_B<!@207PFHPU#-6C"8*XD/!D6#-++)->S
MG&050B[I=K- X^8T"4CV&/H>R9,MN0HR"QPXA\BQS&L  6<*Y9 "-^$3T0T:
M#\($3?""\F,!C4]-FR$L[1S8^([DX@]0!($N0'83 $C=S"UQ!X2C;#V0\%WV
M!O>.7Y<,W3"EQ4@WN(A09RC_ !SRXRV!;_-Q?H;2 0EVR+-NX[* SPA+?![=
M78D9<+&+/XN/;#B<"!+Q!9B+P<YNX 8LX\3"?%)Z$M(((N7,%AF68%70<5<$
M<$7.0_J-W_Y1M_Z9N.&*IW/JM?P?]7LN 7V#]@?]''=8PT&P]%]XQC-LY[Z+
ML</B&&68"V@U1QG 6+9L$&!B"]-/JCCJN>*IW/JM1??_  ?^D7C&.HVQ>BU@
MH=\/JG&XY+JJ<N<_PHX[FNSU?,ZM<O/<?REBY?(['U1B6U;&62J&>ZA9'\WC
M;F%1<A*L#*RU-C72\&WB/);^J;[<A.-]@W"=^G;U"=W%8,@@LW1,!/\ @;QD
M@^MX0^>5F$/:>7VD<O18&2Q^:9C(V"I6$Z-CYE;89N-W9!%7:4NV.J[8;#.1
MRS60E*5*6/'3UR+.30L[281^Z6_5$6C?[4FHU!9VNPRUL9N^=U:URB8)GN7'
M#Z&-+)<VUXF26^\6U1:&B9N J%81O-OEK4QHE%A+!8;9/Q5"J;>1+#5E*5L\
MV<A6:Y!<LQ#X<GKOO-.^\E+ FA(00$1#I+H1WL0T'<=@ ['W'8 ._< ]N"*J
MOG8\,ZN<XF;JCE::OZ]:BX3"^5L6V:FE@1E&EKG;36[)$8?O2C\9%L#![AF6
MNMVL\0EZ)P+J5DT1!Y&@U!V;F>%A)>9=V+.]J4Y]5T'$Q80 &B [PV4L^<7U
M3&8<\(-7%69L$YG>9S3OTMBK$U%QC=Z_;*"+ZIY;?*.,YR.:[Y.PKBVOHQ"Y
M7Z?S=)S%8FSD7DJ41.<AEG%BKUK?-"=QB;Q&^/A8>%!(C" )H:";%S:%@E\,
MWXF(EZ3BPD$"K1<0P8.Q2Z+X=N8HP^"JE5LUXG1PKBO.^6\YW#%5EPK97\;?
MYB_<PUFS31HM=S7,LU4&\;AMO-LQJ<6]1D*[(7Z-B+W-U,4HB$KS1P\9PGAD
M%_ROPN#\,XJW#X6'!=@?VO-Y#T3$3X<4$$\;%B /A9CQ'!+ _N&63$NZN-*&
MBE#8CHH!L0 HCH [B4 *!1'W$   #V  ]N,***'.=RZ.^:WEOR=@V.N1L=3M
MM:Q3VH9"2CAE7E%O%1L4=<Z1;4(L7L8$A\%M4!$NRM/6,A$$!<^K7Z/+/G#_
M !?U'V96K2\,UZLUW<:4C)51// FIOPO)-5@LZ66K4JY%Y4&->9UV(7B+%0(
MW!J\#(Y=>5JQLK&DLUM.<K#5X2U+S)&[)O 3[1JL^C+"54Z*5!!<"Q]R]KY[
MJ-W=H:^[%KQ=Y*W[PT)&\8]K-9/DREU.TP_)C=>5&SVJF8H;U]K=7,](8@-#
MVZ1B8ZS1R\;#L(/$IJV^J[283,W;65Z:!FX-./0ZIBP^)G #4JP\GYAB(:@0
M0[/F: DB@<Z4^94ON37EYE.5[!<3B21LS*UNVMIR#;!<PL+)UVMQ WV^V*\G
MK%;93]ENEL5@JR,_\)B']FM5CL#QBS;KS"Y9 [AJ3IBQN.'A+/AP# XJ?"+V
MBE-=LX<(PG$0_P"HN1$6RUK[J6*@%4("9BD$3I]'S@)0. @ '( &'J#[M'V8
M!["&^_'/%A\>$BWHMC%X<0-W<<NZ75#UW\$^MW++V0LIJ9LD&J]QYM*CG5E#
MJU %RU_#",W9[GE/EV;."V1ON R;?[Q<K@_G_31PH.W;,OPZ3% 7@S!@\&$
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MOZ/U/?!6[QE;]S%^4LM^/$T49I8T $0^M?(+'M?!)N$%'S3&G<R\)"IME[Q
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MZ!<]--/RA#H)HQ2"(=)="/OL>W?O]_$74 ?H@4-ADN$8A ,8 (4  P@  4-
M&_;VXKG,]2N9PX7,"IL,UIZ"?P2_XH?S<'.9ZE1AD.@1T$_@E_Q0_FX.<SU*
M,,AT".@G\$O^*'\W!SF>I1AD.@7PA2^:7Y2_ID^@?</ZN#G,]489#HEW[>W$
M51P1'!$<$1P1'!$<$1P1'!$<$1P1'!$<$1P1'!$<$1P1'!$<$1P1'!$<$1P1
M'!$<$1P1'!$<$1P1'!$<$1P1'!$<$1P1'!$<$1P1'!$<$1P1'!$<$1P1'!$<
..$1P1'!$<$1P1'!%__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>img129881027_8.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img129881027_8.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (C LL# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M9H&I)[!1110,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MD=2%Y.[ICDBHR2?@F/\ KK_[6K?A^']Q#I\VECQ%=#2Y"6^SK"H.>V6STSU
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M_P#OI/\ &CSO%/\ SZQ_]])_C72T4 <UYWBG_GUC_P"^D_QH\[Q3_P ^L?\
MWTG^-=+10!S7G>*?^?6/_OI/\:/.\4_\^L?_ 'TG^-=+10!S7G>*?^?6/_OI
M/\:/.\4_\^L?_?2?XUTM% '->=XI_P"?6/\ [Z3_ !J"Z@UZ^C$=WIEK<(#D
M+,L3C/T)KK** .2M+;7+!&2STJTME8Y(A6) ?R-6/.\4_P#/K'_WTG^-=+10
M%K'->=XI_P"?6/\ [Z3_ !H\[Q3_ ,^L?_?2?XUTM% '->=XI_Y]8_\ OI/\
M:/.\4_\ /K'_ -])_C72T4 <UYWBG_GUC_[Z3_&CSO%/_/K'_P!])_C72T4
M<UYWBG_GUC_[Z3_&CSO%/_/K'_WTG^-=+10!S7G>*?\ GUC_ .^D_P :/.\4
M_P#/K'_WTG^-=+10!S7G>*?^?6/_ +Z3_&CSO%/_ #ZQ_P#?2?XUTM% '->=
MXI_Y]8_^^D_QH\[Q3_SZQ_\ ?2?XUTM% '->=XI_Y]8_^^D_QH\[Q3_SZQ_]
M])_C72T4 <Q)=>)XHGD>WC"HI8G*' 'XU;34-=>-6&DQD$ @^<HS^M:>H?\
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M'E^1)A<<@Y3G-:%9\WF?V]:Y"^7Y$F#WSE*T* "BBB@ HHHH **** "BBB@
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M0^>IRG&*T*SYGSKUJFQN()#NQP>4XK0H **** "BBB@ HHHH **** "BBB@
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M#ZI6E5"9U.N6J;AN$,I*YYQE*OT %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M;7>KP:AHD%_<#S+TSR3Q!%PF%W*@.,_+TSG)KHY)$BC:21@B("S,QP !U)H
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M<[_+\HS+NW9QC&>M9<FO:D$GU%([7^S(;O[,8F5O-90XC9PV<#YL_+CH.O-
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M)(FC=0>AVL <'!P<8X-7: "BBB@ HHHH **** "BN \ W$TWBSQFDLTCK'?
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M?@DBMJ'_ "#;K_KB_P#(U):_\>D/_7-?Y5'J'_(-NO\ KB_\C4EK_P >D/\
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M[<!M /7D_3-:M]>Q:?9O<S!BJX 5!EF)(  ]R2!0!8HJGI^HK?\ G+Y$UO-
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MW$UN'CVS,LRL7 5B" H;DX8YZ5@?\+F;_H C_P "_P#["C_A<S?] $?^!?\
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M:=9$D9L']RH)V#(S@!!C P>W3?:[?_GO'_WT*/M=O_SWC_[Z% $U%0_:[?\
MY[Q_]]"C[7;_ //>/_OH4 345#]KM_\ GO'_ -]"C[7;_P#/>/\ [Z% $U%0
M_:[?_GO'_P!]"C[7;_\ />/_ +Z% $U%0_:[?_GO'_WT*/M=O_SWC_[Z% %2
M^M9IM6TN>-,QP/(9&R/E!0@?7DU5U>XU22!(+33KO;([)-)#)$'1 >"NYP,M
MV/4>F:U?M=O_ ,]X_P#OH4?:[?\ Y[Q_]]"@#G?[)FECU3RM,-O%-IB6L$,C
M(2"/-^7AB/XE[XY^M1ZGI%R6AD2"+RH;:W4HSJJNR2AO+].1P,\9KIOM=O\
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M4 345#]KM_\ GO'_ -]"C[7;_P#/>/\ [Z% $U%0_:[?_GO'_P!]"C[7;_\
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M6B@!-B_W1^5&Q?[H_*EHH 38O]T?E1L7^Z/RI:* $V+_ '1^5&Q?[H_*EHH
M38O]T?E1L7^Z/RI:* $V+_='Y4;%_NC\J6B@!-B_W1^5&Q?[H_*EHH 38O\
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MI1M;0UKRJ2G>IOI^6GX%74%7^S;KY1_J7[>QJ6U_X](?^N:_RJ/4/^0;=?\
M7%_Y&I+7_CTA_P"N:_RIF1+1110 4444 %%%% ')^-)#--I>F6]AI]S?WLCK
M#)?1!TA50"QP0>>E5?"T<FD^))]&O[#2EO!:^?'=V-NL1>/=@JP '?'Y5=\8
M+IMS-I5AJ(EA$\S>3>Q2B,V\@&1S[]*M>'O#]AH]Q<7$5_/?WLX DN+F82/M
M'8>U &_1110 4444 9\T:C7K63G<8)0>3C&4[=*T*SY4QKUJ^]SF"0;<\#E.
M?K6A0 4444 -D_U;?0U\L5]3R?ZMOH:^6*%N/H%%%%4(**** "BBB@ HHHH
M**** ._^$/\ R-EU_P!>+_\ HR.O:J\5^$/_ "-EU_UXO_Z,CKVJDP"BBBD
M4444 %07EY;Z?9RW=U*(H(5+NY!. /8<FIZYOQ[_ ,B5J?\ US_K515VD!#_
M ,+(\)?]!;_R7E_^)H_X61X2_P"@M_Y+R_\ Q-> 44K >_\ _"R/"7_06_\
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MG$C <+@= *WL7?K!^1I 3T5!B[]8/R-&+OU@_(T 3T5!B[]8/R-&+OU@_(T
M9.A>&(="U36+Z*XDE;4YO.=6  0[G.!_WV?RK=KF]"\32:[JFKV,4"Q/IDWD
MNS\ASN89'/\ L'\ZY#Q=\2]9T#Q)<Z7;6M@Z0!,O(CDL64-V8>M0Y1C&_0[/
M85Z]5Q?Q67W:6_"QZG17B'_"X_$/_/GI?_?J3_XNC_A<?B'_ )\]+_[]2?\
MQ=1[>!K_ &7B.R^\]OHKQ#_A<?B'_GSTO_OU)_\ %T?\+C\0_P#/GI?_ 'ZD
M_P#BZ/;P#^R\1V7WGM]%>(?\+C\0_P#/GI?_ 'ZD_P#BZ/\ A<?B'_GSTO\
M[]2?_%T>W@']EXCLOO/;Z*\0_P"%Q^(?^?/2_P#OU)_\71_PN/Q#_P ^>E_]
M^I/_ (NCV\ _LO$=E]Y[?17B'_"X_$/_ #YZ7_WZD_\ BZ/^%Q^(?^?/2_\
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MM_"7_0)_\F)?_BJZJB@#E?\ A6_A+_H$_P#DQ+_\51_PK?PE_P! G_R8E_\
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M^^#0!/14'VM/[DO_ 'P:/M:?W)?^^#0!/14'VM/[DO\ WP:/M:?W)?\ O@T
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_'I#_P!<U_E4>H?\@VZ_ZXO_ "-26O\ QZ0_]<U_E3,B6BBB@ HHHH ****
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M (4?\(SX[_Z&>3_P/G_PKT*BG[)&?]I5NR^Y'GO_  C/CO\ Z&>3_P #Y_\
M"C_A&?'?_0SR?^!\_P#A7H5%'LD']I5NR^Y'GO\ PC/CO_H9Y/\ P/G_ ,*/
M^$9\=_\ 0SR?^!\_^%>A44>R0?VE6[+[D>>_\(SX[_Z&>3_P/G_PH_X1GQW_
M -#/)_X'S_X5Z%11[)!_:5;LON1Y[_PC/CO_ *&>3_P/G_PH_P"$9\=_]#/)
M_P"!\_\ A7H5%'LD']I5NR^Y'GO_  C/CO\ Z&>3_P #Y_\ "C_A&?'?_0SR
M?^!\_P#A7H50W-W;6<8DNKB*!"=H:5PH)],FCV<1K,:S=DE]QP?_  C/CO\
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M0!G200QZ];RI$BR/#+N<+RW*=36C6?-&HUZUDYW&"0'YCC&4[=*T* "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IDO^K-/IDO\
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MRKU'*"$-NC*C."2<-QWP*.9#>'FE?3_AE?\ (VZ*YF3Q#<VU_%'//IA\RY6
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M3_E1\R?\(MXA_P"@#JG_ (!R?X4?\(MXA_Z .J?^ <G^%?3=%'U==P_MB?\
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M %S7^51ZA_R#;K_KB_\ (U):_P#'I#_US7^5,R):*** "BBB@ HHHH ****
M"BBB@"C<Z-IE[?0WMS86TUU#_JII(P63Z&A=&TQ-4;4UL+87[#:;@1CS"/\
M>ZU>HH SYG)UVU38P @E._C!Y3BM"L^:13KUK'AMP@D/W3CJG?I6A0 4444
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M_P#H#UZ'X5_Y%'1?^O&#_P!%K7GGQ._Y%JV_Z_%_] >O0_"O_(HZ+_UXP?\
MHM:S7QL]"I_N,/5FO1116AYX4444 <CX1\/7^C>(/$MY=K&(=0NO-@*ODE=\
MAY].&%==5*SU:PU"YNK>TNHYIK1]DZ*>8VR1@_BI_*KM**26AK7G.<^::L]/
MR"BBBF9!1110 4444 %%%% !1110 4444 86A>)X==U36+&*WDB;3)O)=F((
M<[G&1_WP?SK=KSSX>_\ (W^-O^O\?^C)J]#J8.ZNSIQ=.-.JXQVLOQ296U#_
M )!MU_UQ?^1J2U_X](?^N:_RJ/4/^0;=?]<7_D:DM?\ CTA_ZYK_ "JCF):*
M** "BBB@ HHHH **** "L#Q/XD;P\ED([&6Y>ZN8X2R\)$K,%+,?QX'>MN>+
MS[>6'>\?F*5WQMAER,9![&N:U7PQ<-X=ATVSN[F[=+V&X,E].7?:LBL1NQZ#
M@4 5]9\7ZA8:E?\ V/2XKC3M+,8OIGFVOEP"=BXYVJ03GUIMOXSOI]1@G_LV
M(:#<7QL(;H39E+Y*ARN,;2PQUS4&N>'M>FO]8M=.CM'T_6C$9YY9"KVY50KX
M7'S951CIS4=IX7UN"YM-',=H-#M-1^WQW0D)E90Q=8RF.#N/)ST% '7S(HUR
MUD"#>8906QR1E.,U?K->VBCU^WF1,220R;CD\\I6E0 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %,E_U9I]-D&4(H \U\:_\>%[
M_P!<7_\ 037-^!/$ND:-HDUO?W?DRM<LX7RW;*E5&> >X-=_KNE-=%U*[E8$
M$'N*Y ^ ;#/_ !YG_OX_^-9RC*]T=^&KT%1E2K7LVGI;]37_ .$\\-?]!+_R
M!)_\31_PGGAK_H)?^0)/_B:R/^$!L/\ GS/_ '\?_&C_ (0&P_Y\S_W\?_&C
M]YY#_P"$_P#O_P#DIK_\)YX:_P"@E_Y D_\ B:/^$\\-?]!+_P @2?\ Q-9'
M_" V'_/F?^_C_P"-'_" V'_/F?\ OX_^-'[SR#_A/_O_ /DIK_\ ">>&O^@E
M_P"0)/\ XFC_ (3SPU_T$O\ R!)_\361_P (#8?\^9_[^/\ XT?\(#8?\^9_
M[^/_ (T?O/(/^$_^_P#^2FO_ ,)YX:_Z"7_D"3_XFC_A//#7_02_\@2?_$UD
M?\(#8?\ /F?^_C_XT?\ " V'_/F?^_C_ .-'[SR#_A/_ +__ )*:_P#PGGAK
M_H)?^0)/_B:/^$\\-?\ 02_\@2?_ !-9'_" V'_/F?\ OX_^-'_" V'_ #YG
M_OX_^-'[SR#_ (3_ .__ .2FO_PGGAK_ *"7_D"3_P")H_X3SPU_T$O_ "!)
M_P#$UD?\(#8?\^9_[^/_ (T?\(#8?\^9_P"_C_XT?O/(/^$_^_\ ^2FO_P )
MYX:_Z"7_ ) D_P#B:/\ A//#7_02_P#($G_Q-9'_  @-A_SYG_OX_P#C1_P@
M-A_SYG_OX_\ C1^\\@_X3_[_ /Y*:_\ PGGAK_H)?^0)/_B:/^$\\-?]!+_R
M!)_\361_P@-A_P ^9_[^/_C1_P (#8?\^9_[^/\ XT?O/(/^$_\ O_\ DIK_
M /">>&O^@E_Y D_^)H_X3SPU_P!!+_R!)_\ $UD?\(#8?\^9_P"_C_XT?\(#
M8?\ /F?^_C_XT?O/(/\ A/\ [_\ Y*:__">>&O\ H)?^0)/_ (FC_A//#7_0
M2_\ ($G_ ,361_P@-A_SYG_OX_\ C1_P@-A_SYG_ +^/_C1^\\@_X3_[_P#Y
M*:__  GGAK_H)?\ D"3_ .)H_P"$\\-?]!+_ ,@2?_$UD?\ " V'_/F?^_C_
M .-'_" V'_/F?^_C_P"-'[SR#_A/_O\ _DIK_P#">>&O^@E_Y D_^)H_X3SP
MU_T$O_($G_Q-9'_" V'_ #YG_OX_^-'_  @-A_SYG_OX_P#C1^\\@_X3_P"_
M_P"2FO\ \)YX:_Z"7_D"3_XFC_A//#7_ $$O_($G_P 361_P@-A_SYG_ +^/
M_C1_P@-A_P ^9_[^/_C1^\\@_P"$_P#O_P#DIK_\)YX:_P"@E_Y D_\ B:/^
M$\\-?]!+_P @2?\ Q-9'_" V'_/F?^_C_P"- \ V&?\ CS/_ '\?_&C]YY!_
MPG_W_P#R4S_'?B72-9T2&WL+OSI5N5<KY;KA0K#/('<BO6?"O_(HZ+_UXP?^
MBUKC=,^'>A2$?:=.W?\ ;:0?R:O1+:".VMHH(4"11H$11T4 8 HC&5[L6)KT
M'1C2HWT;>MOT):***T. **** ///A[_R-_C;_K_'_HR:O0ZX/4/AS<R:S>ZA
MI'B2\TH7C^9-'"K?,Y)))(=<\DX&.,UT_A[2KK1M*6TO-3FU*8.S&XFSN(/;
MECT^M1"ZT:.W%NE4?M82U=M+/HK>AJT5S/B?PUJ>NW,$MCXCN]*6-"K) &PY
MSU.'6L:W\ Z_#<Q2OXZU.14<,4(DPP!Z?ZVFV[[&<*-)QO*HD^UG_D=_117
M7'@'7YKF65/'6IQJ[E@@$F%!/3_6TVVMD12IPG?GGR_)O\COZ*YGPQX:U/0K
MF>6^\1W>JK(@54G#80YZC+M6CXATJZUG2FM+/4YM-F+JPN(<[@!VX8=?K1=V
MO84H053E4KKO9_\ #FK17GG_  KWQ#_T/VJ?E)_\=KMM)LYM/TJVM+B\DO)H
MDVO<29W2'U.2?YTDV]T55ITX*\)\WR:_,NT5R/B'PCJ^LZJUW9^*[[382BJ+
M>$/M!'?AQU^E5])\$ZWI^JVUW<>,]0O(8GW/;R!]L@]#F0_RHN[[%*C2Y.9U
M%?M9_P"1VU%1W$;36TL22&-G0J''521UK@/^%>^(?^A^U3\I/_CM#;6R(I4Z
M<[\\^7Y-_D=_';PPN[Q0QHTAR[*H!8^I]>IJ2L'PSH6H:'#/'?Z[<ZJ9"I0S
MJ1Y>,YQEF)SGU["MZFMB*B2DTG==_P#ARMJ'_(-NO^N+_P C4EK_ ,>D/_7-
M?Y5'J'_(-NO^N+_R-26O_'I#_P!<U_E3():*** "BBB@ HHHH **** "BBB@
M HHHH HWD-U]KM[BV2-S&KJRNQ'7;S^E)YNJ?\^MO_W]/^%7Z* *'FZI_P ^
MMO\ ]_3_ (4>;JG_ #ZV_P#W]/\ A5^B@"AYNJ?\^MO_ -_3_A1YNJ?\^MO_
M -_3_A5^B@"AYNJ?\^MO_P!_3_A1YNJ?\^MO_P!_3_A5^B@"AYNJ?\^MO_W]
M/^%'FZI_SZV__?T_X5?HH H>;JG_ #ZV_P#W]/\ A1YNJ?\ /K;_ /?T_P"%
M7Z* *'FZI_SZV_\ W]/^%'FZI_SZV_\ W]/^%7Z* *'FZI_SZV__ ']/^%'F
MZI_SZV__ ']/^%7Z* *'FZI_SZV__?T_X4>;JG_/K;_]_3_A5^B@"AYNJ?\
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M^?.V_P"_I_PH\O4/^?.V_P"_I_PK6HH R?+U#_GSMO\ OZ?\*/+U#_GSMO\
MOZ?\*UJ* ,GR]0_Y\[;_ +^G_"CR]0_Y\[;_ +^G_"M:B@#)\O4/^?.V_P"_
MI_PH\O4/^?.V_P"_I_PK6HH R?+U#_GSMO\ OZ?\*/+U#_GSMO\ OZ?\*UJ*
M ,GR]0_Y\[;_ +^G_"CR]0_Y\[;_ +^G_"M:B@#)\O4/^?.V_P"_I_PH\O4/
M^?.V_P"_I_PK6HH R?+U#_GSMO\ OZ?\*/+U#_GSMO\ OZ?\*UJ* ,GR]0_Y
M\[;_ +^G_"CR]0_Y\[;_ +^G_"M:B@#)\O4/^?.V_P"_I_PH\O4/^?.V_P"_
MI_PK6HH S%_M).EI;?\ ?T_X5)YNJ?\ /K;_ /?T_P"%7Z* *'FZI_SZV_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
F**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>img129881027_9.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img129881027_9.jpg
M_]C_X  02D9)1@ ! 0$#O@.^  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %1 EH# 1$  A$! Q$!_\0
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MCP367!J"::BA%$RG, J^&EXBR4<X-!<<._[<L_+%<SLS8W]H]H[!V8RH*?\
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M[&.2Y5/XM[?I.+J>W;KBYK@11H-W-VHRJ&,#:8#:?S:;*AI@;A>QKBTD!/\
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M+V4,<!^1O&]H Y$O'8.'A>6$!Y;\N7/MMMMWWT18O:W_ )U;^S*?CT1-K?\
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MK=Z[0!;P7"B9B?;O]5!M2S,ED7+*N8^9N&\N_L#==M#*(J(3THDNA)3:0D1
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M ,ZM_9E/QZ(FUO\ SJW]F4_'HB;6_P#.K?V93\>B)M;_ ,ZM_9E/QZ(FUO\
MSJW]F4_'HB;6_P#.K?V93\>B)M;_ ,ZM_9E/QZ(FUO\ SJW]F4_'HB;6_P#.
MK?V93\>B)M;_ ,ZM_9E/QZ(FUO\ SJW]F4_'HB;6_P#.K?V93\>B)M;_ ,ZM
M_9E/QZ(KYA[<\4_M08D4?#'P_( \!7Q>1=N?F#"3P^'+?C[W+C\-]$66T10$
MI3?2*!MO3< ';]NB*DH0A2[@D0>_?W"CL&P]]MR[]]M^_IWT14Q%,![I% -@
M$1%,@AW'Z6Y3F$"?#<"FV$0W$?02*<GAF,)?#3'8-Q$I0,4._ISXAW'??8 [
M;#W^ $53PT_T9/LE_=HB>&G^C)]DO[M$3PT_T9/LE_=HB>&G^C)]DO[M$3PT
M_P!&3[)?W:(GAI_HR?9+^[1%KEO3)\V)\  A>4/*!] />_[@Y$2]MO7;OZAV
M]-) !)T.&N7GUDL*E-]1CV,=NES2-[2;3.4&#,'DM>L%NKN.\<2]ZM\DA"5*
MF5-_:[),O$U5&T1!0$*I*RT@X3:I*N3(,F#59P8C9NNNH!/#22.<P;,1<2!
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M:T;<N\BL@9"0<M';BX%R#8&]<<%M934D+C=D6MGN;BDC O+7--FCNPK27A%
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M&;L9_-%/%Y>GDD%9QRHI/&LI,GC8RMDC5(:4#,Z-<]G&DNTPI,"N"L:*R*
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M24 M*^:4>&N'L1%[;$ZTA&KN7%39+S*"BQ0\L&SZMT$X91,#@)DG#'#OE=<
M":I!;-%S*=0?ZPZHUSVDY $,.]QW>['4_J>Q9<&LJJB^E8:1C[)*P(5N6K5K
M86M\=E8,B0#9RVJ3F#;3ZCB76Q3>7*<(I'!-,&U<D596/04)X*\Z_G1">L_
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M$",(Z/FGCB9&_GG@9_*AO%[9'+ND<9 U*U]GT<JQ5YJ$Y&V6I$KE1MK*UUZ
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M&QRE'8! !$I1$O(-C<1$!VY!V';U#1%;"P:FV 4B" "0>(D(8-B  $+N8IC
M!1 1#8P&W,;WMC;:)W*(,FP;"*1#" %#<R:8F]W8"B!N'(! I2D+L( 0I0 @
M%'OHBB+)N) ()-R@(B "/+U,0XEV, @!#*)IJG(  110@&4*<3'YICKN^Z&^
M-_Y!]0HE9MBB(^"F;?8  R9!  *4I2A]$.7$"]CJ<U Y& #\1X@13>5;?5T/
MN4_PZ(GE6WU=#[E/\.B)Y5M]70^Y3_#HB>5;?5T/N4_PZ(H@V;AZ((A_8D0/
M^1=$DC PM>MR1"5BP&33(0P0TG[Q2% 0 6+@/4  0]?718U"XL>)L6D&2<(R
MXJDS1#V/'' $BB+-J)E5B&,0IA:EW.8A Y&  #N(&("11\<QC>%X:CCI?GUP
ME*;7-I-I4W$/J4VTVB-XEQ<WZ?I+3?=Q$WRC"\)P.EL=- YBD+NIX0 43@4_
MH*A!YIF#B?Q4/& H'-S()"&\47 G3.V  MC'V,7QSS:'ANXZ7/82',+7 %X
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M8 *8 *5(V_)8IDS;\#"=8J6SA-0^8+2)D<+BXQQ.! \9%EH=3JM!)8<8PG
MG"X%Q$@R ZYB%KU>MM7M\<M,5N7CIJ/;3MEK+E\U4%1N6:I-FEJG;HM7Q2 *
MBT!8X&=BGJ!BB"3N.> U.8A$CIX_,8)!= OQB,3D#A!PUR6VILFU,+6NI.%0
MM:XC=,0\C=!Q_<'M+1-Y$1BM<9Y?Q7(VYG08^W0;VY/W-MCFL B51S)+'H80
M1;CXI6[8R;="N&L$ TE'*RB#)JYEXN.3<%?ND&H!5ID_N!,Q:[K3/*";C7,%
M;ZO9NW4:3-H.S5&TWL!94(AAWHC=(B28, .N!A%SB"9\PL91JV0R%73N']N+
M28]%JX!9=:V.+#=*Z2%:MVB1C*/33F/[LQ6!-(R*A:G-JNCK,6;A8NI^TT@
M=YN(8#Q() L"9^G Q82MS>QNT+@;-4G<=7<"V^X"P$Q: #4:-XR 3>)78VA&
MK@I#%13*44TP%,#$$4Q_FCG)NBJJ G$Q2"Y.550BQ? (=5R4H>'N:X.:"/L<
MO/G/FNN?3<QQ#@YI%H+7-P)O>/"+ZV5T5JV$XI\ , ;G$!(F!!-XA#''@5,I
M-SB0@'';WN.^W(1.-SF3A'7IT5CW<?NJGDF^VPIE-^7<I._<^^X%* ;F!0Q1
M';?;N @?WM%9Z]?'/FH@S0+N($+N)4R"/AI!V1'^;V*5,"!P+L0-B@' I"B
M@0NQ10\BVW+ND02DV\,IB)B"?O<C"0PD\0!4,!1.(G'Z(<>(<MR*(LFQM^2*
M9A';N9-,VQ@#8#  D$I1#<W8  H\C )1+L $QQN@,VX;_P V7<QS'$0(F43"
M=0RIN7 A>>YS"(F4Y'$PBH)A5$3B5D]==7U4!8MA(9,R0&(<!*<NP%(8A@#D
MF)" 4GAF-NH*8% @J&.?;D<XF*"V'4S[E3%9MRB812(H)A$P^(1,VQA$1,)0
MX !>6X<@* %$0Y"',3F,13>5;?5T/N4_PZ(GE6WU=#[E/\.B)Y5M]70^Y3_#
MHB>5;?5T/N4_PZ(GE6WU=#[E/\.B)Y5M]70^Y3_#HB>5;?5T/N4_PZ(GE6WU
M=#[E/\.B)Y5M]70^Y3_#HB>5;?5T/N4_PZ(GE6WU=#[E/\.B)Y5M]70^Y3_#
MHB>5;?5T/N4_PZ(GE6WU=#[E/\.B)Y5M]70^Y3_#HBAY5ON @@D4Q1W*8B:9
M3 .PAN!@+N'81]!#<-P'<HB D4@,FX<MR 8#@(* 8B9@5Y$*D85 $@\S&3 R
M9A-N)DSB0?=*D"9$\BWVV @ '$"AN!3; 4HE*/OE-N)2B ")N0G*4A%.9"@7
M1$!BV#?9(@"/(=_#3$0.8  3]R" B'$G$I@,F4$TB@0"I)@4G\=> 4 8-@ "
M^&02@)!XBD@!! GH D*D!!#D)S[<>QCB)>(%2!-)U3A%M//UOS06#3;8$4P'
MB  84TSF P (<]U"' 3CN/(Q@-S'N<##HG\J;R3;D!@2( E$1+Q(0!*83BH8
MX& O/D8_$XB)A #ID,4"F 1%)UZP]+) TZQ];J4K%L4  $R"( '$W!,#$,
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M)HB:(FB+6KB)OFM8 +MWAY,#?EX^1<#N'<.X" >OPWT6NJ2&.C0ZX0=-<._
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M+$S/+V/XMV;9MGV?9ZO9U%@I.IC<I2VF\4]IH[2'U 7/J?,(HADL<UKFNJ-
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M-$31$T1-$31$T12G,!2B(_V!Z]QV'8.W]FB*D"I]MC !3[;[F]TH!N ;B!A
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M9"NQB:=&=.%J1.762?5]X_\ 9SZ:E9"#:R#MQQ:FT5A9L$EV8,!I&D@<;S'
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M8Q+:0LTU&0;!U+2:PI1\4D]DUFR*KZ37Y-VK-(ZBZPJ*%;MS@7@#/KKT06$
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MF8"RI)2-E89JI$MH:4P1E.J2\C(&;1T;=Z@_IT@Z:6)PRC5:!.G>>I[DZZ.
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ME#83[FWY*;!L!3E%;N81*GX)2@<W;B<X"5+P^W$G)4NPAWY&6 4RG#GQ-R4
MA2'62*97P^0JF H'26%-,I1Y$$@& GX^_EKXH0A3E-MXA>'AB >Z @0@"D(
MGL;P/$3* F Q2* !Q*(%40]PA$@97TQ''*\^EE35 J:9QW$Q=O#*0P 8H%,!
MQ  2 . !S FX$*!0W 3!LFF)* 20 1W]=7YB.>&M,B<[6O\ <7C*"1&>],9<
MAB"8=R <?$Y@!BB<A4P$IC*(\#E!-,04.!A*8Q"G3 =BB B()'&.N:HN Z1!
M&N$X8QH9. S(544R;&*?F!0*?8Q=^0$ ZG%052F XJ"4PBB<QA4*L)U=S&$#
M#$4XE* "78"[<2F,*9"\.!1X',<#EVXE,3@8IMRB00+W$=B*B!"[\?>,)SF
M0 2@)5 4+L8>.^Z@B!3>.<AQ(= 03$AC)@!.OYR44DB*& WNB $+Q$"CL40$
M#@)"K <O)4B@E5.!2JD A$S&-L4VB===75\5,I!$0$PB/J)AY"(]N_(VYO@
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MK](9Q\!02KD96&LUNMP5C6N.0X92.L]>?N7BSXKQJ^]A2G<;OS.[R,Z9_8<
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M;?W@$  2*@9P8N^X &VP]TU1,(""8B0 *!BF6 1,4$2G$QAV$.Q3;D4IG"@
M'$""< [EV$>?N@.X&Y@1(#=S)>8,F"NY$A.F)_$*0\/7KVY*J18Q@*.WJ'8-
M@]\1*4=@$JARDX"82G[G#<H[&[=R*(JF .X% P& !*!BF[#RV#<QTP VP?G"
M/8?=VV'1%4*<#^@"&WKZ"'P[<BB8NX;[" &$?71%*L0QP*!1V]\!$?U !O\
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MHB:(FB)HB:(FB)HB:(FB*@N(\2 41 PG$ V, ;[)J&$./O>)[H&]P$EA$=A
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M";VTR&O'"V.&0P"Q%0$F6X ' V%I\!.L X"T7:*9#*@',W$R8F\+Q-PX@<#
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MNNF'U[B>2LIA^/P'L&WP]=Q[ZF9Y#U*N0YG[+:.(<N7??CQ_5MOO^W544#D
MX;#OZ[]O\?R@/Y=0B8N1!FR*4J92CN FWVV^'ZOU?JUE-H@8S.:D"2<S^/91
M A2B)@]1#;X 'P^   ?#454XAO\ E]=^W_7]6H1.N,V^_!%;NCBFER+R$PF
M"@4P%,)A =B@(^[N<=BE WNB8P;B7Z9:,0H; \NM/5?/_+F9\WXKR]D==FT:
M6C%]>I>!I*'AG5=?0;&+E\J95M&/K=,3^0(YE8%DZ]CN%@&UUFDT*VH*,.[5
M/).6+023$?Q:M5],DAI=>  UTWF[CO1NBQ(@%QB(N1[;LCLOL;;NSZ!VFM6H
M;4_:#3>65:#MZBVFYY^31J"F7U7'= WZ]-M,![KMW6GCR/7?G%E#24Y8^GX$
ME7=BP^G4Z@Q4O[&S(UG(F)H>[S\A*.YK'Z,4Z=05H7G*W#&!.#?R3R%F8F7K
M</(UJ2%_H?M=8-)%$M +8+IN-V3<1/ Q$X@@%=]LWP9\/[7M9V9O;9HGY-5W
MSJYV?Y7S65J; VHP.WJ3@USBZF'5 YK2]E< M#L;F?JCZLL?8JQK<ZC0E+;(
M.,)]0-ZR=%GHEA=6-*:JDQ0J3C92&C(I[&^7/%S%]2N-HA@*ZD)ZC5FT.8,C
M22;-U M.I4<UI@;Q)D7  RBX-C<W,@6(-QP=E^'NPJNV]I;)4[5;1;LNVT=D
MV.L0VI3VDFCM%>J=YK<'#9RUE2&TVN(:X/)#5[\-D'(:>4H"FDQRFO2Y6N^T
MY2_GE+$@YC9(C25<)Q80B=&5KZR2ZS9DW15?WJ,=CXZW*)5,BT3D.2:CP8W0
M1&(G&0)QP[^_&/+U^SMA9LM2M3V^F^L-H=3I[*V'.;3:\-=5JU \@ -@[H$G
M>!:Z&F?#E/SWU7WV878KU]QCJP+]6-<QU#U6=Q:_.W0PL_Q;CK+=D?6.:/95
MF2,O3J\&2()6T0KMY69W(2]5B&"*:,@@@_UBN]SMWY8D3^YIL)$'>WA< G(R
M-V!FO5;9V5\-[$S:&4=H_NZ3>QVUZ==E=F\.TB^G3=2(%(L=2<:E1K02VHPL
M^JH\, 7U3:;<S]_>V.(E[")>2FW$P;FX#N3<H%,!#<C;%]S<>7C!(@Q?.YN<
MSGH87S@$00)@F2#E$@1 %L<N^ZO]$31$T1-$31$T1-$31$T1-$31$T1-$31$
MT12F(!A*([^Z.X;?X>O;]6B*(AN'J(#Z@(  B']G(!#N&X#V]!';;1%2! @%
M O\ 5#;W1 FP[ 7U "AN!A*!C!Z";OMZ;$3P"=]N10$=]BB!1^B)>QP#Q [&
M$-P. AN/$0WT13%2*0XG 3"(AML(@ =P(!A$"@7F8WAE'FIS.'<"&*41*)%4
MT1-$31$T1-$6OVS^B]A_N63_ ,FMJ.P/(^BK<1S'JK^'_P"$Q?\ =S+_ "R6
MJHK\Y .'$V^VX".WQV^&_J #Z#ML.W;?1%052(/ 1*!Q\0-Q.!1$"]S<>0E[
M@(E I>1@$1$"B<0$2F(K7N5, $3=RG$#G,0#&$P$Y*B8JAN*11V6.0YSB*1A
M$R9A3V KUT,.2K-@*8YU [[AN ]S;%4*F<"B;@4 -Q\,PCOS5*8@*B<R(& H
ML-8?_O=4_P#F9+__ $LWJC'N=Z%0X=[?4+9M15-$31$T1-$5!P7D0H=]P4(<
MHA\#$'D41#80$ $ ["&V^P_#10@&)R(/>#*M"M$1$3'* F,/,YMMC'/MQ,HJ
M  4IN9?I=MB^Z*0)B4HED"9@'KKHE9E[R #4? :&@!Q W1/TP+0=XR.,B#!4
MOED=Q$! 5#"(^Z %-L)A,;<P%(;81$0_*7W1(8H@ @+6D$$# 91,",K3&MD%
M1TB'.-R/W.,?2X ?NL&[QW1E,8&$%H0=PX^^;?8?<.)C"83B83& QMP.8%0]
MX"%.0I@ -MA@:!_ \;#[YK$&!#9 )>203?? :X&\01P&=X58K4"@( 0O%00
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MW]>/;8-_CN Z(1((DB<QBIDTBIE I=QXE NX[;B ;]Q$ #N/Q[ '8.W;1 (
M%S&N*J:*IHB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB*DLBDN0"+$*H0#IJ
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M"&XB/,2E+N.^WJ.VX[#XT&6R1!TPUFW<%^R+@ &/JDV_Z)@<I:X2+W5R;^:
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MB\!'< W$W;TV"*J<1 H"(^@>O_K_ -"/P 1[:(J9U.(A[NX"(>\([%V'T'<
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MNS0:LF"#9JV03(F(F(K-!BS+<Y9P1L@FN->KQQ7312(J(G>VG<!4 G(Q0WW
MIA$-P 1 1 !#!Q.\(<1=LP<0=X$&9MAI@+V6;0+&!(<2.^ ?)QZE?%GY;LQD
MZ1@4Q#&*8UJMY!,&VX@,3$;B/;Z7;U]/AMMKXA^M?;O:G8_9.SN[.VNILSJV
MT.I.=3<YK@UK*@!:6D0ZP,F1(%K!?0?T[^&>POB/;-LI=M]F[-VC2I;/3^73
MVFFVHQIKU';[@' PX"B&M(B&N>(,@M_.MXZXAL*Q]C%. [\!#90ITS (&+L8
M!(<P;" [=A .P:_-M+XN^*:<M9V[VB[=#+U*Y)W7M#C< 8$#=M(&J^K4?TL_
M3BB*K/\ Q-["+&50&@[(V9AUYD $@02!@3 FXHE J8"F0J9"#XH;$3(0O%8>
M:A>)"@ \C@4W(P&.42@4ARD$Q1V'XN^)KEW;_:(=H*PB<;_3)YF2<22N6/TZ
M_3]L!OPKV0UL79_;,+;P"(D2+9F\F<56!RL0@$(JH!2E*4H<S"4"EWVV*(B4
M!#?;<.^P?#N&M;OC+XK<"'=N;?NB"TBL9!)#20<K$F(B>%EHJ_IE^FYIUGM^
M"OA[YGR[O.Q N(WF@M)#Q8F"0 )M*^DWR3RZI^LZE <XG *K?3!RV'8?FX[*
M'P^ >F^^PCVV[;?4?TB^).W=K^):FP;9VGM6V4!3?4_YQ5<]Y.\VQ(W6[MR8
MW9N;Q9>*^-_@'X1^'^PCM_8O8>P]F[2U]"'[+0ITH%4EKVV;.Z9F)N0"287Z
MT>7'<!$??.)/\2F/M\/U=]^P[!VW  U^L"8>T39P-C&(B(XW,WN.,+XOD).9
M [@#'K^)*\S=9&5+7AKITR3DVDG8IV>IQ+1W&&E&H/V ++R3)D8SAH)T3+%!
M-R8Q2D72,!]C"<Y .D?L.SZ#-HVEE)Y+0[, DSO-M;43B"-1F/#?J/VWVE\.
M?!W;7;?9#:+^T-@V<5MG9M #J)<'@'YC=UQ+8))#=UQ($/:)7YW ^5PZO0$X
M$?X] 0$>8)4T0-R RH")N$J7N(D[@&P";^J';;WSOAG8J>X*O]RT.87"JX L
M)M]('RY!(^H220+<5^"&_P!5'ZC.#P-G[(%6F2*C:6S.&Z\-J6N"2"YMOJO>
MP-U:F^6"ZMR )A?4DI/.I,N9J8<I2G5523*83&FTP-N)C   )0,(E$!$ '?1
M4^'^SA@ZH8.;0=1?Z(%XO<XRT+TE#^H?]3*[0YE/LT3L%/:X-)I.\YS 1!:!
M$.,-G'=_S2"5%I\L'U;/R&,W?4,VQ>0D7J ;D#QET YI^VE# )C-SB \2[%'
M;?;<1QI_#_9[ZC&?\X.\8_R6,+^?U!@@'&YR-EH[0_J-_5+L_9Z>T'9.RJX>
M(+30LUT/=O?LG=AH$ $C>,FU[L/E<NKH.)A>8]'8Q1V)4E$]^("82G.G+)F,
M0PE$# 10IA*/NF*;8Q>13^&]DWZPJ_W3:=.FXL<^FQI+@1$QOWB<!?$$1?@]
MF?U1_J#MFV[#LU79NQPW:-I;1JBE3E[&_*J/):YKJ=]YD226Q(+"2"W]2U,E
M7$I6:_)KG$SF2AF#UQNF()^.NW345$A2&*0H"8>W?L&Q=S".OG6U[C=IK4J5
M1A^6\@-W73N@FYN+R;P )R&"_H?V/6J[7V9L.TU&GYE?9*%>H9&[\RHQI<UD
M1 FX!N!F5MIECD NZ8B([@/NB0O+B(@ &$3 4!$!#<W;T#L(@ ZA.?E^3K_$
MKL2< +R8&/G =D/SK1*[,8XI[% P  B(E'CON/8OO;G#82#S* D # !C<A -
M8R9NV!DXD03I8DY'P/)0$&1F+'3AB ;CAZVJ'<B0H"(IE$3; )A,4OH(["([
M;#V[;B&X[%VW$!U=YN;@!S'NAMD1Q(('C$7RU4A7?(_ #)CV$1X@8PEVVV[;
M]]]_>VV\,0 IMQ,70.:[]KFG/$8:X^.,2-1*<L>4F]M!QX9<D,Y4)N)S(E+R
MV 1 0]=]OI*DWWVVV+R, B @0P 80Q:*SG&-PLB?I:YSK8S<  7O?VR.Z/W$
M-_XC$\,,8O)@0#P4Z"YU3\3 3Z!C>Z"GYX 783E* AQ'WA#?W@$.VP@%WAO;
MF]]0!)&Z0;&)F2(&&I/(J:D [N&]<@F <=T#4XX0KO62)HB:(FB)HB:(FB)H
MB:(J"WJ0! PE$1Y% IS (;!Z@1,XB(>I/>)L8 $!'80T1?/KY0;J^END[$<S
M+U:'@)&^3N/\Q3=-D[=8&$!48B6QKCY]9FR\B5^4"6Z;?R#B+:P>.V:C"8MA
MFDFWC7[==JF<KK+NR/5E#-NHMB;B1A [UY'M/7+U42F7(:D4& Q\:F_RDKT.
M;EI!G((V83&ZW\_8!%9C$$4F&:CUC4, NXYL9M(&67EY]]87:"3X\5#0J8RG
MU\,#RXG@K''4'G)T$B/&W.>GUWY4R-LE"0R-%X#MCJMJX\RYF1X=M967F4L=
MXGQMCG)\THVCWL#%.)2ZG:Y$95A[6FQ"0Z=HC'R\7;;#5U&ME=.O93#K'$VX
MK9HSY2]%9]5DWN#YL8N4<54MEF82X-I-%FTO&7+!ANJRE+B)"N05DNS*4L45
M&.@%Y!4]X5G(/T56"$E#ILI8KUUU;PFA"_*?PLX]QO&,,4)SKN_XXA\HKIT[
M*57LC:$KEK)-!6XM2=&/C*>%MCEH8$\F05@M-5;T5*5BUXJ7NQ7'NNNH4G2\
MB?'#&!XQA99NY?*")0>#<+]0+*J)OX>[O<X(6.DP3F4>/V\CA>FY6?RU.9V"
MU1-"?1TXC;L:N8*4<2-#=,V[\CB.,1I& A;E!,08MG)B.,6B!YCG%_G X::7
M/0Q7LS 66G.9J2_LTA5C4R9@K]D_&UFK833:Q-H^SXNR%8L?S)HZ<:,X\DI%
M/W5>-)1CI:/BW?DGB)7,>BMS*4@N!UPCN(/-=OT1-$6OVS^B]A_N63_R:VH[
M \CZ*MQ',>JOX?\ X3%_W<R_RR6JHLCHBI+H(N45$%TR*HJE$BB:A"G(H0>Q
MB&*<#%$IB[E'MOL([" ["!%A4*I6FQ&2;> A4"1K-6.CB(Q3!(C".< 0%X]D
M5-L4K5DMX9.;5 $T1 H% @$*4H$60;Q;%JNY<MVR*#AZ8BCQPBBDBLZ4213;
MI*.54DR*.%$FR+=L0ZQCCX#=!,PF!(FQ%AI\A2O*N( '(]D3*8W$H&V]C31A
M]XI2CW$H".XCZ?EU1CW'T*AP[QZA;,!  0-ZF HEYCMRXB.^PB !N&X!_P _
M41$8JIM$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$
MT1-$31$T14E3BF7<H 8PCQ*41V$QA >)0 1 !$QMB]S% H")S& I1T16X.A.
M(@F4IO=Y".^PE  W'<IA)S,)@.3BF<Q4SIG*HH4Q1+HBBDN94P@/'^;'?W2G
M'D&_'<N^W;B8%! ?> JJ8E*=/@JL1:\D !;9<.11-\W8 "@ [B'"0LY0$X=N
MVPB [#ORV] UB1?D6^I]UD#AQ=]VG[+XD_+?&#YD8& ?I!;+<8-O00"*B '?
MU]!$/CK\\_KX [LG8@3_ .^53;@*@XX3?CHOK_Z0'_RCV@/_ (?9#/$OKVCQ
MNOSI[_E^ ".P .X@&YA /78=MQ =A]-MM?F%['$O# 2?\D=VXX3Y"Z^[,(+]
MI#B /G$ X7&\!CSORR4>!@W$2_ =@WV'< *;;XAOQ.4?3?\ 5W[:3LVU$[VZ
M2.(,= Z$]ZQ-:D#!<,1H;88V.IPCO4/ZH;@)1 =N(CW#X[^@?\O^6LPYVZ6/
M;#ANG,?ZVR+G4K95#/[>JYKI)9AH-YO"_.87TH^2:[]:-(#X&JM\ ?[!KKOT
MU];_ $:O\9U!K1=_VV+Y_P#J?_ZK'C4V,>-0#[K];!0+S'D&X JIWVW$/?,&
MX?K_ .@CV'TU^RR-XM))$;T1;,#[>*_,]MTSD;=^,]P7A_Y1\A%>C3-ZVZ@B
M6O1IBE*.Q1$;+#([B'<0V*<VV^Y=P*(AVW#K>V>W]I^&]CK]I;-0%>K0; :/
M].\-[?,D2&Q%BUUQ!LNM[1^#Z'QWL=;X9KU*]*GVJ!0+J$_,$2X;L Q): 9D
M;LB#*_'2"B.YC"BJ!AYE'8X  @)U=R@/$1VW$=@VW[;COW$?D]7^I[MVE_E[
M1L@^6PP/F;Q:'B0  *X@[N\+\0,0OGE'_P 'GV&YKMJ/;?:;'[2ZHU]*MM(9
M38"US!NG^VW@]K!@7.!D@X0K7R4?N802=")W)7/'S*@!XA!(<NQ2[ !2'3*8
M V >0;B;;TXCOZG>T3^W9=FN3.^7L: <?J.T$%PR;F"3DO3L_H2[)V:BT_XW
M7(&S,V*VU8TV0X&U ?7+09 #3DT$@"=)K')JG<IHK N9(R1S^9,83IF4%4"B
MF;DF(D4$PE, ;[&$!WY#K?LO]3G:M)[JC=B[/>YC'$-=4WABT2&OJ"]S!F=)
MNN-M_P#0=V/VOL V6KVYMU-M$;X.S[1+B&M-,[^]0/TP^3#1>!G)K%.U#;^9
M5'<.("8Y3<1 H@']4=_4 'XB(AON&VLMF_JD[8VW:&T*VQ[)1;7J!A=1!<"7
MV +65&. QN26R!:XCH-F_P#![?"78;*7:7^/;16?0?\ .<W:ZP<&AK77!.S@
M%PF "V2TDDR2OWDT4B84NJHHF$I$Z[$EW[ 8H>00/QW -A-OL =MA#8! !VV
M^R[)MS>T=FH;<V)VNFVJ\Q]0+VAUL( .&\'3/[M?J-'86=FT:?9U.M\RGL36
M;,QS1 >*+=P.)(B2 3  UW1@-G,4G\X [FV*.VYMQ'MZ[&W*(@.P@/'W3;#\
M #6[=:U\[SG$LDAQ!:((R !M&<V-EM87$[N\6 N+0X$@W%[R,B#:#W&_XV^I
M'/6:8KJ)SQ#QN7\ML6$1F?)\9',&60[6V8L(]A>)]FS9M&J4J1NV;-&K=%N@
MDD0A2)E NQNQA^(]I?U!CL+M';^SSV;2VH;'M=?8V_Y+C I/@./S*A:70"TE
MK0;V $KSVU_TK=H_%^TU>V]F_4/XJ[.9MM5VU#8^S^V-JHTJ8J$NW&TMQ[64
MQ(!%S.Z-Z,>!3/4)U"/&)VC/-V7TA,8%3>+DRYD!46X&<HH\DILAR@+I)N<0
M*( 8A#)B(D,.L*?]2=&L8=V+18V)'^0P?4"+27$?MOJ3!P$'E[+_ $B=M=GD
M/=^H?Q/M @-C:NUZ[VSO-<"2ZF6XMM ! X @TT<_=0C:0.J&<,PJM%%71P!Q
ME*XJK) OX"KDZ8A+E3#QE$TC& Z8B78 2$@"<#;:O]0;/DO?2[*HET?M%%AM
M$DV(L)'"3$SCR>T/Z5NW.T:#*+?CKMW9_DU6UG/V3M+:652QK'L<QQ:V=PN>
M";&[62)B,S_M'9W$"&/FS,0@(&]T,G7 .X&*!-Q+,@8.P=S 8 W[]^XZX+/Z
MDZO]HYA["HD_,#0X40,G7);4!C4881$!=8W^C7MG;(K4/U/^-*-6C#WTW]MU
M&4GL NT[^RO)^HMBX=8G> F?U*?)?66QW#I$Q_8+98K!:)QU)7A!Q+V68?3<
MFY3:729;-RJO9!9=<W@())($ 3; 0I0W$ #;ZU\*?$K_ (J[(I]J/V=E U'D
M ,  W2-X"Y<Z,[GND+N-G^$*_P #TQV!M/:FT=JUMG)+MIVJO4KUG _[GN(;
MB9AK&Q,"+@_0[7I%O31$T1-$31$T1-$31$T16SD0_FP$@&W-N!C$Y 0Q1 Q.
M^VP"<P 4I1$HJ&$$RF*8P& BYI>;;C*">5:$R)*U1L\M<NI%4^.LPQZJLM-%
M0.W<%BF;M(YO&40?BQD'!$4$VJC\C15;=VF"A.8URY3?PMY8KS9+=:'2A&W6
MCU)C;:7-J7)IE"P/+A"/:.6JT*,Q"PBKI:)2^RLE.QR\<X5/=(>3@V,2QF)V
M54LR5H)'-8#SEG1);C8Z9C37@1PCAME6ZH.DR7ORV.:KD3&)[:XBH2S)I1X,
MF[-^WR':K34T&K6:1:#"R<](6N@SD)/0"<C[?83K&/CK!%L9-TP(LX=_><>_
M7[IRSMX<< )G.V!X[1_+9TSU];&4&6_XF@U,L1U5F,2Q))>MM#W.)L4HR5J<
MI3V)%2)R,;)S\Y'^PW34HMY"P3#?V<!I639ED7?U?KO3NO,##OZX8&RT,O5+
MT5>R8N88Y:PC)-$JO:KE6R0TM6I-12N)L++*V>4K;=CR-M+,*Q<%5$62;=6P
MEKEK48%=>S)I1 <O;VZR0:CG_$Y>N*YGB7KXZ6LIP]:(RCSTZK/JA=;2S>6U
MQBQ2LUQE4(?IL6E*_)%I=ZMI8>?F"]6.-JW#UI%BI(S,DK,-5V'A/ZPK;'IY
M^"DSX=WB%[MI<Y5+/ 1-EI$M"3M6L;$9Z&F*ZY:/(>5:RR@21I-B\CSKLG82
M;EXXD7+HBQEG"[L57 JJ")RE>L>M<8OW+;M$31%K]L_HO8?[ED_\FMJ.P/(^
MBK<1S'JK^'_X3%_W<R_RR6JHLCHBMGBRK=LLL@@HZ533.<C9(4"JKF(0QP12
M,Y<-&Q5EA*":(N7+=N*IR%6702$RR9%Y]#J0K97*C!U6K3'R2,;<Y!2->K4<
MK]=Q1'=K9S,%#M4KRJXM,\HM3)E,K2H)V%"+,+<T\ZC$4WBK9UY3WIUU,7]<
MI$$]$QYDV R2S6?0/CE1;I1OCINS1Y'23I]&MY!9JHV9R,@8BL:HNI%20B;R
MJ$NR?,V;R1!NLJBZ\4[^M?-7UNE6D>YJPNUO"_\ 'TG ;(JJ !/9<LD(#X?(
M1'=78 V* B&XB =A14):*>[)/U;P)^F#,01!F()MKJ&ZYY : 8()Y Y21>8U
MM-EM /A.*9DB>*BJ7D0Y2G[@8HF*)MP]P  />$^P!L/?TU"2' $8R)QOI;"T
MWPXZPRTP0<8M>.<9<<.*F([,(<C\"%W$NX@8 YCOQ*4YC 13L4PB)!';8.VD
M_5$'=@F3CB .%Q)63F[O[G-!/[2;"]Q-R0?8\)G375,'<$S#L([)\A']G?\
MQV$?R;AZZRMD3/&!WXGJ\K$;P_<&ZRT[W=%K^/<HBX';?=/L/<! P#\0_K"
M>NWQ'_#U!ND8VQO$X<!QCHRF\V\21D"=V]LR"-;9]Q4@NCB( 0$MQ$0$IA-N
M&P;@8=N^P"&P@!1'W@[AL.L0X1C)&(B/"3/"-5D+V@3E#@>X@ B8O^Z!Q4".
MS#OOX8B&P&*4#@9,3 )D^8'XF#D7_P"#;<I@W 1*&L6N)$N&)BP/WN?ODFZ[
M P#!-YC.+Z:FUY"G6<F2#N!3&#<WN@80,4I!.(% !Y"8" 8X;;\@(8  -P,&
M9@!Q&0) F]AY\A?18W#2XD6N0 28X">..'#-4BO1$VQ@(4#$%0H;#N4 ,4H<
MS"8"CS$3<1  [$$1 .6Q<6O#B  [#>)@Q$@8V!,X7N-%D8 !G$;P)L,8 SOG
MRFUKU =?D$AQ'?8";"(B!1';NI\  1']0;=M]]9$@"V\;X #QQ6(,G%HY&?L
M,I/<H X5,.P!OZ_0)ML   \A$RA@XGW]T..X;#N(]]L0Z\0X20)(,#$WB=/(
M]V47B0;8 @3R)M; \3S4?,* 8 XG-RW !$FY-P*)NYB]BA[H@!CB!.6Q1$#&
M* GNW"!NN<28L#]P(T4!!P!&A):1/(&8X]V)"$<''N(D. ]P$J9@ H#O[IC
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M39=E/,_-K?8X+\YSHK@R*R3,"F75(*1>2I4A A]@7,F<P"0%BHBH*0G 2 <
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M)U =1:0(F9-!X[B!.NL0^6_R> ;$PG1C (%-_-V&P<@$_("@8I43G[<#@81
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MZI6PN2"JD@Z."8>6> F43.(]<B<@U$2E7:D R9U"*UL"@G<U<3%$I L*9Q,
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M:59I['J%C:A>"*=1M0@$@#?:YHM,W$&!C%_1?WNQOK4ZYJ[,*F[NES77@_\
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MC$ DP3&>'. OK]\BPBJGU4W01()=L%6?N;EL.]^QD @ BH??U 0]TN^P^]L
M:^N_H?V7M&Q?$?:#ZNQOH?\ ,7@/<'BQK;+]'U$\3&HC!?.OU5VBC5[%V-M.
MK3J ;;2@-C?$[/M9+C$0) '?Q7ZB4MP[#MN(#MW$>Q#<0WW* ;]_>][?TV+M
MWU^J@($>J_/ZKZJ)HB:(FB)HB:(FB)HB:(J:IS$* EX\A,!2\^0%Y&[% 1*
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MU#^A7Q4?_>]E'(#_ /ZH/U6[!'_NNU'F6G_N*/\ V._5^&P^#C,NP[[FNC@
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M &\Y_P!.N=Q!S6O;/U/[$J[-M%/9Z=8NJM=_YP3CO QNAHY2>&*_4#63RT3
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M&[))OV?LIG6DW6;]XQ\U?[_;@"!M>T &QBL\2-+&^&&"S:-8KI3%-[!AA-P
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M+"1!@D>!$V.HG# 2+-@6/[I@WP%[\B""M]V 0 "\A'ON CN7;X=S&,;MN(
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MTS.E))_,JK'3%KX9U%Y>5E)1=0Q146?2+YPJ8QW*HF@&[^V&F(EH ,2#$QJ
M>8G$F3CO&77/&8&. F+25@76%<7O'L.^<4N .>"!Z,>@,5'^4*=\[!ZJJJW\
ML)%54W(KJ-S&[(>;>%3 "N52CEO5)GYC\[ @8]T]TQP6,-T& &$X7SF\WE7[
M;$V-V1"$9TNN-03=K/TQ1AV!!(\<,(Z*76+_ -W$ !:+AX:,40V\J>.AXA@9
M 6D6P1;XN&]9Y+P+[KX<)R.&(!(Y$K)IW3+0 3(,#$&)'*PX\;!5F.+<=1I'
M*;"EUIF1WYKS!&T-'HE4*]4CU'*>R;<O!-7V1$IF(GP+X,5&H[>&P:E2H@"
M  , +#KTO"KG.=$G#+K7$\5O (E =P,<! -@'EOQ[;#P P"! $ #<A *0=@]
MWL&H1.9'*RQ45$_$V]X0V[@'J&_?OMVW$/@(B(%'N  8 $+ .(E%IA\;T9:8
MDK"O5*\M.S!3%E9A2%CAD9 %&;".6%VY%N)UA<1\5%,7)C>\X:Q44BL8Y(UD
M"$ @RWZ3JT '&<8S-^82!_M!UX\#?OY\+*C'XNQY$H+-HNFUN/0<)O$5DFD-
M'(D50D$()H]05*5L *(.6=7K3%5)3D06%>A6(%!I&,T4<B7F3\Q\G,$3GPRD
MQS4@1&Z//AQX7U5>0QQ19;G[2JL$\$[A=V)UHMEXI73IZZDG+E-P1 KA)==^
M^>NEE4E2'57>OE#F,:0?"Y!SQ_[1^F/L!@@:T&0 #P[I\8"R$'3*M6GDO(0$
M#%1#V?<"[FG$<P:,U)-V9Y(2*CEYY=%,JJZTE+RTDNIQ 5I"5D7JO-P\74/#
MO&)>XQ83!@:"W4J_>\K8/!((B.YNX[_  #^SW?30P1$#KG]E(O,GEDH"W*/]
M<X?V"7_J4=0B<R. ,!93&0\)];>4J*B":R9DE0YE,7B<#E(;F0?4ARF*)#D,
M&X&*8HE, B @.^@D8.((S$3Z?GBH8-B!!RQ'FM1?8ZH\G&-H62JT'(1#*$/6
MF<8]C&3E@TKZBL2N:&;-54#(H1WF(&%<$:I$*DBO%1RR)4U&34R5&\/];M<L
M8B;#GXG)2 1$#PXSZWYB<5M96I"[['4'L4 W$@ 78 */$H$ I2G*4@'3 /"W
M(4Y4RJ"8Y@G_ '$\XQDF; &;YI O;''RGE,"8^Y42MDR\MA/L;?L)M]M_P T
M1 1* ?U2@($+WXE#<=\2TDR7.PB)$#P"  8#[^NMO!52IE)L(;]@V[_$-P'O
M^4>WK^O;TVVH$9D\U3<SSY7_ (4^JB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(
MFB)HB:(FB)HBE,4#  #OV$![#MZ#Z#^4!#<I@'U 1#1$ FQA-R,(B&VPB&WT
MA,'PWW#D(!W[!V]>^B*;1$T1-$31% P;[=Q#8=^P%'?L.WT@'T'8P;;#R*'P
MW 2*04BF 0$3<1/SV PAL;L/NF#8Q=C!R]TP#N(]^([:(J?ER;  &.'$4Q >
M0"(>&!2]C& Q@%0I2E4, @<2A[IBB(B)$\LEML "7N)BF*! ,4XIF3Y[\1YG
M AA+R4YB(=C;@)@$B>63]X.X@82F, @0W(2!L4QA,0QC'#8!\0QA4$2EW./$
M T11%NF8  ^YQW*83'$#")RB40-L(<0W$H")2E*3L <  I0 BG(D5/Z(F[[B
M.^P[B($#?T]W8"   3B4>XB43=]$4QB@8  ?0! ?AZE'<H]P'T, &#]8!ON&
MX"12 B0 VW-]+D8>0@)S>[OR$-NQN("8@<2&[@8HE$0$G77Y4OER<>/)3;<1
M'<XF$0,)MP$3<AVX&,D @(&!,0 !Y$2,0BF\$N_+<W+<H[\MA'B!M@[=MMSF
M,(;>^(CSY (@).NO!"HE)] 1*  4"E*!"@4"[CQ "E#<NXB/$VY2[B! *41
M2(FD5,=P,<?= FPB AQ*  0   #8"[#MMMW.<3;B("!)]^N:JZ(I3% P;"(A
ML._;;UV';U ?HCL8/R&*4?AMHBD!$   Y&V+] !XB!/= I>("4>Y0#<HFY"
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M7SO$Z8\.'!9)UUBX:CWX14D^G(Z36E!9L8Y_!K,W\G%I2]F@'5HBF:C@7$K
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MU?9\B@(>,2+I%I>&#R<0[6*ZZ_" ZVSPR/#+A,7TQ7*6"O2:T/#M8TN%6O\
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M8KKKQ3J,O#!89#!.&FL4\A&>,:,RB'Y2E>Q[.KPK9JY D-5JZEXJ*3(I3>%
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M3ROFNB3'3SBN>B\2PSUE)&C,(.:BK062$R\X,%Z9*T^3KI'J9EW)G#^/E:'
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MB6<8:/G&$M;)AUU*7Q/I&IBVD]"%H#;H,QTVJKN!/)LW[YS&.HU&7E:I%RB
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MWAW(I2MDR@ !R]TH$(.X;D " F E$ #<X%*4 .?D8-@ ! .VB2@-R<!((F,
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M   3#Q^B(B "7W )[HD*7AL'(" 3B"93F33 B0@F!%.*).!4PY 0H; 4IA*
M%  X@ @(&+Q$"F(8H@<@@ %,!=RB12@V3XF*.Y@-]+<";&#B0A@X@0"E!0I-
ME"D H& QNP>[Q(HB@F(;"'(!V$_(J9N9@ H <_(@[F 2$-N&P<B%';ML)/YZ
MY*/@D]W<1,)3 ;<=MS&+N(&,( &X@([A^00#;8!, D4@-DRB80$_(0  ,(@(
MEV,H?W0$!*&YE5.P@)0*<4RE*E[FB*8Z"9Q$3 ([AL(".Y1+Q$H$,0=R&(&X
MF IBB4#^]MOHB@#<@?UCB(F QA$2B8Q@+PY";B!@$2@0-RB42^&02\1 1$B
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2FB)HB:(FB)HB:(FB)HB:(O_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>img129881027_10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img129881027_10.jpg
M_]C_X  02D9)1@ ! 0$#O@.^  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $W CX# 1$  A$! Q$!_\0
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M'O2^5^'T\0 ./\,XOX,'(!]WG5R AVX-[_ZA^? @(#\^_IJ3Q>:*9+ZL&'Q
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MLAV&XNYL:/>J;7F_2GTKE3)DJ=+D2RB8I"B$)#%*BDU8D5!=ZZ6!CID\?+Q
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M:7]*O2YE+$O 3)040A:@M.=(-"0E(3GRD%0!(25)L&CRA\?3Q N2C[WQ=P4
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M;CY:DEV# -RJ>\Q #$DDZWL!'Y=/_=*?(0.U4P<E/[YRL;DO "!A8T<0#OW
M!X 0[\CP'T#7%XI**DN-E$N[  N335F&Y=AN/B'TU*/L7"LJ0I0FS7#/;J;T
MH*4.[6K'R&QC.8?A=B5#4RS<<[U!L?=!E@\*K@MO6G;V1.AC;%9)!"PC/6F
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M0!H27UCR?1F1Q";A\8K"3>(X3"RYQ$PR&(4$F:4%0"P)LQ2 L(,Q2<Y)S34
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MA+%ARJO9Y1([(J[  DJ:K!PY432@U%[1 X9(Q,X)F\-EX'J^*XF0A$N7/_\
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M?2:$I/NJX> =Q=]D54HN/@RMB.XYY(N91!PL9,LJD26!9#Y0?LAZA-3N^:S
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M/*=4X3Q,(V0E&;>XQIWY*[6+VT"IRMS-+R#2-/<HM!V[F5@9C+)N(I%_"OF
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MX[*.0HQO9GYY:R$9W*UQZ-@E'()"M)60J$FFG+O7 ((B+MR5V\-Y2(.7:@I
M?6="YJ0,I4*5+JK0:@U)9GK<DQMR.)\5D=:G S9ZA,GKQ&)1+FK2GK%J*E9\
MJFHY!<.&V=0X4,H9-:L[%&LLCW]O&7%V^D;3'M[A946MI>R8'"2D)]L61]WV
M-Q(@HH#Y:2*\75*J8%W2H"8QK%<]1%5D49RIJ"H%6:PL2 -0*I>*XABIDS"X
M=<^6J<KVN=(E35H09DT9E%2$K S#, %D$L7=F!ZK"_WF+K3^F1UWMT?3)E7S
M)6J,K1/,JM)"OY0"I(U]F]5CI199PV12,0S-PF\(V06<"H1,AM5R3E.2M;$
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M9E5\CY#H[=^A2,@7>FH2Z9$Y9K5;7.5]"5(4ADR$D$H=^S2?$*FH<A/:B*E
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MD9&&EXY=)XREXEXZCY:/<-U.4GD>[;\/ >]12MFP-3%.FJD=9(0$.0IEF@D
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MK.94N<"04)4HLAE'*G*0!9A1^&2?R,K(/9.6?/I25DG3EW)R4FX<N9*0>.C
MH\=OW3LZCMP[=*$ [E1TH==4X!YQSG+SJLQT#FU3N26).I)8.3=JQH2)LU*I
MJIX)F%:S-S',3,<J6[NYSE1))+J42[N3G4EF7+\I7C526RQDE_4O8VD<-<D[
M];W-=]WLBIE9QRL(YE#12K%J5)(L<S;,A2;$23#J**8"$25S'I,6Q_QJK8@,
M#0#W>!CIHQ_$9Z1)1.Q'5!(0F6B=,4E*  $($N4I65(2 ,I2& 8"AB.>1$#
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MKP1E2D2Y,L2$3U$RB3+RY43%RDS9B5(RLHH*2 Q'S$Q_CR,S?F_'.,L7Q<U
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MQ'3FH[:B   IW %!F#<WJ+$$.0 #?YUQJ2HXO$)ZI,F6F?.3+R($L! FJ":
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M:O,PF.8EA TAI)4ZQM'M97=UV&9-V;&>/%>^A!5\I[P [M8RD^RXMPV8"U5
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M%I$1B1WKI9=^[29(H)B!%3<',4"\\=ZP J<H #U- WIH^^(!2D @ @#,U'4
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M^(>3=NGMR/<?J/KSJ7&X\Q\X,= ?*.0H) '(BG\0@8P]?8Q@   PAV*(@!2
M7D.P  !P!"\G&X\Q"KM5_?SCB/Y)>P%(("83?";@.KJ$W/!3=AZC&'G@OQ"(
MASR.H?\ Q)]?YH,HW!\C%W4B!0Y!,PB <ATE,/XO3\0B/ CTATCR//'80X[:
M/_B3Y?\ [0KH].^GJL %#_U@&X'MR4! H_G#@>_'<>0YX[CP.I<;CS$2RF9E
M-M5O*   ]P!L #WX$O?@0XX'@0Y'CL/;O^C4/_B3Z_S1#)U!YU'R[XM$I1YY
M,AW]0ZNWJ(\<<^@"(B ?+D=6SC=/DG\7B,CV"FTJ?<WX1< ]/'29J''I]0X
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M C]!$0 !^7("/.D#7\H>4<"])1(!/7MR #^<1X[\^OKQSW]>^AB &'QYG>*
MD8QA$P@'8"B8.!$P%$P@'(=^PG,(";N F$>.XZ1)J"-XJ)2@ DX;B3@2])@
M>2]@$#!QP/(%+U!QP/ =NP:0% !M 0(' ^48P\B81(!N.H1Y$Q>/J/)N>W(\
M=^_(6#L*I\<K]YI^?**DA[+/=F^?PI'( %[!Y? F*(B)B]0 )P^(#B/<1'@
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M!@'@1YXXY'@?7@PAS\7&IT(W_/\  D$&#!1!#DIU')O<(Y0(D/4F*91$14$
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MTCXMF4.OQ)8D5FSJU9_M@?&+B80'*U/S63^+'RBOWP9(#M]L9@..W'MX]O\
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MVD(J  'H !^@ #_PTA%> XXX#@>>0^0\^OZ_GI"+0*4/0I0_0 ?NTA%VD("
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MCTY^?'YM(0TA#2$-(0TA#2$-(0TA#2$-(0TA'F.5.E-8PJ'X(5P/\#_"")B
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M0XG-Y;"SU8=;"459"W6A(:84FJR[@YB JQ)<BK"/+I5/6@*(4A18D"@"E,2
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M4)<69- E@0$I HE(8)&5*0 &B&FT^UHYKRM6HI5J $&PC94R*@B(<GX 1
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M %"/YCXP_23 :B:.Y*3\519^$,PM_DR]?]3,OE^B4U8?3-T08/\ 6(+!QU2
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M^(00<S3F.9.YL[M5LD=*Y4J[G>Y]WDU-HKD27!2G=LHO:M"QTJVM:UX'6VC
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M.#KS]ALIQ6@6BZ#FR6^H*42R2Q6)DCLGLI*TQ5>OR;,2':NH%PJR.91F/DC
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MD (#FA:C7%W\;DO5A0;9]TAVY#N \_%R(]7)1Y$3$3,)N2$$3"0AA$A1$I1
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MLT/+4BC'55=+5<5+2)T%#MTB' ^AP$3 ()F2^(3<F$X)'.F(F$3=!SD$>#&
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M]?)K<.IP7H6RLS[5<\ZVCX=V8AYYLM$'J  $1?6(>H"\=(#_ (#'D X#@.1
M. X] U"?H)Z0L#]8\*<@%U3,05DD5*CU9)47.8N222Y+Q0]%\;;KI!;8K;P[
M/IXJ'AVYA#N%GH "/_SZ>Y[^9V'F% ?_ (57GD '^$4Y#XS<Q_8-TAK_ ._X
M75[+G-7_ /UV,6_1G&T>?(=AJK_K.O,P_!W9AY_]\] [%Z0'VV=_%X$.D/\
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ME(<!$07,(#QSW !/SQ\PY#D [>G :QRL).ES@= 2171RW=2X-&T>HB;B@L$
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M-NQ9M6Z90*1!NU;)I(H)%*4 !--,I    "AQK=E2),E(3)E2Y:0  $(2B@
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MF#T^1A !,'T$0 1]> TA%=(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(1PF$
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M>,%^&_C5\_B;MEO,D/(QDI*13R//NXW;2+QG(UN#K=LFR+,8K*C]X8*S4;K
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M+IV^D'M,A7+Q\Y<G$3KN7;A51==<PB=950ZAA$QA'3WPB8   #@ X .P 'H
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M:@$*\K,0D9M7MP\5< ECU.Q5*RA!OW,5-A6[&PG@A9-D8YGT9,!'KG+$2S,
M()F#U=-8C<2K/6@*BX:I2PV&G+79J:=YNT8SQ28"0$O]H!B20!J=S0L!0 @E
MV8E=PT,W561<V"F(JHJ6 %DUIUHFJBK4FY'MI:+)*O$G)'$ T63<RS?RTG40
MT,DO* !C&Z\1(<L+=]=JNQI2A[R]8J.*8K,0)%.T7.:H!(%ZA]&#@&N8@QKM
M<O$KP9C^:>UVU6Z$83L>T;2CJ,1=1TLY)".\DQV*V,\!8J640/'O+5()@H!5
M2K,X5C,3;]E%DC73(\;6TU].X#T\Q&9/$L40'P^@L+ABHUH'J ] U6% =C(W
M<(SF:T>XP$G6[-5P:/Y-";K,TUG8=^PC%5$'AV4Q%++L%")NB*-E5D%#IM1(
MD7J6ZP7-D2 R7 L*D#[H))O?9G%=1%!Q1;LI!!<@@&B2[%+A3]DT%=O'3UOX
MJV+D:9$9$L=5RI3*9:<76K,-&G+90Q9)9#I%(JS6ZV,:HA%V*=<&L9*F[&>B
M8"680<A(Q[1^Y*W<'C';,MBD58 FU12_<"*6MI>D9TX]1T/@:N12Y(%=0"'O
MK$XX\WJ,<@6H*$YIMVQY=EJN%SC*YD>OH0+NQ5))^WBY">K3B,L=@AIAO%OG
ML2UG8]O/C+UU:<@UY$I8V;8R LHLPL&;WO=OCXM&(\2F@DY0V8@7L]#0_@-;
M,3'KSN\JDP.8*/@=_.1896O\%8[17ZFR%TY<?9ZL,U'<G,S:RAFB4-%K%34;
MPBSP[-U-R;)^VC$'H1TVA&LH.GN-G T&^Y%*VO4<2G&R"UGJ'+&^U 5 7L"[
M@'(;+N>C:E9JU5)E=JE,VMI99=DFF515E&URILFSBP6N?<B_;A"5>(<.X^,>
MRKP"%]\2D2V2*!)4!;F!T3WMYTT(M=Q6UH?6<T?L$N'_ &F&QN#8.0PIWO'L
MU[<-%6YFO*U2P5"T1;&2=QCQ_6;"RL#%I)L")B]AW[Z-D%FC629K*)^UL554
M9%,73$H,"MQ<D+#!R,H&NI:M- #X$;,PBWUE-8'(:@$ /4,>9O0LY() J'B#
MLO;_ .A85L"=>MS*S/UV-?CKE<9&K5N1L4)CVC2=C&LL+I?9%B9%."@G4XFZ
M:(+@#B0<LXFQOPA!8P$FZ:VRBO9%PU[#N#=]K 5>)&/FEJ&S$ %W-79P010%
M-:*&I$>4/B)8]-9)JN)QMO<&BU<EMHF=9U&96KM\G\--5E,D5*B+I*KO[%8:
ML9I)'?1B+*/&25@IIO6U[,6-?B:,O)-ZT]_<>3ML7I)Q\VE%:4L]S]ZFG?S%
M(V3K>="V^OPEHK:\;+UZR1#&>@Y9BX.Y82D)*M$7#"09.VRITSD61437(*2@
M@(* )3" @.F7<#5]!2[4L!5P6J3%#Q4COJ[DT8L;'0T\*C?V_O2FA]6K$?\
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M'-,SF&0WT[<R0TQCRUT&T8]KMWI=8E\HPUDHDE3?LCD6\(7%K%6FFLC27OR
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MN P;=L#$.!B*$POB]-0#$%,Y%"T>"*8#)B(B0P&]2"81*/PB/(#I")I !
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M<Y-;&@$!/%C4L'(#AJ,U]1KW:.K:G:7CV?Q9MOQ+1;84C2Q0U30--1Y3@L,
M^F73J<4JZ2WF+ HE62/T8%NH10Y"M(Y!) WDI)<8S?8/I4,^EMJ::$1JS<JV
M9*02[G* 2Y=S2Y+.7J2SG78T $.HQP#GY@'<.>>_'8.W/IV#M] UC S*)8 "
MXI4UOS^4:P27;4DWTY=PB\  0 > [ASZ!JAN>\_&!#$C8M#@/H'Z@U$(<!]
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M!'Y:0BND(:0AI"&D(:0AI"&D(XSE,8AR@(<B!@*'/U^8_+D '@.P@ ]Q$>>
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M=(!54.HZC5A(B@4I4EE52J'#V?D$^DQ@Z )SQIQ&6J=PK&I"1,F3L+-HH!1
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M0[_(I0] #A" $( F$"E 3\"<0* "<0 "@)AXY-P4 *'//   >@:0BH  #R
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M\D7_ +O[M(0Z0_DB_P#=_=I".,4E.>0, !R(E#D0Z>?D' <!^?C2$:L[AXW
MDA<-LHYJDEH^R1N>XQW@%!)Y.-0F<SEIEQ(PBE@B&CAJX;'JBMK="C-.&\;Y
MJ!%#\.6[8I4/7KURL8VL(8#D(<# 8#%*8#%#@I@, "!B@(B( (#R "(\ /J.
MD(NTA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0T
MA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA%!*4W'44!X].0 >/T<Z
M0AP'T#TX] ]/I^C\VD(IT$_(+^R'[M(0Z"?DE_9#]VD/Z^.\5  #T  X].
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MPMPF<(4%$X64P.5+2Y94I9(1D4Z$I2OK&0 5DE18E)O?J\*6_5RZAVR).CW
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M4\9-(T%&V%B\@&"L)*/J-3((FJ=.5U KS+"=*O0NU26<D$*9:9.&=R *ER0
M2Q8T#&M0WCW1%VYO=P^W(*K'>PMBK[6;O;C(UQKQ;'77-97M+^+*B^6K41'8
MUJLO%B<[J6.VD[S+7F1CXN1+'ING@IJ*J='A_"3(E*"5J 0,B0%*!"4T8DUJ
M$I=B 2'9R -F1+("GKE<,KEY%A2U *#8XEN-SAC_ # SHT30,>W#&54QU#A6
M*;1GN0(2WU*M5XS8SB<>QK5CCBJS*MNLUB,M.6FVV.:D7LY(%<L#(G:,&29,
M&$P4Q,]YDW/,S**UI2I#J*C5*5+60!0,5JL25$J+XPE2IC. 'L+EC4,&&[WJ
M0(V/B_$8FHMAF.OO<9-Y&IY7VV4_!2$0^M)B'J-MIN'4\.&RG O3UE,"R,G5
M4I="8JOL";5_'232*<V9FX@V[Q?5G< 5,Q*EIF]GVJ=.6 FBTS)\V:9:@7(;
M.!F<**D))[*E(51>#!6HL "5"P+U-,U:'PKK5HQ2C[Y$\74^K4.@X_GI.J1-
MWEK1,0.5,F$OL6A7[)CVV8UNV.\<"RI]:<XZKEFKUPL!+$\24DII:<9P3M-X
M$FU53'*K@04LJSE/V0"GLD9)B9DLDOVC+6@% /92ZTL<RH>RG3=A[Z-1PQ%C
M2C%ZQ&M/S3A2E1F4JE!XFR:%-RM2H^GS*CO,$ O;(MS%Y)J5_AY-G,)X?-#%
M:QQZNE%JMCU0LD8BCY=9\9RP;*EV5\.FE$@&<09*@K]M22!*F2LH&=T?^0G,
MY)#I:I;*J64H K1(%#LVH9R2P(9B'9A2/%MV:<;9 IE(K]GQ=:5['BRERV-L
M=6&-R-$LFYZ.:6F9NH1]\@"T1 ;!8J@>PNT/><%(4A*Q1+=DT70:*( [4SR,
M"M"E%.(6RR"05+<*2D([*@MLF4"A2259E/V@!$M)U)-?VFT=F#JW;,W/2-8B
M](E*/4/< 'N85![A\U/+1\P?^?Y275^-Y9.>D-S(H4-2*$DN21<UK6]8V6:F
MU*6I%-9 D,' =@]!"*#SQV_G^O'YN?\ \@^7RU*!+"G40VU#X-Z_ O7KU^0>
M0] $?YP[?]O?]?U[Z"6C,HYCE*B0*FA)( %F -+69FA%P 7MR;@1#\D>P_/Z
MA_VZR&5) S%9K4 TOR_K:EH @NVA;QB@"'<0$.WRXY]?UAZ:Q%4M)[ "N\ C
MWCT7A%!$ $ ^8_\ GVU'6(#A24YE.104S58=P+"U;/&$$YB'/VSK2I<#N8LW
MA 0 >.#>@]^!^?T'\X?/0A"F:A0,JF(#D7);GJ:TK%RE3GM$5H*VTU$5$ ]>
M?T_3Z\\=N.>>W;T#].KY$!1)(8RDJ -0ZASU +]\2IPF[EA4/YT]_.+0$.D!
M$1^0=Q^?/_\ W^;UU3]7U*"_:*V>U-02[FGEO5A4+&KZ?"KUWB[@1X#CCGL'
M(\"/KP(<^O/YQ[_]FI6LJ6 3D2EDC(2GLB@L:TMRC%B)LV4J6F3)3.,Q*5*4
M4A125!)+.DD,2W<-H^MG@8E'\*#MJYX$#?>J'KW'C#U_'U]> [!P'/'3QV#M
MKQO3U"_JPS4S%J24HEJ!42,R5 *+.Q)RES=CXQAXLA"<"ZVSE *@6)"LK$ 7
MH0KNH'TC^BFB/6!!*<P"4"]91$1#\7OP CZ"("'?T]0XX !^)AR 2*D/XZWY
MQX4$&S4V;\(N#@#*B*AA#CD/B'L!N_P@(\ (=@*)>W</F.GKUZ[H ,]2=N0]
M:QK7:-V^WVF7&?HMGR?&0L]4I:N0%O%[&V'[/U*9MR,.[K3&TW!*'"HUQU)M
M+!!.D4)FR1YO99-FHH0PNRB")\#I_7F-VY[-&Q*2PJD*H50%"%#I$2*]9C%*
MH!1[D J2BYE4SMQ* HF(<%0#SN"\HFF_JO+N-K;&+S'-Z>88#"40$3B).DP?
M )A(4I#@3H**GF"043"(GZ4B]@1$1K6<PX\N<3;+#7;?'.J[2):T0UGLK@7$
M97HF0IBKIK:RK3$B1E%K,ZXY:/6$Q*M';N'CWT>Y]I5*<"\H>OQC!*]NNV\V
MR$N-C@,MUQU!T&KA=[8\=+NX<(RCJ(KKM+J"<VTBW4A2WS=B]68VZ*2<P+[V
M5P#26=B!2G0_+TU:1FU@S3C>JT*.R=9K@SK](E21!HV8FFS^)<2#J>,1*&BV
M,0_9(3#R>EU#E0AJVE%DG9%^=".;1+V17!KI#U3\_?[M([..<MT/+D,XL>.K
M;'VN(:24C R1X\CANYAI^+531D8.<A7J3.=K\[&@<#NH&:093)RK)JE9E2X!
M-ZOZ:'JWI_7<)%(J;K,*ASB/</@$I@+R0IRH^2D90ZBW ^:/E\B5 2B*P\<F
M0B\RA@$?X4H '(B AQSS]!,X 2 @/*ZP@!BG;F)Y8B7@-(1894Y2CP8W4)RI
MDZP,00$PB8@B50X@L7L/()#YYBAY!@\XARZ0Y;>KZ_",=KEQK-Q;R;FLV*,G
MFT189FJ2AXB0(Z3C['7'2T=88-=RB<P>]89TD=N^: )#MG21RG,90!TA3?\
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MB<[5N@0F9/#)2$]A(&9*0HE1+@"SJ+L')KJ5*#$DJQE(J&#;:,? 49FTL P
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M"K!5#ST!3X(.MGV:6B3*DA *)2$)2"' $L )-222PJ23FKF!#OD*0P LP8
MAF 9F84H!0:M'<QYGK(.+JS9*A7$Z<^JMMGJ[9)>%O% J5ZCS6*J)3S2L2B*
M=OA)9./EHGWW,HL4FY?*=MURNUU/-74,;47@):IG6Y67EF)"DNFDP(4H$((!
M#H21F<ACE(J8J$(>B 'NR4N:"]"U'=ZG?2)9Q+]V&>LE.);/V2[5!7VR2X2+
MVZ34;&66'EGWM*9T$95D[.S;-H_A)NF#)<5HAHU02:(-R,VR*1?@OTN=(/I.
MZ%8*9QKH/POAO$.'R)Z?:\.K#XR9BE@2CF2!+F +<AR$T4HD@&@C[ET%Z/\
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MZ0-V*0X!U=)A 3>H /81 !'C7]$906D*45*622JI*FJ: DEAH&T (T;\.+(
M",S9F)2"P<A_LT -P:<K7C^V8NJ%RM^.;W/-G+BPXH<VU_45D7CP&;56Y5-U
M39Y1Y'(*%0EDE(1^HW0*Z(<[5UYB[<0.!AUD!=C0/785_"*L -2P9[GQ+5)
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MW2]>9CV7.:LTNYZ&M+S*V4'=HKK!Q%0%D<WNS+ST'&.P5*\CH>84FC2$8P=
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M&]?GI"/-!\W57>-T7B:J[%9('2**B:JK8RJ8*D2<HD6.LB843%<%*L1#S4C
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MY_;OSA[3B/W\W^-7SBX=O6"1$1'"^)Q$1Y$1QY41$1'U$1]S=Q'3ZSXI_?\
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M,/';YF ##]3  ^H!I"'03D3=!>H> $W2'(@4PG* CQR/2<1,'T,(F#N(CI"
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MPXDI6'EVAVF*%)B2H._NO!-+5E5RN6T[M\JH7JCV-R[-%*.W:U*8IN64N]5
M\@QD%EC139PV4,[,B&N=]GYMY6<UB8\*[':;0G-JN%R1A+3E&0RO?,C5*?=S
M%OL-8K<G:B*-ZY)EH\[8"U5Q/1#-VZ,H^]V%ENI0ZD?*)*G!72&G=Z+_ "ML
MT89BC9QD& EK(5_)T7!M6EZ9)5J4KNW^2F)ZHW:R+6F#LB>228=S)4+'BS$"
M[-6+F"(U2JPUL,*=ZF?>%G-+14(X3 $?B>;OW5K;WB!J1<:@:MI>K!Q1MJB-
ML&6%WL)AG(&*V5TE;2\M5:M\1'S]HAJ'#J-G%GA7,4F1RRQC1*-73-DW"PF,
MH2#]M\D  0]" /KT&]4@*/[G[FW>E.\O&G65=F^7YVM5"L4>PXR63?[9,9[;
ML@OK0M:4/<Z..+5%6A.T4M&(A94UD]\+$EXA:.L2M=0B5_<\BL[EFZSZ#3#U
MI\3[JQ!]=^G]=(QEQX;95*(^@D2XH2LZVW#<!B-"R%K)O:$[UEO**>08"YG<
M*Q:[_H@7)GIGKTZBTNC,KJ.D4G8F,_,>C<_7F+\VNU9:HY OH3MRI6_<+QYS
M_P .^^3\['I3TKB4M7J.126%O*-HV9=67+D7/;N\:;FYT<LL'\25FG,5.'HB
ME%IWM,M<VT[*3,A97;FHQL@$&F]>_ONT!WM[[ACX5V/(6::MP>R1MFV_9#MC
MAMCX6=II&U2G0+>?@?;WT"RP9GVPY3M35,5(Q8C9I:("71K\0V:"5%9TDLV>
MD]B H:0Y$@?GW/>T:[6?PSK+(Y<G+J22ITS3K7>+:_+2_MYE/&\=CNMS6329
M'0G:Q'X[08(3T\N_6<-+!7UW%;:$?1M?GBVA0PR#15Z]>^#5YZ>X[/LVF^C9
M@Y\-A,]!?P#9/%"-H<;;L]XC2L/V= RPWS+61&]WAKFM(#"^W*MX@Y7;=\_,
M490'RP*HM7*1C.Q>OG^/QY1'?7U3Q%/?:C8JCX<M_E96+;V5SA.*@ZQEZ7O/
M-<CK ZE,OP5TWBTC<Q,M\LHNX=-,D[48.C>X:R@U>6*/G9R:D7[J1@&0NV)T
M2WHD>.PT_#OQ[(/ALY>R?E]]=)BQXC&E*7&U22+!HK*I%GJ'/9NQ9DZ&JSO'
MD%28C'\"[@8/'#N'E)M1[>9G($\["P6*79-U4JXR6-._NLWYVK9WB&Y!C0DF
M^A+>5*EKVCV[)X9EE>Y9FKDC)4V:H]LNEN=FI WS*F,(S'-;F<K$R.TG*LPQ
MLV12L,XZ4<NH^=K+MW5(])_$UN:^UAS%?M3N[W^OGW1+5U>@%+/JVKO44L"]
M(W#E]FF.[UGS+.7,K1+&Y1-QA<1QD'75;#<6<<V2Q^TL7O)*Y55I.-:G:&3U
MY*-19-9N%F$UD/.*Y!0JBG4AK\#WWU;;0-O>-.V/AD6!.SS:D[*TJ=8)9IB,
MCL[18+SE&Q2-MK3S=-1MP-B@;1C"1:%QY".BQE7"K$>-%;,WFYAE'S)%J>P5
ME8;0;:>'Y> \HBQ)U).[[5O?5O%V<R1<-BU_LM"SSBEHYQ#&0]]N]CR%4\BM
MAM$9E&Q&L>;XK,X8QO\ )04;'+P&/H].'1QN=U7)>TKS%=0@)!"$@5H%: DT
M2WJMO/2K:#9HP^)\-J4)"WA1=#&L18K5064)$)N++?<I$I%O#.*F6)*887G(
M$0A-&3?MC,%G"T/$5TAK'[8[95UBBH5R" %3W!K[GOT/+7D(GA#:O>8S:W6<
M$JU; E[/3[Y/2I:S=T[,SIUMJRMLM4Y77Z-FAX-2>Q5DAD2:CIT;+!0%K;Q$
M[$N(N)*8)/WW%(AJ!F=[,WP'-A<TK2^$T'9WF"CW.I728?XFRDDDU6B'E>RU
M)7Z\I8-K['+SS*U?;XCL]IC9BV7I]!)298-M,VU]37J+JNU:;;/21\&VI[A6
MPWM<D^N_DT3SY=S#U>VY-(PN&\/6ZC:Z2ZLS[$*E?QK=<?ND31,7-GF\MP=4
MS%)957M>5F+Z/6C#Y#0*X;,8YLC(V9(LO)6"PFLS0DZ6O(/7KU^;UM7SMWVC
M*<%;![9B7(-ZL 9 ?5M9Z]R4I5,J4:]V>9O\E'9*R@GD-U&2F-LC5>QX>KIX
MUNBWK[QZDUOCV8]G1E87[ LR.(*2?*GG7P_&%>5ZZ. #N^II^.LK;HMMF0\Q
M3<$_JS#%LN]84I_58')UBL5^QAF7%%ED4UT5+U2[UBR-7>6]@\2=1\J[QJZ<
M4:"=3,$S%>PF9OGQ8U\OGN]?ZPUY4H:,U2VX/??O81B;91E ]7SC0WDMAZ=+
MDMU:+'&9HLL%)JY;GINT25$F'E/MT8UAF+!AC4[^J#$3+=G9)A*:K;F-AQK+
M1.)06?@_YU]5KJ33O@/P/E?F=-*;L+8:KX=5JMC7,LE:9O'%+F\NXPSS58R/
MQXUEG\+B.?S#)8\,DWI$BK$5:6<5Q5E0%0LS]DPK,W-2]BF21K%DW75=.X;G
MW.V[U/)SK:G.%1?O-WTM=G&E2[<XQN1\/#(_V':HU:/Q=4LDO;#;';F95S#E
M>^Q54^T4!CJNFETF64J)=Z;D^-DXK'\4-AQA:,;UF)<LFD.SA+= RJ,M<Y2=
M]7WV\O5K0 T=@+$:7;F?*E*4$;'9GVD7:[V++=SJ,OCE.V77!^ \4521L-98
M*'C_ +K,C7JYW=(BCJK7*-I3&WU^V(0L+-,Z];%J?*IDFF5?<NF,.S5'ERO[
M_P H=]?7I]^4:NX]\,2]5Z RNA99K&#BRW2+<!2'+=U:K<XQ^^?9_D<UD(RM
M=IAD;(]7CVSA&,-9T&S!>6E6*;U6&:E'RFSX5IS+5]?UAFW- ')>SB(/JVR_
M+N7;!)UI"@LJ!%X5KU3A8RVV&/R%B22SM*U+/,KD!-K>[3%PB,B+B1C7#Z5/
M<<;K9.J$79'#6T(6:S/Y5S"U]Z\-/Q@'LQ:SFY)?Q[O=:/HVGLW<_<UMVQLW
M+4XP^'LE3F1)9@O-7&]1" 62GY>A'\-7;'<_;K.\.SGLCM7B,D_3@&8,XY=:
M'C(#H9QC:/?W_P!(DAZ'O!VU!J?Z^,0HV\/FY0\;AVN0DAB5"(K^--I=,N<^
M:(EH^U4R7VKW@,A2$[AU!"*.59#,+YPZKUJ5DY.MO82/;MIP5;DX<#"(2?EZ
MI[_?K$ '0\O>S]H%KZTYV,<$9X;0QM!CJ\U+B=G9HS;+A?#R-B0K ('1OF-\
MH.,@3EQ2=IQ"3M-I+MW#<S:1*)95&1%4!,3J,834'CZY'2_@-3%S>C7HQ>PL
M:T<<M:@3]>-KMZLV>'UG9S]62Q/;,MX0S[:T7II-&_Q]PP9#-H6(K4"S304A
MG<%:G5?J\K)33^:C'4%[-,Q3>!D59U.2B%V?3SLP\-/Z5GN'/9KNUWT-==8C
M'*NR_)5CRIDW(]4982G8ZXWU_;XJLY(;69./>EN&WBN8*L![*1C4YGIEJ<]K
M'VMIRJ:$@:QMK19ZJ^?4X'+.=5$5\J7'K7O[@RX'-[AKG5V^3<WC9>[[?9.=
MV<R6V=E94Y6=)@5+$+.WV1,ZHO9-O2PJ!;!) "KI9-67<)BY6X<+JB@Z7266
M4*8YCH1K;G'8W=\RS^4:NM=*9"8;RG<WF7YB9*2=4R-#7P-M3K;NWB8^, "0
MCNI(+)PEZ7G'4ZQ?(N&#VL_9]RTE#3[*;^?Q]4B&9G\'O:_OOS$;#;?<0Y7Q
M_:;_ '[)*N/W-HRN]IK:R,Z5)V)>&KD-C"AQ],K2L2I+P#!U+2%B>HR,W-&<
MH0[:LH22$$16SECRRBL1.]?SK2]?3MMN(7CI+QZ=(<?B^G'_ #?A_9^'Z=M(
M1=I"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"
M&D(:0AI"&D(:0AI"&D(:0AI"&D(:0B,,MY!+BO&^0,DJP=@M2%$JD]:5:W56
M9I"Q3A(*//)'A8.- 2JNY>131\AH4A@+_">800-ZO?#W<^^/D^Q\4"[V1J*Y
ML<TW"<@EBZ:R VIVXA_=*Q=[O)0ERME0)5Z57H2NR3QV>9D:F8T*Z0-8',HY
MG6D6SAG+MF+5\]?A\:<F,'\"*DO3>]*AGWJ(G3%F]6]Y2R!?:VG!XKK\E0W[
M])7!+RT3SS<9,'BL70&0'+%C#G8M:XUFBO;$6LD:O!72<+QSIX99*-4:'(A4
MMW.QN!5_?Y5K$G;7-U5ASFK:6]CC\=)2->J</97D!1+'81OM1E'ZLJWEJ!?\
M8Y%K-+R!7[+$.H84&DN\A&<+85C/6Z"<2\AG"2CU[V^-.^#Z/M1]=O)S4"D3
MO0LR&O!; L[QEEG':5>8ED%%LD5)I!I2* ^>/D0AXZ:GU9-R@5FZ<J(IMCB
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M7R'9V@VR$N60\J067AM#"0A))Y3+=78F3AO9Z;#VV"L=3;5R7)8KG)V&LV"
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K#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(1__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>img129881027_11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img129881027_11.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )A N4# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ME_[XH VZ*Q/^$KTO^_+_ -\4?\)7I?\ ?E_[XH VZ*Q/^$KTO^_+_P!\4?\
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M2VVVQFB*QR[U.3A.V<]CVH\<Z%J6L7NC26%MYRVTS-*=ZKM!*^I&>AZ5K_\
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M@#VR: -&BN>T+6=1OKZ^AN=.N4C2Y9%D=H<0@(IVG:V2<GJ >O6NAH ****
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M3M3M[*:]M [NR3%IU4PX4D%A[\#MUK9BECFB26)U>-U#*RG(8'H10 ^BBB@
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MS3?[1DN98[5;NWFD158,&(*,$ !4X';/)]J .EHK/CU:&30%U?!$)MOM&#U
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MPL=2UJ:X>:2".:V1$4YV[PJ\ G &6R:OW.MVUK>7-J\<[26\"SMY<>[<&8J
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M9?(OFL+@@8$BE]J/CH&!*YQZGVQU% !1110!4L/^7K_KX?\ I5NJEA_R]?\
M7P_]*MT %%%% !1110 4444 %%%% !1110 4444 %%5[RY:UA#I:SW+EMHCA
M"Y/XL0 ..Y'YXK,;Q-!Y FALKV=!")IO+1<P+DCY@6&3\K<+D\?3(!MT5DKX
MALS/,A280QH6$^ 4DQMR% .XGYU[<YXS6I&Q>)79&C+ $HV,K['&10!5N?\
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M')%UW=X?M]3%JWF7&Q8X-X^^[!0"W3&3R?YT 6DTNW2:_D.YQ?$&9&(QP@3
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MR+)$T;(2,@%6 (XYK.'B.&XU2WMK%6N(Y(I9"1$R^9LQCRV;"L#DC()'3D4
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MR#<R_99<A?[^-OW./O?=]ZEN-?TRVG\F2X.X%0S)$[JI;&T,P!"DY& 3SD4
M#Z4EG821:)':Z=*6#@QP*$8@CA@!T(&,]1GBJ4&DWUUK8U+4$M;8K;/;[;.5
MF:0,0<LY52,8X'8G.:FU769+.X$%O$CE7@$CN3A1)*$  '?&X]>,#KFK+ZUI
MZ6QN#.QC$IA4I&S%W'4( ,OT/W<]#Z&@ LM'@L9C+'/?2,5VXGO)95_)F(S[
MUG6'A^2&^EO#!86#B-XX([%,A2V,R,2HW-\J\8XQWS6M;ZI975E)>1S@6\98
M2.ZE-FW[V0P!&.^:SH?$/VO49X;.VFN(X[9)53RC%(Q9B./,VC;@9S]<9Z4
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MOZ9;3^3)<'<"H9DB=U4MC:&8 A2<C )YR*@U769+.X$%O$CE7@$CN3A1)*$
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M;.WCGF#?9K=SY<"[<$I\HR20#C"CD_CFW'AS4;J.[WBPBGEM)()+B'*F[9@
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MWPWJWB'^R_[+M/M'D>;YG[Q$V[MF/O$9Z&N_J0"BBB@ HHHH **** "BBB@
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M* "BBB@ HHHH **** "BBB@"I8?\O7_7P_\ 2K=5+#_EZ_Z^'_I5N@ HHHH
M**** *>IZI9Z/8O>7TPBA3 SC))/0 #J:H:3XKTK69((K>5EFGC,L<<B[2RA
MBI(_$'BH?&5BEYHJ2->6]K):SI<127)Q'N7H&]CFN.\&6P?5]+CN]8TJ46 F
M^RPVLFZ21GR6)]@,T >I4444 %%%% !1110 4444 %%%% %.Y_Y"=C_VT_E5
MRJ=S_P A.Q_[:?RJY0 4444 %%%% 'FOC#2]0NOB;H%W;V-S+;1?9_,FCA9D
M3$S$Y8# P.:M_%[_ )%.U_Z_D_\ 1<E=_7 ?%[_D4[7_ *_D_P#1<E,#Q6BB
MBF 4444 %%%% !1110![5\3?#>K>(?[+_LNT^T>1YOF?O$3;NV8^\1GH:[^B
MBI \ ^)'_(_:G_VR_P#125RM=5\2/^1^U/\ [9?^BDKE:H HHHH **** "BB
MB@#O_A#_ ,C9=?\ 7B__ *,CKVJO%?A#_P C9=?]>+_^C(Z]JI, HHHI %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%>;?"G6]2UNXUR
M;4;R:X(:$JKN2J9\S(4=%' Z>E>DU,9<RN;XF@Z%5TY/5?Y7"BO)O^$%^(7_
M $-7_E0N/_B:/^$%^(7_ $-7_E0N/_B:GG?8Z?J='_G\OQ/6:**Y/QMH7B'6
MOL/]@ZK]@\GS/._TB2+?G;M^X#G&#U]:MNR..E!3FHR=EW.LHKR;_A!?B%_T
M-7_E0N/_ (FNM\$Z%XAT7[=_;VJ_;_.\OR?](DEV8W;OO@8SD=/2I4FWL=%7
M#4X0<HU$WV.LHHKR;_A!?B%_T-7_ )4+C_XFG*36R,Z%&%6_--1MW/6:*\F_
MX07XA?\ 0U?^5"X_^)KUFB,F]T%>C"E;EFI7[!17)^-M"\0ZU]A_L'5?L'D^
M9YW^D21;\[=OW <XP>OK7)?\(+\0O^AJ_P#*A<?_ !-)R:>QI2PU.<%*51)]
MCUFBN3\$Z%XAT7[=_;VJ_;_.\OR?](DEV8W;OO@8SD=/2NLJD[HYZL%";C%W
M7<**\F_X07XA?]#5_P"5"X_^)H_X07XA?]#5_P"5"X_^)J.=]CL^IT?^?R_$
M]9HHKD_&VA>(=:^P_P!@ZK]@\GS/._TB2+?G;M^X#G&#U]:MNR..E!3FHR=E
MW.LHKR;_ (07XA?]#5_Y4+C_ .)KK?!.A>(=%^W?V]JOV_SO+\G_ $B279C=
MN^^!C.1T]*E2;>QT5<-3A!RC43?8ZRBBO*OAOJ>MCQEJNBZIJ4]XMM%(&\R5
MI!O214RI;G')IN5FD9TL.ZE.<T_A/5:***HYPHHHH J6'_+U_P!?#_TJW52P
M_P"7K_KX?^E6Z "BBB@ HHHH Y/X@V[W&A6_EV-Q?-'=QR?9X4+!P,Y#8[8S
M^E5=!OM/FU>W2'P5<Z=*<XN7LE01\'^+''I^-4_$[D:M>P"R\42"5HW,MA_J
MQM7HAQTYY]Q4'A>+;XAM6%MXM7!;YK]LPCY3][C_ "<4 >DT444 %%%% !11
M10 5B:AJ&H_:[R+3S:J+*!99!/&S&4G<0H(8;>%Z\]>G'.W67?:)'>W$DHN[
MJW\Z,13K R@3*,X!RI(ZD94@\]>F #(M?%%VUO)+>)#:^9M,1N(VA2%2Q!+L
MQPX V_,N 2P ]1U2,KHKJP96&0P.01ZUF3:%;RHVV6:*4NC)*FTM&%&%5=P(
MV@$\$'[Q/7FK]M;QVEK%;Q B.) B@GL!@4 5+F>'^TK0^:F$+AOF'R\=_2KX
M(90RD$$9!'>J%S!#_:5H/*3#ERWRCYN._K5\ *H50  , #M0 M%%% !1110!
MQ7B/Q?J&D>-])T6WAMFMKSR?,:16+C?(4."& Z#TJK\7O^13M?\ K^3_ -%R
M5E>-_P#DK'AS_MV_]'M7JE,#Y6HKZIHHN!\K45]4T47 ^5J*^J:*+@?*U%?5
M-%%P. ^)OB35O#W]E_V7=_9_/\WS/W:/NV[,?>!QU-=_7E?QF_Y@G_;?_P!I
MUZI2 \ ^)'_(_:G_ -LO_125RM?5-%.X'RM17U311<#Y6HKZIHHN!\K45]4T
M47 \5^$/_(V77_7B_P#Z,CKVJBBD 452UBSDU#0]0LHBJRW%M)$A<X +*0,^
MW->1?\*A\0?\_FF?]_9/_B* /:J*\5_X5#X@_P"?S3/^_LG_ ,11_P *A\0?
M\_FF?]_9/_B*8'M5%>*_\*A\0?\ /YIG_?V3_P"(H_X5#X@_Y_-,_P"_LG_Q
M% 'M5%>*_P#"H?$'_/YIG_?V3_XBC_A4/B#_ )_-,_[^R?\ Q% 'M5%>*_\
M"H?$'_/YIG_?V3_XBO4/"6CW&@^&+/3+IXGFAW[FB)*G+LPQD ]".U(#:HHK
MB/BG?WFG^&+:6RNY[:4WBJ7AD*$C8YQD=N!^5 ';T5\U_P#"3^(/^@YJ?_@7
M)_C1_P )/X@_Z#FI_P#@7)_C3L!]*45\U_\ "3^(/^@YJ?\ X%R?XT?\)/X@
M_P"@YJ?_ (%R?XT6 ^E**^:_^$G\0?\ 0<U/_P "Y/\ &C_A)_$'_0<U/_P+
MD_QHL!]*45\U_P#"3^(/^@YJ?_@7)_C72^ -=UB]\;Z=;W6JWT\+^9NCEN'9
M3B-B,@G'4"BP&M\$_P#F.?\ ;O\ ^U*]9JI9:5IVF>9]@L+6T\S&_P B%8]V
M,XS@<XR?SJW40CRQL=.,KJO6E52M?_(**^>?B9_R4+5/^V7_ **2N3K)UK.U
MCTZ.2^TIQGS[I/;O\SZRHKY-HI>W\C3^PO\ IY^'_!/K*BODVBCV_D']A?\
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MEC@:>Y2%KB1=RPJ>K$=.W>N8\-ZWJ<_BBSD-XCV>I-.1:+&%\N-.%?\ $@T
M>E4444 %%<CXH\77&AZF;6""!DBLGNY7F8\\E450.^_&?:I?"&LZM?W&H6&L
MK ;JT\IM\(P")%W!3[C_ #ZT =31110 4444 %%%% %.Y_Y"=C_VT_E5RJ=S
M_P A.Q_[:?RJY0 4444 %%%% '%>-O!-QXAN[74],N_L^I0;$5I)"B*BEFR-
MJE@VXCG-8'_"$>/_ /H:/_*A/_\ $UZI10!S_A#2M8TC29;?6K_[;<M.763S
MGDPFU0!E@#U!X]ZU=4@N+K2;RWM)?*N98'2*3<5V.5(!R.1@XY%6Z* /*_\
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M_G[+0!ZI17EWACQ/XJ7QU%H&O3*[,&$D92/*'RRX(*#'IZ]:]1H *X#XO?\
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MW1Z.1_PY^H4445@>X%%%% !1110 5]#?#/\ Y)[I?_;7_P!&O7SS7T-\,_\
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MB1;GCM9 BM#O&!(2#\N[ICO^%;WA<Z=_:.N"V%T+X77^E"YZ@<[-O^QCI_\
MJJ+Q;X-/B1A-;WQM)S%Y$A,8=9(]P8 ]QA@#D4GA.V2RUC6K>XO9K[5@86NY
MVB$:$%?D"@'L,^E '5T444 %%%% !1110!3N?^0G8_\ ;3^57*IW/_(3L?\
MMI_*KE !7E?P9_YC?_;#_P!J5ZI7E?P9_P"8W_VP_P#:E 'JE%%% !1110 4
M444 %%%5-41)-)O(Y;D6J/"ZM.6P(P01NSQC'6@!(M7TV>[-I#J%I)<C.84F
M4N,=?E!S5RO)5TRTTC3=.@UG2XX[5)T:#7M*E0L[$Y4MD;L>_L,5L'Q+J_\
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M+E8BV,MCO]#6O/K7BG3+S5-$2:/5K^.T6ZMIA L;8+ ,"@."0"2![=\XH ]
MHK@M*\3WMO#JLMUJ@OC:V9N/LUS:?9KB-P.A4  K[@G'%5= \1^)KC4M-FN%
MO;JTO#^^0Z88XH PX9)!]X=.3V_.@#T>BBB@ HHHH **** "BBB@#RO_ )K[
M_G_GUKU2O*_^:^_Y_P"?6O5* "N ^+W_ "*=K_U_)_Z+DKOZX#XO?\BG:_\
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M:?RJY67=37']HVY%KRI<(/,'SC'7VK20LR*67:Q&2N<X/I0 ZO*_@S_S&_\
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M.?J%%%%8'N!1110 4444 %?0WPS_ .2>Z7_VU_\ 1KU\\U]#?#/_ ))[I?\
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M@ HHHH **** "BBB@#RO_FOO^?\ GUKU2O*_^:^_Y_Y]:]4H **** "BBB@
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MZ_HSK*\F\"_\E=\2_P#;U_Z/6O6:*Z)1NTSYZC7]E"<;7YE8****HYPHHHH
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MSZ["?[O3]%^04445)T!1110 4444 >A_!S_D;[O_ *\'_P#1D=>WUXA\'/\
MD;[O_KP?_P!&1U[?771^$^2SC_>GZ(R?%/\ R*&M?]>$_P#Z+:OF.OISQ3_R
M*&M?]>$__HMJ^8ZSK[H]'(_X<_4****P/<"BBB@ HHHH *^AOAG_ ,D]TO\
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MG;_8O.;9"CL6WXX+ X_(_AUK.?6-8?2;>%;R-+Y-5^P27(A!60 GYMAZ9&.
M>M '5F[@%Z+,R#[08S*$QSM!QG\S4]<Q>:K>:-?O%-<M=QV^E27+[D53(ZL.
M> ,<<<<4TW.KZ6NEWMUJ(NX[R>.&>W\A55/,Z&,@9X./O$Y'I0!U-%<]H4NI
MWVHZC/<:AFUM[N6".V6%1P,8);&>,_XYJI:6\T?Q#U&5K^X=5LXW,96/!4M)
MA>%S@=N<^I- '645QIU36$\.KXF-^&B.)C8>2NSRBV-N[&[=COG&>U=D#D T
M %%%% !1110 4444 %%%% !1110!Y7_S7W_/_/K7JE>5_P#-??\ /_/K7JE
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M45<8J*LCAKUYUY\\]S)\4_\ (H:U_P!>$_\ Z+:OF.OISQ3_ ,BAK7_7A/\
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MJ4444 %%%% &!XUW?\(E?;2 WR8STSO6F+<:CI6O6=K=W[7T%['(?FA5#$Z
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M29OM<?EVZ GSVR?D..Q&:J>'A!_:]L5\#OIKG/\ I148CX/MWZ?C0!W5%%%
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M_P#-??\ /_/K7JE>5_\ -??\_P#/K7JE !1110 4444 %%%% !1110 4444
M%%>8_"'5=1U/^V?M]_=7?E^1L\^9I-N?,SC)XS@?E7IU3&7,KF^)H.A5=)N]
M@HHHJC **** "BBB@ HHHH **** ,GQ3_P BAK7_ %X3_P#HMJ^8Z^G/%/\
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M_K=W:VMM=FP4V$=W-)'&KNS/P%&X$ #!SP3TJ%-<U'R+>&25?M$.L+8S2I&
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M"$*PF6-GV!]Q."<X.W:.#UK6O/$NDV%Q/;W%RPE@ :54A=RBD9#':IP,=^E
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MYO[CR=NS?('^]N.<8QT%=910TF.%6<$XQ>CW"BBBF9A1110!4L/^7K_KX?\
MI5NJEA_R]?\ 7P_]*MT %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10!3N?\ D)V/_;3^57*IW/\ R$['_MI_*KE !7ELOP:C:5S%KC)&22JM:[B!
MZ9WC/Y5ZE10!Y7_PIG_J/_\ DG_]G1_PIG_J/_\ DG_]G7JE%%P/*_\ A3/_
M %'_ /R3_P#LZ/\ A3/_ %'_ /R3_P#LZ]4HHN!Y7_PIG_J/_P#DG_\ 9T?\
M*9_ZC_\ Y)__ &=>J447 \K_ .%,_P#4?_\ )/\ ^SH_X4S_ -1__P D_P#[
M.O5**+@>5_\ "F?^H_\ ^2?_ -G1_P *9_ZC_P#Y)_\ V=>J447 \K_X4S_U
M'_\ R3_^SH_X4S_U'_\ R3_^SKU2BBX'E?\ PIG_ *C_ /Y)_P#V='_"F?\
MJ/\ _DG_ /9UZI11<#RO_A3/_4?_ /)/_P"SH_X4S_U'_P#R3_\ LZ]4HHN!
MY7_PIG_J/_\ DG_]G1_PIG_J/_\ DG_]G7JE%%P/*_\ A3/_ %'_ /R3_P#L
MZ/\ A3/_ %'_ /R3_P#LZ]4HHN!Y7_PIG_J/_P#DG_\ 9T?\*9_ZC_\ Y)__
M &=>J447 \K_ .%,_P#4?_\ )/\ ^SH_X4S_ -1__P D_P#[.O5**+@>5_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MJ*J?V79_\\?_ !X_XT?V79_\\?\ QX_XT 6Z*J?V79_\\?\ QX_XT?V79_\
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MI_9=G_SQ_P#'C_C3)+'3XMOF*B;V"KND(W$] .>M %ZBJG]EV?\ SQ_\>/\
MC1_9=G_SQ_\ 'C_C0!;HJI_9=G_SQ_\ 'C_C4-S:Z;9P^=.FR/<J9RQY9@H'
M'N10!HT54_LNS_YX_P#CQ_QH_LNS_P">/_CQ_P : +=%5/[+L_\ GC_X\?\
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M?_'C_C1_9=G_ ,\?_'C_ (T 6Z*J?V79_P#/'_QX_P"-']EV?_/'_P >/^-
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MN666'4)%1@)$V9E^4L0"0#W]3GED=_(]HIUK4KNT(LE:R82M"TS[G^; QO?
MC^0YZ].:[1[*-]2AOBS^;%$\2@$;<,5)S[_*/UJS0!P-U;SW^CZQ=:E<7@F@
MDA#1+=2)''^[B9_E4@=2QYZ=:EFO+IM;>*"]A0K-#]B\W491YL.U"=L84B8'
MYLL23[C%=S10!Q GBFU6P^T7LS:F-4<26S3-A(QY@4^7T"XVX;'.>IS70Z!D
M07J YB2^G$?/;=DC\&+"M5U+(RABI(P&7&1[C-1VMM%9VR00J0B=,G)/<DGN
M2><T 2T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
F%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>img129881027_12.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img129881027_12.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ([!4T# 2(  A$! Q$!_\0
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M;S4+JP@\)%[JUQYT?]H(-F>G)7!_"NX0LT:EUV,0"5SG!],T .HHHH ****
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M<R7&FJ#(NU?WA() 3GD\=\4 ;-%4]*O9-1TR&[FLYK.20$F"<8=.<<_SJY0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!POA?\ Y*/XJ_[9UB^)S+I?BG6--MQM;Q!!"L1
M. Q?8W3VW&O1K71K"RU*[U"W@V75WCSI-['?CIP3@?A1=:/87NHVFH7%N'NK
M3/D2%B-F>O .#^- 'G'AYKC4?$FD:9,&:3P]!.) 1P7#;$Q^&S\JH06=I?\
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M_#<*VKO&L]RL4SH^P[,$XW=LD#FM>Q\&>'M-OQ?6FEQ1W .Y6+,P4^H!) _
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M>CW.DV5WI)TN>#?9%%C\O>P^48P,@Y[#O44>@:9#?VM\EMBYM8!;POYC?+&
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHKB==NM?A^(?AJ-KR&#1IKF6-;:#<7G(MW;
M=*3@8!'"@$=R<X  .VHKAE@F\5^)O$L,VI:A;0Z8T=I:+97<D 1VB#M(P0C>
M<L  VY0%Z<G.7IFOWWBZW\&6-S=S0+J%G/=7[VDK0/*8=J;0R8906;<=I'3'
M3J >FT5R?A&ZGBUGQ'H,MS-<Q:9=1_9Y)Y#)((Y8PX1G/+8)8 DDXQDG%=1/
M/#;0M-<2QQ1+]YY&"J.W)- $E%0VUW;7D9DM;B*= =I:)PP!],CZU-0 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MPRC21-&2,X^ZP!'3N*X3Q:=6O_BEH.GZ9#9N]K83WBO>AFBB<LJ>9M7!=@.
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M4DVV]N8GFBBV,=R(0&.<8&-PZGO7,>(;RX\*>%M#T?0C'#<W<]OI=K+(F]8
M1RY7C)"J>/7%9D%AJVG_ !6T&+4]9.JYTR[,<KVR1.IW1;@=F%(Z8X!'.2:
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MCK-BIC2[\@2)(C8WH\>1E3@'@@@]#4WAKPXVA+>W%U?OJ&IW\PFN[MXQ'O(
M5551]U5 P!D]^:W:* ,:QT#[%XJU?6_M._\ M&*"/R?+QY?E!AG=GG.[T&,=
MZS(_!/E^!-4\,?VAG[=]I_TGR?N><[-]W=SC=CJ,X[5UE% 'GGB^"RT/4]&U
M,>(&T._BMC9_;I;(S6TT0(/ER\@*2>5^8'[W6LGPWH>J>(?#_B81WDDMKK6I
M)F^NH_)>XM@J+*R(HXR RKD#CFO6:* ,7Q/X?7Q%X4O="2<6B7,0B$@CWB,
MC^'(ST]:@;POY7BZ+Q!87GV622'R-0A\O<EXH'R$_,-KKSAN>#BNAHH \+U\
M0V6AZUX5T3Q-=[9GEAMO#QTS_20[L?E5VY\DDEMVW[O1J]9U305UGP9/H5R0
MAN+/R"PYVMMP#^!P?PK;HH XJ.P;QMX-M[/4'GT_6M.F3?*J O;7D6,.H/#*
M<Y'9E:I].\(ZK'XHLM>U?Q%_:$]K;2VPB2R6%,/MY&&)!^7G).<C&W'/744
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MPDFO_;_(^U?Z/O\ (SL^X<8SSTQ745S^D_\ (W^(_P#MV_\ 19KH* "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O-T\*ZVGB.6RD
MLK1M$.KOK37GG#S)VQE(2A'4/@[LXPHKTBO$?$/A_1KK6-0U/Q/IES=7%CK
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !7 I)XP\5:CJ4NF:[;:%86-[)9Q1FP%S),4P&=RS  $] .U=3K^AKK]
M@EH^HZE8!9!)YNGW)@D. 1@L.W/3V%<M%\*;""6:6+Q/XKCDG8-*Z:LP,A
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MQP*'Y[X)P?0@UU%[]L^QR?8/(^T\;//SLZC.<<],T 8^D_\ (W^(_P#MV_\
M19KH*Y?PW]L_X237_M_D?:?]'W^1G9]PXQGGIBNHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HKS_7_B#K-A
MXY?PMHGA8:O=+:+=%CJ"V_RDX/WEQQQW[U=\,>/FUC7+W0-9T:;1-9M(A.UO
M+,LJ/'TW*XP#C/\ GG !V=%>:CXH:KJLES<>%O!EYK6DVSF-KX7*PB0CKY:$
M$N/I^E6M4^*MA;_#<>,M,LWO(O-6%K623RG1RV"K'#8(_6@#T"BO-+GXFZ[H
M26UYXI\$3Z7I4TBQF]AU".Y$>[H650"!_GD\5JZ[X]NK;Q%_PC_AK0)->U..
M%9[E5N4@C@1ONY=LC<>#CT- ';45S/@OQC#XOL+I_L4UA?65PUM>6DQRT4@[
M9[C_  -=-0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>1RGPU/XBUV+QEX
MGNK348KYA% VJR6T:6Y ,6Q591C;C/4YSFO7*\FL[R#1-8U^*]^'VN:HTVIS
M3I>IIL<OFJQ'=FS@'('M@\9Q0!W'@Z/0(]*F'AW4SJ%IYQWRF]:YVO@9&YB2
M.,''O[UT-87A6_M]0TV66W\/WFB(LQ4V]W;+ SG ^8*I(([9]JW: "BBB@!L
MD:2QM'(BO&X*LK#(8'J"*JW&DZ;=Z:-.N=/M)K$!5%M+"K1 +]T;2,8&!CCC
M%7** (+2SM=/M8[6RMH;:VC&$AA0(BCV X%3T44 <_I/_(W^(_\ MV_]%FN@
MKG])_P"1O\1_]NW_ *+-=!0 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M8(\[Y9%1<=<DX%?4E>6^!OAU?:?JT>J:TB1&W.88 P<ENS$C(P.H]_I7J5#
M****0!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MT"#_ . \G^-=E11]5J?\_6'M(_RG&_\ "0>)O^@0?_ >3_&C_A(/$W_0(/\
MX#R?XUV5%'U6I_S]8>TC_*<;_P )!XF_Z!!_\!Y/\:/^$@\3?] @_P#@/)_C
M7944?5:G_/UA[2/\IQO_  D'B;_H$'_P'D_QH_X2#Q-_T"#_ . \G^-=E11]
M5J?\_6'M(_RG&_\ "0>)O^@0?_ >3_&C_A(/$W_0(/\ X#R?XUV5%'U6I_S]
M8>TC_*<;_P )!XF_Z!!_\!Y/\:/^$@\3?] @_P#@/)_C7944?5:G_/UA[2/\
MIQO_  D'B;_H$'_P'D_QH_X2#Q-_T"#_ . \G^-=E11]5J?\_6'M(_RG&_\
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MJAAZD9)NHV)S35K!111769A1110 4444 %%%% !1110 4444 %%%% !1110
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MW'N,BMRM$[ZH\^<)4Y<LU9GF=W\((%?S-,U>>%ARHF0,?^^EQC\JJ_\ "/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M ):L-S_]]')K7HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MN8?*NL?+<Q##_C_>'U_2NCHI-)Z,NG4G3ES0=F>--;^,/AK*7@;[?HX//!9
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M3>>WX  ?A7145G&FHNZ._%9C5Q%-4Y?\.%(RJZE6 (/8BEHK0\\J2Z5IT_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MS6Q_X^=&GC]?+E#?S K1@^+_ (>E_P!9!?1?[T:G^3&NXGT^RN<^?:6\N?\
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MSQ7/V)M.('G?:?\ GF/7USZ9[\4:9\0M53Q)IVB^*/"TNB2:F&^QRBZ6X1V
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M?ZUZ%16G)'L>=''8F.TW]YY9-\&(@VZVUR5".@> ']0PJ(_#+Q1:?\@_Q-M
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M2HU8[Q:^1I44Q)HI%W)*C#U# T\$'H:9D%%%% !17+:_\0-#\.WWV*ZDEEN
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M]Y>ZE<+MDOK^<S3,O]W=Q@<#H.PJSX8\(Z=X4BU".PDN)%O[I[N7SV#8=L9
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M="PMQ?-$UV(E\\PYV%\?-MSSC.<9J>BB@ HHHH **** "BBB@ HHHH ****
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M'5E(!Y!QD>O)JL?!.FIIMG:VL]Y:W%I,T\5]%(#<>:^?,=F8$,7R<@@CG@#
MP 4_"@,/C'QI;Q+MM5O8)5 ^[YCP(9./4G!/N:ZB]EN(;222TMOM,XQMBWA-
MW(SR>G&3^%5-%T2VT.WFCADFGFN)FGN+FX8-)-(?XF( '0       "M.@#E_
M#<MQ/XDU^2[MOLTY^S[HMX?;\AQR.O&#^-=17/Z3_P C?XC_ .W;_P!%FN@H
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\N<3%3-\ISEL?-@\>U:G_"*I_P!!G6?_  *_^M0!OT5@?\(JG_09UG_P*_\
MK4?\(JG_ $&=9_\  K_ZU &_16!_PBJ?]!G6?_ K_P"M1_PBJ?\ 09UG_P "
MO_K4 ;]%8'_"*I_T&=9_\"O_ *U'_"*I_P!!G6?_  *_^M0!OT5@?\(JG_09
MUG_P*_\ K4?\(JG_ $&=9_\  K_ZU &_16!_PBJ?]!G6?_ K_P"M1_PBJ?\
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M (15/^@SK/\ X%?_ %J/^$53_H,ZS_X%?_6H WZ*P/\ A%4_Z#.L_P#@5_\
M6H_X15/^@SK/_@5_]:@#?HK _P"$53_H,ZS_ .!7_P!:C_A%4_Z#.L_^!7_U
MJ -^BL#_ (15/^@SK/\ X%?_ %J/^$53_H,ZS_X%?_6H WZ*P/\ A%4_Z#.L
M_P#@5_\ 6H_X15/^@SK/_@5_]:@#?HK _P"$53_H,ZS_ .!7_P!:C_A%4_Z#
M.L_^!7_UJ -^BL#_ (15/^@SK/\ X%?_ %J/^$53_H,ZS_X%?_6H WZ*P/\
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M15/^@SK/_@5_]:C_ (15/^@SK/\ X%?_ %J -^BL#_A%4_Z#.L_^!7_UJ/\
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M_H,ZS_X%_P#UJ/\ A%4_Z#.L_P#@7_\ 6H WZ*P/^$53_H,ZS_X%_P#UJ/\
MA%4_Z#.L_P#@7_\ 6H WZ*P/^$53_H,ZS_X%_P#UJ/\ A%4_Z#.L_P#@7_\
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M_H,ZS_X%_P#UJ/\ A%4_Z#.L_P#@7_\ 6H WZ*P/^$53_H,ZS_X%_P#UJ/\
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MERQ31-%)$V,X9' 93@@C(Y!!KR_PQ<Q2^&_!,<4,T5M!KLR.)+=XER1<;,9
M!&2!QT/'45VNE9/Q+\2%/]4+*R#]<>9F;\,[2OZ4 =71110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %,FACN()()D5XI%*.C#(8$8(-/HH YO
M3?!EGIUY9SM?ZA>1V 9;&WNI%:.U!&WY<*&8A?E!<L0,^M=)110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %<S?>!["^N;LF\OX;*^D$MY80R*(+AAC);*EANP P5E
M!QSU.>FHH 0 *H50  , #M2T44 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &7K6A6^M
M?9I&GN+2[M)#);W5LRB2(D8;&X%2"."""/Q -.T71+;0[::.&2:>:XF:>XN9
MV#232'^)B !T        K2HH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@".>W@N45+B&.55=759%#
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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K HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>img129881027_13.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img129881027_13.jpg
M_]C_X  02D9)1@ ! 0$#O@.^  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #I E<# 1$  A$! Q$!_\0
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MFY*NH#$A2&AT6]0[D=/J#6+_ -)']IK35;'O%HMD'->=)$IR#M\WL[#U]/V
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M0M>507:]WP-W( K3=O;6<^S6HN6KDLTZNV;E%^XD5_P9M8L*P+!QTQ"SZDD
MC )S^'$4A52SH773TE='JW92Q9 @1WXD7#HA']H/S!:TS[;WGVH/_2K34TU
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M8=%*?O34M>.2KE2YH3<<-<.7^(366J45].EU"9VGW1U)1IQ\7TIG\8+=(=\
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MFCK,E'F%/;\HG_"<J/09^6#N",G;(&^^W$IWV(ZCZUCH7L2:]2GM7T:<VO\
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M(TC @8DAH?U;&[(H8I<E2_98T(92K#E)@"7<M",]H=AG).Z=^WO5,W$#BU1
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MN(F%FYKXUVK=((\T#R[*DFZ#U/5$;8 'IG.Y.0-R3\^,/($HA7**RDB[AP-
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M.= GVI?M&77G_P!?UD2CDC6I>4?2.7*6K3J,(K9%[4M^9U19WG5A8V=7E[<
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M+ENB2P"DDT;'PMDFQN01ZC<_,C&?K0@! L1Z_,:%3Q G!]/E'TJ$W\IXJ_\
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MW''Q8!)JX=KV>_>VQ;WEB2C%F1+I7<W.-1V3ZY:<.,Z9(QRXZ0:_3*%/EM5
MG;WVC.D.G4M=/=T*@YK7YS*/W<"51+')BD;CW9K:7;PEH[/]H%TP'("Z7C[H
MMY8A!$X(8."XUN9S70.;#E]B_+3JS-=$FO5-JU7<=-U:=C73^$H.QLDBONK8
M)$V*E77=R1(G!$A=HLWN@CKB[M#O4%>.U%J&#]]]K>P$G1;V+"]WD&60/37D
MRMZ:;)OHG!<U=V0]%9HL(O)4.[2L2*DKDVJE2!7\$U4CN(<VP?=#O\7C&V79
MT*>G>:IE&90[]6<CHS#(4WCXD=2M-<7UM@0HE*9;<;;Z=;VC';6)-'^K 7-/
M0I$P<]Z6<.I#1OG :=\MJCD$(1A%?/-#(MO18X*E$B7K7=0G:4BJ\HO+P@;$
M:9D;$:A9\4JZ9M9D90L;><DEL;26AHP#D^'B]]_A!0/R@IA3-KGEAZ,[#TJO
M(KZ2U>K;+:SI[R8I+BFRA\Y,F2IDKD<_ K5_6HU.6O)P[#'I5N_-'=V,Y19(
M_.\A>P-TIG>DLAAFN^G;4X:8/48>T^H&BZE2G!7JS$71*I4.212B2$+D*["E
MM<G,9:'4JUC21\)4.( @YWU*G'L-A29Q^&4GW85])3EHY@F'F;Y?-&M?XPGN
M6&+5F%,$G[?5;56;Z%4M3A+(VM3]D;1Y[1N;:<C&46#GT.AZINI7;'=JA)RR
MF<),RJ+V:Z YMEEO5@FW182J"HO6\$[=6E"7JOIW Y.P^2([^(D @0& 6,RS
MEO3 15J*5(DAQ$.P?UR51*+KE!N7U5FY?'G5*D]BV/-Z91^JX"OI ,8_1(^N
M^1Q7,R2/P2.;'>HPB #^0#R<;5 Q[>3D/N\T/+?3K[IBQ5+-<^7&-KWFZWH+
M 4.6H^B04A5*XP2@_7G^'+A[V1G/A'V9(TL^>\ ')1'1$_?\^EJT]ED@^XL_
MY=Q5%YKDTB3-ZM"S2%R;&Q[LCKD*%>H3I%:<) GZE2F(R' (<-O=0 #4#D9W
M,PME>V/4/D1=Z;]EK&.>2*T$]FM53;L4J*#T^0#?Z7;/TW)\.V2/M#<8P<<0
M) LI39KX5%TT9WU]4[O3FN2"[YG.CRBV?MXM<R^AH!I_R?\ A,C9^GT^>,>O
MS /$N+X+/E8<((>R%#45CH"B['Z_N)KZNW&Z44J?[]_I?V\*O#(W'O4%OMUK
MRBURD0^E/^=K4Z[1),;>Y*C^1FHQQ@CY9."1ZG'KCBG_ !:23FR(O4O9:S_U
M%0J(9 )E2"=H,HEZK82I8IA5HTHK=%ET4-CAINS/='3!8V,"-*C53]];562*
METB>W<QL.8<<%H2K0,D <9,'TV0W*(<JH:<G)A/5U&!T@_\ E:BSE/Y4I)SY
M\S<5Y8V.ZY-NGK1Y$YY@I<AN!/[MZ5HU20&-=4A.[QJ(M"9C:VS!'QJQUJ(#
M022+>Z]$(LT)ZEWJJT*PLCY11E2NH 1*^@9 ('$=,(;%]/X$P-T6A4/9T$<C
M,=:$U*1L9&EM3=*A0)4GTL#; &0!DY/%IICN;TON%*'"E#A2F?<[7-G"^2OE
MWG6NLS2WG>IDM)VB'Q%$1W.=:C2)34@A4.;2?T0Z/6>Y*A_1#/UCP<A$>&IC
MOOUII<QWH/LTU3"DDEFFLNHTOUWYEWIZU U=EIZF6)HPD5*T^F<1:,*JH/IR
MF-3CV6,QYD6 [MKOW9W]Y'=V/J:@NOO^ N/7-151+&X]0=@RYAP:6U^1H;\;
MTQ=[+)U++;4ZC/O;*$J1D<Y&I2/L;C;6YRR5H4I*)P[(%#=VQMRTNQ'W0T?&
MN[L% &2VTRK(!]_6D'&ZT48CR:1O*V*2B_)XW/HRQ:?124)AJ5%U*)A:$K7J
M;+.M1N,=1-T>9':5%KB <J9%+OA:6FGXOQ-&>'Q_DX/Y1: B8LJFQ&,W!KFX
M/ \7^6?,^&I'ER#.@;-@Y^@4C=']F3P1O8'%.ZE5$ID\RUND9;RC:WAHG;%'
M([VM4U(49180O;$0UNG<<- D2P!V:.J X\/^KO/>+Y?Q?@_PL?\ ]U/G0J6
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M.J//,GITRT*;MF[>-FFLI0>F5VZ\*5*C&ZE(,@X;@#G/IDU'&X'!\0<@EK;
M:).U&S(P0'ON3JL;U\[CVQO(Y?Y&.;A^MQ5&;&ANNE]XU.T>K\&6YI3+7/,J
MT[/_ .<(@]J\$ @F./$<S@G[.""%UF,7P -.J$5I0NV6S]JB@%B_<^Q5:N F
MS^9MX\CU5 X V'J3D8.,#\.(%0F-3ZK!9T<![!@IUG) ;'\<CE%L)/-\5?,U
MH7>NW*[N$X_]9D0! &WB^@-6X]"-\\0!W&7W*BP!>QNXJDA$=+J6A"WUPR5]
M6WC=2BE3_?O]+^WA5X9&X]ZA9]LT@1KN77350MO].C9->V&2*JZ?U@)XY ]4
M5?R(_NDM6WI\O\8&F![=/N>A1VK)G"IG_P UTE!88"B14[U'7EMM,5AP5$EA
M@_>W-8>J\AM?I<7:=.27IEQZU%VONWVO09.<_/C*.%3)WV-MG?>JLH'M W4V
M5;HP*VJU1[!+EMM:4<F*/7)^;J:-2^;%]4:JOZRY83VUB>#HU2QGTG8=\DH1
M%TAD8P=W:1K!OCBHG?XDU9T0W,P[6]7AJG4M?S=/[_\ B/"I63A2API7BY7X
M*35C/R'T^9W_  V^7KZ?CPI53?VR6MJG67G#AW+LA0U2" <KT403J6-:2X?/
M6ZR:HM2KW>ZG.4%0A^GH2N(;')OW,M69/]$#A?.\+LO:6J&/M_DFA0H(5 4.
M4!$=+Y?G< D%NTFM/6GS]&S4S-<PCE;HQN:QG5U!X2OS;(F96$.>A6>C:Y;Y
M[.&?-7"0%3(N[7]OS4#1[D+EE)DA5#2Z"M^>S>1:E:3Z6OCZXJ5:S3N6S;3&
M=/"5'T3F_NSLVI-1(#)Y8ZLZ3HC(5T*:)5&Z7-QSAW@B,-/B[L>"!99#^ @:
M+RK0]5T1,:SZH"75&?2N;OP2IKYJ-^AR1KF)G56EZ.WY"=L7D(W#L28KP5RU
M^1($25MSD=W=RK.#Z<:7PN/@"%P2C$@Y)!N5NB( 4FN+C\+XAX8_F^&_E_,0
MMX=BANVYS2\CZ(P;52W%7)M:IXF5J&^'35A"E4GCLYC,NRFD48I5/*..+F)P
M7,3P6URJ<6YG,1EOR^Z#3Q\^_5@\/Q/-?"/BT?[,)")(L\-T62HK^K?X(^</
MQ+]#_K[]*HOC_$O*^1^4HK^5"!BAN[.+_*2"L=%=#75U:.9Z3\M>J%^>Z3Q+
MEEYBV^=:0S='2U<U>C$M>-'IY'(HQ2MKZ-Q&K$+*UV<6Z-3K3)Q[2\82O#OX
M7? 'N?"\7^=X:P'92RGV*9$&QK^:/.</A^3\SXX/_B!YMRD '^[YB#DB& O8
M\.TO3HWB#R=NO+X:Z+7C3Z(&"MX=%3TIF2_WH@BM2Q0E2S=QZYQ*#;M@<F:0
M@>\30S#N_>&CCF^4^$SA+@Z(NN""KL0H('Y?#P_/XA\P&-Y?YI!>Y?5%W-7=
M:-2JV>\\QEK8'>,Z>M^F,B;H8K3TH),HCBJ1]5)Q 4",QV+.!9 H;=0^W-O9
MW9W6!Z=P"\$<$^?Q/YOAR?\ Q3JI<VG2,*1')P\9'B?TQ4>#Y818*B6!"@9Z
M$NIYNN9T+&^WK$QAZUHM-,1D*^TM9^EU)9D\=:RSTZ=)FM>C*U<4/O$2ZND+
MD;N'@HTA[0"D+/QY?]6?#?#\UY;^=Y1O,""07*!Q"H .6U?:?X0?KC_8?ZB'
MP;S2<7P?XG_P?F_*(3Q9*W!1D11S2I?O9@^S(@>HON]SB<PU$<U&LVE/E\OF
ME7;$XA<&;X\M6-M4YE;0$712C48O212&LN1=FB-M*)(2"\>$,O8_37Q'Q?B'
MPT<7B@%"T(1&QPCG,5^+_%SX!X'Z7_7'Z@^ ^#'"?)'B*?,G]1Y/A\V.$@J$
MXN'S:F6L06LHVA2;5O-)  !&V?E\LX^>"/78Y]0,_O #@X4$ %%ZU\O']PX+
M(B 1">\^M&?&JM8_*M_XO^VK^WA2H@/:5^S/2<WC>T:MZ/+8]I[S3P:QT3)*
M7:CPQG46,_X1!-2NA25K5B$#+A%WW!=HX[CP9[.L=:>%$51FV_W6JLC EFCB
MBF,;NMTC:G:-2,0[5N(HCT:B)2Z#*E?4F1Q-EW)CBU8Y=M<RW=HRK2#U'!EY
M)R[13<HJU"MO35T6'1 S.B.@L*D[#>2++Z1$LK^\+*9TKH4K[R-1TH2]T3*D
M._:.A1N1#8?Z8=^K.,=IP/?+J2M_1*2"+V=#]@A*+U)I_,DY6H,S>S5T"Y@)
MS;U&8M4= -2]3X$YIXA;AWGR-JUGU-5IH4IU@3O+BY&'QN.EWB<CI=)$/?F(
MM#N:>SEV>:1P<#ZGEB<IKLE "H 'M9UR;PD$B%)5D\J8VR)W&50VKI&XTR"Z
M[JE#A(&>,MZ<."-2C9Y8UQX(EKE]T1Z;]RBH$C[.[O :!C >:AP55W/??Y,M
M>$=K63Z+?"!,NJJM4UI4-VZ@2)(F[H/"G%:7IW.72-T6)DI*7JZELG<"R1Y0
MX.9;N\-#.T-/9_N<@'A<B-3^%BXD4D*Q:RKU( 0E$M!5V.F="^W^X7FAH0/5
M2R,2=4\VUMQCOL9C*QK5]2^CK5C:A0&.HNY.37G[V[PC)9^[X(!D?1L_C/V6
MHI54B^'/NS!]F7:D\G;7V8F[%XE&8Y>;V.,-+#*B91?>DR"(M92-:95WE]<D
M/0$4]P);HVTDR]V5N^V!EWCET3<VBJ2UT=@ZV7<Z1<T8(T:9J9HN_*T$@='*
M5]XNQL,CBG4)VR/QQT5,ZI5(DR!'[Q(E\B>TBAN;  S-':"K=P/7AZ:]W<?:
MKE\=^E_5*?=[-[FEN\J'-7$-+79DCC3IES:2QO@LENH[;FI>V?5L-O2:</SF
M^O#EXN@<ZDJJ*NC7VW =GF/=HP>[X)]MX=KV^D45;LQ3$V(7U^JV[Z ?%<N6
MK6?,R/G@9^GR!W^0^9X4HRX4H<*4.%*HS^UBY3;'*SSDR.01>0Q)3">9M=)]
M9&'3QO*E/*M.EQ+2SS5R*94 V!FD4I6*7%K<Z<9=W=<T$_9P8=.GO< 1R?--
MU8'."F[VIC<&O^&2([-U9739N7E"BZIKN=8H46,!.I*3P^KCA8>U  _>ZL?3
MBCOU]1VM352()4'#APP5U6%+ @U9#_)]D)0L/- @NV*+90RN!H:Z=B>K1-\H
M3*B?E^G;J_QC^X#@(XG5^'JA7[X= )HQ^4BXXDV^8;$X)+E%,U"C^4[BZ/:
MP.L4@4VN6"!G[%O8'^$74\>IWWV/[,XQDCC)SJEE*A&7MG:M?3T[Z/DFJ\C>
MT*G'JJK%Q-92H_%857U05$U=9CIDV$!<_O  @8; ,=%\SC(P0UI4LOJ6+7YT
M3&LW]W *M "U;:_)RN1] W-,HY[9BVJ%"QVNR#2_E[4.K<4_P"/"74C41,D
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M]T?Z+.F,':-,M/()ITQ)[:5E@<0B\-:DU&QH;XXV(V9(3C8GX(9VW&?38FT
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M.$/DU<([*-6>76/L4(8:RH;UBS633I*M7MB5,Z-)<2A7>]3B*?O'M)+35]\
M#Q54\WA?K3X=P ^+\4\'^D^(*)!<04/".)W^9V %U'#7YWQW^ 'QOSGB^6\S
M^D/&\K^I_(?%3Q+YP>=\AY7Y>'Y>+B'$>$\7"H*</"?E'%Q'B/#_ &CA^8\*
M=F\4IU&?X-HUH4B4/CSS$1F(1U!(G2)B-RIYU'A\8I>9K#X7)5*IM*W3J.%G
M32IS#DY-)+NC1N[N>T(V@.V?&_57F?-G^E^%>7/FO,(_G"  - 22H5"5 <V*
M)W/A'\%OTY^E/AI^(_Q%^/\ D_AB%OA'DOF\X?E"NGD^%00A X>$\2@ C^XM
M8RY-/9^V=#E<5GFK[TTSC4&&Q%AA>G3*UM/1PC26,,;44"9LB3;4:12N/Q <
MGT(&HUE8J-6'96]*W;]'X7^GSX7'_5_%?,CXE\0'#_GQ?+\O &CA-PH<75'*
MUY3]=_Q.^%^>^%__  =^@_@X_3_Z;'&OG.+YU\W\6(5_$"'Y>!4^4</%Q<7%
MPH"1PCY3*9:%L44"H7#X]@1C&X&!Z'&Q^1SC& ?0>G)^5W;WU9GS$37P\\+G
MAXI=>3VY1?%;0 %.+V/7[/U]-_T<[>G[_7Y< $"4K8XM*'"E#A2FY\TVE33K
MCRZZX:2/5EMNH=0M+IO&::G9&F<T3>O>&%:B:W/HE605[6O"5Q;3XJ<.R/Q$
M_,LS!B:'3OW[ S5&?1,+7G3V/-LGLLDK<D*IGCSG6I87UR?%\NJ<D4'2CN;.
M'%:QQ@(>HD;D^CM.6@%G^Z2L!+\][_:U.]V/H.3UV>[JY_ O(G7F5:^7K0OW
MJY?(XNU@T[:+</U/]ZGR6M"I)#6Q^*D:HE"R-"Y&_&6.66]W#N&E8S@[YX%L
M'*.B+B7$:U%?"FYG1X^X*ZV6^8[2W17FAY97+FD30Y2'#4KE:3KW^<Q%2JCN
MH+QHG2V)-;#IDFD*$![Z"1O;0E9'7MWWOVE8MI!.."+V,.O>CTV*7@J\<Q=0
M>E5%H)K[IM*84L?B\)&]7(&Q@D:V.QU&EOTL*A4^)4Z9L4PMH+B%K>@7*U4=
M+4W-[N[]G5Q[_K?O+N\.OHNJ%;Q(;%JA-A!2>J):50N#+J["/Z/ZN2#3)FEL
M\$>T.TJ4WEZF%J^8*VIB1ER@O@5S]BA,!;T9U+?%ZZII#BUMO;VAH=@B2Y=_
MEP]^HZ+H+)+YFAB^3Z,H5=42U9)&T:2%R:+5ZMU?M+6]>;#5%XG6E@4WE_=P
M0ZOKI-7E9))$N7R/HTSDZNA[0T-#0D1M+0T-(1EH![<Y^CG;"L0"*-M @ ,D
MP,/8P0:2^I-;1-=8Y-+FYJD-IMD=Y/#8E?ELC]_W!)&$?1I(0V1Q5&6%MCB)
MH)5TMG8NVO#PS@+0,O%+OPUQ^,\FYT*\M%9C*$+HE^5:[JFC1CLG@[:I67GJ
M/H'=CDZ](.KB(?WA4L[FFA2H'KNWQU=48[WUS#0SX1K.T9 X=]]_6H]V=L6'
M4P(F%6K2_LAI#=DGLXN52XH=4KNM8M.[\)6J4-?F6$EV#2=XAP:_UM81?:D3
M.F;A3Z_"^HI--/#IR[990YO)UW'>>>D"3#A2API0X4I#3N%1G4F&2K3N:-B=
MXB4YCCU$9,SK+?FV'1@DC6K:'AL5$#Q86H5J@#&,DC!!P2I7SU=7]$W[EDUV
MUPY5Y>XKGA]T-=T/N?*7.@)/>[21W:TKQ"7[J5ZKQ=P+&K$><@<D/#4L/S X
MB9ZQ*%L ]V-)A"X&0HA@CCWF4JQ'^3YU&Y%^96HT7K:3WA@'36K]HVTPRTO!
M7%.A!RE^. !LD_9&Y).W%SR3Z]ZFH&1#:=;(D!+5$!^4A66%;[2#2AND=E06
M7^+;!5[E81J^@<%Z9',=9U25L2N?;EG0KUJU'V[J1U=7QF^YSQ#SD8V$L7?I
M=%UW]<-'K*0MOR<[E^TXG/,MK=S:1N(2EC@VCL,;M-X2UR]X32%2PZNZB]8)
M$8](>C;J7L1^$HB#W'+NS^]PR!20. RG0Y)+;R2F)J?FQ:)]68]'N$(/%73>
M_-5I[HR+BA-Z=3N2J5YR0,[[9/X;9XT'_&7G\6$5"WYQI^;F:V+E^NQYU-N^
ME0W1?O\ DVUUK-5L>OIOANR%-/=?#GY8QGBN, K=5Z.UE1]EJ,<D)9$G+/=%
M;=*.&^[;MN":Q5:"8X/YHW%1%T @_K)Q3@8SG?T^9.RY"(QEU]@C,7YE*2C@
MN'A-Y=WC5 M+=>2&Y3Y])N6/*OV?+IW^63@''KG_ ,=L\9[[BMF^RYD:[X*2
MZ5&![8341S@?L]>8!8B=G=CNR=EB.F_7M-;:5Z9-J),8['I&H*AV#>C_ .BR
MMS']($9)!'V22-K],XTSR$5+D! UGLI!*2C% &F:HJ.%N-,MU%'I+I8H5K+<
MF<'1SU MS%T3ZB.T32,8"5A'1+)' PPHBKL2(.;>VEX\2RIJ#QX4PQ+ICV=(
M:S5;3.!=!*P7O!@ $&N:)&%6]+XO#W*J.QE8X+A%B]2]"]V$R#WB<NHJ,A5(
M4DB*&E$L=AXG-M#OAH5$ 58WM7A\,_\ 2)0D$@6<C?;0!C1SIVT0LZNV&?7U
MWU"9M)DDD?K.IKWHPG8UDF:4T>;%8229C;).C*)ZC*(HRXEM;VSN[Q$TH[.=
MN.+QN'^9X?C>$6;Y3%@=956*6AZ[WD/-'P/-^2\4%3Y?S7E$#H4X@Q(!0'0$
M@N 2GS/GG>BLLEFGVH&HW*_T.K\$;9"O?=5M8H?&TKGJ(SZ50YA1B*O\?BBZ
MEMEP:)$N22-RDS9'6XN[.[(TC3+NT-*+-7B?T7X'A>7XO,?!?$(XO'\KQ$%6
M*.A15*HJ#5A7])?QR\F/U!X'P?\ 7/A@CP/BWDOF\JO]PX3Y7R?">+A)<+P@
MHC_,A/"P%<QT(YKI&UPRO1QXF+FY\NEIX&H:1&\QU--K&C<G5JEOO#+TL=78
M0SO3N7A8H;M5M'W(=FD;0[R/M7:)<TL[O1[G^9Q\9/BJ!X!"$%H=5TAT<DH[
M_P N\/\ >1Q^(JDD@BP#F2@9')^4)PEK/JY?M*]3-+UW.;S/<D,LTY=)'I5R
MF:C6%4*B4V]YI5I)J)(5<$D+:("E2L9.I.D:Z$(W*1Z5/KDW?=&T2E]31+XX
M[%XW\WA>6\(L"DLJ6?)6R0$( 05CB_J/'\3R_B\!3Q_F583YD9U=]PY7_*GU
M?PP1#VL>K_(9RM:^Q>7-6K>FNDD&YFM797!4['5"9+$9WI0C<)]#Y"J*SK8J
M@D+XKB>.VUNOA>-J:1X<L_#P>)\O#\_F/EX6M8D,K@CA;(*":YSP?R_/>!X?
M@IXZ*Z*[(O"H4#B"$Y5'-/T]EAR]Z<Z5S;F?5Z.HY'7HM8U)L0"#2.7N7O#*
M'/L+F[2*7I>YIK#<>T^]#PWAK<CC+0E2"K=&'>KR7Z;X?ZSXU\?^, _Y^)P>
M&'5@IXBH'RE %T@ N*_H7^*'R_I[] _P]_1?GEX?B_PWR7G_ #WG?*$?*G^U
M3P?TG&003\W OFT'$ J*2/[?FG&L*+)JMVZ::Z::;!O"YY>$V,8QYF?KC?/I
M_5QZ_P +^_@\/C+J@74A#.?>OYW '#X9X^! #Q6F&]W0JY4R:-;]\6*<46JK
MA&WAH/AQG\3_ %Y^I]<\;J414/=I71>MH*0K-NM18NUV03;H&22=CG8;[XVW
M/H>*C+V>UO3DL;7E[I;TH^M6!38MVZQYAI _3)&-OV$_3(^N?PXE*V>%**'6
MW54F4U48N5"T/S1^F2,_/]OH?7.!\Z&(."*&#J".H3]JY[2VUN(H\5M1;J66
M/)65^:J\JA.<$I,9VR:OH,;_ +Z1E!<NYCD%)PR&4?(."4@*&OAS&7)"I9BW
M/=[,S1CG^:()?GLAET U!T]N]!'M4X$&SWKLQ!8Z)%SQ#U]+RB<F1>WK^C3.
M6'%N!9WCQO#3L33QGO\ -:F&8 Z@V0&2$-[D*"S-=5?R>?E'F2***H+J!KI
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MH<8_$_3Z$#ZA2LMNX*QCTJQN/E^T'Z;^GK_OX4KQ>L^;C?\  @^F-_P.^_\
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MJR;X];,#=2UC9216LWR)%$&=PI8HFT/DD>V=.B2W-16A3J5 9186*>J5)72
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M,'.$UOL#E&K,>V9T+-KFY]D]S16&E-9<$_-1IGH%,%E'2J1?L+-0XY.M/RJ
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MZV:BP'3J+)5Q9)4KIC"+4NNTF41?3#K$_3-LF<^N+<A14H>C[<Z,GO"TN_\
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M_P ']!OOML,+>T.%??U^TO9(,LS69MC>9KE^WQT>767;EXYA6A<RQU':5/\
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M^\D3B7<W)O):'=6.\'=W>!8#\^_>-A18F][Z"06YHL)4(O,MR]ZA<IFL<[T
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ME:-*\I'I$[(EB9-'E(0)7Y&J2^[_ %$@6JNC6975)ONYN+0[EH5K&D'!))
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M\*@Z.-P4($$EDL0:7)SU#T_T^A+2[MNG&I\^U#<Y4H=%<FUNU1A)?5L=B:2
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M$,PZ/GO/6L*D=';37J/*I3&]8M>+XG'E*\D#T(]38R,Y]=MABR7NO,NGK4+
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M%,?8W5GYJ-4:&E@3-EFVBTY3(U*5K<TJ9(V(2O\ X>7=G; Z]O+N[-%2MXP
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MFVW65HONEQ3H2^2-4K3%0C5*5/2O&H?0+EZTA5_2)J:<>$EIJW(B<]^?WB,
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M^D)4M'*S)OEA>] #^[2=3NEP&(DBO-JASZ<V^J-M^95&KB[2."/:EQ4J=,=
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M=L_O.X/X%.:AU ?0/VDS6O9;:K5=-=Q*E%ZH8%RTG%A1;3@[)3G)6?4@ C8
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M;J0W+PO7+C0?/3J4V/UM*E0TN1Q]20"3D$CUX*@(]1@<LH84T0L5Y$WR7P2
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M 1B6NVUQ4;\'O92TM4M.E?L*N>N7(T$MUBIT9Y180HJ3W'.4:\3]L42=/8)
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M=*$RR;#G]-WEDI**?8T>TX\/G6N3Z76/#>47J+5EQTU5*1?/68)_EKCYD]K
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MV3_"?>9RID5(>'=*DIJ.:0 !.S]N@S9J$ A[_78F"&.YBGI0OVOOM HF4_\
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MJ_YN%$X<C_3]J Y>%(Q]WW=OETIP?W>+;]@S^[8\/"XSP>)X 26/(#373[:
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M7[O^(<7AD;CWIQ_XGE[BL?\ A'_G_$XE:K8X4H<*4.%*'"E#A2L-'\R/W_\
L$>,\?^)Y>XI6;C5*U^.O2MCCL4H<*4.%*'"E#A2API0X4H<*4.%*'"E?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>img129881027_14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img129881027_14.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &[ _@# 2(  A$! Q$!_\0
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M_P">:I1;C<Y9XJ,*ZHOJKW^__(Z&BN0T34+J;6F>YN)/*>-Y-C.=JCZ5H?\
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MM;&2Z<KO)!VKCZXI<DAK&T))M/MT?7;IK\C3HJEI>I)JEIYZ(4(8JRDYP?\
M)J[2:L[,WA.-2*E%W3"BBBD6%%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MRRLCW\%7E7H1J2W=_P SO:***@Z@HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH ***I2WDTLK0V,2R,AVO+(<1H?3U8^P_$B@"U++'
M!$TLKJB*,EF. *BM)9IXVEEC\M68^4I!#;.Q;W/)]@1WJ*+3AYJSW<K7,ZG*
MEAA$/^RO0?7D^]7: *MS<M:S1O(%^RM\KOWC;L3_ +)Z>W'X6JI7NHP6L@@D
M5F+*"Q"Y503M!;V)XXS638?;H$MX+,R>:!_I,-S&PCC.#G8V..<  9&.0.*
M.CH[55MKQI)3!<0F"X W;2P96'<J>X_(^U6NU '+^)O]4:=3?$W^J-.H SM=
MCDFT6YCB1G<@851DGYAVKG[K3;XV]DT$4@>> 03#:?EP1C/IQC\J[&BKC-Q1
MQ8C!1KR<I.VEOQ_I',KILH\031)%(MN;7RED*';]P#KTJA;Z<((S;W.ASSW
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M)[A1^M7KFP@77KW4&B@GC:Q:^C3.^,R<!AD<, =QKE'O)Y+.*T:3]Q$S,B
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M_P#O?T%9-:VE?ZA_][^@H T**** "BBB@ HHHH **** "BBB@ HHHH ****
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M64>F-I[374EOO#QAY.82.1L( Q^M366A06EZ+R2YN[NX5"B/<R!M@/4#  H
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ IK_<-.IK_<- 'DOQ-L8YHEO>!+ 0I/JI.,?F?YUY9(N#
MD=#7KGQ(_P"0-=?5?_0Q7D_6/YO2LYKFO$]/ S>'Y:ZV;Y6ON(**];TY]5M9
M/"-EH]JKZ+=VL37VV$,DCL3YV\^PZ9_7I6=#HNB+HVKW[^'&N8H;F:"QDAFF
M+7!WMM.U3@(HP,]\>M<_LSWUCE?6/W-=VM=K;>9YK4L-M/<+(T,$DHB7?(40
MML7U..@]Z[T^$[ 6S7/]G2?9QX86]$NY]OVHX.<YQGK\O3VK4N=*T.TU+Q38
M6&F26RZ?I[.Q6]EQ.2JL PW#@<C!SFCV;'+'PVBG^'EY^9YC-87EO;17,]I/
M%;S?ZJ5XRJO_ +I(P?PJO7<_$R[66^TJVCA\J..QC<!9&(PPX&"<#&.HY.><
MXK%F7PA]BD\F77#=^6=@>*()OQQG#9QG\<5+C9V-:5=SIQG);]C HKT[P)=2
MV?@'59H9+Z-Q>I\UC"LLO1>BMQ6PVF?9/'NM>(&%E;K:VT9MFG<1H9I$ !<G
M@'KD?[0JE3NDS">/Y)RBX[>>[T\O,\9HKU22RO-#\8:K?:5:F?3KN%+DW5FJ
MS3Q1R$\Q D Y<'. ?E /%:>L?:;*7Q+J&D1;=6\FR,30P[I?+8_,2,<,<'(]
M */9B>8*Z26]NO>V^FFYXQ17LJMJ=MXTU@:?##::5!/%=7US%!NDE/E(3"H[
MY))P!D%B<\X/.:'J1GNO%]L--AM(I;&\N@C0XE3*C"Y/( !S@<9)H<"HXUR3
MDH]$]^_R_KR//:***S.\**** /K%?NBEI%^Z*6O0/SX**** "BBB@ H[444
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M&@"S15;^Q[G_ )^9O^_AH_L>Y_Y^9O\ OX: +-%5O['N?^?F;_OX:/['N?\
MGYF_[^&@"S15;^Q[G_GYF_[^&C^Q[G_GYF_[^&@"S15;^Q[G_GYF_P"_AH_L
M>Y_Y^9O^_AH LT56_L>Y_P"?F;_OX:/['N?^?F;_ +^&@"S15;^Q[G_GYF_[
M^&C^Q[G_ )^9O^_AH LT56_L>Y_Y^9O^_AH_L>Y_Y^9O^_AH LT56_L>Y_Y^
M9O\ OX:/['N?^?F;_OX: +-%5O['N?\ GYF_[^&C^Q[G_GYF_P"_AH LT56_
ML>Y_Y^9O^_AH_L>Y_P"?F;_OX: +-%5O['N?^?F;_OX:/['N?^?F;_OX: +-
M%5O['N?^?F;_ +^&C^Q[G_GYF_[^&@"S15;^Q[G_ )^9O^_AH_L>Y_Y^9O\
MOX: +-%5O['N?^?F;_OX:/['N?\ GYF_[^&@"S15;^Q[G_GYF_[^&C^Q[G_G
MYF_[^&@"S15;^Q[G_GYF_P"_AH_L>Y_Y^9O^_AH LT56_L>Y_P"?F;_OX:/[
M'N?^?F;_ +^&@"S15;^Q[G_GYF_[^&C^Q[G_ )^9O^_AH LT56_L>Y_Y^9O^
M_AH_L>Y_Y^9O^_AH LT56_L>Y_Y^9O\ OX:/['N?^?F;_OX: +-%5O['N?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M ,51[&0?VQA>[^X]-HKS+_A8NK_\^UC_ -\/_P#%4?\ "Q=7_P"?:Q_[X?\
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M=5UW4IK:/WZNZ]>I3D2[?PI8^0)#$"WG"/[Q&XU8TJ#3GOHI=,OY(6'^LMY
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MPHHHJ3<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:^;<3;6V$A5WLHP 1C@#&#4]U'=IIZW$NR2[LSYBM&,>:H'S#';<,C&3S@T
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ML#ZUV%%5&3B[HQQ&'A7AR3V/,O\ A76K_P#/S8_]]O\ _$T?\*ZU?_GYL?\
MOM__ (FO3:*OVTC@_L?"]G]YYE_PKK5_^?FQ_P"^W_\ B:/^%=:O_P _-C_W
MV_\ \37IM%'MI!_8^%[/[SS+_A76K_\ /S8_]]O_ /$T?\*ZU?\ Y^;'_OM_
M_B:]-HH]M(/['PO9_>>9?\*ZU?\ Y^;'_OM__B:/^%=:O_S\V/\ WV__ ,37
MIM%'MI!_8^%[/[SS+_A76K_\_-C_ -]O_P#$T?\ "NM7_P"?FQ_[[?\ ^)KT
MVBCVT@_L?"]G]YYY_P (5XA_L_["+VQ%MNW%%+#)]R$R?QJK_P *ZU?_ )^;
M'_OM_P#XFO3:*/:R*>48=[W^\\R_X5UJ_P#S\V/_ 'V__P 31_PKK5_^?FQ_
M[[?_ .)KTVBCVTB?['PO9_>>9?\ "NM7_P"?FQ_[[?\ ^)H_X5UJ_P#S\V/_
M 'V__P 37IM%'MI!_8^%[/[SSJS\$:_83^=;7ME&^"I.YB"#V(*8(IU[X+\0
MZC(KW5]9.47:H#,H4>P" "O0Z*7M9;E_V50Y>76W:YYE_P *ZU?_ )^;'_OM
M_P#XFC_A76K_ //S8_\ ?;__ !->FT4_;2(_L?"]G]YYE_PKK5_^?FQ_[[?_
M .)H_P"%=:O_ ,_-C_WV_P#\37IM%'MI!_8^%[/[SF?"/AV[T#[9]JD@?S]F
MWRF)QMW9SD#U%%=-16<FY.[/0H48T::IPV04444C4**** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "H;JV2[@,3$KR&5EZJP.01]"*F
MHH HI822NKW]P+C8<HBQ[$!]2,G)^IQZ 5>HHH " 001D&L\Z=-#E+*[-O W
M6,IO"_[G/R_3D>U:%% $<$$=M;QP1+MCC4*H]A4G:BCM0!R_B;_5&G4WQ-_J
MC3J *FJ7O]FZ7<WOE^9Y,9?9NQNQVS61)XBU"TM$OKW1?+LB%9I8KD2%%.,'
M;M'K5SQ/_P BQJ7_ %P:N<U"#4(]-TN/4=2\S2;AHXYQ%"(R@(!4$Y.1G@GB
M@#H]0ULV]S#9V5JU[>2IY@C5P@5/[S,>@HT_6GN+]]/O;)[*\">8J%PZNO3*
ML.M4K;9;>.KN.0!//LX_(SW"G! _PI]\Z3>-=)CB^:2""9YL?PJP 7/XT $>
MNZI=27?V/14FBMKAX"QNPI8J<9P5_K3O^$HADTVVN+>UEDN;B4P);$A6\P?>
M!/0 >M8UK%K(L]=N-,OD3R[^X(@, 8L0><,3Z>U;&C76FZ7X4BO4G8VQ4RN[
MG+,Y/(]SGC% %BQUF:74SIU_8&TN3'YL>)1(KKG!Y '-6[^XOH!']BL4NB<[
M@TXCV^G8YJAI-I<75\^M7Z&.62/RX+<]88\YY_VCU/ITK;H YW3-?U35-S1:
M+&(HYC#(QO!E2#SQMYK7DU73H21+?VJ$.8SNF488=5Z]?:L?P;_QX:A_V$)O
MZ52TFQM+F;Q,\]M%*_VJ1=SH"0,=* .G;4K%)U@:]MUF?&V,RJ&.>F!G-4+_
M %B[@UA--LM/6ZD:W\\EKCR\#=M_NGVKE196J_"[[4((_M&W?YNWY@WF8SGK
MTXK7N'U!O%ML]BML\[:7EOM#%5QY@S]T'G.* -*SUUGOI;+4;-K*X2(S >8)
M$=!U(8#MZ8JJOB2]FLCJ$&B22:> 6$GGJ'*CJP3']:?%IUR-0FUC6Y+8B&W:
M-8K=6953JQ.1DG\*JI:7&G:4;_0=55]/"&9+:Y7<FWDD!N&7Z'\: +UWXITZ
MWM8YHYHG>01N(W?8=CL!GD=LY(]JM#7])*PM]OA"3,RQN6PK%<9&>G<52EL(
M/%>G6-U<F1+=H2_D#^^PP#GVYQ^%3W=MJ"Z?:V,%O:WIV;99KH808 P2@ZYY
MZ>E &N"& (((/((JCJ>J#38T/V6YN7?.U($ST[D] /<U5T/0CH_F,;MY#)UB
M4;8D_P!U><?G6G=_\><__7-OY4 5-+U:/4=%BU.11;Q.K.0SY"@$C)/'I5^.
M1)HDDC=71P&5E.00>A%87A"-)?!UC'(BNC(P96&01N;@BMU$2.-8XU544 *J
MC  '8"@#G[;7M4OEFDM-$26*.5XMQO I)4XZ%:=+XH3^Q(]0M[1GD:X%LT$C
M["DF<$$X-9WAXZU]DNQ8)IYA^V38:=W#9W>@'3\:34]+;2M @CEE$UQ-J<<\
MT@& SLW.*8&NFN7%O=PPZKIILUG81Q3+,)4+GHI( P31K?B)=&24BQN;@QJ&
M=D7$:@\#+'_Z]5_&3"32[>T1O])GN8Q"HZDALD_A4WC+_D4M0_W5_P#0A2 V
MHG\V%),8W*&QZ9J*_NOL.G75WLW^1$\NW.-VT$XSVZ4ZT_X\X/\ KFO\JJZ]
M_P B[J?_ %Z2_P#H!H I6^K:U<P13IH<7ERJ'4_;AT(STV5-?:U)%J0TZPLF
MO+L)YD@\P(D:GIECGD^E5=&L]7%AI\AU>(V_E1L8?L@SMP/EW;O3C.*2P<1>
M,M;A<B.:XCADA+?Q*$P<#O@T 7=-UAKR\FL;JT:TO85#F(N'#(>-RL.HJC8:
M]J^I6,5Y;:'$8902I-Z >N/[GM3K"[U*'Q4VEWE['=1_8OM&Y81&0V\+CJ>W
M\ZS_  K9ZO)X<LGM]6BA@(.V(V@8@;C_ !;J -:ZUF^BU*'3[;3$GN'MOM#@
MW(0)SM(SM.>:FTW6)+N^FL+NR:TO(D$FS>'5D)QD,/>LW4(;N?QM&ME=K:R#
M3B2[1>9D>8.,9'MS[4>&UD?5]3DU&9I-5B80MD!5$752H]#UH Z.:>*WB:6>
M5(HUZN[!0/Q-,AO+6X@,\%S#+$O61'#*/Q%8>M)'<>*-%MKM0UJ1*X1_NM(
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M6C7\]P;FSO /MEFX21E& ZGE7 [9';U!K4K BPOCRX"=&T]"_P#O;R!^E;]
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M8#%>1T.00:M44 9UEH.F:=<&XMK4+-C'F.[.P'L6)Q5J]LK?4+22UNH_,@D
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MZ* (;2T@L;2.UMDV0QC"+DG ^IYIJV-LE_)?+'_I,B"-G+$_*.<8Z#\*L44
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M(X]D7E@EL'=MP#S@_7K0!Z-1112 **** "BBB@ HHHH **** "BBB@ HHHH
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M]$_*C^TY_1/RJE10!=_M.?T3\J/[3G]$_*J5% %W^TY_1/RH_M.?T3\JI44
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MN30/^?+4_P#OW'_\77B-%'MI!_8^%[/[SV[_ (7)H'_/EJ?_ '[C_P#BZ/\
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M_P!GHH^&O_,4_P"V7_L]%<=7XV?8Y5_ND/G^;.]HHHK,] *:_P!PTZFO]PT
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M&I-<*(+*.?<;2/E3B-,[C_%].F<YS5B]OQ=Z3<PM \#E(SL8@YC=L \?B,4
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M]*WZI3Z:LFIP:A%*T4T8*/@9$J==I_'D&@#F;6QNU^&#6C6LXN?+<>28SO\
M]83]WKTK<^PZA-968M]2ELMD"JZ"!&R<#KN'%:]% &%>:)J-[I4]E-K;OYQ7
M+M;J,*.JX7'7C\O>LV32M9C\2::?MRND<+J)DLL)&./E/S8Y[5U]% ',0RW&
M@ZMJF_3KNXANI1/"]M%O!)&"IQT.:;%#+H_@*[^V+LF>*5V3/W6<G"_J!74U
M2OM.34);8S2'R(7\QH<<2,/NY]AUQWXH 728'M='L;>08>*WC1A[A0#5RBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ K6TK_4/_O?T%9-:VE?ZA_\ >_H* -"BBB@ KS+XB_\ (P6__7JO_H;U
MZ;7F7Q%_Y&"W_P"O5?\ T-ZUH_$>5G'^ZOU1R-%%%=9\D%%%% '3:+X:$FH6
M@OY;;;*AD-J92)2I4D' _ XSG%9]IH%Q=6\$IN+6 W!(@2:0JTO..!@]^.<5
MLVVHZ1)KMOK<VH&&3R@);<PL2'$>S@@8QW]:I1W6F7R:9/=7K6LMDBQ/'Y3-
MYBJQ(*D="<XYK*\CTW2H625MWU6J]W5]NNA3MO#]S/&SS36]H!,8 +ARNYQU
M P#_ (5-!H,\]JL/E1)<F_-KYC2G@[<XP!C'OG\*OVVL6EQ+<327ZVZ3732R
MVMQ;^=&ZD\8P#AL<'UXYI;#5]*MGC".884U4W"H58[8MF >!^G6FW((TL/IK
MIZK^E^'ZF1=Z#/:VLDZW%K<"*01RK Y9HV.<9X'<8XJ:3PQ=1I<9N[(S6\1E
MF@$I+H ,D8QC/XTZSU2WM;35?G!EEN8985*GYPKL3].HZUM&TMXYM>U%9IE,
M]K*6AFMV0QLY!P6/'7@8SFAR:%"A1FKQ_/;?_)'+:4M@]VJWZSNI(")$0,DG
MN3T'TK931;:7Q+J]A%;EUA@E-O&&.0X'R]^>?6N=MG6.ZA=CA5=23[9K??5;
M(^(-:NA-^YN;:9(FVGYF9< 8QD?C3E>^AEAW3Y4IVW_"S&VWAVXM],U.XU&Q
MEC,4 :%GR,-N'H>>/6LG3Y;"$RR7MO)<$+^ZB#;5+9_B(.<8]*LZ3>6]MI^J
MQ32;7GMPD8P3N.X'''2F:&FG&_\ ,U.=8X8QN5&5B)&[ [0<#UHUUN)\C=/D
MLO6W=[FNNE:;-):7;6S01&SENIK02$Y"YVX)Y ;K58PZ1+96FJ/:26\ N&AG
M@A<MNPNY2"QR/0\_2IOM]HNK37-SJD=TMY#)!*T4+KY*LN 0"!D#C@5"7TI;
M.STHZAO@-RT]Q<K$P"C: % (R>G7'>IU-Y>SUMR_AOI;Y/K;3<;/#IMQH\.H
M"Q>S7[8(7$4A?>FW+$;CU'Y<TLL>F7VCZC<VNG-:_963RI/-9M^YL88$D9QS
MQZ4[6&L+QXO)U:!;:(B.&W2&3$:$C)Y49/<]S3M6;3)+)+:QU:(6MNI9(/)D
MW2OCEF.T#<>GH*8I)>]\.W]W5VW7;OIKL<Y1116AYH4444 =]\-?^8I_VR_]
MGHH^&O\ S%/^V7_L]%<=7XV?995_ND/G^;.]HHHK,] *:_W#3J1AD$4 ?/\
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M<$XSY;X4YQ\W'R].^*@F=9/'%@Z,&4V,A#*<@_,*QM.51\--0P!SYQ/'4YI
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M.>V/>L[5+D_\)7';BZBTXBSW?:V12T@W?<!;@#O7/B02>$O%#+<&X0W>X2X
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MBW_DM_\ 958E\"7D\"P3>(IY(5Z1O&2H_ O7:T4>UGW&LKPJVC^+_P S@O\
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MHH **** "BBB@ HHHH *.U%% '+^)O\ 5&G4>(XV>,X%53J-J#_K#_WPW^%
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MZ=:>+>!9A,(8Q*$\L.%&X+UVY]/:H/[2M/\ GH?^^&_PH_M*T_YZ'_OAO\*
M+=5'TO3Y+C[0]A:M-G/F-"I;/UQFC^TK3_GH?^^&_P */[2M/^>A_P"^&_PH
M MU7NK"SOMGVNT@N-F=OFQA]N>N,CCH*9_:5I_ST/_?#?X4?VE:?\]#_ -\-
M_A0 ZUT^RLF8VEG;VY;AC%$J9^N!5@@,I! (/!![U5_M*T_YZ'_OAO\ "C^T
MK3_GH?\ OAO\* &W>FQS:1-IUOLM8I(S&/+C&%!ZX'3N?SJQ;P):VT5O$"(X
MD"+GT P*A_M*T_YZ'_OAO\*/[2M/^>A_[X;_  H GA@AMU*PQ1Q*6+$(H4$G
MJ>.]$L$4^SS8DDV,'7>H.UAT(]"/6H/[2M/^>A_[X;_"C^TK3_GH?^^&_P *
M 'S6%G<3I--:02RI]UWC#,OT)Z4HL;06IM1:P"W;.8O+&P\YZ=.M1_VE:?\
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M?_/)ORIM% #O)L_^>3?E1Y-G_P \F_*FT4 .\FS_ .>3?E1Y-G_SR;\J;10
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M% $L:V<;9$;?D*V[5DD@5T!"GUKGZV]._P"/-/Q_G0!;HHHH **** "BBB@
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MFA4K2<>?9I]+:W_R,.BBBH.P^L$^X*RY9IKJ[:-"=JDA4$IC& 2N6(Y))!
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MCFN@1UEC61&#(P#*1T(-2;#J*P=3\3+I]TD"V%S*#,L+3%=D89O1CU/T%;U
M!165+?3SZ\FG6C*J0()KJ0C/!^Z@]SR<^@JS_:VFY0?VA:9DX3]\OS<XXYYY
MXH N444UW6*-I'8*B@LQ/0 4 .HK)TS5[C5)1)%ISI8-G9<R2 %_0A.N#ZU'
M<ZY<G4I[+3=--X]LH,S&81JI(R%&0<G% &U17/S:]))HT&M6BG[/$Y%W;NOS
MA<X;!]5//N*WD=9$5T(*L,@CN* '4444 %%%% !1110 4444 4[S3UOIH&ED
M/DQ-N,6.&;L3]*N444[DJ$8MR6["BBBD4%%%% !1110 4444 %%%% !1110
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M ?1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MT*I ]_$D$>VW@\I B_4[R<D]3UIV%*2][5/2W372U_Z\O4Y^BBBM#S0HHHH
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M&=0NHVNFF6:19#N<>Y.<^V>E78;*Y/B>XT?^UM0^QK;K<<S$R9SC&_J!SG%
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M/?':@#JZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "MO3?^/-?Q_G
M6)6WIO\ QYK^/\Z +=%%% !69J/A[2]6N%GOK7S950(&\QEXR3C@CU-:=%--
MK8B=.$URS5UYF!_PA7A__H'_ /D:3_XJC_A"O#__ $#_ /R-)_\ %5OT4^>7
M<R^J8?\ Y]K[D8'_  A7A_\ Z!__ )&D_P#BJ/\ A"O#_P#T#_\ R-)_\56_
M11SR[A]4P_\ S[7W(P/^$*\/_P#0/_\ (TG_ ,51_P (5X?_ .@?_P"1I/\
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M?_%5OT4<\NX?5,/_ ,^U]R,#_A"O#_\ T#__ "-)_P#%4?\ "%>'_P#H'_\
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M.I&[>U#"%5@$8!88)."<\?2MFB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *V]-_X\U_'^=8E;>G?\>:_C_.@"W1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M#&VW=\P\LL#C&!MR<\< XN:7K$VL^'X]1L[11-)]V&=VC7AL'YMA/3G(7VH
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M,?I716UW!=J'@9G0HKJ^PA65AD$$C!X].E8J>([BZ6_-EIJL;)CO^T7*H&4
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M$BJR!@I925PXR1RN>M2KXDTI[:2<7#@1R+$4:"02%V *@1E=QR#D8!R,^AH
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MZHPSLYVYQGJ3Q75Z%I<NGF[EGCCCEN'4D+<RW#8"X&Z20Y)Z] ,# YZUL44
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MJ 2 2<#).!UK4HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
:HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>img129881027_15.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img129881027_15.jpg
M_]C_X  02D9)1@ ! 0$#O@.^  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #2 2H# 1$  A$! Q$!_\0
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M8*>.;W%EKDWD:K#F9_373?!TW><0TM7(V3L>P=Z(^7_$+71J4@[D9]L$6BV
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MG4J( *A%" L)BF!,EOX[]>/355R0 ,4>W4_80$1\B!N0*<OVG,<2 '("!.>
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M)2@( F7H7D $P 42CV2X'@R)R'X#W!U%5-%*4H 4I0*    !0         .
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M()Q25?(Y;K&%19BJE!-1AB+-UTO=C7#A(P>V\7!2GONW=E ,\N)T^_>:R'2
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M)"#\E*/@0\E ?!OZ@^/@W(\A^?/G1$%,ABB0Q""0W'8HE 2FX  #DHAP/
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M9X>EB9/.ZASG3+,>IG6\6L1I*D_2PSRUW(>J/ZJ&7FF*<VX7:V6A;-6:6/\
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M^=GW"GK3^KCVZG V-]C93<E+U.*>,+(0X]>..!4(80 W(C_5R(" Z'[#N_\
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MSI=1R^427]O*T].)C^3=$'CE[P,[1I/ ZKUU-Q$Q!.)NP'-W(/83A[9BE%,
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M$31$T1-$31$T1-$4LL82&$_80*"?(E XD*)0-_,,<Q@$A0* E$HD %A$1 !
MOP18R;G-X>W#9O17&0]QV6JSCB#)P6/9R+Q1Q9;"X(7W2Q]8JK#ZZR6.15(0
MW5K&L%@(?VRN@137%10G(7-K:W[_ +7A2]4/.7J.>I%NPP7;=NN*=S&/-OV2
MGDSC?9E$SD0?'[VWR*M+=L\IW8BK-9JNS_>ZK/K*K+N9]X9H3'P.V"OL(1TD
M=M#S\NO+FGE?+WM]YZ\I7NTV>[:,;;2MN^-<&XSI<%2X6I5N+1EX^$]UTG(V
MM9@W5M$V^EWAE)&=>RDT=ZY/*R:AGJR*B22I4O:!,M3W638D((" D*(& P&
M2AP8#\=P$./(&X#MS_5P'/.B+D2E'CDI1ZB AR >!#G@0_00Y'CCXY'CYT1
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M1<@4I0X*4"AX\   '@ *'Q^A0  _0  /@ T1<Z(FB)HB:(FB)HB:(I54X <
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M6?3\P1-*13-VT!RDNQ3SSDZ&<#*V-ZG[2#@\$W>NQ9K%-]"_K;]5XU2:7US
M/>O80Y\8R)'TX6^NJ^$^H%%P5ZG6W:3POZ:>;XG#.WW$.1\ -;QC[ 59/4"W
M&_7/'3NF9&A+*M.-Y"7@Z_",;8$_=)LWX\S&3EB((/%5W;Q^[]>_),UZ0D!(
M<AP* &3 X]1\F*<H@4X"!A 2GX$W7L0ZI>2B G*<#))D4P  'P !_;^W'_(
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M,LM.^JV HD+P(F IS=Q'W."CV#DIB]1X^"<$( !P "F @ <!P11?;)_N$\"
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M=NV'ZKO0BJ5%8^S,2K,+"F7\#:4FHSM?7>MYBM$9FC$9N= T]CX$WBZ5ID)
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M  RE5Y!7P)A^UO$2;]4P!QT(*21U#]1 X&.(\XO+FS FW \[\(]^2TC5:/\
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MM(WJF)=<&6MW8;8?\F$R+F;C(77(S"_IS3D5]H;?#R/E+*5%S3.0WJ8:!>3
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M]Q)#B)!ESLK:YDE5FTVP;<H\X?285QHD)0*(G4IL"L/)>>0Y78KAP(<"<#'
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MCTP"VD_X>I# 6?-(D_+!FPOGSLNPI[>KT6;E&AAJ#2=XG#4_AG>L-[>ACMX
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MC>J2NX;$586MUUQTEC>+)^\,#"MX]I)M(6TK*I,Y*;AY-JFU!'HLO>^P@@9
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M"S+)Z1_(%*X*OV1>==??(3:_IYIWKI$WO?6_'AEN-;B'0W!NP@<0.///*@
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M0K![:I"BX3.DH)#DT3OKWY*=3$1 >1'GMY 1 >@B "8@&#^H"F$0Y_(>2_
M&B*)HBX$I1\B4HC]OR #_0;L3Y_W3?<7_=-Y#@=$7'4H@("4H@(  AP' @'@
M $..!  \ &B+L  'P !Y$?'CR(\B/]Q$1$?U$>=$31$T1-$7 E*(@(@ B'(
M(@ B #X$ _3D/G]?ST1=?;)]OV$^W@2_:'VB =0$OCQP'@... \!XT1=A*40
MX$H" !P " < ' AQQ\<<"(?V$0^-$7(  ?  ']O[<?\ ( #^P:(FB)HB:(FB
M)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HBAG'CY$2A]H 8!_,PB!@X^ X .>P^
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M'RJ#)ZC(M47"C!Y'N03(Z8(JJ(D<BBX31%!VD= _4Y%7E9KT#5:_"U>LPT;
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MF%AB9*>K(,"6>'83#%[+U\TD@=U'#-L&ZWUL2I(-N';8'C=N9RU3!PFT224
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11-$31$T1-$31$T1-$31%_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>img129881027_16.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img129881027_16.jpg
M_]C_X  02D9)1@ ! 0$#O@.^  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #9 -\# 1$  A$! Q$!_\0
M'@   0,% 0$               ()"@$#! <(!@7_Q !;$  ! @4# @,#!0D+
M!0P+   ! @,$!08'$0 ((1(Q"4%1$Q0B%3)A<9$*%A<C,T)R@;$8)C<X.5)V
MH;*VPH*SP='P)"A#5G5W>(.2M.'Q&2<I149F<X2FM]+_Q  < 0$  04! 0
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MHEKW-U#8.D@R).L05O\ E$4N.ED%&N0T9!KBX=$2J$F#?L8Z%+WXSW>+9ZW
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M'_\ /:A_T<?5KHVPR?R:T39N?*!ZHEY)RC0223;B3O7MGT.'_P!#[*U@5L0
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M5G5:1MR;H5O$5JMZ.C93::4JFMO869HAIA$^^52S72(V%AY>U/5R)N#@VJ6
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MMC&HD:3?@JK0(F9,\(M$>WP6@?NBX(%E=N74GJQ<^I1E200/WK-J3@GT7\0
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MXAIEA+#8*X>=.A7L@!A>0A14H=96D*5A0XH5PDG5:-^Z+@$V9VY@  "YT_
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MYS"4[/H:&>;9J&G6)O%14S8DTY1$RQF-BWXIN&#SCCBR+JB':0AI" EO" I
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MBGI=!/QL()?%OPL.Y$RY+Z(E$!$+:2J(@D1#8#3Z(9TK82\R TZEL+; 0I(
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MMR92YLM;58UCR  #G+H)(*PZ]9U(NYEIJ.9 I-!M4S /?(-CE<YS.D3 ;&D
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M'3*6S%M*H[WN"K^C(^H)-.YE!-;=F"IXFB,<QN6GB&TW5*8$4W&D UI<SU7
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M%3I3S\(^(@G@<D  $^I   )\@/0:(J="#W2D\A7S1\X=E=NX\CW'EHBJ  ,
M  =@!@?8-$5=$1HB-$1HB-$1HB-$1HBQWNX_2:_M+T1(/SV_TT?X]6Z>_N^]
M%CM?E83ZE?\ <V-7%+M3VGWKZ>BA&B(T1&B(T1&B*VKYQ_ZK_.'1$I/8_I+_
C +:M$2M$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$7_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>img129881027_17.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img129881027_17.jpg
M_]C_X  02D9)1@ ! 0$#O@.^  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #- /D# 1$  A$! Q$!_\0
M'P   0,% 0$!              @)"@$" P8'! 4+_\0 6!    8! P("! @(
M" H&"P   0(#! 4&!P ($0D2(3$3%")!%3(X47&!L;<6%R,Y87)W>"0S0G21
MH;*T"A@T-E)VM;;!\&*"L\+1\1D:*4535V.2EM7A_\0 ' $!  $% 0$
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MZM0_*1I+R-H>B8!CJ@ <I G/-6 W9H[(R@B;QZ4X8'$GGVS]7I4 !>FGL.
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MV?*0R:)E#I*IF1$JQ"G3[.PX"8HZ*?'/E[K8Y\MW2_BR^ %YY-P  4 [A$W
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M!HE7QS5X2G4N+;PE7KS((^$B6QUU$6# BBATFZ9G"JRPE**AAY.J?Q'@G!
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M<VK $Q5>V/=C<V&2N,;_ -1I0),!C8FPGS;(@YSQ...-NAYCZH&>;_TS9O\
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M4O<0Y3#<;HVD5 'LHUW-.#F-):8L8/,$'C*H-2FTD%[01B)'-?/_ !MXI_\
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M<MY>Q?((K/\ X=O;FE5ZQ1,O<Z.5D9D9ZWJ#:1L<.U:2#H(EPDGZ4Y,C&/,
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M-#];@5_T/R2+C9-&F:F1/7+K1G @RJ@>1#TW"+4OL&]5,H]<E,8G<'@)?5!
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M\CDNHIS4?)Q[16649%F$'B-;=-VP@$; 3#SU:-E8_OF/%LL^U09.)-Y.??\
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M[N67Y2@QQ)MG.0-\3F" 3-[;PIMS,2BU0,G_ !9DRG3#@ X3/[1"^ FY[2"
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M YW0I()@8ZAUEW3A=X^>N%%WDB_<.9!ZLL[<K*GK))))Q,3V-#1[FA40&V&
MD>_QV6DKHZ8"!"\B(B(<\CY^T(FX]_ESQ]6H%O?[S**_1$:(C1%3@.1'WCHB
GKHB//1%0 X#C1%71$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(O_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>img129881027_18.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img129881027_18.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )&!$<# 2(  A$! Q$!_\0
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M#6,5QDWMT#=W3'J9).3GZ# KD=;N(?"_QO?7->MIFTR[TX06MRL#2JCC&4P
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MKJVN]P6?;RBDKS@'DCO@5SWP^&O#QYXO.H0V*1M<Q&<PE_O^6-NS/5<=<]Z
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M_)1R:N^)_$-]IFFZ7#IL<4FJ:K.EM 9<[(R1EG8#J% )Q3/B4I;X=:V%4DF
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MCC+# )9  ?IFN0C72)O >C>&],TQX?&%O- OEBV*S03(P\R5GQ]W )SGD$4
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M"L_&%[]A_L2XD0R6"QD2PP.P57\S/S-R"1C'->A7]Q/;Z9<7%I;&ZN$B9XH
MP7S&QPN3TS7DEQJ\>L?#6Q\#16]P/$#""QGM#$P,/ELNZ1CC&W"YSGG(KU?4
MM0M]#T2XO[G>8+2$NX1=S$ = .YH XJYUOQAX=&DZCKDVG3V]_=16LUC!$5>
M!I.FU\G?M[\<U9\;>.+O0[F&PTJPEFG$\"W5S)&?)MTD< <_Q,>P'2N9\/>*
M]"\2>(K/6_$6K)]M#[=,TE8I"EH6X#,=N&E/KT':NN^)JEO"D052Q_M"U^Z,
M_P#+5: .R'2N$U*]\<^1JNJQ-INFVEBSM!:7,>]KB-!G<S@_)NP<8Z=Z[L=!
M7CNN^-]%\4Z]=:5JVJ'3O#ME+LE@\J3S-0=3R"0.(@>W5OI0!UXUKQ+XBL=$
MFT&VAL;:^M1<W%Y=+YGDD@8C5,C).3R>,"K/A#7M2U"^UG1]7^SRWNE3)&US
M; K',KKN!P?NL.XK#\8_$"TTBSTK3=&N8K4ZE"'COI(6,5K!TW!0,EN,*OYU
MK_#Z7PT-(FMO#MZUZ8Y-]W<R*WF32MR7<L!DG]* +>N2>*+G68;#1%M[.S\D
MRS:C<)YOS9P(U3(Y[DFL?3O%'B6\T;6+2"QM+W7=-O19&2-ML#YP?-()R, Y
M*YSQ4'Q!\=?V/J%MX>M;U=.N;J/S)]1EB9UMHNGR@ [I#@X'0=34FB:]X>T#
MP8\_AF"YU:TMIU%X\2L9B6/SRMN&7/<XH M:)KNM0>,CX<U6ZL]2+VAN?M-G
M'L\@AL;)%R<9['KQ6[XDN=:M]/C70;2*XO9IEBWS-A(%/61AU('H.M<+HO\
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MB6%G=+\1%G1BS1/]H%SO'F,YQC9C=STQ7MVH:C%I&C7&HWN[R[:$RR^6NXG
MYP.] '$W.M^,?#L>E:GK<VG36U[<Q6T]A#$5> R' V/D[RO<8YYJP=:\4Z_K
M>LQ:#+86=GI$WV;%S$9&NI@H8C((V+R!GDUS.@>+="\3>(K36_$>JHMTLFW3
M-)6*0I:D\!W.W#2GUZ#M5C6Y]/TKQ9K9;4-6T.2XVM);6\7FKJ>5'S1?*=K_
M ,)QS0!Z!X5UY?$OANTU41>2\JD21;L['4E6&>^"#6S7*?#C19] \"Z?8W,3
M0S8:5HG.3'O8MM)]0#BNKH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *KWEY'8VYGE25U! Q%&SM^0&:L44+S QO
M^$FLO^?;4?\ P!E_^)H_X2:R_P"??4/_  "E_P#B:V:*N\.WX@8W_"367_/"
M_P#_  "E_P#B:/\ A)K'_GC?_P#@')_\36S11>';\?\ @ 8W_"36'_/*^_\
M .3_ .)H_P"$FL/^>=[_ . DG^%;-%%X=OQ_X C'_P"$FL/[EY_X"2?X4?\
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MT?\ Y\(OUHM#NP- / #D-&#[$4OF1'^-/S%9O_"-Z/\ \^$7Z_XT?\(UH_\
MSX1_F?\ &BT._P#7W@:7F1D??7\Z3,/JGZ5G?\(UH_\ SX1_F?\ &D_X1K1_
M^?%/^^F_QHM#O_7W@:9:,X)93CIS2[U_O#\ZR_\ A&='_P"?%/\ OIO\:/\
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MY4TRWN[73XH;Z\%Y<*"&G$0CW<\?*.!QQ5NBBF(**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "O)_&&K:JGCRW5=8T".'2[>>]B2<'<AVA=K_ #<M
MR<8KUBN"U_X=QZU>^(;OR--\_48(H+=Y(<F/'WV8X^\<\$>@H J>#M.UF^^&
M]K:VNM6-M/<2>=-<V:[WC23+N.I DRW7MZ5J?"F,0_#ZRB#,P229=S').)&&
M3[UT^F:38:/9BVT^TAMH^,K$@4$XQDXZFL[P?H<_ASPY#IMS+'+*DDCEX\[<
M,Y8=?K0!O4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%<_XUAO)?"EZ]A<SV]S OG*\$A1B%Y(R/;- '045R'A[Q+YGPX&KSR%Y
MK6W=9&=LEG3@9/J>/SJM\.Y[M/"T^KZSJ,TB32%E>ZG++'&O&?F/'.?TH [B
MBL+3?&7A[5KT6=EJ<<EP?NH49-WT+  _A7&Z#K.G:'XW\5W.I726\1F !;)+
M'<> !R?PH ]/HKG[W5]-UGPG>W=EK!@MO+(:\@5BT)Z_=^]GVX/-+I&I:?IO
MA"TO+C63<VBI_P ?MP"IDY/8\^P')XH WZ*R-'\4Z+KTCQZ;?QSR(,E"K(V/
M4!@"1[BN4^&K*EYXF9B HO,DD\ 9>@#T*BN?@\<>&KG4!8Q:M"TY;:/E8*3Z
M!R-I_.N@H **\TL[C6O'^L:BUKK5QI>EV<GEQ"VR&DZ\D@@]L_B/K6SX5N/$
M-EKE[H>L?:;RVA7=;:@\# /T^4MT/7U)R#R: .RHKGIO'/AFWOC9R:O")@VT
MX5BH/NP&T?G5[4O$&E:0+5KZ\6);IML+;68,>.X! '(Y- &G16)I_B[0-4U
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ I'571D8 JPP0>XI:* /![V:YT:WUCP;&A+7%_'Y/NI/\
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ME2(S/@^:T8;G;T]LUZ$0&!! (/8T !1@  #L* %HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 53N]4M+&\LK6
M>0K->R&.!0I.XA2QZ=.!5RO$_&NH6<7CV]EDU/Q,@TVREF(MU?9#*P 780.%
M(')Z4 >E7GC?0K'1%UB:YD-F]P;9"D+,SR!BN%4#)Y!Z>E6- \4Z;XE$YT\7
M0\@@/]HMGAZ^FX#/X5YUX>T"YU/PSX7M]-U>>VEL[HW4O]J0G?YGE\^2C8W
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M9>.G<5'J'BO2-+O'M+NX=)D + 1,0,C/4"M@(JG*J!]!08T8Y9%)]Q1>-]M
MM*VY5;5;1=)_M,R'[)Y?F;]I^[ZXZU2T[Q3I&JWBVEI<,\S L%,;#@=>2*V-
MJ[=N!M],<4BQHIRJ*#Z@47C8/>,O4O$NE:1="VO;GRY2N\+L8\?@*M6^J6=U
MIG]HPR[K7:7W[2.!UXZ]JM-'&YRR*Q]2,TH50NT* OICBCW;!K<Q;+Q;HFHW
M<5K;7F^:4X1=C#/&>XJQJGB#3-&ECCO[D0O(I91M)R!]!6@(8E8,(T!'<**5
MHXW.716(]1FB\;[:![UMRKI^JV>J61N[.820 D;L$<CKUKCKF3PIKMYJ</\
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M!67D%8P"*?-:V]P09X(I=O3>@;'YT_=OY![UB&PU.RU2W-Q8W4=Q"&*EXSD
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MLG&T=!5/3_#&CZ5=BZLK-8I@I4,&)X/U-'NV#WKFHTT2'#R(I]"P%*'4IO#
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MB@ HHHH ",C!Z5E'PSH1.3H]CG_K@O\ A6K12<4]T7"K.'P-KT,K_A&-!_Z
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M?^$/^)MII.G3S/8W\!>2&1LX.&Y^N5Z^YJY\-/\ C^\2_P#7[_5J /0:***
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M>B@32:LSY^U;2;O1KZ2UNXV1E/RL1PX[$&M+PCH%QK6L0,(V%K"X>67'''.
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MP5:2&,MY:=^1W/3\Z[&BNF4&X<M_F>-2Q,*>)]OR*R=^7I_2/F+_ (1?7_\
MH#7_ /WX;_"O6?AA>ZO;V;Z-JNGW<*1#?;RRQ,!M[KD_I7HE%<]'"*E+F4CU
M\QXBECZ#HU*2\G=Z,**P-9\8Z1HDWD7$S23CK'$NXK]?2K&B^)M,UY6^Q3_O
M%Y:)QM8#UQ75S*]KGRJQ-%S]FI+F[#/%.IW>E:!/-86LUS>,-D*1(6(8_P 1
MQV'6OG^3PWXAFE>632-09W)9F,#9)/X5]-45SU\-[9IMGT>59V\NA*,*:;>[
M?Y'E_P +;C6=.:71M2TZ\BMFS)!))"P5&[KD],]:Z'X@Z'/JVD1SVJ&2:U8M
ML Y93UQ77T5I"ERT^1NYY6;U89E.<I1Y>;>W?N?..UB^S:=^<;<<Y^E>P^ -
M#GTC1GEND*3W3!RAZJHZ9]ZZ7[!9^?Y_V2#SLY\SRQN_.K%$*7*[L\# Y2L-
M4]I*5WT.;\;:'+K>A%+<;KB!O,C7^]ZC\J\6DC>*1HY$9'4X*L,$&OHVJ\EA
M9S2^;+:0/)_?:,$_G3J4N9W0\?E2Q4U4C*S. ^&_A^XAFDU>YC:-63RX0PP6
M!ZGZ<5Z/1C P*H:QK%GH6G/?W\A2!"!P,DDG& *I)0B>C@<'[*$:%)7?YME^
MBF12I/"DL3!HW4,K#H0:?5FS5M&%%17-Q%:6TMQ.X2*)2[L>P%5])U6TUO38
MK^RDWP2C@D8(]01ZTKJ]B_9S<.>VFU_,NT444R HHHH **** "BBB@ HHHH
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MM7NA;(\D$K'""9<;C[&NFHP])4TU%W1./SN.;.-512:TNOU"BBBN@\X****
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M(0\C,5&T#IM+9+<'G-0>(O$-]XE^&)OXH+>*+S/+O58L2"&7:8_J2,YJ_P"
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ Q1110 8HP/2BB@ HP!VHHH 0@'J!7,>+O&>G^%X(HVNK
M,7TTT4:03R[?E9@"Y[X R<^U=17G'CN/4KOQGH-I9P:.Z1++?$WBL3^[7'S8
M_A^?CW% &SH_CO2M3EU^<WED+#2W $T<FXL@4%G(';.0,=<4_P &>+_^$P;5
MY!8O:P6=UY$(F4K(Z[0P9E/3.>GI65\+K#4#X<-UJ-KI8MM09[I/LZ'>Q=RV
M&SQC&,8JUX'.?$OC;G.-6'_HI* .VP ,8I-JCHH_*EHH 0@'J :  .@ I:*
M$V+_ '1^5! /4 _6EHH 0*!T 'TI-B$YVK^5.HH 0@$8(!'O0%5>@ ^@I:*
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M24\%06\3S#6X[PW1DV<9Z8W9] I^M;T<.I.3<7;9>7_#&D*:=]#USQ[XGO\
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M0+R^\K4[U0UO!Y3MO!) ^8*5'*GJ1TH VZ*** "BBB@ HHHH **** "BBB@
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MYI&GW'PAU&YFM(7N&2>3S60%PRYVX/48Q73?#^*#5/ NF->V\5PT0>-3*@?
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M3X;:YJ.JZ)KTMI!XFN[>S%MJ%J;DV1F89.]'4J%Y8\>W0YX=9^ ]6M/!]_\
M8O!NB6MS=W:2S:5<WDEUY\*@_*9'8JLN2<,#C![&@#M_#'BS5M7U2XTS6_"M
M[HMW%&)5<R"X@D4XZ2J N[GI]?0UUE>6_#7PGKVA^([^]DTQO#^A20!(]&.H
M_:QYN03(#R!T/OS7J5 !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %<#XPT/4-7\9:2\%_JMM:VMM-<LUJ%VK(!M7&0?F.YN/2N^HH
M\QT'0M:T#P%%>>3<:U=RE;B?2[[;\N7+.4&/]9SGGN*OV1G\4?$#3=;M])O-
M/LM-M98I9KR'RGG:3&(PIY*K@G/3-=_10 4444 %%%% !1110 4444 %%%%
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M_P!HW3X;FSM9]VD>=*6MUQ)*"W[PC&-W'6O8XH8[>%(88TCBC4*B(H"J!P
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZ'K=AXCT:VU73)_.M+A=R/C!X.""#T(((/TK0H **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "N/O7E\)>(;G53#)+HVH8:Z,:[C;
M2CC?CKM(Z^_X9["D(# @@$'@@U496)E&YCR>+?#\=J;DZQ9&/&<+*"Q]MHYS
M[8K,T9+GQ!XA_P"$BN+>2WLH(C%I\4HPS!OO2$=L]![?KMKH&C),)ETBP64'
M.\6R!L^N<5HU7-%+W1<LF_>"D8!E*GH1@TM%9EGB_ANX\1_"F'5- ?PGJFM6
MKW+W&G76GQ^8KA@ %DQ]SH,G'KP1@FE=_#WQ!!\$M:@FM&EU[4;X:C-:P@,P
M^8?(,=2 "<#UQ7NM% 'C^GC4];^+/A/73H&K6-HFD20S&[M63RG!E7#'& 3P
M1GJ"/6LH^"]<UK3OBA81V5Q;S7VI">S,\9C6Y"R,V%9L @XZ].17NM% '@WA
M;0+K5=?\.QZCIGCX3Z6XE>34YXUM+=E _P!62F9%) & 0<>M=A\$M+OM)\$W
M,&HV%S93MJ$K^7<0M&Q4A<'# '''6O2:* /,O'^C:S8>.-"\<Z+ILFIBPB:W
MN[. _O6C.[E1_%C<>!SP.W3G/"_A]]2^+]IXETGPAJNAZ=&DSWLFIAHVEF<-
MRJLQ/\0^[Q]*]PHH \R^#6EZAI=AXC74+"ZM&EU>22,7$+1ET(7##(&1[UB^
M/-/NH/&-_?P>'_$]M=S0J+75?#<A?[00!A;A.B@$ >X%>ST4 >->+M-\13?!
M;3=8UQ8X_$FBSI?YPH^Z^ #MXSM*D@=Q5&W\,:B/V=]6D6VN+S6-<9;^6.*(
MO(Y>5",*.3\HS^)KU'Q;X,L/&=M;6NIW5_':PR;W@MI_+2?I\L@QR..V,5OQ
M11P0I%$BI&BA551@ #H!0!Y-K&CZI+K/PLDCTV\=+),73+ Q$'[N,?.<?+R#
MUQTKE/'FEZA;ZG\3K^>PNHK*XM;00W#PLL<A$D6=K$8/X5]#UD^)O#UIXJ\.
MW>B7TD\=M=!0[0, XPP88)!'4#M0!Y @UKQO<^ -/A\-:E8PZ,T-U=7UU$!
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M." 6;+%L$DGJ.M7/&6DSZWX/U/3K7'VF2$F$'H74AE!_$"I[.^B\2>%Q<VC
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MM8^)M076[32M<T9=.EOD=[22*Z%PCE "R,=J[7P<]P<'!JGH_C:^UF6"YM]
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MD\DTBJRJ,LB!5^8D\'/3B@!?$WCK3[7PMK%WH6IV-Y?V:K'LBF63RG=Q&K,
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M05./5>AX +NH>.[Z"WUN_P!/\/\ VW2](,D<UP;U8WDDC&7"(5.54\$E@>N
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MBQ#2$"(B20+LZJ" V>^:Z?P]HLFI?#:ZT2]O;.\29;FVC>UN6N(XT+,$3S"
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M1#9QS2Z?I=\TWV60%B)E4HGEL<+C:.60'K0!ZG17ACO-??#_ ,4ZCXC,B>)
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M&"',D>[CMSFJTUAHFM>-?$<?BH6\GV-(39QW4NU8K<QY,J#/!W[P7'(V@9%
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MEU;QSL\_W-\B+L ,;!@<D%N"!R 3Q0!U@M;=;MKM;>(7+H(VF"#>R@DA2W7
M))Q[FD@L[6UMOLUO;0PV_/[J- J\DD\#CDDD_6N%O;W6(/B9;M::1%<W\F@C
MS(?M>R*(^=DYD*Y(SP,)D^@J[!X^-YINFFUTICJU]+-"+&6X5%B:%BLI>4 _
M("." 2<CCT .ET[1-)TAI6TS2[*R,QS(;:W2/>??:!FDM="TBQOI;ZTTJQM[
MN;/F3PVZ)(^?5@,FJGASQ =<BO(Y[3[)?6,_V>Y@$HE56VA@5< ;E*L"#@'U
M K(/C:^FU/48]/T!KVRTZ[%K<M'=#[2#QED@"G<HW=V!(!(% '3?V3IOV.*S
M_L^T^RQ.)(X?)78C [@P7& 0><^O-13:!HUQJ::G/I-A+J"8V73VR-*N.F'(
MR,?6L;4_%MW%JE]8:-I":@^GHKW;2WBVX!8;@B95MS[><':!D<\U63QU/J.J
M:9::%HK7T=_IZ:@)I+D0B*,OM(8%2<CT&<GC@<T =?/!#=0/!<11S0R#:\<B
MAE8>A!ZU0A\.Z';V!L8-&TZ*S+B0VZ6J+&7!!#;0,9! .?:LF7QEY7AOQ)J_
MV#/]BSW$7E>=_KO* .<[?ESGT./>JT_C'5Y-2U2STKPZEX=.AAFD>2_$(<.F
M_:OR'YNW. ?44 :OB;PQ:^(M,NK?$-O=W$:1&\\@.X19 ^W/!(R.F<<YJ_8:
M+I6E232:=IEG9O.=TK6\"QF0^K%0,]3UKEK/Q]=7*:+?RZ ]OHNKRI#;W+W:
MF96<90M$!@*2,9#D^H%;/B#Q#/I5YI^FZ?IW]H:G?ES%"TWE(J( 7=WP< 9'
M0$DF@"^-#T@:H=4&EV0U \&[^SIYO_?>,_K2:AH.C:M/%/J.DV%Y-#Q')<VR
M2,G.>"P)'/I7 V'B.ZT)?'>N7>E,+FWO;??9K.IR3%$ORN!@@YR,@'ID ].J
MA\2:@FIZ-8:EHRV<^IM/A1="0Q+&H8$X7!)SR >/4T :VHZ-I>KI$FIZ;9WJ
MQ-NC6Y@60(?4;@<&G0Z3IMNT+0:?:1-"SO$4A52C/]\K@<%N^.O>N;O?'7V6
M34[>/3&GO+?4H]-M8%G"_:97C60$DCY  QSUX7/M5W1O$E_?>(KO1-2T=;&Y
MMK6.Y+I="9'#LRC:=H./EZD YSQC!(!J:CH>DZNT3:GI=E>F(YC-S;I)L/MN
M!Q5QHHWA:%XU:)EVE",J1TQCTKFK[Q1J)U>^T[0M#&IOIRJ;MY+H0 .PW"-,
MJV]]N#SM R.:2?Q;=SW-G9:-HDMS?SV@O)8+V7[+]FC)P!(2K$,2"  I^Z><
M4 ;(T'1QI0TH:38C3AG_ $3[.GD\G)^3&.I)Z59L[*TTZU2UL;6&UMTX2*",
M(B_0#@5R<_CXQZ-;W<6C3R7K:H-+GL3*JO%-D@X;[K#H0<@$'.1TH/CR33UU
MB+7-(:SO-.CAE6&VN!<"X$K%(PC;5.XN-N"!CKG'- '6V]G:VK3-;VT,+3R&
M64QH%,CD %FQU. .3Z5 ND:8B%%TZT"F?[45$"X\[.?,Z??SSNZUBP>)]1M'
MG_X2'0FTV".U>[%U!/\ :80J<LKL%78X'(&"#S@G%5]/\:74]_ID>H:,+*SU
M4E;.87:RR!MI=5E0 ;"5!/#,,C!(H ZDVMN;L79MXOM(0QB;8-X0G.W=UQD9
MQ5:YT/2+R_BO[K2[*>\B_P!7<2VZ-(GT8C(KD;/XAZA<:;I^KS^&S#I%U=+:
M-/\ ;5:1&:0QJPCVC*;L<Y!Y^[QRW1/%/B(W_C%]6M+1K726+1QQ763&1"K^
M6#Y2[@<D[CR"<8(YH [^BN4L?%&M7OAM-6_X1>42W/E&SM4NU=I%< [I&QB-
M1GD\G';/%8_B#QIKMOX;\2QPZ9;V.MZ3;"=S]K\V-8G1RLJ,8_G8%"-C*OUQ
M0!WLUG;7$T$T]O#++;L7A=T#&-B,$J3T."1D>M8.F^"M*M;R[O+VTLK^YFOY
M+V&::T4O;[R#M5CD\$=1CZ52&IO)>>$#K&G1_P!H71F*20W;%(2(B2V-JA]R
M]B!MSQG%1?\ ">W0L!KC:$P\-M*$%\+D&787V"7R=O\ J\\_>W8YVT =@;6W
M-V+LV\7VD(8Q-L&\(3G;NZXR,XJOJ&B:3JSQ/J6F65XT)S&;FW20H?4;@<?A
M7/7WB[5EUO5],TKPZM\=,CBDDEDOA"KAT+8'RGYN.!T]2*MV'C;1M4LK+[)?
M6:ZE?VJW%MI]S<K'*Q9=RJ0,D?4 ^O- &\]G;23P3O;PM+;Y$,A0%H\C!VGM
MD<<5(Z+(C(ZAD8896&01Z&O,-)\2:GJ.B13^)+""Z \1"TMVAO&4HPG91D+&
MN0F!C.=_?%:UYX^U*VM=:U"+PWYVFZ/=2074WVY5=D3&YXT*\D Y()7V)H Z
MJP\/Z+I2S+IVD6%FLPQ*+>V2,2#_ &MH&?QJ[;V\-I;QV]M#'#!$H2.*-0JH
MHX  '  ]*YBS\6WS:]I]AJ>B?8(-2BDDLYOM:R,=@W%9$ &P[3GAF'O52+X@
M/(EMJ7]D :!<W*V\=[]K7S?F;8LAAQQ&6QSNW8(.V@#>N/"7AN[B@BN?#VDS
M1P*5A22RC81@G)"@C@9)/%:-G8VFG6J6MC:P6MNG"101A$7Z <"LK7O$$NEW
M=AIUC8_;M3OR_DP&7RD5$ +N[X.U1D#@$DD8%4#XOO+:"T&H:%-:7<NIQZ=)
M&TN8_G&1+')MQ(N/8'.0<$4 ;>HZ#H^KRQ2ZGI-C>R1?ZMKFV20I]"P.*NM#
M$\)A>-&B9=A0J"I7&,8]*Y3Q#XX.@SZU$---R=,L[>Z^6;:9?-D9-H&WC&W.
M><Y[59MO$NH)JNE6.KZ,M@VI";RB+L2[70!@C84#++N/!.-I'/6@#;DTVQFT
M[^SI;*W>QV"/[,T2F/8.B[<8QQTK-B\%^%;<L8?#.C1EE*,4L(AE3P0<+T/I
M60GCPW-M;?8M,$UU?75Q#8QO<A$DBA;:TSN5^1>.  QY&,YXU_#_ (@?6X+Z
M.2S%KJ-C,8+BW\X2(&VAE*N!RI# YP#UR.* -B:"&XMY+>:*.2"1"CQNH*LI
M&""#P1CM339VK61LC;0FT,?E& H-FS&-NWIC'&.F*\JT'4[G0[#Q=XPU#0[:
M>_AOYH3)'>L\K@2A/)!:, (O&#WQT%=C/XHU6WBL+:30%&M7[R>18_;5*K&@
M!,DD@7"@9 ( ;D@#- '41QI%&L<:*D: *JJ,!0.@ IU<9<^.Y;'0]:N+S1VC
MU32&B$]B+@,KB0C8R28P5.3U .5((%$GB_7H=<BT:7PJHO;N%I[0KJ*F,HI
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M0;DPG+9'&T9STYJEXA\7I=W&@V]A'K5H\NKVZR--I]S;(Z$G*EG100?[N>:
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MJQC+(S!1L<97L1SP3B@#L:*XVU\:ZA)I&EZE>Z!]DBU.[M[>W0W@=]DH)WL
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M>I0W<GF$C*)G(& >>?\ Z]9&N>"[G6M7UFY^U10QWEE:Q6[@%FCFAE>0,R\
MKDKQGGGI79T4 <G;:)KNI^(M-U3Q =-A32UD-O#8N\GFR.NTNQ=1M 7.%&>O
MWCBL+_A#/%,>BV_AZ.;1VTNUU".YCN'>0321K.)=I4+M5NHSD@XZ#.1Z310!
MSFCZ#?Z=9Z_$+R."?4+Z>YMYXEWF$. %)5A@D$9QR*P]&\(ZO:^)[/6+RWT3
M3_LL<@N9-(5P^HEA@>8FU0 /O8RYST-=_10!BZ4+S7O"2)K]HD$][ ZW%NJE
M=J/D;2"20=I&>>N:YZ+0/&D6C1^'$U/38=.C58%U.)I%O! ,  (!M$F!C>&]
M\5W=% '!RW^L2:O<1Q:S<00QZNFG+$L43 1F!7W99"V\$G!)(]0:S=:\5:O8
M:' RZLD4\8OL37#11?:6@EVHO^J8,Y Y1%4GD@KBO3J* ..T_7KZ[\8BR:[!
MTTH'618UPTYC!-MNQ_"#YF>ISC/RFM"^\!^%-2O9;R]\/Z?<7,S;I)9( 68^
MI-=#10!SWBO0+C6[#3;>S:&/[)J-M=,)"0-D;AB!@'G X_G4OB71KC65TD6[
MQ+]CU*&[D\PD91,Y P#SS_\ 7K<HH \XUW0)]'TO4M6FO;:WFBUP:K:2LDLD
M:@J$VR[%RH(W L,A<YJGH4NH>,-=\378DT^:*?2%L([FR9VMA(3)\HD8#S"-
MP)*K@9 ZCGU.B@#DY/"]Y):>$(3);YT:1&N?F;YP('C.SCGEAUQQ6%I'PZET
M>2VLX]%\*7%O;SATU.XL]UV8PV0&4( 7QQOWCUV]J])HH \[\0>"M>UF]G!_
ML1RUPLEKK+1F*^LTW9V+L7#%>@.\9'4&M[^P]2M_B =<MVM9+&YL4M;E9799
M4*,[*R *0V2V#DC'O7344 <QJ^CZS%XECU[038//);"TN8+YW160,61E90Q!
M!9N,8(/48K)M/!FKQZ/96]U<V+W46OG59FBWJA0R,Q"@@D'YNA./>N]HH Y;
M6M&UM?%5MK^AFPED%FUG/!>N\:[2X<,K*K'(.>".?6N3NM(OO!NGZ3JMYJ6E
MQ:E;W]XQ>83+:2)<.7*LX4F+HI!;(R,9/6O5:* .#^'%Q=ZE=>(]8N/)>*]O
M4,,]NC+#*%B128RW+*""-V "02 .E3KH'BG29-2L]"O--2QOKJ2Y2ZN0QGM#
M(=S[4"E9.22N2N,\YQSVM% ')2Z+X@TK6[^_T*33KA-16-ITU!WC,<J*$\Q2
MBG<"H7*_+R.",U!IG@F?29O"XBNHIDTHW+W4C#:TLDPR2J@8QN).">!ZUVE%
M '#7G@K4I;[4]0MKJUCO#JT6IV._<R';"L1248R 1N^[G&0?:IM2\-:]XIT7
M5++7KRQMTN5C%K:VJ>=%"R,'WNSJIDW, "N -HQU.:[.B@#@K+P9=I!?J=!\
M)Z7)+8RVR2:;;GS)'=<;B^Q2B^JX;KUXYTG\,7K6O@^(2V^[194>X^9L,! \
M9V<<\L.N.*ZNB@#SX^"]:_X1?Q%H(DL##>WCW5G-YC[L/-YC"0;<+CH,$Y]J
MU/&?AJ_UYM+DM5L;N&T=S/IVH.ZV]QN7 +;0V2IY *D<GH<&NMHH \TA^'FJ
M1>%=;TY!H]M<7>IQ:A:Q6B-';IL\H["-N5&8R,C/7.!TK=OO"UWK>K"ZU,VT
M<-QHLNG7,<$C,5>1@24)494 'DX/3BNNHH XA/#?B/45T?3]:GTO^SM,GBN#
M-:[S+=-%]S*,NV,9P3@MG&!BI)O"-_)X6\6Z6)K;S]8N+F6W8LVU1(H"[_ER
M#QS@&NSHH Y[7= NM1TG319SPQ:CIL\=S;M*"T;.JE2K8YP59AD<C(/:LQ_#
M.LZM=ZGJFKOI\-[-IDFG6EO:N[QQA\EF>1E!))V]%& .]=I10!P-CX6\37$/
MA_3=:FTD:=H\D4WF6AD,MP\:X0%64! "<D@G..@SQ#XA\%Z]K5[< _V(Y>X6
M2UUEHS'?62;L[%V)ABO0'>N1U!KT2B@#S>;X=RV^HZBUMH_A?4HKZY>X6[U6
MUWSVY<Y88"'S0#D@;DQG&:ZG1]#N-.\2ZUJ+M!]GO4MEA2+(*^6A4Y&, >F"
M:WZ* .1TKP<]AXUU'6))HFL) [65NN<PO+M,Y/'\3(",?WFK$TCX=2Z/);V<
M>B^%+BWMYPZ:G<V>Z[,8;(#*$ +XXW[QZ[>U>DT4 <!J?A3Q*FGZ_HVCS:2=
M,U8SRK)=F02P-*#O7"@A@6)(;((ST;'.WK'AZ[U#1=%LXI(5DL;RUGD+L0"L
M9!8#CKZ9Q^%=)10!QDWA&_D\+>+=+$UMY^L3W,MNQ9MJB10%W_+D'CG -:NM
MZ7JEUX?@M-.FLO/BV>9!>1>9!<H!AHWX)4'KN R"!P>16]10!YS;_#JYN=#\
M06%V=/TZ'4GB>WL+ &2UMGC(8-AE4'<0-RA5! ]>:LV/@R[2"^4Z#X3TN26Q
MEMDDTVW/F2.ZXW%]BE%]5PW7KQSWM% '(ZEX7U"X\&Z-I]K/;+J6E/;31F3=
MY,DD0 *D@9"GGG&>G%8^H^#O$NMMKUQ?R:3#/J-G;6T,<$DC+&8I6<[F*Y.0
M>H ],<9/HU% &%=:+<S^,]*UA7B%O:6<]O(I)WEG:,@@8QCY#GGTIOAG0[G1
M9]<>Y>%A?ZG+=Q>62<(P4 -D#G@],_6M^B@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
G **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>img129881027_19.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img129881027_19.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )J [$# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\_P#BG_S)7_8UV/\
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M" ,E[;M&67"M]PL.I'3'%7["^\0^%-&\#7%_KIOM,NYDM;I?LD<01)8AY R
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M_P D ]0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KS_XI_P#,
ME?\ 8UV/_L]>@5Y_\4_^9*_[&NQ_]GH ] HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *Y[Q=X?U+Q)IJV%CKTNDP2%DN_*MUD:>(C!0$\H?]H5T-% &<
M=&MX_#C:): 6]L+4VL6!G8NW:..^*C\,Z+_PCGAG3M&^T?:/L<"P^=LV;\=\
M9./S-:M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %>?_ !3_ .9*_P"QKL?_ &>O
M0*\_^*?_ #)7_8UV/_L] 'H%%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M (1S4?!UY_PDWB/5-_B6RB\G4[_SXUR6.X+M&&XQGT)]:]HKS_XI_P#,E?\
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M=Q5PO!=3P6ZGO7H5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M$/Q-F\'^&=0CTN*WM5G,DGR>:, EMVTGJ0,#T-5E\ ?&(,"?&=J1GG_29/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J"]O;;3K*:\O
M)XX+:%"\DLAPJJ.I)HO;VVTZRFO+R>."VA0O)+(<*JCJ2:\4EEU7XY:\;>W,
M]AX&L9?WDF-KWCC^OMT4<GG H )9=5^.6O&WMS/8>!K&7]Y)C:]XX_K[=%')
MYP*N_$GX>^$[%O"36FB6\!N-=L]/F\HLHD@;=N4@'DG ^;[WO7K>FZ;9Z1IT
M&GZ?;I;VD"!(XD& H_SW[UQ/Q3_YDK_L:['_ -GH [?3]/L]*L8K*PMHK:UB
M&$BB4*J_@*LT44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %0W=Y;6%NUQ=W$5O"I ,DKA5!)P.3[D"IJI:MI-CK
MNESZ;J5NMQ9SKMDC8D9&<]1R.10!Y9XV^%WB7Q3XT;Q#I?B2&S1$5;4JSAXA
MMP<,O8G)Z]ZS5^%'Q)# GXA7) /(^U3_ .-7KOX*ZOI;NW@_QGJ.G0$Y6UED
M;:#W^92./JI^M00_"SXBWK^7JOQ#N([?'/V>21B?;&5H ]BCO+5;E+$W<+7G
ME[_*\P;RHX+8ZXSWK@?B-\);;Q]J-OJ8U66QO8(1"N85EC90Q897(.<L>^/:
MM?P9\-]#\%/+<V?GW.H3+MEO+E]TC G)'H!D?7WKSSXW:OXUM_$%G8>'I-77
M37M%DE_L^-@2^]@?WB#(X XSCVYH Y_5/#^I?#BWC;7/#O@K6;/EO,9E@N''
ML&*Y/LJM7:_"?QIX2\2:W/;:1X0@T34UMFD>2".,J8PR@KO 4]2IQC'%>5:4
M\-A(L][\+-3U6ZSN>>^GG=G/N @4_B#7L?PR\83ZMJD^DKX!_P"$;M4@,PD2
M,QHS!@-N/+49.XGKVH ]0HHHH **** "BBB@ HHHH **** "O/\ XI_\R5_V
M-=C_ .SUZ!7G_P 4_P#F2O\ L:['_P!GH ] HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MU!JQX@\'Z;XBO=-OIS+;W^G7"SP7=MM648_@)(.5/<5@/_R7Z/\ [%H_^E%
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MMM4F\X;7X\R,X^3!YQ^M>KUYY\9W\SP/%IT8#75_J%M;P1YY9_,#8'_?->A
M84#VH 6O/_BG_P R5_V-=C_[/7<7\-Q<:=<PV=U]DNI(G2&X\L2>4Y!"OM/#
M8.#@]<5X_P",-#\5:9J/@Z;7/&/]M6K>);)%M_[,BMMKY8A]R')P 1CW]J /
M:**** "BBB@ K(?PIX<D=G?0-*9V)+,UG&23ZGBM>BDTGN5&<H?"[&,?"/AH
MC'_"/:3_ . 4?^%85OX>TG2+=+*\\'VU]Y0V1W4%E#(95' +YP0^.IZ$\YYP
M.VHJ7")O#%54K-MKU9RNG>#M'EN9[Z\\.Z9 )55(K4VL3"-1DY; QO)/.,C
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M(_&ZYUG3M GO2+18+E60[9,J"&1@#@XVCH>A]:OK\?-29@/^$"NADX_U[?\
MQJND\6ZC\5H/$ES'X:T:QN-) 7R996CW'Y1NSEP>N>U<CJ?COXM:'?6%OK&E
MZ79"]E$,4LB QECV+*Y /UH ]ZC;?&K8QD X]*JZGI6GZS9M9ZG96]Y;,03%
M/&'7(Z'![^]6DW>6N[&[ SCUILMQ!;X\Z:.//3>P&?SH H1>'='M]$GT:VTZ
MWM].GC:.2WMT\M6###?=QR1WZT[1="TOP[IZV&D6,-G;*<[(AU/J3U)X')YK
MCO!/CZZ\0>*_%FFZC)8Q6NE78AM'C^4NNZ098EB#PHZ8J32O&NHW_P 8M6\*
M,EJ=,M+%;B*1%/F,Q$1Y;."/G/;TH [ZBBB@ K'\,>&[/PIHXTRQEGD@$LDN
MZ=@6R[%CT &,GTK8HH XC5/A=I%_J]UJ5GJ>M:-/>'==KI5Z8$N&]77!YZ],
M=3ZUT.A>&M)\-Z*NDZ79I#9C.Y#\QD)ZEB>6)]_ITK6HH \];X.>'"Q@%[K2
MZ29/,.CK?M]C)SG[F,]>>M==K/A[2M?T.31M1M$EL'4+Y0^7;C[NTCIC QBM
M2B@#B]&^&6DZ3K%MJD^HZQJUS: BT.J7AF6VR,?(,#''KFNTHHH *\_^*?\
MS)7_ &-=C_[/7H%>?_%/_F2O^QKL?_9Z /0**** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 45Q^M_%+P;X<UB?2=6UG[/?0;?,B^RS/MW*&'*H0>"#P:U-"\8:#XDT>
MXU?2M06:PMG9)IWC>((54,V=X!P P.>E %CQ%X@T_P +Z'<ZOJ<OEVT"Y/\
M>=NRJ.Y)X%>6_#_P_J'CSQ,WQ%\4Q8B!QI%DW*QH#P^/0=O4Y;TJC$MS\</&
MWG2"6/P3H\N%4Y7[7)_]?_QU3V+5[E%%'#$D42*D:*%5%& H'0 >E #J***
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M@ HHHH **** "BBB@ KS_P"*?_,E?]C78_\ L]>@5Y_\4_\ F2O^QKL?_9Z
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MY^K=3[#BO0: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%  2 "2< =2:^8
MO'7QJ\0IXOOD\+:^ZZ2K!(E:S@(!4 ,59E8LI(+ G'7IQ7N_C[7--T7P;J9U
M'48[(W%K+# Q.79V0@;5').2.E?$U 'M/A_XD>/?'.G+X4TVZ,NKW<CO<:DZ
M)#]GM\*-J[ ,8.26QN^; [&O:? GP^TGP)IAALU\^^F ^TWL@^>4^@_NKGH/
MSR>:^?\ X!:3?7GQ(@U"!&^R6,,C7#X^7YT9%7/J2<X_V3Z5]6T %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !7"_&*:6#X6:S)#(\<@6/#(V"/WB]Z[JN/^*.D7^N_#K5=.TVW:XNY@
MGEQ*0"V'4GK[ T >;:/XZ^%4N@Z8->M+>ZU2.TBBN)9K R.SJ@!RQ'/2M;3_
M (B?![3;M+FPLK6WN%/R2QZ;M9?H=O%=5X8^'?AV+PMI4>J>&=-^WK:1BX\R
MV1F\S:-V3CDYS6J/A_X/!!'AG2LC_IU3_"@#HU8.BL.A&12T@    P!T%+0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MH :B)%&L<:*B* JJHP !T %.HHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\_^
M*?\ S)7_ &-=C_[/7H%>?_%/_F2O^QKL?_9Z /0**** "BBB@ HHHH ****
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M?_,E?]C78_\ L] 'H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !116-K_BW0/"\:/K>J6]GYGW%<DLWN%&21[XH V:*R]#\1Z/XD
MM#=:-J,%["IPQB;)4^C#J/QHUKQ)HOAVW\_6-3M;)",CSI &;_=7JWX"@#4H
MKR*_^.46H736'@KP]J&NW?02>6R1CWP 6(^NVJW_  B?Q4\;?-XC\01>'[!^
MMG8??QZ':>1]7/TH J_M"^+?LVBV7A^POHB]U*S7L<4@+JJ8VJP!R 2<_P#
M:^<*^JO^% >#UT*>R7[8U[(HVZA)+N=&ZY"C"X]1C.#U[UP,/[-NNG4@D^MZ
M<MANYE0.TNW_ '"H&?\ @5 #_ASX(U3XG>&DN=?\4:D-'LYOLD5A&W#!%4@Y
M)P -V/ND\5[1X<^'?A7PKM?2]'@6X7_EYE'F2Y]=S9(_# K3\.>'K#PMH-KH
M^FQE;:W7 +'+.3R68]R3S_\ 6K5H **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBN<\:^*QX2T:*YCM#>WUU<):65H'V^=,YX&>P
MZG/^- '1T5YTOBWQCX=U;3(_&6G:.--U*=;9+K2WD/V:5ON+('ZY/&1Q[UZ+
M0 5Y_P#%/_F2O^QKL?\ V>O0*\_^*?\ S)7_ &-=C_[/0!Z!1110 4444 %%
M%% !1110 4444 %%%% !1110 5G:YH=EXATQ["_0F,D,KH</&PZ,I[$?U(/!
M-:-% TVG='F2?".3S5$OB M!N^8)9A7*^@8N0#[[?PKT/3=.M=)TZ&PLHA%;
MPKM11S[DD]R222?4U:HJI3E/XG<+Z622]$E^04445(@K*UCPUH^OJHU.Q2<J
M,!@S(V/3<I!Q[9K5HHM<<9.+O%V,_2="TS0X##IMHD"-]X@EF;TRQ))_.M"B
MB@)2<G=NX5'-!%<)LFB21/[KJ"/UJ2B@2=C@O''@&PU2QBN-.TZVBN(&)<00
M*K2*>O3&XC /KC.,G@^5_P#"'QSW7V=#;B0G&V.Y#/\ ]^@3)^&VOI&BA62:
MY4[]U<ZX8RK&WOR5NTFOOWN>.VWP6N#81RIKDMI<MRT31;@/0$ANN,9ZCMSU
MJ _#[Q]HS%],U6"8=A%.T;'ZY 'ZU[3141BXJT)-?,TEF-2H[U8QEZQ7Y[_B
M>+CQ!\3]#P+S2;JX1>N(A,/^^ER?UJS;?&N6"3RM5T8HXZ["4(_ YKU^H;FT
MMKR/R[JWBG3^[*@8?D:J]3NGZK_*PO;867QTK?X9-?@[HXFP^+GAB\P)99K9
MCU\Q,C].?TKI;+Q1H6H &VU6U?/0&0*3^!P:S[[X=^$M0SYNAVR$]X,Q8_[X
M(KG+SX*Z#(2]C?7]H_8;U=1^8S^M+GEUC]S_ ,_\P]G@Y_#4E'U2?XIK\B?Q
M-\3/[.U"6PT:TCNY86VRSRMB,-W48Y/O5OPC\0DUZ]&FZA:BTOG!,11LQRXY
M('<'V]J\3?2]4L)I;;[3LEAD9'C<=&!Y]:GTV3Q FKV1L[-;F[BF6:%8QDL4
M^;H#TP#GVKH:BJ//*,D^]DU^ _J<9573IU(/YM2^YV7W=/O/IVBO)Q\6M9TL
MXU_PI<08X+J'C'Y,.?SK9L/C%X5N\">2ZLV[^;"2/S7-<RJ0>S_KYDRR[%15
M_9MKRU_*YW]%8UAXL\/:GM^QZS92,W1/."L?^ G!JUJ^L66AZ;)?WTNR!< ;
M1EG)Z*H[D_YXJSD<))\K6I?HKS>/XMQF[Q+H<ZVN?]8LZM(!Z[,8_#=7H%C?
M6VIV,-[9S+-;S+N1U[C^A]CTJI0E'XDT*VETT_1I_D6****D04444 %%%<IK
M/Q#T/1KUK-C<7D\9*RK:('$9'8DD#/L"2.]-)MV0U%O8ZNBLK0O$>F^([5I]
M/F+%"!)$Z[9(R>FY?Z]#@X-:M(&FG9A1110(**@O;VVTZSEN[R=(+>(9>1S@
M#_/2N0C^*?AY[ORFCOXXLX^T/;_)CUP#N _X#32;V*4&]4=M13(9H[B%)H9$
MDBD4,CHP*L#T((ZBGTB0HHHH **** "BN4UGXAZ'HUZUFQN+R>,E95M$#B,C
ML22!GV!)'>M;0O$>F^([5I]/F+%"!)$Z[9(R>FY?Z]#@X-.SM<IPDE=FK111
M2)"BBJ6JZO8Z)8M>:A<+!"#M!/)9NP4#DGV% TFW9%VBN,L?B?X?O+M8)%O+
M-6.!-=1!8\^Y!.WZG KLZ;36C&XM;A1112)"BBB@ HHKC+_XG>'[*[:",7=Z
M%.&EM8PT8/LQ(S]1D4TF]$4HM['9T51TG6+#7+%;S3[A9H2=IXPR,.JL#R#[
M&KU(333LPHHHH$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>=_$(?\5M
M\/S(/W(U-P3Q]_9\OZUZ)7.>,_"W_"5Z/%;PWC6-_:7"75E=JNXPRKT..XP2
M,>] '/?&O9_PKJ7=_K/MEMY7KN\P=/?&:]#7[HSUQ7G:^$O&/B+5M,D\9:CH
MYTW39UN4M=+20?:95^XTA?I@\X''M7HM %>_FN+?3KF:SM?M=U'$[PV_F"/S
M7 )5-QX7)P,GIFO%_'_B+QE=_P#"+_VCX$^P>3X@M);?_B;PR_:)ANVQ<#Y=
MW/S'@8KW"N?\5>&/^$F_L3_3/LW]F:K!J7^JW^;Y>[Y.HQG=UYQCH: .?_X2
MWXA_]$P_\K]O_A1_PEOQ#_Z)A_Y7[?\ PKT"B@#S_P#X2WXA_P#1,/\ ROV_
M^%'_  EOQ#_Z)A_Y7[?_  KT"B@#S_\ X2WXA_\ 1,/_ "OV_P#A1_PEOQ#_
M .B8?^5^W_PKT"B@#S__ (2WXA_]$P_\K]O_ (4?\);\0_\ HF'_ )7[?_"O
M0** //\ _A+?B'_T3#_ROV_^%'_"6_$/_HF'_E?M_P#"O0** //_ /A+?B'_
M -$P_P#*_;_X4?\ "6_$/_HF'_E?M_\ "O0** //_P#A+?B'_P!$P_\ *_;_
M .%'_"6_$/\ Z)A_Y7[?_"O0** //_\ A+?B'_T3#_ROV_\ A1_PEOQ#_P"B
M8?\ E?M_\*] HH \_P#^$M^(?_1,/_*_;_X4?\);\0_^B8?^5^W_ ,*] HH
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MW_PKT"B@#S__ (2WXA_]$P_\K]O_ (4?\);\0_\ HF'_ )7[?_"O0** //\
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M]\7PH!TJR8@=2T.3^3TOV_XO_P#0(L?^^XO_ (Y7J=%'L_[S#Z^O^?4/N?\
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M .%>@44 >?\ _"6_$/\ Z)A_Y7[?_"C_ (2WXA_]$P_\K]O_ (5Z!10!Y_\
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M7P.#TQ_/L >GT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 =J\[^#A$'A;4=-8J+BQU:ZAF7H0=^<G\_P!*]$KC=;^&
MNDZOK$^JP:AK&D7ER +I]+O#!]I &!O&"#^&* ,WX?-]L\<^/M1BPUK)J$5N
MC@Y#/%'M8?AD?G7HE9F@>']-\,:/#I6E6_DVL62 226)Y+$GDDFM.@ HHHH
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MZ@%Q!?ZS=7$#9SN0L!G\P?RKT.JVG:=::3IUOI]A L%K;H(XHUZ*H_SUJS0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
>*** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>img129881027_20.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img129881027_20.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" .6!%$# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH S]:US3?#NERZEJUW':VD7WI'[GL !R2?0<UYS#^T)X)DO
MQ;,NJ11;L?:7MAY>/7 8MC_@.:P/C7NUGXB>#?#=P^W3YY4:1=V-Q>0(?QP,
M#ZFO7-6\+:/K/AJ3P_<V42Z<T?EI'$BKY/& 4XPI';B@"_;ZG8W6F)J4%W!)
M8O'YHN XV;,9W9Z8KS;4?V@/!5A?-;1?VC>JIP9[:!?+_ NRD_4"L_XK:?;^
M!/@O_8FA_:([2:Y2!BTA<[6+.V2>@)7H,#GWKL_AKX>T_1/A]I,-K;Q@W5K'
M/</L&97=026]>N/H,4 :GACQ=HGC'3VO=$O5N(T.V1"I5XSZ,IY'UZ'M7+V'
MQF\-ZAXR'AA+74X[TW3VHEDBC$6]21U#DX)'''<5Q'AZVA\)_M+7FD:3B&PO
M86+V\8^1,Q>9C';##CI@'%>=RV4W]M^--<M5Q<Z+JBW:.,9'^D,/Z@_A0!],
M>-O'>D^ M,M[[54N95GE\J..V56<G!).&8# QZ]Q5&W^)^BW/P_N/&:6NH#3
MH'V-$8T\XG>%X&_'5AWKR_XH:C'XXUJ*.V)>PTSP[+JK @X#R)E?QP8S^=5]
M)_Y-4U;_ *^?_:\= '7#]H[P>2 =.UP>Y@BX_P#(M>C>&/%.D>+](74]'N?.
M@+;'##:\;#JK#L:\3\,?&OPUH_P_L?#USI&I7EU#:F!H_*C,,K'/&2^<'/\
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M2(M?^%'B329\;+RYDAS_ '28EP?P.#^% 'LWA_7+/Q)H-GK%AO\ LUW'O02
M!E[$$ D9!!!YK%L/B%I6I^.;WPG:6U])>6:LT]P(T\A< 9^;=GJ0.G6O-/@[
MXO\ ^$?\">)].U/Y9O#[23B)CS@YR@_X&I'_  *M3X!Z/.VB:MXKOV+WFL7#
M8<CDJI.X_BY;_OD4 2O^T9X01V4Z=KF0<?ZB+_X[6]X.^+_A_P ;Z[_9&FV>
MIQ7'E-+NN8HU3"XSRKDYY]*\=^%/C76_"UEJT&E>#=0UY)KD.\MJ7Q$0,8.V
M-OKVKVKP1XXUSQ3J-S;:IX+U'08HHO,2:Z+[9#D#:-T:\\YZ]J .XKR>^_:#
M\)V%_<V<NGZT9+>5HG*PQ8)4D''[SIQ7K%><?'7_ ))/J7_76#_T8M $&@?'
M3PQXCUZST>SL=72XNY/+C::&,(#[D2$_I5_Q5\8_"7A+4'T^YGN+R\C.)8;*
M,.8SZ,20N?;.1WJQX:O9--^"NGW\()EMM$$R #))6+(_E7%_L\Z-:2Z%J7B.
M=!-J=Q=M$9Y!EE4!6."?4L2?7B@#N/!_Q1\,>-I_LNFW,L5[M+?9;J/9(0.I
M&"5/X$FJ7C'XP>'_  3KITC4K/4Y;CREEW6T4;)ALXY9P<\>E<)\<K.W\.^+
M/#/BC356VU)YSYK1K@R["I#$#J<$@^H(%>YWASIUP?6%OY4 >3_\-'>#_P#H
M&ZY_WXA_^.UTWBWXL>'_  :FFG4(+^9M0@^T1I;1HS(G&-VYQC.>V>AKD_V;
M_P#D2M4_["!_]%I65;Z9#\4?B_XLDG^>PT^QDL('ZA'(* _GYC"@#V[2-4M=
M;T>SU2R8M;7<2S1D]<$9P?<=#[UA^'_'NE^)/$VL:#9V]XEUI3LD[S(H1B&*
M_*0Q)Y'<"N-^ >KRR>%[_P .WF5O-&NFC*$\JC$G'X,'%9OPJ_Y++X__ .N\
MG_HYJ /;:"<#-%(WW3]* /(G_:,\(([*=.US(./]1%_\=KI?!_Q:\,>-=0_L
M_3Y+JWO2I9(+N,(S@=<%20?7&<_E7B/PS^(&I>"-(UI[;PK=ZM:-<"6>ZBD9
M(X,#&&(C8#UY(KJ_!5KJ_P 2/BC:_$$:=:Z9I5L"A$<ZR/(ZJ5PV,$M\PR2!
M\H'6@#M?%7QI\.>$/$5SHFH66JRW-N$+M;Q1LAW*&&"7!Z$=JSK']H/PGJ&H
M6UE%I^M+)<2K$A>&( %B ,_O.G-<9XAUZ_\ #G[1FJ:AINAW.M7"VZ(+2VW;
MR#"F3\JL>/I7=Z'\3_%&JZY96%U\--8L+>XE6.2ZE,NV$'JQS"!@?44 :'C'
MXP>'_!.NG2-2L]3EN/*67=;11LF&SCEG!SQZ5S__  T=X/\ ^@;KG_?B'_X[
M7K-]_P @^Y_ZY-_(UY!^S?\ \B5JG_80/_HM* .WT_XC:1J7C,>%H;:^6^-L
MMSYCH@BVM&K@9#9SAAVZU/XV\=Z7X#L;6[U2"\FCN9?*06J*Q!QGG<R\5YU8
M_P#)U>H_]>8_]$)3_P!I#_D6=$_Z_C_Z : .Z\;_ !'T?P#'8/JMM?3"]W^7
M]E1&QMVYSN9?[P]:Y*+]HOP=)*J-9:U$I."[P1X7W.)"?R%8_P"T#,]O=>"Y
MXX6F>.>5UB7JY!B( ^O2J'BKXK:UXJLY_!<G@5K#4M3011IJ%SM()Z$+(B<\
M?*21SCK0![#J/CC1K#P0WBY'EO-*"+(&ME!=@S!> Q'()Y!(Q@U)X0\8:7XV
MT-=5THRB+>T;Q3 "2-AV8 D#(P1ST(KS37?#%YX1_9JO=(OY$:[0))($.50M
M<*VT'OC/YYKB_AKJEY\-=?T674)<Z#XFME8R'A8WR0">>JD@$_W6S0![EX:^
M(>B^*+G6X;9+FU&C-MNI;L(B 98%@0QX&PG)Q5ZQ\7:7?:UJ6F*[1/8/ C32
MLBQS-,NY!&=V6R/8=>,UY1\&+2'4-=^(=I<0PS0S7*HT<R!T8%YNJ]Q[5N>&
MO@RNA>(+#6)KC3KF0.[WL#62^4&SF,P#_EF5XYH ]9HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#"LVU2I]\. ?:O;:* /,/A+X!U/PTFIZ[XA8'7-58M(@8-Y:Y+')'!8L<G'
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M./SGMX&:,,6&Y78# &Y%<YKZ$T+2(M!\.V&DP8\NTMUA!'<@8)_$Y/XUI44
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MM7>M]T_2EHH \>^!&A:CIFB:_;ZQI5U:"XNAB.\MVC\Q=I!X8#(K'T30-?\
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M=O;6-)+LBZ2VCA#\JN]\Y8CG'I4#_$JV3PO#K!TNZ68:BNG7=BW^NMY2<$8
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M6XN8K]+%K1\;MK(\9 '&5P1V/-:WQ3MH;SPM9VMQ&)(9M5LXY$/1E,R@C\J
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M*208+(.%8%3G''(_'H+^Y\5^)O%6IZ5H&N0:%8Z2L22W!LEN9)Y73?C#G 4
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MN1N0C(R#@=^H%:6B>'3I6LZWJL]V+FZU2=7R(MGE1(NU(^ISCDYXR3T%;M%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %5I+"VEU"WOWBS<V\;QQ/N/RJY4L,=#G8O7TJS1
M0 4444 %%%% !5"+_D/WG_7K!_Z%+5^J$7_(?O/^O6#_ -"EH OT444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%>?VT.B_P!D7FL^(M;U"U!U*^C,CZY<V\85+J5$55655&%50 !VKF9?'GAJ
MSUW2)?"[^*=:VW;I<);S7=TDR>1+\BK,^UF#;&X' 0G/% 'LU%<!_P ++OEY
M?X?^+ @Y)6S5CCV&[FE7XO\ AJ!PFKV^L:*QQQJ6G21X^N 10!WU%9ND^(-&
MUZ(R:3JEG>J!EO(F5ROU .1^-:5 !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %4(O^0_>?]>L'_H4M7ZH1?\A^\_Z]8/\ T*6@"_1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MT63H!VFF'=CV';^;M$TB]^(.JV_BKQ) \.CP-YFCZ1(.W:>8=V/8= /U]*H
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 50B_Y#]Y_UZP?^A2U?JA%_R'[S_KU@_P#0I: +]%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%([K&C.[!549+$X %
M$5U=6]C:37=U,D-O"A>21SA44#))->;Z=:W'Q3UB'6]3A>+PE92;M-L9!@WT
M@X\^0?W/[JGK^>6NTOQ:U@Q(7C\$6$WSL,J=5F4]!_TR4C\3_P".^G1QI#$D
M42*D: *J*,!0.@ ["@!U%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 9/B'PSH_BG36L-8LH[F'JA88>,_WE8<J?I7$&
MX\4?#/!O)+CQ'X47CS\;KRQ7U;_GH@]>H]@,'TVCJ,&@"EI6K:?KFFPZAIEW
M%=6DPRDL9R#['T/J#R*NUY[JW@K4/#^HS>(/ ;QVUS(=]WI#G%M>>N!TC?T(
MP/ISG>\)^--.\602I"LEIJ5L=MYIUP-LUNW0Y'<>A_D>* .DHHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J$7_(?O/^O6#_ -"E
MJ_5"+_D/WG_7K!_Z%+0!?HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBN8LO%UWJ5A;WUGX2UR:UN8EFAD$EFN]& *G!N 1D$'! - '3UYCJU_
M<_$W6I_#>C3O#X9LWV:MJ,1Q]I8=;>(^G]X_T^]2U'QE?_$36G\%^'H[G24
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M;!E8'N".M2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/[HK8H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *9+%'/$\4T:R1N"K(XR&!Z@@]13Z* /.K
MGP-J_A.YDU'P!=K%$S;Y]#NV)MI?7RSUC;].G0#%%O\ %:&[N;/1UTLV7B2>
M?R9--U29K=8QL=MXD",&4E HP,DL.E>BUQOCS0-+\17?AFPU6SCN;>;4GC<'
M(;;]DN&P&&"/F53P>H% &E]L\8?] +0__!S-_P#(M7= U276-*%U/;);3+//
M;R1)*9%#12O$V&*J2"4)' Z]*X]? _BKP]QX3\82FU7[NGZS']HC'L)!\ZCV
M%9/AGQ;XMT72YXK_ ,%7%_"-0O2UUI,ZR!I#=2F0"-OF #[@"3R * /6:*X
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M-+R<-]X2QZ>V?KF>NRHH \STOX6>&=7EU>YUCP='8I/>!K6W9UC:.(0Q*?\
M42%0#()#@'O[U=_X5)I-MSI6N>(]*QT%GJ;@#\&SD?XUW]% ' ?\(?XXL/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **S=;UVP\/V:76H2,D3RK&-JECDY)./15#,3V52>U:5
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M&1E$/V**! 3T;C)XJQ)X)TB:)XI9]:>-P59&UR](8'J"/-Y%;MM;16=I#:P
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M %Z/$_B?3?">COJ.I2D*#MBA3F2=ST1%[D__ *ZYGPQX8U+6M9C\8>,(P-0
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M4]-LYK#2H+.6^FO)HH]AN9P-[G^\<8%<8?#GQ(MR3!X]L[ON%N='CCQ[90T
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M? ^C6\8C@EUB&,$D)'K=XJC)R< 2X')- '.^&-*\56/B"72CXE@32=*D58[
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M_LW[#;?8-GE_9?)7RMO]W9C&/;%.L-.L=*M5M=.LK>SME)(AMXEC0$]>% %
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MYMW^]%-&'5OJ#P:GHH J:=I6G:1 8-,L+6RA)R8[:%8U)]<* *MT44 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 50B_Y#]Y_UZP?^A2U?JA%_R'[S_KU@_P#0I: +]%%% !1110 4444
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M86Z 95N?:M#P=XQ?Q/)J5E>Z7)I6K:9*L=W9O,LH3<,J0X # @&@#J:H1?\
M(?O/^O6#_P!"EJ_5"+_D/WG_ %ZP?^A2T 7Z*** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "N8\1_#_ ,.^)I1<W=F8-07F._LV\FX0]B''7\<UT]% 'G/D
M_$/P=_J98O%^E)_!*1#>HOLWW9,>_)]JW/#GQ"T#Q)<&QCFDL=40XDTZ_3R9
MU/IM/7\,UU58?B/P?H/BNW$6L:=%.RC]W,!MEC_W7'(^G2@#<HKQ[Q#HGC'P
MJ^DVECK%_P"(='FO"B6#W;6MX<0ROL^T(02H5"W)'*J,$5I^'M4\':_=G3I+
MWQ%I>KJ</IVHZU?0S ^@!FPWX'/L* /3J*P/!K2'P^Z2333>3?WT"//*TK[$
MNI40%F)8X50,DD\5OT %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110!\^_%2[L[;QV\C66HZ)K2,K6FIV4KN+\"%PORA<!@^Q
M.^0Q!.*/&-W<S:IX?G\;7&H:%$=!.[4-/B*RRW3?>A=E!P,<E, <GIFO>;JP
MMKV6UEN(M[VLWGPG<1M?:RYXZ\,PY]:LT >#W$6IQ_"'P-JUYI1MX]&U2&ZN
M(H(2I%NK-^]*#H2,$^N<]ZZKX;SIKWCGQCXKLA*=)O7@AM)G1D$WEIAF 8 \
M''YUZ=10 R9&DB9$E>)CT= "1],@C]*SK&%X=;O5DN9;@FV@.Z0*"/FEX^4
M5J50B_Y#]Y_UZP?^A2T 7Z*** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MNEYP*U*H1?\ (?O/^O6#_P!"EH OT444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 50B_Y#]Y_P!>L'_H4M7ZH1?\
MA^\_Z]8/_0I: +]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% $<MQ! T2S31QM,_EQAV +M@G SU. 3CT!J2O /BAH\D/CQM3\
M3V6J76AS2QBTN[&7)M$6%RZJF>&#@29/&$/7D5T7Q#\0RW_@E/#_ (;U"2[,
MVDF_N[Z7EA9JG5L ?/(0%Z#^+@4 >NT5X?J4TTGP@^'NCK-)%;:M=VEG=>6Q
M4O$P.Y<CL>/RKHOAO F@^.?&/A2R,HTFQ>":TA=V<0^8F64$DGDX_*@#TZJ$
M7_(?O/\ KU@_]"EJY--%;Q-+-(D<:_>=V  ^I-9UC=6]WK=[);3Q3(+:!2T;
MA@#NEXR* -2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %4(O^0_>?]>L'_H4M7ZH1?\ (?O/^O6#_P!"EH OT444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ JA%_R'[S_KU@_]"EJ_5"+_ )#]Y_UZP?\ H4M
M%^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M23^%G0L!]0",_G6<MCJ:WDER+ZTWR1I&1]D;&%+$?\M/]H_I0!J450\K5O\
MG]LO_ -__CM'E:M_S^V7_@&__P =H OT50\K5O\ G]LO_ -__CM'E:M_S^V7
M_@&__P =H OT50\K5O\ G]LO_ -__CM'E:M_S^V7_@&__P =H OT50\K5O\
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MM %^BJ'E:M_S^V7_ (!O_P#':/*U;_G]LO\ P#?_ ..T 7Z*H>5JW_/[9?\
M@&__ ,=H\K5O^?VR_P# -_\ X[0!?HJAY6K?\_ME_P" ;_\ QVCRM6_Y_;+_
M , W_P#CM %^F32I!#)-*P6.-2S,>P')-4_*U;_G]LO_  #?_P".U%=6.IW=
MG/;27UH$FC:-BMHV0",''[R@#4HJAY6K?\_ME_X!O_\ ':/*U;_G]LO_  #?
M_P".T 7Z*H>5JW_/[9?^ ;__ !VCRM6_Y_;+_P  W_\ CM %^BJ'E:M_S^V7
M_@&__P =H\K5O^?VR_\  -__ ([0!?HJAY6K?\_ME_X!O_\ ':/*U;_G]LO_
M  #?_P".T 7Z9#*D\,<T3!HY%#*P[@\@U3\K5O\ G]LO_ -__CM16MCJ=I9P
M6T=]:%(8UC4M:-D@# S^\H U**H>5JW_ #^V7_@&_P#\=H\K5O\ G]LO_ -_
M_CM %^BJ'E:M_P _ME_X!O\ _':/*U;_ )_;+_P#?_X[0!?HJAY6K?\ /[9?
M^ ;_ /QVCRM6_P"?VR_\ W_^.T 7Z*H>5JW_ #^V7_@&_P#\=H\K5O\ G]LO
M_ -__CM %Q)4D>148%HVVN/0X!Q^1'YT^LN&QU.&6XD6^M"9Y!(V;1N#M5>/
MWGHHJ7RM6_Y_;+_P#?\ ^.T 7Z*H>5JW_/[9?^ ;_P#QVCRM6_Y_;+_P#?\
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MJY@D\N)XU6* I]XJ222[?W!^=7Z "BBB@ HHHH **** "BBB@ HHHH ****
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M3L^7:<Y  )QS6GX_\4W]G:^#M&CO=5@BU2#S+N;2UWWDH5%PD9Y.YF/7^F:
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M@-(>C/QGT';O7JE !1110 4453U::_@TNXDTNUCNKX+^YADDV*S>[=@.OX4
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH ***XK4_#7CB[U.YGL/B$+&TD<M%:C18
M9/*7LNYFRWU- ':U!>WEOIUA<7UW((K:VB::60@G:B@EC@<\ &N&_P"$2^(?
M_13_ /R@6_\ C61XL\+^.X/!VN37?Q%^UVT>GSM-;?V) GG((V+)N!RN1D9'
M3- ';_\ "9:7_P ^NN?^"*]_^,ULV5Y;ZC86]]:2"6VN8EFBD (W(P!4X//(
M(KR;[=JG_1>M#_\  &R_^+JSX3\+^.Y_!VAS6GQ%^R6TFGP-#;?V) _DH8U*
MIN)RV!@9/7% 'J]%>?\ _")?$/\ Z*?_ .4"W_QJUIOAGQS:ZE;3WWQ"%[:Q
MR!IK8Z+#'YJYY7<K97/J* )_B7XJO_!O@N?6--BMY;F.6-%6X5F3#-@\*0?U
MK@M2^(/Q9\-6!U?7_"6CQZ7$R^<T4P#$$@ #$S'.3_=-=#\><?\ "K+O/3[3
M#_Z&*\8UO2OA3I^BS7GAWQ3JMSK,(5[:&>W+1NX(.&#0J,?4_@>E 'T$_BV:
M3QKH.F07.GQVFI6)NC;SQ3?:F^4D;2!Y8 P,ACG@^U2ZO\2O!V@ZM_9>I:[!
M!>@@-&%=]A]&*@A?Q(KA([J^O?B_X NM2B\J_FT-GG3;MVN4<GCMSV[5G>"]
M8\/:#X4\:Z9XKN+6#6&O+@WD-T0);D%?EV@\N,[L 9QG/?D ]/\ &_BY/#'@
M:ZU^S,-S(4068SN25W("]#R.<\'H*K?#?Q?=^,/#TTVIP0VVK6=U);7EO$"H
M1@>."21P?7J#7A\<OB>^\.^!O">G:>+[4+4-JYM+A@JE!(QB#DLOR[<G&1PR
MBNM\!ZAXDT#XNW5OXLTJ#3)?$T1E6."0-$98P3D8=L$C=G)ZD4 =+;_&;2=0
MUO7]+M-J364#FP,L;G[5)&CL^0 -JC8.I!/-:OA_XBV1^'&F^*?%%W::?]JW
M!O+5MI8,P 5?F8G"Y[]ZXG2[RUL_&/Q8L;FYAAN[J(M;PR2 /*!%*QVCJ< @
M\=JP[369;'P!\.;!9['34NYIR=8N[2.8V960_<W\*3GD\=!R,4 >X>&_&/A_
MQ=#-+H6IQW@A($BA61DSTRK '!P><=JW*\+^&][86OQ6\87D>O3:K90Z>LDM
M_*=YEV[2[#:,$#! QVQC->RZ-K.G^(-)@U32[C[193@F.38R;L$@\, 1R#U%
M '(:%\0)+C5/&@UK[-;:;X?N BS11N6\OYLEADY/RCH!5ZS^*?@B_P!2M=/M
MO$-M)<W04Q+L< ENBEBN W;:2#GC&:\Q_P"7'XS_ /77_P"+H\76L%O\#? C
MPQ)&ZW=HX91@AF1BQ^I/- 'L'B3QKX<\(K$==U6*T:7_ %:%6=V'KM4$X]\8
MJ_H^M:;X@TV/4=)O(KNTD^[)&>XZ@CJ#['FO,KF^T_0_V@[R\\0W$-I;W&D*
MEC<7;A(A@KN4,W /#=^_O6WX3\9> ;2PM[;0Q]@@O]0>V@06L@$\_&2& (((
M*\D],#C&* /0:*** "BBB@ HHHH **** "BBB@ HK*\0V&KZCIGD:+K0TB[W
MAOM1M%N/E&<KM8@<\<UDC0?%W_"-&P/C53JOG[QJ?]E1<1X_U?E;MO7^+].]
M '5TUW2*-I)&"(H+,S'  '4FN6&@^+O^$:-@?&JG5?/WC4_[*BXCQ_J_*W;>
MO\7Z=ZQ]6T?Q/=Z+#X1F\6+<ZE?/)+<ZC_9L:>7:!<%#&&VG+E5ZC(+>AH [
MNQOK74[""^LITGMIT#QR)T93WJQ7G%EHGBG289?#2^+DBO+N1K^VU0:7&0?F
M_?0^5NV@Y97![[GXXK<&@^+O^$:-@?&JG5?/WC4_[*BXCQ_J_*W;>O\ %^G>
M@#JZ*Y0:#XN_X1HV!\:J=5\_>-3_ +*BXCQ_J_*W;>O\7Z=ZU?#UAK&FZ:8-
M;UL:Q=>86%R+1;?Y<#"[5)''//O0!PVB_%.:Y^+6J>#M3BM88$D:*QFC5@SN
MO.UR21DC., <C'>MOP1XNO\ Q+KOBJQO(;:.+2+\VL!A5@S+EAELL<GY1TQ7
ME[^%YO$OBGXD/I[&/6-.O[>]T^11\PE3S#M'UZ?7'I5[X.^)@FD^/?$]^JQG
MSQ>3(.F[:[$#\>* .@U;XKWFG_%--!2TMCH$5S#975XRMO2>120 V[: #UR/
MX6KH_B+XVN?!VG6"Z=IXO]4U*Y%M:0LVU-Y[GUY(&..O45X5%H_Q$UKP)J,T
M7AJUGT[5KDZM)?&51/N!SE09 <<' VYP3CK7<>)_%^B^(OAEX7O_ !)HDU[I
MEZ_E7=[;S;9+&=1M+ ;3NSAC@\8'?B@#=\/?$+Q=;>+K#P]XZ\.VVG2:D&^R
M7%H^4+*,X/SN#Z<'(R..<U2U+QY\1[OQKKNB^%-!TB_M]+E1&:8E' 9<C):9
M0>AZ#M7,Z!XJ32_'FA:9X,\8:OXCT^]G$5S8ZA$[>3'W8.X7&!EOE4#Y>2>E
M;.C>-O#W@[XK>/#KVH?9/M5Q;^3^YDDW;5;/W%./O#KZT =?X \?W_B+4M0T
M#Q#I/]EZ_IZAY8DSL=#CYER3CJ.Y!!!!-8^@?%>\U7XG3:%/:6T>A33SVMA=
MJK!Y9H@"06+;2#ST ^\M<A=^-X[OQ=XK\>Z,LHTVST@:?;W$J%1+<.RA,#\V
MQUP!G&:YRXTCXAZ+X)TBXF\,VMOINB3C4XKU)5,Y+'<2X\PG!R,C:",#T- '
MOGC[QQ!X(TB&<6DE]J%W*(+.SCZRO^ / ]@220.]<--\2?B-X:1-3\7>"[>/
M1"P#R63YDB!/!;]XWL.0N3QD9IWQ(U0R6_@7X@VUK+=:993"XN(XQN*)(JG/
ML1M(R>,XKG/B#\;+'6--U70=+MX+VQO[9$@N<O&\3'&X2*Z@9ZX*G' Y.> #
MWQ=1M'TH:F)U^Q&'[1YO;R]N[=^7->2'XE_$+Q"DVJ^#_!T$^@QLP2:[/[V8
M*2"5&]?3H V#QDUV]KX?G;X21^'XY%:Y;1OLH='!4N8MO!'&,GK7!>!/BOX:
M\*^";?0]?>YT_5M+5X);0VSEG8,3P0, G_:(Y_.@#T3PMXTMO$'@U?$5];/I
M,2!OM"W7RK'MZD,0,K[_ (=12:#\1?"7B:_:PTC6H;BZ )$11XV;'7;N W>O
M&:\^\>^(;OQS\$AK=MI=W:6OVQ'N('()DMU8@L".JYP>1V/;FD\9ZMH7B+7O
M 5MX0N;2YU"&]CD3[&03;VP +*V/N# ^Z<< \4 =F/B_X!*Q'_A(X!YLAC4&
M&4$$?W@5^4<]3@>_%:6G?$#PIJ^OMH>GZW;7&HKG]TFXAL#)VOC:Q ]">A]*
M\0TFU@'[-'B680Q^:^H99]HR<21 <^V3^9KJ-5MX;?Q+\(%AB2,"' "KCCRX
MS_,G\Z .\U+XI>"](O+RTO\ 7(X+FSD$4\1AE+!CGH OS#CDKD#C/45NVOB+
M1[S01KMOJ5N^E^69#=;\(JCKDGICN#R*\B\)ZWX<T7XQ>/&UR[L[2>60""6Z
M8*"@SYBACQDY3COCVKEA9WL_P/URZL89AHK^(#<QQ*I&;0$ D#^Z& [<;3Z4
M >Y:#\1/"7B?4&L-(UJ&XNQDB(H\;-CKMW@;OPS56X^*O@>UU=M*F\0VZ7:/
MY;#8Y16[@R;=@_.N%\::OH/B+7? =OX2N;6ZOX;U)%^PX+6]J "RL%Y48'W3
M@\'BN0NIH?"^A7K>&O&.@ZOH"W+2R:#K-H!,S[@-OENN]B,#GY>F: /;8O%<
MB^/-6TBXO=-^PV-B+HQ1Q3_:4&%)9CCRRN">%)/2LSP1\6-$\8W&J1>8EF]H
MTDL:2[AFU0+F5V("KR3QG('YUS_@NX>[^-VI7,EI]C>70+9VML8\DE8CLQVQ
MT_"N-T^1I/A!X^T>UN(_[4CU26XDM%<>;Y"O%O;;G.T8.3TX- 'M6A?$7PEX
MDU1M-TG6H;B\7)$6QTW8Z[2P ;UXSQS745\_:1:6>L7_ (,$OQ-MKN:WDCDL
M-/M=%02Q;0NZ)FB.8Q@8._C@GG%?0- !1110 4444 %%%% !1110 445A>)M
M+U_5(;=-!\2#1'1B97^PI<F4<8&'("XYH W:*\__ .$2^(?_ $4__P H%O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6%=^+M,LM
M>AT:5;TW4H8KLM)&4XV],#+#YQEE!5<'<5K=K+N?#NDW>JKJD]H)+Y#&R3%V
MW)LW;=O/ ^=L@<')SF@#!OOB-I]CK;6C6%Z]A$94N-255\J)HVC5^,[F53(
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MXQ(QD9%4$D  G)/0<'&9K5Q-J>IW_ASPW!%;W<ZJ=5U01KMM@RX _P"FDI0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *QK'0/L7BK5];^T[_P"T8K>/R?+QY?E!AG=GG.[T&,=ZV:* ,C4]#.HZ
MWH^I"Z,1TYIFV!,E]\93KGC&<]#65_PBFHWVJZ5=ZWK%M?1Z7(TMOY>GB&9V
M*E?WC[R",$Y"J@) / &*ZRB@#E-)\(WVD_8K%-=D_L6PE,MO:QQ,DQ'.V.27
M?AXUW'Y=HSA<DX.<R^^'FH7&B:OH-MX@CMM)U&>6X*BPW3HTAW%3)Y@#+N[;
M <<;N]=]10!CZ/H1TK4]7O3<^:=1FCF*B/;Y>V)8\9R<YVY[=:Y[Q1HR>)/&
M.BPPPWB?8G+7\Q@=(9+?Y9!%O8;7S(L?"DX ;.*[FB@#G]1\/7C:_P#VWH^I
M165[);BVN%N;8SQ2HI+*=H="&!8X.[&">*H/X-OHKC2-0M-=9]5L$FC>YU"W
M-PLXE(+_ "AT*88#;M;  Q@BNOHH XFU\ SQ0RBXUIKF:76HM8>5K8+EE"@Q
M@!N 2O![# YQD]7JFFV^L:3=Z;=J6MKJ%H9 IP=K#!P?6K=% '-Z=X?UF"ZL
M3J/B)KJTL%*Q106Y@:8[=H,[;V$F!G@*HR<XX %>#P3Y'AG1M'_M#=_9M\EY
MYODX\S;(S[<;N/O8SD_2NLHH X?4/ =_-INI:/8:]'9Z/?S/.T!LO,EB9VW,
MJOO V%N<%2<$@$<8MZOX(_M5M?/]H>5_:R6J?ZG=Y7DG/]X;L_ACWKK:* .6
M\1^&8-1N[W4[I)[N!])EL'L;=%\R0,P;*,S ;N, 'OWKG=&M]8U;Q9X>N);J
M]N;/28I=[W&CRV&-T>Q=WF']Y(>Y0!1@\#(KTNB@#'\5:%_PDWA?4-%^T_9O
MM<?E^=Y>_9R#G;D9Z>HK,N_#&KZW'!::]K-G/IL<B2R6UEI[0&<HP95=FED^
M3(!( !..N,@]710!R]UX8U*+4]3O-#UJ/3QJ8!NDFM//VR!0@DB(==K;0/O!
MAD#CKDF\*7=M?VVH:-K#6]['9"QFDOXFNQ/&IRK-\Z'S 23NS_$<CICJ** .
M8G\)3H-(N;#6)UU338WB6[O5-R)T?&\2KN4G) (PRX(';BFCPE=32Z=<WVM2
MW5W;:D=0D9HR(S^[9!'&A8^6@##NQR"3DG-=310!R=]X*^VZ7XJLO[0V?V]+
MYF_R<^1^[1,8W?-]S/;K39_">K)J>L76G:_';1:ML$T<ECYIB"Q+'F-MXPQ
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&BBB@#__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
